<SEC-DOCUMENT>0001558370-25-003341.txt : 20250320
<SEC-HEADER>0001558370-25-003341.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320071548
ACCESSION NUMBER:		0001558370-25-003341
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		143
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40886
		FILM NUMBER:		25754484

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cgtx-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/20/2025 2:05:20 AM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: ce023ef5-a376-49f3-9432-de4192ec4619 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cgtx="http://www.cogrx.com/20241231"><head><meta content="text/html" http-equiv="content-type"/><title>COGNITION THERAPEUTICS,&#160;INC._December 31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" xs:nil="true" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_yB3S44WBzkSCxQ_MyylJDw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" xs:nil="true" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_lJMDeb9ukUanvgtD5SPkYA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityCentralIndexKey" id="Tc_3SBPfqdtO0K558WUPv34rg_2_1">0001455365</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentFiscalYearFocus" id="Tc_LT4igiY0fEGzBeH5uDSYYg_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_m-BwCBI14EWUvACw2rExkg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:AmendmentFlag" id="Tc__SSz0MQCa0Kts8n_7VNtmQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_GL-2adXFeUizAwQ5N41cTQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Urf2s1Q96USpg0nHJ-TRoA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_uMeajRfbFUGIUvxcTr5haQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_VySIEQuZ8k-gIQvt_w4Aag">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_SVdrYoXmtkuaCv6uYbJIpg" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_gQWcEjdNw0GcGiE_v49Xrg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l87oZJuNJEGMXeOLZRLP6g" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_azpgbY7v70GTdLavwIY4qw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Hidden_W3VI9jjkKkCKLtXgnWQvTg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Hidden_yK0ETgeUAkG1nAZvss5hbg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" xs:nil="true" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" name="us-gaap:PreferredStockValue" id="Hidden_ubdKuvpJkkaqTeUDY-0ehg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" xs:nil="true" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" name="us-gaap:PreferredStockValue" id="Hidden_eE1i52D_kU6U1m60PuvXSw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_zXsuiyXa10mQAw1pz6nYnw">59854877</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_HBFneHzl_k27D95-1wTmDQ">32165478</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_jnCsFL2IEUeXVQTdgotWyQ">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_1YSK4YZY_EWesDCIHCGuNw" decimals="-3" name="us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths" id="Hidden_Z7RNwB4W3kOANqH6RLEDhQ">544000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_1URyjcdy8kqivgwhPCDv3A">32165478</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_S56iJzBGFkm4V3mtGIvG2w">59854877</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_v1k3Dg8VREagvH4eZzhc2g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_z0Vdnv6oQU-dhLEWmZmyvg">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_aC02QIKoOUyPVq4UeX7GUA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_Nt8kwa65QE2wzlLEyRX9NA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden_u4Jf8gqGbEGJb2oeDKiKTw">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_wu-IG5I7IEGcFveZXiNmug">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cgtx-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_r3tUz6_Kt02MxBdQeEQGEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_afVnL3lb_EefS-cEGQ-jZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ZUcWSgSFkE2BmPuI7ICu_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_2iDgdVMqskqqMckLxknrRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_JcEslU1uvkSAJq_z28KWWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_xK7RvHxIJE-jH9loOV_v-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_-GLOfDTDzEKj9t_Ctbu54Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7tSX_qWQF0CIUXnoJZQz_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_alChYiDeMkO9Ns2J7rmKPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_kEmqrIBPs0isxn2okOqBaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AJXFpogTYkiyXpWcopwd_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vT5FlUfgiEqOtSWVevEpAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yK322Z1bEU6-t8t4b8J1mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jrmNuQdewkuQ3tIVwaV50A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rv7evwVvGkaNCERTqKzo4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3GnPNkowakSAyYLtWMwr0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nl1R_JUOlEOS0QXSjoW9fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3B_2Jrx_WkO-PPVkUC_P7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_JlfyE0xns0CU4LcciEPTeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_9IPUhdlJ5kOeFe2ILc4Vlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_wRqYBX88ck2Z32XFXD3SKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_QnBbkut1Gkme18p813MRFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0Ur3_enFS0W4_rr4CTlI6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Hkyrmv-pfEyH9afz2yTZxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_FGsA0l5PX0ikfIe99ENvTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_EZEO1er5NEyxL_p2ZKMavg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_4KKeiPcUyU2k6n2tgFWd3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_iZBC1Qycd0ODSeXIqiMLDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_kR9dLuqQQUK9opN7bHqIBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_v1k3Dg8VREagvH4eZzhc2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mjymGu0RfUeiL7Co7NPZdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_o-vcv2H3AUS1ElrISMMh5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_8KtOhdlvBUG2HVj7Nj0Rvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_1YSK4YZY_EWesDCIHCGuNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wq0C1MAIcUClHQZnNmyrcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_OmwuH19ITkWRHopUzOVYJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3QteG7Thn0O_-zTGlyV6yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_R4fyJmu5eUuklOk2TqC2fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5QUb6H7RJEmzgSXAtn5DaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kPOqaHj9s0i-PXHu6jVcxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_-QVbP29W8UCUFnMbcV9xXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_GafOTV2hp0qNoyDaJ5nlAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_HTF3nxxkYEqnzjZbaDO4Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_6WFEkFQXEUSicyyzDQI4qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_3ws-31ywLkGQlI_tbXjBpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TMZ1hC5jjUm23pil46C8GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jrR6f4WA_E-O8mTJmjvxRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_XKQMBwzNm0isw3SpIMHyCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_WWHICw6P30W1vl__ISJXDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_k0qbPwttZEipB5XrOo8yFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l87oZJuNJEGMXeOLZRLP6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_6nqsHazxDUGfwWNKMnAR-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_SVdrYoXmtkuaCv6uYbJIpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_gX0jdGPEx0-lwTPLQjPt9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_P2TM13gBZU6xZncj0GmnAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_N80InueOO0ax6JSU1_GDkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_O4eMoPkn-UiB3yEL9wwhEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_SefUZ0-stEK6Wo6PqsHRnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JSDRzJzk2kCr9Ut2IvY5WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_YMzsuYYScUGAVgdtaKBakQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BZ1BPutL2kCFpmBC9iHmpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cz7E_hdUVUWwa9Vuq9Mihg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2Q9ZkTw_DUCugaCKI_H91Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6w45MJ0QnUikkNsbjaNclg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynoIxvwk10KeE1sFcDzURw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DNorcmrr9ECUu3JPRu-YqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_77w6B15sK0-_YLNNtOcqPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2025_6c0TrOxXNESMzxicg2S8JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_28_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_qj_sVYxNbUS8cYEAWDZ8pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_wg_K7cTOH0eZ6E1DJZAUYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_r74j6G3Wr0ynHLld-HIi-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_jRWdRQ2nq0mpessnxLTvMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_EKWIjPiMsU2M7X5y-zyRPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_JXRbb9ivf0eQ2WygjyfFaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgtx:LifeScienceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgtx:LifeScienceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IEL8SilDn0ONwVf8eHAjSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_LuMhXlg2UU2lMoQFfA7XFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2022_To_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_Q6DBrXT7LEaflz65yXd2EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratorySpacePittsburghPaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_9ytlK5UIFkOJ1P2Vw2TIqQ"><xbrli:measure>cgtx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_2EZlvjH0wki-oLaHkndxvg"><xbrli:measure>cgtx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw"><xbrli:measure>cgtx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:0pt;padding-top:1pt;text-align:center;text-indent:0pt;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_883999a0_c55d_4dd9_98e5_080faee8e7c9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentType" id="Narr_rH9CF9xq6UCGRc7sUIRyeg"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentAnnualReport" id="Narr_W7JoiO9k906_TxXN3aL_jw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">For the fiscal&#160;year ended</span><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentPeriodEndDate" id="Narr_dgTlXsIo1UWh_89mLTQVZw"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:CurrentFiscalYearEndDate" id="Narr_umWSqSjG70am2c10XYXY3Q"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentTransitionReport" id="Narr_6NMIXRN9jk23cVagUiHezw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For The Transition Period From&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityFileNumber" id="Narr_7vZZyBkcG06CQkSV2KJUCQ"><b style="font-size:8pt;font-weight:bold;">001-40886</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityRegistrantName" id="Narr_6guUTVRaYU6q_ByhuKrP3g"><b style="font-weight:bold;">COGNITION THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_0bd4c4e5_d908_49c7_81ef_291d7e378540"></a><a id="Tc_NW6frD1UpUO8gtT3Kn-omQ_2_0"></a><a id="Tc_Ml844UhsoEGKlGxYrDS-_w_2_1"></a><a id="Tc_sLGtqZWb6ki6jor7_xpA2w_5_0"></a><a id="Tc_crRsMyZ5A0yNjST4oNNqJw_6_0"></a><a id="Tc_7zhdmEF2dkul_8Lvi1kwKQ_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_cUFHBjVeike6nip9kmufAQ_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityTaxIdentificationNumber" id="Tc_8WEjFKGokEO3dDRiXW1cbQ_1_1"><b style="font-size:8pt;font-weight:bold;">13-4365359</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityAddressAddressLine1" id="Tc_XHUTOz27n06KSwn-PwKQtA_4_0"><b style="font-size:8pt;font-weight:bold;">2500 Westchester Ave.</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityAddressCityOrTown" id="Narr_t4_lZZeD2UijamiYiJFyDA"><b style="font-size:8pt;font-weight:bold;">Purchase</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityAddressStateOrProvince" id="Narr_wDgVh0OO5k6VCBssPmylZQ"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityAddressPostalZipCode" id="Tc_H1LZfNfHaESkFQ59jCsL1Q_5_1"><b style="font-size:8pt;font-weight:bold;">10577</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code:</span><b style="font-size:8pt;font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:CityAreaCode" id="Narr_cWICjoDkHkyzONDByPtUtQ"><b style="font-size:8pt;font-weight:bold;">412</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:LocalPhoneNumber" id="Narr_Pc70zPQ9WkOy_RwOwluzPA"><b style="font-size:8pt;font-weight:bold;">481-2210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_6a81bc1b_1939_4c30_9a32_7126c7b10385"></a><a id="Tc_unZ9vtaEeUeL-26AHl6E1A_1_4"></a><a id="Tc_jDX9y6VD00yBHlZh4s_60Q_2_0"></a><a id="Tc_BjwruNDuPke2usIO-U8TEA_2_2"></a><a id="Tc_oBX_QOD_nkCrf61ybhu7Mw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:Security12bTitle" id="Tc_RFx2fZi19k6LrIT0T4cEqA_3_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, par value $0.001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:TradingSymbol" id="Tc_BakisGNLvk6xRBewoQFjAA_3_2"><b style="font-size:8pt;font-weight:bold;">CGTX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:SecurityExchangeName" id="Tc_OnXrX6HbRESn87EkDxAMcQ_3_4"><b style="font-size:8pt;font-weight:bold;">The Nasdaq Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;<span style="white-space:pre-wrap;">of the Act:  </span><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_ir01iOrvDEKTKmJwxdbFhw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityVoluntaryFilers" id="Narr_zsleFX3YW0ut7ac9fr-eUw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityCurrentReportingStatus" id="Narr_yTJcsw-y7kGA9e3RKEyNVA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityInteractiveDataCurrent" id="Narr_ZRyxiKVdYESmnOkW-69f-Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityFilerCategory" id="Narr_DER5W-6HT06xBYISc2eupw"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntitySmallBusiness" id="Narr_MWFb1ljlj0mK25cUObvWyw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityEmergingGrowthCompany" id="Narr_clcvGsnKGku5HmSR1KEFuA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityExTransitionPeriod" id="Narr_E9g2xWpRPUmvX1ilKM8LDg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C.&#160;7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_co17D4skd0yTD3h6Z32vwQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:EntityShellCompany" id="Narr_UYv7kEfxZEulpO6mko3mxg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The aggregate market value of the Registrant&#8217;s Common Stock held by non-affiliates, as of June 30, 2024, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2024_77w6B15sK0-_YLNNtOcqPg" decimals="0" name="dei:EntityPublicFloat" id="Narr_NUf_G-6HekSDPB13XoJdew">56,312,451</ix:nonFraction>. Shares of Common Stock held by each executive officer and director and by each stockholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of March 17, 2025, was <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_17_2025_6c0TrOxXNESMzxicg2S8JA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_-KUYTp1_zkSGqQqfeGdNPg">61,972,946</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_Azrh82Xfxk-PNp270GJhug" escape="true"><span style="font-size:8pt;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024.</span></ix:nonNumeric><span style="font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5dce0578_0c4a_4bcf_80c3_5e7777be47c2"></a><a id="Tc_4zGsDXMsoUepW7koZZge7Q_1_0"></a><a id="Tc_TeQ3QW3Uq0CJ9q13ohG21A_1_2"></a><a id="Tc_86gb7sK9h02TjXlKMPyF7Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Firm ID:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:AuditorFirmId" id="Tc_TF7ONv0Bo0K95mM_TJLvPw_1_1"><span style="font-size:8pt;">42</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Name:</p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:AuditorName" id="Tc_LgGnw0RVYkODCQ2DVnIjBw_1_3"><span style="font-size:8pt;">Ernst &amp; Young LLP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Auditor Location:</p></td><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="dei:AuditorLocation" id="Tc_yNKcrE21GU6lQXkDs9fyaQ_1_5"><span style="font-size:8pt;">Philadelphia, PA</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e6154d44_da2b_462b_8653_b1d0eb5046da"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTI_883693"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1Business_571021"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1ARiskFactors_361684"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">38</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1BUnresolvedStaffComments_685711"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">99</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item1CCybersecurity_492794"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item 1C. Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">99</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item2Properties_347022"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">100</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item3LegalProceedings_272268"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">100</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item4MineSafetyDisclosures_494562"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">100</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTII_331600"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item6SelectedFinancialData_500456"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;6. [Reserved]</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">111</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">112</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">134</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9AControlsandProcedures_434960"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">134</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9BOtherInformation_878908"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">135</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item9CDisclosureRegardingForeign"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">135</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PARTIII_479695"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">136</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item11ExecutiveCompensation_635596"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">136</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">136</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">136</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item14PrincipalAccountantsFeesandService"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">136</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#PartIV_346291"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item15ExhibitsandFinancialStatementSched"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">137</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:auto;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="#Item16Form10KSummary_806161"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Item&#160;16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">140</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f36a769b_96c9_401e_a795_dc322cb4ec57"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or Annual Report, contains forward-looking statements concerning our business, operations and financial performance, as well as our plans, objectives and expectations for our business operations and financial performance and condition. All statements other than statements of historical or current facts included in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements including &#8220;we believe&#8221; or similar phrases reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements. These risks and uncertainties include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue as a going concern for the next twelve months;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain the listing of our common stock on the Nasdaq Capital Market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical nature of our business and our ability to successfully and in a timely manner advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which health epidemics and other outbreaks of communicable diseases, geopolitical turmoil, including the ongoing global and regional conflicts or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our dependence on the success of zervimesine (CT1812), our lead product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the novelty of our approach to targeting the &#963;-2 (sigma-2) receptor (&#8220;S2R&#8221;) complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competing therapies that are or become available; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential scope and value of our intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with global political changes and global economic conditions, including changes in the U.S. presidential administration, inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risk and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221; in this Annual Report.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#8220;Risk Factors&#8221; set forth in Part I, Item 1A of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_52aaa78a_9c4b_44bc_9c24_8251bd72e259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SUMMARY OF RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects, and/or cause the price of our common stock to decline. These are not all the risks we face, and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Additional detail about these risks is included in Part I, Item 1A &#8220;Risk Factors.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-size:9.5pt;">Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs; Discovery, Development and Regulatory Approval of Our Product Candidates; and Business and Industry</span><span style="color:#ff0000;font-size:9.5pt;font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">There is substantial doubt about our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">If we fail to comply or regain compliance with the continued listing standards of the Nasdaq Capital Market, or Nasdaq, we may be delisted and the price of our common stock, or ability to access the capital markets and our financial condition could be negatively impacted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have completed Phase&#160;2 clinical trials but have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#8203;&#160;</span><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, zervimesine, for an adequate amount of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, zervimesine.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We rely on third parties in the conduct of all our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and for which we receive approval and ultimately harm our financial condition.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales or affected products. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;font-style:italic;font-weight:bold;">Risks Relating to Our Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">The market price and trading volume of our common stock have been and may continue to be volatile, which could result in rapid and substantial losses for our stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Concentration of our capital stock ownership with our directors and their affiliated entities and our executive officers will limit stockholders&#8217; abilities to influence certain corporate matters.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PARTI_883693"></a><a id="_1f03f65f_021d_4880_bc76_46ee33d6c851"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_571021"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including &#946;-amyloid, or A&#946; and &#593;-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer&#8217;s disease, or AD, and dementia with Lewy bodies, or DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The company&#8217;s initial focus has been on the development of zervimesine for the treatment of Alzheimer&#8217;s disease. We believe our evidence demonstrates that zervimesine displaces A&#946; oligomers from their neuronal receptors. Based on this mechanism, we believe zervimesine has the potential to slow the loss of synapses and cognitive decline observed in AD. The direct healthcare costs to care for patients with AD and other dementias in the United States is estimated to exceed $350 billion. Approximately 7 million people in the United States have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35 million people globally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Enrollment has concluded in the company&#8217;s Phase 2 COG0201 (SHINE) study of zervimesine in mild-to-moderate AD. Top-line results were reported in 2024. Enrollment is ongoing in the COG0203 (START) Phase 2 study of zervimesine in patients with Mild Cognitive Impairment (MCI) and early-stage AD. We are conducting the START clinical trial in collaboration with the Alzheimer&#8217;s Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias. Both studies are supported by grant awards totaling $110 million from the National Institute of Aging, or NIA, a division of the National Institutes of Health, or NIH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, company research produced evidence that zervimesine prevents the binding of &#593;-synuclein to neurons, rescuing cellular function that is compromised in DLB. Based on this information, we conducted the Phase 2 COG1201 (SHIMMER) clinical trial in 130 adults with mild-to-moderate DLB, which concluded in 2024. Top-line results were presented in December 2024 and later at the International Lewy Body Dementia Conference (ILBDC) in January 2025. The trial was funded by a grant of approximately $30 million from the NIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA. As of October 15, 2024, approximately 477 subjects have received zervimesine in our clinical trials, including people with AD, DLB and dry AMD. Zervimesine has continued to be generally well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, for AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In 2024, we reported top-line results from both the Phase 2 COG0201 (SHINE) clinical trial, which evaluated zervimesine in 153 adults with mild-to-moderate (MMSE 18-26) AD, and the Phase 2 COG1201 (SHIMMER) clinical trial in 130 adults with mild-to-moderate DLB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Top-line SHINE results were presented in July 2024 at the Alzheimer&#8217;s Association International Conference (AAIC) and additional data from a biomarker-defined population of AD patients from the SHINE study were presented in October 2024 at the Clinical Trials on Alzheimer&#8217;s Disease (CTAD) conference. Top-line results were presented during an investor webinar in December 2024.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Top-line SHIMMER results were presented at the International Lewy Body Dementia Conference (ILBDC) in January 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We initiated the Phase 2 COG2201 (MAGNIFY) clinical study of zervimesine in 2023 based on evidence that zervimesine may be effective in the treatment of GA secondary to dry AMD. Based on the favorable results from our dementia programs and the need to preserve capital, we made the strategic decision in January 2025 to focus our resources on the development of zervimesine in AD and DLB. As a result, in February 2025 we voluntarily concluded the MAGNIFY clinical study and began investigator site wind-down procedures. The conclusion of the study was not the result of any safety concerns. At the time of the study conclusion, 100 participants had been enrolled in the trial. Results are being compiled by the contract research organization (CRO) following participant completion of final clinic visits. We intend to conduct an analysis of the changes in GA lesion size as well as safety and tolerability, which will be reported in the second quarter of 2025. We continue to believe that zervimesine has the potential to alter the biological processes that contribute to dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our objectives are to develop and advance our portfolio, beginning with our lead product candidate, zervimesine. We want to leverage our understanding of zeryimesine&#8217;s mechanism and its ability to regulate pathways and biological processes. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance clinical development of our lead product candidate, zervimesine, in mild-to-moderate AD and earlier stages of the disease</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Our lead product candidate, zervimesine, has progressed through Phase 2 clinical trials. Funding of trials to this point has come primarily from the NIA. We are evaluating zervimesine in earlier symptomatic stages of AD and MCI, which is a slight and noticeable measurable decline in cognitive abilities due to AD. Our COG0203 (START) clinical trial in patients with mild dementia associated with early-stage AD has been funded by a grant of approximately $81 million awarded by the NIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Develop product candidates for other CNS and degenerative diseases, including synucleinopathies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We intend to develop and advance other product candidates to treat other conditions, potentially including the synucleinopathies, which include Parkinson&#8217;s disease (PD) and DLB. Preclinical data published in February 2021 showed that our candidate&#8217;s mechanism may play an integral role in the pathology of DLB and PD, which we believed merited further study. To that end, we conducted a 130-patient Phase 2 COG1201 (SHIMMER) study of zervimesine in patients with DLB, which was funded primarily through the NIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our pipeline through internal development, in-licensing and acquisitions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;We intend to leverage our expertise in drug development and business development to evaluate additional product candidates as well as bring forward novel chemical matter using libraries generated with our molecule generation and screening strategies. To achieve this objective, we may supplement our internal development initiatives through selective in-licensing arrangements, as well as investments in strategic collaborations, and partnerships which complement our initiatives.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Optimize the value of zervimesine and other product candidates in major markets. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We currently retain all worldwide rights to zervimesine for all indications. We plan to develop and pursue approval of zervimesine and other future product candidates in major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs. We and our key opinion leaders believe zervimesine also can be used in combination with other therapeutics and thus may have many partnering opportunities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to pursue non-dilutive funding opportunities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The majority of our research and clinical efforts have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA. We intend to continue our work with these research institutions and potentially expand to include pharmaceutical partners, advocacy organizations and others to seek additional non-dilutive funding for our clinical development when possible.</span></td></tr></table><div style="margin-top:6pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Zervimesine for the Treatment of Dementias: AD and DLB</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Neurodegenerative diseases including AD and DLB are defined by progressive degeneration of nerve cells, or neurons, which often leads to neuronal death, causing dementia, a progressive decline in memory, language, problem-solving and other cognitive functions, results in decreased quality of life and shorter life span. Two of the most common causes of dementia are AD and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Zervimesine is designed to stop the binding of A&#946; and &#593;-synuclein oligomers to neuronal synapses, thereby protecting neurons from the toxic effects of these pathogenic protein species. We believe that zervimesine represents a functionally distinct and promising approach to synaptoprotective therapeutics where neurons remain viable and functional.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Indication</b></p></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Study Identifier</b></p></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Clinical Phase</b></p></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Status</b></p></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:46.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Key Findings</b></p></td></tr><tr><td colspan="9" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Alzheimer&#8217;s Disease (AD)</b></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">MCI-early</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG0203 (START)</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 2</i></p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">ongoing</p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">The study is enrolling up to 540 participants with MCI or early AD<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">mild-moderate</p></td><td style="vertical-align:top;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG0201 (SHINE)</p></td><td style="vertical-align:top;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 2 (n=153)</i></p></td><td style="vertical-align:top;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">complete</p></td><td style="vertical-align:top;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Participants treated with zervimesine experienced a cognitive benefit compared to placebo<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">mild-moderate</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG0202 (SEQUEL)</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 2 (n=16)</i></p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">complete</p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Participants treated with zervimesine exhibited improvement across prespecified EEG parameters<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">mild-moderate</p></td><td style="vertical-align:middle;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG0105 (SPARC)</p></td><td style="vertical-align:middle;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 1 (n=23)</i></p></td><td style="vertical-align:middle;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">complete</p></td><td style="vertical-align:middle;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Treatment with zervimesine was assessed using various imaging modalities, including PET imaging and volumetric MRI (vMRI)<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">mild-moderate</p></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG0104 (SNAP)</p></td><td style="vertical-align:middle;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 1 (n=3)</i></p></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">complete</p></td><td style="vertical-align:middle;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Confirmed preclinical findings showing an increase in A&#946; oligomers in CSF, suggesting increased off-rate from receptors<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="9" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dementia with Lewy Bodies (DLB)</b></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">mild-moderate</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">COG1201 (SHIMMER)</p></td><td style="vertical-align:top;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Phase 2 (n=130)</i></p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">complete</p></td><td style="vertical-align:top;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Participants treated with zervimesine experienced benefits across behavioral, functional, cognitive and motor scales<br/><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Alzheimer&#8217;s Disease (AD)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Zervimesine was designed to selectively target and displace A&#946; oligomers bound to neuronal receptors at synapses, a new and differentiated mechanism of action. In our preclinical studies, zervimesine has demonstrated the potential to protect synapses, facilitate their restoration and improve cognitive performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Overview of the Disease</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">AD is a progressive neurodegenerative disorder characterized by cognitive dysfunction, memory loss, dementia and the impairment of daily living activities, along with numerous behavioral and neuropsychiatric symptoms. In the advanced stages of the disease, an AD patient is unable to recognize faces, use or understand language and displays a lack of awareness for their surroundings. Continued functional decline ultimately results in the patient&#8217;s death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Due to the size of the affected population, we believe that AD is one of the most significant unmet medical needs of our time. Nearly seven million Americans are living with AD and disease prevalence is expected to more than double by 2050. The direct healthcare costs to care for patients with AD and other dementias in the United States is currently estimated to exceed $350 billion and projected to increase to $1 trillion by 2050. Absent the development of meaningful intervention in the course of the disease, the number of people diagnosed with, and dying from, AD is anticipated to escalate appreciably as lifespans lengthen, since prevalence increases significantly with age. The Centers for Disease Control listed AD as the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. The disease is equally devastating worldwide, with the World Health Organization estimating that AD affects as many as 35 million people globally.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Currently Approved AD Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Only two FDA-approved disease-modifying therapeutic options for AD are currently available in the United States: Eisai&#8217;s Leqembi (lecanemab), which received complete approval in July 2023; and Eli Lilly&#8217;s Kisunla (donanemab), which was approved in July 2024. Both are approved for the treatment of people with MCI or mild Alzheimer&#8217;s disease (MMSE between 22 and 30). Biogen&#8217;s Aduhelm (aducanumab) was approved in July 2021 but was discontinued in January 2024. Leqembi and Kisunla are monoclonal antibodies administered via infusion designed to slow the progression of cognitive decline by reducing A&#946; plaques and protofibrils. They represent approaches that are distinct from our small molecule approach of blocking the binding of A&#946; oligomers to synapses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other therapies approved for AD are indicated to treat the symptoms of AD: acetylcholinesterase inhibitors, or AChEIs, antipsychotics, glutamatergic modulators and an orexin receptor antagonist. AChEIs are designed to slow the degradation of the neurotransmitter acetylcholine, helping to preserve neuronal communication and function temporarily. Glutamatergic modulators are designed to block sustained, low-level activation of the N-methyl-D-aspartate, or NMDA, receptor without inhibiting the normal function of the receptor in memory and cognition. Namenda (memantine), an NMDA receptor antagonist was approved in the United States in 2003. These therapeutic products do not modify or alter the progression of the underlying disease and provide only modest efficacy in treating the symptoms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Current Status of AD Therapeutic Approaches</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Numerous therapeutic approaches have been evaluated to remedy the causes of AD. Those focused on reducing the aberrant production or removal of intraneuronal neurofibrillary tangles of tau protein have yielded limited clinical benefit. Development initiatives intended to inhibit hyperphosphorylation of the tau protein and related kinase activity, enhance microtubule stability or block tau aggregation have largely been discontinued due to toxicity or a lack of efficacy. Microglial activation and its role in AD-induced neuroinflammation has emerged as another potential target for therapeutic development as has the proper functioning of processes dictating synaptic plasticity, believed to be of central importance to neuronal activity and continued viability. These efforts have also not yielded meaningful clinical advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Among the more prevalent and targeted mechanisms implicated in AD is the accumulation of A&#946; aggregates in the neuronal synapse where disease progression leads to synaptic dysfunction and dysregulation. The accompanying deterioration in neuronal activity ultimately results in neuronal death. As a result, the reduction in the levels of A&#946; aggregates at the synapse has been a prominent objective of a significant number of therapeutic candidates, including active and passive immunotherapies, designed specifically to target A&#946; aggregates. As exemplified by Leqembi&#8217;s clinical results, we believe that preferentially targeting A&#946; protofibrils/oligomers has the potential to prevent synaptotoxicity. Several therapeutics in this class have recently been approved by the FDA, including Aduhelm, Leqembi and Kisunla, which are monoclonal antibodies designed to reduce A&#946; plaques and protofibrils, approaches that are distinct from but potentially complementary to our small molecule approach of blocking A&#946; oligomer binding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Emerging Role of Biomarkers in AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Biomarkers have become increasingly important in the development of treatments for neurodegenerative diseases for a number of reasons, including monitoring drug activity in patients, assessing changes in disease pathology during treatment and identifying responder populations for clinical trials. Given that biomarker-enabled therapeutics have a higher rate of success at gaining product approval, we elected to employ biomarkers in our programs to mitigate clinical development risk. To that end, in addition to a number of cognitive tests, our clinical trials use a variety of biomarkers to measure target and/or pathway engagement and assess changes in disease progression. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For example, in AD, tangles of A&#946; and phosphorylated tau (p-tau) build up in the brain and can be visualized through a positron emission tomography, or PET scan. Recently, tests have been developed that can detect levels of p&#8208;tau in blood plasma. Increasing levels of p-tau, whether visualized with PET or measured in blood plasma, indicates increasing disease burden. Data generated by pharmaceutical companies indicates that individuals with lower AD pathology at baseline, as reflected by lower levels of p&#8209;tau, have greater response to amyloid-based therapies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other potentially useful biomarkers include neurofilament light chain, which can indicate dysfunction in membrane trafficking and autophagy processes. Quantitative EEG and PET imaging agents as well as vMRI may also have utility in several neurodegenerative disorders to measure synaptic function, synaptic density and brain atrophy, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">The Role of A&#946; Oligomers on Synapses and the Downstream Impact to Brain Function and AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synapses are specialized points of contact between neurons, where electrical signaling and communication takes place. It is well established that synapses are routinely sprouted and resorbed as part of the normal process of learning and memory. Each neuron is covered with an estimated 10,000 synapses and these synapses participate in a complex electrical circuit with other neurons. Neurons do not divide or reproduce as part of normal physiological function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Scientific evidence has demonstrated that A&#946; oligomers, formed over time through the buildup of A&#946; and its aggregates, bind to specific parts of the synaptic structure and interfere with the normal process of memory formation. This ligand-like activity confers to A&#946; oligomers potent synaptotoxic activity. In response, the neuron dismantles and resorbs the synaptic structure to prevent its abnormal function from interfering with what remains of the normal circuit behavior. If a large enough number of synapses are lost, the neuron dies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Synaptic loss, however, is not necessarily permanent and synapses can be regained or sprout again once the oligomers are removed. We have observed this process in our research involving preclinical AD models. This observation leads us to believe that displacement of synaptotoxic A&#946; oligomers may enable synapses to recover and potentially slow cognitive decline. We are further encouraged by the numerous precedents which exist that demonstrate the therapeutic utility of blocking ligand-receptor interactions in the brain with small molecule drugs capable of crossing the blood-brain barrier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Zervimesine&#8217;s Mechanism of Action Prevents Binding of A&#946; Oligomers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our proprietary zervimesine product candidate employs a novel and fundamentally different mechanism compared to other approved or experimental treatments, which facilitates removal of neurotoxic A&#946; oligomers through alteration of S2R activity. Experimental evidence suggests that A&#946; oligomers likely occupy binding sites contiguous to the S2R complex. The preferential binding of zervimesine to the S2R complex produces changes that alter the binding affinity of A&#946; oligomers to their targets. Zervimesine binding to the S2R complex is hypothesized to modulate the conformation of the S2R complex, which in turn allosterically alters the oligomer receptors causing displacement of A&#946; oligomers from the neurons and neuronal synapse. Displaced A&#946; oligomers are less able to rebind as long as threshold concentrations of zervimesine are present and are rapidly removed from the synapse. Based on our preclinical studies, we believe that zervimesine not only prevents binding of A&#946; oligomers, displacing them from neuronal synapses, but also slows A&#946; oligomer-induced loss of synapses and restores synaptic activity, which may reverse downstream synaptotoxic effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Zervimesine Clinical Results in AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have completed multiple clinical trial evaluations of zervimesine, in both healthy volunteers and patients with mild-to-moderate AD, and have one clinical trial ongoing (START) in patients with MCI or early AD. The clinical trials we have conducted to date have enabled us to evaluate the safety profile of zervimesine; validate its mechanism through proof-of-concept trials; assess clinical efficacy signals; and identify predictive biomarkers of treatment response. The following is the status of our completed and ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Overview of our Completed and Ongoing Clinical Studies of Zervimesine for AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 20.15pt;"><i style="font-weight:normal;">COG0201&#8201;&#8212;&#8201;Phase 2 (SHINE) Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0201 SHINE study was a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the safety and efficacy of zervimesine. A total of 153 adults with mild-to-moderate AD were enrolled and divided into two zervimesine dose groups (100 mg or 300 mg) and one placebo group, dosed daily for six months. Endpoints included safety and biomarker evidence of disease modification as well as cognitive function, as measured by ADAS-Cog 11. ADAS-Cog 11 is a globally recognized cognitive scale that is used to assess cognition in patients with AD. Top-line results were reported in July 2024 with additional data reported in October 2024.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:136.54pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A prespecified analysis conducted on SHINE results identified plasma p-tau217 as a biomarker that may predict an optimal therapeutic response in patients with mild-to-moderate AD. Participants treated with zervimesine (pooled 100 mg and 300 mg) who had baseline levels of plasma p-tau217 below the median of 1.0 pg/mL experienced a 95% reduction of cognitive decline at week 26 as measured by ADAS-Cog 11 relative to placebo-treated participants. We believe P-tau217 is an important biomarker that has shown the ability to distinguish Alzheimer&#8217;s disease from other neurodegenerative disorders with a high degree of accuracy compared to other available biomarkers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the overall modified intent-to-treat, or mITT, population in SHINE, participants treated with once-daily oral zervimesine experienced less cognitive decline than those treated with placebo. As measured with ADAS-Cog 11, zervimesine-treated participants (pooled 100 mg and 300 mg) experienced a mean 38% slowing of decline at six months versus baseline compared to placebo-treated, but did not achieve statistical significance. There were consistent trends favoring zervimesine in other cognitive measures: ADAS-Cog 13, cognitive composite, MMSE; as well as in functional measures of activities of daily living (ADCS-ADL) and of clinical global impression of change (ADCS-CGIC). No discontinuations due to AEs occurred in the 100 mg zervimesine group. At the 300 mg dose, ten participants (nine at scheduled visits and one at an unscheduled visit) experienced treatment-emergent liver enzyme test (&#8220;LFT&#8221;) increases (greater than 3xULN) that subsided after cessation of drug without evidence of serious liver injury. There were no LFT elevations observed in the 100 mg dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k001.jpg" alt="Graphic" style="display:inline-block;height:135.99pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:278.73pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k002.jpg" alt="Graphic" style="display:inline-block;height:136.24pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:279.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Proteomic measurements were also performed on cerebrospinal fluid (CSF) and plasma from these patients, from which we have comprehensive datasets of whole proteome changes observed in AD patients given zervimesine versus placebo for six months. From this, we identified product candidate pharmacodynamic biomarkers that could reflect processes of target engagement, pathway engagement and/or early disease modification.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 20.15pt;"><i style="font-weight:normal;">COG0203&#8201;&#8212; Phase 2 START Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0203 study, referred to as START, is a randomized, double-blind, placebo-controlled Phase 2 clinical trial that is currently enrolling 540 patients with early-stage AD and using the Clinical Dementia Rating Scale Sum of Boxes; or CDR-SB to show a change in the rate of cognitive and functional decline. We are recruiting patients with MCI due to AD or mild AD who have elevated levels of A&#946; as determined by PET imaging or as measured in CSF. The trial is being conducted in collaboration with ACTC and will utilize approximately 50-60 sites including research sites associated with the consortium, as well as other qualified sites that are not part of the consortium. Patients will be randomized to receive zervimesine or placebo for 18 months. In addition to a battery of cognitive and functional measures, we intend to use a variety of biomarkers to measure target engagement and assess changes in neurodegeneration and disease progression. We have been awarded a grant of approximately $81 million from the NIA to fund this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Completed Proof-of-Concept Clinical Trials for the Mechanism of Zervimesine</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 20.15pt;"><i style="font-weight:normal;">COG0202&#8201;&#8212;&#8201;Phase 2 SEQUEL Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0202 SEQUEL study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of 16 patients with mild-to-moderate AD to evaluate the potential efficacy of zervimesine in restoring synaptic function in patients through quantitative EEG (qEEG) measurement, as reflected by relative theta power. The trial is a two-arm crossover trial, in which half of the participants received 300 mg of zervimesine daily for 29 days. After a 14-day wash out period, these participants received placebo for an additional 29 days. The other half of the participants received placebo daily for 29 days. After a 14-day wash out period, these participants received zervimesine treatment for an additional 29 days. CSF and qEEG evaluations were taken periodically throughout the duration of the trial. We completed enrollment in the first quarter of 2023 and presented results in October 2023. Results showed that zervimesine-treated participants exhibited a significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters, reflecting improved synaptic function after just a matter of weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 20.15pt;"><i style="font-weight:normal;">COG0105&#8201;&#8212;&#8201;Phase 1 SPARC Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The COG0105 SPARC study is a randomized, double-blind, placebo-controlled Phase 1 clinical trial of 23 patients with mild-to-moderate AD. The primary objectives of the study were to evaluate zervimesine for safety and tolerability. The secondary objectives were to evaluate potential effects of zervimesine on biologically relevant endpoints using various imaging modalities, including PET imaging and volumetric MRI (vMRI) as well as CSF biomarkers, and cognitive and clinical endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Participants were randomized to receive treatment with 100 mg or 300 mg of zervimesine or placebo once daily for 24 weeks. A preliminary analysis has been made of safety, clinical laboratory measurements, PET imaging, functional MRI and vMRI, CSF biomarkers and clinical outcomes in patients treated with zervimesine compared to those in patients receiving placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Seventeen patients completed the study protocol, eleven in the zervimesine arm (six in the 100 mg cohort; five in the 300 mg cohort) and six in the placebo arm. Zervimesine was well tolerated with similar adverse event rates across treatment arms. Most adverse events were mild or moderate in severity with no deaths and no treatment-related SAEs reported. We observed mild and transient elevations of liver enzymes without any other indications of liver injury in two patients in the 300 mg group. The patients were discontinued from the study and the liver enzyme levels returned to normal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Top-line results from the analyses of secondary endpoints demonstrated that after 24-weeks of treatment, there were no significant treatment differences on the ADAS-Cog 11 change from baseline. In addition, there were no significant treatment differences on SV2A signal change compared to baseline. However, vMRI showed a trend (p=0.0641) towards a significant reduction in the loss of composite brain volume in zervimesine-treated patients (pooled) compared to placebo. A significant (p&lt;0.05) reduction in loss of brain volume was also observed in three brain regions (hippocampus, prefrontal cortex and pericentral cortex) in treated patients (pooled) compared to placebo, as shown in the table below.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:217.92pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">LS Mean Change from Baseline in vMRI (composite) over Time by Treatment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:136.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:287.26pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">COG0104&#8201;&#8212;&#8201;Phase&#160;1 SNAP Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0104 SNAP study was a randomized, double-blind, placebo-controlled Phase 1 clinical trial that enrolled three patients with mild-to-moderate AD to measure the effects of zervimesine on displacement of A&#946; oligomers. Patients were randomized 2:1 to receive a single dose of zervimesine (n=2) or placebo (n=1). Patients enrolled in the trial had an indwelling catheter placed in the lumbar CSF space. CSF samples were collected hourly over a 28-hour period. Five CSF samples were collected before and 24 samples collected after administration of a single 560 mg oral dose of zervimesine or placebo. CSF samples from each trial participant were analyzed to measure the concentration of A&#946; oligomers over the trial period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results of this clinical trial revealed an increase in A&#946; oligomer levels in the CSF over the 24-hour period following treatment with zervimesine, but not in the patient administered placebo. These findings were measured using two independent methods, microimmunoelectrodes and western blots. This effect of zervimesine was specific to A&#946; oligomers, as no zervimesine-related increase in A&#946; 1-40 or 1-42 monomer was observed. We believe that these results corroborate our mechanism of action previously demonstrated in preclinical studies, providing the first evidence that our preclinical studies translate to patients with AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">First evidence of target engagement in humans, which mirrors that found preclinically; and we believe this reinforces that our mechanism of action extends to patients with AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:217.92pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:338.99pt;"/></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:121.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">COG0102&#8201;&#8212;&#8201;Phase&#160;1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0102 study was a randomized, double-blind, placebo-controlled, Phase 1 clinical trial of 19 patients with mild-to-moderate AD. Participants were administered one of three oral doses of zervimesine, either 90 mg, 280 mg or 560 mg, once daily for 28 days. The primary endpoint of the trial was safety with a secondary objective of establishing the pharmacokinetic, or PK, profile of zervimesine. Also included as exploratory endpoints were measurement of zervimesine in CSF, and protein expression changes in CSF and plasma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Zervimesine was well tolerated in the COG0102 study. All AEs were mild or moderate. Some of the participants in the highest dose group experienced lymphocytopenia or elevated liver enzymes. These laboratory abnormalities resolved in most patients with continued dosing of zervimesine. One trial participant was discontinued from zervimesine prior to study completion because of elevated liver enzymes with subsequent resolution of this abnormality. Lymphocytopenia or elevated liver enzymes were not observed in either the 90 mg or 280 mg dosing cohorts. There were no SAEs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Our Phase 1 Safety Trials with Zervimesine</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to Phase 1 clinical trials conducted in our targeted patient population, we also conducted a series of Phase 1 clinical trials in healthy volunteers to evaluate the safety profile of zervimesine; as well as numerous preclinical in vitro and in vivo studies to assess its neuroprotective function as well as determine potential drug-food or drug-drug interactions. These trials and their results, which are summarized below, indicated that zervimesine was generally well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">COG0101 &#8212; First in Human Phase 1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0101 study was a randomized, double-blind, placebo-controlled ascending dose Phase 1 multi-cohort clinical trial of 93 healthy volunteers to assess the safety and potential drug-food interactions of zervimesine. The trial was conducted in two segments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The first segment was structured as an ascending single dose trial, in which participants received one dose of zervimesine with increasing doses given to each of six cohorts. In this segment of the trial, eight participants were enrolled per dosing cohort with six participants receiving zervimesine and two receiving placebo. The doses evaluated were 10 mg, 30 mg, 90 mg, 180 mg, 450 mg and 1,120 mg. A seventh cohort of six patients received a single 90 mg dose after receiving a standardized meal. All doses were administered as scheduled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The second segment was configured as a multiple ascending dose trial, that enrolled 39 healthy volunteers, divided in three cohorts of ten participants, with one additional cohort consisting of nine healthy elderly volunteers. Each participant in this segment of the trial received a single dose of zervimesine each day for 14 days. The doses evaluated in this second segment were 280 mg, 560 mg and 840 mg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zervimesine CSF concentrations correlated to a &gt;80% S2R predicted receptor occupancy in brain</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:121.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:190.21pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following completion of each trial cohort, bioanalytical evaluation of plasma zervimesine PK was conducted.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">This trial demonstrated that administration of zervimesine in single doses of up to 1,120 mg, administered once, as well as up to 840 mg of zervimesine dosed for 14 consecutive days was well tolerated. Significantly, zervimesine concentrations detected in the CSF correlated to an estimated receptor occupancy in the brain of greater than 80%. There was one SAE in the multiple-dose portion of the study that was deemed unrelated to study drug. There were no SAEs related to the product candidate or TEAEs leading to withdrawal from the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">COG0103 &#8212; Phase 1 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our COG0103 study was a Phase 1 clinical trial of 15 healthy volunteers designed to evaluate the potential effects of zervimesine on select CYP isoenzymes: CYP2C19, CYP2C9, CYP2D6 and CYP3A4/5. This was accomplished by assessing its effects on substrates of these isoenzymes: 20 mg omeprazole, 500 mg tolbutamide, 50 mg dextromethorphan and 4 mg midazolam. The 15 healthy volunteers who participated in the trial received the substrates of these isoenzymes two days prior to the initial dose of zervimesine and PK assessments were performed. A dose of 560 mg of zervimesine was administered to each of the trial participants for the following six consecutive days. The Day 6 dose of zervimesine was administered concomitantly with the four-substrate cocktail and PK assessments were repeated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A weak drug interaction was observed between zervimesine and midazolam and dextromethorphan. A lack of any clinically meaningful interaction was observed with coadministration of omeprazole or tolbutamide. Based on the small magnitude of change in PK parameters of the probe drugs observed in this study for the isoenzymes CYP2D6 and CYP3A4, clinically meaningful interactions are unlikely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In all blinded and unblinded clinical trials, several patients experienced asymptomatic, reversible elevations in serum liver chemistries prompting harmonization of monitoring, increasing frequency where appropriate, across our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to entering clinical trials, the therapeutic potential of zervimesine was observed in numerous preclinical studies. As is demonstrated in the images below, the addition of A&#946; oligomers to neuronal cell cultures resulted in synaptotoxicity as illustrated by the reduced expression of synaptic markers neurogranin, synaptotagmin and SV2A. The lack of immunoreactivity of these three synaptic proteins can be seen in the middle column of the image below. However, the presence of zervimesine blocked the A&#946; oligomer-induced loss of synapses, as reflected by the presence of synaptic protein expression displayed in the right-hand column below.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:300.01pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zervimesine prevented A&#946; oligomer-mediated synaptic damage</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:299.26pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:299.26pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Results showed that zervimesine also slowed the loss of synapses that is triggered by A&#946; oligomers. A higher resolution image of the cell culture exposed to A&#946; oligomer is shown below, before the addition of zervimesine, which is presented on the left, and after the addition of zervimesine, which is presented on the right. A&#946; oligomers shown in red bind to synaptic receptors and reduces the number of synapses shown in green. The addition of zervimesine displaces A&#946; oligomer binding and appears to block the effects induced by the A&#946; oligomers, with the synapse numbers remaining at levels similar to normal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zervimesine&#160;slowed loss of synapse numbers in the presence of A&#946; oligomers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;width:280.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The protective benefits of zervimesine observed in these <i style="font-style:italic;">in vitro</i> assays are supported by functional in vivo assessments of zervimesine. In one such preclinical study, the memory of mice was tested based on the subject&#8217;s ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below, performed significantly worse in both the fear and maze tests when compared to normal, non-transgenic mice, represented by the blue bars. However, after administration of zervimesine, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal mice. We believe these results are illustrative of zervimesine&#8217;s ability to restore synaptic proteins and numbers to normal levels and with it, the animal&#8217;s functional capabilities.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:102.6pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zervimesine restored functional capabilities in a mouse model of AD</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:102.6pt;width:175.88pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dementia with Lewy Bodies (DLB)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Substantial cellular and clinical biomarker evidence demonstrate that zervimesine may have a beneficial impact on the pathways impaired in synucleinopathies, namely the localization of &#945;-synuclein aggregates in Lewy bodies, which is a chief hallmark of DLB, Parkinson&#8217;s disease (PD) and other synucleinopathies. More recently, human genetic evidence has linked SNCA, the gene encoding &#945;-synuclein, to the pathology of synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have conducted preclinical studies of compounds in our library, including zervimesine, to explore their potential to rescue the biological processes that are impaired in synucleinopathies. We are currently developing zervimesine for the treatment of DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">An Overview of DLB</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">DLB is the second most common cause of dementia. The abnormal accumulation of the protein &#945;-synuclein into fibrils, the primary component of the Lewy bodies within brain neurons, is characteristic of DLB. Increasing evidence suggests that &#945;-synuclein oligomers disrupt key cellular processes including autophagy and elicit neuronal dysfunction and loss of synapses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">DLB is challenging to diagnose and identify as it shares many Alzheimer&#8217;s disease symptoms. DLB is referred to as a &#8220;whole-body&#8221; disease, as it disrupts biological processes affecting autonomic, digestive, cognitive, and motor systems. Varied initial symptoms may include day-to-day fluctuations in alertness level, hallucinations, delusions, movement disorders and REM sleep disorder (acting out dreams while sleeping). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the United States, an estimated 1.4 million are diagnosed with DLB. According to the Lewy Body Dementia Association, the direct healthcare costs for patients with DLB are estimated to be approximately $31 billion per year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Limitations of Current Treatments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Most approved therapeutic products treat the symptoms of the diseases and modulate dopamine. While some existing products provide meaningful symptomatic relief, they have significant side effect risks, fail to address the progression of the disease, and over time gradually lose their effectiveness in treating the symptoms of the disease. There are no currently approved disease-modifying therapeutics for DLB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Rationale for Zervimesine in the Treatment of DLB</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The protein &#945;-synuclein is primarily found in neural tissue that plays a role in neurotransmission. In DLB, &#945;-synuclein builds up in brain cells and forms oligomers that saturably bind to neurons where they impair critical cellular processes, causing synaptic dysfunction. Our decision to pursue the treatment of synucleinopathies with zervimesine is based on internal and third-party data, indicating that zervimesine can prevent binding synuclein oligomers and that the S2R components PGRMC1 and TMEM97 regulate cell pathways known to be impaired in synucleinopathies, such as autophagy, vesicle trafficking and lipid synthesis; &#945;-synuclein oligomers bind directly to PGRMC1; and synucleinopathies share certain mechanistic similarities with AD, including pathologies related to aberrant oligomeric protein formations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:129.01pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As summarized below, we believe our preclinical studies provide compelling evidence supporting the use of zervimesine as a potential therapeutic to treat DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As with oligomers of the A&#946; protein in AD, oligomers of &#945;-synuclein are highly toxic when bound to brains cells and internalized. This binding causes cellular stress, including three major pathway disruptions: upregulation of the autophagy receptor LAMP2A, dysregulation of lipid metabolism and a reduction in membrane trafficking. The S2R complex components, PGRMC1 and TMEM97, directly regulate these processes and activities which are compromised by the binding and internalization of &#945;-synuclein oligomers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Compounds that block &#945;-synuclein binding and/or internalization are therefore expected to be disease-modifying.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Preclinical Study Support for Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The results of in vitro studies suggest that S2R modulator, such as zervimesine, may have disease-modifying effect on the synucleinopathies by reversing pathway disruption and dysregulation caused by &#945;-synuclein oligomers. In work funded by grants from the Michael J. Fox Foundation, &#945;-synuclein oligomers were found to bind to brain cells in culture and are internalized as indicated by the red dots in the image to the left below. With the addition of zervimesine, the binding and thus internalization of the &#945;-synuclein oligomers is inhibited as indicated in the image to the right below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Zervimesine blocked the binding and internalization of &#945;-synuclein oligomers in the neuronal synapses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k009.jpg" alt="Graphic" style="display:inline-block;height:129.01pt;width:198.31pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The potential for S2R modulators like zervimesine to reverse the deleterious cellular effects of &#945;-synuclein oligomers is also reflected in the in vitro analysis of LAMP2A expression presented below. LAMP2A is a critical component of chaperone-mediated autophagy, one of several processes that eliminate damaged cellular proteins. Its expression, noted in orange, is upregulated in the presence of the toxic &#945;-synuclein oligomer, likely a compensatory mechanism in response to the cellular insult. S2R modulators, which block membrane trafficking deficits caused by &#945;-synuclein oligomers, are observed to inhibit the upregulation of LAMP2A, as evidenced by the dark and light gray in the below chart. As these antagonists are selective for the S2R complex, their ability to reverse the effects of &#945;-synuclein on LAMP2A expression provides compelling evidence of the S2R complex&#8217;s importance in the regulation of this autophagy pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In vitro analysis further illustrates &#945;-synuclein oligomers&#8217; dose-dependent inhibition of membrane trafficking. Importantly, oligomer-related inhibition was noted to be four-fold higher than that observed with high concentrations of monomeric &#945;-synuclein, illustrative of the significantly greater toxicity of &#945;-synuclein oligomers. The addition of zervimesine was observed to reverse the membrane trafficking deficit related to the presence of &#945;-synuclein oligomer, while having no effect on membrane activity when dosed in its absence.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:92pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">S2R antagonists reversed the effects of &#945;-synuclein oligomers on LAMP2A expression and trafficking</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="cgtx-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:92pt;width:351.34pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">COG1201 &#8212; </i><i style="font-style:italic;">Phase&#160;2 SHIMMER Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We completed the double-blind, randomized Phase 2 COG1201 (SHIMMER) clinical trial of zervimesine in adults with mild-to-moderate DLB. We enrolled 130 participants who were randomized evenly to one of three dose groups: two treated with once-daily oral zervimesine (100 mg or 300 mg) and one treated with placebo. To be eligible, participants were between 50 and 80 years of age, received a diagnosis of probable DLB, and had a mini-mental state exam, or MMSE, score of between 18 and 27. Clinical endpoints of the trial included safety and tolerability, neuropsychiatric, functional, cognitive and physical activity measurements. PK and pharmacodynamic biomarker analyses were also conducted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The study met its primary endpoint of safety and tolerability. Zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPI) A-L at the end of the study. This tool describes the frequency and severity of 12 behavioral symptoms including hallucinations, delusions and anxiety. &#160;Compared to placebo-treated participants, those treated with zervimesine performed an average of 52% better on the ADCS-ADL scale, a measure of activities of daily living; an average of 91% better on the CAF, a measure of cognitive fluctuations; an average of 62% better on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, a measure of motor function such as gait, balance, and tremor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Initiatives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Zervimesine and other chemical structures in our pipeline originate from a screening technique developed by Cognition&#8217;s founding scientists. This screening technique relies on the use of mature primary neuronal cultures designed to replicate the mature brain and its intricate connections and patterns of electrical signaling. &#160;provides us with information-rich measurements more indicative of normal brain function and predicative of functional benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition has generated proprietary small molecule libraries derived from natural chemical scaffolds through a proprietary process which we refer to as conditioned extraction. Conditioned extraction was pioneered by a cofounder and allows us to eliminate undesirable properties of well characterized, biologically active compounds sourced from natural products, while retaining their biological activity. The resulting molecular configurations are then subjected to proprietary functional in vitro screening using the mature primary neuronal cultures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The candidate library produced through this process is predisposed to compounds with attractive drug-like properties such as low molecular weight, low number of reactive hydrogen bonds, lipophilicity and relatively neutral chemistry properties. These characteristics reduce the reactivity of the molecules and related toxicities, while also enhancing their ability to cross the blood-brain and blood-retina barriers, which we believe will reduce development risk. We also believe this platform provides us with differentiated libraries which may lead to development candidates beyond zervimesine.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (Dry AMD)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that several lines of evidence suggest that zervimesine may be effective in the treatment of GA secondary to dry AMD. Human genetics points to TMEM97 as a promising therapeutic target for GA secondary to dry AMD, as indicated via several large-scale, independent genome-wide association, or GWA, studies. In addition, unbiased pathway analysis of AD patient proteomic data obtained during our clinical trials provides independent evidence of a relationship between the S2R complex and GA secondary to dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Early proof-of-concept studies with zervimesine indicate a role of S2R modulators in rescuing key aspects of dry AMD including maintaining homeostatic functions of retinal pigment epithelial cells (RPEs), ameliorating lysosomal dysfunction and preventing RPE cell death. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of zervimesine in retinal tissue through oral administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In 2023 we initiated the Phase 2 COG2201 MAGNIFY study of zervimesine in adults with geographic atrophy secondary to dry AMD. In December 2024 MAGNIFY passed a masked futility analysis conducted by the contract research organization, or CRO, which provided evidence that zervimesine treated patients were experiencing a slower lesion growth rate than those on placebo. However, in January 2025, we made the strategic decision to focus our resources on our promising dementia programs in AD and DLB. Therefore, we voluntarily discontinued the MAGNIFY clinical study. The discontinuation was not the result of any safety concerns. At the time of the discontinuation, 100 participants had been enrolled. Results are being compiled by the contract research organization (CRO) following participant completion of final clinic visits. We will conduct an analysis of the changes in GA lesion size as well as safety and tolerability, which will be reported at a later date. We continue to believe that zervimesine has the potential to alter the biological processes that contribute to dry AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Proposed Synucleinopathies Clinical Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to additional funding, we may plan to study several next-generation S2R modulators derived from chemically distinct series to measure their ability to rescue cell death in synucleinopathies such as PD and DLB. We may also study &#945;-synuclein pathology and motor deficits in two mechanistically distinct in vivo models of synucleinopathies. In parallel, these studies will elucidate the mechanism of action by which S2R modulators are efficacious in PD and DLB and provide essential data to support potential biomarker nomination for PD and DLB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Additional Product Candidates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many degenerative disorders are likely to involve a dysfunctional cellular damage response mechanism and significant evidence is emerging which highlights the importance of the S2R complex and its components in regulating this response. The complex likely contains a number of relevant binding sites that may allow for multiple disease intervention approaches, making it an attractive therapeutic target. Accordingly, we have engaged in a number of earlier-stage discovery programs which are built upon our identification of five structurally distinct chemical series. From these series we have multiple leads which will be optimized from each of our lead series. Each of these leads has demonstrated favorable potency with variable selectivity in early preclinical testing and each of the molecular series possesses distinct bioavailability and PK properties, including differences in half-life and blood-brain and blood-retina permeability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Our Team and Collaborators</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have assembled a management team with extensive experience with CNS and degenerative diseases, significant expertise in the drug discovery, clinical development, general management and business development. Collectively, our management team has a track record of managing drug development programs that have received regulatory approval and been successfully commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, our management team has built companies that have initiated innovative technologies and investigational new drug programs. We augment the strengths of our management team with an experienced board of directors and scientific and medical advisory boards. We believe our team, with its deep scientific and drug development background, positions us to become a leader in the development of therapies for age-related degenerative diseases and disorders.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date, we have been awarded approximately $171 million in cumulative grants awarded primarily from the NIA to support our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Funding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Historically, we have sought grant funding to strategically advance our programs. To date, we have secured non-dilutive funds from the NIA, the Michael J. Fox Foundation and other groups to pursue our commonly aligned interests of developing therapeutics for neurodegenerative disorders. The company has been awarded $171 million in cumulative grants for the advancement of our pipeline programs. As of December 31, 2024, we had approximately $50 million available from NIA funds for applicable expenses to be incurred in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Funding Org</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0101 Ph1b first-in-patient trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0102 Ph1b/2a Clinical Trial for CT1812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,410,669</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0104 Ph1 SNAP Study: CSF Catheter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,527,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0105 Ph1 SPARC Study: SV2a PET</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,795,774</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Study</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,848,329</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0202 Ph2 SEQUEL Study: qEEG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,445,051</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0203 Ph2 START Study with ACTC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,974,766</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0108 Study: hAME</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,642,783</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG0201 Ph2 SHINE Amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,634,548</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Institute on Aging (NIH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COG1201 Ph2 SHIMMER Study: DLB</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,498,048</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NIH and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2010&#8209;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ten Preclinical Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,859,971</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 171,047,879</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Each of the grants awarded to us relates to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to CROs, research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for our eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIA grants do not contain claw back provisions, the NIA or other government agency may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. To date, we have not been found to have breached the terms of any NIA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, in the United States and internationally, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company Owned Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2025, our intellectual property portfolio contained ten issued U.S. patents, forty five issued foreign patents as well as five pending U.S. provisional applications, three pending U.S. patent applications, one pending Patent Cooperation Treaty applications and forty five foreign pending patent applications directed to the composition of matter of, pharmaceutical compositions of, methods of use of, and methods for selecting subsets of patients for treatment with our chemical structures, including our lead <span style="letter-spacing:0.2pt;">zervimesine</span>. Our current issued patents relating to <span style="letter-spacing:0.2pt;">zervimesine </span>are projected to begin to expire no earlier than 2035, with the composition of matter patent covering <span style="letter-spacing:0.2pt;">zervimesine</span> set to naturally expire in 2035, subject to adjustment or extension of patent term available in a particular jurisdiction. We will likely be awarded Patent Term Extension, or PTE, when <span style="letter-spacing:0.2pt;">zervimesine</span> is approved as a New Chemical Entity, or NCE, that will extend the term of the <span style="letter-spacing:0.2pt;">zervimesine</span> composition of matter patent by up to five years, and we anticipate pursuing additional patents to further protect <span style="letter-spacing:0.2pt;">zervimesine</span> and to further extend the patent term associated with <span style="letter-spacing:0.2pt;">zervimesine</span>. We expect to file additional patent applications in support of current and new product candidates as well as new platform and core technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of eight patent families that include several granted U.S. patents and pending U.S. patent applications, as well as granted patents and pending patent applications in numerous foreign jurisdictions, relating to compositions of matter and pharmaceutical compositions of <span style="letter-spacing:0.2pt;">zervimesine</span>, analogs of <span style="letter-spacing:0.2pt;">zervimesine</span>, and the use of <span style="letter-spacing:0.2pt;">zervimesine</span> for the treatment in certain diseases, disorders and conditions including AD, GA secondary to dry AMD, DLB, PD, and other synucleinopathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The first of these patent families is directed to compositions of matter of zervimesine, pharmaceutical compositions of zervimesine, methods of using zervimesine for inhibiting amyloid beta effects on a neuronal cell, and methods of using <span style="letter-spacing:0.2pt;">zervimesine</span> to treat AD, and we are the exclusive owner of this patent family in the United States and certain foreign jurisdictions, including Australia, Brazil, Canada, China, the European Union, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa. As of March 1, 2025, this patent family includes granted patents claiming composition of matter of <span style="letter-spacing:0.2pt;">zervimesine</span>, pharmaceutical compositions of <span style="letter-spacing:0.2pt;">zervimesine</span>, methods of using <span style="letter-spacing:0.2pt;">zervimesine</span> for inhibiting amyloid beta effects on a neuronal cell, and methods of using <span style="letter-spacing:0.2pt;">zervimesine</span> to treat AD in the United States (three patents), Australia, Brazil, China, the European Union, Hong Kong, India, Israel, Japan, New Zealand, Mexico, South Korea, Russia and South Africa. This patent family also includes a pending U.S. patent application and pending application in the European Union. This patent family has a natural expiration date in 2035 subject to any adjustment or extension of patent term that may be available in in a particular jurisdiction such as PTE following approval of the New Drug Application, or NDA, in the United States or extension of patent term via a Supplementary Protection Certificate, or SPC, following EMEA marketing authorization. Upon approval of the NDA for <span style="letter-spacing:0.2pt;">zervimesine</span> in the United States, the patents in this family claiming compositions of matter of <span style="letter-spacing:0.2pt;">zervimesine</span>, pharmaceutical compositions of <span style="letter-spacing:0.2pt;">zervimesine</span>, and methods of using <span style="letter-spacing:0.2pt;">zervimesine</span> for inhibiting amyloid beta effects on a neuronal cell, and methods of using <span style="letter-spacing:0.2pt;">zervimesine</span> to treat AD will be eligible to be listed in the FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. These patents complement the regulatory exclusivity by providing the basis for an additional waiting period prior to the FDA&#8217;s &#160; approval of an abbreviated new drug application, or ANDA, or 505(b)(2) applicant. If &#160;an ANDA or 505(b)(2) applicant were to file its application referencing the NDA for <span style="letter-spacing:0.2pt;">zervimesine</span> before expiration of our composition of matter, pharmaceutical composition, and method of use patents and the applicant asserted that our patents identified on the Orange Book to be invalid or not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory 30-month stay if we sue for infringement, or a shorter period if the patent expires or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to patent exclusivity, under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that <span style="letter-spacing:0.2pt;">zervimesine</span> will be eligible for five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety as the chemical entity in the <span style="letter-spacing:0.2pt;">zervimesine</span> NDA. When approved in Europe, <span style="letter-spacing:0.2pt;">zervimesine</span> will also be eligible for 10 years of data and market exclusivity which is extendible for an additional year upon market authorization for one or more new indications during the first eight years of the data and market exclusivity period.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>We also own seven families of pending patent applications directed to methods for selecting subsets of patients with AD for treatment with <span style="letter-spacing:0.2pt;">zervimesine</span>, methods of modulating amyloid beta monomer and oligomer levels using <span style="letter-spacing:0.2pt;">zervimesine</span>, methods of treating GA secondary to dry AMD with <span style="letter-spacing:0.2pt;">zervimesine</span> and methods of treating various neurologic diseases including PD, DLB and other synucleinopathies with <span style="letter-spacing:0.2pt;">zervimesine</span>, as well as a pending provisional application directed to treating certain subsets of AD patients with <span style="letter-spacing:0.2pt;">zervimesine</span> and treating Niemann-Pick disease. Any of these applications, if issued, will have a natural expiration between 2038 and 2044, subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are the exclusive owner of four patent families that include several pending U.S. patent applications, as well as pending patent applications in numerous foreign jurisdictions directed to additional product candidates. These patent families have expirations no earlier than 2038 subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We oversee and manage third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if we receive marketing approval, we will rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the zervimesine drug substance and with a single third-party contract manufacturer to manufacture clinical trial supplies of zervimesine. We expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of zervimesine. We continue to develop the commercial route for zervimesine drug substance and to meet all requirements for our planned clinical trials. The current drug substance manufacturer is able to support all of our needs for the planned clinical studies and commercial supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Zervimesine drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially-available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We will transition from our current drug product manufacturer to a larger third-party manufacturer for our late-stage clinical and commercial supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Commercialization Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may seek third-party support from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the geographic market for a product we develop on our own is limited or that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to establish direct sales capability until shortly before the products are approved for commercial sale.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We face substantial competition from multiple sources, including large and specialty biotechnology and pharmaceutical companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to the current standard of care treatments for patients with neurodegenerative diseases, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess technologies and product candidates in the CNS field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the biopharmaceutical sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retain qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Currently available therapies for these diseases are limited, with two approved disease-modifying treatments each for Alzheimer&#8217;s disease but no approved treatments for dementia with Lewy bodies. However, our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2025, we had 28 employees, 25 of whom were full-time and 20 of whom were engaged in research and development activities. Seven of our employees hold Ph.D. or M.D. degrees. None of our employees are represented by a labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are dedicated to conducting business with the highest standards of corporate responsibility. Our goal is to build a culture of talented and passionate people striving to positively impact patients, our communities, and broader society. Our human capital resource priorities include attracting, recruiting, retaining, incentivizing and integrating our existing and new employees. We promote values such as purpose, drive, transparency, and fairness in our workplace. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. During 2024, the Company took proactive steps to enhance and improve our policies related to employee welfare and engagement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#8217;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 6pt 0pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 6pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s good laboratory requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee, either centralized or with respect to each clinical site, before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA after completion of all pivotal trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including potential requirements to conduct any post-approval studies required by the FDA or the potential requirement to implement a risk evaluation and mitigation strategy, or REMS; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with the Pediatric Research Equity Act, or PREA, which requires either exemption from the requirements or may require conducting clinical research in a pediatric population.</span></td></tr></table><div style="margin-top:6pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <i style="font-style:italic;">in vitro</i> studies assessing the toxicology, PK, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial or drug candidate. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, or DSMB, which may review data and endpoints at designated check points, make recommendations and/or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the registration of ongoing clinical studies and posting of clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;One</i>:&#160;&#160;&#160;The product candidate is initially introduced into a limited number of healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Two</i>:&#160;&#160;&#160;The product candidate is administered to a limited patient population with the target disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning Phase 3 trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;Three</i>:&#160;&#160;&#160;The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk relative to potential benefit and generate the data used by FDA and other regulatory agencies to evaluate suitability for marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Sponsor may voluntarily pause or stop a clinical trial, or the FDA may place a trial on full or partial clinical hold at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or concerns related to chemistry, manufacturing and controls. A clinical hold is an order issued by the FDA to delay or suspend an investigation. Following the issuance of a clinical hold or a partial clinical hold, a clinical trial may only proceed after FDA has notified the sponsor that any deficiencies have been corrected and FDA is authorizing the trial to proceed. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Finally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move &#160; forward at designated check points based on access to certain data from the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested by the sponsor. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on plans for the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trials to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug candidate and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <i style="font-style:italic;">in vitro </i>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NDA Review and Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product candidate. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and is adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with and approved drug and to enable patients to have continued access to such drug by managing their safe use. It could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission to and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drug candidates that meet certain criteria. Specifically, new drug candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the drug candidate and the specific indication for which it is being studied. The sponsor of a fast track designated product has opportunities for more frequent interactions with the applicable FDA review team during product development. With regard to a fast track designated product, the FDA may also consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Any drug candidate submitted to the FDA for approval, including a drug candidate with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A drug candidate is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug candidate designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, a drug candidate may be eligible for accelerated approval. Drug candidates intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the drug candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA generally requires that the sponsor perform adequate and well-controlled post-marketing confirmatory clinical trials which must be conducted with due diligence to verify and describe the predicted clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA may require, as appropriate, that such confirmatory trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct the required confirmatory trials or if such studies fail to verify the predicted clinical benefit. &#160;In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive Breakthrough Therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;Breakthrough Therapy&#8221; if the drug candidate is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a drug candidate is designated as Breakthrough Therapy, the FDA will work to expedite the development and review of such drug candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Fast Track designation, priority review, accelerated approval, and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development, review or approval process. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our drug candidates as appropriate.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, untitled letters, Form 483s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on post-approval or Phase&#160;4 clinical studies, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under PREA, an NDA must contain data to assess the safety and efficacy of the applicant product for indications in applicable pediatric populations. It must also contain information to support dose administration for pediatric populations where the drug may be utilized. FDA has the ability to grant complete waivers, partial waivers, or deferrals for compliance with PREA. PREA requirements may be waived for applications for approval of drug candidates intended to treat, mitigate, prevent, diagnose or cure diseases and other conditions that do not occur in pediatric populations. Generally, PREA does not apply for drug candidates which have obtained an orphan designation, unless otherwise regulated by the FDA. Despite this, separate PREA compliance or waivers may still be required for each product indication. Although noncompliance with PREA will generally not be considered for withdrawal of an approval it may be considered by the FDA as the sole basis for enforcement action such as injunction or seizure as non-compliance and may render the drug misbranded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five- year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. The FDCA also permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for an NCE in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. During the NCE exclusivity period, the FDA may not approve or even accept for review an ANDA or an NDA submitted under Section 505(b)(2), or a (505(b)(2) NDA), submitted by another company for another &#160;drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. Any competitor who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must make patent certifications to the FDA that (1) no patent information on the drug or method of use that is the subject of the application has been submitted to the FDA; (2) the patent has expired; (3) the date on which the patent has expired and approval will not be sought until after the patent expiration; or (4) the patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the 30-month stay is extended so that it expires 7 1&#8725;2 years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. The indications the Company is currently pursuing for its product candidates will not be eligible for pediatric exclusivity because they are age-related degenerative diseases and disorders that do not occur in the pediatric population. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities &#160;from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:38.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; applicable manufacturers also are required to report such information regarding payments and transfers &#160;of value provided, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Foreign Corrupt Practices Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the SEC, and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not &#160; &#160;to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The Inflation Reduction Act of 2022, for example, contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. The Inflation Reduction Act of 2022 also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. Additional drug pricing proposals could appear in future federal legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, there are also new laws and ongoing ballot initiatives that create additional pressure on drug pricing and may affect how pharmaceutical products are covered and reimbursed. A number of states have adopted or are considering various pricing actions, such as those requiring pharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or to place a maximum price ceiling or cap on certain products. Existing and proposed state pricing laws have added complexity to the pricing of pharmaceutical drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. There have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code, commonly referred to as the individual mandate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress that include aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which remain in effect through 2031. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act has also been subject to challenges in the courts. &#160;In the most recent challenge, in June 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:justify;text-indent:0pt;margin:8.44pt 30.95pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt -0.7pt 12pt 0pt;"><span style="color:#231f20;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:justify;text-indent:0pt;margin:8.44pt 30.95pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:justify;text-indent:22.5pt;margin:8.44pt -0.7pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware on August 21, 2007. Our principal corporate office is located at 2500 Westchester Avenue Purchase, NY 10577, and our telephone number is (412) 481-2210. Our website address is www.cogrx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_da8a3d60_430c_422f_8378_c418dc336192"></a><a id="Item1ARiskFactors_361684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. We have listed below (not necessarily in order of importance or probability of occurrence) what we believe to be the most significant risk factors applicable to us. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. Some of the statements in the following risk factors constitute forward-looking statements. &#160;Please see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses over the foreseeable future and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses were $34.0 million and $25.8 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $175.2 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have devoted substantially all of our financial resources and efforts to the development of our product candidates, including conducting preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating losses over the next several years. We expect that it could be several years, if ever, before we have a commercialized product. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially for the foreseeable future as we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">conduct our ongoing and planned clinical trials of zervimesine, as well as initiate and complete additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">pursue regulatory approval of zervimesine for the treatment of mild-to-moderate Alzheimer&#8217;s disease, or AD, and Parkinson&#8217;s disease, or PD, and dementia with Lewy bodies, or DLB, and other age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seek to discover and develop additional clinical and preclinical product candidates from libraries generated using Novel Improved Conditioned Extraction, or NICE, screening platform, as well as other molecule generating and screening strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">hire and retain additional clinical, manufacturing and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">incur additional legal, accounting and other expenses in operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">scale up our clinical and regulatory capabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval, including zervimesine. </span></td></tr></table><div style="margin-top:6pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our candidates or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our stock and could impair our ability to raise capital, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is substantial doubt about our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our management has concluded that, based on our current operating plan, there is substantial doubt as to whether we can continue as a going concern for the twelve months following the issuance of this Annual Report. To date, we have not generated any revenues from product sales and have incurred significant operating losses in each year since our inception and we anticipate that losses may continue for the next several years or until such time as we can generate substantial revenues and achieve profitability. As of December 31, 2024, we had $25.0 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures into the fourth quarter of 2025, which assumes no usage from the remaining ATM Facility (defined below) nor the equity line of credit with Lincoln Park Capital Fund, LLC, or Lincoln Park. Our ability to continue as a going concern is dependent upon raising capital to maintain current operations and continue research and development efforts. We plan to raise additional capital to fund our operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangement or other sources. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us or at all. If such additional capital is not available on satisfactory terms, or is not available in sufficient amounts, or if we are unable to enter into a collaboration, we may be required to delay, limit or eliminate the development of zervimesine and our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations will be materially adversely affected.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply or regain compliance with the continued listing standards of the Nasdaq Capital Market, or Nasdaq, we may be delisted and the price of our common stock, or ability to access the capital markets and our financial condition could be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our common stock is currently listed on the Nasdaq Stock Market LLC, which has minimum requirements that a company must meet in order to remain listed. These requirements include maintaining a minimum closing bid price of $1.00 per share, which closing bid cannot fall below $1.00 per share for a period of more than 30 consecutive trading days. On September 12, 2024, we received a deficiency letter from the Staff of the Nasdaq Stock Market LLC notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were given 180 calendar days, or until March 11, 2025, to regain compliance with Rule 5450(a)(1).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We did not come into compliance by March 11, 2025. On March 12, 2025, we received approval from the Listing Qualifications Department of Nasdaq Stock Market LLC to transfer the listing of our stock to the Nasdaq Capital Market. Following the transfer of the listing, we have been granted an additional 180 calendar day period to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The additional 180-day grace period will end on September 8, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If we do not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that our common stock will be subject to delisting. At that time, we may appeal the Nasdaq staff's determination to a Hearings Panel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We intend to actively monitor the closing bid price for our common stock and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1), including effecting a reverse stock split. However, there can be no assurance that the Company will regain compliance with the minimum bid price requirement. If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face negative consequences including the reduction of liquidity and market price of our common stock, our ability to obtain sufficient additional capital to fund our operations, and our ability to operate as a going concern would be substantially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have completed, Phase 2 clinical trials, but have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We commenced operations in 2007, and our operations to date have been largely focused on developing our clinical and preclinical product candidates and our NICE screening platform. We have limited experience conducting and completing clinical trials and not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We may also need to transition from a company with a research focus to a company capable of supporting commercial activities. Our inability to adequately address these risks and difficulties or successfully make such a transition could adversely affect our business, financial condition, results of operations and growth prospects.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our operations have required substantial amounts of capital since inception, and we expect our expenses to increase significantly in the foreseeable future. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several years as we complete our ongoing clinical trials of our product candidates, initiate future clinical trials of our product candidates, seek marketing approval for zervimesine for the treatment of age-related degenerative diseases and disorders of the CNS and retina, such as AD, PD and DLB, and advance any of our other product candidates we may develop or otherwise acquire. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for the foreseeable future, if at all. If we obtain marketing approval for zervimesine or any other product candidates that we develop or otherwise acquire, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had $25.0 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from our non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the fourth quarter of 2025. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including, but not limited to<span style="letter-spacing:0.2pt;">:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">progress, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and results of our ongoing and planned clinical trials of zervimesine, as well as the associated costs, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs we </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur as a result of preclinical study or clinical trial delays due to supply chain disruptions or other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing and receipt of any future non-dilutive grants from the NIA, or NIA Grants, or any changes made to existing grants as a result of political or regulatory pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to establish collaborations to commercialize zervimesine or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">macroeconomic factors such as inflationary pressures, rising interest rates, liquidity constraints, failures and instability in U.S. and international financial banking systems, supply disruptions due to political unrest, conflict and war or other factors, and pandemics such as the COVID-19 pandemic;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We believe our existing cash and cash equivalents and income from our non-dilutive grants will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of zervimesine and our product candidates. If we receive regulatory approval for any of these product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. In addition to our existing cash and cash equivalents and income from our non-dilutive grans, in March 2023, we entered into a Purchase Agreement with Lincoln Park, providing for the sale of up to $35 million worth of shares of our common stock. In addition, in December 2022, we entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, or the ATM Facility, subject to the limitations of General Instruction I.B.6 of Form S-3. There can be no assurance that we will be able to sell all of the shares under the equity line with Lincoln Park or the ATM Facility. Amounts available under the equity line with Lincoln Park have a strong and direct correlation to the Company&#8217;s publicly traded price per share and volumes. There can be no assurances of our traded price per share and volumes being at sufficient levels to provide adequate funding from the equity line with Lincoln Park or the ATM Facility. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by recent volatility in the equity markets in the United States and worldwide. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The economic environment may make it difficult to raise capital on acceptable terms or at all. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, the continued challenging capital markets environment, lower prices for many securities and concerns about potential recessionary factors may affect our ability to raise additional funding through sales of our securities or issuance of indebtedness, which may harm our liquidity, force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or cause us to grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our product candidates or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, liquidity constraints, failures and instability in United States and international financial banking systems, geopolitical tensions resulting from the ongoing conflicts between Ukraine and Russia and in the Middle East, heightened or fluctuating inflation and interest rates and the related impact on U.S. and global economies or other economic or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our stock to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to our product candidates or any future therapeutics candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have partially relied on the availability of NIA Grants. Although we have applied for and currently anticipate receiving additional NIA Grants, we cannot be certain that our grant applications will be successful, that additional NIA Grants will be made available to support our clinical trials or that we will continue to satisfy the award criteria of prior NIA Grants that have already been awarded to us. If we fail to continue to receive NIA Grants, or fail to adhere to the terms of those grant agreements, our ability to continue our clinical programs for zervimesine may be impaired and delayed, and we may otherwise need to seek additional financing through dilutive methods, such as through equity or debt financings. Such dilutive financings could have an adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, government funding is subject to the political process, which is inherently fluid and unpredictable. Under the Trump administration, the U.S. National Institutes of Health, or NIH, announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect costs. Indirect costs represented more than 25% of total grant dollars awarded by the NIH in 2023. While, as of the date of this filing, the order has been temporarily stayed, there can be no assurance that it will not take effect or that other adverse actions will not be taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could be subject to audit and repayment of our non-dilutive NIA Grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition, in connection with the NIA Grants, we may be subject to routine audits by certain government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. Any audit by the NIA could require significant financial and management resources and may result in a material adjustment to our results of operations and financial condition and harm our ability to operate in accordance with our business plan. Additionally, negative results in any of our ongoing and planned clinical trials of zervimesine that are funded with NIA Grants may result in our failure to receive additional NIA Grants to fund future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are currently focused on developing product candidates to address age-related degenerative diseases and disorders of the CNS and retina. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our lead product candidate, zervimesine, in identified indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways and decide which product candidates to pursue from time to time and the amount of time and resources to allocate to each such product candidate.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties with respect to certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the market of age-related degenerative diseases and disorders of the CNS and retina or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and status of enrollment for our clinical trials;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability, timing, and receipt of any future NIA grants;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">future accounting pronouncements or changes in our accounting policies;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the level of demand for our product candidates, if approved, which may vary significantly over time.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Discovery, Development and Regulatory Approval of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of zervimesine and any future product candidates that we may develop or acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently have no products approved for sale, and our lead product candidate is in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of zervimesine, currently our only clinical-stage product candidate. However, given our stage of development, it may be many years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The clinical and commercial success of zervimesine and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to complete an investigational new drug application, or IND, enabling studies and successfully submit INDs or comparable applications;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates, if approved;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the convenience of our treatment or dosing regimen;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or &#160;in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, the FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions. We have not yet conducted an end of Phase 2 meeting with the FDA to discuss the registration pathway for zervimesine, and our current clinical development plans for zervimesine in mild-to-moderate AD may change as a result of future interactions with the FDA. For example, the FDA may not accept the results of the ongoing zervimesine clinical trials and may require that we conduct additional trials, including more than one pivotal trial, in order to gain approval in AD. Furthermore, any approval of zervimesine for AD may be limited to zervimesine in combination with the existing standard of care.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for zervimesine or by in-licensing or acquiring additional product candidates for other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to build and expand our pipeline of product candidates, including by developing zervimesine for the treatment of age-related degenerative diseases and disorders of the CNS beyond indications in AD, and by identifying other product candidates from libraries created using our NICE platform as well as new molecule and screening strategies. In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We have devoted significant resources to discovery efforts through our proprietary NICE platform, and we cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable product candidates from other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development of pharmaceuticals is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 6pt 0pt;">We <span style="letter-spacing:0.2pt;">are at an early stage of clinical development of our only clinical stage product candidate, zervimesine. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our product candidates may not successfully complete preclinical studies or clinical trials;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in our efforts to further develop our current and future product candidates. Each of our product candidates will require significant clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not be acceptable to the FDA or other regulatory authorities or demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may encounter substantial delays in our preclinical studies and clinical trials or may not be able to conduct or complete our preclinical studies or clinical trials on the timelines we expect, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:18pt;margin:0pt;">Clinical <span style="letter-spacing:0.2pt;">trials are expensive and can take many years to complete, and the outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">delays in obtaining, or failure to obtain, regulatory authorization to commence a trial;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">imposition of a temporary or permanent clinical hold by the FDA or comparable foreign regulatory authorities;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identifying, recruiting and training suitable clinical investigators;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining institutional review board, or IRB, approval at each trial site;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">new safety findings that present unreasonable risk to clinical trial participants;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a negative finding from an inspection of our clinical trial operations or study sites;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">recruiting an adequate number of suitable patients to participate in a trial;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">having subjects complete a trial or return for post-treatment follow-up;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">addressing subject safety concerns that arise during the course of a trial;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtaining sufficient supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated or continue;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulators may revise the requirements for approving our product candidates or such requirements may not be as we anticipate; and</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval in some countries and not in others;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">have the product removed from the market after obtaining marketing approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">available </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapies, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new drugs that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications we are investigating; the severity and difficulty of diagnosing the disease under investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patient eligibility and exclusion criteria defined in the protocol;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the proximity of patients to trial sites;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competition with other companies for clinical trial sites or patients;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the design of the trial;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the study drug and safety concerns;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient referral practices of physicians;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting health conditions;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">ability to monitor patients adequately during and after treatment;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">availability </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and efficacy of </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medications or therapies, or other clinical </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">trials, for </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the disease or condition under</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our ability to obtain and maintain patient consents.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable and unforeseen side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Adverse <span style="letter-spacing:0.2pt;">events or other undesirable side effects caused by our product candidates or related to procedures conducted as part of the clinical trials could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the data safety monitoring board, or DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a new approach to inhibiting the synaptic binding and signaling of soluble A&#946; oligomers through the use of small molecule receptor antagonists, like zervimesine. As a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to conduct additional clinical trials or post-approval studies;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be subject to fines, injunctions or the imposition of criminal penalties;</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the product may become less competitive; and</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our reputation may suffer.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Preclinical <span style="letter-spacing:0.2pt;">and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, top-line, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain Phase 2 clinical trials of zervimesine targeting mild-to-moderate AD and DLB, we do not know whether zervimesine will perform in future clinical trials as it has performed in these prior trials. The positive results we have observed for zervimesine in past clinical trials may not be predictive of our ongoing and future clinical trials in humans. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. In addition, changes to the design of our current or future clinical trials may be necessary if there are new developments in the field of Alzheimer&#8217;s research. A number of companies in the biopharmaceutical, pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, some of our past clinical trials have utilized an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in a controlled environment with a placebo or active control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">For all of the foregoing reasons, we cannot be certain that any of our ongoing and planned preclinical studies or clinical trials will be successful or acceptable to the FDA or other regulatory authorities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.3pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have initially concentrated our research and development efforts on the treatment of AD and DLB, diseases that have seen limited success in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Efforts <span style="letter-spacing:0.2pt;">by biopharmaceutical and pharmaceutical companies in treating AD and DLB have seen limited success in drug development. Only two disease-modifying therapeutic options have been approved by the FDA for AD, and none have been approved for DLB. Specifically, Biogen&#8217;s Aduhelm received accelerated approval on June 7, 2021 (and was later discontinued in January 2024) and the FDA granted accelerated approval to Eisai&#8217;s Leqembi on January 6, 2023. Leqembi is monoclonal antibodies administered via infusion reported to reduce A&#946; plaques and protofibrils. We cannot be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products. With the exception of Leqembi, the only currently marketed drug approved by the FDA to treat patients with AD address the symptoms of the disease. As a result, the FDA has a limited set of products to rely on in evaluating zervimesine. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of zervimesine for the treatment of AD or DLB</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We will need to successfully initiate and complete pivotal clinical trials in order to obtain the approval of the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to market zervimesine or any future product candidate. Carrying out pivotal clinical trials is a complicated process that requires significant financial resources. As an organization, we have not previously initiated nor conducted any later stage or pivotal clinical trials. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA submission and approval of zervimesine or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We<span style="letter-spacing:0.2pt;"> may seek a &#8220;Breakthrough Therapy&#8221; designation for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The FDA granted zervimesine Fast Track designation in October 2017 for the treatment of mild-to- moderate AD, and, in the future, we may seek Fast Track designation for other of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many small molecule product candidates that have received Fast Track designation have failed to obtain marketing approval.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in funding for, or disruptions to the operations of the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September 30, 2025. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. The <span style="letter-spacing:0.2pt;">ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. A prolonged government shutdown significant leadership, personnel, and/or policy changes, or other substantial modification in agency activities (including due to global health concerns or geopolitical factors) could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities and clinical trials, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at agencies that fund our research and development activities and our clinical trials, or changes to such agencies&#8217; budgets, may negatively impact our operations and ongoing clinical trials and may limit our ability to seek additional funding in the future. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have conducted clinical trials of our product candidates outside the United States, and plan to continue to do so in the future. For example, we initially conducted our Phase 1b SNAP clinical trial of zervimesine in collaboration with the Karolinska Institute in Sweden. In addition, the Phase 1 single and multiple ascending dose studies of zervimesine in healthy volunteers (COG0101) as well as the first-in-patient study (COG0102) were conducted in Australia. We opened additional clinical trial site in the Netherlands, Czech Republic and Spain for our SHINE study. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, any comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data are applicable to the U.S. population and U.S. medical practice;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the trials were performed by clinical investigators of recognized competence, or GCP, requirements; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Many foreign regulatory authorities have similar requirements. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Although <span style="letter-spacing:0.2pt;">a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that help restore normal cellular damage responses in age-related degenerative diseases and disorders of the CNS and retina. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate zervimesine and other product candidates discovered through our NICE platform in other diseases beyond indications in AD, such as synucleinopathies, including PD and DLB. However, we may find that while we have seen promising results in one neurodegenerative disease, that effect is not replicated across other indications with promising similarities. Even if we successfully identify additional product candidates, we may still fail to yield additional product candidates for development and commercialization for many reasons, including the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may be unable to identify viable product candidates through our NICE platform and other molecule generating and screening strategies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">competitors may develop alternatives that render our additional product candidates obsolete;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">additional product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an additional product candidate may not be accepted as safe and effective by physicians and patients.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the European Union, or EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of zervimesine, our lead product candidate, which is still under clinical development, and if zervimesine does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of zervimesine, currently our only clinical-stage product candidate. To date, we have invested a significant portion of our efforts and financial resources in the development of zervimesine for the treatment of AD and DLB. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for and successfully commercialize zervimesine, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to zervimesine, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, while inhibition of A&#946; oligomers has been validated as a therapeutic approach, the use of small molecule receptor antagonists, such as zervimesine, to inhibit the synaptic binding and signaling of soluble A&#946; oligomers is an innovative therapeutic approach, which exposes us to certain risks. For example, we may discover unforeseen safety events or that zervimesine does not possess certain properties required for therapeutic effectiveness. Even if found to be effective in one type of disease, zervimesine, or the associated therapeutic approach, may not be effective in other diseases. In addition, given our therapeutic approach, designing preclinical studies and clinical trials to demonstrate its effect is complex and exposes us to risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market zervimesine in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for zervimesine and may not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory approvals for zervimesine, we will not be able to commercialize zervimesine in AD, PD and DLB or other age-related degenerative diseases and disorders of the CNS and retina, and our financial position will be materially adversely affected and we may not be able to generate sufficient revenue to continue our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of March 1, 2025, we had 25 full-time and 3 part-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize zervimesine, our lead product candidate, or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth and we expect will lead to increasing costs. Our need to effectively execute our growth strategy requires that we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our clinical trials effectively;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">identify, recruit, retain, incentivize and integrate additional employees, including personnel focused on research and development and, if our product candidates receive marketing approval, sales;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our future financial performance and our ability to develop, manufacture and commercialize zervimesine and our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize zervimesine, if approved, and our product candidates and, accordingly, may not achieve our research, development and commercialization goals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, particularly our President and Chief Executive Officer, Lisa Ricciardi, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth or raise funds to support our growth could delay the execution of our business plans or disrupt our operations. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our current or future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">injury to our reputation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">withdrawal of clinical trial participants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">costs to defend the related litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">diversion of management&#8217;s time and our resources;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">loss of revenue; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the inability to commercialize our current or any future product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may explore strategic collaborations that may never materialize or may fail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We may attempt to broaden the global reach of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations, we intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may seek to grow our business through acquisitions of complementary businesses, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could harm our financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">From <span style="letter-spacing:0.2pt;">time to time, we may consider opportunities to acquire other companies, products or technologies that may enhance our manufacturing capabilities, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including: problems assimilating the acquired service offerings, products or technologies; issues maintaining uniform standards, procedures, quality control and policies; unanticipated costs associated with acquisitions; diversion of management&#8217;s attention from our existing business; risks associated with entering new markets in which we have limited or no experience; increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters; and unanticipated or undisclosed liabilities of any target.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired service offerings, products or technologies. Our potential inability to integrate any business, products or technologies effectively may adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant disruptions of information technology systems and infrastructure, data breaches and other cybersecurity incidents could materially adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems and infrastructure to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and infrastructure and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other &#160;third parties on which we rely, are vulnerable to damage, disruption, security compromise or incident, or other unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, malicious internet-based activity, online and offline fraud, phishing attacks and other social engineering schemes, denial or degradation of service attacks, ransomware, hacking, wrongful conduct by insider employees or vendors, data breaches, and other similar activities. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The risk of a security compromise, incident, breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data breaches, which could lead to the loss of confidential information, including intellectual property, proprietary business information and personal information. Like other companies in our industry, we, and our third party vendors, have experienced and will continue to experience threats and cybersecurity incidents relating to our information technology systems and infrastructure. Further, and due to our reliance on internet technology and based on the number of our employees who work on a hybrid basis, at home and in the office, there may be increased opportunities for bad actors to exploit security vulnerabilities. The costs to us to investigate, mitigate and remediate security incidents, compromises, data breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have in the past experienced threats related to our data and systems, including phishing attacks, and we will in the future experience such threats and cybersecurity incidents. While we have implemented security measures designed to protect our data security and information technology systems and infrastructure, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss or misappropriation of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, if a computer security compromise or breach affects our systems or infrastructure or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information or clinical trial data, it may be necessary to notify affected individuals, governmental authorities, regulatory agencies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged. &#160;We would also be exposed to a risk of loss, governmental investigations or enforcement, litigation, fines, penalties, and other potential legal and financial exposure and liability, which could materially adversely affect our business, results of operations and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are subject to or affected by federal, state and foreign data protection laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section 5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;">For example, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January 1, 2020 and grants the California Attorney General the power to bring enforcement actions for violations beginning July 1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Foreign data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects in the European Union or the United Kingdom. The GDPR went into effect on May 25, 2018. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to &#8364;20 million or 4% of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of European Union or United Kingdom data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal information, and honoring and providing for the rights of European Union or United Kingdom individuals in relation to their personal information, including the right to access, correct and delete their data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Environmental, social and governance matters may impact our business and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In addition to the changing rules and regulations related to environmental, social and governance, or ESG, matters imposed by governmental and self-regulatory organizations, a variety of third-party organizations, institutional investors and customers evaluate the performance of companies on ESG topics, and the results of these assessments are widely publicized. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. Reduced access to or increased cost of capital may occur as financial institutions and investors increase expectations related to ESG matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Developing and acting on initiatives within the scope of ESG, and collecting, measuring and reporting ESG-related information and metrics can be costly, difficult and time consuming and is subject to evolving reporting standards. We may also communicate certain initiatives and goals, regarding environmental matters, social investments and other ESG-related matters, in our SEC filings or in other public disclosures. These initiatives and goals within the scope of ESG could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Furthermore, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals, including our previously announced commitments to reduce greenhouse gas emissions, within the scope of ESG on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected. In addition, in recent years &#8220;anti-ESG&#8221; sentiment has gained momentum across the U.S., with several states and Congress having proposed or enacted &#8220;anti-ESG&#8221; policies, legislation, or initiatives or issued related legal opinions. Such anti-ESG policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in the Company facing additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, zervimesine, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our current and future drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future drug development programs and product candidates, successfully defend our intellectual property rights against third-party challenges and successfully enforce our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, some of our product candidates are not, and in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. The patent applications that we own may fail to result in issued patents with claims that cover any of our product candidates in the United States or in other foreign countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable, and vice versa that may affect the regulatory approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patents and patent applications that we own may fail to result in issued patents with claims that protect any of our product candidates in the United States or in other foreign countries. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may obtain. Even if patents do successfully issue based on our patent applications, and even if such patents cover our product candidates, uses of our product candidates, or other aspects related to our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our products and technologies. Other companies may also design around technologies we have patented or developed. Any successful opposition to these patents or any other patents owned by us in the future could deprive us of rights necessary for the successful commercialization of any of our product candidates, if approved. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any such outcome could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September 16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, and derivation proceedings. After March 15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, post-grant review or interference proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, zervimesine, for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Patents <span style="letter-spacing:0.2pt;">have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success will largely depend on our ability to obtain market exclusivity in the United States and other countries with respect to our drug candidates and their target indications. Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, certain of our product candidates may be eligible for marketing exclusivity. The Food, Drug and Cosmetic Act, or FDCA, provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. If market exclusivity is granted for an NCE, during the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, dosage forms or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and prohibits the FDA from approving an ANDA or a 505(b)(2) NDA submitted by another company with overlapping conditions associated with the new clinical investigations for the three-year period. Clinical investigation exclusivity does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of an NDA for the same drug. However, an applicant submitting an NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we are unable to obtain such marketing exclusivity for our product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products and launch their product earlier than might otherwise be the case</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates including our lead product candidate zervimesine can be challenged by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non- infringement. For example, if a third party files an application under Section 505(b)(2) or an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed in the Orange Book with respect to our NDA for the applicable approved drug candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our drug candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Periodic <span style="letter-spacing:0.2pt;">maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering any of &#160; our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">issuance of a patent does not give us the right to practice the patented invention. A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Third parties may also have blocking patents that could prevent us from marketing our products or practicing our own patented technology. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The risks described elsewhere pertaining to our intellectual property rights also apply to any intellectual property rights that we may in-license, and any failure by us or our potential licensors to obtain, maintain, defend and enforce these rights could harm our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we may license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our potential licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, zervimesine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. However, while certain research, development and commercialization activities may be protected by the safe harbor provision of the Hatch Waxman Act, other activities may subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside &#160; the United States remain confidential until patents issue. Therefore, patent applications covering our products could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products that are held to be infringing. We might, if possible, also be forced to redesign products or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Competitors <span style="letter-spacing:0.2pt;">may infringe or otherwise violate our patents or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as </span><i style="font-style:italic;letter-spacing:0.2pt;">ex parte</i><span style="letter-spacing:0.2pt;"> reexaminations, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, or post- grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could harm the price of our common shares</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because <span style="letter-spacing:0.2pt;">of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protects our product including our lead product candidate, zervimesine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The <span style="letter-spacing:0.2pt;">United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain &#160; patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Filing, <span style="letter-spacing:0.2pt;">prosecuting and defending patents covering any of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Because <span style="letter-spacing:0.2pt;">we expect to rely on third parties to manufacture our product candidates and expect to continue to collaborate with third parties on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants, independent contractors or we have wrongfully used or disclosed confidential information of their former employers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We do and may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Even <span style="letter-spacing:0.2pt;">if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In <span style="letter-spacing:0.2pt;">addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to rely on trademarks as one means to distinguish any of our drug candidates that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Certain <span style="letter-spacing:0.2pt;">provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, the NIA has provided grants to fund certain of our preclinical activities and clinical trials. If the United States or another jurisdiction decides that the NIA grant bestows rights to our patent applications, that could affect our ability to obtain valid and enforceable patent claims protecting our rights as they relate to our lead product candidate, zervimesine, our other product candidates and our NICE platform. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries. Such a loss of patent protection could harm our business</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Once <span style="letter-spacing:0.2pt;">granted, patents may remain open to invalidity challenges including opposition, interference, re- examination, post-grant review, </span><i style="font-style:italic;letter-spacing:0.2pt;">inter partes</i><span style="letter-spacing:0.2pt;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may be able to make product that is similar to product candidates we intend to commercialize that is not covered by the patents that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we, or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we or any collaborators might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the patents of others may harm our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Should any of these events occur, they could significantly harm our business and results of operations</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Even <span style="letter-spacing:0.2pt;">if one or more of our product candidates receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the safety and efficacy of our product as compared to other available therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the availability of coverage and adequate reimbursement from governmental healthcare plans or third party payors for any of our product candidates that may be approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">proper training and administration of our product candidates by physicians and medical staff;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">public misperception regarding the use of our therapies, if approved for commercial sale;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the revenue and profitability that our products may offer a physician as compared to alternative therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">limitations or warnings contained in the FDA-approved labeling for our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">any FDA requirement to undertake a REMS;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the effectiveness of our sales, marketing and distribution efforts;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">adverse publicity about our products or favorable publicity about competitive products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market opportunities for zervimesine, if approved, may be smaller than we anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">expect to initially seek approval for zervimesine for AD, PD and DLB and other age-related degenerative diseases and disorders of the CNS and retina. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if we obtain significant market share for zervimesine after FDA approval, the potential target populations may be too small to consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">do not currently have, nor do we plan to build or acquire the infrastructure or internal capability to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in conducting our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which we may not be able to do on reasonable terms, if at all, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We currently rely on third parties at key stages in our supply chain. For instance, the supply chains for our lead product candidate involves several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, but not atypical, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We do not have complete control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical studies or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, if approved, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#8217; or suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, if approved, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial- scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates, if approved, would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;">product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that our third-party manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would adversely affect our business, results of operations and financial condition</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">currently do not have the ability to independently conduct clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting preclinical studies, clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for &#160; the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of product candidates for the treatment of the diseases and disorders for which we have research programs, including AD, PD and DLB. Companies developing therapeutics for similar indications include large companies with significant financial resources, such as AbbVie, AstraZeneca, Biogen, Celgene (as acquired by Bristol Myers Squibb), Eli Lilly, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, Pfizer, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of age-related degenerative diseases and disorders, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221; The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates, if approved. Even if we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates, if approved, or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved, and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially- reasonable revenue and profits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad &#160; &#160;to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">currently do not have a marketing or sales organization. In order to commercialize our product candidates, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">If <span style="letter-spacing:0.2pt;">our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">issue warning letters, untitled letters, or Form 483s;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose civil or criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend or withdraw regulatory approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">suspend any of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">seize or detain products, or require a product recall.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. The Centers for Medicare &amp; Medicaid Services, or CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. There have been significant ongoing efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code or the individual mandate.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress that include aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which remain went into through 2031. &#160;The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">The Affordable Care Act, or ACA, has also been subject to challenges in the courts. In the most recent such challenge in June, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Under <span style="letter-spacing:0.2pt;">the Hatch-Waxman Act, a pharmaceutical manufacturer may file an ANDA seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications a paragraph IV certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. &#160;Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accordingly, if we choose to develop a small molecule product candidate, and the product is approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">False </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Claims Act (which can be enforced through &#8220;qui </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">tam,&#8221; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or whistleblower actions, by private citizens on behalf of the federal government), prohibits </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">person from, among other </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">things, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly presenting, or causing to be presented false or fraudulent claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the government or knowingly and improperly </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">avoiding, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreasing or concealing an obligation to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">pay </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">money to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">HIPAA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which imposes criminal liability and amends provisions on the reporting, investigation, enforcement,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">penalizing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;">for,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">among</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">things,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">knowingly</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">executing, or attempting to execute, a scheme to defraud </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefit program, or knowingly and willfully</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">falsifying,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">concealing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">covering</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fact</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statement, in connection with the delivery of, or payment </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefits, items or services by a healthcare benefit program, which includes both government and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">privately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funded benefits programs; similar to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal Anti-Kickback Statute, a person or entity does not need to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual knowledge of the statute or specific intent to violate it in order to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">have </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">committed a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">violation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations, including state anti-kickback and false claims </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">laws, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apply to our business practices, including but not limited </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">to, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">payer, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including private insurers; state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">U.S. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government, or otherwise restrict payments that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be made to healthcare providers and other potential referral sources; and state </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided to healthcare professionals and entities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursable</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicare,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Medicaid,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Children&#8217;s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Insurance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Program to report </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">annually </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to CMS information related to certain payments made in the preceding calendar year and other transfers of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; applicable manufacturers are also required to report such information regarding payments and transfers &#160;of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">value </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nurse-midwives</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">similar </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data protection and healthcare </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">laws </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governing the privacy and security of personal data, including the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.8pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union and European Economic Area (including with regard to health data</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">).</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">New <span style="letter-spacing:0.2pt;">income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti- &#160;money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In June 2024, the U.S. Supreme Court overruled the Chevron doctrine, which gives deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This decision may result in more lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In 2017, the U.S. Congress and the Trump administration made substantial changes to U.S. policies, which included comprehensive corporate and individual tax reform. In addition, the Trump administration called for significant changes to U.S. trade, healthcare, immigration and government regulatory policy. With the transition to the Biden administration in early 2021, changes to U. S. policy occurred and since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stock price may be volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">The <span style="letter-spacing:0.2pt;">trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. Our common stock began trading on the Nasdaq Global Market on October 8, 2021 and was transferred to a listing on Nasdaq Capital Market on March 14, 2025; since its initial listing, our stock has traded at prices as low as $0.34 per share and as high as $13.80 per share through March 13, 2025. In particular, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to acquire, license, or develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">innovations or new products developed by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with manufacturers, suppliers, licensors, future collaborators, or other strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our stock by insiders and stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our listing on the Nasdaq Capital Market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, product liability, or other litigation against us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including with respect to the financial markets in the United States and worldwide resulting from inflation, the COVID-19 pandemic and ongoing global and regional conflicts.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, the stock markets in general, and the markets for biopharmaceutical stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with the auditor attestation requirements in the assessment of our internal control </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to comply with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be adopted by the Public Company Accounting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oversight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regarding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandatory</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">firm</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rotation</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supplement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">auditor&#8217;s report</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">about</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">reduced </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosure obligations regarding executive compensation in our periodic reports,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">proxy </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements and registration statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">not </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being required to hold a nonbinding advisory vote on executive compensation and stockholder </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">approval </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">golden parachute payments not previously</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="letter-spacing:0.2pt;">, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we sell shares of our common stock in future financings, stockholders may experience dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because we expect our expenses to increase significantly in the foreseeable future and because, based on our current business plans, we believe that our cash, cash equivalents and income from our non-dilutive grants will be sufficient for us to fund our operating and capital expenditures into the fourth quarter of 2025. As a result, we may from time to time issue additional shares of common stock or other securities to raise capital. These issuances may be at a discount from the current trading price of our common stock. Our stockholders would experience dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders will experience additional dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As of March 17, 2025, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially owned approximately 15% of our outstanding common stock. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions<span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Sales <span style="letter-spacing:0.2pt;">of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. Sales of significant number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We have also registered or intend to register all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be available for sale in the public market subject to vesting arrangements and exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates may in the future establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In December 2022, we filed a registration statement on Form S-3 relating to the registration of our common stock, preferred stock, debt securities, warrants, units and subscription rights or any combination thereof. Concurrently with the filing of such registration statement, we entered into the ATM Facility, which provides for the offering, issuance and sale by us of up shares of our common stock from time to time for aggregate gross proceeds of up to $40 million in sales deemed to be &#8220;at-the-market&#8221; as defined by the Securities Act of 1933, as amended. For the year ended December 31, 2024, we sold 19,913,189 shares of our common stock pursuant to the ATM for gross proceeds of approximately $12.8 million, subject to the limitations of General Instruction I.B.6 of Form S-3. For the period ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park pursuant to the equity line financing arrangement. As of December 31, 2024, $34.8 million was available to draw pursuant to the Purchase Agreement. Any additional sale or issuance of securities pursuant to this registration statement or otherwise may result in dilution to our stockholders and may cause the market price of our stock to decline. Furthermore, new investors purchasing securities that we may issue and sell in the future could obtain rights superior to the rights of our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">We are also authorized to grant stock options and other equity-based awards to our employees, directors and consultants pursuant to our 2021 Equity Incentive Plan. The number of shares available for future grant under the 2021 will automatically increase each year by up to 5% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. Currently, we plan to register any increase in the number of shares available for issuance under the 2021 Plan promptly following the effectiveness of any such increase. If our board of directors elects to increase the number of shares available for future grant under the 2021 Plan, our stockholders may experience additional dilution, and our stock price may fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">of December 31, 2024, we had federal net operating loss, or NOL, carryforwards of approximately $38.1 million and state NOL carryforwards of approximately $12.6 million available to offset future taxable income. Of the federal NOL carryforwards, $11.5 million begin to expire in 2035, and $26.6 million can be carried forward indefinitely. State NOL carryforwards will begin to expire in 2028. As of December 31, 2024, we also had $3.8 million of federal research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2029, if not utilized. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the &#8220;ownership change&#8221; provisions under Sections 382 and 383 of the Code. An &#8220;ownership change&#8221; is generally defined as a cumulative change in the ownership interest of significant stockholders over a rolling three-year period in excess of 50 percentage points. Similar provisions under state tax law may also apply. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change. We may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. Such ownership changes could result in the expiration of our NOL carryforwards and other tax attributes before they can be utilized and, if we are profitable, our future cash flows could be adversely affected due to our increased tax liability. In 2023, we completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $0.6 million of federal net operating loss carryforwards expiring unutilized. We updated the analysis through December 31, 2024 and determined that it is more-likely-than-not that our existing net operating loss and research and development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additionally, under the Tax Cuts and Jobs Act, or the TCJA, NOL carryforwards arising in tax years beginning after December 31, 2017 are limited to 80% of taxable income, and may be carried forward indefinitely and are prohibited from being carried back. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, allowed federal NOL carryforwards arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to each of the five tax years preceding the tax year of such loss and temporarily suspends the 80% limitation mentioned above for this period. The changes in the carryforward and carryback periods as well as the limitation on use of NOL carryforwards may significantly impact our ability to use NOL carryforwards, particularly for tax years beginning after December 31, 2024, as well as the timing of any such use, and could adversely affect our results of operations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and second amended and restated bylaws each contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the ability of our board of directors to alter our second amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the required approval of at least </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;">6</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">2</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8725;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;">3</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">%</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">of the shares entitled to vote at an election of directors to adopt, amend or repeal our second amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:justify;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law, or the DGCL. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our third amended and restated certificate of incorporation and second amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;">Our <span style="letter-spacing:0.2pt;">third amended and restated certificate of incorporation and second amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our third amended and restated certificate of incorporation or our second amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our third amended and restated certificate of incorporation and second amended and restated bylaws, however, provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce this provision, if applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision contained in our third amended and restated certificate of incorporation and second amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We <span style="letter-spacing:0.2pt;">do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic or political conditions has in the past and could in the future adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our <span style="letter-spacing:0.2pt;">business is susceptible to general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, including rises in interest rates, liquidity constraints, failures and instability in the United States and international financial banking systems, inflation, recession or depression, or political disruption has and could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Key national economies, including the United States, have been affected from time to time by economic downturns or recessions, supply chain constraints, heightened and fluctuating inflation and interest rates, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies and overall uncertainty with respect to the economy. In particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#8217;s measures to slow inflation, the stock market has been exceptionally volatile. &#160;In addition, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Further, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the United States and China or the conflicts between Russia and Ukraine and in the Middle East, including any additional sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries against governmental or other entities in, for example, Russia, also has in the past and could in the future lead to disruption, instability and volatility in the global markets, which may have an adverse impact on our business or ability to access the capital markets. Additionally, significant political, trade, or regulatory developments, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. &#160;Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. Political developments impacting government spending and international trade, including changes in trade agreements, potential government shutdowns and trade disputes and tariffs, including tariffs that have been or may in the future be imposed by the United States or other countries and future legislation or actions taken by the United States or other countries that restrict trade, and protectionist or retaliatory measures taken by the United States or other countries, may negatively impact markets and cause weaker macroeconomic conditions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. &#160;In March 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. &#160;Similarly, in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. &#160;These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. &#160;Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. &#160;Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The <span style="letter-spacing:0.2pt;">trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We <span style="letter-spacing:0.2pt;">have incurred, and will continue to incur, significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Capital Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">We are subject to Section 404 and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are deemed to be a large accelerated filer or an accelerated filer, we will be required to include an attestation report on internal control over financial reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we identify any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could materially and adversely affect our business, financial condition, results of operations and prospects, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs and other third parties to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Capital Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred, and will continue to incur, increased costs and demands upon management as a result of being a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As <span style="letter-spacing:0.2pt;">a public company listed in the United States, we incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and The Nasdaq Stock Market LLC, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_33171304_7f70_44ea_b8b2_db357891f8db"></a><a id="Item1BUnresolvedStaffComments_685711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_874684d0_3c06_4d36_bd8b_b631cb2d4fec"></a><a id="Item1CCybersecurity_492794"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1C. Cybersecurity</p><a id="_Hlk160105269"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_MweEvaBAm0uxPBwZ09dBew" continuedAt="Tb_MweEvaBAm0uxPBwZ09dBew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cyber Risk Management and Strategy</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_7bPEZznDXE2NgkaY97kYuA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. has <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_43POmQF7XUq9E4pxSogMsw">implemented</ix:nonNumeric> and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_o8R502OJi0O7WG7kD-sbfg">We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises.</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_P0OofV7gokStjsH0upEpbw">We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate.</ix:nonNumeric> Employees are required to complete an annual cybersecurity awareness training program designed to raise awareness of cybersecurity threats across functions, as well as to encourage consideration of cybersecurity risks across our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As part of our cybersecurity risk management, we have adopted an incident response plan that has been designed to identify and manage significant events that may impact our information technology infrastructure, including those arising from or related to cybersecurity threats. We recently tested our incident response plan using a tabletop exercise with the goal of improving our processes and preparedness.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_z7XRxDJNEUyAJEhosdgigA">Although such risks have not materially affected, and we do not believe they are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition, to date,</ix:nonNumeric> we have, from time to time, experienced threats related to our data and systems, including phishing attacks. For more information about risks from cybersecurity threats, see the risk factor entitled &#8220;Significant disruptions of information technology systems and infrastructure, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition&#8221; included in Item 1A &#8220;Risk Factors.&#8221; </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_MweEvaBAm0uxPBwZ09dBew_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_-ZMEZMqEg0KERnzwJFmWZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Governance Related to Cybersecurity Risks</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_x0hCs0nBxUiZVygH0qoUbA" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_lCzb_cEJgkab_rtUwBA-Zg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our cyber risk management program and related operations and processes are managed by the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_sxLtDH0WI0G9ZHg_0BsKiw" escape="true">Chief Financial Officer</ix:nonNumeric> in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.</p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Corporate Controller reports to and meets with the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_JzT7dOZfj0SX5lPdKkHnIg">Chief Financial Officer</ix:nonNumeric> periodically to discuss and review risk management processes related to cybersecurity and potential cybersecurity risks, with input from the Company&#8217;s third-party information technology advisor as appropriate. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Group_9TPNBNlffUqD_HcO6hPUqQ" continuedAt="Group_9TPNBNlffUqD_HcO6hPUqQ_2" escape="true">The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter.</ix:nonNumeric> The audit committee is responsible for discussing cybersecurity-related risks with management, including the steps management has taken to monitor and control such risks, including our risk assessment and risk management policies.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_ARNaWKM7ekGnEMWi2ZoGgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><ix:continuation id="Group_9TPNBNlffUqD_HcO6hPUqQ_2">The Chief Financial Officer and the audit committee periodically <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_eGhg_RnnrEiV-r1lXHMXLw">report</ix:nonNumeric> on cybersecurity risk management to the board of directors</ix:continuation>. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_mQSl3ecybUWdCkFyLU-wFA" escape="true">The board of directors</ix:nonNumeric>, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.</p></ix:nonNumeric></ix:nonNumeric><a id="_8e5433b7_61d4_4a04_8148_e02778597fef"></a><a id="Item2Properties_347022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. We lease approximately 6,686 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_395fcacb_a4c5_480e_b5cb_70844d8a0c25"></a><a id="Item3LegalProceedings_272268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We are not aware of any pending legal actions that would, if determined aversely to us, have a material adverse effect on our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We may, from time to time, become involved in disputes and proceedings arising in the ordinary course of business. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations, and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0aa490a7_5916_4efd_a690_a3084578fed1"></a><a id="Item4MineSafetyDisclosures_494562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PARTII_331600"></a><a id="_6eafc964_fe9b_48aa_a481_e79225086c3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;CGTX&#8221; on October 8, 2021 until March 13, 2025. Effective March 14, 2025, our common stock began trading on the Nasdaq Capital Market under the symbol &#8220;CGTX&#8221;. Prior to October 8, 2021, there was no public market for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of March 17, 2025, there were approximately 61,972,946 shares of our common stock outstanding held by approximately 280 holders of record. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">We have never declared or paid any cash dividends on our common stock, and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our common stock may be limited by any future debt instruments or preferred securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Information about our equity compensation plans is incorporated herein by reference to Item 12, <i style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i>, of this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">There were no unregistered sales of our equity securities during the fiscal year ended December 31, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer or Affiliated Purchaser</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our registered equity securities during the fiscal year ended December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f0f8a216_5aa7_4b37_8edc_61d16175ae85"></a><a id="Item6SelectedFinancialData_500456"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;6. [Reserved].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cac4f777_2601_413c_986d_0fcaa0483932"></a><a id="_643054"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Item 1A, Risk factors, in this Annual Report on Form 10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. Currently available therapies for these diseases are limited, with few Alzheimer&#8217;s disease (&#8220;AD&#8221;) treatments, two approved treatments for geographic atrophy (&#8220;GA&#8221;) secondary to dry age-related macular degeneration (&#8220;dAMD&#8221;) and no approved treatments for dementia with Lewy bodies. Our goal is to develop disease-modifying treatments for participants with these degenerative disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2007, we have incurred significant operating losses and devoted substantially all of our time and resources to developing our lead product candidate, zervimesine, building our intellectual property portfolio, raising capital and recruiting management and technical staff to support these operations. As of December 31, 2024, we had an accumulated deficit of $175.2 million. We incurred net losses of $34.0 million and $25.8 million for the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging (the &#8220;NIA&#8221;), a division of the National Institutes of Health (the &#8220;NIH&#8221;), and proceeds from our initial public offering (the &#8220;IPO&#8221;), completed in October 2021, proceeds from our follow-on public offerings, sales of our common stock through our ATM (as defined below), sales of our convertible promissory notes, convertible preferred stock, simple agreements for future equity (&#8220;SAFE&#8221;) and stock option exercises. Since our inception, we have raised approximately $138.0 million in net proceeds from sales of our equity securities, convertible notes, SAFE, stock option exercises, IPO, follow-on public offerings, ATM, and equity line financing with Lincoln Park. As of December 31, 2024, we had cash and cash equivalents of $25.0 million. As of December 31, 2024, we had approximately $50.0 million available from obligated NIA funds for applicable expenses to be incurred in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On December 23, 2022, we entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc., or the Sales Agents, providing for the offering, issuance and sale by us of up to $40 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings (the &#8220;ATM&#8221;). For the period ended December 31, 2024, we sold 19,913,189 shares of our common stock pursuant to the ATM for gross proceeds of approximately $12.8 million. As of December 31, 2024, we have approximately $21.9 million remaining in gross proceeds available for future issuances of common stock under the ATM. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Lincoln Park Purchase Agreement&#8221;). The Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park to purchase up to $35.0 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023. We filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Lincoln Park Purchase Agreement. During the year end December 31, 2024, <span style="background:#ffffff;">we did not sell any shares of common stock to Lincoln Park</span>. As of December 31, 2024, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On March 14, 2024, we completed our follow-on public offering, pursuant to which we issued and sold 6,571,428 shares of our common stock at a public offering price of $1.75 per share. On March 28, 2024, the underwriters exercised their option to purchase 985,714 shares of our common stock at a public offering price of $1.75 per share. In connection with the follow-on public offering, we received net proceeds of approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of zervimesine for preclinical studies and clinical trials, as well as for commercial manufacture if zervimesine obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute zervimesine, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of zervimesine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Grant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0 million grant from the NIA to fund our Phase 2 (COG0203-START) study of zervimesine in participants with early-stage AD, an approximately $30.5 million grant from the NIA to fund our Phase 2 (COG0201-SHINE) study of zervimesine in participants with mild-to-moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase 2 (COG1201-SHIMMER) study of zervimesine in participants with dementia with Lewy bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income, net consists primarily of interest income from money market funds, offset partially by other fees such as costs incurred to establish financing opportunities.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Interest expense for the years ended December 31, 2024 and 2023 consisted of interest expense related to the insurance premium financing arrangement with a lender.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December 31, 2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our results of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations Data: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,676</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,480</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,290</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,528</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,238)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,242</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,966)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50,724)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,242)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,549</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,805</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,256)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 666</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 508</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on currency translation from liquidation of subsidiary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (195)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (195)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,941)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33,971)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,788)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,183)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our research and development expenses (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,495</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,752</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,559</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,241</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,890</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (649)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 810</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,503</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,693)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 198</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 430</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (232)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total research &amp; development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,676</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,480</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $41.7 million for the year ended December 31, 2024, compared to $37.2 million for the year ended December 31, 2023. The increase of $4.5 million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $6.5 million in clinical programs primarily related to increased Phase 2 trial activities with contract research organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.6 million in personnel costs associated with expanded research and development activities, and equity-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $2.9 million in preclinical programs, and other expense primarily due to decreased research spend; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.7 million in manufacturing related to lower costs with contract manufacturing organizations for the production of pre-clinical and future clinical trial supply.</span></td></tr></table><div style="margin-top:6pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $12.3 million for the year ended December 31, 2024, compared to $13.5 million for the year ended December 31, 2023. The decrease of $1.2 million was primarily due to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $1.0 million in equity-based compensation due to vesting of stock option grants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.9 million in professional fees driven by lower consulting and outside services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.6 million in personnel cost related to increased employee headcount, compensation and benefits; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.1 million in other expenses.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:12pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Grant income was $19.5 million for the year ended December 31, 2024, compared to $24.8 million for the year ended December 31, 2023. The change in grant income is correlated with the decrease in eligible reimbursable costs related to clinical trials incurred during 2024 as compared to 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Other income, net was $0.7 million for the year ended December 31, 2024, compared to $0.2 million for the year ended December 31, 2023. The change in other income, net was driven primarily by interest earned on money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Interest expense was less than $0.1 million for the year ended December 31, 2024, compared to interest expense of less than $0.1 million for the year ended December 31, 2023. Interest expense was not significant in either period.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20.15pt;margin:0pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFE, stock option exercises, follow-on equity offerings, sales under our ATM and equity line financing, and our IPO. Since our inception, we have been awarded grant awards primarily from the NIA in the aggregate amount of approximately $171.0 million and have raised approximately $138.0 million in net proceeds from sales of our equity securities, convertible notes and SAFE, stock option exercises, our ATM, our equity line financing with Lincoln Park, our IPO and our follow-on public offerings. The net proceeds from our IPO, which closed on October 13, 2021, were approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On November 15, 2022, we closed our follow-on public offering, selling 5,000,000 shares of our common stock at a public offering price of $1.20 per share. The net proceeds were approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On December 23, 2022, we entered into a sales agreement with the Sales Agents, providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in ATM offerings. As of December 31, 2024, we sold 22,772,263 shares of common stock under the ATM for gross proceeds of approximately $18.1 million. As of December 31, 2024, there was $21.9 million of common stock remaining available for sale under the ATM. In addition, in March 2023, we entered into the Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, giving the Company the right, but not the obligation to sell to Lincoln Park up to $35.0 million worth of shares of our common stock. As of December 31, 2024, we sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of December 31, 2024, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement. On March 14, 2024, we closed a follow-on public offering of 6,571,428 shares of our common stock at a public offering price of $1.75 per share. As part of the follow-on offering, the underwriters exercised their option to purchase 985,714 shares of our common stock on March 28, 2024, at a public offering price of $1.75 per share. The net proceeds were approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;">As of December 31, 2024, we had $25.0 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from non-dilutive grants, and net proceeds from our March 2024 follow-on public offering will be sufficient for us to fund our operating expenses and capital expenditures requirements into the fourth quarter of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 20.15pt;">Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of our ongoing and planned clinical trials of zervimesine, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to a pandemic, such as the COVID-19 pandemic, or other diseases, macroeconomic conditions, global or political instability, such as the ongoing global and regional conflicts, inflation, or other delays;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we develop, in-license or acquire other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, timing, and receipt of any future NIA grants, or any changes to our grants based on political or regulatory pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations to commercialize zervimesine or any of our other product candidates outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 6pt 0pt;">Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the effects of the COVID-19 pandemic or other diseases, the ongoing global and regional conflicts, inflation, liquidity constraints, failures and instability in U.S. and international financial banking systems, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our cash flows for the periods indicated (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,474)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,018)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (147)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,565</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,521</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,913)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,640)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the years ended December 31, 2024 and 2023 was $28.5 million and $16.0 million, respectively. The change in cash used in operating activities of $12.5 million was primarily driven by an increase in net loss of $8.2 million from a reduction in grant income, combined with increased research and development expenses during the year ended December 31, 2024. Additionally, decreases in operating assets and liabilities of $3.5 million driven primarily by a decrease in grant receivables, and decreases in non-cash adjustments of $0.7 million from decreased equity-based compensation expense drove increased cash used in operating activities for the year ended December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, we used less than $0.1 million and $0.1 million of cash, respectively, for investing activities related to purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $23.6 million and $4.5 million for the years ended December 31, 2024 and 2023, respectively. The change in net cash provided by financing activities is primarily related to net proceeds from the issuance of common stock in our follow-on offering in March 2024 and under the ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contractual Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The following table summarizes our contractual obligations as of December&#160;31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3&#160;to&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More&#160;than&#160;5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 226</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 249</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 130</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 605</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 505</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 249</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 130</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 884</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, we entered into an insurance premium financing arrangement with a lender whereby we financed $0.7 million of certain premiums at a 8.65% annual interest rate. Payments of less than $0.1 million are due monthly from November 2023 through October 2024. As of December 31, 2024, there was no outstanding balance on the loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2024, we entered into an insurance premium financing arrangement with a lender whereby we financed $0.4 million of certain premiums at a 8.65% annual interest rate. Payments of less than $0.1 million are due monthly from November 2024 through July 2025. As of December 31, 2024, the outstanding principal of the loan was $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have entered into operating leases for office and laboratory facilities under non-cancelable agreements that run through May 31, 2029. The amounts reflected in the table above consist of the future minimum lease payments under the non-cancelable lease arrangements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, we entered into an agreement to lease 2,980 square feet of office space in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. The annual base rent under the lease is less than $0.1 million throughout the term of the lease. Total payments due over the term of the lease are $0.2 million. Additionally, on August 31, 2022, we modified one of our existing lease agreements with the landlord for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On July&#160;1, 2021, we entered into an agreement to lease 2,864 square feet of office space in Purchase, New York. The lease has a term of 89 months and commenced on December 9, 2021. The annual base rent under the lease is less than $0.1 million for the first lease year and is subject to annual increases of between 1.82% and 2.04%. We provided a security deposit in the form of a Letter of Credit in the amount of less than $0.1 million pursuant to the terms of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development and other services and products for operating purposes. These contracts typically do not contain minimum purchase commitments and generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses include, among other costs, personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable advance payments for research and development costs are deferred and expensed as the related goods are delivered or services are performed. The estimated costs of research and development expenses incurred, but not yet invoiced, are recorded in accrued expenses on our consolidated balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs, contract manufacturing organizations and other companies under these arrangements in advance of the performance of the related services are recorded as prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for stock options subject to time-based vesting on a straight-line basis over the requisite service period and account for forfeitures as they occur. To the extent any stock option grants are made subject to the achievement of a performance condition, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Term. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected term represents the period that the stock-based awards are expected to be outstanding. As we do not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk-Free Interest Rate. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Volatility. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected Dividend Yield. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The expected dividend yield is zero as we have not paid and do not anticipate paying any dividends in the foreseeable future.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">See Note&#160;9 to our audited financial statements for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested time-based vesting awards was $2.1&#160;million, which is expected to be recognized over weighted-average remaining vesting period of approximately 1.9&#160;years. As of December 31, 2024, the total unrecognized compensation expense related to unvested performance-based vesting awards was $0.5 million, which is expected to be recognized over a weighted-average remaining vesting period of approximately 0.8 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">For a description of recent accounting pronouncements, see Note&#160;2 of the notes to our audited consolidated financial statements for the&#160;year ended December&#160;31, 2024 included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our IPO.</p><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As a &#8220;smaller reporting company,&#8221; as that term is defined in Rule 229.10(f)(1), we are not required to provide the information required by this Item. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_91ce3621_ac58_4f1b_8bb7_e5f143c6a8f4"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk130366833"></a><a id="_f155cb79_d984_4de9_b18d_14154ac87c84"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">As of and for the years ended December 31, 2024 and 2023</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42)</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bb4de708_cd60_4fc4_a6ea_bf92cbbb72e5"></a><a id="ReportofIndependentAccountingFirm"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:center;margin:0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:18.0pt;background:#ffffff;margin:0pt 0pt 18pt 0pt;">To the Shareholders and the Board of Directors of Cognition Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of Cognition Therapeutics, Inc. and subsidiary (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">The Company's Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">March 20, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_25649f5d_d4b1_46ad_89e8_7fd8d13d25b1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_54f3b420_0b09_47cd_9448_1231a4edc769"></a><a id="Tc_Ae3r5HChg0izVabK_WmtbQ_2_2"></a><a id="Tc_RFnARshwmECD_4btwt8m0w_3_2"></a><a id="Tc__glpHYWOIkOjtAkl8QPwjg_3_5"></a><a id="Tc_xDD9cIbv2E-TYjxIcGBmFw_4_0"></a><a id="Tc_9xQJOx6ttU2UuvXaK5E_Iw_5_0"></a><a id="Tc_wtp9EbtCYk6X9XZaDLE13w_6_0"></a><a id="Tc_XTbxVJmWkUeDNTzfsccVIg_6_2"></a><a id="Tc_NL0iWm37CkS7LGwE3u0_Ew_6_5"></a><a id="Tc_e4BHqvBl2U-OuDQSOOOolA_7_0"></a><a id="Tc_LCpTia0ubki3aEMY8LZSTw_8_0"></a><a id="Tc_UM8auc7AQUWc_0MT8EQZzw_9_0"></a><a id="Tc_OcGYpLdUYkS79puvUwW4_g_10_0"></a><a id="Tc_4zPShoiky0S6p9Ci_Wz1Sg_11_0"></a><a id="Tc_aJUevz4BgEK07pihaWD8UQ_12_0"></a><a id="Tc_wGvt36z5akGDxjr1lJfCHQ_12_2"></a><a id="Tc_44lKnqX0WEmhX5Gcf5OFkw_12_5"></a><a id="Tc_npNp_1uBXEKspMjLMhiEQA_13_0"></a><a id="Tc_YVvxLUquuUeVb8T313McUg_14_0"></a><a id="Tc__qzm47klc0a-dBVnKOP6ew_15_0"></a><a id="Tc_sTUAhcSIkEGHqD5p3OU-rg_16_0"></a><a id="Tc_WldwbxH7HkW9m6SycKOfrQ_17_0"></a><a id="Tc_3bHMXNA1bUWfe65tdI8CIQ_18_0"></a><a id="Tc_Iyr3uxC4HE2EZiWhqDMArw_19_0"></a><a id="Tc_movqVH3HMk--abQZDVtWJA_20_0"></a><a id="Tc_F-nSBCEfGEyL_D21liLtew_21_0"></a><a id="Tc_32Mer1CHLEerY4fF_ih2Tg_22_0"></a><a id="Tc_Uk8V4W-aHEioAd9XqdyY5Q_23_0"></a><a id="Tc_HHSLOHxHq06nQdkgc3zA3w_24_0"></a><a id="Tc_K5nCBg1oDUG-ke1Kw3BDmw_25_0"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a_2"></a><a id="_145dec51_a9c8_448e_a961_684cfd97c27a_3"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_2"></a><a id="_848a0fad_bf8f_444c_8c47_7964842b5682_3"></a><a id="Tc_y4QO_6usk0KwbyoHKDgUfQ_26_0"></a><a id="Tc_oE-DOuSYsEC0E6gJgrWTnw_27_0"></a><a id="Tc_vuvSB2T-hEK6udotMTQzvQ_28_0"></a><a id="Tc_vbWs23VlukKazcKOJX37xA_29_0"></a><a id="Tc_JNc5Yth350y8hmUPYyp5Yw_29_3"></a><a id="Tc_uPZXc2y8bESBRkXGra0-cw_30_0"></a><a id="Tc_m35Bk5BXGUeEXvRnNW3X-w_31_0"></a><a id="Tc_50TdibN45Ear6NpS1Gz7ng_31_2"></a><a id="Tc_HJdRTZn4i0qKUO9-mf-OGg_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_KYBX0BN9W02B5fmQ6z8aJw_6_3">25,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Ow1ftq1pMkaYtV8_G1GU7Q_6_6">29,922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_xRzvqcjphUCjVPji1c39Rg_7_3">2,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="3" id="Tc_S82APCHRwUajyuhGFbmdyA_7_6">1,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_TWPHX26qgE2CYinoFIUhjw_8_3">1,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_aHigSl2r7kGneR1JcXhGfA_8_6">3,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Nyf2KQO-PU-PZpOffkHO5w_9_3">29,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_7MS7BpPtkk6ngIgMxzYfCw_9_6">34,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_WMcx1LBViUiFw4O5rNGxIA_10_3">181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ljLVruDTe0WT7WEV9Hq9TQ_10_6">284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_OhG5uS93DkO9iB4eJ4n3XQ_11_3">498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_3gkJ6OrsdkmtNB3PUSJpCw_11_6">657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_C3gbwFQIB02OZQkp6FNxxQ_12_3">30,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_p5TWqtwm7kiLSgpAgEQy6A_12_6">35,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_VFC3gAYXuEug1p7IuVDeyA_15_3">1,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_OKEX7W_CRUyuWe_mYMsUyA_15_6">3,695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ojDft0olqUa4ueU_ukQHRg_16_3">7,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_M2PqWPkoSEWxeZ6L6HEeyg_16_6">4,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Deferred grant income, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_S0-mE5n3JkeCqHsDd6t7Iw_17_3">1,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Tc_kWRiFtJAwUu9MdyfDFt46g_17_6">1,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_aevqQlGbHEyHRtphhOD3Sw_18_3">193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_2uJ7jQwGr0aQNXN_55Sgyw_18_6">174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_7f2kO6LHLU6yCJvO3oj9OA_19_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_BzQBLlOJREiR1TMM4g-tXg_19_6">544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_piIoLKs540CmwIoRAB1axw_20_3">11,142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_HoCOmrLT6EO5LZwu3qW4Ug_20_6">10,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_zqM97PvO-0mjx7-OJlFAmg_21_3">342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_S-FtkagpFkeeFhvMeCqOWQ_21_6">520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_2PCXJL1_cUG4pN4o_NDfKA_22_3">11,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_zJL0nr7jd0SqOstCSvJp8A_22_6">10,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_iBlDNZYbvkm10m2u0bmuQw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr__NXL8OqvpUumnpwQKMVQxA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_jHmfYhBlUUWuCMW0a11DvQ"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_0jWFiaIFRk-eOv1gHhtRcw">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; no shares issued and outstanding at December&#160;31,&#160;2024 and December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ubdKuvpJkkaqTeUDY-0ehg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eE1i52D_kU6U1m60PuvXSw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;">Common stock, </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OaIyhNKdokaW1jDAik5RaA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_W9m4RdndxkGcMZMRVa21fw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_NWjklu6yQ0qOxwZ2OXZDiQ"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_puGP3Bl-2kGhVjebQptCRw">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_rVhitrU-s0uEFPTo_tF8YA">59,854,877</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_qLmiIJMY9kyU5ENdFiQmHQ">32,165,478</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_zXsuiyXa10mQAw1pz6nYnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_HBFneHzl_k27D95-1wTmDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at December&#160;31,&#160;2024 and December&#160;31,&#160;2023, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_E2G2OjzO1UuhgyGpFtLnQQ_26_3">60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_emMnTLds8EaZt1ElDsI8FQ_26_6">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_m8xkWY_3ikqiY6XmlO2drg_27_3">193,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Q6_q4NGPZkS7jr0Mzn1Z6A_27_6">165,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_GnBqF7LDDE6uO37z3jxz7Q_28_3">175,160</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_iruigIXhj0KK8W-wYYqFig_28_6">141,189</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_OJC2g6YuTUGyx5RR4qFMQQ_29_6">195</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_B53PKZjyH0-xkAMuXZlyJQ_30_3">18,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qh3Ev9-3gk6yXQ4b4PMXaA_30_6">24,474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Vty5N8Rxgk68XmGodiWOQg_31_3">30,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_XbPwPacjdUKowpKizU4NOw_31_6">35,163</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e28c1ceb_b495_465d_aac6_6a6d54c1513c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. </p><a id="StatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_cbd2e53e_0778_4387_a69a_47f92c968321"></a><a id="Tc_cUpp8UoXNUyOH6TkFEJTfw_1_3"></a><a id="Tc_gZIBLociwUOYvBpvXzx3iQ_2_3"></a><a id="Tc_WrLNRegBMUK2eNi9VLWfJQ_3_3"></a><a id="Tc_qVWYMbKEUUi6ee5JSMRNGw_3_6"></a><a id="Tc_5f9fCgizrEmcEU3-yDNxBQ_4_0"></a><a id="Tc_dXV44iJj10ulgJf7BFjQQw_5_0"></a><a id="Tc_qUxHAk6Fpky5AIZnY1ttvQ_5_3"></a><a id="Tc_MUKrBWf_cEGSTZzYNSysnQ_5_6"></a><a id="Tc_IoaJhTZpjEKksUPVbGE6Wg_6_0"></a><a id="Tc_6ab0iMbpUUuMIxCZ7jbO2g_7_0"></a><a id="Tc_i_dKWA5YVEG6UMXcjV5_tw_8_0"></a><a id="Tc_26y_B3ynukmKkv3t3bgrVQ_9_0"></a><a id="Tc_5QP_UeSA2UC_jBC4aqOEYw_10_0"></a><a id="Tc_Wzbkea3E_0iT0UAnFy6G_Q_11_0"></a><a id="Tc_CxAQsHiWWkijDY-AOyLVhA_12_0"></a><a id="Tc_gqdoywrLpEybj69Uq11eFw_13_0"></a><a id="Tc_4sQEhw2xvE-2h9LifW63wA_13_7"></a><a id="Tc_54ziVpSfV0er794VmHYAqQ_14_0"></a><a id="Tc_0qUjV8mHikuLjg3aEkcXHQ_15_0"></a><a id="Tc_kGp8Pm31F0WNIZ0sFtxkXQ_16_0"></a><a id="Tc_jk90kKHP8U2WFCaK5Nrg-Q_17_0"></a><a id="Tc_iSFucaIqNkWZSeZTSJXbWQ_17_3"></a><a id="Tc_taJAuMBBBE-AFi1_oiyyYA_17_6"></a><a id="Tc_rHESymLPskakX3aTolPLXA_18_0"></a><a id="Tc_w0dJ2u3fRUWVTyzzjMR7eA_19_0"></a><a id="Tc_VvPH5Bt31EOF5ZP0Uv-QVg_19_3"></a><a id="Tc_d7DUWTwhfk-v2gTjxAbmNw_19_6"></a><a id="Tc_2To3lq4FJEqNm5L5abSqRg_20_0"></a><a id="Tc_H7VFqQKuMEqvbR6T02KTkQ_20_3"></a><a id="Tc_wKetzSAPMk-vxLJFynmWfw_20_6"></a><a id="Tc_g8xJ8MshBUaBqCxAljEDlQ_21_0"></a><a id="Tc_rm1nz3uGK0-fmq5ahALcIg_22_0"></a><a id="Tc_ofNKkyPB3U2Yf7v-ZB5qjA_23_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the&#160;Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_vFSUskrTxU-3zlA7gB_16Q_5_4">41,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0HHyikgs20y6pa8t1nnIxQ_5_7">37,196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_KTtgisTyVkWdQhGins6qFA_6_4">12,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_uoLrgXnoqkSwrfpP2j1zBQ_6_7">13,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_V6NhkpmS_0u_-sbho1wmTA_7_4">53,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_U1CRA2wRYUCEWRVFWz1InQ_7_7">50,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_r-CXQkeHfUG0LPKNBQu8GA_8_4">53,966</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_bbRWp7frIUONc0RrAl8-Yw_8_7">50,724</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:GrantIncome" scale="3" id="Tc_mwchgxzsCE-OTu804b9WAg_10_4">19,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:GrantIncome" scale="3" id="Tc_1NbbwFzoRkiy8LYyRn4xcQ_10_7">24,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc_6YcHT9W1oUWnm4yfqJbEvg_11_4">666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc_uSzfohJRaECfgrZkJFEmkA_11_7">158</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" sign="-" scale="3" id="Tc_efbWzqCkZ0mauk7gypyRLg_12_4">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" sign="-" scale="3" id="Tc_4pB7OOminUGW97CDfA_kfA_12_7">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss on currency translation from liquidation of subsidiary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="Tc_biTluad0K0ycQvLxzqny4w_13_4">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_XTJK3oTdK0Wf1rSY-VT09w_14_4">19,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_rmK-Nlhmt0yFyyiecCOEZg_14_7">24,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CzOQYH9ALkekLW1tQVPfJA_15_4">33,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_vfH4zbAQX0GBMvpfpTRIiA_15_7">25,788</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency translation adjustment, including reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" scale="3" id="Tc__FKBKQiwOEO8iYby3HRJsg_16_4">195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" scale="3" id="Tc_FFxZ3Qytbkqd9NiRY4axJQ_16_7">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_njyRfcqQMkui91a6UdMhDg_17_4">33,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_FFPfHe6QrECt3LpB3IWQ4Q_17_7">25,784</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_SPcidUsVw0ednS7US4ZsAQ_19_4">0.86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_M6isVoZqvkKTptRfRJZTbA_19_7">0.86</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Fq6iDrSQy0eG7Eesm64vfA_20_4">0.86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_UOP9NApCxUW1ic8s99ZPGQ_20_7">0.86</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7NnNomaHVkyaU9D9efmwNw_22_4">39,730,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2Z2oAbNbwUqRHJrlrrvOlA_22_7">30,029,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_DGKYr5P9mEOPgXg88OM5jw_23_4">39,730,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_drgYhUbpYEKFh4ydAzVGAQ_23_7">30,029,087</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk191644334"></a><a id="_5de848a4_4a9e_4e20_8b2b_f0e3b008d849"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. </p><a id="StatementsofStockholdersEquity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f1d84c4c_1bc3_480b_881e_038b6f5c88aa"></a><a id="Tc_5BVOCuIqREmRsH0ikfrrKA_1_12"></a><a id="Tc__zbaQbgGCUqFZA65nauT7g_2_6"></a><a id="Tc_f2iuUkLat0yLLWfIaMKpiA_2_12"></a><a id="Tc_fd8vQQmGA0q4SIG5KWRoWQ_2_15"></a><a id="Tc_i86yYB9oOUSyHpFdeOBW3g_3_1"></a><a id="Tc_jQlTcF2Uc0Gyr8qxovboMg_3_6"></a><a id="Tc_9wUgFqSyMUajKM_INMJoaw_3_9"></a><a id="Tc_OYqVgqgCQkC9_AyHdhC-iw_3_12"></a><a id="Tc_LeCXXBE-6U-phv99LK6p3g_3_15"></a><a id="Tc_JuLJKSMl7kG1aIx9aAUMIw_4_1"></a><a id="Tc_c7Vb42eAOE-L07uLk2pElg_4_3"></a><a id="Tc_jvxQjo6KxkOICg8c0wBy6g_4_6"></a><a id="Tc_de202BGK5E-PqpE3-s_IqA_4_9"></a><a id="Tc_N7QHCRk-iEOfKTNIsyDJhw_4_12"></a><a id="Tc_iijJh6OQKES80uPzMiWrdw_4_15"></a><a id="Tc_BYDe4hGecEOBU6HxtKMhcw_5_0"></a><a id="Tc_RM8VCFmziUGpoUkQTJoTxg_5_3"></a><a id="Tc_47SlZB3stE2NHla-xJKUxA_5_6"></a><a id="Tc_K2fq73JZwkG_N6Q8G1YRyw_5_9"></a><a id="Tc_aBvYmQBBt0Ss62wZmZ1lkw_5_12"></a><a id="Tc_YPYJjFJ-c0ObQjqYOR90rw_5_15"></a><a id="Tc_f9joWHRq00ecLiv44HbGnA_6_0"></a><a id="Tc_878dQmQc-Eefz0tpMkqsBQ_6_10"></a><a id="Tc_MXiVECbiYkWfayhXuoeqbQ_6_13"></a><a id="Tc_K7rrRAYJZUiTlXAKOwSRng_7_0"></a><a id="Tc_DbCYtqjCl0aLdlOKXFB-DQ_7_4"></a><a id="Tc_DGT-m5eAaE6sfCwlFyUPzg_7_10"></a><a id="Tc_w4nE7E6yTE--hPxpIPYTuQ_7_13"></a><a id="Tc_mHM8TG_y_0SPH_ixrK6lGw_8_0"></a><a id="Tc_wF8CGdbHlEmtzHJnvsyq1w_8_4"></a><a id="Tc_UqUVjfXGbU-vBg6qXj5Tpg_8_10"></a><a id="Tc_dC_uZsN3AUa2gDqONFKhfg_8_13"></a><a id="Tc_mPcns7dyhkmllC4D_H5yHQ_9_0"></a><a id="Tc_H6tA7_37EUWoIdQ3VMvvNQ_9_1"></a><a id="Tc_CNndA_zR8kmvXQjkECSaKA_9_4"></a><a id="Tc_9w9_TK87bkaEdtUUTvj49w_9_10"></a><a id="Tc_efSWifayrkmN_sZ0ZpRqwA_9_13"></a><a id="Tc_kvfm65G5l0ilcmlXMOEgtQ_10_0"></a><a id="Tc_PhA0E8MUEECeR9VaPcDs-g_10_1"></a><a id="Tc_j-LlQMsIjUmJNOQyGnWzZA_10_4"></a><a id="Tc_v3VAeYb9GU2bOGVB0fZ5Pw_10_7"></a><a id="Tc_dbwkygETaE6tTt5Gch3Rqw_10_10"></a><a id="Tc_AXHbDtEeukaHCc4sXXdjeA_11_0"></a><a id="Tc_8t5sUxAZpU2LOU5zUfcFFQ_11_1"></a><a id="Tc_91zC8gGQ_U2q7Se5bt0wpA_11_4"></a><a id="Tc_ryH2NsJcOE-4HH100UsalA_11_7"></a><a id="Tc_Hy6l_vQna0m7wit9-60hBA_11_13"></a><a id="Tc_N6l4rVL27kiSKocGWoOSIw_12_0"></a><a id="Tc_iaGaKZa7SkSeU1KvHTKpKg_12_3"></a><a id="Tc_BQGLN8JlsUGPa0-PER8eRw_12_6"></a><a id="Tc_b5OPckPT-EyXSRIJfEcZIQ_12_9"></a><a id="Tc_i5osiTmX6E6PzO5xo1ZGPQ_12_12"></a><a id="Tc_NDHkpydUVEqK31e6Elvjfw_12_15"></a><a id="Tc_GYmnopIEZkWpC8bWj1-iTg_13_0"></a><a id="Tc_TDrMw8ALPE2HOrmcWW_n3g_13_10"></a><a id="Tc_VPV_6l-9sE-4BmLlfH-q1g_13_13"></a><a id="Tc_04qO6ix1GUSQR8G8_6-ecg_14_0"></a><a id="Tc_NdUALKxNqkyQFJPrvtYvpA_14_10"></a><a id="Tc_0gyOztQjn0qgMIF5ZNNyeQ_14_13"></a><a id="Tc_7jPcnfLaB0a8QB3NFNSJqQ_15_0"></a><a id="Tc_XARHFoQn4Um9WeNxCkdbGw_15_4"></a><a id="Tc_W4zWaad1U0qMZv3NNluA_Q_15_10"></a><a id="Tc_Q4wJ5BGzm0ubeWNB71-trQ_15_13"></a><a id="Tc_SfhwNMm5akqY7pnnGcagZA_16_0"></a><a id="Tc_EfTcDfkcHk6CdChWW5l8TQ_16_4"></a><a id="Tc_7VPNAX_yLEqKDbXdhpy4fw_17_0"></a><a id="Tc_P0myhzwW9k-2Q5r47pEB5A_17_1"></a><a id="Tc_EIcUj-FZakaOtuviOziEWA_17_4"></a><a id="Tc_7P4wO1iEBUKulCW0s5DOug_17_10"></a><a id="Tc_-K1sn1bozUO_e-raVpxYOA_17_13"></a><a id="Tc_Z7QABefQ70GEfAEOHLy9mg_18_0"></a><a id="Tc_-fMy_CG0Qk6hkfLastUZjQ_18_1"></a><a id="Tc_m1wiwvr7pEWDvT9psyhANA_18_4"></a><a id="Tc_vRFtbb4pvU2E3ft87Mec7A_18_7"></a><a id="Tc_vEIpoHg1A06x3quKvJ6FCQ_18_10"></a><a id="Tc_rY4iTQD4BE-j5S5ODI-6_g_19_0"></a><a id="Tc_20p1WD8l0kmborMyJ6l2GA_19_1"></a><a id="Tc_E1RCu6ynfU2oNoCwuUMVsw_19_4"></a><a id="Tc_C6k3cxGvuEKjsb2lXY07cQ_19_7"></a><a id="Tc_cAI2UCq-PEi1Wvg-0BEvOQ_19_13"></a><a id="Tc_MTJ6R5TNsUiQxcuBzaTEoA_20_0"></a><a id="Tc_do_BoWNQWkiTyxPzrAIX1g_20_3"></a><a id="Tc_lxWdCSNRmU63McY3U5bd5A_20_6"></a><a id="Tc_eFAsZ9c_FU2S-tKbAqE9dA_20_9"></a><a id="Tc_idOWy_Gv0EO7_T7ppj8-Uw_20_12"></a><a id="Tc_RfXb1C8b70GJVwBsudaAgg_20_13"></a><a id="Tc_dL0HwkMNXkyO-sPjzRnw3g_20_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.2893448%;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__zcPJziEiUK1kDuDCRM8tw_5_1">28,991,548</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1fOibsT4wEevrVfYXe6GIw_5_4">29</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nl1R_JUOlEOS0QXSjoW9fQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hIkYKCgvLE29UW4iO5cgBA_5_7">155,820</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3GnPNkowakSAyYLtWMwr0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Czyp7xUGLUq2uuO8dJ9RnQ_5_10">115,401</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3B_2Jrx_WkO-PPVkUC_P7w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VOtdr8bNxE22AV_0IYdUWQ_5_13">199</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_O6cH3K8Aakq6vqmd7e_bVA_5_16">40,249</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock under the at-the-market (ATM) sales agreement, net of commissions and allocated fees</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_t8Zf-cOc0UGKTTyAsZYwhA_6_1">2,859,074</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WzzkpVELUUyVSv_U5L-pFw_6_4">3</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_afVnL3lb_EefS-cEGQ-jZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Jpc3R2aeNUeiLIW74I55lQ_6_7">5,124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_jc5HZhHN2ECw-bztr90cgw_6_16">5,127</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock as commitment shares for equity line financing (Note 8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_kEmqrIBPs0isxn2okOqBaw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_e4I1zFIrskiZvKyKhShR5w_7_1">189,856</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_xK7RvHxIJE-jH9loOV_v-A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_RvGd-xyNeEWA18b2tH6WYw_7_7">318</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_-GLOfDTDzEKj9t_Ctbu54Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_8zbIWy9j-EOzur3uQFt3Iw_7_16">318</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock related to the equity line financing</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_alChYiDeMkO9Ns2J7rmKPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ODlnGFZD8UCClcfFpisD2g_8_1">125,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_JcEslU1uvkSAJq_z28KWWg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_qsiEPubfWkyHQSX4CyW73A_8_7">210</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Vze4JiUZ4UmUJitt4WZ6Aw_8_16">210</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DNorcmrr9ECUu3JPRu-YqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_KMmRysrjRkKnsbvTfKDCmw_9_7">4,354</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zcs6Mr-yHUakDhDuVhNcoA_9_16">4,354</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Other comprehensive gain</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3QteG7Thn0O_-zTGlyV6yQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_ZEBU2ND0QkeLhwplXck5Tg_10_13">4</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_9w6S222wDECHw9KScPIblA_10_16">4</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kPOqaHj9s0i-PXHu6jVcxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PQ0I8Rp-MU60Z3ZYcSRIkQ_11_10">25,788</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_SNUcA8nP9UKt-SJnV4uVSA_11_16">25,788</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wF82MNzH8kGdoR2xK6Bl4g_12_1">32,165,478</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_M96xKsssaUeSNN8MdO9oJw_12_4">32</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jrmNuQdewkuQ3tIVwaV50A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__RFV1x3JKkKiMIP57AwRvQ_12_7">165,826</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yK322Z1bEU6-t8t4b8J1mg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1Y-D9Q_au0GFzyQyLrBAwg_12_10">141,189</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rv7evwVvGkaNCERTqKzo4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FiPJcjcteEGIlW7HG--2aA_12_13">195</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uTQP7q62BEKbC4zsEBn_6A_12_16">24,474</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock in follow on public offering, net of discounts and issuance costs of </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_DdYdpDCBWUitS-wn2cJKQQ">1,329</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_SK6sUdJCEU26eN6m5fLGRA_13_1">7,557,142</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_X32cKDNA_Uq1lc0X3emK-w_13_4">8</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ZUcWSgSFkE2BmPuI7ICu_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_TC5Sm4tHSkiR_Q5STXJ-Pw_13_7">11,888</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_kvxd1a54fk-uv44yHz27nQ_13_16">11,896</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__lPoLpYzaE25XNW6eTM-Aw_14_1">19,913,189</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_m-B2Nbq3j0aOY4hhlu2DUA_14_4">20</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_2iDgdVMqskqqMckLxknrRA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_jKLwZVt_5ky_38a9YeKogw_14_7">12,434</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Q18M_iEPs0GerGyj6W-Ing_14_16">12,454</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_jRWdRQ2nq0mpessnxLTvMw" decimals="INF" format="ixt:num-dot-decimal" name="cgtx:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_L2qPTAUii0ua5St0UMVdNw_15_1">125,718</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_wg_K7cTOH0eZ6E1DJZAUYA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" sign="-" scale="3" id="Tc_lBXbsXaCWkmNipRBA6MzAQ_15_7">128</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_r74j6G3Wr0ynHLld-HIi-A" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" sign="-" scale="3" id="Tc_fmRPYJeaRE-byMrQ18VtLg_15_16">128</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Exercise of common stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7tSX_qWQF0CIUXnoJZQz_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_eRkDR21W60eqpo-2Pi4y5g_16_1">93,350</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_bzq6nP-hSUGhkmo5AI3CKw_16_7">82</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_niFwyRZ440WnnMWg7MIclg_16_16">82</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Equity-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bcB4rVZ4v0KleE2rVZjbZQ_17_7">3,748</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_7IZvn4Q8dEqH0aRH2YvViA_17_16">3,748</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IEL8SilDn0ONwVf8eHAjSA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" scale="3" id="Tc_jPMmxBSPu0mg3kpODelg-w_18_13">195</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" scale="3" id="Tc_iEmSbenlN0CBwXV9AatuXg_18_16">195</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5QUb6H7RJEmzgSXAtn5DaA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xUG4ewqqcUmVjYP061lo_Q_19_10">33,971</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jEmsOJeSbEaaoWUs0DFmCA_19_16">33,971</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Balances as of December&#160;31,&#160;2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_qYiGMJtl40mT4WyBE2zobw_20_1">59,854,877</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jTtspkdpCEyNK8Ky_NpQag_20_4">60</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vT5FlUfgiEqOtSWVevEpAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YUxUe7YNhEew62G_CYd7lA_20_7">193,850</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AJXFpogTYkiyXpWcopwd_A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_L9YfWQlTQkeKqbqKSDlOEA_20_10">175,160</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bAQcfFAlhUmMbxJg36ZNqQ_20_16">18,750</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c4d80279_e330_468d_98c9_742dd0a88e35"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC. </p><a id="StatementsofCashFlows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bb87a9fc_583a_4719_a1bb_e1fbd8ec0021"></a><a id="Tc_Q7VmVkAMlkavMx3IDWNxwA_1_2"></a><a id="Tc_Xu15lOg9PkCzM9ZTc-zpQw_2_2"></a><a id="Tc_cnZAwqDLGEq2eRoQRmjq_A_2_5"></a><a id="Tc_lgK8s0rCRkqPpXrZtcJ5WQ_3_0"></a><a id="Tc_f-iQ9pyNJ0K5W5ZrwVF2pA_4_0"></a><a id="Tc_JFN6Ppki-k-KBtO028VwZw_4_2"></a><a id="Tc_tpuvtejd9U-txsHCynpx3A_4_5"></a><a id="Tc_z9tRW5o0BEWUrCEBZysogQ_5_0"></a><a id="Tc_-n_qA4BAOUiqzU1rww7L3w_6_0"></a><a id="Tc_VKCCjswI_E-eXNkyWssVtw_7_0"></a><a id="Tc_OvpETp_l20SSGapSyClVNA_8_0"></a><a id="Tc_OpEimN4R40KMIR6I8MtHOA_9_0"></a><a id="Tc_MfsdxL0zd0mrdIBAC8T4Mw_9_6"></a><a id="Tc_yyNa06jvFEeQXXb4Ih-dxA_10_0"></a><a id="Tc_UgqOGvUC4E6_JjsF06cAeQ_10_3"></a><a id="Tc_DL4CGgLchke_211woywQVQ_11_0"></a><a id="Tc_JGkN4dXRIUG2MGQuQe3GmA_12_0"></a><a id="Tc_XY_mbJ3LBkWZWfweCQC1aQ_13_0"></a><a id="Tc_c3NLMeFVaUuCuMrGKyE7Gw_14_0"></a><a id="Tc_q9KWSyuxB0WBoU6aP2yQZw_15_0"></a><a id="Tc_L80izc6bHkCSYFfd-EhGOw_16_0"></a><a id="Tc_M-8HZrRFKkyQrZUfswf3uA_17_0"></a><a id="Tc_56dCSNp5kkWg_JpkGNz4EA_18_0"></a><a id="Tc_aEYgGvGPy0WFkL8MUhjheQ_19_0"></a><a id="Tc_IGoySWPjt0OSSw_WpDt35A_20_0"></a><a id="Tc_ONJSS3saK0yO-xWfcoIXxA_21_0"></a><a id="Tc_gC32ELHuHECn8bw-gAm8yA_22_0"></a><a id="Tc_UqLoWNysn0aEj2jk1Z_dWA_22_6"></a><a id="Tc_c4_Kuklz2E2cOsYDYGiOxQ_23_0"></a><a id="Tc_MsXPrDSopU-bTDeQvTjEfA_24_0"></a><a id="Tc_57-YiWqYAUmstPReXkl-tw_24_6"></a><a id="Tc_OBh31LXviUKEzpdf92NxsA_25_0"></a><a id="Tc_mijlNDI_LU-TkB6RuICVoQ_25_3"></a><a id="Tc_d5alm3VnjEu9g9L-IdGi6Q_26_0"></a><a id="Tc_iHx0LtqN102IxQTH3UNn4A_26_6"></a><a id="Tc_nu5ddIQss0mfUyKX-VKw0w_27_0"></a><a id="Tc_avv9LZC7VEWAX2ce-gEoWA_28_0"></a><a id="Tc_r4u5p3ojJ0G-pi_EoiSzLw_29_0"></a><a id="Tc_EHAFhzp5WEmSLsMXU5WvLQ_29_3"></a><a id="Tc_XHN3xG35_Eu2ldkbRLiyUg_30_0"></a><a id="Tc_lR1xjQysNEGUVdRVjyGOtw_31_0"></a><a id="Tc_WA2-uncYMESBGPKeVAmzJA_32_0"></a><a id="Tc_qfnRy_ZL20GiKgVnbdBn7Q_33_0"></a><a id="Tc_g48Hj937iE2YqVTN0ZoP5A_33_2"></a><a id="Tc_XLu93H3Ghkau5T5o09wP3g_33_5"></a><a id="Tc_rUlIu2EFKEGrH3dAKV0GaA_34_0"></a><a id="Tc_8hDkDnYnyUeHrgewa54LFw_35_0"></a><a id="Tc_lidyWFOAe0-HKHKSNzjtOg_35_2"></a><a id="Tc_hQG1Wn3WuU-FZF7YuVEtDw_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4Ynr5J_210e1GqwJ8H3UCA_4_3">33,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_V5oXfGynokGWm2K53saErw_4_6">25,788</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_a8JLGSM4DketerdqJMCKTA_6_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_71G84C-ybkSkXZfIwK2Q-w_6_6">96</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc__8Zi5O9ah0OmGBZSmBCeQQ_7_3">3,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_x_nlpUgukkmUb5aTh8Qrcg_7_6">4,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_D8HBOSnXYECmsVmOx8Ighg_8_3">159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_oK73YIu2ZkGxQNzgkZNjRw_8_6">156</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Loss on currency translation from liquidation of subsidiary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="Tc_sKGIxy4qMUaIvIKPQ5HEIg_9_3">195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Issuance of common stock as commitment shares for equity line financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" scale="3" id="Tc_4wsoGYMRZkquhBbaEPAJ1Q_10_6">318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Grant receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:IncreaseDecreaseInGrantReceivables" scale="3" id="Tc_e6QdQBjZ70e54pxg-wDMig_12_3">1,405</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:IncreaseDecreaseInGrantReceivables" sign="-" scale="3" id="Tc_VNXI5Da2ik-E3IoFbm3sXg_12_6">2,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_VYPzt6IpFUWLHwo8j066Tw_13_3">1,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_HlG4xjIDqUqwWEJIfcTedA_13_6">1,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_6BCsZPykgEOvSELgPNFTTg_14_3">1,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_D9QxZPLTrkSdLxDQifVE5Q_14_6">2,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Deferred grant income and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" sign="-" scale="3" id="Tc__2uvzYNgwUC9LXrhmRMATw_15_3">635</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent" sign="-" scale="3" id="Tc_nWoMbJnve02gjHsuJfaZJw_15_6">1,687</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_mQ-vYEaHy0Ol1QGxWOLgLg_16_3">159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_R1NOYNJBD0ihGPGRinQyIw_16_6">150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_VWx0j381bk2x377q1durKw_17_3">28,474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_LH91wlDKBEOl3SSfpbizHg_17_6">16,018</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments for property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_cg4CFks3XEKkHyMq78sA0A_19_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ge7z0KLHlECH0_GRvR9sjQ_19_6">147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_NHoCHwOLck6CvHFhIJO5CA_20_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_KbXYur--MUaR_SMNL9e7tA_20_6">147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock in follow-on public offering, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_FJgSUJ58zkCix8Et5IYDuw_22_3">11,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock under the ATM sales agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Ckqv-8_V60SSS3Mr2zUJ-g_23_3">12,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_xRJVE9no_0qMZCqSd10m9Q_23_6">5,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_mRjgVQlPk0KD-cM8x5OHzg_24_3">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Proceeds from sale of common stock related to the equity line financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_O-NMNtixsU-2BokgEbSRAA_25_6">205</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payment of employee withholding taxes on vested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_6vvgRCn5lk-MwN41nhCHvg_26_3">128</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Payments on loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_kF18paSWEUeCRnSAnYzrtg_27_3">739</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="Tc_Jet9hb2CY0qP45hocSnHiQ_27_6">811</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_xh2JZf9RCEaNnFJ4vozFBw_28_3">23,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_aBIrfknTJk6FTNHJQFXjCw_28_6">4,521</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_u158yNTfvE6-z5SRqgTa-A_29_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_ZZHqijGaB0eQWHvkf6DQag_30_3">4,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_YkBjf4hjT0G26r9-lTeu8g_30_6">11,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0K1Lp9NTeEKHQzyfkWHGpw_32_3">29,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GpXQ0jRYk0OhbcRGHU6iYw_32_6">41,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents&#8201;&#8211;&#8201;end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_02LGTxYJAkGOcsZEeY2bWQ_33_3">25,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_KNw6fb4R20KAmNCk045FjQ_33_6">29,922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:71.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prepayment of insurance through third-party financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_jb8LzEjo20uh-V1qThXxxQ_35_3">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing" scale="3" id="Tc_7T8P4XqSgkebEBvc5LUfHg_35_6">721</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0f1dd0d9_d9ce_440f_b1f8_94b92b61185a"></a><a id="NotestoConsolidatedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COGNITION THERAPEUTICS,&#160;INC. <br/>NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS<br/>(in thousands, except share and per share amounts)</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_U8WbOZ4WjU-UyDnKFZ-7Aw" continuedAt="Tb_U8WbOZ4WjU-UyDnKFZ-7Aw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company ceased operations at Cognition Therapeutics PTY LTD, a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) and completed its liquidation of the Subsidiary (the &#8220;Liquidation&#8221;). In accordance with the Liquidation, the Company removed the Accumulated Other Comprehensive Income (AOCI) balance associated with the currency translation adjustments and recorded a loss on liquidation of the Subsidiary in accumulated deficit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_kKnE2riEPEyLJ8oMSAz2DQ">200,000</ix:nonFraction> in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (the &#8220;Sales Agents&#8221;) providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_LuMhXlg2UU2lMoQFfA7XFg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_5n83gSgCCUCtb2ZHlReLgw">40,000</ix:nonFraction> of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). During the year ended December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TvwQzyvoKk235BxXf9onFA">19,913,189</ix:nonFraction> shares of its common stock pursuant to the ATM for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_vDTlfbqRhU6QM1-J05vnVg">12,454</ix:nonFraction>. Please refer to Note 8 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_PPq5QYWGYkeTY7b0KKQ8EQ">35,000</ix:nonFraction></span><span style="background:#ffffff;">&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;</span><ix:nonNumeric contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" format="ixt-sec:durwordsen" name="cgtx:PurchaseAgreementTerm" id="Narr_ZhHfTwusm0qNJYkTvPLioQ"><span style="background:#ffffff;">36-month</span></ix:nonNumeric><span style="background:#ffffff;">&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VXdNpforpkq9Z9hM-zlj7w">189,856</ix:nonFraction></span><span style="background:#ffffff;"> shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:RemainingValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_lH6r0bs6ZEOPae64K0TgGQ">34,795</ix:nonFraction></span><span style="background:#ffffff;">&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On March 14, 2024, the Company closed a follow-on public offering of <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_sqUuGBVqzkuvQ-mUtFuaxg">6,571,428</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_7bkwJwweUEaG1mKDSNd2Nw">1.75</ix:nonFraction> per share (&#8220;March 2024 Offering&#8221;). As part of the March 2024 Offering, the underwriters exercised their option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw" decimals="INF" format="ixt:num-dot-decimal" name="cgtx:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_XuOCaa8VNECOKSpYS25nBw">985,714</ix:nonFraction> shares of the Company&#8217;s common stock on March 28, 2024, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_q6ZbGa7J9UyE_sqqQEMmNQ">1.75</ix:nonFraction> per share. The gross proceeds from the March 2024 Offering were $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_ezO69WgM_km9I2jRENXy8Q">13,225</ix:nonFraction> and the net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Narr_42BtVQ1b2UahOhX7tvtLfg">11,896</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_U8WbOZ4WjU-UyDnKFZ-7Aw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Going Concern </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_WycRa_svQkCQ305iNTaQ0w">33,971</ix:nonFraction> for the year ended December 31, 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_NB9Je6cPN0aZQvQunfgUaw">25,788</ix:nonFraction> for the year ended December 31, 2023. As of December 31, 2024 and 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_aqQupbszHk-Ze8ffXJCs5A">25,009</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_dQa_8kT9cUuXNb0Ms4c2VQ">29,922</ix:nonFraction>, respectively. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_82n5kIm_6USQvG5IHONU7A">175,160</ix:nonFraction> as of December 31, 2024. The Company expects to continue to incur losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 20, 2025, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of December 31, 2024, is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_-cqvWwUF2kO1ERq2KI2rAg" continuedAt="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_4dXAKhIJCkq9MSFFq_GzXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:UseOfEstimates" id="Tb_C63X8xRuEkWREeJisFZdnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_cGF0fq8RMkukzSBVBeDHkg" continuedAt="Tb_cGF0fq8RMkukzSBVBeDHkg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont1" continuedAt="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont2"><ix:continuation id="Tb_cGF0fq8RMkukzSBVBeDHkg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_97vNa-7PLkmqRabkYLB5Ww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (&#8220;NIA&#8221;) a division of the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt-sec:numwordsen" name="cgtx:AllowanceForCreditLossGrantsReceivableCurrent" scale="3" id="Narr_05XTJEvlo0ez5KqXS-BQeQ">no</ix:nonFraction> allowance for doubtful accounts required on these grant receivables. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cgtx:GrantIncomePolicyPolicyTextBlock" id="Tb_6LUHmeJeDUu-wjLof5eymA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2024 and 2023, the Company generated grant income of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:GrantIncome" scale="3" id="Narr_c0t0uybn1kCOmCvr2r2uZg">19,549</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:GrantIncome" scale="3" id="Narr_no3NZG4kmEC7lbgD5iYCpA">24,805</ix:nonFraction>, respectively, primarily from reimbursements from the NIA for aging research. For the year ended December 31, 2024 and 2023, deferred grant income was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_7fH9HLtavUWmhOI_Z8Cb6w">1,066</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredGrantIncomeCurrent" scale="3" id="Narr_ijSIc0cCS0qZaNzlWUUtYQ">1,701</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_8xK0cuzcL0u-RdmQ8I7Irg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the financings. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Me5U_oAq9U-BDrAac6Jr5g" continuedAt="Tb_Me5U_oAq9U-BDrAac6Jr5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_jnCsFL2IEUeXVQTdgotWyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and <ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_XsXdNHFLME-UsRX1yXLT4w">6&#160;years</ix:nonNumeric> for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2024 or 2023.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont2" continuedAt="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont3"><ix:continuation id="Tb_Me5U_oAq9U-BDrAac6Jr5g_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_KMVhnAm2RUW_CNL_6qHo4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_6iZM095orUylSOzcAfFf6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under ASC 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement is a lease at its inception. Leases are classified as either operating or finance, based on the Company&#8217;s evaluation of certain criteria. If a lease has a term greater than one year, the lease is recognized in the balance sheet as a right-of-use asset and a lease liability at lease commencement. The Company elected the short-term lease practical expedient, therefore, if a lease has a term less than one year, the Company will not recognize the lease on its balance sheet. The right-of-use asset represents the Company&#8217;s right of use to an underlying asset for the term of the lease and the lease liability represents the Company&#8217;s obligation to make lease payments arising from the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If the Company&#8217;s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease right-of-use assets and operating lease liabilities are determined and recognized on the commencement date of the lease based on the present value of lease payments over the term of the lease. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease, and right-of-use assets are subsequently re-measured to reflect the effect of uneven lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">For finance leases, right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset. Expenses for finance leases include the amortization of right-of-use assets, which is recorded as depreciation and amortization expense, and interest expense, which reflects interest accrued on the lease liability. </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_2kR4QummV06hc6irpqNWqw" continuedAt="Tb_2kR4QummV06hc6irpqNWqw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_RUqcEa9IPUudA8THKtxMSw"><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr__iycQKia9UamFzaprYlgBQ">no</ix:nonFraction></ix:nonFraction> uncertainties as of December&#160;31, 2024 and 2023 that met the recognition threshold.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont3" continuedAt="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont4"><ix:continuation id="Tb_2kR4QummV06hc6irpqNWqw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_FJwfKL5mV0S0sxlYqcm03g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_itfOAqqNYk26c_zBICJx9A">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to note 9 for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_9DO4kNA4zkST7VFSjhXslA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_oS0tuzuv1EKiZQlJA9TtCQ" continuedAt="Tb_oS0tuzuv1EKiZQlJA9TtCQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont4" continuedAt="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont5"><ix:continuation id="Tb_oS0tuzuv1EKiZQlJA9TtCQ_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:6pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_kbkbH7qWbEiDSB2oW1QQVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Comprehensive Gain</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Narr_goArU09pDke5EJigFIm6Zw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Narr_riIwN4SKJEWrsBz-xsiNBw">4</ix:nonFraction> in other comprehensive gain related to foreign currency translation for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_87Q9bj1HrkSVQcjq4FhQ_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_QRiuhOlEHEyXaeeOcBvF3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages <ix:nonFraction unitRef="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_1dfo9wqowE2cB4YwSy8kmQ">one</ix:nonFraction> operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 13 &#8211; Segment Reporting for more information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cgtx:EmergingGrowthCompanyPolicyTextBlock" id="Tb_xNnDxhasM0OivEpv7ESvgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_6qepeRTeP0C8gDpRVoZriw" continuedAt="Tb_6qepeRTeP0C8gDpRVoZriw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 13 - Segment Reporting for more information.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-cqvWwUF2kO1ERq2KI2rAg_cont5"><ix:continuation id="Tb_6qepeRTeP0C8gDpRVoZriw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p></ix:continuation></ix:continuation><a id="_d11d9ff2_a834_4232_af98_d34c9aa23701"></a><a id="Tc_Xa3vYMM1HkKIp-NlvIsyUw_1_2"></a><a id="Tc_G7am3yHuVkmibaVYQf33uA_2_8"></a><a id="Tc_-lDjZ8sYhECRlDRoPT28Hg_3_2"></a><a id="Tc_lUk_9K24e0-vdbCvfn12Lw_3_5"></a><a id="Tc_kDeRUnI7nk-8VOU0FDup8Q_3_8"></a><a id="Tc_TiJO4EUOoEusfcDGvC_Adg_4_2"></a><a id="Tc_PY-0nGHNeUGxFE5yo-Ceag_4_5"></a><a id="Tc_bH70nvWGY0aszaCqd_ksig_4_8"></a><a id="Tc_CS7zJN_4zkOdJOSb33U1MA_5_2"></a><a id="Tc_kMCQ8Tzfjk-HL_QZ9ttm1w_5_5"></a><a id="Tc_FlsLO17QVUOBif1kwlBW5Q_5_8"></a><a id="Tc_wFLfK20cQk6wx2xh1kLQOg_5_11"></a><a id="Tc__xN8vi8AekKOeqmTuj1LoQ_6_0"></a><a id="Tc_RvO8_GYic0WnOECKfB89tg_7_0"></a><a id="Tc_4EZ_4C2Ick-ShdN_7n-7nQ_7_2"></a><a id="Tc_v2WTIhjLy0mYMxscW6oNXw_7_5"></a><a id="Tc_mKpvmWwEp0qu3afagyWaIw_7_6"></a><a id="Tc_WnjzzfVTRkiGunqm-4b0yA_7_8"></a><a id="Tc_JJ0UfpIJ40G_DESiPewz_Q_7_9"></a><a id="Tc_oDhfZu50RkefbgrQe8uBgQ_7_11"></a><a id="Tc_79ZdSMqAh0Kp5uhsJytO5A_8_0"></a><a id="Tc_ZrMRzV4c-0m7cjWr-sjslA_8_2"></a><a id="Tc_y96u0MZhDk6Sd1Kqwtvaxw_8_5"></a><a id="Tc_ncgj2WRtNEK-WmrU0NeA-Q_8_6"></a><a id="Tc_OMoFvKawCEazuGl9XHdALQ_8_8"></a><a id="Tc_BBrhKrIo106494_Fnc3Syg_8_9"></a><a id="Tc_AmOs-K60gUG_h2cIBW8cQw_8_11"></a><a id="_69c15f46_951c_49d5_976e_9ebc5ba4826b"></a><a id="Tc_N7CEPkY-CU65V9xS1Zaong_1_2"></a><a id="Tc_gkoa8LlnvUOK1nQN3DehNg_2_8"></a><a id="Tc_f5RTMMvxJ0CB1IBXkA3-iw_3_2"></a><a id="Tc_SMfq0qU8-Ei8zkOIHqh4Jw_3_5"></a><a id="Tc_xSe89o7-ME6yjVht8Cplcg_3_8"></a><a id="Tc_nRAK9EnxFECDDn9zNbP1sQ_4_2"></a><a id="Tc_OTvPJqhzP0KfxkF8o990IQ_4_5"></a><a id="Tc_MMtHFI22qU6CMT4ge-h5iw_4_8"></a><a id="Tc_vNNRv7vlIUGdtfsG1KWE_w_5_2"></a><a id="Tc_KWDlijYbW0uER32lfwYpgg_5_5"></a><a id="Tc_K_Q9W8PHaUqI6TAjhznR1g_5_8"></a><a id="Tc_Bz7fCJ1R4EGhmTwKvckCuA_5_11"></a><a id="Tc_u4EhUDajEESoAzkvjIKwhg_6_0"></a><a id="Tc_KOkQhG2whU-z3deALUSIlQ_7_0"></a><a id="Tc_sbW7HntCXk2L8JD7ji9XSg_7_2"></a><a id="Tc_s71524RYxU2P250uNX8uOg_7_5"></a><a id="Tc_BahyC4bfSkmgscFKlWkZqA_7_6"></a><a id="Tc_2IuFP2qEaEWda-PRoZEoCg_7_8"></a><a id="Tc_Grcq0If1mkqCutU5zKp2Mw_7_9"></a><a id="Tc_zxz2Rhic_EyVIbzkTPZhiA_7_11"></a><a id="Tc_z2CEqBe0xUiesc7SCBxFhQ_8_0"></a><a id="Tc_GEkrNPj6xUm7KzbVwFMNjg_8_2"></a><a id="Tc_mTxgF6VYhkiw1BXykHJoEQ_8_5"></a><a id="Tc_1Ni5N-TLnU-xaI3RsNwizQ_8_6"></a><a id="Tc_j4br5iySI0anwlNTPbNswA_8_8"></a><a id="Tc_v-5E9SQL50K2IB5XrCeuzw_8_9"></a><a id="Tc_hQC85GVuOEG7ZVWEZbESJg_8_11"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05_2"></a><a id="_7f7d12c5_7677_443c_9f6a_4cfa0835ba05_3"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_EQwUC08ZJ0u3c_6HqkjmTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_HrOvCM1Tl0yE2ynE5JON8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jrR6f4WA_E-O8mTJmjvxRA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_vuyOqrgqVEmnLzb8HXhcZA_7_3">23,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_XKQMBwzNm0isw3SpIMHyCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_S5_lkPOTQkKJGx7Tarc1nQ_7_12">23,999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_6nqsHazxDUGfwWNKMnAR-Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_7xjmSN5ZC0KXHS3WBFvwkg_8_3">23,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_f95N-ZsjWEu8tYISkZtlDQ_8_12">23,999</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_WWHICw6P30W1vl__ISJXDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_U_vDdgHOuEKPGIw12ZDW7A_7_3">29,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_k0qbPwttZEipB5XrOo8yFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_kMvSv2fqh0qkoIrml2j0kA_7_12">29,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_gX0jdGPEx0-lwTPLQjPt9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_8gfYbTOfqkaMxdZ-_X_Hkg_8_3">29,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Dl1UHDQcGUm12jOf6hxrhg_8_12">29,391</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_BDxC3qa7P0mu-MwglQJrmw_1_2"></a><a id="Tc_egpsXII8_0aU91KKnNFLXQ_2_2"></a><a id="Tc_8rv5w2w9fk6P9l6LPVBtFg_2_5"></a><a id="Tc_xehSurTmMke4DUAuPlrNRQ_3_0"></a><a id="Tc_UTRxoZjgu0ChMSKiZVkSrA_3_2"></a><a id="Tc_HSV8JeuEx0mJIZfnVnxLKQ_3_5"></a><a id="Tc_SQOkJWzRIkmqzFVt6jrl-g_4_0"></a><a id="Tc_CBAdbM-6tU6yNil2NrLMpA_5_2"></a><a id="Tc_GGtjjj9t40mYr2R1hloc8A_5_5"></a><a id="Tc_9nyuCeMkCUOGluBiTCCcpQ_6_0"></a><a id="Tc_1Gpb4YoM3kygD6k7CMdkgw_7_0"></a><a id="Tc_0iV5t_eJVEmi0SgSH-iLAg_7_2"></a><a id="Tc_gbEK2A2rwkWnPz_SzWbMMw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_NQSoBwRANkGOb_4p4VlAxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_sDDJ6a-rmkOIRCtDknhgkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_4V2lLZkI50e3bUlSERsjLQ_3_3">1,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_OmwuH19ITkWRHopUzOVYJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HGs6dcTvfUSH8zy2AWUlWg_3_6">1,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sz3eBn3Rh0On5LYqPU1ezw_4_3">140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wq0C1MAIcUClHQZnNmyrcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_WFnI15rlb0-GLt8kTdlkFQ_4_6">140</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_f_NQ-Tz7u0CANlDeJf7MeA_5_3">1,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_53No9keJX0WWtIML1V7chg_5_6">1,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_HjaEjpid8USWfhu7fQxDzw_6_3">1,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_wDijjjXM_kaB11U775elog_6_6">1,049</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_6yGw_N5tUEy8jJunu3Ii4Q_7_3">181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_GP9h1ADzj02BtoHXN-wNqw_7_6">284</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Narr_f6pcA9aqfkq0TB96-MKw4Q">107</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Narr_Radge8zKV06g4ivGg47qZg">96</ix:nonFraction>, respectively. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_5_nk-jRklk6LjGF5iXfZAw_1_2"></a><a id="Tc_vHoHfpKPSUikIue63d22VA_2_2"></a><a id="Tc_ba-bm7mzTEW-Oqy4e7q8nw_2_5"></a><a id="Tc_9OPZhRDyyEOncRJXeyHGwQ_3_0"></a><a id="Tc_OQNILPwJL0Seouf0nsmrdA_3_2"></a><a id="Tc_L8if4jmQf06wvJoczEUZ9Q_3_5"></a><a id="Tc_O2yTeVTPiEebfE-inIHpAg_4_0"></a><a id="Tc_eJ6hWrFl6kKXf4XYHec4XQ_5_0"></a><a id="Tc_BTe-IlNoz0KX9vLIDw2RFA_6_0"></a><a id="Tc_haEwFSEIt0mJmR3xb4Nf2A_6_2"></a><a id="Tc_X8Gwf1dfIEe-RC1JbKiNkQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_Cow9T_VNN0SVJ0Acg5lquA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_RvoElEQg6EOfVSO9gJQlsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_aRH5IHCeAkGx6y36bRbhJw_3_3">1,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_iFOwC-mOLEmJPVh7RP6l2w_3_6">1,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_cnAVL8q3RUq83GJVOB2Cuw_4_3">5,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_kMrsSvL4YkeqY-YmK2trLg_4_6">2,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_vEekVP1hbkmnY-ajRmw3DQ_5_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_f18o1NaAGk6kO7HY9czNMw_5_6">370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ycExTxqLmk-Aq-9PyVKhXw_6_3">7,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Bwlm0d-wzESKSFyTkAruZQ_6_6">4,055</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f7ecfde1_b524_46af_8b76_0001b95bfaa7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="cgtx:OtherCurrentLiabilitiesTextBlock" id="Tb_XM828ogD3k6snLqdOLuvJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_bLp8qxcDbE6lPG67I0B-Bg">721</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_C9V0e_i9FUWbafaiTYtKsw">8.65</ix:nonFraction>% annual interest rate. Total payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_3ws-31ywLkGQlI_tbXjBpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_jJ-4qwEX90mS3_jE-Lm77A">62</ix:nonFraction>, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_9IPUhdlJ5kOeFe2ILc4Vlg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Narr_5WYpckqpeUytCDHmlqhePg">544</ix:nonFraction> and the amount was paid off in <span style="-sec-ix-hidden:Hidden_Z7RNwB4W3kOANqH6RLEDhQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span>. In October 2024, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_vn6A4M638UWPNSay_J_DXA">356</ix:nonFraction> of certain premiums at a <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_1dDq6NOGUkOBZ1xJwrH6vw">8.65</ix:nonFraction>% annual interest rate. Total payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_6WFEkFQXEUSicyyzDQI4qw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_a57mhVbqYkqPknTp2y9-7Q">41</ix:nonFraction>, including interest and principal, are due monthly from November 2024 through July 2025. As of December 31, 2024, the outstanding principal of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_JlfyE0xns0CU4LcciEPTeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Narr_DDtuG6FVCEGPjMSx8wy8Vw">279</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_pHUrNAs1Fk-8WxrX4LPMmA_1_1"></a><a id="Tc_J5uhETHgUUq8P10q6KRErQ_2_1"></a><a id="Tc_y20DNRKZPkK3yklYmJn6NQ_2_4"></a><a id="Tc_wG2wB1kDT02UwQYpZTvMmA_3_0"></a><a id="Tc_AJsMI3tky06WW4w6sCNkOQ_4_0"></a><a id="Tc_Xr1myf-2V06eeHQzvMqbGQ_4_1"></a><a id="Tc_JUaFsgtquUWVZ5XR3FD-9Q_4_4"></a><a id="Tc_dy-EawzIG0OCigUNoEDC6A_5_0"></a><a id="Tc_DQ7XaUJryUiC-ed9GicpuQ_5_1"></a><a id="Tc_xndK53eymUuXQvP2-AMDpw_5_4"></a><a id="Tc_2QSudxQA2UeXwZQBExkbrw_6_0"></a><a id="Tc_neDTNo_-DkW9ky3jHQT5zw_7_0"></a><a id="Tc_agQq4-LtTkCMJXBzxEGIbw_8_0"></a><a id="Tc_WjdwJ4GtbEuf39nUCBMkCg_8_1"></a><a id="Tc_7F0moYbDFEqI4rX7gh6HxQ_8_4"></a><a id="Tc_hRfH2WSLPkaQPV8yyFEl8w_9_0"></a><a id="Tc_jkdOwd3GAkyey7adwZWLLw_10_0"></a><a id="Tc_6bQnCTL8fECzNwV-mP8rIQ_11_0"></a><a id="Tc_msIOeyC0RUOueKfIn32lHQ_11_1"></a><a id="Tc_rI68Is-uaU6waXqnQzcWpw_11_4"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_o_r1qLoyekCrRnvGUehe_Q" continuedAt="Tb_o_r1qLoyekCrRnvGUehe_Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy <ix:nonFraction unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_P2TM13gBZU6xZncj0GmnAg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_8N4DQ9hxF06Bw2h0WLesfw">2,864</ix:nonFraction> square feet of office space under a lease that expires in May of 2029. The Company also leases approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_N80InueOO0ax6JSU1_GDkg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_wXqVbT2rPkCs6XQQVMz7kg">6,068</ix:nonFraction> square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_O4eMoPkn-UiB3yEL9wwhEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_tqLenB_kL06An8YfF1GPKQ">2,980</ix:nonFraction> square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of <ix:nonNumeric contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_-QVbP29W8UCUFnMbcV9xXA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_gISGfd3-g0afzlWpcj6wtQ">45 months</ix:nonNumeric> and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified <ix:nonFraction unitRef="Unit_Standard_lease_9ytlK5UIFkOJ1P2Vw2TIqQ" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" scale="0" id="Narr_FO5VzQH2G0yZ-iXmFvM4eA">one</ix:nonFraction> of its existing lease agreements for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w" contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_oOwTKNosH0m0Npilt_mVYw">3,706</ix:nonFraction> square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2024 and 2023 were as follows, in thousands:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:LeaseCostTableTextBlock" id="Group_x7cRPiKUGkigcDc-NhZUYg" continuedAt="Group_x7cRPiKUGkigcDc-NhZUYg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OperatingLeaseAssets" scale="3" id="Tc_8Zj8I6rcrESHWQ1Q157zQQ_4_2">498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OperatingLeaseAssets" scale="3" id="Tc_H8lyrDkk_E2eCJo7GrPGmQ_4_5">657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc__mqHjQ--z0SYpoee9eHViQ_5_2">498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_LNP8cbGKnUKcD_wOSDPj7g_5_5">657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_gR-wrtw9aEKwpzTAKDO7HA_8_2">193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_y-6Bo7GUiUOjR4mQwtc0_w_8_5">174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_4zH8DhnQhU22DYe1Xs47Fg_10_2">342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_t1JsaLZJDUGXMWmZJyYphQ_10_5">520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_Mj2hRSG6X0CrGmPRLEqdug_11_2">535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_Nl7l8JDz00OvRgqLOwPMqw_11_5">694</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_922b3997_28c5_4b68_9e9c_0737a2d9c5b8"></a><a id="Tc_1ZNnYiWH80qPLDVDme378A_1_0"></a><a id="Tc_TJeEV94UKk6wKVpNhcE8pg_1_2"></a><a id="Tc_tNPP8n-KbUChfQQYKzwWog_2_0"></a><a id="Tc_nrtjS0dUpUyCZqnRStvUUw_2_2"></a><a id="Tc_ufKn8tI_EEaXo5rVGNK76Q_3_0"></a><a id="Tc_nzn3AKEysEeLYtaVTJYZsQ_4_0"></a><a id="Tc_Y47N4sqaCEKnpL8egEjliw_5_0"></a><a id="Tc_zQycOm7u1kS6JsYO4IJWUw_6_0"></a><a id="Tc_Ne04TNslvUukNqzPu1a2bw_7_0"></a><a id="Tc_J5xwXISOMUihXDoeGCFkCQ_7_3"></a><a id="Tc_OGdY3B19VEWDKvAIw4j78w_8_0"></a><a id="Tc_fs_fdSVc7kGRNT7gV0Bj_w_8_2"></a><a id="Tc_btQU1ltOeUitA2_U2MmFcA_9_0"></a><a id="Tc_YOyolHQd50-JwZuysSMt1w_10_0"></a><a id="Tc_i8luKYpX8UGa6bphUoZ3-g_10_2"></a><a id="_5cd29646_248f_4e6d_8182_c84b5c23c9bf"></a><a id="Tc_IqFwUbEOM0SaQMzaruo1TA_1_1"></a><a id="Tc_9WKOd8TIQkq_V9mRJwvH0A_2_1"></a><a id="Tc__G_GpfCABkW5nFAr6LBOUQ_2_3"></a><a id="Tc_hTeMJK8Gv0e_Pm9HOvja4A_3_0"></a><a id="Tc_1-PH22m-dkaW4uWs7BpWuQ_4_0"></a><a id="Tc_-qn-mAFivky8W9dyGRAxsA_5_0"></a><a id="Tc_f0SJ_IjvoUGRniOhxUS_ZA_6_0"></a><ix:continuation id="Tb_o_r1qLoyekCrRnvGUehe_Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_F9WGg6fHp0GILoYx-pjZBA">218</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_2wr3LC8uWkSeV1EgIB_3uA">215</ix:nonFraction>, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_eauDUlYYaUSsVDhV97yeqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_pE5obtDbiEq5hHldSrfKJw_2_3">226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_3OGEexEmQE2aODCyoSIVhQ_3_3">158</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_CiVg5Ea56Um5nVFxnKekPg_4_3">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_b521lRMMCkaOuCqhLoCgKQ_5_3">92</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_uVqUr-mBCkeu1YVUgAgtBQ_6_3">39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Ce9C_7X_YEaQ5WLnExjpkQ_8_3">605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_iirlxRK1QkOwLU9GMq-2Pw_9_3">70</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_6mRd_MdNwkyz0aI29ng0Ug_10_3">535</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:continuation id="Group_x7cRPiKUGkigcDc-NhZUYg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_6QhQ1wm8nEuUrH9BCHhxjw_4_1"> 3.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_DHAEGcZ3zkuLbp1kKAfNvg_4_3"> 4.1</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_SiJwpTEVrE2wLAT9pVoEwA_6_1">8.1</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_u7M7QESOiEmsl9h3ZYGVfQ_6_3">8.1</ix:nonFraction>%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_9bsTzbPD6k6JfK9POIdPYA">224</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_CSil1_dMbkasZ3fnrFvpig">209</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2024 and 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_Rsw8SPKW9Emq0TEevEgKtQ" continuedAt="Tb_Rsw8SPKW9Emq0TEevEgKtQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DE--e9CilkKZKhu-FPjgWA">250,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_yUEvrM_7bEqibpYVKIggkQ">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_uh91Fqs5DECqTlL7wzea9Q">10,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_rjn4C7oPG06EbvJL0FEuXA">0.001</ix:nonFraction> per share. As of December 31, 2024 and 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_9K8AU7d9N06BKPISHINnpg">59,854,877</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_hGg8jdc_lU222rd6JQiI_g">32,165,478</ix:nonFraction> shares of common stock <span style="-sec-ix-hidden:Hidden_1URyjcdy8kqivgwhPCDv3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_S56iJzBGFkm4V3mtGIvG2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2024, <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="3" id="Narr_UEmnHCzNx0eOPhEMZEfntA">no</ix:nonFraction> dividends on common stock had been declared by the Company.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Rsw8SPKW9Emq0TEevEgKtQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumAggregateOfferingPrice" scale="3" id="Narr_d9lF9ppN-kCNVOWFSA_YcA">200,000</ix:nonFraction>&#160;in aggregate (the &#8220;Shelf&#8221;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_12_23_2022_To_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_Q6DBrXT7LEaflz65yXd2EA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_vKmXMJVkcUWzJKekF9r0IQ">40,000</ix:nonFraction>&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_UD5vrIPd_0i3MSNlVttang">19,913,189</ix:nonFraction>&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2024 for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_Tvljg-sJ7UqSQGkMgNnTEw">12,840</ix:nonFraction>. As of December 31, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_EKWIjPiMsU2M7X5y-zyRPg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued" scale="3" id="Narr_NxHpafApvUubdxapLc-mUw">21,874</ix:nonFraction>&#160;remaining of common stock available for sale under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:MaximumValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_FqlgUW00CkOoTdcd83v4Wg">35,000</ix:nonFraction>&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;<ix:nonNumeric contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" format="ixt-sec:durwordsen" name="cgtx:PurchaseAgreementTerm" id="Narr_7vbkdd7TDEyaq86fQUFj9Q">36-month</ix:nonNumeric>&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_K0__uDJXiE2AHb2njPuJtw">189,856</ix:nonFraction>&#160;shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement (the &#8220;Commitment Shares&#8221;). The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Narr_3-zBgVAql0SvJDsVCh8NLw">318</ix:nonFraction>&#160;to other expense, net during the year ended December 31, 2023 in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_A2d2e-0x9UudhRWUl0CT0A">125,000</ix:nonFraction>&#160;shares of common stock to Lincoln Park for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_DFqodTPiu0G7O8BP9Nj6gQ">205</ix:nonFraction>, as part of the equity line financing arrangement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:RemainingValueOfStockToBeIssuedUnderAgreement" scale="3" id="Narr_rZ4H-eaZnku_LSj1Eplq7Q">34,795</ix:nonFraction>&#160;was available to draw pursuant to the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">March 2024 Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VLoEsFsbhkqrCJC0oUeSqg">7,557,142</ix:nonFraction> shares of its common stock, which included the exercise of the underwriters&#8217; option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA" decimals="INF" format="ixt:num-dot-decimal" name="cgtx:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_i8N77viL9kO_cyMjzYthcg">985,714</ix:nonFraction> additional shares of common stock, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_8KtOhdlvBUG2HVj7Nj0Rvg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_7tcZTSkBoEOWSi-bNHaHWA">1.75</ix:nonFraction> per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwriters&#8217; option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_3_28_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_qj_sVYxNbUS8cYEAWDZ8pw" decimals="INF" format="ixt:num-dot-decimal" name="cgtx:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="Narr_djuEHSd5IECmAJUwoZmjrA">985,714</ix:nonFraction> additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ProceedsFromIssuanceInitialPublicOfferingGross" scale="3" id="Narr_8RjS99hvAEm4VMoHn3XRMQ">11,896</ix:nonFraction>, after deducting $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses" scale="3" id="Narr_5xl_Lpc1oUuh_B2sIoSsAA">1,329</ix:nonFraction> of underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_sLrdLyTbQkWSGwu0xL0yPg" continuedAt="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont1" continuedAt="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the aggregate number of shares of common stock of the Company that may be issued under the Plan is <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_oGMCdwzfIEam4flhzJxGxA">2,587,917</ix:nonFraction>. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TMZ1hC5jjUm23pil46C8GQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_uvhCJ7LKzk6Ii5lqaCU_Tg">643,309</ix:nonFraction> shares, representing <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_QnBbkut1Gkme18p813MRFg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_OQTrT-JqrECM0wZDfo31iw">2</ix:nonFraction>% of total common shares outstanding at December 31, 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_wRqYBX88ck2Z32XFXD3SKQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_LqPPj9k0qEWL9oCkVIcsfA">5</ix:nonFraction>% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s board of directors or the compensation committee. No more than <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_B5mjxP_v_UCcg2VfDgRccw">7,543,185</ix:nonFraction> shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ" decimals="INF" format="ixt:num-dot-decimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" scale="0" id="Narr_-dw2mJ14xk-Ra572lQV-oA">4,334,131</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_q6unYfC8qkuDXCuMsqUs1g">4,334,131</ix:nonFraction> (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_FGsA0l5PX0ikfIe99ENvTQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_7bZ75CLe-UKw6TpeCXJXSA">209,532</ix:nonFraction> shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_o-jKPUlZBUioRmU5d46iGQ">1,000,000</ix:nonFraction> shares of our common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_P0aQTSJEQ0az_sFPFCVNLw">1</ix:nonFraction>% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_EXH4x_HixUKlXDyPyAv8ng_1_2"></a><a id="Tc_98tfDUZ2zkCs50wL3fcdKA_2_2"></a><a id="Tc_FH-rkSnOKkOFtcJQblGz_Q_2_4"></a><a id="Tc_oYBUpoR5uUKkCaJRhS9rkw_3_0"></a><a id="Tc_C7D6rWE45kC3XDcsgTALkQ_3_2"></a><a id="Tc_GdmW0wG7sUuNyOBj1op9-Q_3_4"></a><a id="Tc_RZoWJB5HfUSVjF3Gj6SBmw_4_0"></a><a id="Tc_8q6WFubo9EiJnd8oTN8z_A_4_2"></a><a id="Tc_TOnkb2CmGkuoK4MXlQ8Rag_4_4"></a><a id="Tc_sSf4tib4-k2fje3e8PsUvg_5_0"></a><a id="Tc_szNAgJkCAU-b8AS-ugWbtw_6_0"></a><a id="Tc_Butt9A7G9kGclPRVLcKxIw_6_2"></a><a id="Tc_SMabn3WyZE24LCSGdd-hFA_6_4"></a><a id="Tc_LLN2JtC8PEazGzVatrop6A_1_2"></a><a id="Tc_F4nIyldiYUa_9bw-AKQUfQ_2_10"></a><a id="Tc_OXbKdVBJKUeUnA4qhz4VXw_3_7"></a><a id="Tc_M8pcb8t2pUGdmcxYIHQyBA_3_10"></a><a id="Tc_8_ecJsv88E6bpPtjuc8Znw_4_2"></a><a id="Tc_AAyWz3lZ4EujU9TqBJOd6Q_4_4"></a><a id="Tc_MGjA7cIz2kSQUmM2-BkcQw_4_7"></a><a id="Tc_Rv1oY2fk60-cz9yr0G3A4A_4_10"></a><a id="Tc_X9YQvoQH1EWa7zFEKcgnZQ_5_2"></a><a id="Tc_wJPQXhLZJk-k7L3DvbooKQ_5_4"></a><a id="Tc_jY8kGHniNkeQQFFqKMJFyw_5_7"></a><a id="Tc_sP9ZMnAmR0-F3MfHfWyvSA_5_10"></a><a id="Tc_J57b4Efd10KeOxkA8brcrA_6_0"></a><a id="Tc_u4N8AbONfkGFqzU6hM00KQ_6_4"></a><a id="Tc_ReerleewxEWaE5AnCHcW2Q_6_7"></a><a id="Tc_GhrOOeQRU0ihIFJvGeRM-Q_7_0"></a><a id="Tc_anKo68m490G8WAXXxLYi2Q_7_4"></a><a id="Tc_vRJXuKnY-0unZUpHWelpug_8_0"></a><a id="Tc_91qkAc3yl0Sh2WXNLTyDFg_8_4"></a><a id="Tc_as0PnAJZA0-ze20pngTV6g_9_0"></a><a id="Tc_EvEsDre4iEqtCxC-1ovGow_9_4"></a><a id="Tc_g76CY0Z6QEGYOp1ZbqFgHg_10_0"></a><a id="Tc__RIxbc1xjkOm2BR_iim-CQ_10_4"></a><a id="Tc_Y_09pzD1DEipZlSp-QNLRg_11_0"></a><a id="Tc_QJgbGZmVB0-332eEiMveDQ_11_4"></a><a id="Tc_ixEJkOzDRE2Wjt3zIAi5EQ_11_7"></a><a id="Tc_UB7wgcb7XESqsYWM2ST4tA_11_8"></a><a id="Tc_6cCscKxjuU6zulsYJl_dpw_12_0"></a><a id="Tc_ucj5gw7YcUaguZZ1V9jh1Q_12_4"></a><a id="Tc_JEfxDFcf40CoA_WYowfnKQ_12_7"></a><a id="Tc_ZdMMA-LjmkqUwiqg6TtX5w_12_8"></a><ix:continuation id="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont2" continuedAt="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_f6L5hLlV4UK0Z0BbyECLsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_eW72qFbwZU-OgFNkeiMnLA">91.78</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_0UiSUFGZAUWFDypQLHDQ1w">92.29</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_QQ5wHE-cQUC-0Ume8DO_pA">91.47</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_9v-Z97BlmkWY6q9NoYGDRw">92.68</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_WrXaWSuAnkuoNdQ66KIuIQ">4.23</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_Atgkb2QDqkWnnmt03e_8Tg">4.45</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_5LkGyXDUZ0GC7oULw3sfVg">3.46</ix:nonFraction>%&#8201;&#8211;&#8201;<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_ZSuwYQ6mv0WMkQOjKZGPCA">4.71</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_p9Znd5LFZkSH_xiXlcs-Ww_5_2">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_BWlMDYFpAEiBf6X3rMHJhA_5_4">0.00</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_4KKeiPcUyU2k6n2tgFWd3g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_uteOZctC4Um1EclUJpoG7Q">6.08</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_EZEO1er5NEyxL_p2ZKMavg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_AF_oANlaPEKM7NyONNQ8Aw">6.20</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_iZBC1Qycd0ODSeXIqiMLDw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_HmTgWNvIgkyABTk2PXBzQA">6.18</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_kR9dLuqQQUK9opN7bHqIBQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_CbjH0tQLTUSZMnRTqEaXxQ">6.37</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_FQ1d8QnOWkCWjse8M5V5Yg">zero</ix:nonFraction> as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_xgbXf2MMfkWcUnVv1UIRSQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:61.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_cQy2Owp5J0uRSJ74KVZn3w_6_2">4,213,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_79zo-ee39EeJ439i0cnAkw_6_5">4.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_YDnBRnlahUyJAH8g9ffcAw_6_8">1,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_AGOwSCyDiU6on4bag6pf8w_6_10"> 6.5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_ftHYuaY6W0SZg5o2DPhDjw_7_2">247,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_m6uqYj6tDEmbFBceJ-hAxg_7_5">1.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_PlO1obwYyEaAyh7xjaJbtQ_8_2">93,350</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_yzBc3YtGWUmdpzxpdLzTug_8_5">0.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_mia7ZcaLNE-LroUhuipXww_9_2">12,815</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_XYbzTG0KuECE5gWtmSB1oQ_9_5">2.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_i2fK3EmXNk2I4yRIUJ225A_10_2">1,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_krDsBl5KjUWgAFO6FOZizw_10_5">2.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_F7bt3glgk0CBTsFYuD4-mg_11_2">4,353,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc__nVZrRCo8UWRJ72jANv1lA_11_5">4.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_rv4nATE_Y0u7HUCeYlvvJg_11_10"> 5.8</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_4xlLMpMig06p1EXXVAcPjQ_12_2">3,688,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_JAPzVUrFl0yQgW3ohD9EgA_12_5">5.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_rdctpMYs00ynLDm_dq7qHA_12_10"> 5.3</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The weighted-average grant date fair value of stock options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_3FCsVfeEpkucfbgHMiliuQ">1.56</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_EavnrQGuyUq5s9rUlc4JRA">1.56</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively. There were <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_cX8nR_PK1EyyCBNysJAixA">247,500</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_a0yy9ZJKhk2_gaeNhN6TaA">385</ix:nonFraction> for the year ended December 31, 2024 and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_0IVz5PCI106ewKroggeT5Q">628,769</ix:nonFraction> stock options granted at an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" scale="3" id="Narr_Ri_KjwIGEkWigwxT66Bclw">983</ix:nonFraction> for the year ended December 31, 2023. During the year ended December 31, 2024 and 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_6H7v3kB36kW6oNBlejeqNQ">93,350</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_tnXEjC64-0aWCGfMA61NsQ">0</ix:nonFraction> stock options </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_h9TvllRRLEe79qHyLpElrg_1_2"></a><a id="Tc_aZstCOkJq0mFtvJU2oMNgA_1_4"></a><a id="Tc_riXkO_I-iE2eFfmVUmYRJw_2_2"></a><a id="Tc_tEBcSIEF8kimLGF8oS5qAA_2_4"></a><a id="Tc_1EU1vjMiYkCS_M0hgwEDzg_3_0"></a><a id="Tc_a-1_MJt-eEWNukYYKKGp2Q_3_4"></a><a id="Tc_FWCOa6KZ6Ea6cboNSpGWmA_4_0"></a><a id="Tc_siTJdVfla0STXWT8n9sXIw_4_4"></a><a id="Tc_plOV28E7C0y1D7RCksL2mw_5_0"></a><a id="Tc_eEqLHvjA1ESH9qhHkt4w-A_5_4"></a><a id="Tc_IyNbmuFk1kSEcx15_hyUbw_6_0"></a><a id="Tc_HrYcci3IGUePomlR1_Q6YA_6_4"></a><a id="Tc_kOIjKtUFKkeSPCkqZFdodw_7_0"></a><a id="Tc_p8qfZx2x20ydJQvMYmyLMw_7_4"></a><a id="Tc_7R5a846gfkyTPzF495OkDg_1_3"></a><a id="Tc_tB7Mr3MEfki95E8xRkZCrA_2_3"></a><a id="Tc_vH3IOMj-Z0maXQSktkJ7tQ_2_6"></a><a id="Tc_BoUKLM07XEOi3qks2pzOAw_3_0"></a><a id="Tc_ysF1XalwLkOUEriJC32qxA_3_3"></a><a id="Tc_z51IfP_lfUO0XdixNiG8uw_3_6"></a><a id="Tc_fYW0fv2Dx0yo1ST_BLktMQ_4_0"></a><a id="Tc_decQ2DXeU0mknDholwyCJQ_5_0"></a><a id="Tc_cyHosuNrT0eLbxwl2BMAMA_5_3"></a><a id="Tc_a7f9FWRPoU-rSKMJND9MAg_5_6"></a><ix:continuation id="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont3" continuedAt="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exercised, respectively, with an aggregate grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_cOV9QkON7kKxZBqdob-Qqg">58</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" scale="3" id="Narr_YdIlcxE9qEmFro0GfJ2UUQ">0</ix:nonFraction>, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_HmgvmMqiPkKYpGW2BXrQcQ">121</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_X78mf6Fag0GKNPRdstdB8Q">0</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The fair values of RSUs are based on the fair market value of the Company&#8217;s common stock on the date of grant. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" scale="0" id="Narr_ANu-2HaS6EOXfU5O9lbDYg">one</ix:nonFraction> share of the Company&#8217;s common stock upon vesting. RSUs with time base vesting conditions for employees vest annually over <span style="-sec-ix-hidden:Hidden_z0Vdnv6oQU-dhLEWmZmyvg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mjymGu0RfUeiL7Co7NPZdA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_XLeJj_TXSUKdp25EiS6l6w">four years</ix:nonNumeric> on each anniversary of the Grant Date and RSUs for non-employee directors vest on the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_o-vcv2H3AUS1ElrISMMh5A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_O2j0kaOiGkyo8deoqFOMnw">one-year</ix:nonNumeric> anniversary of the Grant Date. RSUs with performance conditions for employee&#8217;s vest on the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_M3K_G0bufEehYVEvbvLxhg">one-year</ix:nonNumeric> anniversary of the performance achievement date, assuming continued service from the employee during that period of time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024 and 2023, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Gs623ATbik2Oe4zo2D13OA">358,200</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Hkyrmv-pfEyH9afz2yTZxQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_3UEbsfixV0elENK10LLNxA">542,419</ix:nonFraction> RSUs awards, respectively, containing time based vesting conditions to employees and non-employee directors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024 and 2023, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_jlzi-Gd0bEqT83ac3hyXlg">515,600</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0Ur3_enFS0W4_rr4CTlI6A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_yqKXqKfKQ0GmmqlYLTbdPQ">0</ix:nonFraction> RSUs awards, respectively, containing performance based vesting conditions to employees. During the year ended December 31, 2024, the performance conditions were achieved and RSUs will vest on the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_5Mbz5yMawEygnFWLL7hjDA">one-year</ix:nonNumeric> anniversary of the achievement of the performance condition. As of December 31, 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_item_2EZlvjH0wki-oLaHkndxvg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_JXRbb9ivf0eQ2WygjyfFaA" decimals="INF" format="ixt-sec:numwordsen" name="cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" scale="0" id="Narr_Yf3JYl_tK02WnCYmdDPbEg">no</ix:nonFraction> outstanding performance condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_l6xBcSdBe0mb-xodUU8-tw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_I9ygSIfkgUCv0l44Z5TfbQ_3_2">522,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_1TM6VunOuUmtujN0VuJszg_3_5">2.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_uXFTi5EC7UeG7-F-7bbj8w_4_2">873,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_0MGeyndVUUK70TI7nL9Y4Q_4_5">1.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_crOog6cDckaKxnTTJ7RGDw_5_2">183,482</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_y6RkuNFPnk6qmUR91ZBHig_5_5">2.17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_WcDJXBfoN0ysW3UQUOVYZA_6_2">39,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_Vbmo5p_QnEmnH1xBZoc5jw_6_5">1.89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_8XoN7_JJ9kKXO8IZ65q-6Q_7_2">1,172,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_rNk4AczNRUK22RMZWtF0yQ_7_5">1.98</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_TyKT3nY1ekKivxZNi5d_rA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cz7E_hdUVUWwa9Vuq9Mihg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JthONBD3Fka3uwTZmEfc6w_3_4">1,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6w45MJ0QnUikkNsbjaNclg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CxG-kTNsjUmqtqvqFr-gIg_3_7">670</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2Q9ZkTw_DUCugaCKI_H91Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dMyZVynBVUaLV-1aaJaYmA_4_4">2,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynoIxvwk10KeE1sFcDzURw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hBbtzbbuUkmSnRae4XcOfA_4_7">3,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GJXnFrVnQUiRqQK6pQ-cXg_5_4">3,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aVB5lGgxtUixkrfU2HwLAQ_5_7">4,354</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, total future compensation expense related to unvested time-based awards yet to be recognized by the Company was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_dz8CP6PLZkqLWBdEigMlig">2,055</ix:nonFraction>, which is expected to be recognized over a weighted-average remaining vesting period of approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_W0HsNXJ1bEiB_0on8HSfUA">1.9</ix:nonNumeric> years. As of December 31, 2024, total future compensation expense related to unvested performance-based awards yet to be recognized by the Company was $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_GafOTV2hp0qNoyDaJ5nlAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_OH55Gsd7TEmepJ17nA2yuw">462</ix:nonFraction>, which is expected to be recognized over a weighted-average remaining vesting period of approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_HTF3nxxkYEqnzjZbaDO4Bg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_9KxI38GtVEi7wCK8s5vUBw">0.8</ix:nonNumeric> years.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_sLrdLyTbQkWSGwu0xL0yPg_cont4"></ix:continuation><a id="Tc_6A7Z62uB_kuEL4Y7XsdtJQ_1_2"></a><a id="Tc_ikeTspEfcEKJgNrE4lZw9w_2_2"></a><a id="Tc_CROPVp2A00Knob1ue2gBWA_2_4"></a><a id="Tc_sF_cW8mFUEasGOXGfS1ziw_3_0"></a><a id="Tc_E_d5uVa1CEKae4_Ak2cWWA_4_0"></a><a id="Tc_hAKdx6zaeU-uTFcRM5rurw_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_xaYaAfCNFEqsIJR89xKpSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_gX-BseuqUUOCI5i13Hf0bA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_SefUZ0-stEK6Wo6PqsHRnA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4-ZlksmwLUyneAqpu4KqvA_3_2">4,353,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_YMzsuYYScUGAVgdtaKBakQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Df2ZHHCv80WK8dFSLAjSww_3_4">4,213,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JSDRzJzk2kCr9Ut2IvY5WQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-EMeXP2xdEWSY1RnRtQUPw_4_2">1,172,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BZ1BPutL2kCFpmBC9iHmpg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_yu4n_7aynUSlx0YbckHgYg_4_4">522,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_NX0eQeVqtUGu_Mlscjajyw_5_2">5,526,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q2s2fOK0BkWKf9Np_yJ0Fg_5_4">4,735,560</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_bVRtltxHXkaxa8T91yaVgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_fOFMLM-CuEqgxsZ9Fokmtw">6</ix:nonFraction>% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_IWmT25LCaUKONjfvVDIMbw">265</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="3" id="Narr_xG-AdUGXIUepPGcC2vqgiQ">199</ix:nonFraction> for the&#160;year ended December&#160;31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_f_bG3kYu7kafNq4mpmvzyQ_1_2"></a><a id="Tc_Uzp8FanR5kGG-8eK808r4Q_2_2"></a><a id="Tc_mQpa7BNnlkGV-6kH6XAMxQ_2_5"></a><a id="Tc_ZF56b2Eyr0GMdkpacOmEZw_3_0"></a><a id="Tc_WjwUqAW3tESLbIV29KG1XA_3_2"></a><a id="Tc_FV1sTYpU-0Ceq5988viSng_3_5"></a><a id="Tc_bCcn_4d1UUahw982mi00_w_4_0"></a><a id="Tc_YL3wS3GOMkqVKe9DmKKE0Q_4_3"></a><a id="Tc_RP2BGMs-w0mI_XujdO1wZw_5_0"></a><a id="Tc_RHwvzu2wBUCmv21kblnbmw_5_2"></a><a id="Tc_cOGeLZpObkurUNA-Y5DfUw_5_5"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d_2"></a><a id="_cd8b0f8b_295f_4eb4_aa76_0b43912ce55d_3"></a><a id="Tc_TVPVZI2Ml026qQ8GzZdo5g_1_2"></a><a id="Tc_DcD41RCazUu5fZTlUSCFwQ_2_2"></a><a id="Tc_w0PUEiaHSkabFyzT_9HPsw_2_4"></a><a id="Tc_TGcgMPvJeEaViL3mD9QvRQ_3_0"></a><a id="Tc_Wwc_Eb2nWEqTxYAtdgEVpw_3_3"></a><a id="Tc_peIgR1aH8kOiegtwxWslQw_3_5"></a><a id="Tc_bRNQiXd8WEibNmyvHpJFMQ_4_0"></a><a id="Tc_KS2eMqte-0CcvklHgmY32A_4_3"></a><a id="Tc_5GQBrg3D-EuazbzzrosSog_4_5"></a><a id="Tc_R4sEKvsaJUWrbsOB7fnnlw_5_0"></a><a id="Tc_pDeRawoQMUKBXFoBuXo1_g_5_3"></a><a id="Tc_ZTfXSEI_Gkif8GShcJrlSw_5_5"></a><a id="Tc_GNEU6Q9wLUqquvE_h0_sAg_6_0"></a><a id="Tc_BoA2Hy45O0q2X8xUoxqPWA_6_3"></a><a id="Tc_9Uph3DEGg0KleKe9puFx7w_6_5"></a><a id="Tc_3cglecOTuU6qmiueres_wg_7_0"></a><a id="Tc_Gw6RJjq3skGu5ZF4ZoRQ-g_7_3"></a><a id="Tc_1udfzXPEK0WvbuciHOLZVA_7_5"></a><a id="Tc_eajJ7YrOf0SJ-8Qnzk7pIQ_8_0"></a><a id="Tc_dOk7mMfCVEmX0eWK-qu9xg_8_3"></a><a id="Tc_nt57Uqh-A06jIWJYXQAg0g_8_5"></a><a id="Tc_LvHHce_xok6MISMnlbCfWA_9_0"></a><a id="Tc_se8N_gFRhE2ssbLKqcZ08g_9_2"></a><a id="Tc_GQoc1FWF9kKGx5yFYLnF-Q_9_3"></a><a id="Tc_R70h8COGiEmD8hC3ouUU1w_9_4"></a><a id="Tc_rGpxxUdH6k2xBqzLs0Va0g_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_BUbmIO2kt0q2ylJRFXWWuA" continuedAt="Tb_BUbmIO2kt0q2ylJRFXWWuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_OrM5AzJddEW1O8CHUR9QfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_nmSx3eMirkOFVE37EywSYQ_3_3">33,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_wmulIUc5eEiROvqS77hRMw_3_6">25,767</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_Qj9VxoqQ6EO1KQ20mua-ww_4_6">21</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lUM1rRnnCEKMsDpWbTvQ_A_5_3">33,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_aiQ-3zYC-0WW8T19mHb4qA_5_6">25,788</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_lIzPUnRHZEGBRCcNLv-PlA"><ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_Zwi6dgP5IE-Ot1f_Ko0hLQ">no</ix:nonFraction></ix:nonFraction> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_GFNzS38JXEqNIBDpQd_yig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_PDVTuC9eP0Wxgc3fJflXmw_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_4-4RjaV_TUy3EgjLjJlPuA_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_gjd689tlskapRTLDv2q10w_4_2">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_iDuhBy94LEG0-6NglX9nyw_4_4">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_zlDWqelg-Eu6zMMcpqqHKw_5_2">21.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_GT2M47WApkyyiMisx0rx1g_5_4">22.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_bCDDIw8TO0qrQadReDEnPA_6_2">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_93Citm8Tc0qNjW-JzpNENg_6_4">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_adU3I8wWck6TkL4XzGGScw_7_2">1.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_aI4eKXXx4U2NKkgNcTdG3Q_7_4">3.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_uE_J7rUhyEuAyCdiOLtsiA_8_2">1.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_r-q0enk4okGS2RQie7DJsQ_8_4">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_DHZkpTsrNUqQwZgIo5TUKA_1_2"></a><a id="Tc_Vd-EizUmZUuf3Qn-_Zi3cQ_2_2"></a><a id="Tc_K3qiyN4hUUKdVzsQ8oPHtw_2_5"></a><a id="Tc_8adcfbGSdUG-xRD4CQR99w_3_0"></a><a id="Tc_tHXAyQXWtUK19kfZBjr12A_4_0"></a><a id="Tc_KOUXoCVrGEG3GhdFcLGmug_4_2"></a><a id="Tc_S0Vvv0WCXEW9gNgi1Sh3LQ_4_5"></a><a id="Tc_jo4rUv_8DUa3JIryQBV_aQ_5_0"></a><a id="Tc_4jgJut7ZCkmfx8lMWY9icA_6_0"></a><a id="Tc_D2Eg6keoC0CIWowiqen-WQ_7_0"></a><a id="Tc_6lb_6jklHkCQ8HACxUgDoA_8_0"></a><a id="Tc_yWX8_sX2v0Ghr0phoiktgg_9_0"></a><a id="Tc_KbSN_p9vIUCKQ1tdpCBnGg_10_0"></a><a id="Tc_-4mK1NIa2UKbpU-WuU5z8w_11_0"></a><a id="Tc_sTjrltZG90ONCA8btikR2g_12_0"></a><a id="Tc_2pnqxECkHU6M8SYvQQ_L-g_13_0"></a><a id="Tc_fQrKz7HUEEq1jh2_sb6E-g_15_0"></a><a id="Tc_tBOqzFu3Z0GOROep5yUXXA_16_0"></a><a id="Tc_nM8oTLXcdEag_3vBIBv3PQ_17_0"></a><a id="Tc_MWqHT-WkdEuJGbVYFTDj0g_18_0"></a><a id="Tc_n9WD0jP910SqHZgJS9jAAw_19_0"></a><a id="Tc_Xm-DGRdHWkWvxqG2q6nWVA_19_2"></a><a id="Tc_0hJJvEAAIk2mJLvyPmR1nQ_19_3"></a><a id="Tc_oIckwziL-kGlKkDg9VARvA_19_5"></a><a id="Tc_oCjpDdP8v0eW2FveJN39jw_19_6"></a><ix:continuation id="Tb_BUbmIO2kt0q2ylJRFXWWuA_cont1" continuedAt="Tb_BUbmIO2kt0q2ylJRFXWWuA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_071RJqjYLUCydZTLamzQ4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_toxutnBT2UmHCMsJ-9Whzg_4_3">8,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_uIIX5KG5W0GOpKnfyZKwiw_4_6">6,847</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_u7ISu3DLs0K-fLZo9SbQLQ_5_3">3,791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_EIOFV82WnkOXu9A0QJQahA_5_6">3,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_2uSKhpRU-USBl-BqrHyRSQ_6_3">477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_zBo8JaDvtUyVSOfLK6KF-g_6_6">407</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_cT6zAmE7gU-E-LoBss9LhQ_7_3">114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_Pdqv_VuJjUuiYN-MyLZ67w_7_6">148</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_mxZniesUek2nqHrk5-41BQ_8_3">16,089</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_Cdl7g7JxREyKJz6_i-vdIA_8_6">11,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_n3FEkgCsmkumzYCiSLx8ew_9_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_a3k3Qifnf0COeVC29ZJZrQ_9_6">223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_ndw8eMM_4E2mh0mnWKegYg_10_3">324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_yJkBtyUsBk2OZvnFYdp6uA_10_6">246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_-rMZ8uTicUapLXpHcwusMQ_11_3">29,510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_IzqbLhlSQku_MuPW_S0UbA_11_6">22,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8tPQTh-6D02DprS7R3nslg_12_3">29,400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Wkxu4qnbjkW3MRP5_KmqUQ_12_6">22,207</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_w-L0HEwAIU6PskWJ_E3fpA_13_3">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_LHmTrkvISkmM8sWerXS6xA_13_6">147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_6udT3rFM9Uaur-9Vdf6O5w_16_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_-kJufBliiUyISqyJGrTc7A_16_6">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_iHz56uBj1EyqBQrnf6j5AA_17_3">106</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_NFsR6ILQJ0-Eerb2F5HveQ_17_6">139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_EgCySVP5FUyPuLrpVgZDtg_18_3">110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_9QMyvWTdi0WfmZ8UL17r1A_18_6">147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2024 and 2023. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2024 and 2023, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_3a1HunjfMkirhf18HP93Cw">7,193</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_6W6heKWxwUCjaLSCHI6Bng">5,772</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. The increase in valuation allowance in 2024 was primarily a result of operating losses and tax credits generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021 and year ended December 31, 2024. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2024, the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_Ty5N7SVpt0q-tMuLyVN5QA">38,063</ix:nonFraction>, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_eVZJB182o0egvEoPsomYNg">38,063</ix:nonFraction> is $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OperatingLossCarryForwardsSubjectToExpiration" scale="3" id="Narr_JKLtf1qMs0KPwEKD3ElJzQ">11,503</ix:nonFraction> that begin to expire in 2035 and $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:OperatingLossCarryForwardsNotSubjectToExpiration" scale="3" id="Narr_PpVfxBeAuEiIHwdtkaNn-w">26,560</ix:nonFraction> that can be carried forward indefinitely. As of December 31, 2024, the Company had state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_R4fyJmu5eUuklOk2TqC2fg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_iXigpGvdwE6iXKIbyRtU0w">12,613</ix:nonFraction>, available to reduce future state taxable income, which will begin to expire in 2028. During the year ended December 31, 2024, the Company ceased operations of its wholly owned foreign subsidiary. As a result, all foreign net operating loss and research tax credit carryforwards were written off with an offsetting decrease to the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_r3tUz6_Kt02MxBdQeEQGEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="Narr_ugjf17RWikSVd8qsz0zKqA">589</ix:nonFraction> of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2024 and determined that it is more-likely-than-not that the Company&#8217;s existing net operating loss and research and </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_BUbmIO2kt0q2ylJRFXWWuA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2021; however, carryforward attributes that were generated prior to January 1, 2021 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_df511532_2d5e_43e1_bcad_7788662bfc06"></a><a id="Tc_heQ0jtT5OEOrwgpQNQs0fA_1_2"></a><a id="Tc_BTcRbxAtmEOSV7KmfywNww_2_2"></a><a id="Tc_cZqxe9VdIEuS9LhryBetNg_2_5"></a><a id="Tc_VSlFrDVQXEio8pp6xfmOjg_3_0"></a><a id="Tc_wKaDI2NbME2Tchx9Ml4d7A_3_2"></a><a id="Tc_oBX3GfRAZ0WlvTYYVe_zMA_3_5"></a><a id="Tc_tSdCmJMr9EWvHv7eju-_0w_4_0"></a><a id="Tc_dmGbLWEGrEqJk26698KhUg_5_0"></a><a id="Tc_N_DjdhTy60qGWFXZjnRHCg_6_0"></a><a id="Tc_J-5UCLlhs0uMk1O5Az0TWw_7_0"></a><a id="Tc_O1tbVo1Jv0eJEc3Jssf61w_8_0"></a><a id="Tc_ttX4XHrOGEOhiUz6JhA2VA_9_0"></a><a id="Tc_e-azJj5UGkikqQ57tp1mIA_10_0"></a><a id="Tc_EoAramILhUix1_DiMM2AZQ_11_0"></a><a id="Tc_3wCAMuzgKkakpOQDWfy-Og_12_0"></a><a id="Tc_U3IX1tiFs0y_b64JxD1rvw_13_0"></a><a id="Tc_YccV5AjHd0agHSkqCoVc7g_13_2"></a><a id="Tc_O8amxM-PFkmRfZ2P07otcA_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_5YDV4qDqB0GVp9hAj4TXag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_7gmChiSwG0mV5IoODBsb4g">one</ix:nonFraction> operating segment related to the development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#8217;s Chief Executive Officer (CEO) serves as the CODM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#8217;s consolidated net loss. The measure of segment assets is reported on the consolidated balance sheets as total assets.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_tHSj4fUS0UGhwSRLOiaFuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:SegmentGrantIncome" scale="3" id="Tc_0rZt3CywmkiRJOEySlOnPA_3_3">19,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:SegmentGrantIncome" scale="3" id="Tc_m14G457Wb0mWpp9msxT-RA_3_6">24,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentClinicalPrograms" scale="3" id="Tc_HbIl6SGWEkmj2SX2R47qZg_5_3">27,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentClinicalPrograms" scale="3" id="Tc_0LH9_qQo4kCZ9VICebnNnw_5_6">21,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">R&amp;D Personnel costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentPersonnel" scale="3" id="Tc_dULuOXE6akO0UGyU0fchdQ_6_3">9,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentPersonnel" scale="3" id="Tc_xcuz2ARI30mPpqUCAx5MAQ_6_6">8,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentPreclinicalPrograms" scale="3" id="Tc_9Htpa336yEyysxXbhpTyGQ_7_3">810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentPreclinicalPrograms" scale="3" id="Tc_YZP47GMu20aawFxBX3Wbhw_7_6">3,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentManufacturing" scale="3" id="Tc_evBR-1Rvpkuy7OTEOAb5qQ_8_3">2,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="cgtx:ResearchAndDevelopmentManufacturing" scale="3" id="Tc_jzTY1tTtTUeglIuOwdC01g_8_6">2,890</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_PhNHz9VgK0aUc5l3ShR-Og_9_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_56h36bGDLUOVrAapwiMqdA_9_6">430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_HwEPTHFshECsAnPpq5woow_10_3">9,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_lSJ88HqHgEW3b-JGW_hh5Q_10_6">9,844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9GmZ8uAKeUibQVYlZ-jnCw_11_3">3,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uKWwt8vKc0ezj7shEFqTXQ_11_6">4,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_uqW-ORNPikGhfCCu-YSiQQ_12_3">446</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" sign="-" scale="3" id="Tc_cGSmp1wSVkaAKfgWOxYrlw_12_6">131</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment and consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eeaFBgY_AUaijH22NRc-Rg_13_3">33,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A" contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_LR_w5N7VLUeDMxsMQrXnfg_13_6">25,788</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> R&amp;D Personnel costs exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup> General and administrative expenses exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt 0pt 0pt 56.15pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup> Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_523116ce_076c_429d_8ff7_7e139b04b7ad"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b49661c2_b163_41fd_8d90_135d559c0170"></a><a id="Item9AControlsandProcedures_434960"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our President and Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Controls over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Our management, including our President and Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met and cannot detect all deviations. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or deviations, if any, within the company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9f0f0a67_433d_4ab3_a53c_22d88e2e5be3"></a><a id="Item9BOtherInformation_878908"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated Bylaws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On March 19, 2025, our Board of Directors approved an amendment (the &#8220;Bylaws Amendment&#8221;) to the Second Amended and Restated Bylaws of the Company (the &#8220;Bylaws&#8221;), effective immediately. The Bylaws Amendment amended Section 1.5 of ARTICLE I of the Bylaws to reduce the quorum requirement for all meetings of stockholders from a majority of the voting power of our outstanding shares of common stock entitled to vote generally in the election of directors to one third of the voting power of our outstanding shares of common stock entitled to vote generally in the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The foregoing description of the Bylaws Amendment is qualified in its entirety by reference to the full text of the Bylaws Amendment, a copy of which is filed with this Annual Report on Form 10-K as Exhibit 3.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Rule 10b5-1 Trading Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">None of our directors or &#8220;officers,&#8221; as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted or terminated a Rule <span style="-sec-ix-hidden:Hidden_aC02QIKoOUyPVq4UeX7GUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b<span style="-sec-ix-hidden:Hidden_Nt8kwa65QE2wzlLEyRX9NA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>-1 trading plan or arrangement or a non-Rule <span style="-sec-ix-hidden:Hidden_u4Jf8gqGbEGJb2oeDKiKTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b<span style="-sec-ix-hidden:Hidden_wu-IG5I7IEGcFveZXiNmug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_eef2777a_2cbe_47c6_b94b_ac331f962524"></a><a id="Item9CDisclosureRegardingForeign"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_625c1a70_349a_476d_8dc7_26ba8f407293"></a><a id="PARTIII_479695"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our definitive proxy statement related to the 2025 Annual Meeting of Stockholders, or the Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We have adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of securities of the Company by directors, officers, and employees that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards. Our insider trading policy states, among other things, that our directors, officers, and employees are prohibited from trading in such securities while in possession of material, nonpublic information. In addition, with regard to the Company&#8217;s trading in our own securities, it is the Company&#8217;s policy to comply with the federal securities laws and the applicable exchange listing requirements. The foregoing summary of our insider trading policies and procedures does not purport to be complete and is qualified by reference to our Insider Trading Policy filed as an exhibit to this Annual Report on Form 10-K.</p><a id="_2536eb4c_a337_4f05_963a_c5384048a662"></a><a id="Item11ExecutiveCompensation_635596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b57f8970_33e5_49c2_bc53_eb31affa94c2"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_71974649_d0f6_4c30_a3be_140886803853"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e9153952_081a_4a2c_a81f_f90029d8f61b"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PartIV_346291"></a><a id="_977cf34d_7f45_486f_9c82_d48a1caac255"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">(a)(1) Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentAccountingFirm"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 42) </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofStockholdersEquity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:92.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;width:92.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">(a)(2) Financial Statement Schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">(a)(3) Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following is a list of exhibits filed or incorporated by reference as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6abc507f_68e1_4093_8c30_e9cd20432dc4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX</p><a id="_cf3c6188_e7e9_494a_9eed_0b8f274b5f54"></a><a id="Tc_scraUAHuoke_xk5hNFYqbw_1_0"></a><a id="Tc_NlW9wJ5BhU6l26GJcySxoA_1_4"></a><a id="Tc_1i41toV_f0S9phkHNHM8Zw_1_12"></a><a id="Tc_Ie0ZeY7JeEGacXuSpXRJ6g_2_0"></a><a id="Tc_6M_N3o5wiUCHYft5VuHmlw_2_2"></a><a id="Tc_s9ljNJthFUSgmSXl-VuPWQ_2_4"></a><a id="Tc_SLUYhf8QpUef1DZDj5WBXw_2_6"></a><a id="Tc_KqooPo4wDkONbK82wFb3Mw_2_8"></a><a id="Tc__xFx8EFORk6PNVKHIEPaTw_2_10"></a><a id="Tc_epFw3m17MU2k_RY5ovIAlw_2_12"></a><a id="Tc_22iEXH96F0ulqEEiYMt5CA_3_0"></a><a id="Tc_j7Hsgf3f8ESOBFw-UoG4Dg_3_2"></a><a id="Tc_zayKFv_qpka9Er9V_ueWeg_3_4"></a><a id="Tc_w6ilj4oXUkO6QTViw37ygA_3_6"></a><a id="Tc_cGpCoQQhQ0StG6aPhmagSg_3_8"></a><a id="Tc_gNiWkGEFckm1R1-oNuBA3Q_3_10"></a><a id="Tc_9_mpbvZ8h0uVT8_yU3imNg_4_0"></a><a id="Tc_Foy6gZw61ECgFjaUtVxeAQ_4_2"></a><a id="Tc_coGy2GfFx0SSXE20YXS4-Q_4_4"></a><a id="Tc_z6kzU2jylEm3GxLn71wqdg_4_6"></a><a id="Tc_uSQz00CZXUq0cKvVEzWREg_4_8"></a><a id="Tc_BSjNAJGqfEONttOYgYYjvg_4_10"></a><a id="Tc_4p5XVGWOOk-T37KkKD2M6w_5_0"></a><a id="Tc_PWQ1dDgrzEiAEI6oUisS8w_5_2"></a><a id="Tc_vAMUeM9HqU-PCeg2cHOC7Q_5_12"></a><a id="Tc_GjyqJRrqBE2E6JfVGLy8SQ_6_0"></a><a id="Tc_BwPlEC2qfEmlGKtwqwsgeg_6_2"></a><a id="Tc_Jr_HDak72kSUeV72EW9Ouw_6_4"></a><a id="Tc_zkQhBq0wi0Cyb9x9qCDPmA_6_6"></a><a id="Tc_R4lVLinkSEeTfeXCEth0mA_6_8"></a><a id="Tc_We83jFVv-EqzOll7_V7tnw_6_10"></a><a id="Tc_pblIa4aGEECnsvYDv96Wqw_7_0"></a><a id="Tc_1ccDVgimZ0isEZE4fzXzvA_7_2"></a><a id="Tc_OnK1poe-wU2c7bfd9Cac-w_7_4"></a><a id="Tc_JUmQn3YhUEuuBXz6boQUWg_7_6"></a><a id="Tc_kQpqdFn5y0KJAQaYhkUQzw_7_8"></a><a id="Tc_NxePRzfWI0u0SxKVZZfMFQ_7_10"></a><a id="Tc_YPTYMmZNSEqFXGhkc3IlBg_8_0"></a><a id="Tc_E6yAZyFztkeLDqRJuxlinQ_8_2"></a><a id="Tc_k64sRzKdTEanKizQJuaWpw_8_4"></a><a id="Tc__3OZLIzalEKrTZp8UrC1ZA_8_6"></a><a id="Tc_QVc9t17Zjk-02R_9CEr0LQ_8_8"></a><a id="Tc_eJNCm6LN5EOIAzRBfxeeSQ_8_10"></a><a id="Tc_hxMjwk0IrE6vvKszRe6Wow_9_0"></a><a id="Tc_B4euZK6hiUOATYl-xjshNA_9_2"></a><a id="Tc_rETLm2giUkOKhZ0CelTCig_9_4"></a><a id="Tc_vrC1I6f-90qxqmGGKDz8qQ_9_6"></a><a id="Tc_sJ7CCZ8EGkeT6P-NZZYcJQ_9_8"></a><a id="Tc_qV9MlkaTyUKOwB9s5bys5A_9_10"></a><a id="Tc_Xds1OUapWES2HABptyd5lw_10_0"></a><a id="Tc_8OJzIMH0ikCw6i9U-LMetA_10_2"></a><a id="Tc_DIjghzQkXU2OtxVj_6u3Zw_10_12"></a><a id="Tc_iV8_l_VH4UmUXHdxlsIPKA_11_0"></a><a id="Tc_qygK2jC5iUaSJub_M_fwig_11_2"></a><a id="Tc_tgOsbYiTnkWVlnq6wGo8KA_11_4"></a><a id="Tc_iYCwqnC7tUi65MTyRo6XdQ_11_6"></a><a id="Tc_K7vULEwuREW6Fk7Kb5q5iQ_11_8"></a><a id="Tc_wg0b3v0NsE2onipJE0J2fg_11_10"></a><a id="Tc_EHOMAI6lfEi7VwfQq84BPA_12_0"></a><a id="Tc_bJtireL2EESiYyDPhwrNkQ_12_2"></a><a id="Tc_cbfw92sLwEir-_KX-cmp8A_12_4"></a><a id="Tc_Wo_r08hKhk6M0TK3e6cmKQ_12_6"></a><a id="Tc_661k8SDg20m3b8VIo3M_Tg_12_8"></a><a id="Tc_foZm91fR6kGqC9KXX9bh1g_12_10"></a><a id="Tc_UXzlmh3FV0afmlvUeJMcJQ_13_0"></a><a id="Tc_bKza6ZOhx02HXgDl2lZ8Eg_13_2"></a><a id="Tc_Xbf8DLpj0EKwC6eipCOP0g_13_4"></a><a id="Tc_3OuodE5rKU64PD_Ud0OC3w_13_6"></a><a id="Tc_1VZEZtKjxUGYJrH62BOGKg_13_8"></a><a id="Tc_DWzX4bnnLEmp_NKSJUczqQ_13_10"></a><a id="Tc_ecqAJYUzOkeJSWGu8tc27g_14_0"></a><a id="Tc_LCpdKIkRrEyAb_s_KvlI3A_14_2"></a><a id="Tc_wccEQl3tPU-nB-yuYIi35g_14_4"></a><a id="Tc_vtyAwTP6nkGWrHTwVVSIIw_14_6"></a><a id="Tc_WEo60ADPg0-UIAp5ms6hOA_14_8"></a><a id="Tc_zlwRs7RklEWx0iId_Tx-oA_14_10"></a><a id="Tc_jCQRvw1VIkmP5VEJ2Fbf7w_15_0"></a><a id="Tc_I0R_fs-6zUyJHmEMG4w9OA_15_2"></a><a id="Tc_c4AS3wqo30aIzZCo71Z4oQ_15_4"></a><a id="Tc_NgH7KHPNuEyz5N4zzFlQhw_15_6"></a><a id="Tc_jF46P7cgu0ivP44hcYZTSA_15_8"></a><a id="Tc_11WlgHseEE-MuYXDASraTA_15_10"></a><a id="Tc_KrwqWJiWR0OWzrVTaUP9iQ_16_0"></a><a id="Tc_r1dltItCFEWlsEKbBMwGmg_16_2"></a><a id="Tc_okWeWxgf3Uej1hl7F0oLoA_16_4"></a><a id="Tc_eD_yFH4RAUG_8zenLbLv0A_16_6"></a><a id="Tc_rpDMz6RBz0KaiqXlQZtATQ_16_8"></a><a id="Tc_NNhlO40xXUC5Aus7_HdPYQ_16_10"></a><a id="Tc_DRI3b15G5kaMB5WECrE75Q_17_0"></a><a id="Tc_3WmDCmruJE2AY9kYSr30DQ_17_2"></a><a id="Tc_kpRvi-eMH0egj59gAultWA_17_4"></a><a id="Tc_VeVcI2_GokaxDNFXL8EWyg_17_6"></a><a id="Tc_YdG2L71IiUWzvOWgYyAM7Q_17_8"></a><a id="Tc_BvzqKhLY70uxK4K8NZfkVw_17_10"></a><a id="Tc_8iBKd2oSG0GNO78JOL8zpA_18_0"></a><a id="Tc_h7db9zeEOU68GsXgy6mEZQ_18_2"></a><a id="Tc_t5-F7swgKkSvOyFWAuoacw_18_4"></a><a id="Tc_3C22GJ_U30OVAwLwwCx22A_18_6"></a><a id="Tc_gQ4D6OUEbkiHXEoWnxUR1A_18_8"></a><a id="Tc_XvwO8N8kOU-YOH_QOCoWDw_18_10"></a><a id="Tc_nVWr6ZLX5Eq5EiAtJ11G4w_19_0"></a><a id="Tc_cAo12NY3S0-WFodcZB5xng_19_2"></a><a id="Tc_bgqDSgJwO0SoK4QjkZANWA_19_4"></a><a id="Tc_0EQUqeAqy0-512VYK9fSBg_19_6"></a><a id="Tc_8cvKa3RrPUW4l0exw4E3uA_19_8"></a><a id="Tc_YpnFChsofkyWESyb7peeww_19_10"></a><a id="Tc_jHmqvFvYB0qYv02uTUsrKQ_20_0"></a><a id="Tc_OdepFQy59kuwQtIhQRM1mQ_20_2"></a><a id="Tc_r2ju2Tj_3k-M64ZSZnQbbg_20_4"></a><a id="Tc_SbP8f1Z9PkSJnPxlZwb95w_20_6"></a><a id="Tc_CrpHIQGy40G2wUTBdPjNyw_20_8"></a><a id="Tc_hQveyW4XNkaUBWQ5UVb6ow_20_10"></a><a id="Tc_NZIHPNeoFUKSvVUnlsp9JA_21_0"></a><a id="Tc_bqlwtV__C0ygVl_E_rxfiw_21_2"></a><a id="Tc_fhpCkBvxAUuNX2XJ9nB2Nw_21_4"></a><a id="Tc_yAW9XSCb_Ua39kzd_8_Xgg_21_6"></a><a id="Tc_1v9P6iiKGUu0A4lSbAVIDw_21_8"></a><a id="Tc_gEBhhH7qlUitzAts0O-JsA_21_10"></a><a id="Tc_Ng8wyF5MSkKgTgbxZvG8cA_22_0"></a><a id="Tc_ufClBG8VeEyxJc4k0Ys7AQ_22_2"></a><a id="Tc_qApJ2Ki3WU2AkVFmCNzIOQ_22_4"></a><a id="Tc_XFspbiZKzUKKRWydTxaxkQ_22_6"></a><a id="Tc_x2Vfz_xjKUOHC2kaPryzHg_22_8"></a><a id="Tc_v8xhLZnrnkiaVXinPrIHDw_22_10"></a><a id="Tc_m2ByyWNHfkuSe_ZLs5pANA_23_0"></a><a id="Tc_bFHtTFJdVUmQitWF9c5-aQ_23_2"></a><a id="Tc_jO96AJ3FbE2Z1T25So11IQ_23_4"></a><a id="Tc_-WimXPfV1kCkBTuFJTvFUQ_23_6"></a><a id="Tc_fMGuVQYF106FlLEC7Q-xaQ_23_8"></a><a id="Tc_xphXJLROW0GQrJHdDr6vrA_23_10"></a><a id="Tc_xkcbfwSCqUuMwtE5KZNEDA_24_0"></a><a id="Tc_7B9wUL21TUC7To4Yi_nOzQ_24_2"></a><a id="Tc_QvfdJpig_0WPCMuyB7La0Q_24_4"></a><a id="Tc_G3ADwJJDPEmKknYFpU04Bw_24_6"></a><a id="Tc_aAfdTx4nuEalp9vdv0kYWA_24_8"></a><a id="Tc_7tAPKnMJVEC130DpIlonwg_24_10"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.08%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc.</span></a>&#160;</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/14/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837023008117/cgtx-20230331xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2023</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex3d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Second Amended and Restated Bylaws of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837022004672/cgtx-20211231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/30/2022</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indenture</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Third Amended and Restated Investors&#8217; Rights Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease Agreement between RJ Equities LP and Cognition Therapeutics, Inc., dated July 1, 2017, as amended</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between 2500/2700 Westchester Avenue Owner SPE LLC and Cognition Therapeutics, Inc., dated July 1, 2021</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2007 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/04/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of&#160;Stock Option Grant Notice and Award Agreement under the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2020, between Cognition Therapeutics, Inc. and Lisa Ricciardi</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/tm2314004d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated April 17, 2023, between Cognition Therapeutics, Inc. and John Doyle</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/01/2023</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15#</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employee Restrictive Covenant Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16#</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Board of Directors of Cognition Therapeutics, Inc. Nomination Letter of Mr. Brett Monia, Ph.D.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/29/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/14/2016</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_uR3PYelHTkmkTWBQu49tFw_25_0"></a><a id="Tc_Vbrp94gbTEGHrc0ujv4waQ_25_2"></a><a id="Tc_uUPKlSz7xESWas7YIlsApw_25_4"></a><a id="Tc_nZ0EcvK4XUm-EJxEN2jzaA_25_6"></a><a id="Tc_ue7b5uC6xUO7yvEv5thOUA_25_8"></a><a id="Tc_Jonn3tEMj0Sgt8pn_8DAIw_25_10"></a><a id="Tc_-t_5jrwtJE2jQmHmSR7Mfg_26_0"></a><a id="Tc_KZnCJEQknkauaBizd2nUxg_26_2"></a><a id="Tc_IipchOQq6UCssIG1PMvf9g_26_4"></a><a id="Tc_s_g03LHAeUuyU62YmaF9QA_26_6"></a><a id="Tc_V3OnOG3r9USapDbZV41eAA_26_8"></a><a id="Tc_sECOWl0DjUWLt3GzOjpHQQ_26_10"></a><a id="Tc_gzvXNeMJ6k2VV8pNdNkzNA_27_0"></a><a id="Tc_T7QF7xP6CUykAt9HGkcilA_27_2"></a><a id="Tc_jVEag0R_30ezkkSEbMxy9w_27_4"></a><a id="Tc_M-LMyrE8iEGQPysgPy4qvg_27_6"></a><a id="Tc_AKeF6n0TrU2zZa61XUitjQ_27_8"></a><a id="Tc_sYdbL0SaCUKTZW3GM_8n3Q_27_10"></a><a id="Tc_LU4adS-ALECHL-VQguBBSQ_28_0"></a><a id="Tc_tJvNBhElq0GL32UZxCVZ5A_28_2"></a><a id="Tc_UeqH5xvh1ke7xz4Ap5H0Sg_28_4"></a><a id="Tc_0YwnFjKwO0ydvc7nLvK5wg_28_6"></a><a id="Tc_S0zbCJhEPUGYe3AvEsRCpA_28_8"></a><a id="Tc_1w_LT-oziUyzdn51p2yARQ_28_10"></a><a id="Tc_ZErFsYAD1kq89kicoGl-og_29_0"></a><a id="Tc_2qkFeLsl2E6gPU2rjiRiiA_29_2"></a><a id="Tc_AyYRt1O0sEeQL488nYwltg_29_4"></a><a id="Tc_Bu4cN-NpikeKrwPh8DTBXA_29_6"></a><a id="Tc_fyg1JTAAXUel88Cgt-5SGQ_29_8"></a><a id="Tc_vMr8kTpizUaFJCulbPzPqw_29_10"></a><a id="Tc_ktgsUZX27kCdrez-5Y0fow_30_0"></a><a id="Tc_6shlWutMkUWo3LVuQvNIGw_30_2"></a><a id="Tc_ysfHv8kAwEOCa5lHQVQ0Sg_30_4"></a><a id="Tc_EQibCAzdmk6WdFAK4nUw7A_30_6"></a><a id="Tc_gb1v-WjoZUewMgghweBFQw_30_8"></a><a id="Tc_tkgkR0AnvkykTgvNqPpeXA_30_10"></a><a id="Tc_jDgpeFAZYEKpMNiaQmksfQ_31_0"></a><a id="Tc_4q-fYqhUs0SEusgN6M6F9A_31_2"></a><a id="Tc_QFdOG5VS_kODooTlLX1boQ_31_4"></a><a id="Tc_3M0Cbgt91UWNaaw5n-GyQA_31_6"></a><a id="Tc_11ujfrNV-k-xYD2fUATuEw_31_8"></a><a id="Tc_DQjUy12520KrVmMwR4D2Pg_31_10"></a><a id="Tc_I6Ju7-5Jc0Or7_Uwg_MxJw_32_0"></a><a id="Tc_pfnhJwjPBEWRjTjBH3fNMA_32_2"></a><a id="Tc_fU7eyAXqwk6PVdTrc1ntQQ_32_4"></a><a id="Tc_mcmbGecRo0mTYnmxuqWKkg_32_6"></a><a id="Tc_sAFabHoSkkaCztGvjtAjQQ_32_8"></a><a id="Tc_JWHRwZy8FEmPU2kfkKxCjw_32_10"></a><a id="Tc_Es3He9cBY0SeffGK9Ne1eA_33_0"></a><a id="Tc_H0lcKDAZUUeSIZFn8A4Ccg_33_2"></a><a id="Tc_Dn02id0Erkif_0tKTXMhCA_33_4"></a><a id="Tc_OY_KC13vukaknzwpSztr-w_33_6"></a><a id="Tc_cqLfnWOFuESOPasbYh-Obw_33_8"></a><a id="Tc_yDRnDdWncUGCFU3dbnN3JQ_33_10"></a><a id="Tc_5V5V-E3utUW7GoIExTCMYg_34_0"></a><a id="Tc_J8eZFHhAXE-lXPHStsnHdA_34_2"></a><a id="Tc_Axj9YlQE0k6k0btMVo5NNQ_34_12"></a><a id="Tc_hBNRzgu9OESdAIJS6zUcsA_35_0"></a><a id="Tc__jviHkZFEUupRe6ncxgC7g_35_2"></a><a id="Tc_pdPpZQ0fCk-fxgrB3YOZ1w_35_12"></a><a id="Tc_-dqAX8hNY0WjKvKb8ToxRA_36_2"></a><a id="Tc_1J9CDk8Z0k-3DKv_q1zeXQ_36_12"></a><a id="Tc_SB8BPJAJUEqen--_RRD5fA_37_0"></a><a id="Tc_nffixDBEjEasqsPTLRC9SA_37_2"></a><a id="Tc_3GiCNPZ3X0OkRUe-idikLg_37_12"></a><a id="Tc_noKgXkZKSUCTvS3puqIveg_38_0"></a><a id="Tc_6PPn7h9tWkS1K6tqzrx7rA_38_2"></a><a id="Tc_C5xOVYb_ok-WSCxnasdskw_38_12"></a><a id="Tc_U_k3scoVfkKH3dNxEXsNMA_39_0"></a><a id="Tc_PKlNT8AlOkmr46pykseG3Q_39_2"></a><a id="Tc_pw_JDazMmU2TDzSHYNucEw_39_12"></a><a id="Tc_xJ4vN3iAhEykoPhj7IXTcQ_40_0"></a><a id="Tc_LM2FMBwptk-1rxhsaCb_5w_40_2"></a><a id="Tc_fVbxV0xgfkawXo9qU3os5g_40_12"></a><a id="Tc_6ngmH09mHki0Yivy3fy9wg_41_0"></a><a id="Tc_K2vpbBVG2UWVye6c1vQiDg_41_2"></a><a id="Tc_lvHHSMKUrUynf2zeRGIOoQ_41_4"></a><a id="Tc_xcyllVI6ZECO8CwAnfa3ww_41_6"></a><a id="Tc_swGuWaXe70ihQ3CdG6Btyg_41_8"></a><a id="Tc_P9gk93ohg0mXNvwbFmsNDw_41_10"></a><a id="Tc_bEeIXcfhbEaI0Ny9uve03A_42_0"></a><a id="Tc_ts-S0uR7EUmkxw9Yk77wGA_42_2"></a><a id="Tc_Nl8MTR7e0UCVM0lVIp1ZOw_42_12"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.08%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 09/08/2018</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 08/28/2020</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 02/03/2021</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/06/2021</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">National Institute on Aging, Notice of Award, dated 05/10/2021</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-257999</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/2021</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465922129904/tm2233311d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Controlled Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:5.62pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;Sales Agreement, dated December 23, 2022, by and among the registrant, Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-268992</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/2022</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465923030852/tm239035d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of March 10, 2023, by and between Cognition Therapeutics, Inc. and Lincoln Park Capital Fund, LLC</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2023</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465924025580/tm246515d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Performance Restricted Stock Unit Award Agreement</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/20/2024</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19.1**</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc.&#8217;s Insider Trading Policy</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Cognition Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Tc_abw6P4GxnkqyNTDsyoaKZw_36_0">23.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP, independent registered public accountant</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cgtx-20241231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837024003949/cgtx-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cognition Therapeutics, Inc.&#8217;s Compensation Recovery Policy</span></a></p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40886</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/26/2024</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Yp8tF2nWY0GuD9PA6HT6Jw_43_0"></a><a id="Tc_bYmNyPWelkG89hqURJiZqQ_43_2"></a><a id="Tc_b7s8BvWS3kKUlRa277p1yQ_43_12"></a><a id="Tc_nW6W13dZfEu5C3SBc6BJEA_44_0"></a><a id="Tc_0OeSMLmAzUKDX3Y95UcdBg_44_2"></a><a id="Tc_kLaexzTLQ06K5zzKlv16pg_44_12"></a><a id="Tc_ln2Ayk1hOEmQJvU4KoPZaw_45_0"></a><a id="Tc_4wWdTt8T8kmpu3O5cPMn2g_45_2"></a><a id="Tc_ReHRuNmj70Ofldz9WKzs8Q_45_12"></a><a id="Tc_jpKwnWXzykesc4YfjhRg6Q_46_0"></a><a id="Tc_5nIJUVdSjEuywfcPqQU9tQ_46_2"></a><a id="Tc_apcuZea630m5eW33KV6ijw_46_12"></a><a id="Tc_C298VckZQkKgOtl81BnxwA_47_0"></a><a id="Tc_ORaAEQZsm0aB4RGWRVvD4g_47_2"></a><a id="Tc_swpkvGxnsUiV42WIvt8-Bg_47_12"></a><a id="Tc_mljzMk-FoUaq1jrdt3mJXg_48_0"></a><a id="Tc_9DCuyfxwH0iLTHLQr-D9jQ_48_2"></a><a id="Tc_MmO_sGnn7kqvhGv8pINiDQ_48_12"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.08%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:7.93%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.52%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.53%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.81%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td><td style="vertical-align:bottom;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">* This certification is deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">**Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"># Indicates a management contract or any compensatory plan, contract or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_740af9c0_3451_4340_8bc5_d47483ebeade"></a><a id="Item16Form10KSummary_806161"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d212c57d_4c84_4559_a62d_19530feae6d2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 20, 2025.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COGNITION THERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Lisa Ricciardi</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer) </i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 20, 2025 by the following persons on behalf of the registrant and in the capacities indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.1pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.05pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer, President and Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ John Doyle</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">John Doyle</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Jack A. Khattar </p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director (Chairman of the Board)</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jack A. Khattar</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aaron G. L. Fletcher, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Brett P. Monia, Ph.D.</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Ellen B. Richstone</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:13.55pt;"><td style="vertical-align:top;width:29.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Peggy Wallace</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>2
<FILENAME>cgtx-20241231xex3d3.htm
<DESCRIPTION>EX-3.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:16 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 3.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECOND AMENDED AND RESTATED BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="white-space:pre-wrap;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font>The Second Amended and Restated Bylaws (the &#8220;<font style="font-style:italic;font-weight:bold;">Bylaws</font>&#8221;) of Cognition Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Corporation</font>&#8221;), are hereby amended as follows, effective as of March 19, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td style="vertical-align:top;width:98.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 1.5 of ARTICLE II of the Bylaws is hereby amended and restated in its entirety to read as follows:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>. The presence, in person or by remote communication, or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock of the Corporation representing one third of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business at such meeting. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section 1.4 <i style="font-style:italic;">[Notice of Meetings; Adjournments]</i>. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:0.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:top;width:98.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Except as specifically amended herein, the Bylaws shall remain unchanged and in full force and effect.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[</b><font style="font-style:italic;font-weight:bold;">Remainder of page intentionally left blank</font><b style="font-weight:bold;">]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF ADOPTION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDMENT TO SECOND AMENDED AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTATED BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="white-space:pre-wrap;">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</font>The undersigned hereby certifies that she is the duly elected&#8239;or appointed, qualified, and acting Corporate Secretary&#8239;of&#8239;Cognition Therapeutics, Inc., a Delaware corporation, and that the foregoing Amendment to the Second Amended and Restated Bylaws constitutes the entire amendment to the Second Amended and Restated Bylaws, as duly adopted by the Board of Directors on March 19, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:98.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:98.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:98.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">President, Chief Executive Officer and Acting Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>cgtx-20241231xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 72.05pt 0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 35.29pt 0pt;"><b style="font-size:20pt;font-weight:bold;">LAB </b><b style="font-size:20pt;font-weight:bold;">LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 45.34pt 0pt;"><b style="font-size:14pt;font-weight:bold;">between</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">RJ EQUITIES LP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 26.45pt 0pt;"><b style="font-size:14pt;font-weight:bold;">(Landlord)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 32.95pt 0pt;"><b style="font-size:15pt;font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">COGNITITION THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 42.5pt 0pt;"><b style="font-size:14pt;font-weight:bold;">(Tenant)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">Dated: January 20</b><b style="font-size:16pt;font-weight:bold;">th, </b><b style="font-size:16pt;font-weight:bold;">2015</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 16.45pt 0pt;"><font style="font-size:15pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:15pt;">TABLE OF CONTENTS</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLEI. BASIC TERMS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 2. PREMISES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 3. TERM AND COMMENCEMENT</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 4. CONSTRUCTION OF PREMISES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 5. BASE RENT</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 6. RENT ESCALATION</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 7. LATE PAYMENT</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 8. USE OF PREMISES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><img src="cgtx-20241231xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:1.42pt;width:1.42pt;">ARTICLE 9. COMMON AREAS/PARKING</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 10. ALTERATIONS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.35pt;width:0.35pt;">ARTICLE 11. MECHANIC&#8217;S LIENS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><img src="cgtx-20241231xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:0.35pt;width:0.35pt;">ARTICLE 12. CONDITION OF PREMISES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 13. UTILITIES AND SERVICES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 14. ASSIGNMENT AND SUBLETTING</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 15. RIGHTS RESERVED BY LANDLORD</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><img src="cgtx-20241231xex10d3004.jpg" alt="Graphic" style="display:inline-block;height:1.42pt;width:2.13pt;"><img src="cgtx-20241231xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:0.35pt;width:0.35pt;">ARTICLE 16. REPAIRS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><img src="cgtx-20241231xex10d3006.jpg" alt="Graphic" style="display:inline-block;height:0.35pt;width:0.35pt;">ARTICLE 17. INDEMNIFICATION AND INSURANCE</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 18. LANDLORD&#39;S LIABILITY</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 19. COMPLIANCE WITH INSURANCE REQUIREMENTS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 20. FIRE OR OTHER CASUALTY</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 21. SUBORDINATION</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 22. CONDEMNATION</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 23. ESTOPPEL CERTIFICATES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 24. DEFAULT</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 25. PROVISIONS RELATED TO LANDLORD&#39;S REMEDIES</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 26. LANDLORD&#39;S DEFAULT; RIGHT TO CURE</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 27. WAIVER</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 28. UTILITY DEREGULATION</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 29. TELECOMMUNICATIONS</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">ARTICLE 30. SURRENDER</p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">24</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-i-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 31. QUIET ENJOYMENT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 32. HOLDNG OVER</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 33. ENVIRONMENTAL COVENANTS, REPRESENTATIONS AND WARRANTIES</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 34. TENANT&#39;S COMPLIANCE WITH LAWS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 35. DISABILITIES ACT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 36. NOTICE</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 37. BROKERS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 38. FORCE MAJEURE</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 39. TRANSFER OF LANDLORD&#39;S INTEREST</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 40. SUCCESSORS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 41. GOVERNING LAW</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 42. SEPARABILITY</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 43. CAPTIONS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 44. GENDER</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 45. EXECUTION; COUNTERPARTS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 46. ENTIRE AGREEMENT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 47. AUTHORITY</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 48. SECURITY DEPOSIT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 49. OFAC CERTIFICATION</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">EXHIBIT &#8220;A&#8221; DIAGRAM OF DEVELOPMENT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">EXHIBIT &#8220;B&#8221; OUTLINE OF PREMISES</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">EXHIBIT &#8220;C&#8221; RULES AND REGULATIONS</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">EXHIBIT &#8220;D&#8221; INTENTIONALLY OMITTED</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">EXHIBIT &#8220;E&#8221; ESTOPPEL CERTIFICATE</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:94.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">EXHIBIT &#8220;F&#8221; SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-ii-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">OFFICE LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;"><img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></font> This Office Lease Agreement (the &#8220;Lease&#8221;) is made this _ day of January, 2015 (the &#8220;Effective Date&#8221;), by and between <b style="font-weight:bold;">RJ EQUITIES LP</b>, a Pennsylvania limited partnership <font style="font-size:11pt;"><img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></font>(&#8220;Landlord&#8221;) and <b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b>, a Delaware colporation (&#8220;Tenant&#8221;).<font style="font-size:11pt;"><img src="cgtx-20241231xex10d3009.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">ARTICLE 1. BASIC TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12.69pt 0.7pt;">For the purposes of this Lease, the following terms shall have the meanings set forth below:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RJ EQUITIES LP, a Pennsylvania limited partnership</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COGNITION THERAPEUTICS, INC., a Delaware corporation</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td style="vertical-align:top;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suites 261, 263, and certain shared lab space all of which is located on the second floor of the commercial building (the &#8220;Building&#8221;) situated at 2403 Sidney Street, Pittsburgh, PA 15203 (the <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">&#8221;Development&#8221;) and as outlined on the Diagram of Development attached hereto as Exhibit &#8220;A&#8221;. The Premises contains <img src="cgtx-20241231xex10d3011.jpg" alt="Graphic" style="display:inline-block;height:2.16pt;width:0.72pt;">approximately 3,706 rentable square feet as depicted on the floor <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">plan attached hereto as Exhibit &#8220;B&#8221; (and which, for informational <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">purposes only, is allocated as follows: 1,577 sq. ft. for Suite 263; 1,472 sq. ft. for Suite 261; and 657 sq. ft. for the lab space).</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commencement Date:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 1, 2015.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(e)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial Lease Term:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Three (3) years.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(f)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Termination Date:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 31, 2018, subject to extension in accordance with this Lease.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(g)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Extension Term:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">One (l) additional term of two (2) years.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(h)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$85,238.00 per year / $7,103.17 per month.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Year for Real Estate Taxes:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2009.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(j)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Year for Operating Costs:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2009.</p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(k)</p></td><td style="vertical-align:bottom;width:34.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximate rentable area of the Premises:</p></td><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3,706.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(l)</p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximate rentable area of the Building:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221,000.</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(m)</p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant&#39;s Proportionate Share:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.68%.</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(n)</p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security Deposit:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">N/A.</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(o)</p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Uses:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab Space and office use.</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(p)</p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notification Addresses:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">Landlord: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">RJ Equities LP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">2403 Sidney Street, Suite 200</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">Pittsburgh, PA 15203</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="cgtx-20241231xex10d3006.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">Cognition Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">2403 Sidney Street, Suite 261</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.35pt;">Pittsburgh, PA 15203</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: President</p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(p) </p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parking:</p></td><td colspan="2" style="vertical-align:bottom;width:59.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant shall be provided, at no additional charge, nine (9) nonexclusive parking spaces. Fifteen (15) visitor parking spaces are <font style="font-size:11pt;"><img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></font>available, at no additional charge, for Tenant&#39;s guests for visits of two (2) hours or less.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 2. PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Landlord, for and in consideration of the Rent (as defined below) to be paid and the covenants and agreements to be performed by Tenant, as hereinafter set forth, does hereby lease, demise and let unto Tenant the Premises, together with a non-exclusive license (in common with others), to use the common areas of the Building and the Development. Landlord reserves unto itself, however, the use of the roof, exterior walls and the area above and beneath the Premises, together with the right to install, maintain, use, repair and replace exterior windows and doors, pipes, ducts, conduits, wires and structural elements leading through the Premises in locations and in such a manner which shall not materially or adversely interfere with Tenant&#39;s use or occupancy thereof. In addition, Tenant shall have the right to maintain Tenant&#39;s existing signage at the Development as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 3. TERM AND</b><b style="font-weight:bold;"> COMMENCEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term and Confirmation</u>. The term of this Lease shall commence on the Commencement Date set forth in Article 1(d) and end on the Tennination Date set forth in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 13.19pt 0pt;">Article 1(f), unless extended or sooner terminated as provided herein, subject to adjustment as <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">provided below and the other provisions hereof. If the Commencement Date is postponed as <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">provided below, the Termination Date set forth in Article 1 shall be adjusted accordingly. Tenant shall execute a confirmation of the Commencement Date and other factual matters in such form as Landlord may reasonably request within ten (10) days after requested by Landlord following the Commencement Date; any failure to respond within such time shall be deemed an acceptance of the matters as set forth in Landlord&#39;s confirmation. If Tenant disagrees with Landlord&#39;s adjustment of the Commencement Date, Tenant shall pay Rent and perform all other obligations commencing on the date as determined by Landlord, subject to refund or credit when the matter is resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commencement Delays</u>. The Commencement Date, Rent and Tenant&#39;s other obligations shall be postponed to the extent Tenant is unable to occupy the Premises because Landlord fails: (i) to substantially complete any improvements to the Premises required to be performed by Landlord under this Lease, except to the extent that Tenant, its contractors, agents or employees in any way contribute to such failure, or (ii) to deliver possession of the Premises <img src="cgtx-20241231xex10d3018.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">for any other reason, including holding over by prior occupants. If Landlord so fails for a ninety (90) day initial grace period, Tenant shall have the right to terminate this Lease by notice within <img src="cgtx-20241231xex10d3019.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">ten (10) days. Any such delay in the Commencement Date shall not subject Landlord to liability for loss or damage resulting therefrom, and Tenant&#39;s sole recourse with respect thereto shall be <img src="cgtx-20241231xex10d3020.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">the postponement of Rent or termination of this Lease in accordance with the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 27.85pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension Terms</u>. Provided that no event of default by Tenant has occurred hereunder, Tenant shall have one (1) option to extend the Lease Term (the &#8220;Extension Option&#8221;) for one additional period of two (2) years (the &#8220;Extension Term&#8221;). In order to exercise the <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Extension Option, Tenant shall provide to Landlord written notice nine (9) months prior to the expiration of the Lease Term. All of the terms and conditions of this Lease shall apply to the Extension Tem, including without limitation, the payment of additional rent as contemplated under Article 6 hereof, except that (i) Base Rent for the Extension Term shall be equal to the Fair Market Rental Value (as hereinafter defined) for the Premises as of the commencement of the <img src="cgtx-20241231xex10d3020.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Extension Term, and (ii) the Tenant shall accept the Premises in its then &#8220;As-Is&#8221; condition. For purposes hereof, the term &#8220;Fair Market Rental Value&#8221; shall mean the then current market rental rate for comparable buildings in Pittsburgh, Pennsylvania, as reasonably determined by Landlord, giving appropriate consideration to the following matters: (i) annual rental rates per <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">rentable square foot; (ii) the type of escalation clauses (including, but without limitation, operating expense, real estate taxes, and CPI); (iii) rent abatement provisions reflecting free rent and/or no rent during the Lease term; (iv) length of Lease term; (v) size and location of premises being leased; and (vi) other generally applicable terms and conditions of tenancy for similar space. The Landlord shall determine the Fair Market Rental Value by using Landlord&#39;s good faith judgment and shall provide written notice of such amount within thirty (30) days after the Tenant has notified the Landlord of the exercise of the Extension Option. The Tenant shall have ten (10) days after the receipt of such notice of the proposed Fair Market Rental Value within which to reject such rent. In the event Tenant fails to reject such proposed Fair Market Rental Value, by written notice delivered to Landlord within such ten (10) day period, then such proposal shall be deemed accepted and shall be the Base Rent applicable during the Extension </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Term. If Tenant timely rejects such proposed Fair Market Rental Value, then the Tenant&#39;s notice <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">to Landlord shall specify that Tenant has elected to terminate the exercise of the Extension <img src="cgtx-20241231xex10d3026.jpg" alt="Graphic" style="display:inline-block;height:3.24pt;width:0.36pt;">Option, whereupon such termination, the Extension Option shall be null and void for all purposes and the parties shall have no further obligation with respect thereto. The Extension Option is personal to Tenant and may be exercised only by Tenant while it occupies the entire Premises and may not be exercised or be assigned, voluntarily or involuntarily, by or to any other person <img src="cgtx-20241231xex10d3027.jpg" alt="Graphic" style="display:inline-block;height:1.44pt;width:1.08pt;">or entity. If the Tenant fails to timely exercise the Extension Option, then the Extension Option shall automatically expire, Tenant shall no longer have the right to exercise the Extension Option <img src="cgtx-20241231xex10d3028.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">and this section shall be of no further force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 4. CONSTRUCTION OF PREMISES</b><b style="font-weight:bold;"><img src="cgtx-20241231xex10d3018.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0.7pt;">Tenant confirms that (1) it has inspected the Premises and accepts the same in its existing &#8220;AS IS&#8221; condition, and (2) no repair, work, alterations or remodeling of the Premises is required to be done by Landlord as a condition of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 5. BASE RENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 14.6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>. Tenant shall pay to Landlord Base Rent, payable in advance without demand on the first day of each calendar month throughout the Term; provided, that <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Tenant shall pay Base Rent for the first full calendar month for which Base Rent shall be due (and any initial partial month) when Tenant executes and delivers this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Rent</u>. Whenever under the terms of this Lease any sum of money <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">is required to be paid by Tenant to Landlord in addition to the Base Rent herein reserved, and said additional amount so to be paid is not designated as &#8220;additional rent&#8221;, then said amount shall nevertheless, at the option of Landlord, be deemed &#8220;additional rent&#8221; and collectible as such, but nothing herein contained shall be deemed to suspend or delay the payment of any sum at the time the same becomes due and payable hereunder, or limit any other remedy of Landlord. Nonpayment of additional rent beyond the expiration of applicable notice and/or cure periods <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">shall constitute a default under this Lease to the same extent, and shall entitle the Landlord to the same remedies, as nonpayment of Base Rent. Where no time limit for payment is otherwise stated in the specific Lease provision applicable thereto, any such obligation shall be due and payable within fifteen (15) days following Tenant&#39;s receipt of a written statement showing in reasonable detail the basis for the amount claimed. Base Rent and additional rent are sometimes hereinafter referred to as &#8220;Rent&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments.</u> All payments of Rent shall be paid when due without any deduction, recoupment, set-off or counterclaim (except as otherwise set forth in this Lease) at the principal office of the Landlord or at such other place as Landlord may from time to time direct. No delay by Landlord in providing a statement for Rent shall be deemed a default by Landlord or a waiver of Landlord&#39;s right to require payment of Tenant&#39;s obligations for any Rent due under the terms of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12.69pt 0.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-4-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11.3pt 0pt;"><b style="font-weight:bold;">ARTICLE 6. RENT ESCALATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Real Estate Tax Increases</u>. Tenant shall pay to Landlord, as additional rent, Tenant&#39;s Proportionate Share of the amount by which Real Estate Taxes incurred by Landlord during any <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">calendar year following the Base Year for Real Estate Taxes shall exceed the Real Estate Taxes incurred by Landlord during such Base Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Real Estate Taxes&#8221; shall be deemed to mean the aggregate amount of taxes and assessments levied, assessed or imposed upon the Development in which the Premises are located. For purposes hereof, Real Estate Taxes shall include, without limitation, real estate taxes, sewer rents, water rents, assessments (special or otherwise), transit taxes, any tax or excise on rentals or any other tax (however described) on account of rental received for use and <img src="cgtx-20241231xex10d3034.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">occupancy of all or any part of the Premises, whether such taxes are imposed by the United States of America, the Commonwealth of Pennsylvania, the county in which the Premises is <img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">located or any local governmental municipality, authority or agency, or any other political subdivision of any of the foregoing. Real Estate Taxes shall also include all reasonable costs and expenses (including, without limitation, legal fees and court costs) incurred in connection with the protest or the reduction of any of the aforesaid taxes and or assessments, up to an amount equal to the reduction of any of the aforesaid taxes resulting from such protest. If at any <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">time during the term hereof, a tax or excise on rents or any other tax, however described, is levied or assessed by any govemmental authority on account of the rents hereunder or the interest of Landlord or Landlord&#39;s beneficiaries under this Lease, then such additional tax shall be included in Real Estate Taxes. Further, any tax assessed or levied by any governmental authority in lieu of the foregoing Real Estate Taxes shall also be included. For the purpose of determining Real Estate Taxes for any given calendar year, the amount to be paid for such <img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">calendar year shall be (a) with respect to assessments, the amount of the installments (and any interest) due and payable during such calendar year and (b) with respect to all other Real Estate <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Taxes, the amount due and payable during such calendar year, but only to the extent properly allocable to such calendar year. Notwithstanding anything in this Lease to the contrary, &#8220;Real Estate Taxes&#8221; shall not include (i) any capital stock, net income, profit tax, succession, transfer, franchise, gift, estate or inheritance tax, (ii) any transfer tax or recording charge resulting from a transfer of the Development or the Building or any interest in the Development or the Building or (iii) any penalties, interest or fines incurred by Landlord due to nonpayment or late payment of taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Cost Increases</u>. Tenant shall pay to Landlord, as additional rent, Tenant&#39;s Proportionate Share of the amount by which Operating Costs incurred by Landlord during any calendar year following the Base Year for Operating Costs shall exceed the Operating Costs incurred by Landlord during such Base Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;">&#8220;Operating Costs&#8221; shall be deemed to mean all costs and expenses of any kind or nature <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">incurred by Landlord in any calendar year in operating, policing, protecting, lighting, heating, air conditioning, insuring, repairing and maintaining the Building, other structures and improvements and the land constituting or supporting the Development, all in accordance with <img src="cgtx-20241231xex10d3040.jpg" alt="Graphic" style="display:inline-block;height:1.44pt;width:0.72pt;">accepted principles of sound management of similar properties, and shall include (without</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 13.19pt 0pt;">limitation) all costs and expenses of operation, replacement, replacement and maintenance, <img src="cgtx-20241231xex10d3041.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">including by way of illusfration and not limitation: personal property taxes and any tax in addition to or in lieu thereof, assessed against Landlord or to be collected by Landlord; utilities; supplies; materials; tools; insurance (including, but not limited to, commercial general liability, casualty, business interruption, rent loss insurance and flood and earthquake insurance); licenses, <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">permits and inspection fees; cost of services of independent contractors (including property management fees); any tax, assessment, cost or fee incurred by Landlord in connection with the Development from any neighborhood improvement district or similar program or initiative; cost of compensation (including employment taxes and fringe benefits) of all persons who perform regular and recurring duties connected with day-to-day operation, maintenance and repair of the <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Development, its equipment and the component interior and exterior common areas, ceilings, floors, walks, stairs, stairwells, elevators, loading docks, trash compactor, malls and landscaped <img src="cgtx-20241231xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">areas including janitorial, gardening, security, parking, operating engineer, painting, plumbing, electrical, carpentry, heating, ventilation, air conditioning, window washing, signage and <img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">advertising; rental expense or a reasonable allowance for depreciation of personal property used <img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">in such maintenance, operation and repair of the Development; those variable costs, expenses and disbursements which Landlord reasonably determines Landlord would have incurred had the Development been 100% occupied at all times during such calendar year; and amortization of Permitted Capital Expenditures (as hereinafter defined).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 13.19pt 0pt;">Notwithstanding anything in this Lease to the contrary, &#8220;Operating Costs&#8221; shall not include the following: costs to benefit, or relating to, a specific tenant, such as legal and other related expenses associated with the negotiation or enforcement of leases, and any penalties or damages from such lawsuits; costs associated with the financing or refinancing of debt or selling of the Building, the Development or any interest therein, such as points, broker&#39;s fees and attorney&#39;s fees; executive salaries and compensation of employees of Landlord above the grade of regional property manager; repairs and/or replacements which are covered by insurance claim or condemnation proceeds; leasing commissions, legal fees, tenant allowances or fit outs (including permit, license and inspection fees), advertising costs, space planning costs and promotional material; costs incurred by Landlord in connection with the original construction of <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">the Building or the correction of latent defects in construction of the Building; depreciation and amortization (except for amortization of Permitted Capital Expenditures); costs paid to subsidiaries or affiliates of Landlord, to the extent that the costs exceed the reasonable costs that would have been paid had the services, supplies or materials been provided by unaffiliated parties on a reasonable basis; interest on debt or amortization payments on any mortgage or deeds of trust or any other borrowings and any ground rent; ground rents or rentals payable by Landlord pursuant to any over-lease or any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord; costs incurred in managing or operating any &#8220;pay for&#8221; parking facilities within the Development; expenses resulting from the <img src="cgtx-20241231xex10d3020.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">gross negligence or willful misconduct of Landlord or its agents, employees or contractors; any fines or fees for Landlord&#39;s failure to comply with governmental, quasi-governmental, or regulatory agencies&#39; rules and regulations, or any costs or expenses incurred by Landlord due to violation by Landlord, or Landlord&#39;s agents, contractors or employees, of either the payment terms and conditions of any lease or, service contract or other agreement covering the Development or Landlord&#39;s obligations as owner of the Development; costs for sculpture, <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">decorations, painting or other objects of art in excess of amounts typically spent for such items in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-6-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">office buildings of comparable quality in the competitive area of the Building; costs of any political, charitable or civic contribution or donations; Capital Items, except for Permitted Capital Expenditures; costs that are properly chargeable to particular tenants in the Development, <img src="cgtx-20241231xex10d3050.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">including, without limitation, costs and expenses for providing heating and air conditioning service outside of normal business hours and damages to the Development or any part thereof caused by the act or neglect of another tenant; costs relating to utilities or other services to tenant spaces for which Tenant pays for such utilities or other services directly; costs properly <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">attributable (applying generally accepted accounting principles) to other calendar years; costs paid by Landlord if and to the extent such costs are incurred by Landlord for any work or service furnished to any other tenant in the Development (other than Tenant) to a materially greater <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">extent and in a materially more favorable manner than furnished generally to the remaining tenants in the Project (including Tenant); costs incurred with respect to preparation of income tax returns; and costs incurred in cleaning up any environment hazard or condition in violation of any environmental law. &#8220;Pennitted Capital Expenditures&#8221; means capital expenditures and capital repairs and replacements (&#8220;Capital Items&#8221;), provided such Capital Items (x) are <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">necessitated by a change in law or regulation occurring after the Commencement Date; or (y) are reasonably intended to have cost-saving benefits over the Term of the Lease. The foregoing provision is for definitional purposes only and shall not be construed to impose any obligation upon Landlord to incur such expenses. No item of Operating Cost shall be included more than once in any given time period and no item of expense charged to Tenant as an Operating Cost <img src="cgtx-20241231xex10d3034.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">shall be charged to Tenant as Real Estate Taxes or any other type of chargeable expense or cost. The property management fees incurred by Landlord shall only be chargeable to Tenant to the extent such property management fees do not exceed the property management fees incurred by other buildings of similar size and quality and located within the geographic area in which the Development is located.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Payment</u>. Within sixty (60) days after the end of each calendar year (including the last calendar year of the term of this Lease), Landlord shall furnish Tenant a written statement showing in reasonable detail Landlord&#39;s Real Estate Taxes and Operating Costs for the Base Year and the preceding calendar year and showing Tenant&#39;s Proportionate Share of the amount of any increase in such Real Estate Taxes and/or Operating Costs over the amount thereof for the respective Base Year. Coincidentally with the monthly rent payment due following Tenant&#39;s receipt of such statement, Tenant shall pay to Landlord an amount equal to the sum of (1) Tenant&#39;s Proportionate Share of the increase in Real Estate Taxes and Operating Costs for the preceding calendar year over the amount thereof for the applicable Base Year; and (2) one-twelfth (1/12th) of such increases for the current calendar year multiplied by the number of rent payments (including the current one) then elapsed in such calendar year. Thereafter such one-twelfth (1/12th) amount shall be paid monthly with the Base Rent until subsequently adjusted in accordance with the terms of this Article.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#39;s Proportionate Share</u>. &#8220;Tenant&#39;s Proportionate Share&#8221; of Taxes and Operating Costs shall be the percentages set forth in Article 1, but if the rentable area of the Premises or Building shall change, Tenant&#39;s Proportionate Share shall thereupon become the rentable area of the Premises divided by the rentable area of the Building, subject at all times to <img src="cgtx-20241231xex10d3020.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">adjustment as provided in this Article. Tenant acknowledges that the &#8220;rentable area of the Premises&#8221; under this Lease includes the usable area, without deduction for columns or<img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 13.19pt 0.7pt;">projections, multiplied by a load or conversion factor, to reflect a share of certain areas, which may include lobbies, corridors, mechanical, utility, janitorial, boiler and service rooms and closets, restrooms, and other public, common and service areas. Except as provided expressly to the contrary herein, the &#8220;rentable area of the Building&#8221; shall include all rentable area of all space leased or available for lease at the Building which Landlord may reasonably re-determine from time to time, to reflect re-configurations, additions or modifications to the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Refunds. Protest Costs. and Expense Adjustments For Prior Years</u>. Landlord shall each year: (i) credit against Real Estate Taxes any refunds received during such year, (ii) include in Real Estate Taxes any additional amount paid during such year, involving an adjustment to Real Estate Taxes for a prior year, due to error by the taxing authority, supplemental assessment, or other reason, (iii) include, in either Real Estate Taxes or Operating Costs, any fees for attorneys, consultants and experts, and other costs paid during such year in attempting to protest, appeal or otherwise seek to reduce or minimize Real Estate Taxes, by the terms of this Article, (iv) credit against Operating Costs the cost of any item previously included in Operating Costs, to the extent that Landlord receives reimbursement from insurance proceeds or a third party during such year (excluding tenant payments for Real Estate Taxes and Operating Expenses), and (v) make any other appropriate changes to reflect adjustments to Real Estate Taxes or Operating Expenses for prior years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments After Lease Term Ends</u>. Tenant&#39;s obligations to pay Tenant&#39;s Proportionate Share of Real Estate Taxes and Operating Costs (or any other amounts) accruing during, or relating to, the period prior to expiration or earlier termination of this Lease shall survive the expiration or termination of this Lease for a period of two (2) years. Tenant shall pay the full amount of such estimate and any additional amount due after the actual amounts are determined, in each case within thirty (30) days after Landlord sends a statement therefore. If the actual amount is less than the amount Tenant pays as an estimate, Landlord shall refund the difference within thirty (30) days after such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 13.19pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Rights</u>. In the event of any dispute as to the amount of Tenant&#39;s Proportionate Share of Operating Costs and Real Property Taxes, Tenant may, by prior written notice (&#8220;Audit Notice&#8221;) given ninety (90) days following receipt of a Landlord&#39;s reconciliation statement (&#8220;Audit Period&#8221;), audit Landlord&#39;s accounting records with respect to Operating Expenses and Real Property Taxes relative to the year to which such statement relates. The audit shall be conducted by Tenant, or an accounting firm engaged by Tenant and reasonably satisfactory to Landlord (billing hourly and not on a contingency fee basis) (&#8220;Third Party Auditor&#8221;), and shall be conducted at the office of Landlord at which its records are kept or, at Landlord&#39;s election, the office of Landlord&#39;s property manager (if any). The audit shall be conducted at reasonable times during normal business hours. In no event will Landlord or its property manager be required to (i) photocopy any accounting records or other items or contracts, (ii) create any ledgers or schedules not already in existence, (iii) incur any costs or expenses relative to such inspection, or (iv) perform any other tasks other than making available such accounting records as aforesaid. Neither Tenant nor its auditor may leave the office of Landlord with originals of any materials supplied by Landlord. Tenant must pay Tenant&#39;s Proportionate Share of Operating Costs and Real Property Taxes when due pursuant to the terms of this Lease and may not withhold payment of Operating Costs, Real Property Taxes or any other Rent pending results of the audit or during</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-8-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">a dispute regarding Operating Costs and Real Property Taxes. The audit must be completed within ninety (90) days of the date of Tenant&#39;s Audit Notice and the results of such audit shall be delivered to Landlord within forty-five (45) days of the date of Tenant&#39;s Audit Notice. If Tenant does not substantially comply with any of the aforementioned time frames, then the Landlord&#39;s statement will be conclusively binding on Tenant. If such audit or review correctly reveals that Landlord has overcharged Tenant, then within thirty (30) days after the results of such audit are made available to Landlord, the amount of such overcharge shall be deducted from the installments of Tenant&#39;s Share of Operating Costs and Real Property Taxes next becoming due. If the audit reveals that Tenant was undercharged, then within thirty (30) days after the results of the audit are made available to Tenant, Tenant agrees to reimburse Landlord the amount of such undercharge. Tenant agrees to keep the results of the audit confidential and will cause its agents, employees and contractors to keep such results confidential. To that end, Landlord may require Tenant and its auditor to execute a commercially reasonable confidentiality agreement provided by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 7. LATE PAYMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">A late charge of five (5%) percent shall be due and payable forthwith on the amount of Base Rent and additional rent not received by Landlord from Tenant on or before the tenth ( 10<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) day after such payment was due. In addition, Tenant shall pay interest at the Lease Interest Rate (as defined below) on any sum which is not paid when due, interest to run from the due date until such sum is paid. The &#8220;Lease Interest Rate&#8221; means four (4) percentage points per annum above the prime rate per annum announced from time to time by PNC Bank, N.A, or its successors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 8. USE OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tenant shall occupy and use the Premises only for the Permitted Uses set forth in Article l. <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Tenant shall not occupy or use the Premises for any other purpose or business without the prior written consent of Landlord. Landlord has promulgated reasonable Rules and Regulations (&#8220;Rules and Regulations&#8221;), which are attached hereto, made part hereof and marked as Exhibit &#8220;C&#8221; . Tenant acknowledges receipt of and shall observe and comply with such Rules and Regulations. Tenant further acknowledges that Landlord, in Landlord&#39;s reasonable discretion, may from time to time adopt, amend, establish, modify, proscribe or restate such rules and regulations with regard to the operation of the Premises, the Building, and common areas of the Development; provided that such rules and regulations are generally applicable to all tenants, do not materially increase the financial burdens of Tenant and do not materially adversely affect Tenant&#39;s rights under this Lease. In the event of any conflict between the provisions of such rules and regulations and this Lease, the provisions of this Lease shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-9-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 9. COMMON AREAS/PARKING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All parking areas, driveways, alleys, public corridors and fire escapes, and other areas, facilities <img src="cgtx-20241231xex10d3058.jpg" alt="Graphic" style="display:inline-block;height:6.48pt;width:0.72pt;">and improvements as may be approved by Landlord from time to time for the general use, in common, of Tenant and other tenants, their employees, agents, invitees and licensees, shall at all <img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">times be subject to the exclusive control and management of Landlord, and Landlord shall have the right from time to time to establish, modify and enforce reasonable rules and regulations with respect to all such areas, facilities and improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Landlord reserves the right to designate certain parking areas for non-exclusive permitted <img src="cgtx-20241231xex10d3060.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">parking for tenant&#8217;s employees, for general visitor parking, and for other designated uses. Tenant shall be allocated the number of non-exclusive permitted parking spaces as set forth in <img src="cgtx-20241231xex10d3061.jpg" alt="Graphic" style="display:inline-block;height:1.08pt;width:0.72pt;">Article 1 for the use of Tenant&#39;s employees, the location of such parking spaces to be designated by Landlord from time to time according to the Landlord&#39;s parking policies and procedures. Landlord agrees to enforce its parking regulations for the mutual benefit of Landlord and tenants <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">of the Development. Except for claims resulting from Landlord&#39;s intentional or grossly negligent acts, Landlord shall not be responsible or liable for damage or loss sustained to motor vehicles (including any contents) parked in the Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 10. ALTERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant shall not make any alterations, improvements or additions to the Premises or attach any fixtures or equipment thereto, without the Landlord&#39;s prior written <img src="cgtx-20241231xex10d3063.jpg" alt="Graphic" style="display:inline-block;height:5.76pt;width:0.36pt;">approval, not to be unreasonably withheld. All alterations, improvements or additions made to the Premises or the attachment of any fixtures or equipment thereto shall be performed at <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Tenant&#39;s sole cost and expense. Tenant may affix pictures and shelving to the walls without Landlord&#39;s consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>All alterations, improvements or additions to the Premises made by Tenant shall be deemed to have been attached to the Premises and to have become the property of Landlord upon such attachment, and upon expiration of this Lease or renewal term thereof, Tenant shall not remove any of such alterations, improvements or additions; provided, however, that Landlord may designate by written notice to Tenant at the time Tenant requests consent those alterations and additions which shall be removed by Tenant at the expiration or termination <img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">of this Lease, and Tenant shall properly remove the same and repair any damage to the Premises caused by such removal. Notwithstanding anything in this Lease to the contrary, all furniture, trade fixtures and equipment installed by or for Tenant may be removed by Tenant at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>In performing such alterations, improvements or additions, or in the removal <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">thereof, Tenant shall use due care to cause as little damage or injury as possible to the Premises and the Building and shall repair all damage or injury that may occur to the Premises or the <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Building as a result thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant agrees in doing any such work in or about the Premises to engage only such labor as will not conflict with or cause strikes or other labor disturbances among the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-10-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Development service employees of Landlord. Any contractors employed by Tenant shall be subject to Landlord&#39;s prior written approval, not to be unreasonably withheld. All such contractors shall be required to carry worker&#39;s compensation insurance, public liability insurance <img src="cgtx-20241231xex10d3034.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">and property damage insurance in amounts, form and content, and with companies reasonably <img src="cgtx-20241231xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">satisfactory to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Prior to the commencement by Tenant of any work as set forth in this Article, Tenant shall obtain, at Tenant&#39;s sole cost and expense, all necessary permits, authorizations and licenses required by the various governmental authorities having jurisdiction over the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 11. MECHANIC&#8217;S LIENS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any mechanics&#39; or other lien shall be filed against the Premises or the Development purporting to be for labor or material furnished or to be furnished at the request of Tenant, then Tenant shall at its expense cause such lien to be discharged by payment, bond or otherwise within thirty (30) days after notice of filing thereof. As an alternative to causing the lien to be discharged of <img src="cgtx-20241231xex10d3018.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">record, Tenant shall have the right to contest the validity of any lien or claim if Tenant shall first have posted a bond or other security reasonably satisfactory to Landlord (such as an undertaking with Landlord&#39;s title company to insure that, upon final determination of the validity of such lien or claim, Tenant shall immediately pay any judgment rendered against Tenant). If Tenant shall fail to take such action within such thirty (30) day period, Landlord may cause such lien to be discharged by payment, bond or otherwise, without investigation as to the validity thereof or as to any offsets or defenses thereto and Tenant shall, upon demand, reimburse Landlord for all amounts paid and costs incurred including reasonable attorney&#39;s fees, in having such lien discharged of record. Tenant shall indemnify and hold Landlord harmless from and against any and all claims, costs, damages, liabilities and expenses (including reasonable attorney&#8217;s fees) which may be brought or imposed against or incurred by Landlord by reason of any such lien or its discharge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 12. CONDITION OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Tenant acknowledges and agrees that, except as expressly set forth in this Lease, there have been no representations or warranties made by or on behalf of Landlord with respect to the Building, Premises or the Development or with respect to the suitability of any of them for the conduct of Tenant&#39;s business. The taking of possession of the Premises by Tenant shall conclusively establish that the Premises were at such time in satisfactory condition, order and repair, subject to latent defects which a reasonable inspection of the Premises would not disclose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 13. UTILITIES AND SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Utilities</u>: Separately metered electric and gas service shall be made available to the Premises. Tenant shall pay for the cost of such utility services directly to the utility provider or to the Landlord, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-11-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Building Services</u>: Landlord shall provide the following to the Premises, the <img src="cgtx-20241231xex10d3009.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Building or the Development, as applicable:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1)</font></font>Water and sewage for the Permitted Use;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2)</font></font>Replacement standard light globes and/or standard fluorescent tubes and ballasts in the standard ceiling lighting fixtures;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3)</font></font>HVAC, including maintenance of HVAC equipment and systems;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4)</font></font>Passenger and freight elevator service and maintenance and repair;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5)</font></font>Hot and cold water for drinking, lavatory and toilet purposes at those points of supply provided for nonexclusive general use of tenants of the Building, and points of supply in the Premises installed by or with Landlord&#39;s consent for the exclusive use of Tenant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6)</font></font>Maintenance and repair of interior common areas of the Building, <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">including the public restrooms in the Building; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.2pt;margin:0pt 0pt 12pt 3.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7)</font></font>Maintenance and repair of exterior common areas of the Development, <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">including but not limited to cleaning of outside exterior windows and doors, snow removal and landscaping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Landlord does not warrant that the utilities or services provided for in this Article shall be free from slow-down, interruption or stoppage pursuant to voluntary agreement by and between Landlord and governmental bodies and regulatory agencies, or caused by the maintenance, repair, substitution, renewal, replacement or improvements of any of the equipment <img src="cgtx-20241231xex10d3074.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">involved in the furnishing of any such utilities or services or caused by strikes, lockouts, labor controversies, fuel shortages, accidents, acts of God or the elements or any other cause beyond the reasonable control of Landlord; and specifically, no such slow-down, interruption or stoppage of any of such services shall be construed as an eviction, actual or constructive, of Tenant, nor shall same cause any abatement of Base Rent or additional rent payable hereunder <img src="cgtx-20241231xex10d3075.jpg" alt="Graphic" style="display:inline-block;height:3.96pt;width:1.08pt;">or in any manner or for any purpose relieve Tenant from any of Tenant&#39;s obligations hereunder, unless same shall make a material portion of the Premises untenantable for a period of three (3) consecutive business days at which point Base Rent shall be abated until such time as the Premises are no longer untenantable, and in no event shall Landlord be liable for damages to persons or property or be in default hereunder as a result of such interruption or stoppage of service. Should said disruption of service or utilities cause significant interference with Tenant&#39;s business for a period of sixty (60) days, Tenant shall have the right to terminate this Lease by written notice to Landlord. Landlord shall provide Tenant with reasonable advance notice of any anticipated interruptions in utility or Building services, and Landlord shall use reasonable efforts to minimize disruption of Tenant&#39;s use and occupancy in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-12-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">ARTICLE 14. ASSIGNMENT AND SUBLETTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 3.95pt;">Tenant shall not assign this Lease or sublet the Premises, (whether by operation of law or voluntary agreement) in whole or in part, without the Landlord&#39;s prior written consent, not to be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, Tenant may assign this Lease, or sublet the Premises or any portion thereof an affiliate controlling, controlled by or under common control with Tenant, without Landlord consent, but with notice thereof to Landlord. Tenant may sublet all or a portion of the Premises without prior consent to third parties and entities related to Tenant either through affiliated or commercial relationships for the purpose of conducting laboratory research <img src="cgtx-20241231xex10d3028.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">and development, and/or commercial prototype manufacturing related activities. Any license, assignment, subleasing or other occupancy agreement shall be subject to all terms, covenants and conditions of this Lease and no license, assignment, subleasing or other occupancy agreement shall relieve Tenant of any liability hereunder. Upon Landlord&#39;s request, Tenant shall provide <img src="cgtx-20241231xex10d3018.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Landlord with copies of all reasonable documentation related to any license, assignment, <img src="cgtx-20241231xex10d3028.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">sublease, or other occupancy agreement and Tenant shall require any permitted licensee, <img src="cgtx-20241231xex10d3079.jpg" alt="Graphic" style="display:inline-block;height:1.8pt;width:0.36pt;">assignee, sublicensee, or other occupant to obtain and maintain commercially reasonable insurance naming Landlord as additional insured. Tenant shall provide copies evidencing such <img src="cgtx-20241231xex10d3080.jpg" alt="Graphic" style="display:inline-block;height:1.08pt;width:1.44pt;">insurance to Landlord upon Landlord&#39;s request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">In case of any assignment or subletting, Tenant shall remain primarily liable on this Lease and shall not be released from the performance of any of the terms, covenants and conditions hereof</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 15. RIGHTS RESERVED BY LANDLORD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Except to the extent expressly limited herein, Landlord reserves full rights to control the Development, the Building and the Premises (which rights may be exercised without subjecting Landlord to claims for constructive eviction, abatement of Rent, damages or other claims of any kind), including more particularly, but without limitation, the following rights for Landlord, its employees or agents; provided however, Landlord shall use commercially reasonable efforts to exercise such rights in a manner that will first attempt to minimize interference with Tenant&#39;s use and occupancy of the Premises:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 0pt;">(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Premises</u>. To enter the Premises in order to inspect, supply cleaning service or other services to be provided Tenant hereunder, show the Premises to current and prospective lenders, insurers, purchasers, tenants, brokers and governmental authorities, and perform any work or take any other actions reserved to Landlord under this Lease or applicable laws. However, Landlord shall: (i) provide reasonable advance written or oral notice to Tenant&#39;s on-site manager or other appropriate person (except in emergencies), (ii) take reasonable steps to minimize any significant disruption to Tenant&#39;s business, and following completion of any work, return Tenant&#39;s leasehold improvements, fixtures, property and equipment to the original locations and condition to the fullest extent reasonably possible, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12.69pt 0.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-13-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(iii) take reasonable steps to avoid materially changing the configuration or reducing the square footage of the Premises, unless required by laws or other causes beyond Landlord&#39;s reasonable control (and in the event of any permanent reduction, the Rent and other rights and obligations of the parties based on the square footage of the Premises shall be proportionately reduced). Tenant shall not place partitions, furniture or other obstructions in the Premises which may prevent or impair Landlord&#39;s access to the systems and equipment for the Building or the systems and equipment for the Premises. If Tenant requests that any such access occur before or after Landlord&#39;s regular business hours and Landlord approves, Tenant shall pay all overtime and <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">other additional costs in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Changes to the Development</u>. To: (i) paint and decorate, (ii) perform repairs or maintenance, and (iii) make replacements, restorations, renovations, alterations, additions and improvements, structural or otherwise in and to the Development or any part thereof, including any adjacent building, structure, facility, land, street or alley, or change the uses thereof (including changes, reductions or additions of corridors, entrances, doors, lobbies, parking facilities and other areas, structural support columns and shear walls, utility lines, pipes, duct work, cables, installations, docks, walks, elevators, stairs, solar tint windows or film, planters, <img src="cgtx-20241231xex10d3082.jpg" alt="Graphic" style="display:inline-block;height:4.68pt;width:0.36pt;">sculptures, displays, and other amenities and features therein, and changes relating to the connection with or entrance into or use of the Building or any other adjoining or adjacent <img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">building or buildings, now existing or hereafter constructed). In connection with such matters, Landlord may among other things erect scaffolding, barricades and other structures, open ceilings, close entry ways, restrooms, elevators, stairways, corridors, parking and other areas and facilities, and take such other actions as Landlord deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 16. REPAIRS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to the provisions of Article 6 hereof, Landlord shall perform all maintenance and make all repairs or replacement necessary to maintain the structural, plumbing, HVAC and electrical systems (including replacement of light bulbs, ballasts and fixtures), exterior doors and windows, roof, exterior walls, demising walls and floor (but excluding interior ceiling, wall and floor finishes), common areas and utility lines and connections servicing the Premises, the <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Building or the Development in good order and condition. Landlord shall commence such repairs as promptly as the circumstances reasonably permit and thereafter shall diligently pursue the same to completion with reasonable promptness. Notwithstanding anything contained in this <img src="cgtx-20241231xex10d3085.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Lease to the contrary, Tenant shall be responsible, at its sole cost and expense, for any maintenance, repairs and replacements made by the Landlord which are necessitated by the <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">negligent acts, misuse or willful misconduct of Tenant, its agents, contractors, employees or invitees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 37.59pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Except as the Landlord is obligated for repairs as provided hereinabove, Tenant shall make at Tenant&#39;s sole cost and expense, all repairs necessary to maintain the Premises and shall keep the Premises and the fixtures therein in neat, clean, safe and orderly condition. In addition, and notwithstanding anything contained in this Lease to the contrary, the Tenant shall, at its sole cost and expense, maintain, repair and replace all lab equipment contained in the lab space portion of the Premises, including without limitation all water freatment systems and vacuum</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-14-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0.7pt;">equipment. If the Tenant refuses or neglects to make such repairs, or fails to diligently prosecute the same to completion, after written notice from Landlord of the need therefore, Landlord may make such repairs at the expense of Tenant and such expense, along with a fifteen (15%) percent service charge, shall be collectible as additional rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c) Landlord shall not be liable by reason of any injury to or interference with Tenant&#39;s business arising from the making of any repairs in accordance with this Article 16 in or to the Premises or the Building and Development or to any appurtenances or equipment therein; provided that Landlord shall interfere as little as reasonably practicable with the conduct of Tenant&#39;s business in the performance of the foregoing. There shall be no abatement of Rent because of such repairs, except as provided in Article 20 hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 17. INDEMNIFICATION AND INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Tenant shall indemnify, hold harmless and defend Landlord from and against any and all costs, expenses (including reasonable counsel fees), liabilities, losses, damages, suits, actions, fines, penalties, claims or demands of any kind and asserted by or on behalf of any person or governmental authority, arising out of or in any way connected with, and Landlord shall not be liable to Tenant on account of, (i) any failure by Tenant to perform any of the agreements, terms, covenants or conditions of this Lease required to be performed by Tenant, (ii) any failure by Tenant to comply with any statutes, ordinances, regulations or orders of any governmental authority applicable to Tenant&#39;s occupancy and use of the Premises, or (iii) any accident, death or personal injury, or damage to or loss or theft of property, which shall occur in or about the Premises, except to the extent caused by the negligence or willful misconduct of <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Landlord, its agents, employees or contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>Landlord shall indemnify, hold harmless and defend Tenant from and against any and all costs, expenses (including reasonable counsel fees), liabilities, losses, damages, suits, actions, fines, penalties, claims or demands of any kind and asserted by or on behalf of any person or governmental authority, arising out of or in any way connected with, (i) any failure by Landlord to perform any of the agreements, terms, covenants or conditions of this Lease required to be performed by Landlord, or (ii) the negligence or willful misconduct of Landlord or its agents, employees or contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Insurance</u>. Tenant shall maintain at its expense during the term with respect to the Premises and Tenant&#39;s use thereof and of the Building:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>Worker&#39;s compensation insurance in the amounts required by statute, and Employer Liability Insurance in at least the following amounts: (a) Bodily Injury by Accident - $500,000 per accident, (b) Bodily Injury by Disease - $500,000 per employee and (c) Aggregate Limit - $1,000,000 per policy year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-15-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt 0pt 13.19pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>Property Damage Insurance for the protection of Tenant and Landlord, as their interest may appear, covering all risks of physical loss to Tenant&#39;s alterations or improvements, personal property, business records, fixtures and equipment in amounts not less than the full insurable replacement cost of such property and full insurable value of such other interests of Tenant, such policies to be in form reasonably satisfactory to Landlord.<img src="cgtx-20241231xex10d3089.jpg" alt="Graphic" style="display:inline-block;height:1.44pt;width:1.08pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt 0pt 13.19pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>Commercial general liability insurance in forn reasonably satisfactory to Landlord with limits of at least the following amounts: (a) death or bodily injury - $2,000,000, (b) property damage or destruction (including loss of use thereof) - $2,000,000 per policy year. Such policy shall include endorsements: (1) for contractual liability covering Tenant&#39;s indemnity obligations under this Lease, and (2) for adding Landlord, Landlord&#39;s mortgagee, the management company for the Development, and other parties designated by Landlord, as additional insureds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 13.19pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificates. Subrogation and Other Matters</u>. Tenant shall provide Landlord with certificates evidencing the coverage required hereunder prior to the Commencement Date, or Tenant&#39;s entry to the Premises for construction of improvements or any other purpose (whichever first occurs). Such certificates shall state that such insurance coverage may not be changed, canceled or non-renewed without at least thirty (30) days&#39; prior written notice to Landlord. Tenant shall provide renewal certificates to Landlord at least ten (10) days prior to expiration of such policies. Tenant&#39;s insurance policies shall be primary to all policies of Landlord and any other additional insureds (whose policies shall be deemed excess and noncontributory). All insurance required hereunder shall be provided by responsible insurers licensed in the Commonwealth of Pennsylvania, and shall have a general policy holder&#39;s rating of at least A and a financial rating of at least X in the then current edition of Best&#39;s Insurance Reports. The parties mutually hereby waive all rights and claims against each other for all losses covered by their respective insurance policies, and waive all rights of subrogation for their respective insurers. The parties agree that their respective insurance policies are now, or shall be, endorsed such that said waiver of subrogation shall not affect the right of the insured to recover thereunder. Landlord disclaims any representations as to whether the foregoing coverages will be adequate to protect Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 13.19pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Insurance</u>. At all times during the Lease Term, Landlord agrees to maintain in force and effect (i) all-risk fire and extended coverage insurance on the Building, and (ii) commercial general liability insurance with limits and deductibles consistent with those <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">maintained by owners of similarly situated buildings in the vicinity of the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11.3pt 0pt;"><b style="font-weight:bold;">ARTICLE 18. LANDLORD&#39;S LIABILITY</b><b style="font-weight:bold;"><img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except for claims arising from the negligent acts or willful misconduct of Landlord or its agents, employees or contractors, Tenant waives all claims against Landlord and Landlord&#39;s partners, members, agents and employees for injury or death to persons, damage to property or any other <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">interest of Tenant sustained by Tenant or a party claiming by or through Tenant resulting from: <img src="cgtx-20241231xex10d3093.jpg" alt="Graphic" style="display:inline-block;height:6.48pt;width:0.36pt;">(a) any defect in or failure of structural, plumbing, sprinkling, electrical, heating or air conditioning systems or equipment, or any other systems and equipment of the Premises or the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-16-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Building or from the drains, pipes, plumbing or sewer; (b) broken glass; (c) any acts or omissions <img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">of the other tenants or occupants of the Building or of nearby buildings; (d) any acts or omissions of other persons; (e) damage or loss sustained to motor vehicles (including any contents) parked at or operating within the Development, from any cause; and (e) theft, Act of God, public enemy, <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">injunction, riot, strike, insurrection, war, court order, or any order of any governmental authorities having jurisdiction over the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 19. COMPLIANCE WITH INSURANCE REQUIREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Tenant agrees that Tenant will not do or suffer to be done, any act, matter or thing, objectionable to the fire insurance companies whereby the fire insurance or any other insurance now in force or hereafter to be placed on the Premises or any part thereof, or on the Building of which the Premises may be a part, shall become void or suspended, or whereby the same shall be rated as a more hazardous risk than at the date when Tenant receives possession hereunder. In case of a breach of this covenant, in addition to all other remedies of Landlord hereunder, Tenant agrees to pay to Landlord as additional rent, any and all increases in premiums on insurance carried by Landlord on the Premises or any part thereof, or on the Building of which the Premises may be a part, caused in any way by the occupancy of Tenant. Notwithstanding the foregoing, Landlord acknowledges that the Permitted Use shall not constitute a breach of this Article 19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"><img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"><img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"><img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></b><b style="font-weight:bold;">ARTICLE 20. FIRE OR OTHER CASUALTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If the Building and/or Premises are damaged by fire or any other cause to such extent that the same cannot be restored, as reasonably estimated by Landlord, within one hundred twenty (120) days after the date of such damage or destruction, then Landlord shall, no later than the sixtieth (60th) day following the damage, give Tenant notice of Landlord&#39;s election either to (a) restore the Building and Premises or (b) terminate this Lease. In the event Landlord elects to terminate this Lease, the Lease shall terminate on the earlier of the date of such notice or the date upon which Tenant surrenders possession of the Premises. In such event, the Rent and other charges due hereunder shall be apportioned as of the date of such casualty, and any Rent paid for any period beyond said date shall be repaid to Tenant. If the time of restoration as estimated by Landlord shall be less than one hundred twenty (120) days, or if Landlord does not elect to terminate this Lease, as hereinabove provided, Landlord shall restore the Building and the Premises, and Tenant shall have not right to terminate this Lease except as herein provided. Tenant shall, in such event, restore fixtures and improvements owned by Tenant to the original condition. Notwithstanding the foregoing, however, if the time of restoration as reasonably estimated by Landlord exceeds one hundred twenty (120) days, Tenant shall have the right to terminate this Lease upon notice given to Landlord within thirty (30) days after the date of Landlord&#39;s notice of the estimated restoration period. Landlord shall deliver notice of the estimated restoration period within sixty (60) days after the date of the casualty.<img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 28.45pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In any such case in which use of the Premises is affected by any damage thereto, there shall be an abatement or an equitable reduction in Rent, depending on the period for which, and the extent to which, the Premises is not reasonably usable for the purposes for <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-17-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which it is leased hereunder. If the damage results from the fault of Tenant, or Tenant&#39;s agents, servants, visitors or licensees, Tenant shall not be entitled to any abatement or reduction of Rent <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">up to the amount of the deductible paid by Landlord.<img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 21. SUBORDINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">This Lease shall be subject and subordinate to the lien of any mortgage, or renewals, modifications, consolidations, replacements or extensions thereof, which now or hereafter may affect the Premises. Tenant shall, at Landlord&#39;s request, execute such agreements and other instruments as Landlord or any mortgagee of the Premises reasonably shall deem necessary or desirable to subordinate this Lease to the lien of any present or future mortgage, mortgages or construction loans against the Premises. The subordination of this Lease shall be subject to any current or future mortgage holder(s) agreement not to disturb Tenant&#39;s occupancy so long as Tenant is not then in default of this Lease. Tenant specifically approves and, upon Landlord&#39;s request, agrees to execute an Estoppel Certificate and a Subordination, Nondisturbance and Attornment Agreement substantially in the forms attached hereto as Exhibits &#8220;E&#8221; and &#8220;F&#8221;, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 22. CONDEMNATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In the event the Premises, or any part thereof, shall be taken or condemned permanently or temporarily for any public or quasi-public use or purpose by any competent authority in appropriation proceedings or by any right of eminent domain, the entire compensation award therefore, including leasehold, reversion and fee, shall belong to the Landlord without any deduction therefrom for any present or future estate of Tenant. Tenant shall, however, be entitled to claim, prove and receive in such condemnation proceedings such award as may be allowed for fixtures and other equipment installed by it, and for moving expenses, but only if such award shall be in addition to the award to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If the entire Building shall be so taken by virtue of eminent domain, this Lease shall terminate on the date when title vests pursuant to such taking, and the Rent and other charges hereunder shall be apportioned as of said date, and any Rent paid for any period beyond said date shall be repaid to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If more than twenty percent (20%) of the floor area comprising the Premises shall be <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">so taken, or if a portion of the Building or Development is taken which materially interferes with Tenant&#39;s use of the Premises, either party shall have the right to cancel and terminate this Lease as of the date of such taking, upon giving notice to the other party within thirty (30) days after notice to Tenant from Landlord or the condemning authority that such Premises are to be appropriated or taken. In the event that this Lease is not terminated as herein provided, this Lease shall continue, with an equitable and proportionate adjustment, effective on the date of taking, in Rent and other charges due hereunder based upon the reduction in floor area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-18-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 23. ESTOPPEL CERTIFICATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Tenant shall, at any time and from time to time, upon thirty (30) days written request by Landlord, execute, acknowledge and deliver to Landlord a statement in writing duly executed by Tenant (i) certifying that this Lease is in full force and effect without modification or amendment (or, if there have been any modifications or amendments, that this Lease is in full force and effect as modified and amended and setting forth in full all modifications and amendments), (ii) certifying the dates to which Base Rent and additional rent have been paid, and (iii) either certifying that to the knowledge of Tenant no default exists under this Lease or specifying each such default, and (iv) certifying such other matters as Landlord and/or any lender may reasonably request; it being the intention and agreement of Landlord and Tenant that any such statement by Tenant may be relied upon by a prospective purchaser or a prospective mortgagee of the Building, or current mortgagee of the Building, or by others, in any matter affecting the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 24. DEFAULT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0.7pt;">The occurrence of any of the following events shall constitute a default by Tenant under this Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Failure of Tenant to take possession of the Premises within thirty (30) days following the Commencement Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>A failure by Tenant to pay any installment of Base Rent hereunder within seven (7) days after the due date or a failure to pay any such other sum herein required to be paid by Tenant within thirty (30) days after written notice thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>An abandonment of the Premises by Tenant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>An assignment of this Lease or subletting of the Premises in violation of this Lease;<img src="cgtx-20241231xex10d3105.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>A failure by Tenant to pay, when due, any installment of Rent hereunder on two (2) or more occasions within any period of twelve (12) consecutive months;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>The failure by Tenant to maintain insurance as required by the provisions of Article 17 hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>A failure by Tenant to observe and perform any other material provision or covenant of this Lease to be observed or performed by Tenant, where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>The filing of a petition by or against Tenant for adjudication as a bankrupt or insolvent or for reorganization or for the appointment pursuant to any local, state or federal bankruptcy or insolvency law of a receiver or trustee of Tenant&#39;s property; or an assignment by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-19-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tenant for the benefit of creditors; or the taking possession of the property of Tenant by any local, state or federal governmental officer or agency or court-appointed offcial for the <img src="cgtx-20241231xex10d3028.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">dissolution or liquidation of Tenant or for the operating, either temporary or permanently, of Tenant&#39;s business, provided, however, that if any such action is commenced against Tenant the <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">same shall not constitute a default if Tenant causes the same to be dismissed within sixty (60) <img src="cgtx-20241231xex10d3108.jpg" alt="Graphic" style="display:inline-block;height:5.76pt;width:0.36pt;">days after the filing of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 25. PROVISIONS RELATED TO LANDLORD&#39;S REMEDIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u>. Upon the occurrence of any event of default set forth above and the expiration of any applicable notice and grace period, Landlord shall have the rights and remedies hereinafter set forth to the extent permitted by law, which shall be distinct, separate and cumulative with and in addition to any other right or remedy allowed under law or any other provision of this Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</font></font>Landlord may terminate this Lease and Tenant&#39;s right of possession, reenter and repossess the Premises by detainer suit, summary proceedings or other lawful means, and recover from Tenant: (i) any unpaid Rent as of the termination date; (ii) the amount by which: <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">(a) any unpaid Rent which would have accrued after the termination date during the balance of the term exceeds (b) the reasonable rental value of the Premises under a lease substantially <img src="cgtx-20241231xex10d3110.jpg" alt="Graphic" style="display:inline-block;height:1.8pt;width:0.72pt;">similar to this Lease, taking into account among other things the condition of the Premises, <img src="cgtx-20241231xex10d3111.jpg" alt="Graphic" style="display:inline-block;height:3.6pt;width:1.08pt;">market conditions and the period of time the Premises may reasonably remain vacant before Landlord is able to re-lease the same to a suitable replacement tenant, and Costs of Reletting (as defined in Paragraph (g) below) that Landlord may incur in order to enter such replacement lease, (iii) any other amounts necessary to compensate Landlord for all damages proximately caused by Tenant&#39;s failure to perform its obligations under this Lease, but excluding consequential, indirect or special damages. For purposes of computing the amount of rent herein that would have accrued after the termination date, Tenant&#39;s obligations for Real Estate Taxes and Operating Costs shall be projected based upon the average rate of increase in such items <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">from the Commencement Date through the termination date (or if such period shall be less than three years, then based on Landlord&#39;s reasonable estimates). The amounts computed in accordance with the foregoing subclauses (a) and (b) shall both be discounted in accordance with <img src="cgtx-20241231xex10d3006.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">accepted financial practice at the rate of four (4%) percent per annum to the then present value.<img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font>Landlord may terminate Tenant&#39;s right of possession, reenter and repossess the Premises by detainer suit, summary proceedings or other lawful means, without terminating this Lease, and recover from Tenant: (i) any unpaid Rent as of the date possession is terminated, <img src="cgtx-20241231xex10d3115.jpg" alt="Graphic" style="display:inline-block;height:1.8pt;width:0.36pt;">(ii) any unpaid rent which thereafter accrues during the term from the date possession is terminated through the time of judgment (or which may have accrued from the time of any earlier judgment obtained by Landlord), less any consideration received from replacement tenants as further described and applied pursuant to Paragraph (g) below, and (iii) any other <img src="cgtx-20241231xex10d3116.jpg" alt="Graphic" style="display:inline-block;height:5.04pt;width:0.36pt;">amounts necessary to compensate Landlord for all damages proximately caused by Tenant&#39;s failure to perform its obligations under this Lease, including all Costs of Reletting, but excluding <img src="cgtx-20241231xex10d3117.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">consequential, indirect or special damages. Tenant shall pay any such amounts to Landlord as the same accrue or after the same have accrued from time to time upon demand. At any time</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 13.19pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-20-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0.7pt;">after terminating Tenant&#39;s right to possession as provided herein, Landlord may terminate this Lease as provided in clause (1) above by notice to Tenant, and Landlord may pursue such other remedies as may be available to Landlord under this Lease or applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reletting</u>. If this Lease or Tenant&#39;s right to possession is terminated or Tenant abandons the Premises, Landlord may: (i) enter and secure the Premises, change the locks, install barricades, remove any improvements, fixtures or other property of Tenant therein, <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">perform any decorating, remodeling, repairs, alterations, improvements or additions and take <img src="cgtx-20241231xex10d3119.jpg" alt="Graphic" style="display:inline-block;height:4.68pt;width:1.08pt;">such other actions as Landlord shall determine in Landlord&#39;s sole discretion to prevent damage <img src="cgtx-20241231xex10d3085.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">or deterioration to the Premises or prepare the same for reletting, and (ii) relet all or any portion of the Premises (separately or as part of a larger space), for any rent, use or period of time (which <img src="cgtx-20241231xex10d3121.jpg" alt="Graphic" style="display:inline-block;height:2.52pt;width:0.72pt;">may extend beyond the term hereof), and upon any other terms as Landlord shall determine in Landlord&#39;s sole discretion, directly or as Tenant&#39;s agent. The consideration received from such reletting shall be applied pursuant to the terms of Paragraph (g) hereof, and if such consideration, as so applied, is not sufficient to cover all Rent and damages to which Landlord may be entitled hereunder, Tenant shall pay any deficiency to Landlord as the same accrues or after the same has accrued from time to time upon demand, subject to the other provisions hereof.<img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance.</u> Landlord shall at all times have the right without prior demand or notice except as required by applicable law to: (i) seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease or restrain or enjoin a violation of any provision hereof, and Tenant hereby waives any right to require that Landlord post a bond or other security in connection therewith, and (ii) sue for and collect any unpaid Rent which has accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Returned Checks</u>. If Landlord receives two (2) or more checks from Tenant which are returned by Tenant&#39;s bank for insufficient funds, Landlord may require that all checks thereafter be bank certified or cashier&#39;s checks (without limiting Landlord&#39;s other remedies). All bank service charges resulting from any returned checks shall be borne by Tenant.<img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#39;s Cure of Tenant Defaults</u>. If Tenant fails to perform any obligation under this Lease for five (5) days after notice thereof by Landlord (except that no notice shall be required in emergencies), Landlord shall have the right (but not the duty), to perform such obligation on behalf and for the account of Tenant. In such event, Tenant shall reimburse Landlord upon demand, as additional rent, for all expenses reasonably incurred by Landlord in performing such obligation together with an amount equal to fifteen (15%) percent thereof for Landlord&#39;s overhead, and interest thereon at the Lease Interest Rate from the date of demand. Landlord&#39;s performance of Tenant&#39;s obligations hereunder shall not be deemed a waiver or release of Tenant therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 35.65pt;"><font style="display:inline-block;text-indent:0pt;width:36.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intentionally Omitted</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.4pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Matters</u>. No re-entry or repossession, repairs, changes, alterations and additions, reletting, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant&#39;s right to possession, nor shall the same operate to release Tenant in whole or in part from any of Tenant&#39;s obligations hereunder, unless express<img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10.39pt 0pt;">-21</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-21-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0.7pt;">notice of such intention is sent by Landlord to Tenant. Landlord may bring suits for amounts owed by Tenant hereunder or any portions thereof, as the same accrue or after the same have accrued, and no suit or recovery of any portion due hereunder shall be deemed a waiver of Landlord&#39;s right to collect all amounts to which Landlord is entitled hereunder, nor shall the same serve as any defense to any subsequent suit brought for any amount not therefor reduced to judgment. Landlord may pursue one or more remedies against Tenant and need not make an election of remedies except as required by applicable law. All rent and other consideration paid by any replacement tenants shall be applied at Landlord&#39;s option: (i) first, to the Costs of Reletting, (ii) second, to the payment of all costs of enforcing this Lease against Tenant or any guarantor, (iii) third, to the payment of all interest and service charges accruing hereunder, (iv) fourth, to the payment of Rent theretofore accrued, and (v) with the residue, if any, to be held by Landlord and applied to the payment of Rent and other obligations of Tenant as the same become due (and with any remaining residue to be retained by Landlord). &#8220;Costs of Reletting&#8221; shall include without limitation, all costs and expenses incurred by Landlord for any repairs or other matters described in Paragraph (b) above, brokerage commissions, advertising costs, attorneys&#39; fees, any economic incentives given to enter leases with replacement tenants, and costs of collecting rent from replacement tenants. Landlord shall be under no obligation to observe or perform any provision of this Lease on its part to be observed or performed which accrues while Tenant is in default hereunder. The times set forth herein for the curing of defaults by Tenant are of the essence of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 26. LANDLORD&#39;S DEFAULT; RIGHT TO CURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.2pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If Landlord shall fail to perform any obligation under this Lease required to be performed by Landlord, Landlord shall not be deemed to be in default hereunder nor subject to any claims for damages of any kind, unless such failure shall have continued for a period of thirty (30) days after written notice thereof by Tenant (provided, if the nature of Landlord&#39;s failure is such that more time is reasonably required in order to cure, Landlord shall not be in default if Landlord commences to cure within such thirty (30) day period and thereafter diligently seeks to cure such failure to completion).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.2pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Upon the occurrence of any event of default by Landlord after the expiration of any applicable cure and grace period, Tenant shall have all rights and remedies to the extent permitted by law or in equity, which be distinct, separate and cumulative to the extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 27. WAIVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 27.6pt 0pt;">The failure or delay on the part of Landlord or Tenant to enforce or exercise at any time any of the provisions, rights or remedies in the Lease shall in no way be construed to be a waiver thereof, nor in any way to affect the validity of this Lease or any part hereof, or the right of the Landlord or Tenant to thereafter enforce each and every such provision, right or remedy. No waiver of any breach of this Lease shall be held to be a waiver of any other or subsequent breach. The receipt by Landlord of lesser amount than the Rent due at a time when the rent is in default</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-22-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">under this Lease shall not be construed as a waiver of such default. The receipt by Landlord of a lesser amount than the Rent due shall not be construed to be other than a payment on account of the Rent then due, nor shall any statement on Tenant&#39;s check or any letter accompanying Tenant&#39;s check be deemed an accord and satisfaction and Landlord may accept such payment without prejudice to Landlord&#39;s right to recover the balance of the rent due or to pursue any other remedies provided in this Lease. No act or thing done by Landlord or Landlord&#39;s agents or employees during the term of this Lease shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such a surrender shall be valid unless in writing and signed by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 28. UTILITY DEREGULATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Landlord has advised Tenant that various utility companies (each to be referred to herein as a &#8220;Current Service Provider&#8221;) are the utility companies selected by Landlord to provide service for the Development. Notwithstanding the foregoing, if permitted by law, Landlord shall have the <img src="cgtx-20241231xex10d3126.jpg" alt="Graphic" style="display:inline-block;height:2.16pt;width:0.36pt;">right at any time and from time to time during the term of this Lease to either contract for service from a different company or companies providing service (each such company shall hereinafter be referred to as an &#8220;Alternate Service Provider&#8221;) or continue to contract for service from the Current Service Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0.7pt;">Tenant shall cooperate with Landlord, the Current Service Providers, and any Alternate Service Provider as reasonably necessary, and shall allow Landlord, the Current Service Providers, and any Alternate Service Provider reasonable access to the Building&#39;s lines, feeders, risers, wiring, and other machinery within the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless caused by the willful misconduct or negligence of Landlord, its agents or employees, Landlord shall in no way be liable or responsible for any loss, damage, or expense that Tenant may sustain or incur by reason of any failure, interference, disruption, or defect in the supply of utility services furnished to the Premises, or of any change in the quality or character of the utility services supplied by the Current Service Providers or any Alternate Service Provider, and <img src="cgtx-20241231xex10d3117.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">no such change, failure, defect, unavailability, or unsuitability shall constitute an actual or constructive eviction, in whole or in part, or entitle Tenant to any abatement or diminution of rent, or relieve Tenant from any of its obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 29. TELECOMMUNICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Telephone Lines</u>. Subject to Landlord&#39;s continuing right of supervision and approval (not to be unreasonably withheld), and the other provisions hereof, Landlord shall: (i) install telephone lines (&#8220;Lines&#8221;) connecting the Premises to Landlord&#39;s terminal block on the floor or floors on which the Premises are located, or (ii) use such Lines as may currently exist and already connect the Premises to such terminal block. Landlord&#39;s predecessor or independent contractor has heretofore connected such terminal block through riser system Lines to Landlord&#39;s main distribution frame (&#8220;MDF&#8221;) for the Property. Landlord disclaims any representations, <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">warranties or understandings concerning the capacity, design or suitability of Landlord&#39;s riser</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-23-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lines, MDF or related equipment. If there is, or will be, more than one tenant on any floor, at <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">any time, Landlord may allocate, and periodically reallocate, connections to the terminal block <img src="cgtx-20241231xex10d3021.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">based on the proportion of square feet each tenant occupies on such floor, or the type of business operations or requirements of such tenants, in Landlord&#39;s reasonable discretion. Landlord may arrange for an independent contractor to review Tenant&#39;s request for approval hereunder, monitor or supervise Tenant&#39;s installation, connection and disconnection of Lines, and provide other such services, or Landlord may provide the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.9pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Installation</u>. Landlord shall install Tenant&#39;s Lines and make connections and disconnection at the terminal blocks as described above, and Landlord shall use an experienced and qualified contractor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.9pt;margin:0pt 0pt 12pt 0.7pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:34.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</u>. Unless due solely to Landlord&#39;s intentional misconduct or negligent acts, Landlord shall have no liability for damages arising, and Landlord does not warrant that the Tenant&#39;s use of the Lines will be free, from the following (collectively called &#8220;Line Problems&#8221;): (i) any eavesdropping, wire-tapping or theft of long distance access codes by unauthorized parties, (ii) any failure of the Lines to satisfy Tenant&#39;s requirements, or (iii) any capacitance, attenuation, cross-talk or other problems with the Lines, any misdesignation of the Lines in the MDF room or wire closets, or any shortages, failures, variations, interruptions, disconnections, loss or damage caused by or in connection with the installation, maintenance, replacement, use or removal of any other Lines or equipment at the Development by or for other tenants at the Development, by any failure of the environmental conditions at or the power supply for the Development to conform to any requirements of the Lines or any other problems associated with any Lines or by any other cause. Unless due solely to Landlord&#39;s willful misconduct or negligent acts, under no circumstances shall any Line Problems be deemed an actual or constructive eviction of Tenant, render Landlord liable to Tenant for abatement of any rent or other charges under the Lease, or relieve Tenant from performance of Tenant&#39;s obligations under the Lease. Landlord in no event shall be liable for damages by reason of loss of profits, business interruption or other consequential damage arising from any Line Problems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 30. SURRENDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 13.19pt 0.7pt;">The Lease shall terminate and Tenant shall deliver up and surrender possession of the Premises on the last day of the term hereof, and Tenant waives the right to any notice of termination or notice to quit and Tenant hereby waives all right to any such notice as may be provided under any laws now or hereafter in effect in Pennsylvania, including but not limited to the Landlord and Tenant Act of 1951, as amended. Tenant covenants that upon the expiration or sooner termination of this Lease Tenant shall deliver up and surrender possession of the Premises in the same condition in which Tenant has agreed to keep the same during the continuance of this Lease and in accordance with the terms hereof, ordinary wear and tear and damage from casualty or condemnation excepted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-24-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 31. QUIET ENJOYMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 4.7pt;">Landlord covenants and agrees that Tenant, upon paying the Rent herein provided for and observing and keeping the covenants, agreements and conditions on its part to be kept, shall lawfully and quietly hold, occupy and enjoy the Premises during the Lease without hindrance or interruption by Landlord or anyone claiming by, through or under Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 32. HOLDING OVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless Landlord expressly agrees otherwise in writing, Tenant shall pay Landlord 150% of the amount of Rent then applicable prorated on a per diem basis for each day Tenant shall fail to vacate or surrender possession of the Premises or any part thereof after expiration or earlier <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">termination of this Lease as required under Article 30, together with all damages sustained by <img src="cgtx-20241231xex10d3133.jpg" alt="Graphic" style="display:inline-block;height:1.8pt;width:0.72pt;">Landlord on account thereof. Tenant shall pay such amounts on demand, and, in the absence of demand, monthly in advance. The foregoing provisions, and Landlord&#39;s acceptance of any such amounts, shall not serve as permission for Tenant to hold-over, nor serve to extend the term (although Tenant shall remain a tenant at sufferance bound to comply with all provisions of this Lease until Tenant properly vacates the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 33. ENVIRONMENTAL COVENANTS, REPRESENTATIONS AND WARRANTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 35.7pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant shall comply with all laws, regulations, ordinances and other governmental standards applicable to Tenant&#39;s use of the Premises with respect to hazardous waste, hazardous substances and any and all other environmental matters. Furthermore, Tenant shall procure and maintain all licenses and permits required by such applicable laws, ordinances <img src="cgtx-20241231xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">or regulations. Tenant covenants and agrees that it shall not release, emit, or discharge at or from <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">the Premises any hazardous or toxic substances consisting of any hazardous or toxic chemical, waste, byproduct, pollutants, contamination, compound, product or substance, including, without limitation, asbestos, polychlorinated byphenyls, petroleum (including crude oil or any fraction thereof), and any material the exposure to, or manufacture, possession, presence, use, generation, <img src="cgtx-20241231xex10d3050.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">storage, transportation, treatment, release, disposal, abatement, cleanup, removal, remediation or handling of which, is prohibited, controlled or regulated by federal, state, regional, county, local, governmental, public or private statute, law, regulation, ordinance, order, consent decree, judgment, permit, license, code, covenant, deed restrictions, common law, treaty, convention or other requirement, pertaining to protection of the environmental, health or safety of persons, natural resources, conservation, wildlife, waste management, any hazardous material activity, and pollution (including, without limitation, regulation of releases and disposals to air, land, water and ground water). These requirements include, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. 9601 et seq., Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976 and Solid and Hazardous Waste Amendments of 1984, 42 U.S.C. 6901 et seq., Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 U.S.C. 1251, et seq., Clean Air Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-25-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12.69pt 0pt;">of 1966, as amended, 42 U.S.C. 7401 et seq., Toxic Substances Control Act of 1976, 15 U.S.C. 2601 et seq., Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. 651 et seq., <img src="cgtx-20241231xex10d3013.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 11001 et seq., <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">National Environmental Policy Act of 1975, 42 U.S.C. 300(f) et seq., and any similar or implementing Pennsylvania laws, and all amendments, rules, regulations, guidance documents and publications promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt 0pt 12.69pt 5.4pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:30.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In the event Tenant receives any notice of the happening of: (l) any event arising from Tenant&#39;s use or occupancy of the Premises involving an emission, spill, release or discharge at or from the Premises into or upon (i) the air; (ii) soils (whether on the Premises or neighboring property) or any improvements located thereon; (iii) surface water or ground water; (iv) the sewer system servicing the Premises, except as allowed under current law, regulation or permit, of any regulated quantities of toxic or hazardous substances or wastes (intended hereby and hereafter to include any and all such materials listed in any federal, state or local law, code and ordinances and all rules and regulations promulgated thereunder, as hazardous) (any of which is hereinafter referred to as &#8220;Hazardous Discharge&#8221;); or (2) any complaint, order, directive, claim, citation or notice by any governmental authority or any other person or entity arising from Tenant&#39;s use or occupancy of the Premises with respect to (i) air emissions; (ii) spills, releases or discharges to soils or any improvements located thereon, surface water, ground water or the sewer, septic system or waste treatment, storage or disposal system servicing the Premises; (iii) solid or liquid waste disposal; (iv) the use, generation, storage, transportation or disposal of toxic or hazardous substances or wastes; or (v) any other environmental, health or safety matter relating to any of Tenant&#39;s activity upon the Premises, including any improvements located thereon or neighboring property (any of which is hereinafter referred to as an &#8220;Environmental Complaint&#8221;), then Tenant shall give immediate notice of same to Landlord, detailing all relevant facts and circumstances. Tenant shall, upon receipt of notice of a Hazardous Discharge or Environmental Complaint, and at its sole cost and expense, promptly and completely take all actions necessary to remove, resolve or minimize the impact of such Hazardous Discharge or Environmental Complaint on or from the Premises, and restore the affected property to its prior condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.69pt 6.1pt;">Without limitation on the foregoing, and in the event Tenant fails to take the actions set forth herein, Landlord shall have the right, but not the obligation, to enter onto the Premises and take any actions as it deems necessary or advisable to clean up, remove, resolve or minimize the impact or otherwise deal with any Hazardous Discharge or Environmental Complaint upon Landlord&#39;s receipt of any notice from any person or entity asserting the happening of a Hazardous Discharge or Environmental Complaint on or from or pertaining to the Premises and arising from Tenant&#39;s use or occupancy of the Premises. All reasonable costs and expenses incurred by Landlord in the exercise of any such rights shall be deemed to be additional rent hereunder and shall be immediately payable by Tenant to Landlord upon demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt 0pt 35.75pt 5.4pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:30.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant, its successors and assigns, shall forever indemnify, defend and hold harmless Landlord, its partners, members, directors, officers, employees and agents, and successors and assigns from and against all damages, punitive damages, liabilities, losses, demands, claims, cost recovery actions, lawsuit, administrative proceedings, orders, response costs, compliance costs, investigation expenses, consultant fees, attorneys&#39; fees and litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-26-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expenses, arising from Tenant&#39;s use of the Premises, including (1) possession, use and storage of any hazardous material at the Premises; (2) the operation of any applicable environmental law against the Tenant, Landlord or the Premises, based on Tenant&#39;s activities during the term of this Lease; or (3) the violation at the Premises or by the Tenant of any applicable environmental law. <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Tenant and its successors or assigns shall pay all costs and expenses incurred by Landlord, its successors and assigns, to enforce the provisions of this indemnification, including, without <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">limitation, reasonable attorneys&#39; fees and litigation expenses. This indemnification shall survive the termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">As between Landlord and Tenant, Landlord shall be responsible for (i) the remediation of any hazardous materials or substances located on the Development, the Building, or any part thereof (including the Premises), existing as of the Commencement Date (except to the extent caused by Tenant or its agents, employees or contractors), (ii) any violations of environmental laws existing as of the Commencement Date (except to the extent caused by <img src="cgtx-20241231xex10d3142.jpg" alt="Graphic" style="display:inline-block;height:1.44pt;width:1.08pt;">Tenant or its agents, employees or contractors), (iii) the remediation of any hazardous materials or substances located on the Development, the Building, or any part thereof (including the Premises), existing as of the Commencement Date after the Commencement Date to the extent caused by Landlord or its agents, employees or contractors, or (iv) any violations of environmental laws arising on or after the Commencement Date to the extent caused by Landlord or its agents, employees or contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 4.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Landlord represents and warrants to Tenant, to the best of its knowledge, as of the Commencement Date, it has received no written notice from any applicable govemmental authority regarding the existence of hazardous materials on or about the Premises or the Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 34. TENANT&#39;S COMPLIANCE WITH LAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 4.05pt;">Tenant shall comply with all governmental laws, ordinances and regulations applicable to Tenant&#39;s occupancy and use of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 35. DISABILITIES ACT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tenant shall comply, at Tenant&#39;s sole cost and expense, with the Americans with Disabilities Act of 1990 and similar state and local laws and ordinances, as well as all regulations issued thereunder, but only if the need for compliance is caused in whole or material part by reason of the specific nature of Tenant&#39;s business operations in the Premises or specific accommodation to Tenant&#39;s employees. Except as set forth in the preceding sentence, Landlord shall cause the common areas of the Development to comply, at Landlord&#39;s sole cost, or at another tenant&#39;s sole <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">cost, or as an Operating Cost subject to pass-through hereunder, with the Americans with <img src="cgtx-20241231xex10d3009.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Disabilities Act of 1990 and similar state and local laws and ordinances, as well as all regulations issued thereunder. Tenant shall promptly advise Landlord in writing, and provide Landlord with <img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">copies of any notice received by Tenant alleging violation of any such law, regulation or<img src="cgtx-20241231xex10d3035.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-27-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">ordinance relating to the Premises or the Building or any use thereof or activity therein, or any governmental or regulatory action or investigation instituted or threatened regarding noncompliance with any such law, regulation or ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 36. NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Wherever in this Lease it shall be required or permitted that notice or demand be given or served by either party to this Lease to or on the other party, such notice or demand shall be deemed to have been duly given or served if in writing and either personally served or forwarded by Federal Express or comparable delivery service or by registered or certified mail, charges prepaid, and addressed as set forth in Article 1 to the applicable Notification Addresses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Each such mailed notice shall be deemed to have been given to or served upon the party to which addressed (i) on the date of delivery if personally served, (ii) one business day after the date the same is deposited with the express service, or (iii) three business days after the date the same is deposited with the postal service, properly addressed in the manner above provided. Either party hereto may change the address to which such notices shall be delivered or mailed by giving written notice of such change to the other party hereto, as herein provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 37. BROKERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">Each party represents and warrants to the other that TARQUINCoRE, LLC has acted as the only broker or agent in connection with the finding and negotiation of this Lease. Landlord shall be responsible for payment of commissions or fees due such brokers in accordance with the terms of Landlord&#39;s written listing agreement with such agent. Each party agrees to indemnify and hold harmless the other from and against any claims, suits, liabilities and expenses incurred by or assessed by reason of any undisclosed brokerage or agency arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 38. FORCE MAJEURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 26.64pt 0.7pt;">Neither party shall be required to perform any term, condition or covenant of this Lease as long as such performance is delayed or prevented by force majeure, which shall mean Acts of God, strikes, lockouts, material or labor restrictions imposed by governmental authority, civil riot, floods and other causes not reasonably within the control of such party and which, by the exercise of due diligence, such party is unable, wholly or in part, to prevent or overcome; provided, however, that such party shall be required to commence and thereafter diligently prosecute performance of completion to the extent reasonably permitted under the circumstances. Notwithstanding anything herein to the contrary, the foregoing shall not excuse either party from the payment of any monies due pursuant to the terms of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-28-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 39. TRANSFER OF LANDLORD&#39;S INTEREST</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Landlord&#39;s obligations hereunder shall be binding upon Landlord only for the period of time that Landlord is in ownership of the Building; and, upon termination of that ownership, Tenant, except as to any obligations which have then matured or relate to an event occurring prior to the <img src="cgtx-20241231xex10d3147.jpg" alt="Graphic" style="display:inline-block;height:0.72pt;width:0.72pt;">transfer, any breach occurring prior to the transfer, or any tort or fraud committed prior to the transfer, shall look solely to Landlord&#39;s successor in interest in the Building for the satisfaction of each and every obligation of Landlord hereunder. Tenant agrees to attorn to any transferee of Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 40. SUCCESSORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The respective rights and obligations provided in this Lease shall bind and shall inure to the benefit of the parties hereto and their respective successors and assigns, provided, however, that no rights shall inure to the benefit of any successors of Tenant whenever, by the express terms of this Lease, Landlord&#39;s written consent for the transfer to such successor is required under Article <img src="cgtx-20241231xex10d3117.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">14 hereof, unless Landlord shall have granted such consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 41. GOVERNING LAW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 4.79pt;">This Lease shall be construed, governed and enforced in accordance with the laws of the Commonwealth of Pennsylvania and the exclusive venue for any action shall be in the Court of Common Pleas of Allegheny County, Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 42. SEPARABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 4.79pt;">If any provisions of this Lease shall be held to be invalid, void or unenforceable, the remaining provisions hereof shall in no way be affected or impaired and such remaining provisions shall remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 43. CAPTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 4.45pt;">Any headings preceding the text of the several paragraphs and subparagraphs hereof are inserted solely for convenience of reference and shall not constitute a part of this Lease, nor shall they affect its meaning, construction or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 44. GENDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 4.45pt;">As used in this Lease, the word &#8220;person&#8221; shall mean and include, where appropriate, any individual, corporation, partnership or other entity; the plural shall be substituted for the singular, and the singular for the plural, where appropriate; and words of any gender shall mean to include any other gender.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-29-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 45. EXECUTION; COUNTERPARTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">This Lease shall become effective when it has been signed by a duly authorized officer or representative of each of the parties and delivered to the other party. This Lease may be executed in any number of counterparts, each of which when taken together shall be deemed to be one and the same instrument. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary, the exchange of copies of this Lease and signature pages by electronic transmission shall constitute effective execution and delivery of this Lease for all purposes, and signatures of the parties hereto transmitted electronically shall be deemed to be their original signature for all purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 46. ENTIRE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">This Lease, including the Exhibits hereto, contains all the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof, and may not be modified orally or in any manner other than by an agreement in writing signed by both parties hereto or their respective successors in interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 47. AUTHORITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">If Tenant is a corporation, association, partnership or similar legal entity, the Tenant represents and warrants that the individual signing this Lease is duly authorized to execute and deliver this Lease on behalf of such entity in accordance with the duly adopted authorizing instruments of such entity which have been adopted or approved in accordance with all legal requirements and the internnal bylaws, agreements, or other organizing documents of the entity, and that this Lease is binding upon such entity in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12pt 0.7pt;">If Landlord is a corporation, association, partnership or similar legal entity, The Landlord represents and warrants that the individual signing this Lease is duly authorized to execute and deliver this Lease on behalf of such entity in accordance with the duly adopted authorizing instruments of such entity which have been adopted or approved in accordance with all legal requirements and the intemal bylaws, agreements, or other organizing documents of the entity, and that this Lease is binding upon such entity in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 48. SECURITY DEPOSIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 48pt 0.7pt;">Upon execution of this Lease, Tenant shall deposit with Landlord the Security Deposit in the amount set forth in Article 1. The Security Deposit shall be held by Landlord as security for the full and faithful performance by Tenant of all of the terms, covenants and provisions of this Lease during the term hereof. In no event shall Landlord be obligated to pay, or Tenant is entitled to receive, any interest or other earnings on the security deposit. Landlord shall not be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-30-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0pt;">obligated to hold the Security Deposit in trust or in a separate account but may freely commingle the security deposit with Landlord&#39;s other ftlnds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event Tenant fails to keep and perform any of the terms, covenants or provisions of this Lease, then Landlord, at Landlord&#39;s option, may appropriate and apply the Security Deposit, or so much thereof as may be necessary to pay any Rent or other sums due hereunder for which Tenant shall be in default of payment. Tenant, upon notice from Landlord, immediately shall remit to Landlord an amount sufficient to restore this Security Deposit to the amount required to be maintained in accordance with this Article. Upon Tenant&#39;s full and complete performance and compliance with all of the terms, covenants and provisions of this Lease during the lease <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">term, upon the expiration of the term and Tenant&#39;s proper surrender of the Premises, the Security <img src="cgtx-20241231xex10d3020.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">Deposit shall be returned to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 12pt 0pt;">In the event of a sale of the Building, Landlord may deliver the Security Deposit to the purchaser, and upon such delivery, Landlord shall be discharged from any further liability with respect to the Security Deposit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE 49. OFAC CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 13.19pt 0pt;">Tenant certifies that: (i) it is not acting, directly or indirectly, for or on behalf of any person, <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">group, entity, or nation named by any Executive Order or the United States Treasury Department <img src="cgtx-20241231xex10d3152.jpg" alt="Graphic" style="display:inline-block;height:8.28pt;width:0.72pt;">as a terrorist, &#8220;Specially Designated National and Blocked Person,&#8221; or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule, or regulation that is <img src="cgtx-20241231xex10d3153.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">enforced or administered by the Office of Foreign Assets Control; and (ii) it is not engaged in this transaction, directly or indirectly on behalf of, or instigating or facilitating this transaction, <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">directly or indirectly on behalf of, any such person, group, entity, or nation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 13.19pt 0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-31-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties, intending to be legally bound, have executed this Lease as of the dayand year first written above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ATTEST:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harold Safferstein</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harold Safferstein</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVP</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ATTEST</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RJ EQUITIES LP</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RD Equities, LLC, its General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Anita Marcocci</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-32-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">sss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8.6pt 0pt;"><b style="font-weight:bold;">Exhibit &#8220;A&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;">Diagram of Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-33-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8.55pt 245.65pt;"><b style="font-weight:bold;">Exhibit &#8220;B&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;">Outline of Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 0.55pt 187.3pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-34-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10.39pt 0pt;"><b style="font-weight:bold;">Exhibit &#8220;C&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 23.75pt 0pt;">Rules and Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 16.5pt 0.7pt;"><b style="font-weight:bold;">GENERAL:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">OBSTRUCTIONS:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 0.15pt 75.25pt;">The streets, driveways, parking lots, sidewalks, entrances, passages and other common areas provided by Landlord shall not be obstructed by Tenant, its employees, agents, representatives, vendors and guests or used for any other purpose than ingress and egress.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">BATHROOMS:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.4pt 72.4pt;">The bathrooms, toilet rooms and other plumbing apparatus shall not be used for any other purposes other than those for which they are constructed.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">GENERAL PROHIBITIONS:</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">No cooking, grilling, smoking, gas or other type of flame in the common areas;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">No animals or birds are permitted anywhere on the premises;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;">No use of the premises as sleeping rooms;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;">No loitering or congregating in the entrances or hallways;<img src="cgtx-20241231xex10d3007.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;"></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">No making improper loud noises or disturbances of any kind;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">Doing anything to unreasonably disturb or disrupt other tenants in the complex;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;">Doing anything to change, damage or destroy the landscaping around the premises;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">SMOKING:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 1.85pt 72.4pt;">The complex&#39;s buildings are maintained as <b style="font-weight:bold;">smoke free</b> environments. This means no <b style="font-weight:bold;">smoking</b> in the building. Smoking is permitted outside of the buildings where several smoking boxes are provided in four designated areas for cigarette butts. Please use the smoking boxes for your butts, not the grounds or parking areas.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">DOORS:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 8.94pt 75.25pt;">Exterior doors are not to be held open. Holding or propping these doors open for 30 seconds or more will sound off an alarm and automatically notify police.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-align:justify;text-indent:-0.15pt;margin:0pt 0pt 13.19pt 0.7pt;"><b style="font-weight:bold;">PARKING:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.1pt 0pt;">To insure that adequate parking spaces are available for our tenants, a specific number of parking passes are provided to each tenant for a specific parking zone. The passes are to be placed on the rear <img src="cgtx-20241231xex10d3022.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">view mirror of each vehicle and can be transferred from one vehicle to another. The parking lots are patrolled daily. Vehicles that lack a parking pass or are parked in the wrong zone will be considered <img src="cgtx-20241231xex10d3008.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">in violation of the parking regulations. Violations are handled as follows:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:82.05%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Violation</b><b style="font-weight:bold;">:</b></p></td><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A yellow sticker will be placed under the windshield wiper;</p></td></tr><tr><td style="vertical-align:bottom;width:29.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Violation</b><b style="font-weight:bold;">:</b></p></td><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">An adhesive yellow sticker will be placed on the windshield;</p></td></tr><tr><td style="vertical-align:bottom;width:29.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Violation</b><b style="font-weight:bold;">:</b></p></td><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The police will be called and the car will be towed, at the owner&#39;s expense.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 0.15pt 0pt;">These rules and regulations are subject to change from time to time at the discretion of the Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-35-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8.6pt 0pt;"><b style="font-weight:bold;">Exhibit &#8220;D&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;">Intentionally Omitted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-36-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7.34pt 0pt;"><b style="font-weight:bold;">Exhibit &#8220;E&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12.69pt 0pt;">ESTOPPEL CERTIFICATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12.69pt 0pt;">{See Attached Form of Estoppel}</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.2pt;margin:0pt 0pt 12.69pt 154.15pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-37-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8.8pt 0pt;"><b style="font-weight:bold;">EXHIBIT &#8220;F&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12.69pt 0pt;">SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11.6pt 0pt;">{See Attached Form of SNDA}</p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 11.6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-38-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FIRST AMENDMENT TO OFFICE LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This First Amendment to Office Lease Agreement (&#8220;Amendment&#8221;) is made this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1</u><sup style="font-size:7.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:top;">st</sup> day of July, 2017, and is by and between <b style="font-weight:bold;">RJ EQUITIES LP</b>, a Pennsylvania limited partnership (&#8220;Landlord&#8221;), and <b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b>, a Delaware corporation (&#8220;Tenant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE I - AMENDMENT OF BASIC TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34.95pt;margin:0pt 0pt 12pt 8.35pt;">The parties, intending to be legally bound, do hereby agree to the amendment, ratification and restatement of certain terms of the Lease (as defined below) as follows:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">a)</p></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">That certain Office Lease Agreement dated January 20, 2015, as amended by this Amendment.</p></td></tr><tr><td style="vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">b)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suites 261, 263, and certain shared lab space all of which is located on the second floor of the commercial building (the &#8220;Building&#8221;) situated at 2403 Sidney Street, Pittsburgh, PA 15203 (the &#8220;Development&#8221;), and all as more particularly described in the Lease.</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">c)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of the Lease is hereby extended from February l, 2018, until June 30, 2020 (the &#8220;Extended Term&#8221;). Any reference in the Lease to the Termination Date shall <img src="cgtx-20241231xex10d3012.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">hereafter mean June 30, 2020.</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">d)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent during the Extended Term shall be Seven Thousand One Hundred Three and 17/100ths Dollars ($7,103.17) per month.</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">e)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The parties hereby acknowledge and agree that Article 3(c) of the Lease is hereby deleted in its entirety&#8212;the intent being that Tenant shall have no further extension options to extend the term of the Lease.</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">f)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Defaults:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The parties acknowledge and agree that the following shall constitute a default under the Lease: &#8220;a default or breach by Tenant beyond the expiration of applicable notice and/or cure periods under any other lease with Landlord in connection with the Building&#8221;.</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">g)</p></td><td style="vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord has consented to the subleasing by Tenant, as sublessor, to Sharp Edge Labs, Inc. (the &#8220;Sublessee&#8221;) of a portion of the lab space comprising the Premises, upon the condition that neither anything contained in the sublease <img src="cgtx-20241231xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:0.36pt;width:0.36pt;">nor Landlord&#39;s consent thereto shall (i) release Tenant from any of its liabilities and obligations to Landlord under the Lease, (ii) constitute a novation, (iii) increase or modify Landlord&#39;s obligations under the Lease, or (iv) create any rights or remedies in Sublessee under the Lease itself. It is understood and agreed that Landlord shall have no obligation or liability under the terms of the sublease.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE II - TENANT REPRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt 0pt 12pt 9.15pt;">By the execution of this Amendment, Tenant represents and warrants to Landlord as follows as of the date hereof:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That the Lease is in full force and effect and that, to Tenant&#39;s knowledge, there are no Landlord defaults and that the Lease has not been assigned, modified, supplemented or amended (except as expressly set forth above).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That there are no defenses or offsets against the Landlord&#39;s enforcement of the Lease that may be claimed by Tenant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cgtx-20241231xex10d3160.jpg" alt="Graphic" style="display:inline-block;height:0.72pt;width:0.72pt;"><img src="cgtx-20241231xex10d3161.jpg" alt="Graphic" style="display:inline-block;height:1.08pt;width:1.08pt;">ARTICLE III - MISCELLANEOUS</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that it has had no dealings, negotiations or consultations with respect to the Premises, this Amendment or the transactions contemplated under the Lease with any broker or finder, except that Landlord was represented by TARQUINCoRE LLC (the &#8220;Broker&#8221;). Landlord shall pay all commissions and fees, if any, due to Broker in connection with this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as expressly modified by this Amendment, all other terms and provisions of the Lease shall remain in full force and effect. Tenant accepts the Premises in its current &#8220;asis, where-is&#8221; condition. All capitalized terms used herein shall have the meaning ascribed to such term in the Lease unless otherwise defined herein. This Amendment supersedes any prior discussions, proposals, negotiations and discussions between the parties and the Lease, as amended hereby, contains all of the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment may be executed in any number of counterparts, each of which when taken together shall be deemed to be one and the same instrument. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary, the exchange of copies ofthis Amendment and signature pages by electronic transmission shall constitute effective execution and delivery of this Amendment for all purposes, and signatures of the parties hereto transmitted electronically shall be deemed to be their original signature for all purposes.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that the individual signing this Amendment on behalf of such party is duly authorized to execute and deliver this Amendment on behalf of such entity in accordance with the duly adopted authorizing instruments of such entity which have been adopted or approved in accordance with all legal requirements and the internal bylaws, agreements, or other organizing documents of the entity, and that this Amendment is binding upon such entity in accordance with its terms.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:13.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">Each party shall indemnify and hold the other harmless from and against all liability, cost and expense, including attorney&#39;s fees and court costs, arising out of any misrepresentation or breach of warranty made in this Amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 11.6pt 0pt;">{REMAINDER OF PAGE INTENTIONALLY LEFT BLANK}</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0.7pt;">Witness the due execution of this Amendment the date first set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ATTEST:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anita Marcocci</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harold Safferstein</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harold Safferstein</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVP</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">WITNESS:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RJ EQUITIES LP</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RD Equities, LLC, its General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Anita Marcocci</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECOND AMENDMENT TO OFFICE LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Second Amendment to Office Lease Agreement (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Amendment<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>) is made this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">20</u> day of December, 2019, and is by and between <b style="font-weight:bold;">RJ EQUITIES LP</b>, a Pennsylvania limited partnership (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Landlord<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>), and <b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.,</b> a Delaware corporation (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Tenant<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE I - AMENDMENT OF BASIC TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34.9pt;margin:0pt 0pt 12pt 2.8pt;">The parties, intending to be legally bound, do hereby agree to the amendment, ratification and restatement of certain terms of the Lease (as defined below) as follows:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;">a)</p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">That certain Office Lease Agreement dated January 20, 2015, as amended by that certain First Amendment to Office Lease Agreement dated July l, 2017, and by this Amendment.</p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;">b)</p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suites 261, 263, and certain shared lab space all of which is located on the second floor of the commercial building (the &#8220;Building&#8221;) situated at 2403 Sidney Street, Pittsburgh, PA 15203, and all as more particularly described in the Lease.</p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;">c)</p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of the Lease is hereby further extended from July l, 2020, until June 30, 2023 (the &#8220;Second Extended Term&#8221;). Any reference in the Lease to the Termination Date shall hereafter mean June 30, 2023. Tenant acknowledges and agrees that it has no further options or rights to extend the term of the Lease.</p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;">d)</p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent during the Seconded Extended Term shall be Eighty-Five Thousand Two Hundred Thirty-Eight and 04/100ths Dollars ($85,238.04) per annum, payable in equal monthly installments of Seven Thousand One Hundred Three and 17/100ths Dollars ($7,103.17).</p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11pt;">e)</p></td><td style="vertical-align:top;width:15.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Year:</p></td><td style="vertical-align:bottom;width:76.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the Second Extended Term, the Base Year for Real Estate Taxes and Operating Costs shall remain the year 2009.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE II - TENANT REPRESENTATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:34.9pt;margin:0pt 0pt 12pt 0pt;">By the execution of this Amendment, Tenant represents and warrants to Landlord as follows as of the date hereof:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That the Lease is in full force and effect and that, to Tenant&#39;s knowledge, there are no Landlord defaults and that the Lease has not been assigned, modified, supplemented or amended (except as expressly set forth above).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That there are no defenses or offsets against the Landlord&#39;s enforcement of the Lease that may be claimed by Tenant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE III - MISCELLANEOUS</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that it has had no dealings, negotiations or consultations with respect to the Premises, this Amendment or the transactions contemplated under the Lease with any broker or finder, except that Landlord was represented by TARQUINCoRE LLC (the &#8220;Broker&#8221;). Landlord shall pay all commissions and fees, if any, due to Broker in connection with this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as expressly modified by this Amendment, all other terms and provisions of the Lease shall remain in full force and effect. Tenant accepts the Premises in its current &#8220;as-is, where-is&#8221; condition. All capitalized terms used herein shall have the meaning ascribed to such term in the Lease unless otherwise defined herein. This Amendment supersedes any prior discussions, proposals, negotiations and discussions between the parties and the Lease, as amended hereby, contains all of the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment may be executed in any number of counterparts, cach of which when taken together shall be deemed to be one and the same instrument. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary, the exchange of copies of this Amendment and signature pages by electronic transmission shall constitute effective execution and delivery of this Amcndment for all purposes, and signatures of the parties hereto transmitted electronically shall be deemed to be their original signature for all purposes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that the individual signing this Amendment on behalf of such party is duly authorized to execute and deliver this Amendment on behalf of such entity in accordance with the duly adopted authorizing instruments of such entity which have been adopted or approved in accordance with all legal requirements and the internal bylaws, agreements, or other organizing documents of the entity, and that this Amendment is binding upon such entity in accordance with its terms.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:30.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each party shall indemnify and hold the other harmless from and against all liability, cost and expense, including attorney&#39;s fees and court costs, arising out of any misrepresentation or breach of warranty made in this Amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0.7pt;">Witness the due execution of this Amendment the date first set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ATTEST:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ James O&#8217;Brien</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">James O&#8217;Brien</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CFO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">:</p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">WITNESS</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RJ EQUITIES LP</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RD Equities, LLC, its General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Anita Marcocci</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIRD AMENDMENT TO OFFICE LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Third Amendment to Office Lease Agreement (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Amendment<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>) is made this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">31</u><sup style="font-size:7.5pt;vertical-align:top;">st</sup> day of August, 2022, and is by and between <b style="font-weight:bold;">RJ EQUITIES LP</b>, a Pennsylvania limited partnership (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Landlord<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>), and <b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.,</b> a Delaware corporation (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Tenant<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE I - AMENDMENT OF BASIC TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The parties, intending to be legally bound, do hereby agree to the amendment, ratification and restatement of certain terms of the Lease (as defined below) as follows:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a)</p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease:</p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">That certain Office Lease Agreement dated January 20, 2015, as amended by: (i) that certain First Amendment to Office Lease Agreement dated July l, 2017, (ii) that certain Second Amendment to Office Lease Agreement dated December 20, 2019, and (iii) this Amendment.</p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">b)</p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises:</p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suites 261, 263, and certain shared lab space all of which is located on the second floor of the commercial building (the &#8220;Building&#8221;) situated at 2403 Sidney Street, Pittsburgh, PA 15203, and all as more particularly described in the Lease.</p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">c)</p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term:</p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of the Lease is hereby further extended from July l, 2023, until June 30, 2026 (the &#8220;Third Extended Term&#8221;). Any reference in the Lease to the Termination Date shall hereafter mean June 30, 2026. Tenant acknowledges and agrees that it has no further options or rights to extend the term of the Lease.</p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">d)</p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent:</p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent during the Third Extended Term shall be Eighty-Five Thousand Two Hundred Thirty-Eight and 04/100ths Dollars ($85,238.04) per annum, payable in equal monthly installments of Seven Thousand One Hundred Three and 17/100ths Dollars ($7,103.17).</p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">e)</p></td><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Year:</p></td><td style="vertical-align:bottom;width:84.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the Third Extended Term, the Base Year for Real Estate Taxes and Operating Costs shall remain the year 2009.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE II - TENANT REPRESENTATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By the execution of this Amendment, Tenant represents and warrants to Landlord as follows as of the date hereof:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:59.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That the Lease is in full force and effect and that, to Tenant&#39;s knowledge, there are no Landlord defaults and that the Lease has not been assigned, modified, supplemented or amended (except as expressly set forth above).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:59.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">That there are no defenses or offsets against the Landlord&#39;s enforcement of the Lease that may be claimed by Tenant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ARTICLE III - MISCELLANEOUS</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:58.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that it has had no dealings, negotiations or consultations with respect to the Premises, this Amendment or the transactions contemplated under the Lease with any broker or finder, except that Landlord was represented by TARQUINCoRE LLC (the &#8220;Broker&#8221;). Landlord shall pay all commissions and fees, if any, due to Broker in connection with this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:58.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as expressly modified by this Amendment, all other terms and provisions of the Lease shall remain in full force and effect. Tenant accepts the Premises in its current &#8220;asis, where-is&#8221; condition. All capitalized terms used herein shall have the meaning ascribed to such term in the Lease unless otherwise defined herein. This Amendment supersedes any prior discussions, proposals, negotiations and discussions between the parties and the Lease, as amended hereby, contains all of the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:58.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:17.39pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:17.39pt;margin-top:0pt;text-align:justify;">This Amendment may be executed in any number of counterparts, each of which when taken together shall be deemed to be one and the same instrument. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary, the exchange of copies of this Amendment and signature pages by electronic transmission shall constitute effective execution and delivery of this Amendment for all purposes, and signatures of the parties hereto transmitted electronically shall be deemed to be their original signature for all purposes.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:58.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:17.1pt;margin-top:0pt;text-align:justify;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:17.1pt;margin-top:0pt;text-align:justify;">Landlord and Tenant each represents and warrants to the other that the individual signing this Amendment on behalf of such party is duly authorized to execute and deliver this Amendment on behalf of such entity in accordance with the duly adopted authorizing instruments of such entity which have been adopted or approved in accordance with all legal requirements and the internal bylaws, agreements, or other organizing documents of the entity, and that this Amendment is binding upon such entity in accordance with its terms.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:58.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12.69pt;margin-top:0pt;text-align:justify;">Each party shall indemnify and hold the other harmless from and against all liability, cost and expense, including attorneys fees and court costs, arising out of any misrepresentation or breach of warranty made in this Amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0.7pt;">Witness the due execution of this Amendment the date first set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ATTEST:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COGNITION THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LISA RICCIARDI</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President/CEO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">WITNESS:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RJ EQUITIES LP</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RD Equities, LLC, its General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jennifer Tarquinio</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:39.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ronald J. Tarquinio</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 16pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>cgtx-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:18 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 19.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COGNITION THERAPEUTICS, INC.<br><br>INSIDER TRADING POLICY</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><i style="font-style:italic;font-weight:normal;">Effective October 7, 2021</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt;"><font style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">I.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;) has adopted this Insider Trading Policy (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u>&#8221;) to satisfy the Company&#8217;s obligation to prevent insider trading and to help the Company&#8217;s personnel and its external advisors avoid violating insider trading laws. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">II.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Persons Subject to the Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy applies to (i) all officers, directors and employees of the Company and its subsidiary, (ii) immediate family members (as defined below) and any persons that reside in the same household as any of the foregoing persons and (iii) any other person whose transactions in Company Securities (as defined below) are directed by, or subject to influence or control by the foregoing persons, and any trust, partnership, corporation or other entity over which such persons have investment control (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insiders</u>&#8221;). &#160;Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy and therefore should make them aware of the need to confer with you before they trade in Company Securities (as defined below) and should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy does not, however, apply to personal securities transactions of your immediate family members (as defined below) where the purchase or sale decision is made by a third party not controlled by, influenced by or related to you or your immediate family members (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><a name="_cp_text_1_10"></a><font style="text-decoration-color:#0000ff;">For purposes of this Policy, &#8220;</font><u style="text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">i</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">mmediate family member</u><font style="text-decoration-color:#0000ff;">&#8221; means any spouse, child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother or sister-in-law (as well as other adoptive relationships), whether or not sharing the same household as the persons described in item (i) above. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">All consultants and outside advisors assisting the Company on sensitive matters are expected to abide by this Policy, although the Company assumes no responsibility with respect to the actions of persons who are not under its direct control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Persons in possession of material non-public information related to, affecting or regarding the Company or its subsidiary (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inside Information</u>&#8221;) when their employment or service terminates may not trade in Company Securities (as defined below) until that information has become public or is no longer material. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Notwithstanding the foregoing, this Policy, including, without limitation, the pre-clearance policy, blackout periods and prohibited transactions, does not apply to venture capital entities or </p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">     </font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">other institutional investors that engage in the investment of securities in the ordinary course of its business, and the related transaction in the Company&#8217;s equity securities by such entities, that may be affiliated with a director of the Company or for Company equity securities that a director may be deemed to have beneficial ownership of by virtue of such affiliation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">III.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions Subject to the Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy applies to all transactions in securities of the Company (collectively referred to in this Policy as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Securities</u>&#8221;), including common stock, options to purchase common stock, preferred stock, convertible debt and warrants, or any other type of securities that the Company has or may issue, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company Securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">IV.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No Insider who is in possession of Inside Information may, either directly or indirectly, (i) purchase or sell Company Securities or, (ii) without the consent of the Company, provide Inside Information to any other person outside of the Company, including family and friends, provided that notwithstanding the foregoing (y) a director may provide Inside Information to their employer provided such employer either (I) complies with this paragraph or (II) has established its own insider trading controls and procedures in compliance with applicable securities laws or (z) an Insider may disclose Inside Information as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Insiders may not disclose, convey or &#8220;tip&#8221; Inside Information to any person by providing them with Inside Information other than to disclose on a &#8220;need to know&#8221; basis to directors, officers and employees of the Company or outside advisors in the course of performing their duties for the Company (it being understood that directors may disclose Inside Information to their employers; provided that such employer either (I) complies with the requirements of the first paragraph of this Section IV or (II) has established its own insider trading controls and procedures in compliance with applicable securities laws). &#160;When sharing Inside Information with other directors, officers and employees of the Company or outside advisors, or other persons involved in the business and affairs of the Company, such information should be confined to as small a group as possible. &#160;Unlawful tipping includes passing on Inside Information to friends, family members or acquaintances under circumstances that suggest that persons subject to this Policy were trying to help the recipients of such information to make a profit or avoid a loss by trading in Company Securities based on such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">V.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition of Inside Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Information</i>. &#160;Information is considered &#8220;material&#8221; if a reasonable investor would consider that information important in deciding to buy, hold or sell Company Securities or the securities of another public company. &#160;Any information that could be expected to affect the Company&#8217;s stock price, whether it is positive or negative, should be considered material. &#160;Determining whether information is material is not always straightforward; rather, materiality is based on an assessment of all of the facts and circumstances and is often evaluated by enforcement authorities with the benefit of hindsight. &#160;When doubt exists as to whether information would be considered &#8220;material,&#8221; the information should be presumed to be material. &#160;While it is not possible </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-2-</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to identify in advance all information that will be deemed to be material, some examples of such information would include the following:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">merger, acquisition, joint venture, partnerships, strategic alliances, collaborations or investment proposals;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">annual or quarterly financial statements;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">earnings estimates;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">changes to operational or financial guidance; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">significant expansion or curtailment of operations;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">material information regarding an existing or potential customer or supplier;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">unusual borrowings; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">public or private securities offerings;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">litigation (pending or threatened);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">changes in executive management or members of the board of directors of the Company;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">information concerning clinical trials and their results, intellectual property, regulatory approvals or other developments (positive or negative), product or technological plans, developments or agreements;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">communications to or from regulatory agencies; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">new product launches or the introduction of new business strategies; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the status of the Company&#8217;s progress toward achieving significant Company goals; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">listing on or delisting from a stock exchange;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">new major contracts, customers, distributors or suppliers, or the loss of any of the foregoing; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">significant related party transactions.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Public Information</i>. &#160;Information that has not been widely disseminated to the public is generally considered to be non-public information. &#160;Information generally becomes available to the public when it has been disclosed by the Company or third parties in a press release or other authorized public statement, including any filing with the Securities and Exchange Commission (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u>&#8221;). &#160;Once information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. &#160;As a rule, information should not be considered fully absorbed by the marketplace until <font style="font-style:italic;font-weight:bold;">after the second full trading day after the information is released</font>. &#160;If, for example, the Company were to make an announcement prior to the start of trading on a Monday, a person covered by this Policy should not trade in Company Securities until the start of trading on Wednesday. &#160;Depending on the circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material non-public information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If you are unsure whether you are in possession of Inside Information, you should consult with the Chief Financial Officer prior to engaging in, or entering into an agreement, understanding or arrangement to engage in, a purchase or sale transaction of any Company Securities. &#160;However, you are responsible for determining whether you are in possession of Inside Information and any action on the part of the Company, the Chief Financial Officer or any other employee or director pursuant to this Policy or otherwise does not in any way constitute legal advice or insulate you from liability under applicable securities laws.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-3-</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">VI.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special and Prohibited Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the other restrictions set forth in this Policy, the following transactions are strictly prohibited at all times:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">trading in call or put options involving Company Securities and other derivative securities; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">engaging in short sales of Company Securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">holding Company Securities in a margin account; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_13"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">ll forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">pledging Company Securities to secure margin or other loans.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If you are unsure whether a particular transaction is prohibited under this Policy, you should consult with the Chief Financial Officer prior to engaging in, or entering into, an agreement, understanding or arrangement to engage in, such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">VII.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions Not Subject to Trading Restrictions Under the Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:none;">The trading restriction prohibitions in this Policy do not apply to:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the granting of options or other equity awards;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the purchase or sale of Company Securities from or to the Company, as applicable;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">bona fide gifts of Company Securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">purchases or sales of Company Securities made pursuant to any binding contract, specific instruction or written plan entered into outside of a blackout period and while the purchaser or seller, as applicable, was unaware of any material non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10b5-1 trading plan</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8221;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy; or </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">transactions between Insiders and the Company with respect to grants under its equity incentive plan (or, to the extent applicable, granted outside such plan), including the exercise of stock options for cash; the vesting of restricted stock or restricted stock units (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RSUs</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8221;) or the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares to satisfy tax withholding upon the exercise of stock options or the vesting of any restricted stock or RSUs.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:none;">Consequently, restrictions contained in this Policy would apply to the sale of Company Securities in the open market to pay the exercise price of an option and to the &#8220;cashless exercise&#8221; effected through a broker or &#8220;same day sale&#8221; of an option, which generally entail the sale of a portion of the underlying stock on the market to cover the costs of exercise or the resulting taxes. &#160;</font></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-4-</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:none;">In addition, any sale of the underlying securities acquired upon the exercise of an option or RSU is subject to the Policy. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">VIII.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Procedures Applicable to Restricted Persons </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt;"><font style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blackout Periods</i><i style="font-style:italic;">. &#160;</i>All officers and directors of the Company, as well as certain key employees listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</u> hereto (as may be amended from time to time), as well as any family members or other persons that reside in the same household as those persons (all of the foregoing being &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Persons</u>&#8221;) are subject to additional restrictions on their ability to engage in purchase or sale transactions involving Company Securities. Restricted Persons are more likely to have access to Inside Information regarding the Company because of their positions or affiliations with the Company and, as a result, their trades in Company Securities are more likely to be subject to greater scrutiny. Accordingly, Restricted Persons are prohibited from trading in Company Securities is prohibited during the period beginning twenty-one days prior to the filing of each of the Company&#8217;s quarterly reports on Form 10-Q or annual reports on Form 10-K with the SEC and ending on the beginning of the second trading day following public disclosure of the financial results for that quarter or the full year. &#160;Attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex B</u> is a list of the blackout periods for the current and next fiscal year, which shall be updated from time to time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Blackout Periods</i>. &#160;In addition, from time to time, the Company may impose special blackout periods on Restricted Persons and other employees of the Company if, in the judgment of the Chief Executive Officer or Chief Financial Officer, it is likely that such person or persons have become aware of significant corporate developments that have not yet been disclosed to the public, even when trading otherwise may be permitted. &#160;If certain Restricted Persons or other employees of the Company become subject to a special blackout period, such persons are prohibited from (i) trading in Company Securities and (ii) without the consent of the Company, disclosing to others the fact that they are subject to such special blackout period. &#160;These special blackout periods may vary in length and may or may not be broadly communicated to Insiders. &#160;Unless otherwise specified, the Company will re-open trading on the beginning of the second trading day following public disclosure of such significant corporate developments or after the termination of any pending development, if applicable. &#160;If, for example, the Company imposed a special blackout period by end of business close on a Monday, the persons subject to such a special blackout period should not trade in Company Securities until the pre-market on Thursday, unless otherwise specified by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Clearance Procedures</i>. &#160;Restricted Persons must obtain prior clearance from the Chief Financial Officer, or such person&#8217;s designee, by submitting (in writing or via email) the information contained in the Request for Clearance to Trade as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex B</u> attached hereto, before such person makes any purchases, sales or gifts of Company Securities, regardless of whether a blackout period is then in effect. &#160;The Chief Financial Officer is under no obligation to approve a transaction submitted for pre-clearance and may determine not to permit the transaction. &#160;If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company Securities. &#160;Clearance of a transaction is valid for no more than the 5-business day period (or such shorter period as may be prescribed in the pre-clearance form) immediately following receipt by such person of such clearance. &#160;Restricted Persons do not need to receive pre-clearance for trades pursuant to an </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-5-</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">approved 10b5-1 trading plan, but must receive prior approval before implementing, terminating, or amending such a plan by the Chief Financial Officer, or such person&#8217;s designee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">IX.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule 10b5-1 Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company permits all directors, officers and other employees to adopt a 10b5-1 trading plan pursuant to the Company&#8217;s procedure for adopting such a trading plan. &#160;All directors, officers and other employees must obtain pre-clearance prior to entering into, modifying or terminating a 10b5-1 trading plan. &#160;The restrictions on trading set forth in this Policy shall not apply to trades made pursuant to a 10b5-1 trading plan. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">X.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of Violations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchase or sale of Company Securities while aware of Inside Information, or the disclosure of Inside Information to others who then trade in Company Securities, is prohibited by federal and state securities laws. &#160;Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys, and state enforcement authorities, as well as the laws of foreign jurisdictions. &#160;Punishment for insider trading violations is severe and could include significant fines and imprisonment. &#160;While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#8220;controlling persons&#8221; within the organization if they fail to take reasonable steps to prevent insider trading by company personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, an individual&#8217;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether the employee&#8217;s failure to comply results in a violation of law. &#160;A violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&#8217;s reputation, and irreparably damage a career.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">XI.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration of the Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s Chief Financial Officer, and in such a person&#8217;s absence, an employee designated by the Chief Financial Officer, in consultation with internal and external legal counsel, shall be responsible for administration of this Policy. &#160;All determinations and interpretations by the Chief Financial Officer (or his or her designees) shall be final and not subject to further review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">XII.</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">You must sign, date and return the Certification set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex C</u> attached hereto (or such other certification as the Chief Financial Officer may deem appropriate) stating that you have received, read, understand and agree to comply with this Policy. &#160;The Company may require you to sign such a Certification on an annual basis, which Certification may be in electronic format. &#160;Please note that you are bound by the Policy whether or not you sign the Certification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-6-</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Persons</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">     </font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quarterly Blackout Periods </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">     </font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Request for Clearance to Trade</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certification</b></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"> <font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>cgtx-20241231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:17 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:39.12%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.18%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:14.83%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:middle;width:41.8%;margin:0pt;padding:0.75pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'JD Sans Pro Book';">None.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>cgtx-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:26 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the incorporation by reference in the Registration Statements: </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-260686) pertaining to the Cognition Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan, the Cognition Therapeutics, Inc. 2017 Equity Incentive Plan, as Amended, the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan and the Cognition Therapeutics, Inc. 2021 Employee Stock Purchase Plan, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-263968) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-270784) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-278241) pertaining to the Cognition Therapeutics, Inc. 2021 Equity Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-268992) of Cognition Therapeutics, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.79;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-276316) of Cognition Therapeutics, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of our report dated March 20, 2025, with respect to the consolidated financial statements of Cognition Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cognition Therapeutics, Inc. for the year ended December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 20, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>cgtx-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:28 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Lisa Ricciardi, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: &#160;March 20, 2025</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Lisa Ricciardi </p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Lisa Ricciardi</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>cgtx-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:29 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, John Doyle, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of Cognition Therapeutics, Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">. JK</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 20, 2025</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ John Doyle </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">John Doyle</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>cgtx-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:34 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 20, 2025</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lisa Ricciardi</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>cgtx-20241231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/20/2025 02:05:35 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of our knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 20, 2025</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Doyle</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer<br>(Principal Financial Officer and Principal </p></td></tr><tr><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Doyle</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cgtx-20241231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 BX# 2(  A$! Q$!_\0
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M*^;;WQCKOQ!\%_LWZ]K>CZI9:[9>,(_[?@;3YU-M-#INH6\TK+LRL33,I5R
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M!1_F<9/S<6?B-^UO:_#)?%M[?:'<ZC:Z1XC_ .$9@M[5XXWDE32&U.69FD8
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M_P >_P#(MO\ ]?5K_P"E$== * %HHHH **** "BDS2T %%%% !1110 4444
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M:*** "D8[5)]/2EI#0!2TG5;?6+07-MO,18J"Z%22#@\'WS5ZL/P;_R+\/\
MUUF_]&O6W6=-MQ39<TE)I"T445H0%%%% !12&J-OK%O/JEQIZ,YN8$#N"A
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MBJHU.T) %U"225 $@Y(ZB@:I9D _:H<%2P_>#H.IZUZ)YA:HJJ=4LU!)NH0
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M=#DUU=% %/2M'L="L8K+3K."PLX@%C@MXPB( ,  #@< ?E5RFYYI10 M%%%
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MD*01O@DD')921T&,>]?K9+_JF^AK\D_!DHA3Q&_EO,WV=E*)=>1\I+;B1QN
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M:A'+9I+$(D=89"6C1G+[BJDX4G'45U-9=J''B"^8QN$:&(*Y7Y206S@_\"%
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M-<I;I(MQ.@^S?<(#XR!U'X_7O6[\9HM0N/ACX@ATN.YEOI;;RXXK.&.:1]S
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M"DZ!QA@K*&&1V.#3 \TE\-^/[RTT&-]7\B^M8A--< KY<DJR,2D@ ^974HO
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M">VDU">.ZN&@N&&Z9&W)(,YPP8[ACO70_P#"16?]Z3_OV:/^$BLC_%)_W[-
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M9VN8I4B8-'(V-S+Z9QSC@\^IK3T*+P_X92Y33+3[&MQ*9I!'&WS-T[] .P'
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M.Y6::VW,LJ;=C@D<$;%Z?W16Y_PD5E_>D_[]FF!IT5F?\)%9_P!Z3_OV:/\
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MUUEU':WUM+;W*Q3V\JE)(I,%74C!!'I65%X1\.026<D>E6"/9,K6S*@_<E0
MI7TQ@?D#UH N^!O$47B[0M&UJ"&6WAOXEG6&;&],Y&UL<9&#79 YKF]'@M;
MVMK:I%!;Q_+'%%@*H] *Z04 +1110 4444 %5=24-9R @$<<'ZU:JKJ/%I)^
M'\Z /*'O_%P^(FK10:=#/X;MH;=848*C2R2)EF5CUVM][V&!S7./\3?&%Q<1
MQ)X,DMT>U:8LT;%E=9A'M(QC#;9"#UVLA]:UO%H\>'QD4T$E;!Y861YMGD(H
MB&_?GG:6+9"_,3MQP#6#-IGQ>NK6!#=PH 4D(,L0<A959U<@_?;: I7@(6#?
M,12 W/#?Q$U_7?%^G:?-X2DLM(N$F+ZA*"-K(@. ".!O^7GKD$9YKTORHQ_
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MWWB/<]Z?LY]B56II_%^!D_9XO^>:_E1]GB_YYK^5='_PB3_\_"_E1_PB3_\
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MR?E5K-+=01UWL>HJ34++XI-X<\-Z7+<:G;S3SWVF7VK:>(Y9XA&\BV=VR-@
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M1@4M% "8HP/2EHH 3 ]*,"EHH 3 %+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cgtx-20241231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $1 B\# 2(  A$! Q$!_\0
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MM5I(C.OWB  [-@*#0!]M>'_$^G^)[:XN-.DEDB@N9;20S6\D)$L;%7 $BJ2
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M50QSE@HSG% 'D.G_ +8?AF_C\.R'0]:MX]=N+.&R>6.,+(MT\*03##Y,9,Z
MN0%RK@%B &P?#?[;VC7G@N36]6\-ZG%+::5)K.HQZ:%GCL[??=B+<Y*@[A9L
MN[@;W4>NWW"V^$_@BR:T:W\':! UFP>V,6F0*86$@D!3"_*1(JOQ_$H/49J2
M'X7^#;<H8O"6AQ%()+52FFPC;#(S-)&/EX5F9BR]"6)/4T >;^ _BQXM\>^$
MOB-/!:Z;9ZUHGB2?1M,B>,O&46&W>/S<2?,Q,Q!*D#&..#7.']IK5)TN;]K.
M'3M*A\)MK3HUL9+F.Z2=89DVF1045MR@'!)4G(XKW;3/ OAO1=/DL-.\/Z78
M6,DPN'MK6RCCB:4!0'*JH!8;5YZ_*/04NH>"/#NK3-+>Z#IEY*T)MV>XLXW8
MQ$[BA)'W<\XZ9YK>G.$5:<;G52J4X*TXW/'[C]H+489[K38[6WDU2VUR*SDE
M*;85M'OEM@<;]QDP6Y' .#CM5;XL_'/QCI]YXZTGP)IVG7&N>&_[.2"'5(VD
M2]DN/,D9!M=-O[N/:IS]Y\G@8/LR^ ?#*/&R^'=*#1N9486465<L'+#Y>"64
M-GU /45!<?#SP]=^)I==FTNVEU&80^:\D2N':$L89""#ATWOM88(W'VQ-24)
M6Y%8BK*G*W(K'S>?VI_&OC:\\1CP38Z2L+^&=)UOP]'JMG,))9;NYDA*3CS%
M.,QD# 7UR1BJ]E^UQXW\6ZKI\GA;PS8ZA;7WA)=:ATB<^1?->)?06MS"CR.J
M$@RRHB$#>\:X8AA7TW)\.?"<MZUX_AC1GNVCBB-PVGQ&0I&VZ-=VW.$;E1T!
MY&*+SX=>%-0OVOKKPSH]S>M%Y#7,UA$TACW[]A8KG;O^;'3//6LC ^:+;]J7
MQCXB\=^$M"T:&WMK;7=,OKJ635-$DBN--GAO4@"749N!Y:QAR)""<E=RG#5Z
MU\0_B!XET'XE>#]%T?6/# MM424WFGZBC"X2,1L1<)()1E1)Y:A-A+;OO+U'
M9ZA\)? ^KRPRWW@WP_>R0PFWC>XTN"1DB)W% 2O"DDG'3-/UKX5>"O$FN0ZS
MJWA#0=4UB&+R(M0O=,@FN(X\$;%D92P7!(P#CDT >5_#KX[WVI^#)D\3ZUH<
M>OW%W?1:=JNE6,\^G/;1-^[N)_+=TAROS%'F7(P01GCC_"/[6>O2Z]X6T/7[
M/3KC[>$\_7-& -O*;F[:VT_9"TI90^%>3:TACW*"/FROT/IGPR\'Z+X6N/#.
MG^%-$L/#=QO\[1[;3H8[.7=PVZ%5"-G'.1S4>F_"OP=H5I8V^D^%=%TF*P\S
M[$MAIT$/V0N<N8MJ#820"=N,D4 <';?M$P1^"-!UBXT6YN[_ %+5KG1#:V3J
MJK<0/,CMND*_(?)8CJ?F YKFU_;9\)2Z)JFIQ:-K$L-CHC:XT:^07>-?)W1C
M$FT.//7AB.A/ *EO2-:^!WA?7-'\,Z7-;RQZ;H%[]OM[0%7CFDP^X3"16WAC
M(Y/0DG.:UF^$O@=VN&;P;X?9KE#%,3I<'[U"%!5ODY&$08/95]!0!X;XF_:_
MG\,>-+C2M;T"?P]9V=YIL,A(COII!<I<N01'*%3"V^0RESS]TUH>*/VN[+PM
M%IVL7FBZE%I-SH4NM)9)';RRW$/F6Z1R)*L^U0?M ^4KGAN1@;O;+WX<^$]2
MU%+^[\,:-=7R&,K=3:?$\JF//ED,5S\NYMOIDXQFN4\>_LY> O'W@^7PY-H%
MGH]D\?DB31[2"WFCB+AWC1O+.U691N '- '"VO[:GA&XU&WL&TC5X[J6[NK%
MT*Q$1SP"8NI(?I^X;!.,[AC.&VUM%_;*LO$=II-W8>#]6,5T9&FMY)8&N5C%
MD+M#&J.5=F0@;=P(->RK\*?!?G0SGPCH37$*[$F.F0;U'S< [./OOT_OMZFF
MQ?"+P+!:"UC\%^'H[8.)!"FE0! P38&QLQG9\N?3CI0!9^'7CW2OB;X-TWQ)
MHTWG6%\A9,_>1@2K(PZJRD$$$ @@@UTE5=.TRST>SCM+"UALK6/.R"WC$:+D
MY.%  '))JU0 4444 %%%% !1110 4444 %8WC'51H7AC4]1:_MM+2U@>9KR\
M3?%"JC)9E!7( '3(K9JCK6AZ=XDTRXTW5M/M=4TZX79-:7L*S0RKZ,C AA[$
M4 ?.O@']J74OL&B3>+--:YOO%EU-)X;TK2+(I<M81CY9IPTC8:09<+@8&/K6
M[IO[6^E:A-9S/X5UJUT6\UF;0(-6D:!H3>1L5V,JR%T#'A21R?2O3[;X2^![
M(1BW\&^'X!'*DZ>7I<"[9$&$<83AE' /4=JUK#PCH>E6IMK'1M/L[8W!NS#;
MVL:(9B<F7:!C>3SNZ^] 'S[JW[9^F>$=-BEU'0M4U:>:YGB LDMX/+"3B$*=
M\^"=S#Y@>1S@5H67[:7AO4?M:6GACQ+>SV%D+Z_AL[19VM4+,O.QCOY1ONY]
M@:]:N/A#X$NV+3^"O#LS%F<F32H&.YFW,>4ZE@"3W/-30_"WP9;LC1>$M"B*
M1- A33805C)W,@PO"D\D=,T >':M^VEHV@'4]1DTV_U72TBM);>*RCA1E2:)
MY-QD>8!^$/&U2#QR<XZ[PG^U;X2\63%H;'6X;$S+;)>C3)IXC.0I\IO)5RAP
MX.6^7&3D5W]]\)/ VIRO+>>#/#]W*X 9Y]+@=FP,#)*<X!(^E:FC^#M!\/74
M]SI6BZ=IES<*J336=K'"\BJ,*&90"0   #T% 'A&E?MC6CQ7)U'PM?H\"WUU
M*UE/%(D-I;3>4TC%F!+$\[5!ZUJ77[7>@VTFGP/X?U>&YU"%I;9;@1H''EF1
M&^\6",!PQ4#TS7K5I\._"FGWDEW:^&='MKJ1)(WGAL(D=ED.9%+!<D,?O#OW
MS56#X3>![66WDA\&^'X9+90D#QZ7 IB49P%(3Y0,G@>IH \ET[]L/1)])FN;
MGP_JOVBTM[:2^%JJO#;R3A3&AD8J,'<!N.!D&K.@?&7QAXF^$.K>(;2RTU/$
M%KK5S80VAC9XGCB<_*=LGWRH/S!L9[=J]53X8>#HQ($\)Z&HDMQ9N!IT(W0
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MD_Y%[4_^O:3_ -!-1^$O^16T?_KSA_\ 1:US6FWFOW/PVOY]5MW.HLER4CO
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MLWDGPWN+>PO-2L+J>X@B6XTPONC!< M((P9#&/XO+&['MFO!O^"='_'GX_\
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MD4 L=J\GUK= Q1AE.--*H[O7I;J+%RIRK-T8N,=-&[]%ULA:***ZSD"BBB@
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MOB30KBQFC8:9#!HTL<ELYSM,KFY82@<9"JF?44DK#;O:YV>*",UP(T7XE?\
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MB:Z>H+ZSCU"SGMI,^7,A1MIP<$8H PM&\3:;+)?L;D0*7\Y6N5,(:/:HWJ7
M!7W%.D\?:*9&CMKEM2D&/DT^%[@\].4!'XYJMI_AS^TK\3:O+#JAT\F"V5[9
M5"DA27.2<MC XP.O'-=1%$D,:HBJB+P%48 _"@#G3XAUJ\'^@^'98P1Q)J5P
MD S_ +J[V_2C^S_$U\3]HU:TTY,_<L;4R/C_ 'Y#C/OMKI:* .;_ .$%M+DD
MZC>ZCJI.#BYNF5,COL3:OZ5J:;X?TS1P!8Z?;6?O#$JG\P*T** $P/K5!?\
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M/_UYP_\ HM:37+:*T\,ZA%!$D,26L@5(U"JHVGH!2^$O^16T?_KSA_\ 1:T
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M_P!>4/\ Z+6LBX\'V&A> ]1TM!)=P&*::1[I][RR-EV=B,<EN> ![5L>$O\
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M+7;MJDVJRW$<4;SW$$4<CE#(=S&-5#$^8>W:NOHHI@%%%(3@4 +13=XHW#-
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M\,_!4W@30I+"XNH;R5YFE\R" Q+C  R"S$L<9)SR2>!779KD/['L_P#GD_\
MW^D_^*H_L>S_ .>3_P#?Z3_XJ@#K\T'I7(?V/9_\\G_[_2?_ !5']CV?_/)_
M^_TG_P 50!QWBSX"2>)O&5QKD6N"QAD=2MLMGN,:E?WP#[QR[!&W$979@=:Y
MU/V</%LD*17/Q1U:=! 8MKQ;E#>8'! R,].YSSP:]2;2K%"H9"I8X ,\@R?0
M?-S2?V98$L ,E/O 7#_+]?FXH S/#WPQO-&^(5QXDGUA[Q)[5(6MY!(=C*H7
MY,L0JG&>F2>I->B9KC8M.T^<$Q8E ."4N7;!].&I_P#8]G_SR?\ [_2?_%4
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ML_\ GD__ '^D_P#BJ/['L_\ GD__ '^D_P#BJ .OS1FN0_L>S_YY/_W^D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cgtx-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $1 C\# 2(  A$! Q$!_\0
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M\X?_ (Y1_:]Q_P! B^_.'_XY0!IT5F?VO<?] B^_.'_XY1_:]Q_T"+[\X?\
MXY0!IT5F?VO<?] B^_.'_P".4?VO<?\ 0(OOSA_^.4 :=%9G]KW'_0(OOSA_
M^.4?VO<?] B^_.'_ ..4 :=%9G]KW'_0(OOSA_\ CE']KW'_ $"+[\X?_CE
M&G169_:]Q_T"+[\X?_CE']KW'_0(OOSA_P#CE &G169_:]Q_T"+[\X?_ (Y1
M_:]Q_P! B^_.'_XY0!IT5F?VO<?] B^_.'_XY1_:]Q_T"+[\X?\ XY0!IT5F
M?VO<?] B^_.'_P".4?VO<?\ 0(OOSA_^.4 :=%9G]KW'_0(OOSA_^.4?VO<?
M] B^_.'_ ..4 :=%9G]KW'_0(OOSA_\ CE']KW'_ $"+[\X?_CE &G169_:]
MQ_T"+[\X?_CE']KW'_0(OOSA_P#CE &G169_:]Q_T"+[\X?_ (Y1_:]Q_P!
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MM"+WNHZCIUNEUJ,>EV4MU]@B?=L:;8#MW;&PHRQQG&* .]HKD_!/Q0\.>/\
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M_AJ[X._]%,\+?^#.+_&CGCW#ZQ1_G7WH]8HKR?\ X:N^#O\ T4SPM_X,XO\
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M3,D4@"@.%+D X4#..GU- &(OQRTVW\?ZKX9U6.#0Y]/+2'^T))(GN;? V3P
MQ[95+$JP5B4QSUKI/#'Q&L/%GB'4-+M+.]A-G"DIEO+=H-^YF7 1P'&"O4J
M001D4SQ9\)O"WCHJ=?TY]4V&0Q">ZF(A+KM8QX?]V<=UP1VQ5_0O >C^&]2;
M4+**Z^V/;):/-<7L\[/&IRN[S';<P_O'YO>@#H,48'I2T4 %%%% !1110!5U
M3_D'7/\ N&I+3_CUB_W!_*H]4_Y!US_N&I+3_CUB_P!P?RH I:?_ ,A;4_\
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M %W'U-&X^II** %W'U-&X^II** %W'U-&X^II** />?V&F)_:E\"\D_OY_\
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M>J?\@ZY_W#4EI_QZQ?[@_E0!2T__ )"VI_[R?^@U0^(O_)/_ !+_ -@RY_\
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M>QJ_RO[CF=Q]:3-=/_PJ[QI_T)WB+_P3W/\ \11_PJ[QI_T)WB+_ ,$]S_\
M$4^5]@]C4_E?W',Y/K1N-=-_PJ[QI_T)WB+_ ,$]S_\ $4?\*N\:?]"=XB_\
M$]S_ /$4<K[![&I_*_N.9R?4TE=/_P *N\:?]"=XB_\ !/<__$4?\*N\:?\
M0G>(O_!/<_\ Q%+E?8/8U?Y7]QS%%=/_ ,*N\:?]"=XB_P#!/<__ !%'_"KO
M&G_0G>(O_!/<_P#Q%/E?8/8U/Y7]QS%%=/\ \*N\:?\ 0G>(O_!/<_\ Q%'_
M  J[QI_T)WB+_P $]S_\11ROL'L:G\K^XYBBNG_X5=XT_P"A.\1?^">Y_P#B
M*/\ A5WC3_H3O$7_ ()[G_XBCE?8/8U/Y7]QS%%=/_PJ[QI_T)WB+_P3W/\
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MDND[N=V<C<BY .<=* />J*** "BBB@ HHHH ***:6 [T .HIN<]Z=0 4444
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MEP2 <C@FI?&O[-7@CQO>&:>TN=,BN;I[G4K32K@VT&K%S&76[11B4$Q)SPV
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M (]8O]P?RH I:?\ \A;4_P#>3_T&K=](T5G/(APRQL0??%5-/_Y"VI_[R?\
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M =L3,/W2<'(]O>N8JS9=+G_K@W\Q50Q-=R7OO[V-3E?<U_\ A/M=_P"?T?\
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MD@6TBOR\09\V\N?*D 4$D-M., DXZ4_;XE_;E][#FEW9W/\ PGVN_P#/Z/\
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MD,<;P271!W!B(]V\[:]JUS5?'EU\;_ 5MK?AS0M/\,QZQ>_8=1LM;EN+N?\
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MG1N'J/SJGB:K"[ 9"@$@G'.!BEI,CU'YT;AZC\ZX[,D/2K5U_P >]I_UR/\
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MOMP]1^=&X>H_.B,YQ5D&J//? GP?B\$S:2QUJ[U5;&=+HFZ11)),D$D"DLN
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M8<C[Q[_[)KV,=*^NR?\ @R]?T1VT?A,ZW_Y&"[_Z]X__ $)ZTJS;?_D8+O\
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MX9U=> 1E)U!!Z$'DC!)RKL!M?9(?^>4?_? H^RP_\\D_[Y%344<J&0_98/\
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M6I;?] ^?_OM:/[0PW\X>TAW.ZI*X;_A:EM_T#Y_^^UJ1_B;;Q0Q2?89B) Q
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M\*ZIX)^'VD:+K-W!>ZC:I())+4,(5#2NRI'NY"(K*@X'"C@5V'6EHH :$4=
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M @$DZ-_"TA2,8_NKS@DXT?%OA#Q%KFHZJ8"K6TT\J1 S!,0O9+%&Q]?*GWN
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MO>/_ -">M*LVW_Y&"[_Z]X__ $)ZTJ^@.D*9#_JQ3Z9#_JQ0 ^BBB@ HHHH
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M^'X]7$T3O;"4RR2&.4 MAV$2N0<K%P<'GZ.I* %HHHH **** "BBB@ HHHH
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M,AY(9P21G#-ZTP_#[PU)I>E:=-H.G75EI2HMC#<VJ2K;!0 OE[@=N J\CT%
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M>OFO_>.8=6^'GA;7HO+U/PWI&HQ_O/DN[&*4?O"3)]Y3]\DEO7)SG- '"O\
MM":0/'6E:0R-;:9=VVH-)=7<;HZS6NTNJ@9!50MR&)QAH"!DY <?VE_!\69;
ME-9T^P2*.YDO]1TB>U@BADD1(YF:55/EL9!\X!4!7)("G'H!\%Z Q0G0]-)0
ML5)M(\KN9G;''=G9CZEB3U-5].^'GA?2+)+.Q\.:39VB+L6""RC1%7#   #
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cgtx-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &T J8# 2(  A$! Q$!_\0
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MXT?V+9?\\!^9_P :N*0ZAE;<I&00>M+CWHNPY5V*7]BV7_/ ?F?\:/[%LO\
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M:9_SZC_OMO\ &M6B@#*_X1C3/^?4?]]M_C1_PC&F?\^H_P"^V_QK5HH RO\
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MXQC(KZ<@^%'@RU\0/KD'A71X=8=WD:^CLHUE+N"'?<!G<VYLMU.3D\U<\(>
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M*Z6W_9"U328H+[1/B+=:)XILM?U'7+#5[?2HI$B6^8FXMY+>1V25"#A6RK#
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MA&\,<HSR77<&'WLXXQ7UH_@7P_)?:/>MI%H;O1XF@T^;RQNM8V4*RQG^$%5
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M;S0;^QFT\I<VMLB7#K;2YP%FC\M5=E!!(R#@T ?7%%>-^"M=\;'X^>(])O\
M7K37/!<>G"5 -/2V>ROC("ENDBN3-^YW,^X94[#P' 'LE !1110 4444 %%%
M% !1110 U>E.IJ]*=0 4444 %%%% !1110 4444 %%%% &<__(?B_P"O9_\
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M^"+?4+>QE\/V-C_:&G300S+(==M9+E%D8AP?L8G)_AQG&6P*R_&/PP^).O\
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M7DQLM_ITA\M!=*I.Z"0B(C+$;F(V/@5^S!XLM_BQJ'CGQ9I>C^$[:WMM$/\
M9)T2ROUE:#28(I5@O)&>>!8I$9!AL_)G+9W'[;VCT%!4$$$ @T >-_L@I.G[
M/7A02\6G^E'30 0!IWVJ;[",'G'V;R>O.,9YKV6FJH10J@ #@ =J=0 4444
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MH1V.GOI^N:3$8XEC"R0RV[0FZ=A() 0).1P, <@'V8#D9I:1>E+0!X5\3_\
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MUYMK+EY;;WO>]^EMNIT%%)D4M:'(%%%% !1110 4444 -7I3J:O2G4 %%%%
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MBBB@#.?_ )#\7_7L_P#Z&M:-9S_\A^+_ *]G_P#0UK1H *1ONG/3%+2-]TT
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MO9+>\NUM(Q90>8V]NYY  P#[^F:4IPIQ<I.R15##8C&UHTJ,7*<]DMV>A8H
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M_@'9"C15%.G57M'+EL[K1KXKVLE?1ZW^6_::U>SZ;I%[=VMH]_<0PO)':QL
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MRSNVG<?OMG-=C\:O VI^/M"T2PTF\;3KBVUS3[][N)T66&*&=7=H]Z.I< '
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MJ#_P A_^)H_X:J^)/_0:@_\  "'_ .)KR2BO>_L;+O\ H'A_X"CY+_67.O\
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M?BJNA>-;5=/U5[+S&TK5+VV,4D09-SO#YRJP#(,[E&" 3G@T >??$CXR^)O
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M%*^L-;L=8ET#Q7H;2Z?I6KVAV/:,LG[V'R'PDT;^64="I5U!QT#  \J^!_Q
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ML;:SU;6M)OK.WC6U>RCTEDMK]8["]M4O;J,R$2WSO>+)+,>&\E0!G##[ HH
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MBBB@"&\_X]9O]QOY5^7<D;2W;(BEF9R%51R3FOU#O?\ CTF_W&_E7QS^RO\
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M/+$Q47>7\JU64 >6_P!YCS&,X^8<YP.] &R.E+2#I2T %%%% !1110 4444
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M)/ED4J?OMV+$X[CGIZ#@ %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;?B'_P!@>?\ ]!KU+2/^079_]<4_]!%>6_M<?\FV?$/_ + \_P#Z#7J6D?\
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M2/:HQOCY8N)71F/E/Q&%X9L9X;C&3U H WATI:0=!2T %%%% !1110 4444
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M'523]46]4^,_A32=0UFP?4'FO=)M)+NXCAMY"I6./S'19,"-I A#% VX!@2
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M'_Q#\:^(?^$9U:WU#Q'IZ)8ZBJK+%)Y4<L@4J'"B2,2-,HDCW+NW+NR,"O\
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M?%=W_P""#4__ )&J.W_;P^"%W"LUOXPGGB;[LD.AZDZM]"+?!KUKQWX[\/\
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M\):!XV\1:+<7=_-JMQJMO+##=75PX+ .T<2A4,HC=]BJ7VL&)WOFA\2?VRO
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MYZ4[P[^U=X5\2:/\2-9MK2_AT7P7;6]Y+?W40@CO8IK)+N-HM^""4=1AL'+
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M9[BW@6$1,D ME*H'9VN3*N6W$95?X23YAX\_:'\4:G:WWB;P]KRZ?#IOA/\
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M8([<3^4$BPC,\DA57(7$;$NN0H /<O[+3_GXNO\ O^W^-']EI_S\77_?]O\
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M P).!$H'K5O0_P!G]K".RCO]:@OA8Z@UY;R1:6D,C*/M31+*^\F0I+=&16X
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M&E>:%L?-D1$+I%R44*K )N(&_.<@4 5O'7CKP7X-\/ZK>7>BG5M*T[='J/\
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M%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\
MXJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T
M_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I
M_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB
M@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^
M'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \
M+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X
M6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\
MBJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_O
MA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG
M_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^
M%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\
MXJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T
M_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I
M_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB
M@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^
M'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \
M+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X
M6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\
MBJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_O
MA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG
M_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^
M%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\
MXJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T
M_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I
M_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB
M@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^
M'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \
M+3_OA_\ XJBB@ _X6=JG_/"T_P"^'_\ BJ/^%G:I_P \+3_OA_\ XJBB@ _X
36=JG_/"T_P"^'_\ BJ*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cgtx-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #U 7X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH ***^2?C+_P4$TOX0?M.^'?A!-X,U#4VU,VZ
MS:M%<A/*,S%4\N'83*!CD[E]LT ?6U)FA3D5\@?M)_M5^)O@9\?M+T]IK0>
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M1._"PE60,2P.7Z=NM;4^C^(KV\>X\0>!+_6KR[\.KI>$ABD1;E7(W,SL-H(
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MSF!DD/[L%=JJ.%2OKFU@CM+:*&(8CC4(H] !@5\A0>)M2UC1M:M9M3U>]/\
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M!,48I:* (IH4N(WBE19(W!#(XR"/0BEAB2&-8T1411A548 'H!3\44K*]P#
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M#5(T(XAVY6VM]=/(^I 1VI:\U_9S\%^+?AY\&O"_A_QQKG_"0^)[&T6*\O\
MS&DWMZ;VY? XW'DXKTJNPY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(DB/F^9C.S,@^YGYLXZ'&:8'0T5@2^)[F.5T'A_5G"WBV@=$BPRE<F<?O/\
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M:+!8Y%&5^^$D90CE>X4G%=9S'K&**!2T %%%% !1110 4444 %%%% !1110
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MEJ6G\>*].\4VM\B0F(&/R[>-1CS $!=0"0<L3S0!]AT444 (1FD*C%.I#T-
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M^K'0_P 6?X:T=(U*74X9GEL+K3S',\02Z" N%. Z[6/RMU&<''4"@"_1110
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MU@E0>O3T)KIO^&D=;_Z(;\3O_ +3_P#Y,H ]NHKQ'_AI'6_^B&_$[_P"T_\
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M7;?LG?M5>*OCSJ^L0:UHNEV=LFG+J5NUA(!);$RLGV:9/.D9F 7[^(^0PVC
MKZ/D\):+-K%OJTFD6#ZI;IY<-ZUK&9XD_NK)C<![ U)I/AK2M!FNY=-TRRT^
M6\D\VX>UMTB:9_[SE0-Q]S0!\<:C^WAKT?APSV5IX:N=9ATS7[RZL1+(S6\E
MC,4A5U#[D##E@>?3%4]6_:8\?:KXFT[0M1ETJSUFS\00VL=SHL]Q!;R)/ILM
MPHEB+DR[67H3@\' K[)'@7PZ)[J8:#I@ENMQGD^Q1;I=PPVX[?FR.N>M6?\
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MMO[<2:7Q'>0OJ6IZ3*R1W(CM6E*!@QX=@,C/.TBO)G_;/^*]OI,6L26/@G[
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M]9S/,L\FW5+DK(PP!O4R%6&% P1T&*LW_P &_"&IWU_>76D++<WTRW%Q(9Y
M9)%(*MPW;:,4 <-XD^'O@.QT_3;"35M1MQI9?6+1-/".^UF )3$1#+\W"#^$
M]"*T]=\)^%_%NH6L-UXJU!)M"6&6,17<$"6C*0RD@( &(X((^[TQ77:M\+/#
MFN:D=0N[*1K_  RBZBN9(I0K  J&1@0O' Z#MBJMM\&O"MC.9[2SN;.?"CS;
M:_GC8X.1G#\G)/)]3ZT >=7'PG\%^(O.N-<\26Z7TER]U(UI+:Q1RAGW*0K^
M8=O YW<X/;BKWAGX:_#OP=J^G3V.N2W4EK((UA-Q!/"I8$#S%5-JDYX8X;.
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M"UJJE?.1 ZQH5B)9T"Y4<MC<O*Y6NR;X*>$98T2;39+D1HD:&>[FD*JDAD0
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E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cgtx-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )7 E<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&$W@S1O%,'B>.[T75M,N=:MYK6WEF<6-M_Q\W#QJI9$B/RN6 PWR\GBEU/\
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MNF]5*XR&P#D'I@UB?!KXOZ-\7?!VEZI87MK-J$VGVUU>VEJS,+=Y4#;,L 2
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M#,7@!?&$6F&6XM;B^U:\TL7,MP8)%E7:D<D2IET&>N!P!WH YK]J#XI?$[X
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M30[86?\ 8FIW#7,4UP'%JTZH5DBW@;$+1N O/S^IK]O/V]<_\,?_ !5QC/\
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MU$F642[-BR*&"^@Z?J:;G*]FP<;R1;L85EC\UIBD:/EO+C,A5,C=E>X P>2
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M,].TO0_A9=Z6VH6VKZYX>OK?]W:7&IHLD$\^PX),/[R,JQ#9 8# !Z\XEO\
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M*JK#G ]1Z5=T3QM)X9U)+J"VAO083"T5\OF(<]2 >GM6'<,( (8W^52-P/\
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M%2^9Y*@!3@'+>U#. P SO QNSWID*,[[>6/).!G\ZUA:*TW8M]P,V[YON#&
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MGQ!IN22/M,6-WIO%9\DA=B3U)S6EX<;?K>FH0,&ZBP?0[UKP.AZ*5M3]"O\
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M +)/P2D^]\(O [?7P_:__$5%7%*K[K7NLIX3FOS/<_GB;Q0B7#[M,LFRW+O
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M?\^M?TF?\,L?!KC_ (M1X*X_Z@%K_P#$4?\ #*_P9(&?A/X*..G_ !3]K_\
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M;7'@CQ9; MAY0;218P!R6VS'I0Y) ]#] J3%?GU'_P %E?AS<3&*'P%XOD<
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MKX&\7';G/-IC';GS:TA3G4=HJXN9'Z'TM?G8_P#P6J^&: $^!/%VT]#FT_\
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M_D1?%WYVG_QVE;_@M;\,EQGP)XN&1D<VG3_O[0!^BM)BOSN/_!:GX9B!)?\
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MW^E5%TM-JJ"23YF2S!"I7&>&(/0_7TS5E)[C2]9B&HQ7-M'$_P#J"<2HF[D
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M7>043 [;>M3AY6HU'V7YZ?YG7R<J45L6-7CE2_EBN%B@E0[7XP20,\@#KVX
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M?%^.2/X@:SNA$-O)</+; (54PL<H5!_AQC'M7K/_  3R /[9?PK)R3_:K?\
MI/+6<9^T@IVW)PE3VM"G4?5)_@?T+1_<7Z"G4V/[B_2G5)VGGW[0O'P$^)/_
M &+6I_\ I)+7\S]Q ]NX20;7V@E3U&17],/[0AQ\!?B01U'AK4__ $DEK^:
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M.UZ[TZZBGMKAX9(V5H]P5PN.WS X_P \5>NXQ?Z#YEQ,'U&!V(5?FW0Y(//
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M  =P//3OTP?6L-O-CD[/:Y^@7_!;P9\)_"@?]/\ J/\ Z*@K\I=, 3S)&56
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MUY]\7$M]*L?"^E6=PUU;1Z:DY>6/:Z22 %T/L"./8UZ!_P $\O\ D\[X5_\
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M_2>6JKRC.<W#:[_,\_+ZM.MAH3I?"S^AB/[B_04ZFQ_<7Z"G5QGI'GW[0O\
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MPDU=QBKV\C]P_P#@E/>_VC^R/I=P6W.^KZ@7/J?-&:^Q*^,/^"2?_)GFDD#
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M<K]V:?X:6SEL$XU2^4$A0H.!.!G '-?3%)BCS%97N?,'_#LO]FG_ *)A;_\
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M%9##%JMY<19&")9 &.., GW(%0XV+4KNQ_4;N]C^5&[V/Y5_+I=WVH6ZP?\
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M=W>QHW?7\J_"+_@J#/=C]L_Q^(=0DMQ%;:>RPB9EWYM8@0H!Z\Y_.OD0ZWJ
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M5?W9B59(F8(.(A]WN,GN>?PZ5YU=<]!SJ]'HO75^B-(14)<L59/7Y]3/+;E
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M[JPR$SS@8P#QG.:],\"IIW@W6I3LEM[^[T^:XLH?-62XA0H9$7S!_JY2%V@
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MTNSBB9WEG0;57<2,Y/'?CM6I?^'[&RTBWU+>HMVG>)+9Y1]JF4-]YE&=BXP
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MGOD\CZ&O"/A98ZYJOP^\?6]E-.VDQ627%Q:QR#:SAL*[)U.!N&0,#/-?0/\
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M[MMH*$?*.,_Y->EC\9"I"BG]F"7RU?ZGQ^08JG-8JK+?VLU?NEIZZ;'[7_\
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M&?;N ?S 24)&%R&!X!KE/%/C:UNO WA"#1+9+);<S0S![@/=7$^X$2-TVK@
M@=CGZUTW[1GB>_\ !D.B?#BWDM&\/:5I<:"WM6$L<LKG>\^\C.YCW&" 2.,G
M/FE\;6XT99KVWLK*6UMP(;2SB$<C%FQF8_>)P00U=%ING3IS=U'739Z;M=_P
MT/D<MI3Q<(8[$OFYY7C_ (;-1NN[3N^B;TL0ZKXPU_6-,:UN[RX321,L<R+*
M9(Y)E7!9B3DG&><X]!7H.A:0?A!\(&\8F[$?B'7Y/(TY3$/,AMN09E8\C?\
M,..V*\QM+#5M=_L;1M/MEEEU><?9[:%U!DEW>7@CL21U/UKOOVGTCT7Q7HWA
MF._DN3X?TV#3I(92"8)%4,P!'RXRV.,].:5.K&EI3LM^GR_SU\CTL7&-7$4<
MOA9*3<I)+>,;;^LFD^]FCQV[O'OG+RN"XS@[0"><\D=3SU-.MIH@46:/J^6E
M5CG;TQZ8[U/J>G1V/V8QWL-T9DWL(L_NSG&#Q56UMC>WD4 DCC,KA!)*P1!V
MR2>@]ZYN937,?5Q<7"ZV-G4;32/[*$MGJ$\LL<QB%M)'@D?\]/0 C'RY)!SG
MM7OO_!.*Z%O^V/\ #*)HHIA+J$N"ZG=&1:S\J>Q]N0<U\]6LEKI^GZE'*XGN
M7V)#Y9^5><L^2.>!CMUKZ-_X)VI_:G[:/PTE$L=I%;WLSI;,S-UMILA !W)S
MS@"A/W=6WZF$=+J5VK[_ '?J=%_P5)6(?ML^*A* P>RTW)0Y*C['&.G8\9^E
M>,_$/P_#;_"_P[J45_<O=7,[+/9W ;<5 (24'NI' R,CI7KW_!5%B/VT_&"@
M#:;/3#G'/_'E'WKC;;5K?Q5\!VFU)Q;ZC:&*RLK9;9@MT@8G=YG/SY./?I7T
M."J6P]2,MK+;U7]7Z'A9Q5GAZN'K1VYTG\TU_P %]K'B[>%-0TK2FO=1M&M;
M*X+10O,H!FD0KE$;G!&X$].*_2G_ ((G:M=2:Q\5-,F$?E6UOI[@[!O#%Y@1
MN'4<=/J>]?F5KOGI>2P7)EB>'(,$X(9#Z$'I7Z4?\$1':?Q+\5WDEWN+/34V
MG.0 \V/\*\>K3Y6];WU1[M*+FE*I9O?^OD?K&*6D'2EK [#Y0_X*EG'[#?Q$
M/^WIO_IPMJ_ G<0I(/%?OK_P5,_Y,:^(G^_IO_IQMJ_ J(CD'&#QD]O>KB^C
M$Q?,+<$ T["QR':VY>@/3(J)QM=@"& /4=ZD1=\1PC,R\D@\ 4<W\P$UO%,T
M<XCD"+M!9"X!<9& !_$<D''L3VJ9K26VNF@DMB;A0$:,C!4^XJO:7/V657\J
M.4 \I(N01W'_ -?KZ5.MU_I#W$<"I$),^4K'"Y.0.3G _I6D.7FML9N]QD\+
MPR*LH*N54\CC:0,'/TJRT;QBWG6)H8<E!-@LK,/O8SZ CCZ>M5Y[][EE+[2X
MXW8 )I8I#L)WJ<'[AS^=>MAXP3Y>;\/^"2^:RN7K.&W@EF%VV\J1&HC?!'^T
M#@@@8Z>];%G;OE[>9DDB$A4S(,MC'!!./E]CCK6%:R1&0B16<8^\.H]_?C-:
MUC&LLLA9Q+!&CR!?-"$L!QP0>^.,<C/UK]$R&='!U'6FW./9=?S.&LFT?47[
M.V@>'[>_NK6Z=)X;Z-S$9%4;GQA5[#.>@'<_4UP7QHN=0N])U6&]$\]U)?AO
M+N)&,L.T'.$ P5YP3[=*\ZT/QG>Z-8211W#FU9U/V620LC8R>5!'0\Y'<5>\
M3>)[_4/#ME()CFWE,CF3#2%I%^8D]67"KP3QGC&:_9,=C,)7P-:4;6<5[O\
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MBGQ#;^*[1=&3PI;S7\X,0>9KL#RH4P<[@2YP!QT;M6WXEL[R[MO"?BO0)?[
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M.V61M^7"GIC)Z<'-=+_P5#@N+G]M3QDELCL1IVG.P3NHLXLY]J\M^*][K#?
M/X76EQIWV/3=LTL4X!Q.V=N[<?;M793@Y4;0EVNM.ZT,,XI3J8W!<L[+VFJT
MZ1D_O=OEN>2II]E:Z7'=IJ$<M\X;-FT178N.NYN&^@K]*O\ @B)>,VI_%2V^
MT2&-(;"06Y;Y%):4;L>IQC\*_,"\N)9IMTJX" 1JAS\H X'/-?IM_P $0)R?
M$/Q9AVIM%KISYVC=]^8=>N/:O,KSYGRK9'UD*;WD[GZR#I2T@Z4M<YT'R?\
M\%3/^3&OB)_OZ;_Z<;:OP'K]^?\ @J7_ ,F-_$3_ ']-_P#3C;5^!+!4;&0P
M_P!F@!N\[=O;.>E6;6W\[<O\0&0/4U7=,<XP#SC-3VUP83QQGK7?@O9JLO:_
M"3*]M"W-I\UDZ":,)\BR $@AE89!X]B*LM8-);Q&(AF527"L-P&[ [\]?\XK
M.=B"1\V.OU]S^=26_P#K%7(4L<;B< 5[5'V:?)-?UY&#4M[FG;V:K<Q_:S D
M84,Q=B=PQ[')/T]*DFN-%MP8EMI)656Q.'.)#_#\N1MP?<].E1:A8/#%#*P9
MEEBW  #(8=0/8=36*Q+#&.?UKT,7C*>%ER48+3J]7_E^!C"'M-6_N.@LM4TH
M3,MQI,<X(&TI,T1#?7GW_P#K5Z[\$]+\$7VL2ZOJ*WD;6:RLULUHMS&'V$QJ
M-[8D)^?@X.(P>]>#1'S)EWN4R>7/0#IVKI_#4\EC?S7!DD.F*3YHWD+,5Y"\
M8S@D'CH.?:N>GBY8G^(E\DEI^1YV98-U\/.G";BVNC_S.\^*GAWP]8VFF:KY
M$EL+RVD,=JDX,ORN0A9<?)GD\DC!'4BO([:Y$%M<*5<^8 G#8&,YY'?G!KH-
M<\3R:W&DZN9)D1HY6EC4MMX (..O.,]17/7MY]MN)I!#';QYW"* 81#P. 3G
M'XFN6O62JRK?<;9?0J4:"IU7=K_/0BW9C\O"[2V[?CY@?3/I3KN()<K%&PN5
M!VJ8P0'^G?FDMD=HI2JL4  8@9 !/?TJ1X@LB':PC)^61^,KGJ<?TKG<>:G)
M0^TCT[V938! 593DX(/I[5]>?\$J9GD_;8\(LS$DV.HJ?H+.3'\J^0)00Y&<
M\]?6OKW_ ()3J%_;3\&D,K$V6I<#.1_HDO6O!:L]39$'_!5#_D]KQQ@X/D:?
M_P"D<5?*E[I5U8*DDT+K$X!24J=K ],'I7U5_P %4#C]MKQQ_P!<-/\ _2.*
MOEN"]6ZM9+>[N[E;>)&:VA4[U\S(P"">!UYJ;2NK$3<E9K;J7K;7;AM"OM,$
MBP6<Q28PA?E:1> 1Z'&:Y\_?_&K396U'NU50,N *]3%P=/E3[(BG",7)QZL_
MH*_X)I_\F1_#'_KVN_\ TLGKZ<KYC_X)I_\ )D?PQ_Z]KO\ ]+)Z^G*\PW&O
M]QOI7\ZW[;=P(OVL?B\804E/B.\20G:5*EQC&>0<CDBOZ*9/N-]#7\Y_[;*>
M9^U]\6AN"C_A);O+,.%&_J?:DQ-7/-M"%MHPT#6&:UOY#>/Y]C=)OC"H5*B0
M#DJ^2".X'XUEZS$XU6^W6YM"DA,D!).P[N@SSCGC/:K^@ZU=: UU:.P@BEBW
M.%P&W!&VD'L2'(^C532W?6=3(!-W,8P56--I+ ?=(..!SD^@S7*DU-R?W_B<
M44U4E)[6W\M_Z^0NC7EAINHPC4-/2YBW[9TD8\KGD#'W?3/)ZXJ._N-]Y)%&
MD=M:QN72,JI"@D$<C.[H*SOM#*CHH"+(!N"C@XY'Z^E2RLUL@6%F59(L..[#
MJ0?;(!K;E][F-^1<W,;&FWD[7$@M[\Q-<OB2WC)C\U2P;''&<@$#'88Z5VEY
MXDT;XCZ(8?$$SV'BI%<Q:H(T\BY1%^2.157<K +M!Z<Y)X%>60NRN,9S_L]:
MZ;P1]KB\1I/:745F!NC-W,RD0[T/S$D'ICD@?EFLYPLF[VL<.*P\&O:WM*.J
M>WZ;/M9_D5](M&L-36/R5O/M*%(UD0X(<$*V!T;!R/K7N-]H\_B;X?)>2/ N
M[3&M=0DA+,Z2Q$%'?D%N%49R5 ?UXKRW1Q#8>'?$,LWV>YB3;&9'7RGE;>2!
M$P&Y>>OJ,#(K>^"OQ)N_"&L0WEV;W^RB5LK@6,:EC&P"N,'Y22H],DA><9SK
M1G&JYTJBT=EUT:U3MY/^NAXN:4ZU>'MZ'Q4W]^E[+M_G8N?"+1;GP_XCTJ\&
MG6VNO<JT"0[QM,AVD)D@[VY4;1C@8/6N,^(/A^YT7Q_>Z;JCQ6<LLY>6"U.Y
M("Q^5>OIMXSQ^&*^B/#WP/TC4?&FK:S'XKN=-T"SE662U\K%WL8@B,,#@GH,
MXS\IZ$"M7XY_"32[+PO)XP\(:6]SJ$T;R));QR/(;<!5^T.!N&\8;<,*!G=[
M5H\+7HPE*JNNZVVUU;Z:/;S/EJ?$N$CFD(\UW4BH[-)2W2;>BT?1/H>&?$J\
MD\/>'-.T.SNK6?05C6*-[:%?]*>,[FEWY.#O;#8QD!?I7G4=E/%<-::C>_8"
ML+!(Y@7 ##>H'90Q(.1ZYJ[=W-S?3-_:,<MW</#+*8K:7:441!5+8R %VY*X
M!('/7(SFLS,&GU">:*XDC2:U^T*6%P@)7!8XP,+@'IQCBN"C#DC9O5]C]!PE
M'ZO2Y&]7JW;=OK_F[?@:?PRU.;3_ ![H#I$MQC4+<E" 68!_N@DC&03W':K'
MBNTET;Q?KFDSQW-B1>$"UOHPTZ@$E%<CD'!P0/6H/#UU]GO+&YM%0:G%.UQ)
M)Y6PQ8Z!><'&"V, _6NOT7P3=?%&6_\ %5M:WLZV4GG:JR*3&.3AP_\ ""=H
MP>>O-?0X/!/'0Y(V33OKVZMMZ*VC^\YL36AAJ[Q%6RARI7\[Z??LO,^O/^"@
M!W?L+_LHD1B$'2(CY:YPG^@0<#//'O7Y[Z2;-)89+B5XY$F5B-FY"@Y/3G-?
MH]^WGIESXG_8X_92M;2(">?3%.QR%" 6$)8DYQP 3^%?GEK$6B:4DEK92OJ4
MYBV/<E-L:ONSE >>G&37D5I051TH-OT[=SU)5%*U/6[73IZGM/[07Q%^'WQ+
M\,:#J&DV%UI>IPYBFMX(E5& 0#<3GU!'KBO&+/1+74[*2\M(WCAM'!G-S*/G
M0G^$#N._U%>P_L[^$]&^(_PX^('A^]N].LM5CM%NK&6[0>9E6#-L8\C[N#CL
M:\DOO%5POAY]$BAA$0.)KB./#2 -D?3GOU-7BTFJ;P]WI%2N^JT?K=)/OJ?*
M93&&$]KE>$YKT9+XFW[LO>NGU6K27='[6?\ !)1XY/V1[-HE"QG7-1VCV\Q<
M5]HU\4_\$B^?V/\ 3_\ L-:A_P"AK7VM32MH?;)65@HHHIC"BBB@ HHHH **
M** "BBB@#P;]NV)9OV0_BJCRI &T.8;W' Y7_P#57\[K%XI'*$;N5(&#UZU_
M19^VSHL_B']E'XH:?;*'N)]#G6-2V 6&".?PK^>R^\+&W:\,-W%=FW42.B J
M2FW+,,\84G;ZD]!BN_#I<DG):?D<LZL(U.1O6VWS)=+U;5M+AM]4CO;FWNK2
M/[/;(L>T&%@P;#'@C)P1@DY/(Q6:+"[NHA +6)FAB9MZ;00OWRQ8'G ]>@XI
M+K7-0DL;6V:ZF-E;LQMH6;Y8R<;B!V/2I;R46RR(MW;W$5S$6618R'0YR5V_
MP%B,'L1[5R.-"F_=5W]WZ?UJ1&,HN]DF_P"OZ^908"PG#))^]C;[T;9&1Z$5
MTMOK.ARZ/KL\UA)'JLHA&GRQG*QR;OWI8=,%<X[@@?6L2/09)M+CGB9YKQY&
M M(H6<^6J;C)N'&.O'7 )Z5G(C/&P!PJ_,?2HG-35H>[;L:2A&KN]OEU_+0O
MZ5>VAUU+G6H9]1M6D9KA(YMDCY!Y#<\Y(/OC'>NYL?%TOA*WDTO1[R.[$DZM
M'-8Q["WEE6CE!*Y)W GGISC@UYL@&T@CGJ#C/X5:>25;I98A]G(.Z-8F/[O)
M) !//%0J"JU$FK^70QQ&&IUU:IJNW338_4_P)XQU;XX?L^0:SHD;P>(Q$JLA
M4$F:-AOV Y&"1D UY]-\-?B)XNO[?0/$<9.@WMXC7D/EE8U0?,SD')0X!Y!P
M2?>NI_8*TZ:V\!3:F67&H2I)+"B%568 JQ'8[@$8XXR:^LAJVFWEPUG'<127
M ',:D9'&:UP.7QKN=HI.+M=[VZ6?=;?*Y_(6(Q5/(<=B\+@X1:4VXNVL;]$_
M[KV/R^_:YUN+Q%X^TWP=I^DW"6^E6[RV45DC.\\LP!VLC#G&U0<9KL_@U^SE
MH'PH@T?QQXZU.+3=4B#SK9BZ1(X5$9;+9Y+8)^0 ]Z^P?']EX=L9)/$$^GQ3
M:O81O;V]RL(EDA9V!^4=CN"G/;%?E?\ %ZX\4>)/$VH3ZG(^L+)<!4U!5)C'
M7Y01\J@YZ>U>I346I4:;7,M^JUOWMKZZ>I][P[C:_$F!CE6%F\/2@K3=[RFW
M>ZBW:R=[OKKHK'NWQ7_:;L]8M]1;P+JEWH=Y>W$L$H@E,_VA%8'>^1F/?CY=
MIY&[/I7S7XD\>W7B6>9-2N6O)BR*-2NB)'CCZ$+C!*\Y[G'%9-E=+X5NUNK>
M[CENEC9HY8?F\MR,;>1C/)Z^E8%W<&YN)I?+BC\UR^R)=JKDYPH[#VK"5:=&
MT8RO)?:ZKR^1^P91P_@<KC[/#PT6TGK+[[7Z+=G2>)?$$5^DUKI\D8TN"X9X
M(WC <@X&0Q&\@[0<$X&:]M_X)WW;W'[:GPM\P!F_M"7YL8./LL_Y]>]?-UU9
MRZ?.T-Q&8Y% )4^XR#^HKZ4_X)S+<S_MC_"]@C/!'J<I9]F<$VLW5OPKD4VX
M[W\^_J?34Z<*44H[?U^9W'_!5R&.+]KOQ)*CN99+'30Z@851]F7&?7I]*\QO
M];N[_P#9:T*R$R7L=A?RRC"%C:[F(^8D<'IC!Q@],UZ)_P %3 +C]M#Q>'*I
M''8:6I;.",VL?./XCR:Y_P"$<4/B+]F7Q[HPLXK\Z7=FY+1@"4J4RC9.2$RO
M/!].*[:52,*5I*]]%Z[H^3XAE&A2H5Y+FY*L7Z7?+_[<?+UU<RS7DLT[F>9R
M2SR?,6)[FOTU_P""'XQXH^+/_7GIO_HR>OS)="I4&/!?E2WI7ZG?\$6O#KZ)
MKOQ,FDGCD:ZLM/81H?F0"2;K^?Z5YDY1A+E>[/L/:1BU%[O8_5 4M(.E+3-3
MY/\ ^"IG_)C7Q$_W]-_].-M7X$E#D<'FOWW_ ."I1 _8;^(F1D;]-_\ 3C;5
M^!@:/(;YAUR >1Z<_6@!5@(BWG9@] 6YZ^E, ^:F\9'.?6IK<;Y ,=375AX<
M\E'NR7H6T03. SA2$Q\XSQCG\A^/I3HI5AMW95!8<;B??/\ 2H+^203NKKM<
M,>HY^GZ5 7=PS8)XY(_F:]>IBE2K3Y=^YDHW1I#593',QF;=)P22=W3!((]>
M0?8TQXOL\BSV[E8%?"R*07!P,^_]*I-=M/<))<%IB-JD$\E5  &?H *UK"SM
M;F*^9Y(K5]C20132$<#)QG'+=  <9YZ5A&O+$OWU>W4F25-7(+;3HIOL[-<I
M!#(X21GY,?/WBHY(QZ>]/U#5KAW"W +A8!! "-JB+MC(R01GFH[\R>8C*JPJ
M%!15ZX(]>_?KZU%)=30.T?VF0@P^268?P_W.>V15XWGHKV45HNO?_@"2YG=D
M<<RI%#MC/GJY8LV&5AQM&T^^?KFEGABD5&20!R"'4J0%(]^^1S44?R1[@0S$
M'Y<=*9$L?F S!O*SSLQNZ=LUY\Y25.W<UMK=&IH%A97=U.+_ %-=-M8X7D$O
ME-(9' RL:J.<L<#)X')/2JVJZM/J$N'.$4 +&#D* .!5$9(QU'I_.@K\F[(Z
MXQGFI=><8\D79,2IKGYV_P#@ Q+8SZ5]??\ !*:5D_;3\)1*Y,;6>HD\=<6<
MN/YFOD!SO.>*^OO^"4\3)^VGX-8]&LM3(Y_Z=)17--\SN:E7_@JE_P GL^./
M^N&G_P#I'%7R7&#D5]:_\%41G]MGQQ_UPT__ -(XJ^4;2+?*N02,Y(%=6&IN
MI420I.R)+XQJ52,DJ%'7UJG_ !"K\.FW6I:BEG;022W4C;4A ^8GTJM<VDME
M=R6\\9BFB<HZ-U5@<$&NC&U56K.S_P"&(@TO=OJ?T"?\$T_^3(_AC_U[7?\
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MY_+;)!#AL!0 V21QQZBF2:M\%=%UT7-CI&NZK#;W!*P:E(#;S(,;0^W##G/
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MK6A:=XDTV73]6L+74[";'F6MY"LT3X((RC @X(!Y'4"N8_X4A\//^A$\,_\
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MBJ4I+9B:3W.*;X)_#YL;O WAIL# SH]MT_[XI/\ A2/P\_Z$3PS_ .":V_\
MC==M14C,.[\#>';^STZTN=!TRXM=. 6R@ELHF2V&-N(U*X3@ ?+CBLN#X.>
M[;?Y7@OP[%OQNV:3;C.#D9PE=A11L[B:3W1QDOP8\ 3N6D\$>')&/4MI%L3_
M .@4T?!+X>C./ WAH9Z_\2>V_P#C==K13;<M6%DC.T+PYI7A>P6QT?3;32K)
M6+BVL;=(8PQZG:@ R:T:**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BD)Q2T %%%% !1110 444TN!U./K0 ZBD!S2T
M %%%% !1110 4444 %%(&!Z4M !1110 4444 %%(3BD#@G /- #J**0G S0
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MF**6N/+_ '<2;6Y<!<"@#VO4/VM-!T"QU^?7=)O=$_LZWL+N"6ZEA-M-%>7
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MQ NE6T^IV^D,((;2PNS=PPQP&XSEIF<L[2,<.0  !@ M^)OVH5\%6UK<>(O
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MM-A:# NFAMC,PCENAN#N&P,1G:S*2_M- !1110 4444 %%%% !1110 4444
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M!%?(=W\$/$\_]H,WPSNY(I?C1!XI\LPV7[S1U1 7QYV,;HS^[/S<@[>:[-?
M/B_2?B?JEUH_P\GM= F^(:ZFM]%%9K<V=F^CQ6LEU9HTVU3)/'+'*S#>(I2Z
M*78%0#Z.U;XJ^"]!L(;W4O%VA:?9S6JWT5Q=:E#'');LRJLRL6P4+.@##@EU
M&>17._"CXRV_CS2=7N=56ST6>U\3ZMX=MHC<Y^TFSNY8 R[@"698BY49QSU
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M0#/"A#''+N;GYFC4<EL7/%G[0?AWP5K]]8:O!>6=C82^3=ZM*(Q;0O\ 8GO
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MEHH 2EHHH **** "DI:* "BBB@!,4M%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cgtx-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "8 C(# 2(  A$! Q$!_\0
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M+_T1M?\ PI?_ +EKUDFU=$3BX2<9;H_5>BORH_X?CR_]$;7_ ,*7_P"Y:/\
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M ,>H:L%S]O**_$3_ (>]_'O_ *E3_P $[_\ QZF2?\%?_CW&N<>%#_W!W_\
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M_P#QZC_A[W\>_P#J5/\ P3O_ /'J.5A<_;NBOQ#/_!7OX]C_ *%3_P $[_\
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MKT5AE3]*\Z_9N_Y-]^&W_8N:?_Z3I7HCG@BN89_/C_P4 7/[9'Q7QU_M8?\
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MKFE^%/A7?V+/&T[Q$8)&<XKO/C)\,=*\+_"!KB.TC%R(@?, YSBOD7P-X/\
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MT5!0PEUW/P?8DDFDK]X/^'37[.?_ $+.J_\ @[N?_BJ/^'37[.?_ $+&J_\
M@[N?_BJZN='AO4_!^BOW@_X=-?LY_P#0L:K_ .#NY_\ BJ/^'37[.?\ T+&J
M_P#@[N?_ (JCG5P/P?(YI5Z_@:_=_P#X=-?LY_\ 0L:K_P"#NY_^*H_X=-?L
MY_\ 0L:K_P"#NY_^*HYUT ]__9N_Y-]^&W_8N:?_ .DZ5Z,WW3]*R?"?AFQ\
M&>&M*T#2XWATS3+6.SMHY'+LL<:A5!8\G@#DUK'D5D,_GM_X*! C]LGXK<'_
M )"P_P#1$5?/F"1TK^A'Q_\ L$_ _P"*/C'5?%7B;P5'J.NZI+Y]W=->3IYC
M[0N<*X X4=!7/_\ #LK]G/\ Z)[%_P"!]Q_\75<RM85C\$+6!IY-HS6D\0MX
M]NTYQ7[O1?\ !-+]G2!MR_#Z)3Z_;KC_ .+K"T_]A+]EW7O%&L^'[7P9!/JV
MDK$]Y;B]N 8Q("5_CYR!64GKJSMH*+IR]UMK7T/PJDM)V.5SBE'R *P^;UK]
ML=&_9+_9*UWQ2OA^T\$E[M[N:QBE-Q<B&6>)=TD:MOY917=M_P $T?V<<@M\
M/H@3V^WW'_Q=5&HI'/5HUJ4K5DTWJ?@B5SU!IVTD=.*_::__ &2?V2],UGQ#
MI<_P[O/MNAO EW'&UW(?WIPA3:YW#U/:O1$_X)K?LW,JM_P@$(W , ;^X!_]
M#IJJI=1SP]2E9SBU?_A_U/P4VD'@&E(.>AK]ZS_P32_9OY_XM_#QU_T^XX_\
M?H'_  34_9O/_-/X3_V_W'_Q=:JHEH8\C/P4P?0T$'T-?O;_ ,.T?V<!C/P_
MA'_;_<?_ !=)_P .T_V;V&1X @XZG[?<?_%TN=6L'*S\$MI/4&@*1V-?O>O_
M  3/_9Q*Y'P^B_\  ZX_^+IW_#LW]G(_\T]B_P# ZX_^+J>9!8_ _!]#1@^E
M?O;)_P $S_V<D4G_ (5W&Q S@7UQD_\ C]<9\)_V*OV4_C+X;GUOP[\/Y39P
MWD]A(+R>YAD6:)RDB[3)V(/-/F%8_$-L@' .ZF1B;/S%B/>OWQ_X=I_LWG_F
MG\/_ ('W'_Q=+_P[3_9P''_"OX?_  /N/_BZ%))D\RWN?@D,@]"*&!9@<&OW
MM/\ P30_9Q[_  ^B&>G^GW'_ ,71_P .T?V<#Q_PK^$_2_N/_BZ<9V30:=S\
M%_-0IM*U5:VS+N ^7Z5^^7_#L_\ 9QSC_A7T6?\ K_N/_BZ7_AVE^SB!C_A7
MT./^O^XY_P#'Z2E;4$DMF?@I(0ZA5'3VI@4CM7[U3_\ !-;]FZTADFF\ 0QQ
M(I=F-_<8  R3]^JVA_\ !.G]F/Q)I-IJFF^!K>[L+N)9H)TOKG#H1D$9?-4I
MJ(TC\'CG/0T'/H:_:ZV_9!_9)U+6M=T[3/ 4^L_V"QCU6[TZ2ZFM[-PNXH[A
M^7 Y*IN([UR_B+X _L?>&&T8W7PQUI[;6;Y-.TZZBBNC%=SN@=50F4'&".2
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MS7V"AC<HC!T?9M*3Z_-;_-7]#E(/VP HOC>>'5C6*2QM[9H+HRK--= %%+;
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MA=Z+<^'_ -U:ZE;:;)=17>3NF7(8+M&0/K6A_P +[ \8R: VBO'+_I2QR/<
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MA::77["* *7$K3C:RC&2#Z G!^AJ75_B9X=T;0[W5YM3AELK-TCF:W/F$,Y
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MS@]>!0!>A^*WA&Y_U/B+3I?N_<G!Z]#_ )Z5);_$WPS=WCVT.LVDLJ?>"O\
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M6%W:E2ABN+=9 5)R0<@]3S4T/@[0[=(UBTBQC6)BZ!;=1L8C:2..#CCZ444
M:Z(L:!5&% P .U.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cgtx-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #. 6(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCKVXP:^<]>_;3@\/:/X[^T^%)E\0>&M;M--CTO[<@%Y:74ZPV]Z)-O$9;>"
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M<H%C0OL#$YP!N^7/KQ7G=AX:\(:O86+0?#RTCT^2[2&:&XL LJM)&NUU&.4
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M;V3J#D9PSS7HR0/^/<#J>=/PMXUUX:E FL6@;194-O%J7DM#(;D3K&BR1')
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M/_Q%<AXX@UF/Q)\/CJ-IX5@A_P"$DM=K:&V9<\_>^4?+5O\ X1)^_P "+/\
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MF0+G;N/4XR<>G:F1^']-AODO(["VCND78LRQ*&48 P#] !]*T** /G/XK_\
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M)J6L>*?A_#>>-=!\21KXCM6%MI<.R13S\Q.3QV_&N@_L#Q+V\ ?#W_P(C_\
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M_P"#%/\ XJONJ7M+SY;_ !3_ )OYGVBU^)^D4O:7J<M[<\]N?^>7:#7XG0?
M;[>?C9X[_M(Z4UW_ &=8Y.B_\>V/GQCCKZU]$"OF[]G;3CI7QC\=6Q\.)X4(
MTZQ/]F1RB0)DO\VX>O6OI$5]#DU_JSO_ #3_ /2GWM^1]3P_?ZF[_P \^_\
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M%>X_\%*O^2RZ!_V!$_\ 1TE>'?\ !)'_ ).EOO\ L7+O_P!&P5[C_P %*O\
MDLN@?]@1/_1TE?R]XS?\C"?^&'ZG[WX,?\E)2_PS_(^1Z^D?^"??_)R.G?\
M8.N__0!7S=7TC_P3[_Y.1T[_ +!UW_Z *_G'+/\ ?*7^)']A\;_\DUC_ /KW
M+\CZ4_;Z_P"/;P;_ -=+G^25\>GK7V%^WU_Q[>#?^NES_)*^/3UKY_BG_D;5
M?E_Z2C_$7C/_ )'=;_MW_P!)1Z'^SU_R6SP=_P!A!/Y&OKO]I^SCU#6_AM;R
MZ6^M1R:M*K6$;[&F'DGY0V1C\^U?(G[/7_);/!W_ &$$_D:^N/VI6@35OARU
MS]N$ U67?_9N?M&/)/W,<YKW\A_Y$M>_\\?SB?4<-V_U?Q-_^?D?SAZ_D9 \
M Z7C_DC>I?\ @Q7_ ..5S?B;PS9Z+XK\ 36_@*[\+.WB*U4W<]V)0XR?DP&/
M/?/M6B+SPYZ_$G_OF7_XFL/6[C2I?%W@$6'_  EOF_\ "0VI/]O!Q#C)^[D#
MYOZ9KV,0J?L]+;K^7NNT4_Q/=Q2I^R]UK>/\G\R[03_$^Q12T@I:_2#]:.=\
M?V5_J7A+4;/2[Z73-0N4$$%W%$9#"S,!NVCG'/)[#)[5XU\+(OB6/%NE7>OV
M-UI]H9;:U-IYS30I8_V:SRLY8 ^;]MV $\[3@CKCZ'I,4 ?*GC/_ (2?_AKF
MR&O+I8T__A O$QTLV#R-*8?M6G_Z[<H ;&W[N1UK\/NP^@_E7[P_%?\ Y.F\
M,?\ 9.O$W_I3IM?@]V'T'\J_H+PI^'&?]N?^W'DX[[/S$K]QO^"97_)F'@;_
M *[ZA_Z73U^'-?N-_P $RO\ DS#P-_UWU#_TNGKWO%#_ )$U+_KXO_29F6"_
MB/T/SN^)O_)2?%G_ &%[S_T>]<U72_$W_DI/BS_L+WG_ */>N:K_ #RK?Q9>
MK/\ 5W+O]RH?X(_DC])/^":G_)&?$'_8>D_])X*^:/BO_P E/\6_]A:Z_P#1
MK5]+_P#!-3_DC/B#_L/2?^D\%?-'Q7_Y*?XM_P"PM=?^C6KNXC_Y%.$]?T/\
MG_I!?\CRO_U^E_Z2CE3TK[8_8+_Y$?Q/_P!A-?\ T2M?$YZ5]L?L%?\ (C^)
M_P#L)K_Z)6O&X2_Y&L/27Y'X/P-_R.J?^&7Y&)XD@TN7XY_$4ZC;>*+DB>TV
M'PZS@+^X&?,V]_3/O5G[)X9_Z!OQ-_[^35+J6MQ:/\<OB3YGC>?P?YD]GA8;
M<2^?B <G(.,?UK5_X32V_P"BUWO_ (+T_P#B:^UAR7G=+XI_R_S/O)/\#]!@
MJ?-4YDK\\_Y/YWWFG^!-^SA':1_%_P <K91:O#;C3[(A-;+&Y!R^=Q;G'I7T
MH*^<OV?[]-2^-'CN>/Q!)XF5M.L1_:,L0C9_O\8'ITKZ-'2OI<EM]5=OYI?^
ME/M=?B?7\/6^I.W\\^W\S[-K[F+1117O'TP4444 %%%% !1110 4444 (1FO
M)'_9^L[OXSZ[XYU+5IM4LM5L$LCH5TC-!$5"#<N7V_\ +,,,("&8D-7KE% %
M32M,AT?3K:QM]_D6\:Q)YDA=MH&!EB22?<U/.76%S&H>0*2JDXR<<#-244 >
M"WOPLUOQ3I.H3:AX?LM,\17VIPW8OK*_V?9BD#Q)*-@&\1JV C [M[$]L87[
M=7AGQ1?_ +.?CZ]TSQ:-*TJR\+W_ -OTXZ<LQOQY1)_>%@8\C(X!ZU]+5XS^
MV=_R:A\7/^Q7U#_T2U 'Y=?\%2/^3B=$_P"Q2T[_ -"FKX]K["_X*D?\G$Z)
M_P!BEIW\Y:^/L5_:'"'_ "(<)_A7ZGSF(_BR/M;_ ()(_P#)TM]_V+EW_P"C
M8*]Q_P""E7_)9= _[ B?^CI*\._X)(_\G2WW_8N7?_HV"O<?^"E7_)9= _[
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M2U\/.--L";&SD$D:??Y!''/6OH<5]!DW^[._\TN_\S[ZGU.07^IN_P#//O\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cgtx-20241231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $# 8T# 2(  A$! Q$!_\0
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M\"M&']FWP7867@ZRTVWO=*LO"=TU]I=O97CHL=PV[?(_4R%A)(#N)!W'CI@
MY:RF^)=A^U!#96WBQ_$?@.?3I[G5M,N=.@BCTA\@6RPS(H=G<A\AV;A6/'&/
M>QTKR31?V7_!.B?%J?XD)_;5SXIFE>9I;K6;F2W#,FSB OY8PO ^7BO6QQ0
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MO0C7,\,CD+! 5 R3U/MZUJ>%B(=7C6W"*Z*7:6;CH,\>E85S*TSJQ?S%[ #
M7VQ4NF/+'?(G(9CL)SZULXM1;1U<_MFI5M?):'6:K<O;12Q2JZSX(96X8'KR
M.O>N36#Y7=3A<[?J:L7,LLSRO=S.TZMR6.6;''-):$6[!G0-$QW9(Z^U>CCL
MQJX[E=1*\5;0]&G0H4ZEJ=^5WM?IZGO'PV7PW%\%-834'"ZHM[%)&V_! (*U
M^PG[ \/V;]E/P/&763;%/\R'(/[]Z_"[2+T'POXC1,>;LBD1 ,X <9-?M_\
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MW//%)I7VAKMDM8!<3.C*(RF_C'.!ZCUH3=KLJ4(NHJ:Z_-_=H4B G!-?;/\
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MJN,?*>*\IEO9AA;E/-/7]X.17JVF>'[?4_ ]Q<3P6U[=PP0(+:!\S0@M\LR
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M>M>G:OXBT*:XO)F9C<021VUDV[<D<*J5.5/4?2N/TSP[8RV.H75SJ*0L(_\
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M*<* >G Y]Z\G,,%ALSY(56YPB[]+/\-?T.&E&K4Q4>6;7*[ZZ*Z6EK[OTO\
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cgtx-20241231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "Z L4# 2(  A$! Q$!_\0
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M_P#'J3[+XI_Z".C_ /@!+_\ 'Z .AHKGOLOBG_H(Z/\ ^ $O_P ?H^R^*?\
MH(Z/_P" $O\ \?H Z&BN>^R^*?\ H(Z/_P" $O\ \?H^R^*?^@CH_P#X 2__
M !^@#H:*Y[[+XI_Z".C_ /@!+_\ 'Z/LOBG_ *".C_\ @!+_ /'Z .AHKGOL
MOBG_ *".C_\ @!+_ /'Z/LOBG_H(Z/\ ^ $O_P ?H Z&BN>^R^*?^@CH_P#X
M 2__ !^C[+XI_P"@CH__ ( 2_P#Q^@#H:*Y[[+XI_P"@CH__ ( 2_P#Q^C[+
MXI_Z".C_ /@!+_\ 'Z .AHKGOLOBG_H(Z/\ ^ $O_P ?H^R^*?\ H(Z/_P"
M$O\ \?H Z&BN>^R^*?\ H(Z/_P" $O\ \?H^R^*?^@CH_P#X 2__ !^@#H:*
MY[[+XI_Z".C_ /@!+_\ 'Z/LOBG_ *".C_\ @!+_ /'Z .AHKGOLOBG_ *".
MC_\ @!+_ /'Z/LOBG_H(Z1_X 3?_ !^@#H:*P[[7;G171K^U#6;,J?:[9MP0
MGC+J>5&>X+8[UN4 %%9^KZU#I"0APTL\[^7#!'C?(WH,\?4GI5=WURZM6,2V
M-A-N&WS@]P-ON%*8/T)% &Q17/?9?%/_ $$M'_\  "7_ ./T?9?%/_01T?\
M\ )?_C] '0T5SWV7Q3_T$='_ / "7_X_1]E\4_\ 01T?_P  )?\ X_0!T-%<
M]]E\4_\ 01T?_P  )?\ X_1]E\4_]!'1_P#P E_^/T =#17/?9?%/_01T?\
M\ )?_C]'V7Q3_P!!'1__   E_P#C] '0T5SWV7Q3_P!!'1__   E_P#C]'V7
MQ3_T$='_ / "7_X_0!T-%<]]E\4_]!'1_P#P E_^/T?9?%/_ $$='_\  "7_
M ./T =#17/?9?%/_ $$='_\  "7_ ./T?9?%/_01T?\ \ )?_C] '0T5SWV7
MQ3_T$='_ / "7_X_1]E\4_\ 01T?_P  )?\ X_0!T-%<]]E\4_\ 01T?_P
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MR(SX']XFN_\ ^%,>'/\ GMK_ /X4NI__ "1536_^2Z>%_P#L"ZA_Z,MZ]%H
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MY:_9KJ*^N88B(Q&LT"RL(I NYB RX/)YZ]"*Z#:/04H '2@#C/B]_P B4_\
MU_67_I5%79CI7&?%[_D2G_Z_K+_TJBKLQTH 6BBB@ HHHH P_'7_ ")6O?\
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MED(*G'.">.E>K:5<RWVF6ES<VS65Q+$DDENYR8F*@E2>Y!)'X5:VKZ"@#E_
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MZ9IMLN"UM)"LH/R8*DF#.=W.[(SQ\HQSJP^'_B FA74$OB6SFU(PQ""Z6W1
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MEGO-3NX?B'K%M->WR7!CB4&*.W6/;]G1'+",%OG+H%8XQG%>G#@4 <9\7O\
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M-]=:M:Z=(D4UQ<E@H"GC:  >IZU\W5I8Z>-5>$4E'366CB[-NR7Q+H?2TJV
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MJBKLQTKC/B]_R)3_ /7]9?\ I5%79CI0 M%%% !1110!A^.O^1*U[_KQG_\
M0#6Y6'XZ_P"1*U[_ *\9_P#T UN4 ?.?[8VGZAKF@:#I-C-XL@2\EN$E_P"$
M<N8HXI%$)/ERQ,5:Y8X.R%'0L0W)("MS_P 7Y/%UG\/?AAXM\/7WB?PNQL;:
M"_TC1W2"SA#P I'+#-'(8B'Q&'.!'N^?..,K_@H#*VG#P#JEN6;4;:[F^S1P
M,XN2_P"[<-#F"2(.&13NDDAP,@,<D5U?Q!\">(_B)9^!-5ET6\\3Z7+HD?\
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M /I37IMWL^S2^9GR]AW8],<UYE-_R<Q;?]BP_P#Z4UZ?<;?)DWKN3:<CU&*
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M[_V&[S_T,5W[_=-<!\&O^0-KO_8;O/\ T,4 1?!G[OC/_L8[G_T7#6E\9O\
MDE?BG_KPE_E6;\&?N^,_^QCN?_1<-:7QF_Y)7XI_Z\)?Y4 9/B7_ )(%<?\
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MN#H*P_''_(J:E_US_J*W!T% ''>-O^1H\'?]?LG_ *+-=CVKCO&W_(T>#O\
MK]D_]%FNQ'2@#Y_C\,ZT_P"UK-JL<&OW.B#3566XBD\NP@D .%?S$4R9[+"S
M 'E@*]ZO;I;&SFN'4LD2%R 0#@#/<@?F:FQ4-]90ZC9SVES&);>=&BDC;HRD
M8(/U!H \;U'X^^&?&7AW5[*%;[39C8M+OU*)88^3@+OW$9/4>N1BNW_X1K4=
M4OO">IVVH6]M;:= ?-MY;4R/+OC .'#C;C'H:RO%GPW\+^'_  _J^J6.BV=I
M>KIHLQ.J\B).%7DXX_.M*^U?Q#8:1I:Z'I']H?Z.GF-(4 QL&-N9%)(]#U]1
MUI-V+A%S?*CM@,"EKR]?%GQ(2UF9O"$,TRS&-%6>--R$<28,QZ'JN<XZ&M72
M]8\;,Q%YH]NJ>9RX==Q7(Y"^9Z9ZGCWJ>;R-WAY+7F7WH[NBO,O$^K?$E3<1
MZ/I5C\LK+%.Y4[DQPVTR>O&#Z5L:3K/BYC8_VCI,$,9M0UTT#ARDW<##\CVQ
MZ<GI1S:VL)T&HJ7,OO.T90ZE6&01@BLS0/#&E>%K>6#2;"&PAED,SI NT,YZ
ML?<UP=[XH^)$]B)M-\-6B2F3Y8KTA3LY^]B;ANGKQSQT%K0]=^(EQ<.=2T'3
MX(!+M1(I,,5PQR6,AQ@A!D ]2<>ASJ]AO#R2OS+[T>C45YEJ'B+XD0&#['X=
MM+M9%._?MC,+;<XQYY# G@$$>_K4L.O?$-]!UN2?0;5=00!=/BMF7+DDC<V^
M3' P<9_/I1S!]7E9/F7WH](HKSBSUKQ__90DNM)M_MQ)4QPQ J,'@\SC.1W[
M8)P>E1PZU\26\/7DLF@V"ZLDRBWM_-PI3!R6;S.<<=-M'-Y!]7?\R^\]+HK.
MT"XO[O1[.;5+5;/4'B4SP1MN6-\<@'N,UHU>YS-6;0C=/Q%<7\'/^2?:=_O2
M_P#HUJ[1NGXBN+^#G_)/M._WI?\ T:U BG\3IO"-_<:;HOB6.&>XN&#VD5P\
ML:D^;''E63G?EQ@#GKT&37F][XF^%7AWP_>3:-H-G<'5M->[^S2K+"]W!$9)
M!Y;E6V[9 S9RN#EAEL5ZQ\1=;T#PO9VNJZOI U6X$HBMDAM8YI]^&<;-Y&,;
M2<Y'.*X+3/C+\-M1\,ZCKD>B"#3--TPZA*\FG0@B!@3M4 GYF4YV<9!H BM_
M^%27O@B77+/2$N?#VC-,KFWCD6*%XW2"1=I8 G,2@^H4D]3GI]#E^'ES+#J>
MGP12&W<:7#+%'+)'&#;&953&55&@D!## (95SG"CFM#\>^"+BVU&RT'PEIT6
ME7<%JEQ']A2(2SW%X;7R9HE0@J&(8ME@0V1D<GM-9\:^'O"FG1QSZ2ZVW]JI
M8);VEM%(//\ +\]7VJQV@!<@G#9 XY!H P-.L_AC)IMEIUGI6G+IWB&"&^AB
M:!A%/# J.I/!"[%97V''WV)&6;-72]3^'_B_XDZRLVAPKX@BDAC^T,&:2ZBD
MMT42,!QL <(#E@?E<'!!J\/B#X#LM&TO4K70]EC,MU>6TG]DB'8L15YG"LH8
M,3)D #<S;AC-7[;7/"VEW7A1K7P_I]G:SWLFFVERL4""T=;:3849,J$9(#$-
MK \HN.H !OZ=\+_"VE:U!JUIHMM;W\!S%,@8&,^5Y1*C. 2GRDXY'6NII:*
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M=1RO(PCNG<KM0XVJ23CB@#V04M%% !1110 4444 %%%% &%XX_Y%34O^N?\
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MNQ'2N.\;?\C1X._Z_9/_ $6:[$=* %HHHH :ZAU*L RD8((R#6!IOP\\+Z-
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M !H OYHS5#^P;'_GW'_?3?XT?V#8_P#/N/\ OIO\: +^:,U0_L&Q_P"?<?\
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MNJDMU.U><* %C^%/A6*VN;9-&@6TN&=Y+;<QA+/.]PS>63LSYLKOG'5O3 H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cgtx-20241231xex10d3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
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2Q)J 6QB4"4X R!_.BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cgtx-20241231xex10d3002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cgtx-20241231xex10d3003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[]HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cgtx-20241231xex10d3004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  4# 2(  A$! Q$!_\0
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6>-9-^YI+]"Q8!N=IZ9Z?A1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cgtx-20241231xex10d3006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[HHHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cgtx-20241231xex10d3007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cgtx-20241231xex10d3008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cgtx-20241231xex10d3009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cgtx-20241231xex10d3011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  %  (# 2(  A$! Q$!_\0
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5.Y>S@WS*)&S&I.2,]<<]:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>cgtx-20241231xex10d3012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>cgtx-20241231xex10d3013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>cgtx-20241231xex10d3018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>cgtx-20241231xex10d3019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>cgtx-20241231xex10d3020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[MHHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>cgtx-20241231xex10d3021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>cgtx-20241231xex10d3022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[SHHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>cgtx-20241231xex10d3026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  '  $# 2(  A$! Q$!_\0
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,5G_X -_C1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>cgtx-20241231xex10d3027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]-H(%GMX)
4&+J6B0D)(R+]T= " /PHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>cgtx-20241231xex10d3028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>cgtx-20241231xex10d3034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>cgtx-20241231xex10d3035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3035.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>cgtx-20241231xex10d3040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3040.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  (# 2(  A$! Q$!_\0
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4)988GDD169C&N22,D]**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>cgtx-20241231xex10d3041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3041.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>cgtx-20241231xex10d3050.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3050.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>cgtx-20241231xex10d3058.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3058.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  -  (# 2(  A$! Q$!_\0
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=P . I('X45D3Z['!/)%]C#;&*Y\PC.#Z8HH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>cgtx-20241231xex10d3060.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3060.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>cgtx-20241231xex10d3061.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3061.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  (# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[WU/Q?J]E
9J5W;P7?E00S/'&BQ)A5!( Z>E%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cgtx-20241231xex10d3063.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3063.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ,  $# 2(  A$! Q$!_\0
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9'_X C_"BL;_A,KS_ )X6W_?+?_%44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>cgtx-20241231xex10d3074.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3074.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cgtx-20241231xex10d3075.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3075.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  (  ,# 2(  A$! Q$!_\0
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-N(Y _B'I]**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>cgtx-20241231xex10d3079.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3079.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  $  $# 2(  A$! Q$!_\0
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+:_\ ?H4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cgtx-20241231xex10d3080.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3080.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]-K**.\M(
2IIH8I974%G:-23^E%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cgtx-20241231xex10d3082.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3082.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  *  $# 2(  A$! Q$!_\0
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:=O\ DO\ A17*?VG>?\_<_P#W\/\ C10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cgtx-20241231xex10d3085.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3085.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[-HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>cgtx-20241231xex10d3089.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3089.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
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2QXHG"1J% 4*./E'M1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>cgtx-20241231xex10d3093.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3093.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  -  $# 2(  A$! Q$!_\0
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867_@,/\ &BL[_A+?^G3_ ,B__6HH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>cgtx-20241231xex10d3105.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3105.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>cgtx-20241231xex10d3108.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3108.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ,  $# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]0?[-L_\
:GRM?^_2_X45S7_"97G_/"V_[Y;_XJB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>cgtx-20241231xex10d3110.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3110.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  $  (# 2(  A$! Q$!_\0
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3Q+#'# $C8HHV'H#@=Z*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>cgtx-20241231xex10d3111.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3111.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  (  ,# 2(  A$! Q$!_\0
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4-K%M ^1Y]I7(SC&WCK1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>cgtx-20241231xex10d3115.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3115.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  $  $# 2(  A$! Q$!_\0
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-L?\ OS_]>BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>cgtx-20241231xex10d3116.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3116.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  +  $# 2(  A$! Q$!_\0
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;8/\ OTW_ ,;HKF/^$EU+_GY_\<7_  HH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>cgtx-20241231xex10d3117.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3117.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>cgtx-20241231xex10d3119.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3119.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  *  ,# 2(  A$! Q$!_\0
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>XHPS <%0>V!UYHJE;2NUI;$NQ)AC))/4[110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>cgtx-20241231xex10d3121.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3121.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  &  (# 2(  A$! Q$!_\0
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2<V<3&0!RS(,G///%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>cgtx-20241231xex10d3126.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3126.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  %  $# 2(  A$! Q$!_\0
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/ V__ ([_ /$4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>cgtx-20241231xex10d3133.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3133.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  $  (# 2(  A$! Q$!_\0
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18TM[?:C%1\AZ _6BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>cgtx-20241231xex10d3142.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3142.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
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12.-@J*0 H4<#'THHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>cgtx-20241231xex10d3147.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3147.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  "  (# 2(  A$! Q$!_\0
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46..XECC1RJHKD!0#P **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>cgtx-20241231xex10d3152.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3152.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  1  (# 2(  A$! Q$!_\0
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KN(5' C0+M4>@^7H**NYE''F-_P!]+_A10!RFH_\ (0N?^NK?S-%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>cgtx-20241231xex10d3153.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3153.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>cgtx-20241231xex10d3160.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3160.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  "  (# 2(  A$! Q$!_\0
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0&K7P ' %R_\ C1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>cgtx-20241231xex10d3161.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgtx-20241231xex10d3161.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  #  ,# 2(  A$! Q$!_\0
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G/V>/!^JZIJ.LWVHWD=Q//<3:Q=EI':YE))_>_H. .!@"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>74
<FILENAME>cgtx-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2025 2:05:36 AM-->
<!--Modified on: 3/20/2025 2:05:36 AM-->
<xsd:schema targetNamespace="http://www.cogrx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:cgtx="http://www.cogrx.com/20241231" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails">
        <link:definition>99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>99940401 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" id="DisclosureCommitmentsAndContingenciesLeasesDetailss">
        <link:definition>40601 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940702 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" id="DisclosureIncomeTaxesNetLossDetails">
        <link:definition>99941201 - Disclosure - Income Taxes - Net loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails">
        <link:definition>99941202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>99941203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" id="DisclosureSegmentReportingDetails">
        <link:definition>99941301 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" id="DisclosureDescriptionOfBusinessAndFinancialConditionDetails">
        <link:definition>99940101 - Disclosure - Description of Business and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails">
        <link:definition>99940303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" id="DisclosureOtherCurrentLiabilitiesDetails">
        <link:definition>99940601 - Disclosure - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>99940701 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>99940801 - Disclosure - Stockholders' Equity - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" id="DisclosureStockholdersEquitySharesReservedForIssuanceDetails">
        <link:definition>99940802 - Disclosure - Stockholders' Equity - Shares reserved for issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" id="DisclosureEquityBasedCompensationDetails">
        <link:definition>99940901 - Disclosure - Equity-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" id="DisclosureEquityBasedCompensationFairValueOfOptionsDetails">
        <link:definition>99940902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" id="DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>99940904 - Disclosure - Equity-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" id="DisclosureEquityBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>99940905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" id="DisclosureEquityBasedCompensationCompensationExpenseDetails">
        <link:definition>99940906 - Disclosure - Equity-based Compensation - Compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>99941001 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>99941204 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" id="DisclosureDescriptionOfBusinessAndFinancialCondition">
        <link:definition>995210101 - Disclosure - Description of Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" id="DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>995210301 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>995210401 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" id="DisclosureOtherCurrentLiabilities">
        <link:definition>995210601 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" id="DisclosureEquityBasedCompensation">
        <link:definition>995210901 - Disclosure - Equity-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211001 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>995211101 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995211301 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>99930403 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99930703 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" id="DisclosureEquityBasedCompensationTables">
        <link:definition>99930903 - Disclosure - Equity-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931003 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>99931303 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" id="DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails">
        <link:definition>99940703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails">
        <link:definition>99940704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" id="DisclosureEquityBasedCompensationActivityForOptionsDetails">
        <link:definition>99940903 - Disclosure - Equity-based Compensation - Activity for options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>99941101 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="GrantIncome" id="cgtx_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInGrantReceivables" id="cgtx_IncreaseDecreaseInGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrantIncomePolicyPolicyTextBlock" id="cgtx_GrantIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmergingGrowthCompanyPolicyTextBlock" id="cgtx_EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceInitialPublicOfferingGross" id="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AllowanceForCreditLossGrantsReceivableCurrent" id="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="cgtx_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AmendedAndRestatedEquityIncentivePlan2017Member" id="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PerformanceBasedStockOptionsMember" id="cgtx_PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" id="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLossCarryForwardsSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryForwardsNotSubjectToExpiration" id="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherCurrentLiabilitiesTextBlock" id="cgtx_OtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InsurancePremiumFinancingAgreementMember" id="cgtx_InsurancePremiumFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityIncentivePlan2021Member" id="cgtx_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cgtx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredGrantIncomeCurrent" id="cgtx_DeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInDeferredGrantIncomeCurrent" id="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseAssets" id="cgtx_OperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cgtx_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" id="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumAggregateOfferingPrice" id="cgtx_MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingMember" id="cgtx_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" id="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityLineFinancingMember" id="cgtx_EquityLineFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LincolnParkCapitalFundLlcMember" id="cgtx_LincolnParkCapitalFundLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseAgreementTerm" id="cgtx_PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumValueOfStockToBeIssuedUnderAgreement" id="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SharesOfferingAgreementRemainingValueOfStockToBeIssued" id="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" id="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonEmployeeDirectorMember" id="cgtx_NonEmployeeDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RemainingValueOfStockToBeIssuedUnderAgreement" id="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnderwritingAgreementWithTitanPartnersGroupLlcMember" id="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritersOptionToPurchaseAdditionalShares" id="cgtx_UnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UnderwritingDiscountsCommissionsAndOfferingExpenses" id="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AaronFletcherMember" id="cgtx_AaronFletcherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" id="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" id="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" id="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RestrictedStockUnitsPerformanceBasedVestingMember" id="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsTimeBasedVestingMember" id="cgtx_RestrictedStockUnitsTimeBasedVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityLineFinancingCommitmentSharesMember" id="cgtx_EquityLineFinancingCommitmentSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaymentOfInsuranceThroughThirdPartyFinancing" id="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="InsurancePremiumFinancingAgreement2Member" id="cgtx_InsurancePremiumFinancingAgreement2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SegmentExpensesAbstract" id="cgtx_SegmentExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentClinicalPrograms" id="cgtx_ResearchAndDevelopmentClinicalPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentPersonnel" id="cgtx_ResearchAndDevelopmentPersonnel" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentManufacturing" id="cgtx_ResearchAndDevelopmentManufacturing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentPreclinicalPrograms" id="cgtx_ResearchAndDevelopmentPreclinicalPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LifeScienceSegmentMember" id="cgtx_LifeScienceSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceNewYorkMember" id="cgtx_OfficeSpaceNewYorkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LaboratoryAndOfficeSpacePittsburghPaMember" id="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceLocatedInPittsburghPaMember" id="cgtx_OfficeSpaceLocatedInPittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" id="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LaboratorySpacePittsburghPaMember" id="cgtx_LaboratorySpacePittsburghPaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SegmentGrantIncome" id="cgtx_SegmentGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" id="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>75
<FILENAME>cgtx-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2025 2:05:36 AM-->
<!--Modified on: 3/20/2025 2:05:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetailss" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSegmentReportingDetails" roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638780331338041263" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638780331338041263" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331338041263" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638780331338041263" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331338041263" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638780331338041263" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638780331338041263" xlink:to="us-gaap_GrantsReceivableCurrent_638780331338041263" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638780331338041263" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638780331338041263" xlink:to="us-gaap_PrepaidExpenseCurrent_638780331338041263" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638780331338051273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638780331338051273" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638780331338051273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638780331338051273" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331338051273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638780331338051273" xlink:to="us-gaap_LiabilitiesCurrent_638780331338051273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638780331338051273" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638780331338051273" xlink:to="us-gaap_AccountsPayableCurrent_638780331338051273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638780331338051273" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638780331338061304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638780331338051273" xlink:to="cgtx_DeferredGrantIncomeCurrent_638780331338061304" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638780331338051273" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638780331338061304" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638780331338051273" xlink:to="us-gaap_OtherLiabilitiesCurrent_638780331338061304" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638780331338061304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638780331338061304" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638780331338061304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638780331338061304" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638780331338061304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638780331338061304" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638780331338071278" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638780331338061304" xlink:to="us-gaap_AdditionalPaidInCapital_638780331338071278" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638780331338061304" xlink:to="us-gaap_CommonStockValue_638780331338071278" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638780331338061304" xlink:to="us-gaap_PreferredStockValue_638780331338071278" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_638780331338071278" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331338071278" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638780331338071278" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638780331338071278" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" xlink:to="cgtx_GrantIncome_638780331338081291" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" xlink:to="us-gaap_OtherNoncashIncomeExpense_638780331338081291" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638780331338081291" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638780331338081291" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331338081291" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638780331338071278" xlink:to="us-gaap_OperatingIncomeLoss_638780331338081291" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638780331338081291" xlink:to="us-gaap_OperatingExpenses_638780331338081291" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638780331338081291" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638780331338081291" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638780331338081291" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638780331338081291" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638780331338091287" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331338091287" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331338091287" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638780331338091287" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638780331338091287" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638780331338091287" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331338101259" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331338091287" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638780331338101259" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638780331338101259" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638780331338101259" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638780331338101259" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638780331338101259" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638780331338101259" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638780331338101259" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638780331338111258" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638780331338111258" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638780331338111258" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_ShareBasedCompensation_638780331338111258" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638780331338111258" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331338111258" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638780331338111258" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638780331338111258" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331338121274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_NetIncomeLoss_638780331338121274" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638780331338121274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331338101259" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638780331338121274" order="11" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638780331338121274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638780331338121274" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638780331338121274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638780331338121274" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638780331338131360" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638780331338131360" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638780331338131360" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638780331338131360" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss" xlink:type="extended" xlink:title="40601 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331338131360" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638780331338131360" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638780331338131360" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset_1" xlink:to="cgtx_OperatingLeaseAssets_638780331338141322" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638780331338141322" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638780331338141322" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638780331338141322" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638780331338141322" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638780331338141322" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638780331338141322" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638780331338151264" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638780331338151264" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638780331338151264" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638780331338151264" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638780331338151264" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638780331338151264" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638780331338151264" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638780331338151264" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638780331338151264" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638780331338151264" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638780331338161262" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638780331338161262" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638780331338161262" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331338161262" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331338161262" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638780331338161262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638780331338161262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331338161262" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638780331338161262" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638780331338171275" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638780331338171275" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsGross_638780331338171275" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638780331338171275" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsOther_638780331338171275" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638780331338171275" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638780331338171275" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638780331338171275" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638780331338181274" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638780331338181274" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638780331338171275" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638780331338181274" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Segment Reporting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentGrantIncome" xlink:label="cgtx_SegmentGrantIncome_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="cgtx_SegmentGrantIncome_638780331338181274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentClinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="cgtx_ResearchAndDevelopmentClinicalPrograms_638780331338181274" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPersonnel" xlink:label="cgtx_ResearchAndDevelopmentPersonnel_638780331338181274" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="cgtx_ResearchAndDevelopmentPersonnel_638780331338181274" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPreclinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms_638780331338191262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="cgtx_ResearchAndDevelopmentPreclinicalPrograms_638780331338191262" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentManufacturing" xlink:label="cgtx_ResearchAndDevelopmentManufacturing_638780331338191262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="cgtx_ResearchAndDevelopmentManufacturing_638780331338191262" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638780331338191262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638780331338191262" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638780331338191262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638780331338191262" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638780331338191262" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_3" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638780331338191262" order="8" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>76
<FILENAME>cgtx-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2025 2:05:36 AM-->
<!--Modified on: 3/20/2025 2:05:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSegmentReportingDetails" roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cgtx-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.cogrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AaronFletcherMember" xlink:label="cgtx_AaronFletcherMember" xlink:title="cgtx_AaronFletcherMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="cgtx_AaronFletcherMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To cgtx_AaronFletcherMember" order="1" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:to="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_PurchaseAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_GrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cgtx_DeferredGrantIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_OfficeSpaceNewYorkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratorySpacePittsburghPaMember" xlink:label="cgtx_LaboratorySpacePittsburghPaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:to="cgtx_LaboratorySpacePittsburghPaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stockholders' Equity - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cgtx_LincolnParkCapitalFundLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cgtx_EquityLineFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_PurchaseAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cgtx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Equity-based Compensation - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsTimeBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="cgtx_RestrictedStockUnitsTimeBasedVestingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_DirectorMember" xlink:to="cgtx_NonEmployeeDirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PerformanceBasedStockOptionsMember" xlink:label="cgtx_PerformanceBasedStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cgtx_PerformanceBasedStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Segment Reporting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LifeScienceSegmentMember" xlink:label="cgtx_LifeScienceSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="cgtx_LifeScienceSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentGrantIncome" xlink:label="cgtx_SegmentGrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="cgtx_SegmentGrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentExpensesAbstract" xlink:label="cgtx_SegmentExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="cgtx_SegmentExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentClinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="cgtx_ResearchAndDevelopmentClinicalPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPersonnel" xlink:label="cgtx_ResearchAndDevelopmentPersonnel" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="cgtx_ResearchAndDevelopmentPersonnel" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPreclinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="cgtx_ResearchAndDevelopmentPreclinicalPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentManufacturing" xlink:label="cgtx_ResearchAndDevelopmentManufacturing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="cgtx_ResearchAndDevelopmentManufacturing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>77
<FILENAME>cgtx-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2025 2:05:36 AM-->
<!--Modified on: 3/20/2025 2:05:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredGrantIncomeCurrent" xlink:to="cgtx_DeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current portion of deferred grant income as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 250,000,000 shares authorized; 59,854,877 and 32,165,478 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncome" xlink:to="cgtx_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income related to grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on currency translation from liquidation of subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on currency translation from liquidation of subsidiary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" xlink:to="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including reclassifications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Including Reclassications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, including reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_FollowOnPublicOfferingMember" xlink:to="cgtx_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to follow on pubic offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-On Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on Public Offering</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AtMarketOfferingMember" xlink:to="cgtx_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityLineFinancingCommitmentSharesMember" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to commitment shares for equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing Commitment Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing Commitment Shares</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityLineFinancingMember" xlink:to="cgtx_EquityLineFinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EquityLineFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line Financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive (Loss) Gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:to="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate value of stock related to vesting of Restricted Stock Units during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:to="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" xlink:to="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications Adjustment of Foreign Currency Translation Included in Net Loss For Liquidation of Subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, discounts and offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of adjustments relating to commitment shares issued for equity line financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock as Commitment Shares For Equity Line Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock as commitment shares for equity line financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInGrantReceivables" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase and decrease in grant receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Grant Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in current deferred grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Grant Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of employee withholding taxes on vested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on loan payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents - end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents - beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prepayment of insurance through third-party financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of Insurance Through Third Party Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment of insurance through third-party financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OtherCurrentLiabilitiesTextBlock" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entire disclosure of other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_GrantIncomePolicyPolicyTextBlock" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of financial assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of options granted using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity for options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock units award activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total equity-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding potentially dilutive common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the expected income tax (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment significant expense categories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald And Co And B Riley Securities Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc.</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LincolnParkCapitalFundLlcMember" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Lincoln Park Capital Fund, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park Capital Fund LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumAggregateOfferingPrice" xlink:to="cgtx_MaximumAggregateOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity impact of the value of new stock to be issued under an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value of stock to be issued under agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PurchaseAgreementTerm" xlink:to="cgtx_PurchaseAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining value of new stock to be issued under an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Value Of Stock To Be Issued Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount available to draw under purchase agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters option to purchase additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters, Option To Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters option to purchase additional shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for credit loss on grants receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Credit Loss, Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts on grants receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain related to foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Priced in Active Markets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation, benefits, and related accruals</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AccruedResearchAndDevelopmentExpenses" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees and other accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_InsurancePremiumFinancingAgreementMember" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to insurance premium financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_InsurancePremiumFinancingAgreement2Member" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to insurance premium financing agreement 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance Premium Financing Agreement 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Periodic payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt, Maturing in More than Three Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of short-term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLeaseAssets" xlink:to="cgtx_OperatingLeaseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating lease assets as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceNewYorkMember" xlink:to="cgtx_OfficeSpaceNewYorkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to New York office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space, New York [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OfficeSpaceNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase, New York office</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to laboratory and office space in Pittsburgh, PA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory And Office Space, Pittsburgh, PA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pittsburgh, Pennsylvania laboratory and office space</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to office space located in Pittsburgh, Pennsylvania.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space located In Pittsburgh, PA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pittsburgh, PA office space</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratorySpacePittsburghPaMember" xlink:label="cgtx_LaboratorySpacePittsburghPaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LaboratorySpacePittsburghPaMember" xlink:to="cgtx_LaboratorySpacePittsburghPaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LaboratorySpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to laboratory space in Pittsburgh, PA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LaboratorySpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Space, Pittsburgh, PA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LaboratorySpacePittsburghPaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pittsburgh, PA lab space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of office space</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of buyout options in dollars in an operating lease under the lessee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number of Buyout Options in Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options at conclusion of the lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows used for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to underwriting agreement with Titan Partners Group LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement With Titan Partners Group LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement With Titan Partners Group LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend declared</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remaining value of stock to be issued under shares offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering Agreement, Remaining Value of Stock to be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining of common stock available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of underwriting discounts, commissions and offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Discounts, Commissions And Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended And Restated Equity Incentive Plan 2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and Restated 2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EquityIncentivePlan2021Member" xlink:to="cgtx_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">.Represents information relating to 2021 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_EmployeeStockPurchasePlanMember" xlink:to="cgtx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of common shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that may be recycled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life -Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" xlink:to="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to performance based vesting of Restricted Stock Units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units, Performance Based Vesting [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Performance Based Vesting</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsTimeBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_RestrictedStockUnitsTimeBasedVestingMember" xlink:to="cgtx_RestrictedStockUnitsTimeBasedVestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to time based vesting of Restricted Stock Units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units, Time Based Vesting [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Time Based Vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_NonEmployeeDirectorMember" xlink:to="cgtx_NonEmployeeDirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person serving on board of non employee directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_NonEmployeeDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options granted during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total fair value of options exercised during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable for each award under share-based payment arrangement.












ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable for each award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of targets outstanding under the share based arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Targets Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award number of targets outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PerformanceBasedStockOptionsMember" xlink:label="cgtx_PerformanceBasedStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_PerformanceBasedStockOptionsMember" xlink:to="cgtx_PerformanceBasedStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_PerformanceBasedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to performance based stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_PerformanceBasedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Based Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_PerformanceBasedStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which the unrecognized compensation cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive common stock equivalents outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of employees' compensation per person per year matched by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contributions to the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax computed at federal statutory rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D Credit (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible stock compensation (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based compensation</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, In-Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets after valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Operating Lease, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that expire</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating loss carryforwards that are not subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry forwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that do not expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LifeScienceSegmentMember" xlink:label="cgtx_LifeScienceSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_LifeScienceSegmentMember" xlink:to="cgtx_LifeScienceSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_LifeScienceSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to life science segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_LifeScienceSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Life Science Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_LifeScienceSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Life science segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentGrantIncome" xlink:label="cgtx_SegmentGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SegmentGrantIncome" xlink:to="cgtx_SegmentGrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SegmentGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income related to grants specific to company life science segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SegmentGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_SegmentGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentExpensesAbstract" xlink:label="cgtx_SegmentExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_SegmentExpensesAbstract" xlink:to="cgtx_SegmentExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_SegmentExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_SegmentExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_SegmentExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less:</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentClinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentClinicalPrograms" xlink:to="cgtx_ResearchAndDevelopmentClinicalPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for research and development incurred on clinical programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Clinical Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical programs</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPersonnel" xlink:label="cgtx_ResearchAndDevelopmentPersonnel" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentPersonnel" xlink:to="cgtx_ResearchAndDevelopmentPersonnel_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentPersonnel_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for research and development incurred on personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentPersonnel_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Personnel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentPersonnel_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D Personnel costs</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPreclinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentPreclinicalPrograms" xlink:to="cgtx_ResearchAndDevelopmentPreclinicalPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for research and development incurred on preclinical programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Preclinical Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preclinical programs</label>
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentManufacturing" xlink:label="cgtx_ResearchAndDevelopmentManufacturing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cgtx_ResearchAndDevelopmentManufacturing" xlink:to="cgtx_ResearchAndDevelopmentManufacturing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for research and development incurred on manufacturing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Manufacturing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>78
<FILENAME>cgtx-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2025 2:05:36 AM-->
<!--Modified on: 3/20/2025 2:05:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureDescriptionOfBusinessAndFinancialCondition" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurements" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureAccruedExpenses" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureOtherCurrentLiabilities" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensation" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureRetirementPlan" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSegmentReporting" roleURI="http://www.cogrx.com/role/DisclosureSegmentReporting" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationTables" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSegmentReportingTables" roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureDescriptionOfBusinessAndFinancialConditionDetails" roleURI="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" roleURI="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureOtherCurrentLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureStockholdersEquitySharesReservedForIssuanceDetails" roleURI="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationFairValueOfOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationActivityForOptionsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureEquityBasedCompensationCompensationExpenseDetails" roleURI="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.cogrx.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesNetLossDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cgtx-20241231.xsd#DisclosureSegmentReportingDetails" roleURI="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638780331338861284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638780331338861284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638780331338861284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638780331338861284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638780331338861284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638780331338861284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638780331338871272" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638780331338871272" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638780331338871272" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638780331338871272" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638780331338871272" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638780331338871272" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638780331338871272" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638780331338871272" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638780331338871272" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638780331338871272" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638780331338871272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638780331338871272" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638780331338881270" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638780331338881270" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638780331338881270" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638780331338881270" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638780331338881270" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638780331338881270" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638780331338881270" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638780331338881270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638780331338881270" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638780331338891273" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638780331338891273" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638780331338891273" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638780331338891273" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638780331338891273" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638780331338891273" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638780331338891273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638780331338891273" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638780331338901290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638780331338901290" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638780331338901290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638780331338901290" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638780331339031275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638780331339031275" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638780331339031275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638780331339031275" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638780331339031275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638780331339031275" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638780331339031275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638780331339031275" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638780331339031275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638780331339031275" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638780331339041278" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638780331339041278" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638780331339041278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339041278" xlink:to="us-gaap_AssetsCurrentAbstract_638780331339041278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638780331339041278" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331339041278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638780331339041278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638780331339041278" xlink:to="us-gaap_GrantsReceivableCurrent_638780331339041278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638780331339041278" xlink:to="us-gaap_PrepaidExpenseCurrent_638780331339051293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638780331339041278" xlink:to="us-gaap_AssetsCurrent_638780331339051293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339041278" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638780331339051293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339041278" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638780331339051293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339041278" xlink:to="us-gaap_Assets_638780331339051293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="us-gaap_AccountsPayableCurrent_638780331339051293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638780331339051293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="cgtx_DeferredGrantIncomeCurrent_638780331339051293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638780331339051293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638780331339051293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="us-gaap_OtherLiabilitiesCurrent_638780331339061290" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339051293" xlink:to="us-gaap_LiabilitiesCurrent_638780331339061290" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331339061290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_Liabilities_638780331339061290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_CommitmentsAndContingencies_638780331339061290" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_StockholdersEquityAbstract_638780331339061290" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_PreferredStockValue_638780331339061290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638780331339061290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_CommonStockValue_638780331339061290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_AdditionalPaidInCapital_638780331339071276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638780331339071276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638780331339071276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638780331339061290" xlink:to="us-gaap_StockholdersEquity_638780331339071276" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638780331339051293" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638780331339071276" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638780331339071276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638780331339071276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesAuthorized_638780331339081275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesIssued_638780331339081275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_PreferredStockSharesOutstanding_638780331339081275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638780331339081275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_638780331339081275" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_638780331339081275" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_638780331339081275" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_638780331339081275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638780331339081275" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638780331339081275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638780331339081275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638780331339081275" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638780331339081275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638780331339081275" xlink:to="us-gaap_OperatingExpenses_638780331339091278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638780331339081275" xlink:to="us-gaap_OperatingIncomeLoss_638780331339091278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" xlink:to="cgtx_GrantIncome_638780331339091278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" xlink:to="us-gaap_OtherNoncashIncomeExpense_638780331339091278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638780331339091278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331339091278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638780331339091278" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638780331339091278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638780331339091278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications" xlink:label="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_638780331339091278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications_638780331339091278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638780331339101278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638780331339101278" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638780331339101278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638780331339101278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638780331339101278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638780331339101278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339101278" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638780331339101278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" xlink:to="cgtx_FollowOnPublicOfferingMember_638780331339101278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" xlink:to="cgtx_AtMarketOfferingMember_638780331339111276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingCommitmentSharesMember" xlink:label="cgtx_EquityLineFinancingCommitmentSharesMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" xlink:to="cgtx_EquityLineFinancingCommitmentSharesMember_638780331339111276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" xlink:to="cgtx_EquityLineFinancingMember_638780331339111276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339101278" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339111276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339101278" xlink:to="us-gaap_StatementEquityComponentsAxis_638780331339111276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638780331339111276" xlink:to="us-gaap_CommonStockMember_638780331339111276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638780331339111276" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638780331339111276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638780331339111276" xlink:to="us-gaap_RetainedEarningsMember_638780331339111276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638780331339111276" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638780331339111276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638780331339111276" xlink:to="us-gaap_EquityComponentDomain_638780331339111276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638780331339111276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339101278" xlink:to="us-gaap_StatementLineItems_638780331339111276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339111276" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockholdersEquity_638780331339121275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_SharesOutstanding_638780331339121275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638780331339121275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339121275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638780331339121275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339121275" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_638780331339121275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_638780331339121275" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_638780331339121275" xlink:to="cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_638780331339131298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638780331339131298" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary" xlink:label="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary_638780331339131298" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638780331339131298" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_NetIncomeLoss_638780331339131298" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_StockholdersEquity_638780331339131298" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638780331339131298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638780331339121275" xlink:to="us-gaap_SharesOutstanding_638780331339131298" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StatementTable_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339141307" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339141307" xlink:to="cgtx_FollowOnPublicOfferingMember_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339141307" xlink:to="us-gaap_StatementLineItems_638780331339141307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339141307" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339141307" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339141307" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339151336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339151336" xlink:to="cgtx_AtMarketOfferingMember_638780331339151336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339151336" xlink:to="cgtx_FollowOnPublicOfferingMember_638780331339151336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339151336" xlink:to="cgtx_EquityLineFinancingMember_638780331339151336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339141307" xlink:to="us-gaap_StatementLineItems_638780331339151336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_NetIncomeLoss_638780331339151336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638780331339151336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_ShareBasedCompensation_638780331339151336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638780331339151336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638780331339151336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_638780331339161306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing" xlink:label="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing_638780331339161306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638780331339151336" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInGrantReceivables" xlink:label="cgtx_IncreaseDecreaseInGrantReceivables_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="cgtx_IncreaseDecreaseInGrantReceivables_638780331339161306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638780331339161306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638780331339161306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent" xlink:label="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent_638780331339161306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638780331339161306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331339161306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638780331339161306" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638780331339161306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638780331339171286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638780331339171286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638780331339171286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339171286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331339171286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638780331339171286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638780331339171286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638780331339181347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_RepaymentsOfShortTermDebt_638780331339181347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638780331339171286" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638780331339181347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339181347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638780331339181347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_638780331339181347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339181347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638780331339181347" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339181347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339191309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_638780331339181347" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638780331339191309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638780331339191309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339151336" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638780331339191309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing" xlink:label="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638780331339191309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638780331339191309" xlink:to="cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing_638780331339191309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" xlink:type="extended" xlink:title="995210101 - Disclosure - Description of Business and Financial Condition" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638780331339191309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638780331339191309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638780331339201300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638780331339201300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="extended" xlink:title="995210301 - Disclosure - Financial Instruments and Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638780331339201300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638780331339201300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="995210401 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638780331339201300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638780331339201300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638780331339201300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638780331339201300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" xlink:title="995210601 - Disclosure - Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OtherCurrentLiabilitiesTextBlock" xlink:label="cgtx_OtherCurrentLiabilitiesTextBlock_638780331339211328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="cgtx_OtherCurrentLiabilitiesTextBlock_638780331339211328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638780331339211328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638780331339211328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638780331339211328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638780331339211328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensation" xlink:type="extended" xlink:title="995210901 - Disclosure - Equity-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638780331339221312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638780331339221312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211001 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638780331339221312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638780331339221312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlan" xlink:type="extended" xlink:title="995211101 - Disclosure - Retirement Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638780331339221312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638780331339221312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638780331339221312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638780331339221312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSegmentReporting" xlink:type="extended" xlink:title="995211301 - Disclosure - Segment Reporting" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638780331339231282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638780331339231282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638780331339231282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638780331339231282" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638780331339231282" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncomePolicyPolicyTextBlock" xlink:label="cgtx_GrantIncomePolicyPolicyTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_GrantIncomePolicyPolicyTextBlock_638780331339231282" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638780331339231282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638780331339231282" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638780331339241289" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638780331339241289" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638780331339241289" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638780331339241289" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638780331339241289" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638780331339241289" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638780331339241289" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638780331339241289" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638780331339241289" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638780331339241289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638780331339241289" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EmergingGrowthCompanyPolicyTextBlock" xlink:label="cgtx_EmergingGrowthCompanyPolicyTextBlock_638780331339251291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cgtx_EmergingGrowthCompanyPolicyTextBlock_638780331339251291" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638780331339251291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638780331339251291" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638780331339251291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638780331339251291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638780331339251291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638780331339251291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638780331339261283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638780331339261283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638780331339261283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LeaseCostTableTextBlock_638780331339261283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638780331339261283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638780331339261283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Equity-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638780331339261283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638780331339261283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638780331339271287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638780331339271287" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638780331339271287" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638780331339271287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638780331339271287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638780331339271287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638780331339271287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638780331339281289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSegmentReportingTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Segment Reporting (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638780331339281289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Description of Business and Financial Condition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638780331339281289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638780331339281289" xlink:to="srt_CounterpartyNameAxis_638780331339281289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638780331339281289" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339281289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339281289" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638780331339281289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638780331339281289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339281289" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638780331339281289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638780331339281289" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638780331339291278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339291278" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339291278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_FollowOnPublicOfferingMember" xlink:label="cgtx_FollowOnPublicOfferingMember_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339291278" xlink:to="cgtx_FollowOnPublicOfferingMember_638780331339291278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339291278" xlink:to="cgtx_AtMarketOfferingMember_638780331339291278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339291278" xlink:to="cgtx_EquityLineFinancingMember_638780331339291278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638780331339281289" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_MaximumAggregateOfferingPrice_638780331339291278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638780331339291278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339291278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339291278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm_638780331339291278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_PurchaseAgreementTerm_638780331339291278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638780331339301278" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_SharesIssuedPricePerShare_638780331339301278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638780331339301278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638780331339301278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638780331339301278" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_NetIncomeLoss_638780331339301278" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638780331339301278" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638780331339301278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638780331339291278" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638780331339301278" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339311288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339311288" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339311288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339311288" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339311288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339311288" xlink:to="us-gaap_EquipmentMember_638780331339311288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339311288" xlink:to="us-gaap_FurnitureAndFixturesMember_638780331339311288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339311288" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AllowanceForCreditLossGrantsReceivableCurrent" xlink:label="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="cgtx_AllowanceForCreditLossGrantsReceivableCurrent_638780331339311288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_GrantIncome" xlink:label="cgtx_GrantIncome_638780331339311288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="cgtx_GrantIncome_638780331339311288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredGrantIncomeCurrent" xlink:label="cgtx_DeferredGrantIncomeCurrent_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="cgtx_DeferredGrantIncomeCurrent_638780331339321279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638780331339321279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638780331339321279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638780331339321279" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="us-gaap_NumberOfOperatingSegments_638780331339321279" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339311288" xlink:to="us-gaap_UnrecognizedTaxBenefits_638780331339321279" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638780331339321279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638780331339321279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638780331339321279" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638780331339321279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638780331339321279" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638780331339331330" xlink:to="us-gaap_MoneyMarketFundsMember_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638780331339321279" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638780331339331330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638780331339331330" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638780331339331330" xlink:to="us-gaap_FairValueInputsLevel1Member_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638780331339331330" xlink:to="us-gaap_FairValueInputsLevel3Member_638780331339331330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638780331339321279" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638780331339331330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638780331339331330" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638780331339331330" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638780331339331330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638780331339331330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638780331339331330" xlink:to="us-gaap_AssetsFairValueDisclosure_638780331339331330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails" xlink:type="extended" xlink:title="99940303 - Disclosure - Financial Instruments and Fair Value Measurements - Unobservable Inputs under SAFE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339341291" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339341291" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339341291" xlink:to="us-gaap_EquipmentMember_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339341291" xlink:to="us-gaap_FurnitureAndFixturesMember_638780331339341291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638780331339341291" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638780331339341291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638780331339341291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638780331339351292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638780331339351292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638780331339341291" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638780331339351292" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638780331339351292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AccruedResearchAndDevelopmentExpenses" xlink:label="cgtx_AccruedResearchAndDevelopmentExpenses_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="cgtx_AccruedResearchAndDevelopmentExpenses_638780331339351292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638780331339351292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638780331339351292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638780331339351292" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638780331339361317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638780331339361317" xlink:to="us-gaap_DebtInstrumentAxis_638780331339361317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638780331339361317" xlink:to="us-gaap_DebtInstrumentNameDomain_638780331339361317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreementMember" xlink:label="cgtx_InsurancePremiumFinancingAgreementMember_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638780331339361317" xlink:to="cgtx_InsurancePremiumFinancingAgreementMember_638780331339361317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_InsurancePremiumFinancingAgreement2Member" xlink:label="cgtx_InsurancePremiumFinancingAgreement2Member_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638780331339361317" xlink:to="cgtx_InsurancePremiumFinancingAgreement2Member_638780331339361317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638780331339361317" xlink:to="us-gaap_DebtInstrumentLineItems_638780331339361317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638780331339361317" xlink:to="us-gaap_DebtInstrumentFaceAmount_638780331339361317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638780331339361317" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638780331339361317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638780331339361317" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638780331339361317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638780331339361317" xlink:to="us-gaap_ShortTermBorrowings_638780331339361317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths" xlink:label="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_638780331339361317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638780331339361317" xlink:to="us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths_638780331339361317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_AssetsAbstract_638780331339371294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLeaseAssets" xlink:label="cgtx_OperatingLeaseAssets_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339371294" xlink:to="cgtx_OperatingLeaseAssets_638780331339371294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638780331339371294" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638780331339371294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LiabilitiesAbstract_638780331339371294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638780331339371294" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638780331339371294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638780331339371294" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638780331339371294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638780331339371294" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638780331339371294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638780331339371294" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638780331339371294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638780331339371294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638780331339371294" xlink:to="us-gaap_OperatingLeaseLiability_638780331339371294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638780331339371294" xlink:to="us-gaap_OperatingLeaseExpense_638780331339381365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LossContingenciesTable_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638780331339381365" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638780331339381365" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceNewYorkMember" xlink:label="cgtx_OfficeSpaceNewYorkMember_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339381365" xlink:to="cgtx_OfficeSpaceNewYorkMember_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratoryAndOfficeSpacePittsburghPaMember" xlink:label="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638780331339381365" xlink:to="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638780331339381365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OfficeSpaceLocatedInPittsburghPaMember" xlink:label="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638780331339381365" xlink:to="cgtx_OfficeSpaceLocatedInPittsburghPaMember_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LaboratorySpacePittsburghPaMember" xlink:label="cgtx_LaboratorySpacePittsburghPaMember_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_638780331339381365" xlink:to="cgtx_LaboratorySpacePittsburghPaMember_638780331339381365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638780331339381365" xlink:to="us-gaap_LossContingenciesLineItems_638780331339381365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638780331339381365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638780331339381365" xlink:to="us-gaap_AreaOfRealEstateProperty_638780331339381365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars" xlink:label="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638780331339381365" xlink:to="cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars_638780331339391308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638780331339381365" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638780331339391308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638780331339381365" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638780331339391308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638780331339391308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638780331339391308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638780331339391308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638780331339391308" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638780331339391308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638780331339391308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638780331339401281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638780331339401281" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638780331339401281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638780331339391308" xlink:to="us-gaap_OperatingLeaseLiability_638780331339401281" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638780331339401281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638780331339401281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638780331339401281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638780331339401281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="99940704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6" xlink:to="us-gaap_OperatingLeasePayments_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stockholders' Equity - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638780331339411300" xlink:to="srt_CounterpartyNameAxis_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638780331339411300" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember" xlink:label="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339411300" xlink:to="cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LincolnParkCapitalFundLlcMember" xlink:label="cgtx_LincolnParkCapitalFundLlcMember_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638780331339411300" xlink:to="cgtx_LincolnParkCapitalFundLlcMember_638780331339411300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638780331339411300" xlink:to="us-gaap_TypeOfArrangementAxis_638780331339411300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638780331339411300" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember" xlink:label="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_638780331339411300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638780331339411300" xlink:to="cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_638780331339411300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638780331339411300" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638780331339421278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638780331339421278" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339421278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AtMarketOfferingMember" xlink:label="cgtx_AtMarketOfferingMember_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339421278" xlink:to="cgtx_AtMarketOfferingMember_638780331339421278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityLineFinancingMember" xlink:label="cgtx_EquityLineFinancingMember_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638780331339421278" xlink:to="cgtx_EquityLineFinancingMember_638780331339421278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638780331339411300" xlink:to="us-gaap_ClassOfStockLineItems_638780331339421278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_CommonStockSharesAuthorized_638780331339421278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638780331339421278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_CommonStockSharesIssued_638780331339421278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_CommonStockSharesOutstanding_638780331339421278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638780331339421278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_PreferredStockSharesAuthorized_638780331339421278" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638780331339431281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_DividendsCommonStock_638780331339431281" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumAggregateOfferingPrice" xlink:label="cgtx_MaximumAggregateOfferingPrice_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_MaximumAggregateOfferingPrice_638780331339431281" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_MaximumValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_MaximumValueOfStockToBeIssuedUnderAgreement_638780331339431281" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638780331339431281" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638780331339431281" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RemainingValueOfStockToBeIssuedUnderAgreement" xlink:label="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_RemainingValueOfStockToBeIssuedUnderAgreement_638780331339431281" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PurchaseAgreementTerm" xlink:label="cgtx_PurchaseAgreementTerm_638780331339431281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_PurchaseAgreementTerm_638780331339431281" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_OtherNoncashIncomeExpense_638780331339441282" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued" xlink:label="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued_638780331339441282" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_UnderwritersOptionToPurchaseAdditionalShares_638780331339441282" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="us-gaap_SaleOfStockPricePerShare_638780331339441282" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_ProceedsFromIssuanceInitialPublicOfferingGross_638780331339441282" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:label="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_638780331339441282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638780331339421278" xlink:to="cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses_638780331339441282" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Stockholders' Equity - Shares reserved for issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638780331339451281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Equity-based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339451281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339451281" xlink:to="us-gaap_PlanNameAxis_638780331339451281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638780331339451281" xlink:to="us-gaap_PlanNameDomain_638780331339451281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_AmendedAndRestatedEquityIncentivePlan2017Member" xlink:label="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638780331339451281" xlink:to="cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_638780331339451281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EquityIncentivePlan2021Member" xlink:label="cgtx_EquityIncentivePlan2021Member_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638780331339451281" xlink:to="cgtx_EquityIncentivePlan2021Member_638780331339451281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_EmployeeStockPurchasePlanMember" xlink:label="cgtx_EmployeeStockPurchasePlanMember_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638780331339451281" xlink:to="cgtx_EmployeeStockPurchasePlanMember_638780331339451281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339451281" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638780331339461279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638780331339461279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638780331339461279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber_638780331339461279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339451281" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638780331339461279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Equity-based Compensation - Fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_StatementTable_638780331339461279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339461279" xlink:to="srt_RangeAxis_638780331339461279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638780331339461279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638780331339461279" xlink:to="srt_RangeMember_638780331339461279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638780331339461279" xlink:to="srt_MinimumMember_638780331339471300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638780331339461279" xlink:to="srt_MaximumMember_638780331339471300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638780331339461279" xlink:to="us-gaap_StatementLineItems_638780331339471300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638780331339471300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638780331339471300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638780331339471300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638780331339471300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638780331339471300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638780331339471300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638780331339471300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638780331339471300" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Equity-based Compensation - Activity for options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638780331339561288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638780331339561288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339561288" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638780331339561288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638780331339561288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387803313395612881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387803313395612881" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638780331339561288" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638780331339561288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638780331339561288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638780331339571297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638780331339571297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638780331339571297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638780331339571297" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638780331339571297" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638780331339561288" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638780331339571297" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638780331339571297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638780331339571297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638780331339571297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638780331339571297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638780331339571297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638780331339571297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638780331339571297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638780331339581375" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Equity-based Compensation - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" xlink:to="us-gaap_AwardTypeAxis_638780331339581375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638780331339581375" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339581375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339581375" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638780331339581375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsPerformanceBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638780331339581375" xlink:to="cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_638780331339581375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_RestrictedStockUnitsTimeBasedVestingMember" xlink:label="cgtx_RestrictedStockUnitsTimeBasedVestingMember_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638780331339581375" xlink:to="cgtx_RestrictedStockUnitsTimeBasedVestingMember_638780331339581375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638780331339581375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" xlink:to="us-gaap_GranteeStatusAxis_638780331339581375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638780331339581375" xlink:to="us-gaap_GranteeStatusDomain_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638780331339591329" xlink:to="srt_DirectorMember_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_NonEmployeeDirectorMember" xlink:label="cgtx_NonEmployeeDirectorMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DirectorMember_638780331339591329" xlink:to="cgtx_NonEmployeeDirectorMember_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638780331339591329" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638780331339591329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" xlink:to="srt_RangeAxis_638780331339591329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638780331339591329" xlink:to="srt_RangeMember_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638780331339591329" xlink:to="srt_MinimumMember_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638780331339591329" xlink:to="srt_MaximumMember_638780331339591329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339581375" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638780331339591329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638780331339591329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638780331339601293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue_638780331339601293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638780331339601293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue_638780331339601293" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638780331339601293" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward_638780331339601293" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638780331339601293" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding" xlink:label="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_638780331339601293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339591329" xlink:to="cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding_638780331339601293" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339611293" xlink:to="us-gaap_AwardTypeAxis_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339611293" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339611293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638780331339611293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638780331339611293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638780331339621295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638780331339621295" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638780331339621295" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638780331339621295" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638780331339611293" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638780331339621295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638780331339621295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638780331339621295" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638780331339621295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638780331339621295" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387803313396212951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638780331339621295" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387803313396212951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Equity-based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638780331339631286" xlink:to="us-gaap_IncomeStatementLocationAxis_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638780331339631286" xlink:to="us-gaap_IncomeStatementLocationDomain_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638780331339631286" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638780331339631286" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638780331339631286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638780331339631286" xlink:to="us-gaap_AwardTypeAxis_638780331339631286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638780331339631286" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_PerformanceBasedStockOptionsMember" xlink:label="cgtx_PerformanceBasedStockOptionsMember_638780331339631286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638780331339631286" xlink:to="cgtx_PerformanceBasedStockOptionsMember_638780331339631286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638780331339631286" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638780331339641294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638780331339641294" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638780331339641294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638780331339641294" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638780331339641294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638780331339641294" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638780331339641294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638780331339641294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638780331339641294" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638780331339641294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638780331339641294" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638780331339641294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638780331339641294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638780331339641294" xlink:to="us-gaap_StockOptionMember_638780331339641294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638780331339641294" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638780331339651296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638780331339641294" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638780331339651296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638780331339651296" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638780331339651296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Retirement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638780331339651296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_1" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638780331339651296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Income Taxes - Net loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638780331339651296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638780331339651296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638780331339661283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_NetIncomeLoss_638780331339661283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638780331339661283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638780331339661283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638780331339661283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638780331339661283" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_638780331339661283" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638780331339661283" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638780331339661283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638780331339661283" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638780331339671294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638780331339671294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638780331339671294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="cgtx_DeferredTaxAssetsOperatingLeaseLiabilities_638780331339671294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638780331339671294" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638780331339671294" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsOther_638780331339671294" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638780331339671294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsGross_638780331339671294" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638780331339681285" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638780331339671294" xlink:to="us-gaap_DeferredTaxAssetsNet_638780331339681285" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638780331339681285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638780331339681285" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638780331339681285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638780331339681285" xlink:to="cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638780331339681285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638780331339681285" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638780331339681285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638780331339681285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638780331339681285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638780331339691346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638780331339691346" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638780331339691346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638780331339691346" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638780331339691346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638780331339691346" xlink:to="us-gaap_DomesticCountryMember_638780331339691346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638780331339691346" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638780331339691346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638780331339691346" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638780331339691346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638780331339691346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638780331339691346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638780331339691346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="cgtx_OperatingLossCarryForwardsSubjectToExpiration_638780331339691346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="cgtx_OperatingLossCarryForwardsNotSubjectToExpiration_638780331339701325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="us-gaap_OperatingLossCarryforwards_638780331339701325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638780331339691346" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_638780331339701325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cogrx.com/role/DisclosureSegmentReportingDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Segment Reporting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638780331339701325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638780331339701325" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638780331339701325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638780331339701325" xlink:to="us-gaap_SegmentDomain_638780331339701325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_LifeScienceSegmentMember" xlink:label="cgtx_LifeScienceSegmentMember_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638780331339701325" xlink:to="cgtx_LifeScienceSegmentMember_638780331339701325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638780331339701325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638780331339701325" xlink:to="us-gaap_SegmentReportingInformationLineItems_638780331339701325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638780331339701325" xlink:to="us-gaap_NumberOfOperatingSegments_638780331339711285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentGrantIncome" xlink:label="cgtx_SegmentGrantIncome_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638780331339701325" xlink:to="cgtx_SegmentGrantIncome_638780331339711285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_SegmentExpensesAbstract" xlink:label="cgtx_SegmentExpensesAbstract_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638780331339701325" xlink:to="cgtx_SegmentExpensesAbstract_638780331339711285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentClinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentClinicalPrograms_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="cgtx_ResearchAndDevelopmentClinicalPrograms_638780331339711285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPersonnel" xlink:label="cgtx_ResearchAndDevelopmentPersonnel_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="cgtx_ResearchAndDevelopmentPersonnel_638780331339711285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentPreclinicalPrograms" xlink:label="cgtx_ResearchAndDevelopmentPreclinicalPrograms_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="cgtx_ResearchAndDevelopmentPreclinicalPrograms_638780331339711285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cgtx-20241231.xsd#cgtx_ResearchAndDevelopmentManufacturing" xlink:label="cgtx_ResearchAndDevelopmentManufacturing_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="cgtx_ResearchAndDevelopmentManufacturing_638780331339711285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638780331339711285" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638780331339711285" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638780331339711285" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638780331339711285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cgtx_SegmentExpensesAbstract_638780331339711285" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638780331339711285" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638780331339721288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638780331339701325" xlink:to="us-gaap_NetIncomeLoss_638780331339721288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 17, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COGNITION THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4365359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2500 Westchester Ave.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Purchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-2210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,312,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,972,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><span style="font-size:8pt;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,009<span></span>
</td>
<td class="nump">$ 29,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivables</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">3,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,555<span></span>
</td>
<td class="nump">34,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,234<span></span>
</td>
<td class="nump">35,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">3,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,620<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,142<span></span>
</td>
<td class="nump">10,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,484<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 250,000,000 shares authorized; 59,854,877 and 32,165,478 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">193,850<span></span>
</td>
<td class="nump">165,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(175,160)<span></span>
</td>
<td class="num">(141,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">24,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 30,234<span></span>
</td>
<td class="nump">$ 35,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,854,877<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">59,854,877<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 41,676<span></span>
</td>
<td class="nump">$ 37,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,290<span></span>
</td>
<td class="nump">13,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">53,966<span></span>
</td>
<td class="nump">50,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(53,966)<span></span>
</td>
<td class="num">(50,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="nump">19,549<span></span>
</td>
<td class="nump">24,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other income, net</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss on currency translation from liquidation of subsidiary</a></td>
<td class="num">(195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">19,995<span></span>
</td>
<td class="nump">24,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,971)<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications', window );">Foreign currency translation adjustment, including reclassifications</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (33,776)<span></span>
</td>
<td class="num">$ (25,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">39,730,148<span></span>
</td>
<td class="nump">30,029,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">39,730,148<span></span>
</td>
<td class="nump">30,029,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including reclassifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Follow-on Public Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Follow-on Public Offering </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Follow-on Public Offering</div></th>
<th class="th">
<div>At The Market Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>At The Market Offering </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th">
<div>Equity Line Financing Commitment Shares </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Equity Line Financing Commitment Shares </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Equity Line Financing Commitment Shares</div></th>
<th class="th">
<div>Equity Line Financing </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Equity Line Financing </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Equity Line Financing</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 155,820<span></span>
</td>
<td class="num">$ (115,401)<span></span>
</td>
<td class="num">$ (199)<span></span>
</td>
<td class="nump">$ 40,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,991,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5,124<span></span>
</td>
<td class="nump">$ 5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">165,826<span></span>
</td>
<td class="num">(141,189)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="nump">24,474<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 11,888<span></span>
</td>
<td class="nump">$ 11,896<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 12,434<span></span>
</td>
<td class="nump">$ 12,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">7,557,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,913,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,913,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary', window );">Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,971)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 193,850<span></span>
</td>
<td class="num">$ (175,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,854,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to vesting of Restricted Stock Units during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, discounts and offering costs</a></td>
<td class="nump">$ 1,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,971)<span></span>
</td>
<td class="num">$ (25,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss on currency translation from liquidation of subsidiary</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing', window );">Issuance of common stock as commitment shares for equity line financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInGrantReceivables', window );">Grant receivables</a></td>
<td class="num">(1,405)<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent', window );">Deferred grant income and other liabilities</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(1,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,474)<span></span>
</td>
<td class="num">(16,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments for property and equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes on vested restricted stock units</a></td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on loan payable</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,565<span></span>
</td>
<td class="nump">4,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(4,913)<span></span>
</td>
<td class="num">(11,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">29,922<span></span>
</td>
<td class="nump">41,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">25,009<span></span>
</td>
<td class="nump">29,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing', window );">Prepayment of insurance through third-party financing</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">12,454<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 11,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current deferred grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IncreaseDecreaseInGrantReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase and decrease in grant receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IncreaseDecreaseInGrantReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments relating to commitment shares issued for equity line financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of insurance through third-party financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Financial Condition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">1. Description of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. The Company&#8217;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company ceased operations at Cognition Therapeutics PTY LTD, a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) and completed its liquidation of the Subsidiary (the &#8220;Liquidation&#8221;). In accordance with the Liquidation, the Company removed the Accumulated Other Comprehensive Income (AOCI) balance associated with the currency translation adjustments and recorded a loss on liquidation of the Subsidiary in accumulated deficit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (the &#8220;Sales Agents&#8221;) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). During the year ended December 31, 2024, the Company sold 19,913,189 shares of its common stock pursuant to the ATM for net proceeds of approximately $12,454. Please refer to Note 8 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="background:#ffffff;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) for an equity line financing (the &#8220;Purchase Agreement&#8221;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to </span><span style="background:#ffffff;">$35,000</span><span style="background:#ffffff;">&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;</span><span style="background:#ffffff;">36-month</span><span style="background:#ffffff;">&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued </span><span style="background:#ffffff;">189,856</span><span style="background:#ffffff;"> shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, </span><span style="background:#ffffff;">$34,795</span><span style="background:#ffffff;">&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">On March 14, 2024, the Company closed a follow-on public offering of 6,571,428 shares of the Company&#8217;s common stock at a public offering price of $1.75 per share (&#8220;March 2024 Offering&#8221;). As part of the March 2024 Offering, the underwriters exercised their option to purchase 985,714 shares of the Company&#8217;s common stock on March 28, 2024, at a public offering price of $1.75 per share. The gross proceeds from the March 2024 Offering were $13,225 and the net proceeds were approximately $11,896, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Going Concern </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $33,971 for the year ended December 31, 2024 and $25,788 for the year ended December 31, 2023. As of December 31, 2024 and 2023, the Company had cash and cash equivalents of $25,009 and $29,922, respectively. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $175,160 as of December 31, 2024. The Company expects to continue to incur losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of March 20, 2025, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of December 31, 2024, is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (&#8220;NIA&#8221;) a division of the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2024 and 2023, the Company generated grant income of $19,549 and $24,805, respectively, primarily from reimbursements from the NIA for aging research. For the year ended December 31, 2024 and 2023, deferred grant income was $1,066 and $1,701, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the financings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_jnCsFL2IEUeXVQTdgotWyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under ASC 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement is a lease at its inception. Leases are classified as either operating or finance, based on the Company&#8217;s evaluation of certain criteria. If a lease has a term greater than one year, the lease is recognized in the balance sheet as a right-of-use asset and a lease liability at lease commencement. The Company elected the short-term lease practical expedient, therefore, if a lease has a term less than one year, the Company will not recognize the lease on its balance sheet. The right-of-use asset represents the Company&#8217;s right of use to an underlying asset for the term of the lease and the lease liability represents the Company&#8217;s obligation to make lease payments arising from the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If the Company&#8217;s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease right-of-use assets and operating lease liabilities are determined and recognized on the commencement date of the lease based on the present value of lease payments over the term of the lease. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease, and right-of-use assets are subsequently re-measured to reflect the effect of uneven lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">For finance leases, right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset. Expenses for finance leases include the amortization of right-of-use assets, which is recorded as depreciation and amortization expense, and interest expense, which reflects interest accrued on the lease liability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2024 and 2023 that met the recognition threshold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to note 9 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Comprehensive Gain</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $0 and $4 in other comprehensive gain related to foreign currency translation for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 13 &#8211; Segment Reporting for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 13 - Segment Reporting for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">3. Financial Instruments and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Financial assets and liabilities measured at fair value are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">There were no Level 3 financial instruments during the year ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Property and equipment, net, consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,333</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 284</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2024 and 2023 was $107 and $96, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Accrued expense consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,165</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,520</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OtherCurrentLiabilitiesTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">6. Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $544 and the amount was paid off in <span style="-sec-ix-hidden:Hidden_Z7RNwB4W3kOANqH6RLEDhQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span>. In October 2024, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $356 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $41, including interest and principal, are due monthly from November 2024 through July 2025. As of December 31, 2024, the outstanding principal of the loan was $279.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">7. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2024 and 2023 were as follows, in thousands:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease costs for the year ended December 31, 2024 and 2023 was $218 and $215, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 158</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 92</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 605</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 535</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating cash flows used for operating leases for the year ended December 31, 2024 and 2023 was $224 and $209, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">As of December&#160;31, 2024 and 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common and Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2024 and 2023, there were 59,854,877 and 32,165,478 shares of common stock <span style="-sec-ix-hidden:Hidden_1URyjcdy8kqivgwhPCDv3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_S56iJzBGFkm4V3mtGIvG2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2024, no dividends on common stock had been declared by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000&#160;in aggregate (the &#8220;Shelf&#8221;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;19,913,189&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2024 for gross proceeds of approximately $12,840. As of December 31, 2024, there was $21,874&#160;remaining of common stock available for sale under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000&#160;of shares of common stock in the Company&#8217;s sole discretion, over a&#160;36-month&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;189,856&#160;shares of its common stock as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under the Purchase Agreement (the &#8220;Commitment Shares&#8221;). The Company recorded $318&#160;to other expense, net during the year ended December 31, 2023 in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;125,000&#160;shares of common stock to Lincoln Park for proceeds of $205, as part of the equity line financing arrangement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, $34,795&#160;was available to draw pursuant to the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">March 2024 Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;">In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwriters&#8217; option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwriters&#8217; option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">9. Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On October 7, 2021, the date upon which the Company&#8217;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,587,917. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by 643,309 shares, representing 2% of total common shares outstanding at December 31, 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#8217;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#8217;s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#8220;2007 Plan&#8221; and collectively with the 2017 Plan, the &#8220;Prior Plans&#8221;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2017, the Company&#8217;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#8217;s common stock at a discounted purchase price. As of December 31, 2024, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.78%&#8201;&#8211;&#8201;92.29%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.47%&#8201;&#8211;&#8201;92.68%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.23%&#8201;&#8211;&#8201;4.45%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46%&#8201;&#8211;&#8201;4.71%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.08 &#8211; 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.18&#8201;&#8211;&#8201;6.37</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8201;&#8212;&#8201;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8201;&#8212;&#8201;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8201;&#8212;&#8201;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Yield</i>&#8201;&#8212;&#8201;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">Activity for options was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:61.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 247,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (93,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,353,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,688,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The weighted-average grant date fair value of stock options granted was $1.56 and $1.56 during the years ended December 31, 2024 and 2023, respectively. There were 247,500 stock options granted at an aggregate fair value of $385 for the year ended December 31, 2024 and 628,769 stock options granted at an aggregate fair value of $983 for the year ended December 31, 2023. During the year ended December 31, 2024 and 2023, there were 93,350 and 0 stock options </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exercised, respectively, with an aggregate grant date fair value of $58 and $0, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2024 and 2023 was $121 and $0, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The fair values of RSUs are based on the fair market value of the Company&#8217;s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock upon vesting. RSUs with time base vesting conditions for employees vest annually over <span style="-sec-ix-hidden:Hidden_z0Vdnv6oQU-dhLEWmZmyvg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or four years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. RSUs with performance conditions for employee&#8217;s vest on the one-year anniversary of the performance achievement date, assuming continued service from the employee during that period of time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024 and 2023, the Company granted 358,200 and 542,419 RSUs awards, respectively, containing time based vesting conditions to employees and non-employee directors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024 and 2023, the Company granted 515,600 and 0 RSUs awards, respectively, containing performance based vesting conditions to employees. During the year ended December 31, 2024, the performance conditions were achieved and RSUs will vest on the one-year anniversary of the achievement of the performance condition. As of December 31, 2024, the Company had no outstanding performance condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s RSU activity for the year ended December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 873,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.17</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.89</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,172,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.98</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 670</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,684</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,354</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, total future compensation expense related to unvested time-based awards yet to be recognized by the Company was $2,055, which is expected to be recognized over a weighted-average remaining vesting period of approximately 1.9 years. As of December 31, 2024, total future compensation expense related to unvested performance-based awards yet to be recognized by the Company was $462, which is expected to be recognized over a weighted-average remaining vesting period of approximately 0.8 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">10. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,353,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,213,405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,172,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,526,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,735,560</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">11. Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#8217; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $265 and $199 for the&#160;year ended December&#160;31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The net loss consists of the following components:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,767)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,788)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;">The Company&#8217;s deferred tax assets and liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,847</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,112</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 407</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 148</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,371</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 246</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,354</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,207)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2024 and 2023. Management has considered the Company&#8217;s history of cumulative net losses and has concluded as of December 31, 2024 and 2023, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. The valuation allowance increased by $7,193 and $5,772 for the years ended December 31, 2024 and 2023, respectively. The increase in valuation allowance in 2024 was primarily a result of operating losses and tax credits generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company incurred net operating losses (&#8220;NOL&#8221;) since inception through December 31, 2021 and year ended December 31, 2024. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2024, the Company had federal net operating loss carryforwards of $38,063, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $38,063 is $11,503 that begin to expire in 2035 and $26,560 that can be carried forward indefinitely. As of December 31, 2024, the Company had state net operating loss carryforwards of $12,613, available to reduce future state taxable income, which will begin to expire in 2028. During the year ended December 31, 2024, the Company ceased operations of its wholly owned foreign subsidiary. As a result, all foreign net operating loss and research tax credit carryforwards were written off with an offsetting decrease to the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">Utilization of the Company&#8217;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $589 of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2024 and determined that it is more-likely-than-not that the Company&#8217;s existing net operating loss and research and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2021; however, carryforward attributes that were generated prior to January 1, 2021 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">13. Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#8217;s Chief Executive Officer (CEO) serves as the CODM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#8217;s consolidated net loss. The measure of segment assets is reported on the consolidated balance sheets as total assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,805</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,180</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">R&amp;D Personnel costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,523</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,503</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,890</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 430</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,844</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,354</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (131)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment and consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,788)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> R&amp;D Personnel costs exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup> General and administrative expenses exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt 0pt 0pt 56.15pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup> Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (33,971)<span></span>
</td>
<td class="num">$ (25,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cyber Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. has implemented and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises. We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate. Employees are required to complete an annual cybersecurity awareness training program designed to raise awareness of cybersecurity threats across functions, as well as to encourage consideration of cybersecurity risks across our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As part of our cybersecurity risk management, we have adopted an incident response plan that has been designed to identify and manage significant events that may impact our information technology infrastructure, including those arising from or related to cybersecurity threats. We recently tested our incident response plan using a tabletop exercise with the goal of improving our processes and preparedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not materially affected, and we do not believe they are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats related to our data and systems, including phishing attacks. For more information about risks from cybersecurity threats, see the risk factor entitled &#8220;Significant disruptions of information technology systems and infrastructure, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition&#8221; included in Item 1A &#8220;Risk Factors.&#8221; </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cognition Therapeutics, Inc. has implemented and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises. We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate. Employees are required to complete an annual cybersecurity awareness training program designed to raise awareness of cybersecurity threats across functions, as well as to encourage consideration of cybersecurity risks across our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">As part of our cybersecurity risk management, we have adopted an incident response plan that has been designed to identify and manage significant events that may impact our information technology infrastructure, including those arising from or related to cybersecurity threats. We recently tested our incident response plan using a tabletop exercise with the goal of improving our processes and preparedness.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Governance Related to Cybersecurity Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Corporate Controller reports to and meets with the Chief Financial Officer periodically to discuss and review risk management processes related to cybersecurity and potential cybersecurity risks, with input from the Company&#8217;s third-party information technology advisor as appropriate. The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter. The audit committee is responsible for discussing cybersecurity-related risks with management, including the steps management has taken to monitor and control such risks, including our risk assessment and risk management policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors. The board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The board of directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter.The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors. The board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Grant Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (&#8220;NIA&#8221;) a division of the National Institute of Health (&#8220;NIH&#8221;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncomePolicyPolicyTextBlock', window );">Grant income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2024 and 2023, the Company generated grant income of $19,549 and $24,805, respectively, primarily from reimbursements from the NIA for aging research. For the year ended December 31, 2024 and 2023, deferred grant income was $1,066 and $1,701, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#8220;CROs&#8221;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#8217;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the financings. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be <span style="-sec-ix-hidden:Hidden_jnCsFL2IEUeXVQTdgotWyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2024 or 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#8217;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under ASC 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement is a lease at its inception. Leases are classified as either operating or finance, based on the Company&#8217;s evaluation of certain criteria. If a lease has a term greater than one year, the lease is recognized in the balance sheet as a right-of-use asset and a lease liability at lease commencement. The Company elected the short-term lease practical expedient, therefore, if a lease has a term less than one year, the Company will not recognize the lease on its balance sheet. The right-of-use asset represents the Company&#8217;s right of use to an underlying asset for the term of the lease and the lease liability represents the Company&#8217;s obligation to make lease payments arising from the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">If the Company&#8217;s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease right-of-use assets and operating lease liabilities are determined and recognized on the commencement date of the lease based on the present value of lease payments over the term of the lease. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease, and right-of-use assets are subsequently re-measured to reflect the effect of uneven lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">For finance leases, right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset. Expenses for finance leases include the amortization of right-of-use assets, which is recorded as depreciation and amortization expense, and interest expense, which reflects interest accrued on the lease liability. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2024 and 2023 that met the recognition threshold.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Following the provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to note 9 for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the Company&#8217;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8201;&#8212;&#8201;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8201;&#8212;&#8201;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8201;&#8212;&#8201;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></td></tr></table><div style="margin-top:6pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Gain</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other Comprehensive Gain</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $0 and $4 in other comprehensive gain related to foreign currency translation for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates and manages one operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 13 &#8211; Segment Reporting for more information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 13 - Segment Reporting for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements</i> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of financial assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,999</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Priced&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td></tr><tr><td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,391</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,333</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td></tr><tr><td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 284</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,165</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,520</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Professional fees and other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 657</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the lease term and discount rate as of December 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8.1%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum lease commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 158</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 92</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 605</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 535</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.78%&#8201;&#8211;&#8201;92.29%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">91.47%&#8201;&#8211;&#8201;92.68%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.23%&#8201;&#8211;&#8201;4.45%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.46%&#8201;&#8211;&#8201;4.71%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td></tr><tr><td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.08 &#8211; 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.18&#8201;&#8211;&#8201;6.37</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of activity for options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:61.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;000&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;Years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,213,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 247,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (93,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,353,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,688,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.3</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock units award activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 873,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.17</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.89</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,172,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.98</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total equity-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 670</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,684</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,354</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,353,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,213,405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,172,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 522,155</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,526,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,735,560</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of net loss components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,767)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,788)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the expected income tax (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax computed at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D Credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,847</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,112</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 407</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 148</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,371</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 246</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,354</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,207)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (139)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment significant expense categories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,805</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,180</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">R&amp;D Personnel costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,523</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,503</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,890</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 430</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,844</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,354</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (131)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment and consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,788)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> R&amp;D Personnel costs exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup> General and administrative expenses exclude equity-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt 0pt 0pt 56.15pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup> Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Financial Condition (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,971<span></span>
</td>
<td class="nump">$ 25,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,009<span></span>
</td>
<td class="nump">29,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,160<span></span>
</td>
<td class="nump">141,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">6,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares (in shares)</a></td>
<td class="nump">985,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="nump">$ 13,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="nump">$ 11,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,913,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,454<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember', window );">Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember', window );">Lincoln Park | Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Description of Business and Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PurchaseAgreementTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement', window );">Amount available to draw under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_RemainingValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent', window );">Allowance for doubtful accounts on grants receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_GrantIncome', window );">Grant income</a></td>
<td class="nump">19,549<span></span>
</td>
<td class="nump">$ 24,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredGrantIncomeCurrent', window );">Deferred grant income, current</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">$ 1,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive gain related to foreign currency translation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property and equipment</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AllowanceForCreditLossGrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on grants receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AllowanceForCreditLossGrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of deferred grant income as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 23,999<span></span>
</td>
<td class="nump">$ 29,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">23,999<span></span>
</td>
<td class="nump">29,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">23,999<span></span>
</td>
<td class="nump">29,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 23,999<span></span>
</td>
<td class="nump">$ 29,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">$ 1,526<span></span>
</td>
<td class="nump">$ 1,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_AccruedResearchAndDevelopmentExpenses', window );">Research and development costs</a></td>
<td class="nump">5,654<span></span>
</td>
<td class="nump">2,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other accruals</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 7,620<span></span>
</td>
<td class="nump">$ 4,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember', window );">Insurance Premium Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths', window );">Repayment of short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member', window );">Insurance Premium Financing Agreement 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months. Includes repayments of short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreement2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease assets</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease costs</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease assets as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember', window );">Purchase, New York office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember', window );">Pittsburgh, Pennsylvania laboratory and office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember', window );">Pittsburgh, PA office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratorySpacePittsburghPaMember', window );">Pittsburgh, PA lab space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars', window );">Number of options at conclusion of the lease term | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of buyout options in dollars in an operating lease under the lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratoryAndOfficeSpacePittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_OfficeSpaceLocatedInPittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratorySpacePittsburghPaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgtx_LaboratorySpacePittsburghPaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Term And Discount (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,854,877<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,854,877<span></span>
</td>
<td class="nump">32,165,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividend declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 666<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,913,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,454<span></span>
</td>
<td class="nump">5,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued', window );">Remaining of common stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember', window );">Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember', window );">Underwriting Agreement With Titan Partners Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,557,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,714<span></span>
</td>
<td class="nump">985,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds</a></td>
<td class="nump">$ 11,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember', window );">Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember', window );">Lincoln Park | Equity Line Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement', window );">Maximum value of stock to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement', window );">Amount available to draw under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_PurchaseAgreementTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_MaximumValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum equity impact of the value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_MaximumValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_RemainingValueOfStockToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining value of new stock to be issued under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_RemainingValueOfStockToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining value of stock to be issued under shares offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of underwriting discounts, commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 15, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member', window );">Amended and Restated 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,587,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">643,309<span></span>
</td>
<td class="nump">7,543,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber', window );">Number of shares that may be recycled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Fair value of options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">91.78%<span></span>
</td>
<td class="nump">91.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.29%<span></span>
</td>
<td class="nump">92.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 4 months 13 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Activity for options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">4,213,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">247,500<span></span>
</td>
<td class="nump">628,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(93,350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(12,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">4,353,490<span></span>
</td>
<td class="nump">4,213,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,688,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired (in dollars per share)</a></td>
<td class="nump">2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">4.67<span></span>
</td>
<td class="nump">$ 4.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life -Exercisable</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">247,500<span></span>
</td>
<td class="nump">628,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue', window );">Fair value of options granted | $</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">93,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue', window );">Fair value of options exercised | $</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised | $</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">358,200<span></span>
</td>
<td class="nump">542,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward', window );">Number of shares issuable for each award</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsPerformanceBasedVestingMember', window );">Restricted Stock Units Performance Based Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding', window );">Share based compensation arrangement by share based payment award number of targets outstanding | item</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsPerformanceBasedVestingMember', window );">Restricted Stock Units Performance Based Vesting | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">515,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember', window );">Restricted Stock Units Time Based Vesting | Non Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember', window );">Restricted Stock Units Time Based Vesting | Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember', window );">Restricted Stock Units Time Based Vesting | Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for each award under share-based payment arrangement.












ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of targets outstanding under the share based arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsPerformanceBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsPerformanceBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=cgtx_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=cgtx_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSU activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance | shares</a></td>
<td class="nump">522,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">873,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(183,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(39,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance | shares</a></td>
<td class="nump">1,172,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Equity based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance | $ / shares</a></td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 4,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to options</a></td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which the unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgtx_PerformanceBasedStockOptionsMember', window );">Performance-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to options</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which the unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 2,668<span></span>
</td>
<td class="nump">$ 3,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgtx_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgtx_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">5,526,454<span></span>
</td>
<td class="nump">4,735,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">4,353,490<span></span>
</td>
<td class="nump">4,213,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common stock equivalents outstanding</a></td>
<td class="nump">1,172,964<span></span>
</td>
<td class="nump">522,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employees' compensation per person per year matched by the Company</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Matching contributions to the plan</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (33,971)<span></span>
</td>
<td class="num">$ (25,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,971)<span></span>
</td>
<td class="num">$ (25,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax benefit (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate (as percentage)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as percentage)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as percentage)</a></td>
<td class="num">(21.10%)<span></span>
</td>
<td class="num">(22.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">R&amp;D Credit (as percentage)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Non-deductible stock compensation (as percentage)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other (as percentage)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,491<span></span>
</td>
<td class="nump">$ 6,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">3,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenditures</a></td>
<td class="nump">16,089<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred grant income</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">29,510<span></span>
</td>
<td class="nump">22,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(29,400)<span></span>
</td>
<td class="num">(22,207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets after valuation allowance</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">$ (110)<span></span>
</td>
<td class="num">$ (147)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">7,193<span></span>
</td>
<td class="nump">$ 5,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration', window );">Operating loss carryforwards that expire</a></td>
<td class="nump">11,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration', window );">Operating loss carryforwards that do not expire</a></td>
<td class="nump">26,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">38,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 12,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_OperatingLossCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_OperatingLossCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SegmentExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 12,290<span></span>
</td>
<td class="nump">$ 13,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,971)<span></span>
</td>
<td class="num">(25,788)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cgtx_LifeScienceSegmentMember', window );">Life science segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SegmentGrantIncome', window );">Grant Income</a></td>
<td class="nump">19,549<span></span>
</td>
<td class="nump">24,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_SegmentExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentClinicalPrograms', window );">Clinical programs</a></td>
<td class="nump">27,675<span></span>
</td>
<td class="nump">21,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentPersonnel', window );">R&amp;D Personnel costs</a></td>
<td class="nump">9,672<span></span>
</td>
<td class="nump">8,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentPreclinicalPrograms', window );">Preclinical programs</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgtx_ResearchAndDevelopmentManufacturing', window );">Manufacturing</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expenses</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,622<span></span>
</td>
<td class="nump">9,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">$ (446)<span></span>
</td>
<td class="num">$ (131)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentClinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development incurred on clinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentClinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development incurred on manufacturing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentPersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development incurred on personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentPersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_ResearchAndDevelopmentPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development incurred on preclinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_ResearchAndDevelopmentPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_SegmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_SegmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgtx_SegmentGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to grants specific to company life science segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgtx_SegmentGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cgtx_LifeScienceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cgtx_LifeScienceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>137
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /0Y=%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /0Y=%H #MP\\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=ZZ:1D24=<+B!-(2$P"<8L2
M;XO6-%%BU.[M2</6@> !.,;^\_FSY%9YH5S Y^ \!C(8KR;;#U$HOV9[(B\
MHMJCE;%,B2$UMRY82>D9=N"E.L@=0EU5-V"1I)8D8086?B&RKM5*J("27#CA
MM5KP_B/T&:858(\6!XK 2PZLFR?ZX]2W< ',,,)@XU<!]4+,U3^QN0/LE)RB
M65+C.)9CDW-I!PYO3X\O>=W"#)'DH##]BD;0T>.:G2>_-G?WFP?6U56]*JJF
MJ*L-YX*O1'/[/KO^\+L(6Z?-UOPOXVO^S?@LV+7PZRZZ3U!+ P04    " #T
M.71:F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( /0Y=%H9E-H1H@@  .\T   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM9MM<]JX%L>_BH;=Z>S.A. G2-(F
MF2&0=-EM4VZ@V]OM[ MABZ"I;;&2G(=O?X]LL'%7%OB.>)-@X_.W]4.6SU\Z
MOGQF_+M8$2+12Q*GXJJSDG+]MM<3X8HD6)RR-4GAFR7C"9:PR1][8LT)CO*@
M).YYCC/H)9BFG>O+?-^47U^R3,8T)5..1)8DF+_>D)@]7W7<SG;' WU<2;6C
M=WVYQH]D1N3G]93#5J]4B6A"4D%9BCA97G6&[MMQD ?D1_Q)R;/8^8Q44Q:,
M?5<;D^BJXZ@K(C$)I9+ \.^)C$@<*R6XCG\VHIWRG"IP]_-6_2YO/#1F@049
ML?@+C>3JJG/>01%9XBR6#^SY-[)I4%_IA2P6^5_T7!S;]SLHS(1DR288KB"A
M:?$?OVQ [ 2<.PT!WB; ^R' #1H"_$V ?VA L D(<C)%4W(.8RSQ]25GSXBK
MHT%-?<AAYM'0?)JJWWTF.7Q+(4Y>CUF8P<\H$4XC=)M**E_1)"WZD_I=NNCS
M;(Q^^?G7RYZ$TZF@7KB1OBFDO09IUT,?62I7 G0C$M4%>G"=Y<5ZVXN]\8R*
M8Q*>(M\]09[C!9H+&IG#/V)^BMRS/+RO"1^;PW_/4CB[HSM[K35^B=[/]?S_
M$_VWX4)(#C?&WSKVA7:@UU:CQ5NQQB&YZL!P( A_(IWK-S^Y ^>=CIM-L;$E
ML1K3H&0:F-0KIO/7-=%A,X>[3O</'1]C5%L^EL1J?/HEG_YA?(9IFN$8/9 U
MXU('RJPC>:;#.S)&M05E2:P&:E""&AS8D3B&AUQ^0S;#,FLM<2RTM(QA;6E9
M$JO1.BMIG1U&:THX96HTBQ \CK1WX!ZE[1#?.,8;X]M"LR16@W9>0CLW-G5&
MPHQ#SR("#4.)[FA,T'V6+ C783-K.8[;#9SS\X&.F#&T+3%+8C5B%R6Q"V,K
M-P_)!_)(U9,1^ML]3K2=S*PS^O3^?C*??+I'\]]N'X;3V\_SR6AV4ESGY'YT
MJJ-HE&Q+T9)8C:+K5#F?<PC'21HR#D-:GFZ<H)F$.Q8QCD8L2R5_A?^1%NX>
M]?&M#I\YJ"T_6VIU@#M)LWL(P#E^09,(QCVZI&&1M#7?P'LD7;\;^(.^W[_0
MTC,&MZ9G2:U.SZOH>8?0&T81J(N3[0?T 8Y#GU)]GS-+>GW'05^(D."+A20<
M#9^(]BXVZ[0&:4FM#K(R$*XQE_X7R)':@AMXSIY3+42SW#3CX0KK4Q5S:&MN
MQ_ (;F427'.:_R.W<N2;<O9$TU#? \V:]U^UV*PZ!UMJ=6R5=W#-2?^/V*9,
M2/ 0?]%U\Z/"K.@Z_;,S+3>K1L*66IU;925<<_Z?WY9#3G S)K- X'I:2%;]
M@RVU.J3*0;CFQ/\#"Z$O35<L-67!>T2"<[?K>:ZCI675.-A2J].JK(-KSO?G
M5();8$OD>K\L?D4;*_&J1696&K$D@;QE)EGX_02M,4=/.,X(^MDY!5.!UO L
M%2O,]0\%J\["EEH=:>4M7+,I *,?T?01S5Z3!8NU)/>XBO?S_VHI674.MM3J
M$["5=?#,R?VVIZ';%\@5TD?2:,'V"-T/9^/A?[23N%:=@BVU.J_**7@'.84O
M)(Z[WU/(R^!>Q0(&N0A-A,CTH]P>S7NFQ6;5(MA2JV.K+()WD$7XD\5@13%X
M434[PH46EEFI 995&V!+K0ZKL@'>039@E'&NYN"*:<I\*(.\-M-#,RM^);JH
MD3FJ-;5CF "O,@'>029@DH)=+%8?U90EWF+44C,K-E&SZ@%LJ=6I51[ .\@#
MY+<C&H%M>F1<FW;LT;EG:1>'(0$9$(D*02T]JT[ EEJ=7N4$/',BOZ$W2W <
MHYM,P-="?W^:=9J67\QAK6$=PQ%XE2/PS,G\!M9M0OBC&LW>@X)<@8=*UCC5
M]SFS8",UJ\[ EEJ=6N4,/',^OZ7VLKMR52S+:)&9U1J7KLQQK9D=(_7WJM3?
M,V?NY?+5'4UQ&E(PHOF44+[OEO-\3AR>"D6IRK>[&#]JU^3WG*89IE6'8$NM
M7M10.03_H,6%V0I27M/-ND>F$98YKG6QPC'L@5_9 _\@>S#-%C$-T5W,L#;Q
M,*NTKO:PZA0V:OU<3969/5WW![[K!7WWLO>DHU.Y /\@%U"?HIBIV0B!/F52
M2)PJRZXE9C/!'VW4!CMM'+@79]Y%,"C;N*%Q#"O@[Y04'68%8.#B,(I-THB\
MH#^(_@8T2SF.XP;]OC_0E4J-S,&M^] QK(!?60'?G+AOG=,=%6H2\BO!W%C"
ML$>NVW6]KN]JL5GU K;4ZM@J+^ ?6$RTR^T.=FI3VCUB3>4>YK#6Q(Z1__M5
M_N\?6%6T(;8IEVEF9I:[TZXYF8-:$SN&"? K$^";<_8AX(H*9)!U:1F9!9KS
M"*M9ORVU.J8JZ_?->?JV8XF=H@YPU0M5++,D,+B%!'V;DQ>);F)XBNHK2LVG
MF*I))98*M>H@5V2G"N?-3^>>>_9.J'IKFM)\*F7*V<OK3A;-28SS.2G)\FA5
M@KLM0OQ(2/X5".?/^!6+(\(%@N<\HKO-64%+:*I:Q<M6P?84<XDFDTEQ9534
MBQL1I ZJ1!RIXL[MZ8&$NBHA=W1/T1R^6><7+LH+?Z:0QBX(6M(8CGRFX$"5
MP$[Q5EZ^NYT-5[D*%7E5O#H6KL[U'!3AUY(;_S>W93$:O*KQDZA::30F(5%K
M8&6UL[:8P?R+M>["QS!A?F7"?+,[&F81E>"TFM83]H3?\E1(] 8GZW?H*\N@
M.WWX,-5"LVJV;*G5JYTKLQ687=(6VAV%#CX9Z[CM40BT2\OFH-85S\<P64%E
ML@*SR=I"4DO,:@C34C)+3%<TQA&)URN*3]!TJ&5FU5;94BN8]7;>$%'S:?F;
M-@*%JM*O>%FDW%N^S3/,WV'I58<7KP)]Q&HZ3J"8+"'4.3V#E(H7;]<4&Y*M
M\_=-%DQ*EN0?5P3@<74 ?+]D3&XWU G*=YRN_P=02P,$%     @ ]#ET6AW,
MV?23!0  6!<  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RM6&UOVS80
M_BN$5VPM8,<B]9XZ!E(G70MT35"GVV=&IF.BDNB25-+LUX^4%4L6*=;%_*&-
M)-^=GCM2]SS'V1/CW\2&$ E^%'DI+D8;*;?GTZG(-J3 XHQM2:E^63->8*EN
M^<-4;#G!J]JIR*?(\Z)I@6DYFL_J9[=\/F.5S&E);CD055%@_OR.Y.SI8@1'
M+P^^T(>-U ^F\]D6/Y ED5^WMUS=3?=15K0@I:"L!)RL+T:7\'R!8NU06_Q-
MR9/H7 .=RCUCW_3-Q]7%R-.(2$XRJ4-@]>>1+$B>ZT@*Q_<FZ&C_3NW8O7Z)
M_KY.7B5SCP59L/P?NI*;BU$R BNRQE4NO["G#Z1)*-3Q,I:+^G_PU-AZ(Y!5
M0K*B<58("EKN_N(?32$Z#C 8<$"- SK6P6\<_#K1';(ZK2LL\7S&V1/@VEI%
MTQ=U;6IOE0TM]3(N)5>_4N4GYXN;S\N;3Q^O+N^NK\"[RT^7GQ?78/GA^OIN
M"2;@Z_(*O'[U!KP"M 1W&U8)7*[$;"K5F[7_-&O>\F[W%C3PEBN2G0$?C@'R
M4&!Q7QSO[A^Z3U6^^Z31/FE4Q_.'DJXX)Z4$6 @BQ;DMGUV P!Y ?UOG8HLS
M<C%2'X\@_)&,YK__!B/OK2V[$P4[R-7?Y^J[HL\76&R 6C60Z0ORO:*/.%?)
M6U=Q%RJL0^D&\#A'H>>EL^EC-QV+59HBM+<ZP!GL<09.G']RK%:$DXPH@/<Y
ML>+;A8BZ;XZ2J ?/-((H@79TX1Y=Z$1WR\D6TQ4@/U3_%$34%65R0[CZ2+N;
MR88Z- $ED==#;1KY'DSMJ*,]ZLB)^HY)G!\!,#++FH9AV$-H6OD!&EKV> \Q
M_DEA%2-Q^5P75._.K>((.08ED3:DL:64L(?3M$%)8$>9[%$F3I0UNTW8>E()
MTM1Q##1P+&GY '*BB,1:V<3 $J1)#Z]I$X6Q'6^ZQYL>L?##"YY:-AOR@QXP
MBU4((]\.#7HMXWA'==^<XGN:4TF)O04W84[4@T\5[3#I#LU"YXI<9AFK5-<%
M6_RLVYLU86CN[C3IKXK%RH_2<&!56DJ$3A;2 'E%V@YG!8B,5\<1ZG<RBU7@
MA4, 6QZ#;B*[(FNB-LX*/-1,0<N,%63\TMVL<'VSGE[4IPN;5>P-\ 5LZ0RZ
M^>SFL#MT=[L;M(6^4K^/V6(4#_0XV'(<=)/<S0&?=0!;<9J$A>*^4K 8A<$0
MSI;5X*_0VL]PFK0%(0Q0'ZG%S(/1  '#EMZ@F]^<VZ!DY<2U%4PF\TW@IE'8
M^20/8;=\!]V$MROQSTIK,I>JK-FP+&9>E R5MN4XZ":Y!2L**K5<V,FQC)6Z
MT*3,%%[P^C.3!,1OK,"=@>U< *RD\O\#'0XP+8DB-XDN)<N^;5B^(ES\40LG
M^6P?9$[*HJ>*=IAURZ+(S:)*AC<D('3^8_#*._,\J$B5 S765(H/H#?VO/H?
M$!O,M52OY(9Q^B]9O55?W,M3*H2FNUK'5U)(=:&_4BR!FC9)<:\ZX<O 6AOU
MG_K68COA_\+&.D&@PQ)W1F.W#M!?%2N'ZZL&0E>!PW2<A,$XB>.Z:CX:PR@<
M!W%RLKJ/U9 HMJ0^_LF?K:M@"A!CW++8^ .C#&HE"G)+E,O5BNK#*=4Z];0X
MH:6:NK=4M5(K3(OP2/TD-*!:[*(P0=$ W%:B(+=$49*O*JH<2[4>*[*F&;72
M$#+%Q@3&:A(P@-H, PB'6CUJE0ER*Y,NTF;J9H7:^1M]GOBH6)4)*T.YP_YR
M\S/5S 0.*6_4RAETC)P1EH9N3<DB5)+8W#26F3X(AC0B:O4,<NL90QC4'^G1
MX&/CZ,@V>-K,+)/GM'/LJ<^<_\+\@99"*:VU\O/.8A6 [XYQ=S>2;>N3T'LF
M)2OJRPW!"K0V4+^OF=(,S8T^7-T?IL__ U!+ P04    " #T.71:61C4B]X"
M  #_"0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V6:V_:,!2&_XJ5
M35,K=>1&"'00B0)3*W4M*MWVV4T.Q*H39[:!;K]^=I)FI(3;-CX0.SGO\?,Z
MQ['[:\:?10P@T4M"4S$P8BFS2],480P)%BV60:J>S!E/L%1=OC!%Q@%'N2BA
MIF-9'3/!)#6"?GYORH,^6TI*4IAR))9)@OG/*Z!L/3!LX_7& UG$4M\P@WZ&
M%S #^36;<M4SJRP122 5A*6(PWQ@#.W+D6UI01[QC<!:;+21MO+$V+/NW$0#
MP])$0"&4.@56EQ6,@%*=27'\*),:U9A:N-E^S?XY-Z_,/&$!(T:_DTC& Z-K
MH CF>$GE UM?0VG(T_E"1D7^C]9%K.<;*%P*R9)2K @2DA97_%).Q(; ;N\0
M.*7 .5;@E@(W-UJ0Y;;&6.*@S]D:<1VMLNE&/C>Y6KDAJ7Z-,\G54Z)T,AC=
MW\WN;V_&P\?)&%T-;X=WHPF:74\FCS-T-L4<4AF#)"&FY^@C>H],)&)U5_1-
MJ4;7.<RP'.FJ&,G9,=(8PA9R[0OD6$Z[03XZ7N[6Y:;R7!EW*N-.GL\]W7B3
MMR)9NSF97FN7(L,A# RUF 3P%1C!AW=VQ_K4Y/0_):OY=BO?[K[LP50M$^ <
M(J1J*WR^0!GF:(7I$M 925'$*,5<H QX\:;/FV:C&,+/A] ?BE5@M2S+[INK
M39N'HFK\[8J_?0I_68X(+V7,./D%41-OD;*S06);Q>\-\A&!-6JOHO9.F_42
MFPBQ;$;VMDC>LNZ+J$%V*LC.7T&JK[^0.(U(NF@B[1PDW1=1(_4K4G\OZ8@E
MB=H#_J&"_:,J^%!4#;Y;P7=/@#^J?KM;$^AXS05\3&2-NE=1]TZGWEV^O2T.
MK]?UVEW??P.\'>@Z=L=K^]UF7MOZL[-9IQ,?J.4RY1'<#9$[P,V-W5D?C;Y@
MOB"I0!3F2FJU?+60>7':*#J29?F&_<2DVO[S9JQ.:,!U@'H^9TR^=O09H#KS
M!;\!4$L#!!0    ( /0Y=%H1Q#'!Q00  '$1   8    >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&ULK5AM<Z(Z%/XK&>[.G7:F+0047ZXZ8]7=[4Q;.]7=_9Q"
M5.X"<9.HW7]_3P !)=#NG7Y1".<<GB<Y)\\)@P/C/\6&4HE>HS 60V,CY;9O
MFL+;T(B(&[:E,3Q9,1X1";=\;8HMI\1/G*+0M"W+-2,2Q,9HD(P]\=& [608
MQ/2)([&+(L)_W]*0'88&-HX#S\%Z(]6 .1ILR9HNJ/RV?>)P9^91_""BL0A8
MC#A=#8TQ[D]L2SDD%M\#>A"E:Z2HO##V4]W<^4/#4HAH2#VI0A#XV],)#4,5
M"7#\RH(:^3N58_GZ&/US0A[(O!!!)RS\$?AR,S2Z!O+IBNQ"^<P.7VE&J*WB
M>2P4R2\Z9+:6@;R=D"S*G %!%,3I/WG-)J+D@-T:!SMSL,\=6C4.3N;@)$13
M9 FM*9%D-.#L@+BRAFCJ(IF;Q!O8!+%:QH7D\#0 /SF:S!\7\_N[Z7@YFZ+%
M$OX>9H_+!9I_1O.GV?-X>0<&:/PX19/YP]/S[.OL<7'W?8;NYXL%ND;?%E-T
M\>D2?4)!C)8;MA,D]L7 E !-O<#T,ABW*0R[!@:VT0.+Y4:@6>Q3_S2 "9QR
M8O:1V*W=&'%*O1ODX"MD6W9+ VCR?G>G 8Z3S[.3Q'-JXLVWE!,9Q&LT>X42
M%%3T=;.4!FGI@ZB2[HLM\>C0@)H5E.^I,?K[+^Q:_^@8?E"P$[ZMG&^K*?KH
M&2(2[FT0Y .4U1[VBRU4O]213B.UDTAJV]F/6MCMN -S7V93M7(ZN%=8G<!L
MYS#;C3"_T!C6)4Q0$A_J*Q!2K=.>ZH"FL=P2!&S;/>L,J,;*:=M=/5 W!^HV
M ETR"3!9GD4TRR(=3+<"H.WTW//YU%A9'54J.IB='&:G$>8]$P*M.(N.4%FL
MA=BIO/Q:AU%G5@^RFX/L-M>BW% .&Y;'(HHNLIF\U-9C]R/K\8."G7#NY9Q[
MS8G.22PSSCJBO6K2]MJMWMEZ5*WL5M=JZY<#6X4&68W@R@MRA6*JW26R&.67
MNY6$T1CA=DWIX9)&XD9\=[&DL"3R6'5:>+B:JW;[')[.J%,#SR[@V6\7';1$
MWHYS&GN_$6QAL0B3ZDN+,0Q^[0(_'6 KZ-E>1. 'T+9IF=A5D) ,YU0:,?W/
M;,:%G.)&]3KNA^]*'$>3V[TJH:J9W>HY-0*#"R'$S4KX"+UX""NDA=:J3K7C
M]#KX')O&SFYWNG697<@?;M8_:(6AT:U)'>+_"PVH4NTK-<?ASE?*PZD7$B&"
M5>#5[^]8(X+5&:\:U>SLN)!)_!Z=A'R K-NHT\:>UL^^6VDI8/8[E<Y#9Z=F
MOPYL(9:X62V/J8% *Y'8$ Y)#&>2P$,7T$[[+ P)+SV\U))(7]$M@[-NNA4.
M;YF=4BBD%#>JEI:"'X0[2?T_(=%]'XFWS$Y)%-J(F\7Q1W+8H_XUV4/3LJ8J
M?R(H@ 0P;*T[*21TB)#]Y?5)G^KY5(42JMJQ<*M[3DEC:5G05'9K9,$N5-5N
M5M4_855>L@9>=E5>:WCI+/6\S-+A-:)\G9SI!8#=Q3(][N6CZ7>#6]R?),?K
ML_$Q[H^34[19A$D_1CP0O@YB@4*Z@I#630=*F:?G^_1&LFUR1'YA$@[<R>6&
M$I]R90#/5XS)XXUZ0?Z59?0?4$L#!!0    ( /0Y=%KXR&=;U0H  +J(   8
M    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULM=UI<YM('@;PKT)IIW8F5>-(
MC4!'UG95;.X;G.S6OB12VV*#0 /(3K[]@FY.&\^3-[$D=_\:Z.A12^)OKE_B
MY'NZHC1C?JS#*+T9K+)L\VDX3!<KNO;3C_&&1OEO'N-D[6?YW>1IF&X2ZB]W
MG=;AD!V-)L.U'T2#V^O=8TYR>QUOLS"(J),PZ7:]]I.?=S2,7VX&9'!\P N>
M5EGQP/#V>N,_T0>:?=TX27YO>%*6P9I&:1!'3$(?;P:?R2>/Y8L.NQ;_#NA+
M>G&;*7;E6QQ_+^ZHRYO!J-@B&M)%5A!^_N.9WM,P+*1\._XZH(/3F$7'R]M'
M7=KM?+XSW_R4WL?A?X)EMKH9S ;,DC[ZVS#SXA>%'G9HMX&+.$QW_S(OA[:C
M ;/8IEF\/G3.MV =1/N?_H_#@;CH,)ZW=& /'=A*!W[<TF%\Z#"N=& G+1VX
M0P>NNDEM'?A#![ZZ26T[/3ETF%0WJ6T?IH<.T[?N].S085;I,)FV=)@?.LPK
M';C6B1L=9VY4/4Y\6Y?39%=GFVN;;7*<;E*=;Y9MZW*<<%*=<=)VM,AQRDEU
MSMFVXT6.DTZJL\ZV'K'CM)/JO'-<6Y?CQ)/JS+?ORW'JR6[NA_NGXNYY+/B9
M?WN=Q"],4K3/O>+&+@QV_?.G;Q 5N?60)?EO@[Q?=GMO6P^VH0J?OX@"\_ E
M_V&*UI<'QI;R>_:]KMB&('H/OS.B^U7]\E_FBOGZ(#!__/:!^8T)(N;+*MZF
M?K1,KX=9OC6%.5P<1K[;C\RVC"S%81Z:5WEV.=MO8;!@[,='F@31$W,?K]?Y
MPP]9O/C>X-Z_U_V\7 9%6/HAX_C!\BK?_GM_$V1^V#"*\,Y1&BBQF_J<Y8>1
M,J:??,]?I]YZ%*1WH;T.@?R>(1H<I=L1_]H&V4_&R!]FI"#RH\5Q]X,L?X7,
MF(>5G]#TM0.B8D;I=80TR)@-L/Y>N., &>\Q>QT.\QTC-#!6-_/*;MJO_*_M
MLT/.*]9BL5UO0S^C2T:@C\$BR!H0]^V(G:UH4LQCO@9=%8O#9\K\8<1I^H&1
M\S5H ^YUXU_BVHX-\U>(T\L$>WJ98'<.U^+<T:<@BHK_$'=^F$]<_D3QLWR?
M%Q^9,?F384<LV_0*T(D62_)/Z<9?T)M!OK\I39[IX/:?_R"3T;^:8A^)"4A,
M1&(2$I.1F(+$5"2F(3$=B1E(S$1BUA[C=UCQ[O;YEIU?#Y\OD[3>A/#\C!V5
MFSGU9E>$\-R(E-NY3>WFE3&]>B-NQ'+G5J7X&I_B:]PWOO[(@S_=O?Q^>%.4
M=0[0-\J0F(#$1"0F(3$9B2E(3$5B&A+3D9B!Q$PD9NVQR664S>;S/()FE4!#
MCNH@,1>)>2"L%+7<*6JYG3YNB=K=6YI5'"YIDO[.[)?\37G*(?,4B0E(3$1B
M$A*3D9B"Q%0DIB$Q'8D92,Q$8A82LY&8@\1<).:!L%+F\J?,Y3N7MVJ:;HM5
M+1,_,HO]IR-IRZ<C=YU2W]Q%8@(2$Y&8A,1D)*8@,96OO?4:D\H*2GM#&QVY
M449]0)94WH":;VAC(3?*1F(.$G.1F ?"2IDV.67:Y%V9=OG&O2G?.M6^^8;$
M!"0F(C$)B<E(3)G4WMF1V7S&3\I/;A4YIH;$](8=8/G1J)).!G),$XE92,Q&
M8@X2<Y&8!\)*N3D]Y>:T,S?%'S19!&D]-^--\;57XQ?UG6+?S$1B A(3I_6U
M2_EI*-5;\(3ERHWDQD;3<B,%N>$J$M.0F([$#"1F(C$+B=E(S$%B+A+S0%@I
M!&>G$)S]K1!\;1'9J?<-1"0F(#%QUO"Y.3\?32N))R$'E9&8@L14)*8A,1V)
M&4C,1&(6$K.1F(/$7"3FU9_#H^;ORN>G[)QW9^?N*YNKXF3P91&>&QJE?I&:
M34'92?4-2B0F(#$1B4E(3$9B"A)3D9B&Q'0D9B Q$XE92,R>UV*&&_.5=8*#
M'-%%8MZ\?E;1Y>:7@I*,3DE95$%T1.7^=,U%Z73-I^;S-.^ZJ;Y1"=4$J"9"
M-0FJR5!-@6HJ5-.@F@[5#*AF0C4+JME0S8%J[D$K97KE9,S.)N70O"@X(IVA
M:=&,">.TN6*HLVOOD$1J E03H9H$U62HID U%:II4$V':@94,Z&:!=5LJ.8<
MM,O,NF+YZ:QREH(+'=5[?=1R7++GN.RNO!&C95?9S;@Q1J%U-U!-@&HB5).@
MF@S5%*BF0C4-JNE0S8!J)E2S2+W89<Q63ED_M"F=03#A9VSE% BGH=T5X0B9
MS:NYU]1PSE=7?O56+,=-VU9_YT(<TEV)4XVSCC*<YFB#UN% -0&JB5!-@FHR
M5%.@F@K5-*BF0S4#JIE0S2+UFIPQFP<7-ZW6Y$#'=:":"]4\E%:.WG-A3O%W
M3M*_7YES8% 1B]0$J"9"-0FJR5!-@6HJ5-.@F@[5#*AF0C4+JME0S8%J+E3S
M4%HYAL^U.@17K$/JE0V5E\_[AB;YHK_Z:8?0W&Q>>1<A-C2KEOM+313+C:NG
M238WJWYGJ'0?K=[)A-0TJ*9#-0.JF5#-@FHV5'.@F@O5/)163J9SQ0WY-24W
MI%[D,.7Y*>'8:E9!ZVF@FMBP$V0^)^/:!R@2=%SYS>,JT'%5J*9!-1VJ&5#-
MA&H65+.AF@/57*CFH;1R4IYK; B^R*:;[/VV&EIF ]5$J"9!-1FJ*5!-A6H:
M5-.AF@'53*AF037[H%V^O,_8ZE<WT"(>J.:1>K7;Q?:7X_-<G4-^;7E.-]\[
M2J$%.E!-A&H25).AF@+55*BF034=JAE0S81J%JD7I\S'8WY4_08(6JH#U5RH
MYKUZ0,J!>B[9(=TU.ZWOW+>;_.8S3;/B2_?\E][#U_1/)J)9<6>?L,Q+D*U6
M-%PRCW'"T/4FC']2RF3^C\:_3'W7O2F]PQ=:] /51*@F0349JBE0385J&E33
MH9I!ZG4E5X2M?/9NOJF5!=TR&ZHY4,V%:AY**_]=]',-$-M= _2KHO>U-7#W
M9O6-8:@F0#41JDE0389J"E13H9H&U72V7EA"6'Y:_5-R!G14$ZI94,V&:@Y4
M<Z&:A]+*@7VN/V*[ZX]ZU;=W6[U3%EJ0!-5$J"9!-1FJ*5!-A6H:5-.AF@'5
M3*AF036;K1?SC*?5/R;O0,=TH9IWT/BV/2AG)WO.SNYB)(\N0C]-@\=@X>\O
M.[G\WS;=7\LJ7]7FJU@:/$7,8ILD-%K\9++$C])PWS2(%N%VF6=NOJZ-#C6@
MNW5O&.2)O-PW*I;&VV]IL S\I/'DU.X-[!W(V&L*82\JA+VJ$/:R0MCK"F$O
M+(2]LA#VTD+8:PMA+RZ$O;H04K.AF@/57+;A*DFU<BJVH8KKHE$YCL_%5&QW
M,557*7UWU]Y!"2V4@FHB5).@F@S5%*BF0C4-JNE0S8!J)E2SH)H-U1RV7L1U
M-1[/I[4+NT'+I%X?M1R7YP*H_&;G.__N4GJN,48[R=XQBM0$J"9"-0FJR5!-
M@6HJ5-.@F@[5#*AF0C7KH%VNPB;5\PP:VI#Y>%8]'\%I:'=%ICRI@BYT%[RF
MS9M-VTX.8,\%1VQWP5&/DOOF"(1>,@BJ"5!-A&H25).AF@+55*BF034=JAE0
MS81JUD&[7#?Q\QG/S:;3:A!"*ZJ@F@O5/)2VC]YANJ(T$_S,O[W>^$_4]).G
M($J9D#[F_.CC-!\M"9Y6ISM9O+D9D 'S+<ZR>+V[N:+^DB9%@_SWCW&<'>\,
M<_\E3K[OQKC]/U!+ P04    " #T.71:HRV4^F("  #G!   &    'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;'U4;4_;,!#^*Z<,;2 QTJ8%!DLCT1=$-: =
M*9OVT4TNC45B9[;3LG^_L]-FG03]$OO.=\_S7'SG<"/5B\X1#;R6A= #+S>F
MNO9]G>18,GTF*Q1TDDE5,D.F6OFZ4LA2EU06?M#I7/@EX\*+0N>;JRB4M2FX
MP+D"79<E4W^&6,C-P.MZ.\<37^7&.OPHK-@*8S3/U5R1Y;<H*2]1:"X%*,P&
MWDWW>MBW\2[@!\>-WMN#K60IY8LUING ZUA!6&!B+ *C98TC+ H+1#)^;S&]
MEM(F[N]WZ+>N=JIER32.9/&3IR8?>%\\2#%C=6&>Y.8.M_6<6[Q$%MI]8=/$
M7EYYD-3:R'*;3 I*+IJ5O6[_PUY"$+R3$&P3 J>[(7(JQ\RP*%1R \I&$YK=
MN%)=-HGCPEY*;!2=<LHST6CV&,_NI^.;Q60,\8*6A\GC(H;9+5FST;>[V?UX
M\A1_@LGWY^GB%QS/F4)A<C0\8<4)' $7L,AEK9E(=>@;TF21_63+/VSX@W?X
MNP$\2,+3,!$IIO\#^%1,6U&PJV@8'$0<8W(&O>XI!)V@#\_Q&(Z/3@[@]MH_
MU7.X_7=P;V5!'?R9.FE>+PN>P"S+4'&Q>JOH@U!VT*YUQ1(<>#1)&M4:O>CC
MA^Y%Y^L!H?U6:/^@T*G6-1,)@LP@D65)BJF-DI=32+E.9"V,!KHL.F[T4Y V
M;UY=PW/N>.QTKZ-N+[@*_?6^.G^O^4I4*S=B&AQ1TX>MMYWBFZ9Y_X4W3\ #
M4RLN-!2846KG[)*H53-6C6%DY5IY*0T-AMOF]!*AL@%TGDEI=H8E:-^VZ"]0
M2P,$%     @ ]#ET6NYC.AUZ!P  *R4  !@   !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6RU6FUSHS80_BL:M]-I9^JS)>&W-/&,+R_MS=Q=,N=<^UD&V58/
M(U<2>>FO[PH<,""4Y$J^V(!7R[.KU3X/%J?W4GW36\X->MC%B3[K;8W9GPP&
M.MSR'=/OY)XG\,M:JATS<*HV [U7G$79H%T\(,/A>+!C(NG-3[-K-VI^*E,3
MBX3?**33W8ZIQ_<\EO=G/=Q[NO!%;+;&7AC,3_=LPY?<?-W?*#@;%%XBL>.)
M%C)!BJ_/>@M\<AYD S*+/P6_UT?'R(:RDO*;/?D0G?6&%A&/>6BL"P9?=_R<
MQ['U!#C^.3CM%?>T X^/G[Q?9<%#,"NF^;F,_Q*1V9[UICT4\35+8_-%WO_!
M#P&-K+]0QCK[1/>Y[63<0V&JC=P=!@."G4CR;_9P2,31 -PV@!P&D/J H&4
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MW?=+AFZ,,I&/H\79^5,Y*>D9+3N/%(;C=3^0V2.T3?L$5N_G1RQ\VIP_56G
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MN^0?%QI5DJ,7\/G,(F&$7^B ],= 7O\O4$L#!!0    ( /0Y=%H O)-)" ,
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MFBNM@7:9ZY\."A.@]S/.56N8 MUO+/X-4$L#!!0    ( /0Y=%I00%#SE0(
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MC#O6--A160.ZKZ0T!\$&&'X5^6]02P,$%     @ ]#ET6C\@*\C9 @  :08
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M.HS/)Q&8KK%U$Z>;T$S6VE%K"I\U_1>@\0:T7VKM]A,?H/]W6?P#4$L#!!0
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MD/?,9URWNXX?!]-I:T[$H6/V\81U=ID8!;/QO'.-4+GUF</)B Y:-31NV^L
M'5,VQ:T)!"P_O>^&(*UH.RY##UL7--CN?^=@@$D<A).)>[4KJ6FP,X#[NZG6
M\EU47?F6TE4-<$>I:,A+KP>^TI0(JC7$B4'-Q[+Q=RF@DZ2_4P_C:?PO:0&Z
M0ZN%?=]37G:^>*59+W[7BS"J*;3Y^-7?]9\.OS1?S+;+S7?'O_)J#:"696(%
M6\/A;')F )R[T*JD[V>72FN5T\^-X*FH< $\7RFEW04>X#^H?O%_4$L#!!0
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MT12A%()_%;)D=^JD]OA]"257HO%G#%Q6-(6PY4ZNII<B#YQ&Z;%NH5<-JP6
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MS&T$2S=2K)CNJ&4BE;[8"_Y-&':TN+N^/0X8;-N5CUBAG6NCJS+ >:R9:#>
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M=!>]YK4VO+#[1";!Z62\/QT&X73$'C[PHCR_9O?H9EHIU&NJ+0)T%![OF<P
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M@U](PM &K*^T=NV #NA^<\W_!E!+ P04    " #T.71:M6,JETX"  "D!0
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MWF2A7Z?H.E\W4;RVW6;/E>Y==ECJGP4($Z"?YYRKX\1L,/Q^DC=02P,$%
M  @ ]#ET6CRE,S@1 @  W00  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&ULI53;CM,P$/T5RT@\H3I)+Z"21&IW0:S$2M4NEP?$@QM/$VM]";:S6?X>
MVTE#0=T*B9?88\\Y<X[C<=YK\V ; (>>I%"VP(US[9H06S4@J9WI%I3?.6@C
MJ?.AJ8EM#5 605*0+$E61%*N<)G'M9TI<]TYP17L#+*=E-3\W(+0?8%3?%RX
MXW7CP@(I\Y;6< _N<[LS/B(3"^,2E.5:(0.' F_2]781\F/"%PZ]/9FCX&2O
M]4,(;EB!DR (!%0N,% _/,(5"!&(O(P?(R>>2@;@Z?S(_CYZ]U[VU,*5%E\Y
M<TV!WV#$X$ [X>YT_P%&/\O 5VEAXQ?U0^YRCE'56:?E"/8*)%?#2)_&<S@!
MI*MG -D(R*+NH5!4>4T=+7.C>V1"MF<+DV@UHKTXKL)/N7?&[W*/<^6-/UX&
M!GTRE'%5HYT6O.)@$54,[8RN@'4&;$Z<+Q8@I!J)MP-Q]@QQFJ%;K5QCT3O%
M@/U)0+S*26IVE+K-+C)>0S5#\_05RI)L<8%O/EF?1[[Y_UE'WSYZ(+IQ(.WW
M<^<P5%F<KQ*::FU;6D&!?==8,(^ RY<OTE7R]H*'Q>1A<8G]GSULF&[=WW]A
MD'^Y@#,=G--)3JZ<!%/'QK*HTIURP^V;5J?>W0Q7]G?ZT/BWU-1<623@X*')
M[/42(S,TTQ XW<8+O-?.MT.<-O[] 1,2_/Y!:W<,0H'I12M_ 5!+ P04
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MQT2A2UAZ <\7QOCZ@A0T/[,]_1]02P,$%     @ ]#ET6A1_ #;2&   8$T
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MO4-.+VZ_F<9.KL-++[FW*!Z_/IYAB"RX9PZI<>#W]/I^!,.% M6PG>TEI\A
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MCXYDEL9_Z-H5_X36M.VZ=LE_+A0E^@8OT/>SEIRK^X -PH^JO?H?4$L#!!0
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MBC;@^DI*LQN0@[:IG?\#4$L#!!0    ( /0Y=%H<=%A(YP0  &,/   9
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M=XY5,$@C@//3JM*;@=F@K:LG_P!02P,$%     @ ]#ET6BSDPHF$ @  N 4
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M/,,U".& L(S? V8PIG2!N_(6_;/GCER6S,"U$K]X9>M9<!:0"E:L$_9!;;[
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MEKGBVIY+9[U '1-06@!%,_5J+!C'[L%<*O1MQ= -%8]:.=LVTP[JO)X!M6!
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MU!9:5;:]DVVWE)D%4%NR6T*KRM[=_;CQGOU$;CK'MUS'.DS-9J.<J[E7_D7
MEUE5+)#/TECFQ50YFE?>$UUYZ_+Q8%Q5Y#=9'6KN8/)R_I[P)8T%"F&A(*WK
MGF+$\PHY[TB69$7F,Y.J9,V:*_57 5P;J.\+QN2VHR<H_U.\OU!+ P04
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M,:GZ&S-,50L*7!NH[W/&Y':B U1-;?0?4$L#!!0    ( /0Y=%I[MW:J+P4
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M;<-TG:B;H&Y\,3]HI-;@AQ4U;S N@/;76N-AXOK#\#O(?P)02P,$%     @
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MZ:I)]#Z"$E>L$>Y&;[]@Y^?4\Q5:V/"%;9>;1% TUFG9@4F!Y*K]L_ON'/8
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M4_!F/,G+_\G+9M_1I$=FZUSRM I61Y#&V>8G_5K](G8"#/M(@%D%F*<&6%6
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MI9BI#O+YEE)Q:B@'[7'H\C]02P,$%     @ ]#ET6F!EHRL> P  '0L  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULK99=;]HP%(;_BI5)4R>MY),
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MZ>TAL4WP);K%1* -IFM ?(%X8;HENIB#PH3*;V-7:0!CXZ;[R:;E9$'+9'Z
M[GBN5A+=Y!EDQP:N)J_P@P/^-.ATG$/:0Z'_'05>$#4 S<Z7AQTX897-T/I%
M;=E\+?3VU)G<<*JS2'5JOYM5(VS-FM)5NOF>M3/_N$WB]4;^8#"J?<;NIAY1
MBR8:5...T*,*/?H .GYM0X\:,8)@Y+U]_!/T%DT\;$;O5^C]3O0'(I\O%P(
MD5R! *F0P HZ,]]O0O$BLPN.D)O'A5'<C!Q7R/$'D=LS'C<C1_T3Y)9Q [\9
M>5 A#SJ1YV1#,L@SM"- LR; 4C^JSWN"UC7B"&I800T[H>[:5[A3:&['*UG@
M%":.OOXDB TXR=<O?NS]:#I&/LGL*,91%>/HO'^FWB@,7>P B^;#M]LF1E:)
M L3*,UB?QAG>R:9PW^D4-1@=A>I[;]>1U[V@[?N_6_G>%?TLM^,X:]>N_SF+
M^A^?:BU&K8MYID-4[8NP=3G=6J'!0"QM_251RM>Y*B_MJK>L\::FQC.%RDF_
MKOVN;<7COMF4A>,=%DNBRPP*"VWI]0;Z!!9E+58V%"]L.?/$E2Z.[.-*UZ\@
MS #]?L&Y.C3,!%5%G/P#4$L#!!0    ( /0Y=%H,P&G\F 0  $\5   9
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M\IT.^'IWC=Z^>8?>(,K0EXQO)&&IG+E*$S/P;E*3N*I(^,^0P#[ZS)G*)/K
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M!6$"]/T5YVH_,#_0O#E9_ -02P,$%     @ ]#ET6F>-PG+T @  &@L  !D
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M    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*U576_:,!3]*U96;:VTD9
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M2_R8@'8%>'^IE-U-W ;=YRG[!5!+ P04    " #T.71:$SOFKGL"  #B!@
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ME-88#2_,--YKB4\YVNGD0Y&*',@7=@1%!F0!*Y 2ED2S(V%*@5:$%4N2<?;
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MHXP9>]*%Z[AG.=H19!!)+4'4WP(&D&5:2?GXNQ*UJCYUX.;SJ_I5 :]@QD3
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MN6LR]SW[#:+'$+I[A'Z[L\MG[/]8OO7M 1O/[' DB:R?>">].)Q*;9MR?77
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M=74KRMH(3UI'P3RI?8'$LZZ(&HP\=XAUJZ)X7$9?=RK!?<F<34AOB1JL F]
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ]#ET6E GUTG+!   $28   \
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MYZVIN_=\-ORW<?4*4$L! A0#%     @ ]#ET6D;'34B5    S0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #T.71:
M  [<//(    K @  $0              @ '#    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #T.71:F5R<(Q &  "<)P  $P              @ 'D
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /0Y=%H9E-H1H@@
M .\T   8              " @24(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #T.71:'<S9]),%  !8%P  &               @(']
M$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ]#ET6ED8
MU(O> @  _PD  !@              ("!QA8  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( /0Y=%H1Q#'!Q00  '$1   8
M  " @=H9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #T
M.71:^,AG6]4*  "ZB   &               @('5'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ ]#ET6J,ME/IB @  YP0  !@
M         ("!X"D  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( /0Y=%KN8SH=>@<  "LE   8              " @7@L  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #T.71:?/L7+$$+    '0
M&               @($H-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ ]#ET6@L".+Z@%P  &$0  !@              ("!GS\  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /0Y=%H O)-)" ,
M %H+   9              " @757  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ ]#ET6CFDAB>Q @  T@8  !D              ("!
MM%H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #T.71:
M4$!0\Y4"   V!@  &0              @(&<70  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( /0Y=%H_("O(V0(  &D&   9
M      " @6A@  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ ]#ET6B!)E6Z$!@  +Q(  !D              ("!>&,  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #T.71:W^@^L/P&  "N$@
M&0              @($S:@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( /0Y=%HLQ<*?* X  %PM   9              " @69Q  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ]#ET6G@G%$3)
M @  :08  !D              ("!Q7\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #T.71:W@ =U@@#   +!P  &0
M@('%@@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /0Y
M=%JY#2,9RPH  )$?   9              " @02&  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ ]#ET6BTH+E][!0  ?PT  !D
M         ("!!I$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #T.71:M6,JETX"  "D!0  &0              @(&XE@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /0Y=%HL=6B^0P(  (H&
M   9              " @3V9  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ ]#ET6CRE,S@1 @  W00  !D              ("!MYL
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #T.71:J?'0
M1I )  !R*P  &0              @('_G0  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( /0Y=%H4?P VTA@  &!-   9
M  " @<:G  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M]#ET6E7]W:;> @  BPH  !D              ("!S\   'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #T.71:C/FH=G8"   7!@  &0
M            @('DPP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( /0Y=%J_@5&9DP(   P&   9              " @9'&  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ]#ET6LU@ST2@ P
MX H  !D              ("!6\D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " #T.71:''182.<$  !C#P  &0              @($R
MS0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /0Y=%HL
MY,*)A (  +@%   9              " @5#2  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ ]#ET6JG)VDUA!   X0P  !D
M     ("!"]4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /0Y=%HZJ5!=) ,  +,,   9              "
M@8[L  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ]#ET
M6A>:*?:3 @  ^P8  !D              ("!Z>\  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " #T.71:LL1:G  $   S&   &0
M        @(&S\@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( /0Y=%KK4J]5&@,  . *   9              " @>KV  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ]#ET6GNW=JHO!0  7B8
M !D              ("!._H  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " #T.71:#=(+)5<"   :!@  &0              @(&A_P
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /0Y=%HEA>3K
M:0(  .0%   9              " @2\" 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ ]#ET6F9P5AA$"0  Z&   !D
M ("!SP0! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #T
M.71:R20.=/4#   :%0  &0              @(%*#@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /0Y=%I@9:,K'@,  !T+   9
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M970U,"YX;6Q02P$"% ,4    " #T.71:9XW"<O0"   :"P  &0
M    @(%A)P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M /0Y=%K!),_GF@(  *H&   9              " @8PJ 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ ]#ET6A,[YJY[ @  X@8  !D
M             ("!72T! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " #T.71:.+\=-1\#  #)"0  &0              @($/, $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /0Y=%KWN%KFU ,
M   .   9              " @64S 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ ]#ET6IC.I*!Z P  ^ X  !D              ("!
M<#<! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #T.71:
M:>CAD$ $  !*$0  &0              @($A.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( /0Y=%KWZ9Q5+P,  .X2   -
M      "  9@_ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ]#ET6I>*NQS
M    $P(   L              ( !\D(! %]R96QS+RYR96QS4$L! A0#%
M  @ ]#ET6E GUTG+!   $28   \              ( !VT,! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( /0Y=%KS((MYZ0$  !(B   :
M  "  =-( 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M /0Y=%JR:$G8U0$  +\A   3              "  ?1* 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !! $$ OA$  /I, 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Description of Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</Role>
      <ShortName>Description of Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Equity-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Equity-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Description of Business and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails</Role>
      <ShortName>Description of Business and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Term And Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Stockholders' Equity - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Equity-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails</Role>
      <ShortName>Equity-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Equity-based Compensation - Fair value of options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Fair value of options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Equity-based Compensation - Activity for options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails</Role>
      <ShortName>Equity-based Compensation - Activity for options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Equity-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Equity-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940906 - Disclosure - Equity-based Compensation - Compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Equity-based Compensation - Compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureRetirementPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Income Taxes - Net loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails</Role>
      <ShortName>Income Taxes - Net loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941204 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cgtx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogrx.com/role/DisclosureSegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cogrx.com/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgtx-20241231.xsd</File>
    <File>cgtx-20241231_cal.xml</File>
    <File>cgtx-20241231_def.xml</File>
    <File>cgtx-20241231_lab.xml</File>
    <File>cgtx-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cgtx-20241231x10k.htm">cgtx-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cgtx-20241231x10k001.jpg</File>
    <File>cgtx-20241231x10k002.jpg</File>
    <File>cgtx-20241231x10k003.jpg</File>
    <File>cgtx-20241231x10k004.jpg</File>
    <File>cgtx-20241231x10k005.jpg</File>
    <File>cgtx-20241231x10k006.jpg</File>
    <File>cgtx-20241231x10k007.jpg</File>
    <File>cgtx-20241231x10k008.jpg</File>
    <File>cgtx-20241231x10k009.jpg</File>
    <File>cgtx-20241231x10k010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="465">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>144
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cgtx-20241231x10k.htm": {
   "nsprefix": "cgtx",
   "nsuri": "http://www.cogrx.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cgtx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgtx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgtx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgtx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgtx-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cgtx-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 269,
   "keyCustom": 39,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 21,
   "hidden": {
    "total": 27,
    "http://fasb.org/us-gaap/2024": 19,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "contextCount": 117,
   "entityCount": 1,
   "segmentCount": 40,
   "elementCount": 556,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 465,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition",
     "longName": "995210101 - Disclosure - Description of Business and Financial Condition",
     "shortName": "Description of Business and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "longName": "995210301 - Disclosure - Financial Instruments and Fair Value Measurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipment",
     "longName": "995210401 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpenses",
     "longName": "995210501 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities",
     "longName": "995210601 - Disclosure - Other Current Liabilities",
     "shortName": "Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "cgtx:OtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210701 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cogrx.com/role/DisclosureStockholdersEquity",
     "longName": "995210801 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensation",
     "longName": "995210901 - Disclosure - Equity-based Compensation",
     "shortName": "Equity-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShare",
     "longName": "995211001 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlan",
     "longName": "995211101 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxes",
     "longName": "995211201 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cogrx.com/role/DisclosureSegmentReporting",
     "longName": "995211301 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "longName": "99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "99930403 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930503 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99930703 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables",
     "longName": "99930903 - Disclosure - Equity-based Compensation (Tables)",
     "shortName": "Equity-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931003 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931203 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cogrx.com/role/DisclosureSegmentReportingTables",
     "longName": "99931303 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
     "longName": "99940101 - Disclosure - Description of Business and Financial Condition (Details)",
     "shortName": "Description of Business and Financial Condition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails",
     "longName": "99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
     "longName": "99940401 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940501 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails",
     "longName": "99940601 - Disclosure - Other Current Liabilities (Details)",
     "shortName": "Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "cgtx:OtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "longName": "99940701 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "cgtx:OperatingLeaseAssets",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "cgtx:OperatingLeaseAssets",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940702 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails",
     "longName": "99940703 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)",
     "shortName": "Commitments and Contingencies - Lease Term And Discount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails",
     "longName": "99940704 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
     "longName": "99940801 - Disclosure - Stockholders' Equity - (Details)",
     "shortName": "Stockholders' Equity - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:DividendsCommonStock",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
     "longName": "99940901 - Disclosure - Equity-based Compensation (Details)",
     "shortName": "Equity-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
     "longName": "99940902 - Disclosure - Equity-based Compensation - Fair value of options (Details)",
     "shortName": "Equity-based Compensation - Fair value of options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
     "longName": "99940903 - Disclosure - Equity-based Compensation - Activity for options (Details)",
     "shortName": "Equity-based Compensation - Activity for options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
     "longName": "99940904 - Disclosure - Equity-based Compensation - Additional Information (Details)",
     "shortName": "Equity-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
     "longName": "99940905 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)",
     "shortName": "Equity-based Compensation - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
     "longName": "99940906 - Disclosure - Equity-based Compensation - Compensation expense (Details)",
     "shortName": "Equity-based Compensation - Compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails",
     "longName": "99941001 - Disclosure - Net Loss per Share (Details)",
     "shortName": "Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cogrx.com/role/DisclosureRetirementPlanDetails",
     "longName": "99941101 - Disclosure - Retirement Plan (Details)",
     "shortName": "Retirement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
     "longName": "99941201 - Disclosure - Income Taxes - Net loss (Details)",
     "shortName": "Income Taxes - Net loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails",
     "longName": "99941202 - Disclosure - Income Taxes - Reconciliation of income tax benefit (Details)",
     "shortName": "Income Taxes - Reconciliation of income tax benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "99941203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "99941204 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cogrx.com/role/DisclosureSegmentReportingDetails",
     "longName": "99941301 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg",
      "name": "cgtx:SegmentGrantIncome",
      "unitRef": "Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cgtx-20241231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r52",
      "r832"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r636"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees and other accruals",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "cgtx_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r113",
      "r488"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r62",
      "r119",
      "r484",
      "r515",
      "r516"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r17",
      "r413",
      "r416",
      "r463",
      "r511",
      "r512",
      "r768",
      "r769",
      "r770",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r636",
      "r895"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r780",
      "r781",
      "r782",
      "r783",
      "r840",
      "r896"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r316"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of common stock, discounts and offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r725"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r685",
      "r695",
      "r728"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r720",
      "r729",
      "r733",
      "r741"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation",
        "verboseLabel": "Equity-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r357"
     ]
    },
    "cgtx_AllowanceForCreditLossGrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "AllowanceForCreditLossGrantsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on grants receivable, classified as current.",
        "label": "Allowance for Credit Loss, Grants Receivable, Current",
        "terseLabel": "Allowance for doubtful accounts on grants receivable"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_AmendedAndRestatedEquityIncentivePlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "AmendedAndRestatedEquityIncentivePlan2017Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.",
        "label": "Amended And Restated Equity Incentive Plan 2017 [Member]",
        "terseLabel": "Amended and Restated 2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive common stock equivalents outstanding",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r94",
      "r115",
      "r140",
      "r173",
      "r180",
      "r205",
      "r209",
      "r222",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r408",
      "r410",
      "r441",
      "r479",
      "r550",
      "r605",
      "r606",
      "r636",
      "r649",
      "r801",
      "r802",
      "r853"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121",
      "r140",
      "r222",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r408",
      "r410",
      "r441",
      "r636",
      "r801",
      "r802",
      "r853"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r628"
     ]
    },
    "cgtx_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to at the market offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r678"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r678"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r678"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Financial Condition",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r71",
      "r72"
     ]
    },
    "cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "CantorFitzgeraldAndCoAndBRileySecuritiesIncMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.",
        "label": "Cantor Fitzgerald And Co And B Riley Securities Inc [Member]",
        "terseLabel": "Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r111",
      "r592"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r68",
      "r137"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r68"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r175",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r291",
      "r293",
      "r520",
      "r521",
      "r522",
      "r523",
      "r619",
      "r764",
      "r775"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r88",
      "r481",
      "r537"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r244",
      "r245",
      "r588",
      "r793",
      "r798"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquitySharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r645",
      "r646",
      "r780",
      "r781",
      "r783",
      "r840",
      "r893",
      "r896"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r538"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r538",
      "r556",
      "r896",
      "r897"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 250,000,000 shares authorized; 59,854,877 and 32,165,478 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r483",
      "r636"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r124",
      "r126",
      "r132",
      "r475",
      "r492",
      "r493"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Other Comprehensive Gain",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r98"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r264",
      "r281",
      "r464",
      "r470",
      "r478",
      "r594",
      "r596"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r752"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r752"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r754"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r754"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r756"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r754"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r747"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r748"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r748"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r746"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r746"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r746"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r749"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r751"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r751"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r752"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r755"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r753"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r750"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r47",
      "r48",
      "r86",
      "r87",
      "r145",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r634",
      "r776",
      "r794",
      "r795",
      "r796",
      "r847",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r450",
      "r451",
      "r615",
      "r616",
      "r634"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsUnobservableInputsUnderSafeDetails",
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r262"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Other Current Liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r634",
      "r776",
      "r847",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r145",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r634",
      "r776",
      "r794",
      "r795",
      "r796",
      "r847",
      "r848"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r43"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r35",
      "r42",
      "r79",
      "r80",
      "r145",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r634",
      "r776",
      "r847",
      "r848"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "cgtx_DeferredGrantIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "DeferredGrantIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of deferred grant income as at the end of the reporting period.",
        "label": "Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r104",
      "r778"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r480"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred grant income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets after valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "cgtx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities",
        "label": "Deferred tax assets operating lease liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets, operating leases.",
        "label": "Deferred Tax Liabilities, Operating Lease, Right Of Use Asset",
        "negatedLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Matching contributions to the plan",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage of employees' compensation per person per year matched by the Company",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r173",
      "r185",
      "r209",
      "r605",
      "r606"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r894"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r318",
      "r349",
      "r350",
      "r352",
      "r624"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividend declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r81"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r678"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r678",
      "r721"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r161",
      "r163",
      "r165",
      "r166",
      "r167",
      "r172",
      "r403",
      "r406",
      "r420",
      "r421",
      "r476",
      "r494",
      "r597"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r165",
      "r166",
      "r167",
      "r172",
      "r403",
      "r406",
      "r420",
      "r421",
      "r476",
      "r494",
      "r597"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r169"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r168",
      "r170",
      "r171"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate (as percentage)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r627"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory rate (as percentage)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r369",
      "r394",
      "r627"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r627",
      "r779",
      "r834"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other (as percentage)",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Non-deductible stock compensation (as percentage)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r834",
      "r835"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r627",
      "r779",
      "r834"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "R&amp;D Credit (as percentage)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r375",
      "r779",
      "r834"
     ]
    },
    "cgtx_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for emerging growth company status.",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which the unrecognized compensation cost is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r106",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r174",
      "r223",
      "r224",
      "r237",
      "r294",
      "r392",
      "r393",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r463",
      "r491",
      "r511",
      "r512",
      "r513",
      "r526",
      "r576"
     ]
    },
    "cgtx_EquityIncentivePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "EquityIncentivePlan2021Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".Represents information relating to 2021 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EquityLineFinancingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "EquityLineFinancingCommitmentSharesMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to commitment shares for equity line financing.",
        "label": "Equity Line Financing Commitment Shares [Member]",
        "terseLabel": "Equity Line Financing Commitment Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_EquityLineFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "EquityLineFinancingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to equity line financing.",
        "label": "Equity Line Financing [Member]",
        "terseLabel": "Equity Line Financing"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r725"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r722"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of financial assets and liabilities measured at fair value",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r433",
      "r434",
      "r436",
      "r465",
      "r466",
      "r467",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r628",
      "r630"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r473",
      "r628",
      "r631"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Priced in Active Markets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r298",
      "r303",
      "r424",
      "r434",
      "r465",
      "r620",
      "r621",
      "r622",
      "r628"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r424",
      "r425",
      "r426",
      "r427",
      "r434",
      "r467",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r628",
      "r630"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r433",
      "r434",
      "r436",
      "r465",
      "r466",
      "r467",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r628",
      "r630"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to follow on pubic offering.",
        "label": "Follow-On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Loss, before Tax",
        "negatedLabel": "Loss on currency translation from liquidation of subsidiary",
        "terseLabel": "Loss on currency translation from liquidation of subsidiary",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r560"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "cgtx_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to grants.",
        "label": "Grant Income",
        "terseLabel": "Grant income",
        "verboseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_GrantIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income, Policy [Policy Text Block]",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivables",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r368"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r368"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r428",
      "r430",
      "r435",
      "r508",
      "r510",
      "r561",
      "r591",
      "r629",
      "r864"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r428",
      "r430",
      "r435",
      "r508",
      "r510",
      "r561",
      "r591",
      "r629",
      "r864"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r369",
      "r370",
      "r379",
      "r389",
      "r627",
      "r837"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r369",
      "r370",
      "r379",
      "r389",
      "r627",
      "r837"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r361",
      "r369",
      "r376",
      "r377",
      "r378",
      "r382",
      "r388",
      "r395",
      "r397",
      "r398",
      "r399",
      "r525",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r105",
      "r158",
      "r159",
      "r173",
      "r188",
      "r209",
      "r367",
      "r369",
      "r396",
      "r495",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r363",
      "r364",
      "r382",
      "r383",
      "r387",
      "r391",
      "r519"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "IncreaseDecreaseInDeferredGrantIncomeCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current deferred grant income.",
        "label": "Increase (Decrease) In Deferred Grant Income, Current",
        "terseLabel": "Deferred grant income and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_IncreaseDecreaseInGrantReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "IncreaseDecreaseInGrantReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase and decrease in grant receivables.",
        "label": "Increase (Decrease) In Grant Receivables",
        "negatedLabel": "Grant receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r773"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Shareholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r720",
      "r729",
      "r733",
      "r741"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r745"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r745"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r745"
     ]
    },
    "cgtx_InsurancePremiumFinancingAgreement2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "InsurancePremiumFinancingAgreement2Member",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to insurance premium financing agreement 2.",
        "label": "Insurance Premium Financing Agreement 2 [Member]",
        "terseLabel": "Insurance Premium Financing Agreement 2"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_InsurancePremiumFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "InsurancePremiumFinancingAgreementMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to insurance premium financing agreement.",
        "label": "Insurance Premium Financing Agreement [Member]",
        "terseLabel": "Insurance Premium Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r771",
      "r786"
     ]
    },
    "cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustments relating to commitment shares issued for equity line financing.",
        "label": "Issuance of Common Stock as Commitment Shares For Equity Line Financing",
        "terseLabel": "Issuance of common stock as commitment shares for equity line financing"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LaboratoryAndOfficeSpacePittsburghPaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "LaboratoryAndOfficeSpacePittsburghPaMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to laboratory and office space in Pittsburgh, PA.",
        "label": "Laboratory And Office Space, Pittsburgh, PA [Member]",
        "terseLabel": "Pittsburgh, Pennsylvania laboratory and office space"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LaboratorySpacePittsburghPaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "LaboratorySpacePittsburghPaMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to laboratory space in Pittsburgh, PA.",
        "label": "Laboratory Space, Pittsburgh, PA [Member]",
        "terseLabel": "Pittsburgh, PA lab space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum lease commitments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "cgtx_LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of buyout options in dollars in an operating lease under the lessee.",
        "label": "Lessee, Operating Lease, Number of Buyout Options in Dollars",
        "terseLabel": "Number of options at conclusion of the lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r47",
      "r48",
      "r49",
      "r51",
      "r52",
      "r53",
      "r54",
      "r140",
      "r222",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r409",
      "r410",
      "r411",
      "r441",
      "r536",
      "r598",
      "r649",
      "r801",
      "r853",
      "r854"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r89",
      "r486",
      "r636",
      "r777",
      "r792",
      "r844"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r110",
      "r140",
      "r222",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r409",
      "r410",
      "r411",
      "r441",
      "r636",
      "r801",
      "r853",
      "r854"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LifeScienceSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "LifeScienceSegmentMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to life science segment.",
        "label": "Life Science Segment [Member]",
        "terseLabel": "Life science segment"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_LincolnParkCapitalFundLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "LincolnParkCapitalFundLlcMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Lincoln Park Capital Fund, LLC.",
        "label": "Lincoln Park Capital Fund LLC [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r251",
      "r358",
      "r613",
      "r799",
      "r800"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r251",
      "r358",
      "r613",
      "r799",
      "r800"
     ]
    },
    "cgtx_MaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "MaximumAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r313",
      "r358",
      "r427",
      "r471",
      "r507",
      "r509",
      "r517",
      "r528",
      "r529",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r589",
      "r590",
      "r611",
      "r619",
      "r623",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r803",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "cgtx_MaximumValueOfStockToBeIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "MaximumValueOfStockToBeIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity impact of the value of new stock to be issued under an agreement.",
        "label": "Maximum Value Of Stock To Be Issued Under Agreement",
        "terseLabel": "Maximum value of stock to be issued under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r313",
      "r358",
      "r427",
      "r471",
      "r507",
      "r509",
      "r517",
      "r528",
      "r529",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r589",
      "r590",
      "r611",
      "r619",
      "r623",
      "r630",
      "r631",
      "r632",
      "r637",
      "r803",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNetLossDetails",
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r70",
      "r90",
      "r108",
      "r122",
      "r125",
      "r130",
      "r140",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r164",
      "r222",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r403",
      "r406",
      "r421",
      "r441",
      "r490",
      "r558",
      "r574",
      "r575",
      "r647",
      "r801"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_NonEmployeeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "NonEmployeeDirectorMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of non employee directors.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non Employee Director"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r720",
      "r729"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r785"
     ]
    },
    "cgtx_OfficeSpaceLocatedInPittsburghPaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OfficeSpaceLocatedInPittsburghPaMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to office space located in Pittsburgh, Pennsylvania.",
        "label": "Office Space located In Pittsburgh, PA [Member]",
        "terseLabel": "Pittsburgh, PA office space"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OfficeSpaceNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OfficeSpaceNewYorkMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to New York office space.",
        "label": "Office Space, New York [Member]",
        "terseLabel": "Purchase, New York office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r599",
      "r784",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLossAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease assets as at the end of the reporting period.",
        "label": "Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Minimum lease commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r458"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "totalLabel": "Total operating lease assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r635"
     ]
    },
    "cgtx_OperatingLossCarryForwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OperatingLossCarryForwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that do not expire"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_OperatingLossCarryForwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OperatingLossCarryForwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating loss carryforwards that are subject to expiration dates.",
        "label": "Operating Loss Carry forwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Financial Condition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive gain related to foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r491"
     ]
    },
    "cgtx_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including reclassifications.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Including Reclassications",
        "terseLabel": "Foreign currency translation adjustment, including reclassifications"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r14",
      "r123",
      "r126",
      "r131",
      "r155",
      "r443",
      "r444",
      "r449",
      "r474",
      "r491",
      "r768",
      "r769"
     ]
    },
    "cgtx_OtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "OtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r636"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other expense, net",
        "verboseLabel": "Other income, net",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r684",
      "r694",
      "r727"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r730"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r730"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding taxes on vested restricted stock units",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Payments for property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r622"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "cgtx_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to performance based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-based awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r279"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r538"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r279"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r538",
      "r556",
      "r896",
      "r897"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r482",
      "r636"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r225",
      "r226",
      "r593"
     ]
    },
    "cgtx_PrepaymentOfInsuranceThroughThirdPartyFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "PrepaymentOfInsuranceThroughThirdPartyFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment of insurance through third-party financing.",
        "label": "Prepayment of Insurance Through Third Party Financing",
        "terseLabel": "Prepayment of insurance through third-party financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cgtx_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r99",
      "r102",
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r112",
      "r489"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "verboseLabel": "Property and Equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r462",
      "r477",
      "r489",
      "r636"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r99",
      "r102",
      "r487"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life of property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_PurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "PurchaseAgreementTerm",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Purchase Agreement, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r296",
      "r313",
      "r344",
      "r345",
      "r346",
      "r358",
      "r427",
      "r468",
      "r469",
      "r471",
      "r507",
      "r509",
      "r517",
      "r528",
      "r529",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r589",
      "r590",
      "r611",
      "r619",
      "r623",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r641",
      "r797",
      "r803",
      "r843",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r296",
      "r313",
      "r344",
      "r345",
      "r346",
      "r358",
      "r427",
      "r468",
      "r469",
      "r471",
      "r507",
      "r509",
      "r517",
      "r528",
      "r529",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r589",
      "r590",
      "r611",
      "r619",
      "r623",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r641",
      "r797",
      "r803",
      "r843",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r791"
     ]
    },
    "cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary.",
        "label": "Reclassifications Adjustment of Foreign Currency Translation Included in Net Loss For Liquidation of Subsidiary",
        "terseLabel": "Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r722"
     ]
    },
    "cgtx_RemainingValueOfStockToBeIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "RemainingValueOfStockToBeIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining value of new stock to be issued under an agreement.",
        "label": "Remaining Value Of Stock To Be Issued Under Agreement",
        "terseLabel": "Amount available to draw under purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebtMaturingInMoreThanThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebtMaturingInMoreThanThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt, Maturing in More than Three Months",
        "terseLabel": "Repayment of short-term loan",
        "documentation": "The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months. Includes repayments of short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Payments on loan payable",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r264",
      "r281",
      "r464",
      "r470",
      "r478",
      "r595",
      "r596"
     ]
    },
    "cgtx_ResearchAndDevelopmentClinicalPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ResearchAndDevelopmentClinicalPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development incurred on clinical programs.",
        "label": "Research and Development, Clinical Programs",
        "terseLabel": "Clinical programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r591",
      "r605",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "cgtx_ResearchAndDevelopmentManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ResearchAndDevelopmentManufacturing",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development incurred on manufacturing.",
        "label": "Research and Development, Manufacturing",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_ResearchAndDevelopmentPersonnel": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ResearchAndDevelopmentPersonnel",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development incurred on personnel.",
        "label": "Research and Development, Personnel",
        "terseLabel": "R&amp;D Personnel costs"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_ResearchAndDevelopmentPreclinicalPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ResearchAndDevelopmentPreclinicalPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development incurred on preclinical programs.",
        "label": "Research and Development, Preclinical Programs",
        "terseLabel": "Preclinical programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r680",
      "r690",
      "r723"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r681",
      "r691",
      "r724"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r688",
      "r698",
      "r731"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "cgtx_RestrictedStockUnitsPerformanceBasedVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "RestrictedStockUnitsPerformanceBasedVestingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to performance based vesting of Restricted Stock Units.",
        "label": "Restricted Stock Units, Performance Based Vesting [Member]",
        "terseLabel": "Restricted Stock Units Performance Based Vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_RestrictedStockUnitsTimeBasedVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "RestrictedStockUnitsTimeBasedVestingMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to time based vesting of Restricted Stock Units.",
        "label": "Restricted Stock Units, Time Based Vesting [Member]",
        "terseLabel": "Restricted Stock Units Time Based Vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r81",
      "r485",
      "r514",
      "r516",
      "r524",
      "r539",
      "r636"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r223",
      "r224",
      "r237",
      "r392",
      "r393",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r414",
      "r415",
      "r417",
      "r419",
      "r452",
      "r453",
      "r511",
      "r513",
      "r526",
      "r896"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding potentially dilutive common stock",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of net loss components",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the expected income tax (benefit)",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r627",
      "r834"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of total equity-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r462"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment significant expense categories",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock units award activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of activity for options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of options granted using the Black-Scholes option pricing model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r77",
      "r79",
      "r80",
      "r81",
      "r116",
      "r117",
      "r118",
      "r175",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r291",
      "r293",
      "r520",
      "r521",
      "r522",
      "r523",
      "r619",
      "r764",
      "r775"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r173",
      "r177",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r602",
      "r605",
      "r606",
      "r612",
      "r638",
      "r863",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "cgtx_SegmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "SegmentExpensesAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Segment Expenses [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_SegmentGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "SegmentGrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to grants specific to company life science segment.",
        "label": "Segment, Grant Income",
        "terseLabel": "Grant Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r192",
      "r194",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r216",
      "r600",
      "r603",
      "r604",
      "r605",
      "r607",
      "r609",
      "r610"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r194",
      "r195",
      "r209",
      "r605"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r212",
      "r215",
      "r601",
      "r602",
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSU activity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Equity based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable for each award under share-based payment arrangement.\n\n\n\n\n\n\n\n\n\n\n\n\nShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award",
        "terseLabel": "Number of shares issuable for each award"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targets outstanding under the share based arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Targets Outstanding",
        "terseLabel": "Share based compensation arrangement by share based payment award number of targets outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options exercised during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options granted during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value",
        "terseLabel": "Fair value of options granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of common shares issued and outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number",
        "terseLabel": "Number of shares that may be recycled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r322",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life -Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "SharesOfferingAgreementRemainingValueOfStockToBeIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining value of stock to be issued under shares offering agreement.",
        "label": "Shares Offering Agreement, Remaining Value of Stock to be Issued",
        "terseLabel": "Remaining of common stock available for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short-term loan",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r86",
      "r636",
      "r862"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r138"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r107",
      "r173",
      "r177",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r242",
      "r243",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r602",
      "r605",
      "r606",
      "r612",
      "r638",
      "r863",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r59",
      "r60",
      "r106",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r155",
      "r157",
      "r159",
      "r174",
      "r223",
      "r224",
      "r237",
      "r294",
      "r392",
      "r393",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r463",
      "r491",
      "r511",
      "r512",
      "r513",
      "r526",
      "r576"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r174",
      "r453",
      "r472",
      "r518",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r642"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r174",
      "r217",
      "r453",
      "r472",
      "r518",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r642"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r683",
      "r693",
      "r726"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r56",
      "r81",
      "r520",
      "r576",
      "r586"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails",
      "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r56",
      "r81",
      "r328"
     ]
    },
    "cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units.",
        "label": "Stock Issued During Period, Shares, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r56",
      "r81",
      "r526",
      "r576",
      "r586",
      "r648"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r59",
      "r60",
      "r81"
     ]
    },
    "cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to vesting of Restricted Stock Units during the period.",
        "label": "Stock Issued During Period, Value, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Options issued and outstanding",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r73",
      "r540",
      "r556",
      "r577",
      "r578",
      "r636",
      "r649",
      "r777",
      "r792",
      "r844",
      "r896"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r139",
      "r278",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r294",
      "r418",
      "r579",
      "r580",
      "r587"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Description of Business and Financial Condition",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "cgtx_UnderwritersOptionToPurchaseAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "UnderwritersOptionToPurchaseAdditionalShares",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails",
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters option to purchase additional shares.",
        "label": "Underwriters, Option To Purchase Additional Shares",
        "verboseLabel": "Underwriters option to purchase additional shares (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "UnderwritingAgreementWithTitanPartnersGroupLlcMember",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to underwriting agreement with Titan Partners Group LLC.",
        "label": "Underwriting Agreement With Titan Partners Group LLC [Member]",
        "terseLabel": "Underwriting Agreement With Titan Partners Group LLC"
       }
      }
     },
     "auth_ref": []
    },
    "cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cogrx.com/20241231",
     "localname": "UnderwritingDiscountsCommissionsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of underwriting discounts, commissions and offering expenses.",
        "label": "Underwriting Discounts, Commissions And Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized income tax",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r380",
      "r626"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Federal net operating loss carryforwards",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r96",
      "r97",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cogrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r167"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r167"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>145
<FILENAME>0001558370-25-003341-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-003341-xbrl.zip
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MFJUA6N(^$=$5$7/DL'O7]42X0QM"I00UMJE%A!QL?56(!;K0TF&(!MH:X(N
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M9R6^&>Q.7N6:8[82&\ \+M9"S>1(Z(M(CY?M5S[UX7^/Q#_=_N&_4$L#!!0
M   ( /4Y=%H<AK+UD \  *W@   5    8V=T>"TR,#(T,3(S,5]C86PN>&UL
M[5U;<^(Z$G[?JOT/7O9E]X%P2S)):F9.$4+FI(J$%' N^W3*L05XC[%9V21D
M?_VV9!ML;-F2[6#A;-54)@&II:^_EM226M+7G[8K4WE%V#%LZUNC<]9N*,C2
M;-VP%M\:&W?>O&K\]/VO?_GZMV;S]]O)2-%M;;-"EJMH&*DNTI4WPUTJ,WN]
M5BWE$6%LF*9RBPU]@12ETSZ[/FN?]91F\SL5<:LZD,6V%"JK>]8)OACXTFSK
M1NFUNFWXU[U0NC?MBYO>I=)_#-(]0LWF1E9"T[#^O"$_7J \!1!:SLW6,;XU
MEJZ[OFFUWM[>SMYZ9S9>0/9VI_7[XVBJ+=%*;1J6XZJ6AAH*I+]QZ(<C6U-=
MJIY0]NT+-@,!O=:N+&8*\E<S2-8D'S4[W6:O<[9U](9?1?(U1R%!\FTLO8^I
M<WU]W:+?[I*"("-%] [V][\HRE=LFVB"Y@H5<>.^K]&WAF.LUB8IFGZVQ&C^
MK:$MW"U Z9YWNAZ0OT]=8)&8Q\"V'-LT=$+JK6H2V=,E0J[34(CT7R8/D=IH
M]@)OX>>J1;YM\8BAP+BTU?H(4+L/G?%\O$:86HC3M_2!O5ICM$268[RBD>T4
M0"Q2AD3J&*C.\MZTWTI"'A)W/)!WAJ.9MK/!Z-ZPP.P,U7R -H)IWT<HN%<-
M_*MJ;M C4DDR^OD=<E7#Y,-=L(0J5/&,;;!"]QTJ-_S/QEB3&N6#G"JI"FA]
M3<,;I ^W:VA4*">1+"%5 ((N8F6X@2U!VW)A1(>1W4#.".QI5SM1C )R)8.=
MCU,>@54 ?0 G;85FZA8Y3\@E8T ^?"ER*H8U09H->C8-.NR-Y[NO;I&%YD;.
MGB=/ 14KX@[-P:]&.OS1=QQ$#7%DJ"]0<S>W7>>07X4:IFA!VMX$K6U,6EX^
ML$PIHI!HK56L!=#\7W<5<4!*2$*WU_)3M)S-:D7MK&F 9]/(5$H@[:!.(%%3
M36UC>K(Z9Y["#J5[M0VE'(%D7SZI3F'G.U1[M'61I2-]]ZGAD@*NKR_(W*K=
M5IK*3B3\/A@_3<>CA[O^;'BGW/9'_:?!4)G^/!S.I@)\$'R$#UN+U,4D4S4;
M)ZN2BIJKS@N5MW&:"U5=$YV>MY#I.L$GU!2I5OT/_O!:12#45%^0"7/C@R];
M%51IL(%V:[FI-?/3_''9N_IRU>[U.KW>51N:VF5O7^>0H?1QM/I@OX%XWY3S
M6?H<VZNXTOR2;)%*VUA'^%NCTU V#E3&7I.R5+.AO"%CL73I-\<E@\Q0B',
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MC%PG1V8>/)DO=353ILM?6YY:_1GF]_\!4$L#!!0    ( /4Y=%I$N!OO12L
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MNAI7B2PK<)TXJVJ;GH8IDK;R*T$46JRH(=6"ACIP<"M57EG'%'M_!J$G$&Q
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MSH]^=]G,1(:-Z1L_1JL#J!*ZU0,"()X[=]ZF2;S$= C>-(9R=PLW1#)%Q4$
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M*\4K[0&1*#V_,,>%@1>/SJ0$BHS*K#Z -U4-;<H,W_#I&)IGB7XE]?NK6[4
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M92-GBG)_FL1+KE6-F7#UPF#6;)HBJ2=+U3$!R&0K$Z61Q"8J#F.]I%8RM31
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M8H$CK#N4+8?9#I@L_%(M R"EHG7(I8JDQ9;;+R<IA[)MJK_^?U!+ P04
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M;GZG:(;?H^KTVO>L<AO<'E8KZ6!/$U2)(&L0M&(G3'Q S5:WJVF*W_54^AT
MVUX[W"ZHE'8XX.64C;OB'8W]R+L(O7.VKF]0?K\=?B>LU6S? RN-<+M?O:B#
M?4^092M@CP#AZ3U/K+4O_8#>[#9/-*Y1N:8)7G]3Z9.YVO[?<7J94LJ^#O9
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M./EIJFRMGLHL0^^QF&XLO?_>)?RARZP6-D<N1BC8P06;>^H&3I+XKCBPKMN
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MP5L)JL-$ WQQHXTQRQ\D,T_)%"_2F5-]4'*U? :T+&/Y+5!>^KONN5"0=$%
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MGSU;#40?2>VHP&=?)SO8(Z68"_2,9;1ZM<U<>UBMJ O;;;E:]TY*(0\X=/W
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MF$4P-\D]2EB7&.#+B)Y4>XAM/,=*)57O8CCU2]^@CGBZ##W(+] \5=*D,L=
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M%3)=LY_^]"_9;R2!/_T?4$L#!!0    ( /4Y=%K<K;D2644  #LK!0 5
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MSXW']I?P'?V[_H1__236$"%.B&.?:A+V'")XXH%<^U[@N\X<H_7*<C'3GE<
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MW+!M +N2,>BH0:ZJ38@F(,&O(0O/$)32>3Y]Z2PP7!TL).A4E(A;$SP(0^$
M4" '@+J!>9IX)2@6\='W["H3QZZ>QO!0L>VL1K]62TN5QH-O-0S' X]256M-
M/:P&XYUU6KP+O8;AR)"EW*P%I[2?6Y3?QN%$DG"SUJ%/Z: )%UB!<R4E=0.&
MI"1+(V&$:#3+?YFY1<^,G-PK9ISTA0@T:R4YGL^=F( GRYG?>]?6JQ-:^_F-
M.:7S?,(IN+_T&P@R=)KERYSBAY<],+^UH(=62\'8MJ-UY.+;,3=@X=@.;?7
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MJ7_O/402/L>9K: ?+5>SE0/G3\@2;YC70"6;T TSC8A^AS!E+.IA\O,=LVY
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M84#N,1*2TCN/''-0M]&6WRD2'>U5=K0\(U*SU;R^C8:GPU&GID4-3G(/%37
MH%X;I$<0XNSK3R"^."QNB(8G14.$&AO@U@:O  [2]K2T0+<6]-#R<DLWQ[;0
MB[=\H7!O'#Q[0"VOFZ;SY)&[SR=%5*^U<PI")SY2QX<=$LI9$FBX:VN0-*:E
M9F:M,@FC3T<MXRD0;Z'E$S\TKGA4Q"7VA*8;N!W>%?# P@DE/ 95F]--^RO(
M/'<@J)(-O;87<4;NF?4NXV8<ED3\Q0T-TI:TM!1;8H4M [-&Z[G$]X?"TW96
M%=TT6D V>_G Y4CKM98^@R6V3%/PBA\,W%U1$5#5DN"\I+5!MCDM]76?;)Y[
MCUJ\9<?>WC@D7'K\FGEP(VA?=*NW/!GEW'@5R>NW[@J%VTN&W5\BT)V,JD?=
M#_Z2?OH/795?80#^[ZW?\$]NE.P-:1/_R[V_(U19-T/ 9G_1&-2@TJPWP+\'
M8+*X#4)G;874Q&'Y0GV7O0 U9CV 4)Y$0,P<"-7M.R*J$VE6>M3,8Y)BZ*!7
MZ#LD)"G3*ID:)=0O\PB:R() J$Y?Q5R=.+->\TH?R+M>67 IJO7L2GV%1 WJ
MS$H01KVP(H8.T>IY3B);=='MM7]9G-2B4ZO,-0K6#0% C,9KJ!OP!ER?\"&Y
MI1.S@[J X-;L.TZJDIA Y,(,B#R ( " O)8I.,LP:O0=$K*D)5"X- ,*V],3
M,1S0BO<=!%)TI4ZG$S,@4/[JPR1-B8-8@YCMO $\MP;,":1"2WT'CBJ24TP9
MXLF\]@GA, Z0=((_KA$!3H@_42-OJ#7ZCA%9TE(L&.+QW";:R.3HRN2"85H4
MH;I]QT=U(E.D&.+RQ"84@A4.R7H#XLXQV>I]QTLM.E/(U/6.:O,8W7Y(KQA6
M.+7Z#I$JY*7(,,2;NA]B(F-)A.KV'2/5B4R1HH>/E7+"<KL&<(G(^@K]'^$*
MVTS+$SEE$:F7Y\K9<'0Y[(7HZQ&8BMT01^DC^)'A&_0]]-$&F267F*V0;::O
MV%%*;PJE9AVJ.F3/G)%C:]%@OM,3]+_:*30'?XE[U3:B3W$NS?:C^K:CN=I<
M62[.;_^\ B!$)C5Z16HAG%B34UTW6\$3 F-O6X727D?[EB7<E#4&GXO&H#SK
MIO8:WW#ZS?8M '54E8_DM=5Z40%(',L;K/=[239E5?ZLJ/+[F3;U5W:5*3?;
M5^UG>P7FD0M(2/I>HDC">:[[0+B!//R_H.WU:;>JSI9#B1.A'JF]UG1&UC%9
MK3\O:CTS6Y_V)J#UM'WMFPD2,H*SO@C9!$IIW0R -,_+ FK$*6U4_UM_03,.
M)9J@)8^%V488D=K#S3<KC/"X!-$BW9*12%+#A59N$+6<]DUVAKDLSC#4W&_:
MSRX:)H'K<IE:R#HV_F'!.4F5&$<B!=@%$RM_$$3K^#O)I:R*3G2S4?5%SEH1
M-\8QLVZ]EC$L*XPLPY*G2<4FT?H-Y[E_CKC?[6OH;>%5 9?,NK7+8]+NQ6["
MKN^>@]B.M5TI8"5[.:)7#<O,NE>\X]CM^M7U-P \ _CFX(.9,@:.73(,'-2\
MF *T2O6</Y%PR&/Q1&+BH%;<WV'!NPWFM7)QNJ5LM)+[H^%)<7]43$FK_<9(
M46[:3GWN7NC,'3?"MR:>@8WW^ X(;M]M-T*BNT,JAQ$?I<\^RZ:U5=^1;G:(
M)52F [])?O3:T9])C2EK5D9%LY+-CZF]05&:*+-+LX*QZWMXQITLMD-,3E23
M/*^2:W3I%G4S%!Q)L6R%&MI-]6/<+A8 ;R]VAF.*5H!X0>;9CNOL_+<2:V?I
M)@U"FR+B375)I$E2$%_&00#(>4OUD 6IUO)\ONC\#D0-D-6GNQ4_05N)A647
M.B5QRX7LPMJO=A2E&>[T+&AO3/?>PH=K@HNK3?*CA!]2IC7=C %+/$Q/8FVB
M>[W;N0&!#9W7>)=W%06.!P)RO2&]AG#M>W,'_WP#0LMQA8W$YY.2IT4RO>%L
MQ6E_\?6&[<6';9>#OR2=:FM#)G!I><Z?A/]HV('O.O/T=8JGC&PRE[V?T3=
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M)P:@H3[Y9CU+&,^4,?%D,9[> J*M-6CEC8)*-6JU>GZ08C\(P'^@)E$G<2Z
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M;R$J&0;-[4$#$*A&>]>F0/TF\H%SL89>01=P*-DU2)+9>QR,(; FBRFPW-L
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M]8KX;S]A96V[05:,.':S4?P7^CE:?Z767X2[6KV+VCGR,P+[#3C+%9K.QF\
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M, \PBGB@52"[-%0>_; V6LK;R#'K_&1X.NKVH*-QP$BPP:SH=.E[IH+7*HT
M346:S4IL\=V#V\=W=SEE@BF81\2M@&]V1"[F#DYY^V"]!O@-G]=7U['Q;C3.
M2HB^>G#63LC,@-% 3^9BLBUFM1)-W]3Q[S-8XO"J*7CU(6:%]-'O:3$E?M+F
M8-NH_F>^^VS@'/C2BG?YBO+^F.X]I#AK@HRK3?*CV%/)PBWI9CM88BEQ RLB
MN,\G1<05CLF[B@)D7H,@H9;U;#&SCG:04"1DRBF"%!MZ#928..8A<JZ,=D"0
M%E>)R+D$=BABRN;XP5F 9]L!GIW.]:4G@<RRVLF2*X>];:T48?T_ Z9;.MY9
MGTA5[=#0G(FORHW>GP ^1E@])HOM;BRUEA3<4,OGV3/L/""XLDB+Z)"C6:N#
M0,I<D1#P%5I>6)I[@5+*0"'+4*K5D1U;M,D!).T:(ZNHX4(6(K</!V?E:62N
M447'MMPGZ"^A59C_)6KJ@@-IX>W)O0:U?;#EY>0]H2Y]S\,]BLI_6\5LP;/)
M[(.)I] %@5U9]TLJ&XX"08+[.Q%\L[QH@7@4031GBB,A5\UL#/!)U2HHHOX!
M=_PL01DK$J;2#KJY%0T 2DUBS8J%^ H\_(X>(G\\7R,SB3F(+W6R<<*I91!(
MJE!J5BP$#DNT\2UWVL,[+*"(538(+S4(5A1UH$U:Q_WM/+&W>!//# SFU#((
M*E4H59763P_34N]Q[/,1XLE%WSU6XG2J6J,VE92"]!4 ^Z>E__8)V/.XNWLO
M<-"X9]":X_@-"'$L>^[@@1.1=/;Y\UDQ%05I=)"T.MAK5C0@*2%9%7%/ONO8
M<<HK6YRX<QYQ:;/DU2*267J."K9!I[U)Z+S>O&"+84<8+%,G^ /MJ*R8WVAE
M](S71&"YV5$A2OW9V<D^];FN!KBOP:XSPH*TNT&N/QE>_/53;&F2[_[V_P%0
M2P,$%     @ ]3ET6I42!X%:$@0 T'4C !4   !C9W1X+3(P,C0Q,C,Q>#$P
M:RYH=&WLO6=SXDJW*/S]_ J]LY\P4\=X))$]>\\M3#(.@ E.M]ZBA-2 C)"P
M L&__J[5+0F1'+$M>_34.;.-0JO#RO'O_S,;:=R$F)9JZ/_\5]CG_\L17384
M5>__\]]<,U^I_/?__/Z?O_^_6(Q3KPX;IYQBR,Z(Z#8GFT2RB<)-57MPP+6,
M\5C2N3-BFJJF<8>FJO2)^XK [V?W^?TX%XNY0QU*%KQIZ ?>$_O"XF;>'1AO
MQW^*//R?F.3$ SYY(/)<[FSQ)'OY5.V:DCGW5G$ H\$'^92X+Z028GSU\28Q
M)ZI,N&.CRU4*!YQ,>#%.>LF8%$^G8HEL+Q[+)N)B3"$)(2L2.9$2LFR,@0U[
M!?NE6P>.%>M+TOB?;P/;'A_\_-F3K.Z^8?9_NC=PSHEO[L.:J@_])Z?3Z?ZL
M:VKT:9'GXS_Q=A<VQ'M<GBO^T_1)B\C[?6/R$VXLC3NSU*5AIW%O4.'GU=EI
M4QZ0D113=<N6=-D?'H=4[.4ON*\E?[*;WJ/JS([!QY<^XDU&U6'>!'?TIVU*
MNM4SS)%DP_[#0$(RQF=B<<$;QS+M]9V"BTNK46?;]DB(![[F/6Z2WM8]3?V$
MN]Z#CFUN?3#[$^X&-T9]X)Q6-U(AZN9S@AO+*[.,A"BD'QJ:/>&^L.E0A6PV
M^W.&$.B-2N0M8 (WEL%D#?Z6QL2["XAZ 4 !E&Q>VD,@(HHQ7HP)J26H5#="
M98I!I>KC1]]>!A79Z)LS^'=$ERV( 'B__QX02?G]]XC8$B<;N@T4ZY]O-IG9
M/]D>XNLQ<N>HDW^^N?=C]GQ,OOW\_;>MVAKYG:^5JY56I5;E6D?%1JY>;+<J
M^>;>?_X24ORO2C6_WRD0F8RZQ.3BPAZ'G_[[)WOU[Y_LZUU#F?_^6U$GG&7/
M-?+/MY%D]E4]9AOC@S@_MG_!/'_"[:5G%-4::]+\0#=T@@^HLP,<C9CL3U51
MB$[_A =*IB3CAG*.KMH-Q(@V_-%IPODHDJETVLU"YUJ<3J;CE'Y8E.Q*/-.I
M)N/E3@XVTSK050TVQ73@*.D>S-@8.:M3ZW4$L1,7.KBLCBC51#->3>3:JI)L
MQ$Y&XN2T,/W&Z=(()NR2O(.\,1JI-O(&*Z<K>1@0F @P$Y58WS@5@/6(SKTS
M/XPW$XG+P_MA,S\[[YS-Y]HQC 9;L;RH=UUDO'.4=\KMJQMB\N+A]5WRHE&9
M)(Y?O$CM^*Q NEEGV);T2=\N))OUX75N^R*KP%1-55Z:8L$Q*;ITA(Y[$"TC
M>"SIXSM1&%SW3H=Y];S3O9]D6Z7!N3=CH$('19B>/<_#;$U)J^@*F9V0.9MG
M2^[$FX?UWIUBU_B39#)SV:Y/X@FSWQ$[@#\\X'PBF8RGDMZ,W1F^[80+KG11
M4BU9TJZ)9);@BN5/^;254/OJ-=\KEN\/R5'2*32OK_N=!$Z98>"'3;8.7S"4
MY>F.8H?3_&%%2!0OVY-<?BJ:Q=FPWTGB=$O7[SK9',Q4H;/5I+X_P4ZS><^?
MG><E_L2V,GHG?5&U1^>=%$ZP)VD6V3+'QW#2&D@FL3KQXMU=I3-5XL/8]5G^
MS!E7>JGF](6(J!!9'<&<_OE6J996\;(.'!]D3Z(T;4,>-NGG:XZ-G IEV27<
M+)_&1$FY*I&V>I^;GB>K"4%NG0/,OY0"O7RUVVGKSE;;-GNB)9QG4^WFN,_K
M1\>Q5L/(?<AJ=WBV%<MRB+*T4.>,2+>-7K?4+E?:DYG<,I,#Z=,?ZX:%7LR;
ME>*Y<Y,9QOJ5\XG=F29R@-,O7^A#'/3!XW0GWBE)JGDA:0XYG/M_'JD$U#)Y
M,#\E$Z+E9JJU_GA%'P/4T@?B9U26ZC0O%//:N!K90T?*3U+.=?>X,NX'-RX6
M7]VWG&41V_)'+0 ]U@S+,<G2MO7/+^7BK5*=\F6YK!8[DT3VROR ;4N\Q;9I
MF;1Q<^Q4CXOELRM2.[UIG-93.]DVZ7[<[UZG)VF^W%).I<FT<IVXF[[#MJWR
MO/@2SXMW-+.D#FXL/<'?];/7@[QY?!R_?&3)!1?!*CJH"Z0ES8JS,=$M<DAT
MTE/MI85?QB\JV=O;X<DP?W)J7_7UR_-)ZSW@Y:7,?E<+GY_PQ5:?M'/#LJ#G
M;B:6E1QTWVKA.U=#EHDHA>QE-M%53IS)^'@XE.Y:I%VXCO%DT/\DZL=CBR-%
M04V*A<ZPG6H+HQ1?=R97S5?H5N_. E&_,O2'^=_]E>6H\RM)X$?GN:DPOD_I
MUSHL,IG-)!.9=/K3"#9KB]TFPQT=EG1R=*]UAF*ZD$W&A&EK5 #1)BX*J60B
MG7F.5KF5&]5-8TQ,>U[7)-T&Y;9XYZACU!@.YZWYF"RQ(O^>RWZZB=[I5)S'
M-?YD1IJ-F^$AL>H;H'?+%]H6Z3G:J=I;AN9;/6^53L5*L4VN+LY;2M^P+^>P
M['IRF^[T7B38VP?0\>V*;@%^XS+H%J%YJ@/78 1=)H"P(]49E50=?L&QYOHF
M(8&-$ZZ;)XGKF^M.\9)8A7SE*%]VJM.':7F#C*4Y-4'4>CB!,\EV3!B[HI\9
M)FD-)+TU@*^<P7H&RU:)FW2C.CU,7,:'M5SU[BC5."T6@'/\3B82H/!_7KS9
M0"2$=F-^*ROSS/!.G?2G@WJ^,(GG'D>9\%/$;42BF4RIQ_>'Y=)PE+B(C^QR
M95(6GT 67V)OL$R[TY#T/J,*^.M,U=61,W+!VL./W!3VS*<>%#4:!-!%E6V7
MA^'N6BUU1*A/Z )NPKI61BD#*MF$P!G8CK5$A^B.T#?K#"5RIHG3PC^+H[%F
MS $/V& 381@O]#,7C:+4GQPER,W]0!;[J[N]&!#V'24DN@V!40_GZ]_$1=)_
MW.DS4Y"PS+3X"T6?I(SS=DP9G!8O1S>C^03$CGK\978@?O/!Q%/Q>F>4DJ;#
M9B+A=#(-]2A_Z*^2R,I!P]&(P'>3 BPJIQAC.(B%2<B3^?.\>%XY,6KM>?WB
M+@'D-UUNYQXV";W#=%OF2+?79UNU,\.IE$J>%\7IO79:G#>NLM6/F6W5T)^R
MOT[BN)?IWY6[Q?)Q5S1(X40]:4W#,.,M6SQU8I5RLI*N%,MR:4)NKM3JR.EO
MF_#/94<%E5D),$/K]]_H;3JPJ",)5L!1[],!.E[^^6:I@+#H5:+7!M3!AQ0C
MYGEU]F>6@OZ9GRMCTI^6X9CT%W7C';B[1-?P5&;NZT8YQQX8IFK/EVA- 6X"
M>LMYP]%M<^Z2%3-NM^]3G1.;%\]FA\HY*9Z7B\!2W7D0:H'W?JD*_NZ!BL_1
M/2 ;7:OYRLFR 7[U96\XB_21_K"?"GQL-M94675E"TX!JJI3Q[Y/WC8O\=MO
M7TW<M,:_?VX<_[<W,7\:/S>M>4R)H3]E6S+M@F03:JZ/\0+\GS^.?\_?/&7Q
MJ"#&XL+B$^R.]]O[R,^ETW\*,*Q:%7S. LR&L1$04NTY<@-#IVZ?($SD%$7%
MT22M+JF@7.>EL6I+V@K_:CI=2U54R9PW)8W4>I3Q+3AB#B0X<TCL6@]@>L']
MI-Z%?AK7NITBZ35C<K%\'KN]R845LA[<KP6 /;AA6P'MZ;/8MM/??N-6'VS>
MZC<#\/C3 3S^5@"^C=J](X"7#$TSIC6][G1A>U? _*8M7S;[S=*P*!Z.Z@[P
MF+S3F49@_AHP?VC#OS0U#P&P;Z'FHEKH*Q=G=];P[NY,'I[.AKK9B*CY9Z+F
M80#P$(@K[ NGJDY\JY8[P+%<M+2VX$R&S=SQ7>=>S)Q<7O8C&'\-C&_=[2\M
MM(03S!?!7\P2YPXX.TDW)D>SRG$Q=GN4U8S:16<2BTC[KL%^\^[_F6BP*]"-
ME4]KO4*K<%\\N<W:G;S==9*)T%HO(J!Y>QDXX&YP821M-Z\Z=Y?G)3Y?:5_I
MQO'-^7WGLY.WM65&4N,S0.)UJI!3Z  P6?I)\4ZJIV.I&V.027UV,?'I /59
MU9^O2-MV8<!2TL(\KVKY0=LI3KJMN\)HJI,(G".C5<B!>@MUOCJZZ]QE8\Y]
MNR846]KIT6!*[#^'W7]6ZAP&0/X@,6.[04H"JGRM%LC9L):M6N)QVAR=U"-8
MCHQ0GPR<MVCOP^+HSJP<UBU>M6:Z: QK=X?29W>=A0.\_P"[P=9 X*?!=X/8
M$NR84I1,'3;,@\G<\55I;/1;UT-U?C6^E(WQ5/GTUH+-:]TE-+"D>GL#>_;N
MO/L!/VQ%G[22):W=ZZO%NYK=O+P@D^(X]]G/^65&[W >]W/YU19\GI_$1?%&
MZ!;;J9B=L1/=S+$P^NS:[;OB<SPD!_PP/M^:HZISKI#IT#F/VY6+J721Y"-\
M_L3'+<O.R-&PE%+-'A 3'S/) '=R0E@<J!?".DF3R?1B4AY*U7RQT;H[N3="
M[ 1ZXM$_=?F?# S$W9#U>%FO5X?&5!HV<_/K4_OR;&I^>G1_5[(NAN2 'R;K
MNB8T.L?MFE:L-?GSJ^:M<9GM?7K<_@"R'IKC?C)9CQ]VQ&-SUKD<UF+U^L6P
MG>_4TY_=.O#19/VMP& 7*:6B%X:G]>9%?J9;?+Z=.)5EM5AOA=<AM;Y>URKS
MY 5_6L7LU=G#V4J]/5"TX^2P1DI$K)S*B0OM*Y[TIQ357N_)FXBEXUFL/\\6
M1\)1L7R?Z57'E=">;QA";T)H6-EPK,9]71X6[V]X1ZE=)5.6<WEQ%QWKYU*L
MUH_UT$Q=G6FED_+P4CKK%X2B.F\7HF/]$,$JWA$2*S3X%2$^S48G5=<F_%61
M)&3+[!YEBD4UO"<;DD";)5K, ]XF7G^Z3XV=P1(S56E$5MVJH"+@E"<$'X W
M!/>$IXV[Z\.K3$8>BC=Q\:IT58@W3T*K)P=7M^3#W+*\+QUUPD"@\TH .-</
MNT/'%LK#$1$RXXP0/VN40HOBGQ, EAY]^SB-)Q:?J1.35B:'G7OK&C1\VXQW
MB%YJ\I>)CFDF\BVMD@JMU75I_UPH>_8&OCYZ8VWG%\+)T[?^2T5NO P!%AZ!
M]2-L--LNB!X-Y^9H$AOWBO.CK-2[%^>MFUEH&>$*B"X< 0\L\4N!PO9J?NO\
MST4(NB5UQY0'@#CXF'ORI;*5X[5D_8I7A[T*R6:+U4DKM">_B0,^O,#/86;(
M=H0DG*20?N D:2UWHN1T!0$=;>$;F;^0=D_VKEFYD&.ZD>5KHQ)_<J27B98,
M+=O9<++/7/#;G+20CO'9F)!\_4F_0HEY!(<SA?+U[5%I<EBLE>_4VD513-T)
MGTJ*?3\<#JDB\_0BB\6;8DT@9K):G,]..V/QYN1,FH3NL&'>!_XJOOW&GTO+
M^-./5)H%CC1Q<D+4NMR>M\5A2A?M?NE2B7^*(PTNXTL?Z:JP_1B6JC>'>>%\
M+BM\K= D5Y4[]>RT$#HW_(=A:1CUI\>P=-C(*J?.W?EY^R1KC*OI[M%=Y3!T
MDO*'86FH]*"7Z,"-S"&Q[?AUK#@?7$SR577>N0]O3<^/UH'?U>7ZDN-LQ<HU
M,9/0[XN2G2;U0;.FC,)KVP_1<>[,U?KGE!,/&5"]F*V_%%RW&HDWG\E7MPZ'
M06!]K@X20F0;W<Y'98=O]-I$/4WGC72U?J.$SH#U8H$K0K8OBVQOC4QTI*JA
M>UM<4$TBVX;IOFC$)O)$/(KGVDVAJ)F5YMG9(+R6WQ""-YW#UOV-0#D4;G6I
M(21N9#76:COIM'K"WUGEX_"QA\BM'G($V!8YB&=5ZP7V8 'X;5TAYM14[6"P
M^J5J#UHJJ$IUF+1.3*ML&L[X5),])\V)71LHVN2P71:/+F[3U5N^$3Z[O0<,
M&U?O@NU+EO]FIH=WCC!\J]9O(06#4"5OA(14O+*)8LDQ@<X[)H'G2NH,__+2
M<RN]EGT\36D5?L37F['.12=>G(26HSUAT0OFLGW5G\PH^::=,[_"2:\L]9,=
M;WS7.#V]X_/"6:XBM_/:T?F-7AW-33G"Z5 E ;WLT%=QNC::.D="MM(:7C:.
MC''[OG9Q?1Q:AT,(<?K-' ^[*ZCO&5AF)\?5BZMZ>BCUDIU,W;HO34.<H1G5
M>=P=4&RIGULHW9=/AOG#>7MD#TC%B<^O;Z>?%B+^P!KCFZ)!:#],8HYA.O/E
MB$Q %MG04-<=NF5(2HZN+)3]5U.8-C\[&29O+_)\ZM2P;F[+-6>0#1T\H;-C
MTR:Y8/3(+KW>FA51MC=HH_3T4C/G-BFG6P.=KW5B]ZVR-K](S4,K\(2YU,R'
M@]!6)?>1[LAT4T%Z/#5D23MV3-525-IFWHNI2O3FQR,G2=K.4*L-Q=9=7NR%
MCHQY9_]8G^1'5AMV57>W'0BVE)A+GK>[J:-TX[@XNN\WKW*VGBQ(H=5W0U-B
M[L-MF[ME(EN 8UBOW4E'MUF+5V/UJR,G=7LAST)+#L()'!_('OC.2LV4IYA+
MJ* +BH0JD^98D@D23V"N%;VNVK;5=<S^H"ZY\!$[O^C6Q>QEIIUOE_2SKGR1
MG5V%EG@\R81"Y="G+?^-^(<8$_@ P+R!)7Q#;,"J&YM*YK4Q4AB/&)2E7JUU
M(0[&_%W5F!>DXZ2NA;>6^";__>.+_"HBP<M.^*A5BNNSV?"Z>*??W]YTI4(M
M<1A:<O_Q)QPB(6 )'H1.G-]UN<K49:DX+)U?%=M-59[/[POGE<1=:#U@X2I7
MN0(GPC/@1(C%^5W""1^4%OG=U[J,3RV [/GT=%@^URH=NWMU>S@.+0D);[A$
M?%D(>$1JY'<I-;X%]8B?)*^3IA,3VI?]>3I3T<YJB=N(>KQ C@@2A%>+AF]
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MSJL#"^0JE8H?@>:.V_ -%27 20Y[=7J?IY8RF^F!WKC[M.W1F$[<5X* L(.
MZ8?%4C*_$O>*W,&7*0.-@/!9%15D'CG]!OW6WS>7ER\:"7*!?G-,?MA_5138
MVP"]VZ?]*39VT7_N%>V0DXI,^&0ZT^'EA-1)=.5>)\/+\4Z2I.%_79)(RVNE
MPA+W9:MP=689;3*^3 ^-FYL^27M]"):>;)'S^/EEO'W'YX^S=T+<&)1%6M)L
M;<Q,JM]-6R?9 2^V;J^TD[/ZO$3'W'7YL9U%'@FI_=36 B]<$H^1\_^* B5V
MW\(%#R 9'4!T -$!1 ?P<0>0B0X@.H"O>0#/B59\MCCT$55]<NA*-$RNA#['
M2N'@F45,GDEMPU#]8;=*LKM_N'T5Q2_MT"JE:]4)?VCP)]GDZ*S3.CZ=U*=N
MQZN'=*F$N(L8J/<_EU= 'M;$B,#N96"W5$_DM%_6IWSCXGI8*^3/Q<*%7KD]
M1*"+/Q:49NJ6S?U'&HU_<=>&H_>YT]/ZKN#P6;SH(^$0R[M31A7R)885%KW]
M\^%Q7CV1S:(HE-LI[?QJ6+"RO;F$!HSD8S; @:I)"M'& U7:X^JYCP@*_! +
MU&ZFKJDZB05$.2_7S*\SN+C$JC?9*Y4(Q7T1S>'+)9V>6N_I0;%KS:+^W(U1
M5&NL27,$ ]>T]>1="F[+4T5%_H6B(O[[/T$IN"O)P[X)M%5!$YUA'G@[)VM$
M,F$O[(%GFA/I^?1)C G94@^P^T#2IM+<<FE.)K,O)KP*7 ?^[L<9G<ED_LTM
M_EQD. 5F@]:_@/2]E)TH\/OQY+]7$A2]BX_(^B[D(XR(PCZ:&T?PTUU70MA/
M)]]<[*?$5N 7WAR)&YA(Y_YJU?(;SQG_!G@R1Y*V!)_NI6^_6]3.2CV[U&"Z
M2)66@D<?V(? H09[.\1@&Q>S=;=V<7'Y3-:VFMU$Y^UW?(+[7TZD;_Y85;B6
M3W.\FFS*+FT9WCL6UQ9.4D(RH202'442NYU$"O[)I)+Q3E=0>-)-\HF4(BW;
MK>DFX^]7'VQV$[U8YWNK1R]N<^2Q0?>3FX:%0\X=GA:Y6HG+UZJM8K75]-UX
M7Z_+1R"37C=H'CT;-2ON9[?*,G^DJ8"!R]M8:[:=@KC//U@E/R2'\/35,JG"
M*QVYG]VJNKW#ZEP)9XD$^@M]9(%/M/V\&+O""M9O!\H[X1$/L83G<H%7EO?>
M .D?6.-[UYM3EQYJ;P"<$&'FGV_Q;T_9'8IE[U\F=GGUDB^P49F<\N#@!_]S
MYQCVKT<_RQ[[M;J%WSS)LYYKM"J=3":>RL;7]OPE![LXH:W2JW=F\&FNPDY-
MVG)RCYDXOC#A>A\J]1'+\Y!M&VE^C _O' &I"/M&NQ!Z:'XG0E.QR4CP,K8[
MR;3 BQL=#F]$<WR-&>?AID3L<]Y\UK3F"#T_,7I^^YW^?&@8,94_'&HCIO)"
MII)KJ-:P)&'2B=6)IX14)O'!C"6WS^&<.'=2$7?Y2GCZ[7<\\_D0,F(O?SC8
M1NSEI3I+6S>)96@3HC1MJ=?#_!;TM'52&=!B/EJ'.=SG%O/CZ 0Y;X81W_E*
M"/SM=S;[^3 UXCM_.-A&?.>%?">?GW>)Z98BFG<263&=_3#%AA/R^]S2A"+F
M\I6P-&(N$=A^0K"-F,O+F(M8-XTQ+AZK>"32O"A^K!HC[G.+&46<Y2NAZ+??
M L]_/F2,6,L?#K<1:WD9:XF?DKZD 367"6UW9G7$M"BF,A_+8.+[')T7%YA8
MQ&>^$KY&?":"V\\(MQ&?>1F?29RI.FE*/6+/"ZHE:X;E8$W"1#:13'VP-I/8
MYW!R')L=%YA>Q'*^$NI&+">"V\\(MR]E.5$:Q5:.1-,H*IUX'.@__R%Y%%$B
M142)_AA*%$IH?D?A-WE&:_7W#'-1@]ABQ:^+=PYL9X-H'RL#)_<Y-D=:/'U[
M17(VW3UX0J.%B /ECV$ VZ95D'6%JV #&Y.K.Z8\D"Q6ZYR]&RA$'(G77XDX
MH'@M?#XR$#&U/QQN(Z;V,J:6:KI-'4M>E[*"9$N=),\GDJF/Y6:I?>[_-@B,
M-B'*_Q]QF:^$K1&7B>#V,\)MQ&5>QF729WYO5@LM\PYM50(J1L[MZ&CT2A_+
M;-*H.JWUCUW,E>I#N4#_29]?8A4XA34]QF> 8SD::RM:&Q-62C/2D;X4%4#N
M)7X^?(^XUQ\.MQ'W>B'WRIUCQU_5I@7D@,C#3\W]Y?F9/YA[Y?:YX!PI)PK,
M,N@.YW)=P[$]0R&FS$?<Z2MA.7 G(=*M(KC];' ;<:>7<:>,KXGX;2\M(/]-
M9SS6Z"_)G'\L=\KL![2EQ20IDUJ:)H>VQX@;?26L1FX4Z4H1W'XVN(VXT<NX
M439/&Q);2.\5T#JDODD8N<>^Q#E9-AS]8[E1=I]SYXA-G)$'+4V3]5IF$[4Q
MP@,;.;L_L5LTOK#@9@N]*F);7PG]@6W%$Y\/T2.V]8?#;<2V7LBV<MC+QS0T
M5)UHNJ+",EOBB6R*_V"&E=OGO-E1]K.87\1TOA+R1DPG@MO/"+<1TWDATSFL
MV0-B5O0>$GW:<S.3SF3Y#T[;SQ[N<W1B7&!F$:?Y2AB+G";Y^7 SXC1_.-Q&
MG.:E5KF%H:I!^I*):RL9)O" #[/&<=G\?L!^QOGSXMR)<<>.J5J**M,0.JXU
MD&Q0?<B$Z#9P)FM,Y"BV[LMA>,29(KC]C' ;I??OG'&Q]/Y*)Y'.IK+)C\GO
MCQ+\(UKTQ]"B4$+S>U9_YPNJ26CWJ.*,R Y&SM9Z/54F)KH%\H8Y-C[6-"/P
M*#*[<]SC_%ERWC2I?X!.U)1LPI6Q+S;ZJB/W])?"<)224Y\/ER/.](?#;<29
M7LB9!)_4YXW1F.@6<Q>DXLED]H/3] 5A/\"(@M.+>,Y7PMV(YT1P^QGA-N(Y
M+^0YHEOC:UZ;ZJ!:#-2QT<O#;DBJ?DAT @J'^L&<1]SWZI#-.7^2F'GO3I/S
MYBEI[GVJ'RT2_=V,_:U5T"(.]I4H0<3!(KC]C' ;<; 7<K"XRP<HA4=?,; '
MM.2Y%+]E2A^<BR+$]WU>M33))<:$\[0DYNW><S-6F V0J^@* 7T+8"(R\7TM
MI(^8502WGQ%N(V;U0F:5J)NJ+JMC20LD'Y8(H<G\Q)RH,OE@9I7 AI'N'(,I
MD3A)ELS/IAFI35\*HR-.%,'M9X3;*"1KYXRJ+IEVY:(33Z3$K/ A$5D744!6
M1(G^%$H42FA^3YDX69P-8.=H0:OU,E=->4"4#Y:)D^C\9G-<*0WB3Y.C\W2T
M2"[^6EB-<G'Z\^%OQ(W^<+B-N-$+N5&J! Q X$^:S@@F,>]D^)20$CZ8 :7V
M,5]NQ E\[(1S9Q;QF:^$K\!G$ELZWOZTI:Y&WO-@A&<<BZ).O'_A'Q]1-2*9
M>"H#]X,Q=D('<?QP0*=^>^593(QMCE_\/WQ27)WZ_P3GWI7D8=\T'%V),7KS
M%T__]RNPJ '#59%"4I_$NB:1AC&I!]\]D+2I-+?<1::S^_%__^H:I@)W>&].
MN N S/OQY+^YP-^X&VM;.9)FL<"&N8 ;TTC//G!?\ZY1H/,O&A9M6'%@4I_C
MA.#H2^/2<P'"<" *^RD$#?CI+BPA[*>3;W12"PCDV-+]<P%"[Y+B5BV_$3H?
M)9HMQ!4:'01WL=3?&IE\'%3IUL9@&Q>S=;=V<7'Y3-:VFMT$^B1_QR>X_^5$
M^N:/E4-8.<T%8?+/$B]M&=X[%HE3E7^^=7KQE)1.9;N=;$K.=A*\0#I2.IOL
M*')<%.5N@LC)]#>V$;LYR#7[S4,&+';6HG_6^5R[5:E5<XUKKEIK%;E&L9QK
M%"K5,E>J-2[AS]AIK7:"OYNM7*MX5JRVFO0 =TXN;AW+5GMS=DE%-SL@-K\O
M)#? ZF+^K8%J<3E==T +;)"Q8=I80Q*YM)?%$SO9XPQS^9D]3H9Y2*IN8??.
MJ60J,<TPANA@L18UD^$9F9@Z7C4<D^LZEJH3RX+A_&8S5 _M^7HH7*=57."]
M/4ZRN"G1-/POOC[6) PI,+JWF$P_<=TX9(:Y]>Y@V$DT^*4G?8C>D;V^./M<
M#CX96(1!J\O8 XK"BZL]#C;.-DQDWK@]LF.:J#_W)-G&8IVRYBA$P:J=]OH.
M2R9Y8-_VN0I\RQ@13L9&IGO<W'#@3QW0 V[#$3^TY]TY!P +)!!(?G_.68X\
MP U$EB?ROR1UM$?_%'[YEV!(])+99.V.93FCM:M=HJEDLG89X8&,QMJ&<?"6
MJCL;KCN:LGI1(18 \]K5];<)0/MHP]<80*Q>[1N2MGI-1<JZ-H&1-%^]Y(/<
MZ@T$R;5K+I4C:R./#:3DZOI$QB;!RA&KERU"AFO7!ILVS0;T)FOO3U5M[5-3
M?-V[AH#/P-M2@?Q()F*326@/*0M!GD&J.SUZ$> >@!VH"\"]#4#LV%@.@]:Y
M<%&,7;$!&12+$@[X *>3/NOM >_#;XM0(+7P-IN ;(S&DDF97@!\*28@(\&/
M[P7!G"$8PKZW,,*YD.FMSE@L:SPP:4M@8,K80)+1"'RZQR9MC%6=+4^GTP4&
M12: &( ^].@947@ ZW";W&<YV^!,U1JRD1VD@$@HL?LPVU( ,,!F!_8 2 42
M!=/MP@4O*FJO![N!<&T"H&B ZJ8Q@O<,>-P]'$I5Z,ZJ@&\J_$2<QTW=>W"*
M,!O<:@+/$$93&#!QNF'#/!4'O@8+G^,F4+(1I$@M>FC;UN62NST@O QD<$@-
M-A\CPFSC@#(\*O[[PBF5)%$PU:2Q10Z\/W[M0"3S9/34X@I*AY1=XAQBF@2K
MMP]ZZHPHFSAH0"SQ)%XFURT;%]S',GCO9_#&J]:PJO#B]*C6NTTGI!-8U@/_
M\U<VE<[^6E4V5Y3%75@"%@+4XS(M8IW$=#&*))**..!B-^"!+(U5&_X+]WH.
M8B4\O\+ /59"L50!9->,,35;(UUR%EPX0(G&IJ$X@); 0!55 8BV%HK?FFX:
MP6@$HT$8]>$-1"B)ZQM(4UVIE@J;C+?-@.B#I KL;03/#R( BP#LJ0 V0A8J
MJ4SLT$"CH,J22\R,T0AY,:;Z>)))5;(4Z8[+NZ3RC#9&B^ M@K>'X,U3E5
M]NK6H9JD4^W2Y9.T6!VH63X;-LF=HYH!Z5$G1&$Z=H!INRJUWH^ , +";4"(
ME$O60,="8XDN47ASB9QOJI%<B2] '$$+D>%6ST%%".]C#Q0.8!FU%)B>3A 4
M)]2(\V3I#\BH:3C] 1,O=<;3 V_X\[11 P/\ *7+OV;9H'2ZEJ>@^(D)+Q,5
M=:$(#2(T>"+O[Q.=T,I'+NEENOX*X%J21C8BAR0/T-I!;_E2!+S5 ^+-GHI
M,0+%ARBR) /!E.2Y1XH!>&[=.K7,M+Y!;*#BA"\Z;!(5\*HUX!P;8/!>8H8[
M3WK8+CQP$:Q&L/H K#*K/D"0@W9<%V#)S%68*,11^Q#^@< X ;(9L'J"*(%%
MYU2B,W"G]DV36#"*3*PEBQ/:]'6B!"Q/$1V-8/-AV$2_#@(1K ?@:D DS08P
M'*L*&:FR%?"SP!'1$ L*PJC?.RA7(@PIJD68MZ]/C+$!_)L)H8XY,E1M+^#P
MP$]Z<FM?,[KP%'X :+1K1C7TGJ:B%Y)Z:F03QP4L,"4%10T+Y%J7R'>)/26$
M&1;:NLKJBB#!W^,:CF6ITAZ7'P")W@NL@";2F2H^8QG4E>KH."C(R?ZD5=WR
M9) ]=.>8AJE:H[V%MX?Z2&$'IA(=4 .TUABO <%>'0$\V"L>X\7R([$]PO'W
M%]L7E0L\2YRKG"(8WV,JZ0C[B!+N>[XE9 3QQQX%5(U(RKH.&@%;!&P/,13=
M !)E^W*Y- 8( G4/.0SS]'ML )<0_Q43N>^6VA]),?$'$'B9C+':QG?7,=X4
M&ZY'_ ?ULFMD1@<"M@ $L$]BIENY0R&N0HI^>H\=,9*I6O2$W8(>U)HSD#20
ML+ Q[91P&&F D2_P'OKF#,Y?1<#:PT)1W+5$*!"AP$,H$*"N"+0^R,-R_$ *
M##0P,)!#QE@I:2*I&AY;I$M&L/4@;(%0:*NN90*H4=^D$J8+<1C9B-(L)73J
M*.".>P.A,X+4"%*?:"PVNM3 NV3M!97/ =YMF'..1G\S1TB/8R(H-;:M0"C&
M>1'4"B=HW.M+KAU.A\DKIM.G*EJE6MA#/JUAB)]O#)3TN0?U\,#R?6K5TWUY
MA>EX4=Q-!.W/H\N,W (EEHTQ\VMHZI!HZL P%(2M +CW "_TO@N9*%).*/E=
M6 G0LJP%W_">"AB[(_",P/,9X!E,&:!AS*H)NKUDNA&P:'?3F?L$]"%[L"U$
M<1WPEHU[P5$Q*P&>]<Q>FZ6.8)X$?3V&KV/H/])HKXXPS-O!W 08P'P(U#]E
M(EP\2H2+$N&^3B)<Q&[^<':S&NIAVR:Z1)B;AXK^EHV1(WU5YB@\=+&%E@&D
MGG*> -?9"\A >VX(_6A$3/3<N.YYZEN%G;0BRTD$DT^&R:78O"!,D2U23M .
M$HAJ&M$(9N;$'[/QJ7-1W28M4;,?D^;A_". C0#V(3,RPB."&<A_4Z",+/V0
M\S,Q7?!;9 YO@=M5X"?FA+A9>>X($21&D+@-$@-FB !K7K9>@,YG#U#/X-0-
M 1G,Z.RVFO=#,!Z VHB51_#XL#7#)X$+<QN H>,'YF-VO(;9TIBB# "&,B*+
MPL<? 'ZV!/!,M9J(^$7 ]A2Y<1$^X/%2@+6 8T%39:);M%NP[_'8\]T=>T \
M>UBP@04GZT#\9/(L,,5+-EG8TS:9XC9P>T]H7=6>MDJZJ(0!J,'<>B9\BQJU
M1ZI%23U,2;+I%2\:;HIIT!/5T"0_KF/SH@QSTYI639$1Y8^0<;LDP@HX6#1T
M$\4+:B]PHT@7 9SR0**A/51R9C>);.C&B-H;W$HY2W9K[PU/>-EO[J,SW&(E
M:S!$51FINDK-%M3Q#KBAN7\"-*N]'BL6LJ@KX1;)H-4M%C-#/"%>T1XO\C00
M'/J4N-B(6T4(L@U!EN1S9IY%FFQX"=D8B40-;1Z?4'4%3L2<TVHZ(0(L/@*L
M4 $6"XI ^KM>/V?9 8A&!858LJEV60$Q+*#*"3FOTE$#QRA)V%+-\FH=;2PS
MMK\='#>[C5)L:YA')23UZ2X)-Y FA.NR) 9:ANB!*D<:QL>R&D;!C.!@E;B]
M16(;+9A$9,FR7<EO*06NBS+<A@I7?A$Y5N2*!2,NZD_1 D]2K^<5FEH\[[/.
M/;_F$RI;?J+1WB(;VK7ONR+S8@B:@T_+8FD(7YY!"VNFJ3W '-U>*\WTZ*:M
M%8.B5:"<L:$_6$_*6BT,MK156#(+I>#^(+@UWE;1(Y4X3$T!WHRD$<Y7908-
M@J'.6S_L%1[<5EMO#X>'?<!U]!V,B;*)^UW<*+_8 =W^/4Y#>D]G[X;EP8XO
M%2'$"2W.7E9-V1G!9'1Y44[,F\J#@$E#I+O$2]M5J/B/"9@<1K)JVCYWO3@$
M&!AK#K(X:LL-*@#&H\%[#U !B]@X!9#H8#[8_H2K[/G4@^D)JY4(:>@6!GC+
M#BW[AH^I([PEN<4,D=FMU"VC^M%+:Y<MURVC"/) )<228R+A'-&:9:Y/X(%=
MIEX!G$P7E2B6X&K#FTRI\A-><2E=XD\5VR)@U#S"M)O*2B>G25,*3C1HSI:&
M&-,.:JGF!L[A=\8._)0INJ#NQ[39!S!M.B L \JBX(^;AUN. 7BJ3J&.T8=E
MLA-4%?=W6#UT>Q'EKUPV.1%%BT31(E\G6L0MFYP4)4E*9Z1.5DYT.XE$5X:_
MQ$0G(R:%KI(6B9C,AJ=L<K-]=H8UDVLEKE%IGG"E7+Y5:^RH,G)V%X+G(V7N
M6P-6#M/GD19M9P"/*"CM&%,WL37 #@>2.=I<"!F8A,=(0<KX:6P1&C$S5C6#
MH8# [RR4;)GXBB\R#DTM_*8JDXVUQ*A-$Z,(B5?8TZO9"?-D!5"IG0A8'R9U
M!=-_O=7BP\C182]A94/0R2@[="Q6\95)>:[TK<U]^0^_HXZ\/6&2LF8907'9
M%X%5*MK.F90$XN2B;(2",3":*Z#;@<JDZG+EY541:(/HM._*3D&FMA/X\Q#9
M97P(6,^'R<?!\,S;2K8!OJ"V84.W0-LF4-M<T%4G&/$!, X'NBCNNN=*> %C
MR<'.=W/#SBWX],%?/?J_9VQ<@)U@ 1-57J=FWWXWZ)9ZC<T!NFNPFXN>6767
M+M--] KR55$_^\450* &211CK@K!U!_:*-UW!N<",>DX=MUU)>0#;EQ\Y3!8
M(ZOB&IR\/0XNTQ58>CTJL+QHT=Q.SVZ;#>!5A[<NFZX.!XO?**Y&YMVG=?;Y
M7&:X9W0CTH@-])*N@$YB7_2,3%0_IS6*+*>+"K[KM=A4G7A$R*II9Z$5^CX0
MET53ER<JBJ;ED)7N!'XK@WVNTD..B:368081OT*R]V%0'74Z0Z(P(P>5+[K4
MZB S @6,DG+&S75L?.\KG8OJ9R2XL5&>R>D!LV&$/W\X_E"Y%V4X:PE-%,/I
MVJX\]O0*RA&@18#V0-NX'M,_5(V!T6BLT1 (K$5'LZW0B$B3L?QL*P_6%+^2
M,D*H(IF*Y1G*-]9/IE9>=H=25M<\J! <AB@+NKE-HZ(#+-5FI,4+Z)S<+WF!
MII[?<)/4[5-TKUV&7PV)*!&R1,CR?*F&QLK["8,PD-0G7%<UQFB+@/4Z;KP'
M=E_1YPR3=,.+:;+\.'N62^['/M'X?0K*U)$#VB)J^LJ2&THS+*P? Z*.6YT7
M_QB[VB4G\GQZG[OT"OLATM!1-@WA%=I'7YU%"(7V@'"%V*J#DF7Z)5$-<TM%
MU B)(B1Z/A)1&&>EDY ;U >215AS-'$M%Q?M)?1YP"+6(&SNE?KSP@:1+WD(
MMN>6#$08'J&#":1R]*.I,CJ&6%T%MUJ#01V"!&-TT=&T4B1G2:] ^QYS1E&M
M0$(LLH)FPXD:(42$$"]#B!8#KCW?C4_C3JF!VR34K0L47C?TF*)J#JTEUD<G
MO,6D."33;GB"+TAMZC?@93:L5=A!F'9%M(5LZ#4%,FCY,Y6B7V "6-L5EA !
M>P3LSP3VVI)#PL+2KA,T?WOE(.V5:I ]1]N6?;O(]-F<A;NHV[-2;F=C"P/F
M8$$L\*+3D5?(%(,B.(_@_/E2#A6C#7LYL1>D<T]A':MC@BY#!-2':YA@P#:U
M,&*QM(4!U6T:Z5>,<J$=*_B!FJO'6/8'C>+V0'EEA V8T/-K"GL5*R/HCZ#_
MF=!?#U3MH\39^Q$LWP-2N*'1KL,<%CZU!W.__S! [832:2J-4R4:EN7'86+5
M;RQ1N4A_"D1_;JL82"03$^M72_UL<,5Z49BLN^IR@&.8D.'31:3_F<C@*;P(
M9D!AF?USOKUZ%5ISQNK$0!%^#5P]WK'^EL=NZ+=ZTL1@S7\]S(!!-U>["FE0
M^VN\UQM=U6\5-O&<X!)W6LS6L2G>8'=A%95@QF/=S7A\EU"$G0:-//%P(T$D
MHKV;:.^F((!-A5_'$NTXXJ4SLT0-2FGA]X#U3O?R6=;)=;"3QN8&!7NN<,ZZ
MC+LI)K1,@%= 96T";)H8=V>Y:H3;<(>&_YF&I/BN-;R-F1#N EE6'>$(#5ES
MO5XL?<=UFH5)BHDP*5R8M*2[!J#*!<T'2EFX^?-N.T@WE)2;&J86.5LC@'L
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MO,1J=2]:DG@E1C#;TIY[C9IAF!Q[RE9'9'F,Q=A[0#QYMT*!.J8:TD!2F-I
MJ%%K86&CXMX^UW /%PTM7<):0X_&JL;T,:^E+R9G+PP*1M L^3W?J/V P](T
M8TJUH,77O8Z-[JHQN])K4,&AR04];9?!DBQ>FCE&'\&S<TM=N YI\BLUV0+\
M:H1NI4630BVF+L%_W3UC31=1>6)!.9Y<3:/\NLL6/[J-%!NP4 J-N8(O,EW\
MDJS$R6IN_:X5K-MHZ)8T+V\ 1$$OH]>M_4#\\"S86K7KL)+%'A[N6A%[.-S^
M6:K9W]VGL5\WD!_5_J;;T_[OG]TWCM=_ODG"H%J_.G$-C<$*'JS\C>1USD6
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MD:4S<5@_CG.HWQ(=@7.' S]!OVBO@J5*M1P/24#;=VGGSFBYBLG**'P66>U
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M'E*'?GER\3R.ZN;R$NQ<3-QNB$7E;+;'&*&,HP.:W^6JO,U8TK=<R.UX^-@
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MHD73":B;BCUD! )&D3$<A,"Q#NNXR5=& !! %BMS&P;LB>4 HKQ5$,.GPMK
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M,41_(,ZZ3;RC;\+*EB%% /EQA[6M#4;1,7UK)>;KP<,CZR;<I/A(*R&V6.B
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M%KYD>;!-C];C.DW?1H>/;KA_(A.9@)9NS^89TO]R%-<<\W,;,@,?!%6,G?U
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M:%",(>1SE2YSSI5)$$B^*AE"PY\@I5W)1^@^+%*#6"U8L2+K5"OSX80_EW,
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M=]+X'JU'8EA+O=ZZJ]RD]#"97H'A9.VM5,> F<T"!WXG:SM9^UQ9([=IJ1P
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M)RLFEBHWW:&<@-ADU;3XBOGEMNK6J,52+5%[L9 _K /+QL-+*_+;,40#?+Z
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M>>W#%&S9T=\P@</]9P($P_\X>*:WEG%X8F.$XQU>UJ(DHY,;KF7"XI3Z$*%
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M.B7?XU@$9;\[K8CX:9!@:G/5A@V?3+![R8 K)@-A8RN3*)%KYK:NUEB2W4'
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M/0!A&8TFE^*;F)/J>UR:_%?MN?%R34J034L3][B;EL2@3Y%??*S%D%IIN F
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MC">&6G_3=QU60MXXT:>V===ND6:+R?):=$)!VK(^3+#.YH;(P.!ZQ_TP_O3
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M4$"8GQU!]]11]&<P8=^#1S12IEJKTTV=[K>+%_\=?];S.(UH:[\0OE_\D-6
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M-1%XK-(M-$HB(4X,/-37BPM8^=>77SZY'+VDRF9PZ''!OH6D[Q9QDKNEP\M
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MRPP><O0<:P)"9A15.1O-X TBC,DV+[*:(NLH9$X7-S4ZK*5GJ/:!HP_6[5C
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MB!]G)NBY-<4VH1T]%#7B;DO7/46%15H2Z'6LF5#C_88U4E@/A$]1MD)& YU
MSF'U/T;+Z5WKQ+F/Y]-[^J=WW]5-Y\8[?Z.#ZK5_:#Q'%)>\R&![SG85-@[
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MMJNC4U:MUV1I&D'&YE9>ZK<SDT<L9K;3M^GPB[[KGB>F<*M5_R)*'U- H &
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M5]$LYE3RIQ?!,2]"#5NM6&[BL1A1U_Q+\$T)=PQT="43(>BK^;$31GK^4B'
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M[_$(4<I=  PO'UT^YJVAN#=3N.Z7'?P5I^.N-K5C8/4!LGTB:'&X))T]Q(W
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M>+7KJD 6B2,;Y4_X[5>!KY+.:*TZ+U"%-J)S")-1L6M(S=-IU*::W[.UANL
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M?>^'/,M@<[Y/L<S&"0Y7,G?3ND"D#TX4^0)B6+ZO%WKSJR$C.Q5XVGQ5<,,
M_J)@71CM##JW7]*S7(]]AV7(>T0C"JHX4_%'8BXJ#W["X4C#KDR@EK"F$HWA
M1PL\>#F7 ^=RX*=3#CP15_07IRPPFRXE0@')"X@-"5QV0U:\:0ZYODE&#565
MHW'F^>*I  7%#J)Q46VBG0A,15NN@P)//.6H\*N#\-9,DQ&TN83VG#IDR]^'
MUNOI4HO>1_2N<.=:TX<YVGOB;$";6M6N4A1]=<YEEL9O(;FD?619_#S"TN?"
M)4PVA]TN2PLBR/7)@,+5^+&-28(I::SR,];$RYAP3LOGF^"4:K9>8).W_N(<
MYK-/>)RFFUPHHCEFU@]A?AUQD\7\2=4F+\T;HZH;.% ']K,,?J7!".RQ#%*V
MD$)I<9S1?M?Y2O#\KUW)8TG:.!-ET,J^O96R4MA/WK'C7_*P:)0UH_B(!UYO
M+:VR7Q#*5G[M'ANJCT4\[B8HT+>%\B0D*N-J]/:-4 '9G]:8QQ!O-H*6%M'(
MJR/3D-PB:6]=Y)@"(Z>38*.">^^)!S+7Y)Q?FGZ)H"#S$O[9;$VX\;9^<M/[
ME,&MTS/"0MF5)N=5D2Q(O<$&<)1R5.9'?0-"I>&QUCT<=/0.::Y?2_,&[ODT
MD68'9,\8P:C2AA=,R82QTA4=/,P3^)A5,N)CV&">#*4/DV].1>#("UE#K11%
M"Y!H_:0 ^.ZTC?T!3&**\L.3YXNKHMV2+.I%J)-#R,3(@'E0-L.&S7O40S6T
M,YDWWL0O0X;!0^]QG&][1@R(GL*E*[/NV T,46IFO0.+I#A\]0,:7?O:F<3V
MP!MVD];PY&#64!:Y$2:/ID[Y.KQA!1B3[,!L%/1-5C&=KST>.V6]05;]:)I1
M84!*#-ZTP[MJG&Z?5JV:0=;:WRC:!)\2Z$-TBGY4BA;IP2G2 ^8NC+0$_:;5
M7=+IH[S'JN*]!.W -:@R8Q?U$[&S8$B<SQ>O\:-!!OU?Q,KP]I<CJO(HY>1)
M"7%4LMR@<N,\M*8'\Z9?D0M9#,$3T#1@CE$X'AN2UG71Y9G (PMC!HK(^>(?
MO@;V<]WM]G![)$ZBU#XM@BH2F&WX4;,J6.S+VZ[E_.3?7 HZ0Z:P_X8'I*PZ
MYG I%\_=LNXP(_JU,MNEM.#5H>?V4MY+K!=GK$3'+P_L_'!SV2'H<MA2K<$U
MJ+E>1/_&'A>\%+&3!<;(2XB;46Z(,(7E)D,7 UT*$=7E02;+_\;,,Y>/P9'9
MY@5#O4DYDDAGZ&?896Z%XYWBI(=G:VS=#K1/6L-A0B^%).@6BBMB?9>6#$JK
MZ3$69<4NFY[Q=&7TI>A7_%9YR@;_%U.*,J<Y[9#RGI$ O ^^'G8=&'MULJ)+
MG&1EZ5;"YBZ<9#V;*)K6[ 'HP)9RBK@7=/K56AIE -XN*#Y,HUXU/MV+B@^_
ME$C3BGZ(;J)#NQV%BTA=Q-$5!9@>>5A+'#&7FMAEM*=%>H.S#=PSPV$Q2;-6
M1P))L&8NA5Q>L-YSWSA 9C5<V.\+I]M#SU&$@\MLL!V3!W#^&8DH.7-#Y8IJ
MI7E2"G:8YUC9>ZZ=,5G7>25M.&I,R1#YA; X1[<W%>?:Y;LEE@A(I?XYRHK'
M<<4>W4JN&HACD.4-?Q5>'SPHGWJO=:Y\>,I 1;:I**2S!28FY6#)0.CR'PXF
MNHUB" _A*^'--%_,%%&]+RR-T+_E0X;8B-L!ZSVV5P 9G#SUG2X%+V)&OMX:
MD5/<Q)J==$7(,:Y:O#U$61&(_-0/&W<SM2EN' /_E%7NL\Y[C_9$A8,3L08/
M*D[3X/YX[I%0FCQBV++?!M\T9 PC $4H._H)@?0GT[Y20&]EH?J5R\I=J/Z&
MQ6.N+PJ]S17X/ CP_2%WF(ZP'&.Z+#KTZIES $F8U:,+'[N%B#\Y&_"5==ZJ
M8@I#MVS[B<-B@T#P#I_F#41GVXK)K17M_Y0,VR_<;Q(BOW%NO;'VT,KS8MT+
MCP.=!@HRD'%&I@J8ODZ9$/TY#$4U/2=J(.CWNTK:L'T8%%]RF1;,URS%OG1#
M (I,N\H06MK(78!:'SY]$L,$8YZ1J5%RZC<,AX<F(G[=%U4]H 4('\)V!(>0
M1GFS:RSFL'D!D^B+AE\U>]]Z@#G6,+;:NQ5>?O""2<3W:;N]46HX085D$1D_
M1D(5-&QO5$>#4_]T;/37X:'P'(IS0!UB*=R'S/W@9A\S+=KCN3HY5R?GZN1[
M:)3SQ!;:_Z5E0&-1""6)<Q=)W \5 1XDUF^/'6VKKRCC2 G<%<1:4W4(VZ23
M8@W+QRADDT31]S0X>M=(@5I$-$/6#2*DWAR'O6QD<8.1#.K?)8VH]#MZ7H-7
M!BM55E;=,M/;%#J:J(-)-\53=BNE+$:3]"NXN2?'"DXD6VM<(XZ1*!<LUY@L
MBPG\%?G,=XIH26&5;2_;Y> R$*$R<Y]'C\.I6F[]]'0H$;M\0^3CM2\)!UI9
MZAWD0J7O#ZRBL-:V8XV_6EA<3>\0?*[,MP9K=]H]\6+1[3&B2U=TB+!5<YE7
M\:_P0_!+#XJ+->H,1 E[ &^E)!VP+(0HTZ> -#XMAI5I"I+#C%TR*-1$COKD
MJ=9]5I]<M]&^\J0?NR-!P:;B1'2A:'O2 VV_*('N)#:)=E\=]X-\"%%05. /
M,J4M-%:P3^9/%B4VN1(0C0"QRY0PGJ4O;_KS'NJ<XYY0R,CW]!<7E\GYU4>K
MJT-:(!F]+> RQ9.C'R0CW4I5-M!U^Y[!JFL,31)SGEMG.'+FX/12O'CK7!@_
MY"D'YH;,T=1NZ8Q+EV"/?#%T^;YQ$:O[\"I1P[HD_0>ZL!I= )[_E&IJ174C
M[2H2D=_C9MK9SXOS+^]BKB-;+?MWEP%*H<FBNB4F[4ILB7B'C8_F <+!U5T^
M]EZH005VWK>!HC:D@AH2D&N(EH*HUKGC$JUOB]]%C0(8EBOVD:]L44N\M^/8
M #%R#$P_TU_N?SKA'MYK]$[O.,\[S_7/<_UWG>LW.*?29<>U;1J4XY8Q-$%D
M6_(R&??M\1L])L]CX)3<QTW^XE1WD9WA8 3K8<[C",K2>"#\^'ZG]N-3_NCV
MF7VR>8^]R?.2.XOL++*_3V0;<$9X+-J58.V*G;)LCK3YS.(RB\M#%!=M'H_I
M1*;,CBDI++N\$)0:=F0MC9PU4-?$BFZ1*/"^X&E#8,I^J]Q)$P%1\QH5D7W3
M&D?18:VNG@5W%MP'*;AC!"G)$884;%#@;KE98F:)>6@2$[5H6784'J6QXS$Z
MY]T;H(ZAU=Z)$FZ6LEG*/DDI,[%7Z+1 &P1+<4U;88N+5@%\6<#W:V-*D[&6
MB)G+UA/LN)KW!F<)FR7LH4F8.'/80-N5K334\2B%L(+5GM-.^E;M9Z4->Y:<
M67(>FN3T<X/<0JOC<U2"BRFNF[;+/*#3")7U]. OSD8X%<Y!#D4F@^^31_[;
M=]P;,L0G16RO90WI:)$=I=:5 O:R6:5[7\P,C28!?0'!@4#99?T^7KV0#(IC
M(U$Y)Y%FA?BP%2)U)8:DD4 <'U5S5&^TN,A=NZT$?6X2H3+"W2H.L]3-4O?0
MI(Z@*!"(A#.U,B!(E4D_)-EO:YVJQD0M!33[YMO])$[(ZF[C(5K0\KD!%?QM
M-!BS),Z2^$E*(@&5:Q]/YG;49C]I\'K2UBMOQC %A#:#/3@?FCGC]XG55Z-B
M=1H]?[T%WJ6G$W&^5MVNX_$1 4K05G=LL(SP+L/,;P$W[;5?]H Q/,(H'IF[
MM8[V&M49ITTK[L-&4\)"9^@V.!]G_!.CHMM!\YU+<=ADW16(<($=:<0^N*4G
MPL_4V"PO:%#[M&D#_!,^E)DAU)A*IP0##,#YZ3> O@O+R\<YS/?%/,PW#_/-
MPWSOK%;ZXWUW-BUY0PWX:@M&#81!-QPB2DB?[\ZYUF.)K QWBB:W*%%ID#W2
MXM"T C&@"E\IB=A,T'0:PW<0+SA5W 86QLQOC-U^_$8XZT5?H?Z2JG:KU)">
M*7>(#!;R&%4B&"N#;XQ^FF86WG)5R7$ +WD- O]IR:6*@X"&I?))OH9^DK_'
M4Q>XDXQKK5@Q.UQL2:R^UWG5-<4A<+E@_RDA4/C]!P$M"8MLT^6"?Q+MV7O@
MR#@E(WN/PU6_>Y3J5=Z\:1:O KW6LT!6\*PW*O8JY+>NE/<+CA9.$[V4".&I
MCQ!.?'S,X^N RMJZ]!K!QK@KDR9^.65G$$]Z9 U# K0[<ZR9)K31^<'0C&-:
M;Z0=Y\-*PN7YP"S\XNXT2!9@4)20Q ^9:A!)ZAH)/!+/1#>.$<(8?81C2SIE
MPY!ZOB9EWA2C&OO:UKHW>AM32QIL)K8LSI=(\)41;P!/##NOPR2URZ\S84 Y
M4)<[!J\+K"[W=I@FTL\\4E.:X7=6_XRYXG2*/0)7">^$,:.P65GV\(S!@8=
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MN'7O[8D(M2X@^R>,R BOB3-1C"U,L]2^D[TJ$@'Z7:4=?+4C?1+&4"Q&R2)
M*A"DD#%$U9)Z54=P#14?Z-9(_'SQO0 ECEX%%\]W(1H*QM K<= &S[*VU$_C
M,!XO(ITOKE8KD#+82XSD;SQ,I*(TITW3U9@\#R!^!+UB[NTQ0TWN7=/A[;:N
MNLU6IN_>:91.INA!%#L7P9PRDB"G_VEB3X&XWS.X\GT<YT^:K."KN;UW;N_]
M=-I[3Q/J^Q?G';G("( I4Q]TG^\=(=L3X>E(BLO[8]AAU-5-1ZUXP7&S8 9]
M;Q5Q@#%>.F.Z;L*:5F37WF7&6 5]) $NM@,GO+E/;?W6-!#]S;U:O'&PE87'
MEV8X:$F[YV23EEU>,%3,[]UR"0GZGC;N#75.AD[A-4999[5@V6=.3"]V6NG^
M:7J=5*'WY)_^^%I=(/LRR9'F8 5?(NX*;!*]0Z9JG^"!+/)EG5*F?H6+@[5T
MC:*,__CBZ?<8V;0(OH:AR@W$U_A_Q%[<51!J=U($:.#+KF37FK8T1X<D"CC%
MW_''RUG8X+<^6@LC+,:!T>>F3FPMM!R]MI\WPO8ZB*C@J00%DOOLW K?2?#L
M!&G( *13M$'.C*"'\#&R9T?X+?P<]1%<97V"9&*GS$.#<'.*C9#"1R'EHVB1
M0VO8P!IKNJ[=5AE8Z\U!HZFNC)_*'J*P=L+<C)T]AC4RB_?H@-OJIL0MH;!]
MF]8[O/3X%#D$Q!CR@O2#>*]D0W;I&_0\W0X6Q[4HME8U_+O(WV ;,D+I'L$D
M]TD#V)<*C[>-!F W8%-6[)%F2B:!:ZMJ;.02EU=!94!,6FQRCN2"92ZXVYLN
M11QWYP9>]O3NVB,ZM=$)[_2XXQ[9"_\6N,3G3Q%*+?X*MJ6C+T[I!-$8/*%X
MGUK\OBWF*SW-9@A1U>L>CUNZ<ATE5QMF8L#**F%0(C[(P8+I;[C']1#")%$-
M1QOW;L/6?W\!R^\WBE]9A^,N$3DU1K648PL\%E,T%KI9$4?#8H*C(;%6\IS(
M621H5'QZ>&L1T\D=*NO)D5!>:G=48R^/A=I3-421==1O2 %%>@.644FUO,3L
M6=I0[\Q=8.[G$LE<(ADOD8PHF]'@P$-DC^'W5C,"Z"PKG[:LC!'KH*" K5AS
M48&DX7[<40FX'#(&914\(XHC\?\96!1C=E9UCE=(9ZF;I>Z3DCHE&W-M3J,P
ME@T(Q2?=D]\M8E.C_S;5EP7>6E.1!:N010U\OK0E$!1,V\UR,\O-IR0WAB:5
M(I$)XR7- 4W%\B.X U0O&\2Y](E1XL&R6A057*>6F$13)Q$<SRQLL[!]HL(V
M)5W*G9CNM?2U= )"!9\FQ&?;F_\_'1*2$%@79T$,S"S2G,Q\7+,(?:HBE(\S
MEW*"K1G+L/E"#Q44-#\=NI.Q=41;S10JA"01<WJYI+FC#(<.:!+-=Z_E/JSI
MEE[D6?QF\?OXQ.\6"\:&"-M?&RI?QC5+:@&0V18N0.Y<1JE -&Y=27"4,9XL
M3YU\Z/;HN-;Q:*K4,5G6L'+UP4HOQ^HN=VK67FOIJ:6&2.S"P_S4:M755L?2
MG =UP*9+>/U2(K$Q@E8SIP(.C A,A8,;+6^HH9+R9"G<BK)8!5)TN[K1;)G6
M8WSW'D/$X!=]%1,SU*8K<X75>X'0X)[NYVE>8,%G@B.;4GGXS NIQ?GBD\UW
M3]2_HW(--UHJG3<..H=>#5-:]K-<<$WMR?"^H>^&?.\-PV]_QNZS8?CC;%+\
M>FY2G)L4YR;%>^\:N*/%^J77G&2;7=!,^*Z:RE=F/(&\&:^A*=ZISO'SQ?<I
M6*=;&S*X5\JV^HS;!]C!=.-; HU)2<(7.%:Q@-.4+Y-H930$,N R]GN,LY'$
MH_]5O4E+)7EC=,2PZA CZ>XM':(FHE'SS?K<=2"@-=B_H_M"L1;//5-ZXGQQ
M549-&5PEUJ8BRCS*K,_ R]1([NC<F"'IH08\P_ZS=3%7CZ#9!>3(HR,8#(A.
M<>#4],.+=7_NB=M0>.XIL(T,26YIX H>?%6 (W/M%.J\V3M&8H_6/GGT$ND.
MS*I0%:3$K=Y/6<=DH@L<F99JBX2DHJ]\1?Y8OF80"-^8R%P/*U>7/".A?A@[
MA6G35'"6VN.,*]9KW--YP2_0>X*8CWTB?@/!);) GD=FZS]Q=^@C>J+^E.=1
MH:(\IP)U0-!/E? !4@B?&U@?]YH<^(R5'2BPJFNDH[ ^".KQ*&D(" VE;Z2T
M[N\)GT]I8FG YP7Z=^MV.)UY2/K:EZ(,&OQJDB$]M4558?VWK_.5?C%"*SDR
M2R7&#*Z([:4%]1,$?!)"_^,.R1);LPTK*.L@H2$-AL*.N*:EI9@GL1I[.S*;
MWSCWIB>#W*M/$Y?''T%Z&\D<UZ:A43!:IAZ'C*AYH,;9)XF2<X1XC84J/!0"
M?]&"&*SK=$=6*G,-;$74/QV/ATTO8]AG'=23/<.X'_^"L]%D^<KWFLNC$W].
MKQ57),)>@D)M.ISV0FQ5I.,[)#/[WY_6BS0 C*S-^R)>8J/=V&RU>6PZ&"X?
M'TLXO<3FW0TYB5BRH^C;9>]]*.[===0?JF#?TSR.*TEA4?+ L]/K(*GXMF/-
M=Z2GAL3 (U,+*FI<F^5VOJFK#EOZ4#5Y6&Y,Q.")Q?'756M]OP]Y2B@+&YV2
MI_H,=S%I.I]>\W.5C<<CAJ^V.") G;<'B/A$%_,F)MKJB\8-?NEZ3> =>E0H
MRU$C>-R_GUJ/61:BW?<&?Z#QK,[F)6;X:AHP9%F'\Q?6#Z?N8<E[67W>OQ4^
MX4C^2X>3^CZM?&LT#CM?/!VY^-)Y_P^3P:[>X=B\P'^E:-ESQ[Q%(XW-89I:
M'D=H="DA^9</Y$*]LS8ZA5K,R)/.U9D3J\[,L)F_ITYSNO7/6>9.7^9,^@FM
M;%KK .0QPFB034(PHL"AT90.1B:;DM(M:*Y1WE(;%I[>Y,0L;;.T_:'29H*<
MI6>J#=Y>"(:3$=&3E#;[XSM"XDE9EF91FD7IH8D2V!BI]W&K0^O@%S46/C#E
M!6%76D;@<MNJ("2'WV/P9OF:Y>NAR5?M$#@,'3ST]'8R+FYKER!C4GJ#"(J*
M>YA&\I3+'AG#%F2Y'?7IJY]D]+O'OXRAG/36\>4]4)VD5IIN^2^I(L+^2^:J
M=)NJS4/!%^-$K*#8RB^F>7<5IECR-8&@MK0*3FB%>\^2/DOZ0Y-T YR";N>J
M[O)6RWL@REP?\M@X7F+S\MK!R]I0G6F6FUEN'IK<A.)I7L+NMYT@#M7N.H<%
M+*NTSLC<O7CU76+*T.T"3:NQ.K/PS,+ST(0'L;.D$6N-*!#EIM')6_ ;P3OK
M2C-DB^A2E/B(W45"U%KE\#PG02(W"]$L1'_P.)-VL:@0<;\J07%S1#:5?K<]
M,95"NLPAT"Q(#U*0HJ@G=)N7W6Z)."OK$/Y84F)O?EJB2)B3\;/\/%#YV:;7
MG"2@[%P3NNY2M3;8F]EV-7?G[JL&ML-C-S.4XUFWGT5G%IV')CI1&Q."LU[G
M/"'+%(91AQ)UA]?5?L^ XJU4OCXUJ_-Q3LM^,T_+SM.RG\ZT[&R_9OMUIQQ$
MEM6N:8S[-QBP%$J(O'&+C$?.&( /V7H_41,V2\\L/7>4'DHZ6(*XD'48ZXYX
M D[@+"BSH#PP00G%5B,I,C R2B1%B08$2LK+N\[]#4CCZ?JYFQ&\3@+!2\='
M Q%IF)D7_ ;B,<)>SL:Y4M$<V.=@5-&('3BY\YBI]*#1[##U<%.3*6,^]"E4
ME+UF!/#ACK2G9B+P0\W\W?](\JSH9T5_%T4OF"HJ16OG,LR=L'*>F$<24'P"
MB6@$&6]794C990>31L>0.#4=$W0327K$SPURF=)D$VJ7';>:"G)0*CQ$B$(4
M^VM(78?V)V\92Z:J/>KX'.O,DOW0)'OH@DVBCJ$&$/3PT.) XF=@I03@(P*E
MS-PJSURRL! PC2@4EO&N22Q$A)'Q$<6@$*!$'6@Q0&%QFSK=S<T2LQP_.#E&
MDQIR%+XAPH,TK<<@58Z*.EC) LZ!(S[.D@""2NVL2.SX/@,B->, '3@> J9X
M]"J*@Z3=@JPL:H)*; ,H</^RF+=<;&%/$)>/8??Z5YXUP*P!'IH&0%&V>1*=
M^5);JTR>%M]N LHN\1_>I7G).&#:?@7_I:!:P>F(4-T"AV%8C1![G4) AM20
MA^SD%)&U^ 1W]U8DCT?4%_=]P4X3L4)9NOJTZ$MFW3#KAC\Z?A?XOFA ;+'#
M[S( /D$W-DA"'$%DO874H8N!2%J8^QN!T2JK\HQ$/"< V./Z)_6]TQ3^3]R1
M%MZ5A+[(DC#*<MF5#!0';E"?\)+@OZ);$8>]=4H0D(VID^ J5<,T!*#NPM#M
MUJ4%/DS>O)ECCUF[/#CMPHT#33NLCMXAQMA@Q^EH>#"+TBQ*#U&4U,.>%AUO
MV92SIHDAYM6K?F='6F0T+XT33QD_#0=F&9UE]*')Z""'?8U-= 82G>'@"5J6
MBLS<&#XER013'GW3@B<W/9MX&@2 L\S-,O?'MN1-0>E;.I>^7<O!H234V:T[
M+ C^(:6N%!"G=..J3D$R=XMEUVI#+!6:JWV;[P3TOGO[1J-[%K@[-XB< $3]
M6RN'DVR$NF/S4^!-\'66.U<QV8%K,1F#YF'2!5NZ0T7X[E43>B&$1JK@-*S;
M[0LJRN0C/ X1D85/L=[=!>PO-1'>'DOEP'6:\&SX44Z<H!GCH0:N%>/OJA+3
MLE5&O$[PH_W[,4X@I?:9VZ]F/MQ/PM;]Z3_S$DD/NE)I%3"+,J<09__NTSWS
M$Y;4$'3\?H(V-"!H<(2Z:.2[<P5P%K"'*6#3,@&_;9 U*!#683$>Y0@E$;VQ
MV2+- C,+3&2 L&*\"DA=2FJSK_:8&J1?^WP"BE(*@5Q=I<2AE>.X>J:LI$@<
MF'U* O9Q D5\.P-%S$ 1TV=U!HJ8K=S#LG+4GU6D2V3;E-8H[N6"M5GR]HXG
M/"/*X=KA/U8!R)(3>3=IC4%=U!6VK'Y%0F_YRZ=D!_]P$7Q\5 0?S1)XDA(8
M\V>8F@'A\07!U$J!K10C[,1B6F1.S C,)_ T3R"W_V+;JV34X'15US@SQ- +
M.C6_(%_V:').S^(?G4<_L0KMW<J>GPZ'.-=! X4XTOGD*Z2$AV7QI!B>$C^5
M)GSBO2)D$O_23G:F2&/$8^6>*]X0.E.6Z@:[< 1SPO#'GQAQ_"_N3F3@(_SI
M.K)N)];'6-+]Y,LR;?(FS+UP0U)Y&$N<P]M3PAG.2M#6C]:3BVJ%B\ <(;_9
M*9PD<!PW^2WHS,0I)5-]9EAQ>4"- N>2>0:XWTJ=R12;'5W&M78=-B(%M*]I
M?QID.&U(@X,1Q=%#9OG>0)A4\NW.%S\KE[POB@LJ^T@32;I:@0T*4PNPZKP.
M#,6P73@V@9N?")^55,RW[.WVL$B.;YO?K9LMPI;@ );N%./!@XCEQ2(G0%\>
MNZY*?AY+J6PN%);'#/)K'@J; 4WFBOJGYN$HGD&>E@V>CHNOJ6%R\:'\$I5!
M7<O>U3@U1*HL<#3O*TQ+(3B);T[3MIJALI99)&[GIFHIIX"8A)85SX=YW)XI
M._.]>]=I7I!<?JC7@)N2[O,(Q.ED-NGBR[UV.'ZH_4'>'T33D*+%B>T,^D(?
M:F>6'^K03I\3"K4$T>$#"E14 A,O,0R7PIJ?L,\"KF2-C@^J81\7T'!+EJ>;
MLFH4>C8#_SUM>)[3SJG"#3[48\[IR+DB\,GZ2D<FT+2<S2$<!RX4\/TJ\<9B
M!3*-DV<07*SSDOT0<5<H*)HE9Y:<AR@Y#0&(BNL^: J)X9C2,BT.E*)9AT2(
M1 H-2%*^PW%."-WW53YS*<XB]4!%"DS*K_E.!J)M+G%FB)]EXP'+!J:M74O5
M8DY+<^X'?YV6N>#QC)$5F(;%67!FP7EP@A.C3WO/:Q:%610>FB@,61*0<;=O
M-6+,."V!1C57-D:N7.G\2""$F.5JEJN')E<H'N[7G#OVEE5&L8MTP9)T8!X\
M71V8PD"@$(D;7FN"7.LGB'/\0F\4?I:I6:8>FDQI.JUV:U?71,"+;6$KKI7O
MMX>&Z_ZS;,RR\=!D Z%GN7;//6 N"[3O-WE1!%1]X<>)>]Y\#&3[(V):+@\G
MCG\2P%L$NJ'\PRQSL\P].)DS<=.N*O/69-4\6GYQ4')==.*X?[Y%P%MLTIR%
M9A::!R<TW O(DC/6UB/CU9>/+]:7C][MP-RQR2>*Q\#0G<*J;N_^.H55_ND_
M=RZ"03!]EAXVSN>23F'%D_NJ$RA3375__-;:ECB>^&!?B_OC3F&-P\WDO3R1
M#3R!#L())3@;_MGP/S3#WZLT".X VEY/,:4)'E!U#7K1)S;4.</NWKI;MXYX
ML;F='B2]$^ANZ:?DDU'N8(:$IGI4U!C1)Y:O1C$$/6R3#MVE.R>.C>M 8O%O
M*4WO3/&$IP37FS>+N$.C*!:U(_)4P]5(GSWL)8?IPT<_,8-40W#)I5NE"+1!
M0&W1A*!A<*KV+0]%RH"A3-F:7<G+IG5IAI^,/Y=*I8]GBP3 F <QJ])YDF9Y
MGJINSA?/</R6QB-]MW 8/V1<?$H=T?CB"O=,\4W1G<$/\(0N)Y_R':$@([)C
MN\*'U!Y*!4;MCPI;\G?E?!\DM0(H,87?O=G@_EPF#5_)Z['#QY/8R"+"YQ\O
M[-67CV;8JQGV:OJL?FRP5Z<)C_#3-+D.JW5+88>:JD-">]!>KAPPVK&F)X.&
MW1?H1*K18F6X38M6)M3'H!02QDV@'D!1F_QA0\6G:![)HL#&6[U:M=NY>I73
M5+T.K!*EM^IY"POE"<+)F_N?#CM!FO>%Q7!!D>=;#YA?L4&X$R #;57$*3C!
M.DAOE"WG)$@QG5X/8+ "KZ F9 LUN^!<(%""&L&^Y\(O6HY.$]&JP\OKVFU5
M,U8&H4; T]3=WKYX.B(#5F5B8,4+AQ>:+G85D1L(G->U8T0PR?6$*\(&TVE8
MCQTCW O\]/-G5YS)V,'#T<;A*<<VO/'EGR]>!8H!VLQQ9\ O^]KA"#510XL8
M&9+&:! 1CWY:X)FDQHR>C$WS19XO7JQ[E[7?36O$(!''\4XN!'(:)+H[_,.+
M5]\1QS7/6,)MVXX3;$AG0EX/7DKIO%(JYNG!T?>"7272,B*U"6Y$2>N,4G//
M7O_PG6S;*.GGF%LMUW[;MRBW(;._8,J5%26U1JX/Q\@<F^-,HS@OC?\#![8%
MH78M#:'Y=.3YXF>MLYRIN$7ORB*LA$:V OW6505Z[#?>3E!%X-5D>H:I>$/8
M1Y3Y1%HU<";/%[^X!9\9?#[E4VUKPM:33X*N;BHXOP7LPA%&*"(7A;V""U,<
M$1TQ_,(Z+V0+QMX2G?L]PL"4!Z.R\]]2]8MIXZ:V%@ZXYW;C]>-2"62 =T7<
M=-H6G=P-YB"6I,GWU]<S&D'DY;^Z6A1*VF[/%U>\5G;EJQ73GJS$=BKY77&8
M=N^7N->NP<PNG.R2K)=/I2:6PP1MJ62R64-4U(]ELA"G9+IN-UE_**#4'_)$
MO= ??%4$[QD)_HE@1L JP1Z0$P,B'#!V?&\$OFG],QAA+R/$](MD4YBJFA04
M03,"I5<G.@*_[^JFHX+O E$52+6DH+/)%&_AC;0J-<VA3/>84%@*_3#U^<&&
MI84P C55T:&"O?KW__7M%U\]652PG1 ;U^CO052VX39< N"$#^]0%>ZJPL&"
MT&:CB2(]V:8;L $-TBH7^1NW^,W5U_@V03! PD*71W*,!5(=U>"8LGD1O^AF
M"[]"F]JEK(C!40"E/(J,?;YXWM7H1"6C;T^4L@%'@KW+'!LGCLY%&<:-D=[+
M)(V1OCG&NG>-J9?%#A'*S@YPD% YYU4VR_JI/!%ARAVU5'3"P2-M1F (.0<G
MI.?$8+ HB&38@YS=->(*WCS1-,HRD)_<(':I^0.M<VL(%-F^" BW:^GHJSIJ
MJ_>,RG4?[VY&Y9I+0G?)14V$!JCN)?[07 -(+.;LLSJ]\>+<L,VV\H>@TLZ]
M =DEI[$DK.E%NDDQ8B)P/%A]ATAW:,5[^-1S_76NOWZRPC9A3IDZ$1VKMZ>J
M)"1J'Y9+YF$6HEF(9B&2J<F4\%S52<7TV#8M-QRLW*2Q\[C(L3\87C=8)">7
MF,?Q9Z%ZJ$)E;$_$&R*2EN_ _& NMC10])(@890ES<%8^>./J@=(X.-8:&D:
M29U::%5))F-&NRJE(%:[:CT+XRR,#TT8CP1J8O)X]%]D%H70<P0A[CKSDB1L
M\&B"#$_AY:,GRR)=O4&V'_KWQ1.E_"'ID^&R4+ZA "]OFLZ3@*<%O BX\#/,
MUOV-YL]6F&]]R0#P]8(?"#ZQ!RV"V:$"JTRF8HO%D*[T[>IX2REO*/M0^*S<
M-,>LT(ZSPND2Q^>,WIC5PZP>'IIZ&'> <VR[8YZ.Q2N<1/V>"P$D-F6V^"'7
M-OS%:Q#SUFT.)."OOO_A-?V [8'(*;'XP<^3+/[:81X6WGS!0HJ2AV.N(1D4
M)6K7?0XRXU4GI&&,]%,G 7UE&S2)4$G45!7ZLU<%CA^-"K-I0T4AU Y8=IDU
MP*P!'J &\ P\8)XS$O"M*[".JMT@BVU:[[1T,D>WL[P\;'D1BVE8_A RF[@H
MM'+ANZLHVO6N]:K&OGCJ'8+_MG/6=1:A!RA"-E?#LD03(@6&>7[$YMH1T\\L
M'K-X/##QP/:8VNV[ED,;KJE#5%3/\Y-_W/SDQSG]=3%/?\W37_/TUZ0$O;\A
MYJBQ77IHXV'6KF'^Y72US=VU;[O/RYA]>2&S*#+*,E$1\VV3"7*Z*H@,MTF&
M-GS\<E$UG&$SC8RTHDYF$_SL[0TM]X]IPH\F;4]SR.]E[7SK#,U2C?$8Y^5U
M56#/:@KN:[EIM\JK! %>@ZVB4J7DN?44P5Y6X,VD-,I-@]$Z7N[LMNW-O?U@
M$%YWM$4>DYW8:5HZO%5:P_;A%3*9\(+KK3MJFY,[T'0+S;3@MY"'GM(^QWIS
M<:8COZ[:D7XB7->1/G.\!=UKG5Y7M?#_\H/"165AO6N>&,6S/0EWT073IZ4Q
M)X,^!==JTS>.>7RQ<9WGJ7CN7<X&-C_J%'V.NX;5[+(M#N$PT1N%B^%F;[JT
M!B%W3I /B"!Z>)P&7!("++ETO;E%F=&3$;&"YK+ +6U66Y=UA2@@(J3FY:[3
MO*!W"L]&$SX+644+[TG1\S@$C%=U&*Y)Q0?1"9H]>/OXBUW></T_?-U^44Y7
M,DZ-3<L*\X#%@=:K2VR0JK4O@-7XX"U3-&_S!H?Q\&_ZX%@0F0*C$ @'.&IP
M\NH#OD^<;GS/<PKWP==\6G,*[^V)P-$RJI@,]AVE!R?Q1LZ;ZD!1R'U-SV,,
M(]<:Y0H6A8!A0+Y+0%7LS^";+I'I[X*RB_7!WB#MB]28M=!"O5B+O QR=(X5
M^9%CS MO/+?QV.0/B1;HLV9;W2R4I0-KC&/(Z;W)7/PL23P8#VGWV6 C %8@
M9%AJRDK"KVAXL6]5!A->VQRLT8W8PJ#UU$*_W.)8Z^78VS$C5S*M2AY<7F00
M=YSMJLR1%KAZ1@MZ]O?O:)XLJVCGWY2P'3=;1^5(>R52P. Q89/"M'5$K9RC
M46WTLYZNL<$SDU>U?^*?:9JSH7R:/Q7ZQ-42!$V99^TZ:(*S&8Z4FVFNV+]
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M9J9E>MO-$5N'7P8_.0_N-5NPZM-^*E@8 K.J,TR&)F;+]-]24:?<V##G!K9
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M(;3QULM!A$UOI8M@RIHF>.I\4Q(:&H?7B.60,,0^:'S<&GKWRI&DJ?XUDN$
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MLI^ XN(WYWZ'<[_#N=_A;J&[ORKW8PWB#$Q^5ZV,]%. @ >=#>FRQ%"APW\
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MP/Y6HM,CR>Q0R4"P;B8H(H=K8@K0-+'''I41O>5&J 1+UBP,(7QAXFBH2M)
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MQ.ULG'^.K[/@OW 3(43#':%F(0!W@C$,-ST>FK$OA)@%#0BE9TE2-+$%$Q-
M7,D&XLR*JM**2N2C&'S&Q7HY]1(ST4U;8-<9A=7V7&>/L>(<7-S;AP*CP3X6
M!#2ME)87\L,DE%M7Q*R@*7 (ZYL>LA-YYB@60 K'T^"F)H<8YV!:+H??/UXR
MSQ3&C]71_;P@ T7_Z53/'V8&_>DY@W[.H)\SZ'<+8?DYZ@BA[%E@BXCZNPT&
MN@.\\CY"4$U;P*/ZLC(E)A2$TEP<[M>07M$.':(D$[=[YV]+8;\09%RUHXXB
MDY>T X[3 RG+E!)YL2L;(NX8I46-^.%N"KD9EB^;WBCWC:>T[")TG':(X>7:
MWO^]<,I6J!F%QZWR%XL?PT\1C 7\"@8FTLH*KS8V_%$[#K@(JS<U5V_^2$3J
M?O)Y*N)W)@A/38WCM+*_1A#N7, D:)+O+C--\&:?+MMULJ^)J0$?BJ^22)4D
M):$?B[&B0S>ZPE)9(1!UY+#0M :TA(6?O/59P@.H9^99C#P*B!K*FJY@QR$Q
M ;UT2< 7<D 3!$#\X?[,/L)'P[\_(U6HW'<>^[1H#H(?F !F&7<>ELU -VBW
MT!"INY(H"-%3%Z/#P R_&P'0[B#KIJF_Z%U+1F!4 @@2NIP$A<\B$I"PY,?@
M%([8((J3QUD*_S;]U7X8UQ5Q+$P>UX9SD>L>X$:$V-P%9]S:2C^%!HB(?1%@
MKB"+8GLO H)7>'401X).5Z 9CNC:,"<'*.Q==%YCBT1[)$$;!:87H&WENIBC
M5(^2/;!S3RT>&+J)A; ]+(KUIP0/4CC6Q/I()05$;1,-XYI9%6%KHC2 :%)P
M9(6M"I1^O05V3%\E%4;>ZB.@XP!EOE..DM(RI=J(#@^MA'$1DB;%<B50JO@&
M*#FM"D\Q:9L5HZO]!N).)CK1.O*P8B$\].?740M-!W7&'PAPQ@1ZO(60HX-@
M86 X538D8K*"E0FM1=23LA% %AR@^IJFOO1KP*<==B"'P&0CY97V)H]P69)E
M:Z:M0\%P\!UO3#!)UT'*(313%F(=V"/$[B5+V0PYK2)DM"B&M; PF^327DI5
MD>34V+KJK]KN2CP5/50J2D)[1C4FJ=C?+'X$LF0D;Z'_JFQ)"RVN,=W2CE2(
M=9;SCWE)OW/:AL#R-EV@0PY6H*S1/,"H\4.1R*IK-Q4GVZ1CKNR@=L'6981D
M92WEIK3;BA,[UF1E,P&93&BV.^S.';CW[;N_:*ZKKF6K4@BY#R(>\.QRYRM2
MJ,X7\M$946-]G_Q58[K$5*VV)7 772TZ?Q=./2G3Q^E.F!R\%U^\^ENALT05
M000VQMTOB#2M-X_,51@Q[A<Q>9#E\DI^SN!@]2X0IBRA2NX7P 8QBM?H=R,Z
M$5PJ#60'?F+\\/WG[JN5N0?-3B;_!2QCWW-AMH,(: V'A)-K_\O@GSZ=WR*:
M7';MWKBMWZG ZH2@'?Y'M*CT7O1OF.HLXJZ/2)K$N2A,<9HI.7(&D5*)&I;(
M;P0^Y* E'0B1^SU3S/I[4@45P%%SI,UC75W]1/M9%XM?0-(I;=NRY?2>X%KE
M'KGC$"E-;:-]Y' :[#-]@2R[(F6BZ30;&1:8M^>].IW?4=.J5'M+<GCPBJF
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MBY]9'Q'(S%Z]?/VST'KV<9;(=7"BD',5Y1XZ3+^8V, T2N*)P$XIS+G[>^]
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M7M =HJ<MX6_@I0>'CJ:Y;>2T!?P>X9%W;>7@S&F2 'Y@U]9N-7)W'W*F]'M
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M-2\SQ4\/R:AV1>=.5_K(Y$K7+?9?]3H+)'>#WTSU(3RK;WU4*47FQUK[9Q'
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M_AY7[ZW!4Y-F<PSW_+USBH&:]#VWQ&\2"=90F7UT7%B'?NA8A22LD##1)(N
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M0^[G;L<$?$_;'^:KP,T@CFRY[!T#4FRVZB;&__"L'YEIK (#OP;KQ$GJD/M
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M /QM5U1?X=X#&R%Q2Q/%\F>;\>G9#)N$(#0QK'_9^Y,'\3H'D+GZ$_,#$<B
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MY!L%H[_A;(S]T3)MN$M,6_M$O!DBLEL$?]1#IRPLF+( C+3!:;Z21:E']QM
MCRA-ZO<&1M1$4DZR$[<L&DMQM7"(P;9Q9,FTZG4]8F.]_^R_W/\-?^)I)95
M<>#1VWZ$E>E][_XB__'L/;BM$LB8OP$/>N;3852/ZO+0CL-?-M5O+NM"&6=.
MX@2:AZ'S_[>6K^(?^S/\VQ_M/_RNK\*4LO=3>4PX//]!S_Q5-3BT,^!OWW3E
M_ID9 #NI/-#__J]OOO[3-WX]AK4=5_Q#4V?^/3BJ\Y' G*X[-< F$%I4J)%P
M6KHMC21')M*^(2M(A#8Q6% > $<;;0&9VG"11Q*)81O#[/T1UOR/N&_>QXF,
M=^7CN?,8'3\]7>=C=3Y6)QZK&RJR4 K8-MF3ZJ86EY;N_['WKDUN&TG:Z%]!
MS,Z[84>@>]22K^N(B6C+E[5W/%9(GG'$^082Q28L$.#@TBWNKS]YK<H"P&[*
MEH9H+4Z\9T=NDD"AD)7W?!XG[)5%TW;^Z!$'*??SU\%H!H #(6Z*CM(@3T:6
M_B@M\7+@E@/W@1VXWWG>-D7(J$<GQ#,S#DH+X00N!V<Y.(_^X!@'<+*)R[M]
M>+Q*H5*[=3&%**:K/.JY[1^S7\+*#1*8FFFFAP*WY80M)^S1GS"&]F"ZF](9
M5/U[W#-J^T6K115;S'E'WMUR+I9S\?C/11RPF(C$4*)R[K.7NK^2"(^RE*U/
MV6,'L2OSH\UO!$"F[05@IGBZ/M21EJ/U%D=+P,V7HS6SHS6:D*<H2$?N_2@Q
M,VI/@@),-LY8;B6E]:5C&VH4;;:A%OZ5,@2+=9MH;:52GP97)ZPIQ:-[![YB
MDK52"Y4U3-*M1_37?L*D\D#;=A(".QZP93\@')NM, SWT>2"=I33E%%&/8$"
M$_Q;W9@4J/0EMU\-VXOUJEJI$O]WQ'CFMSGS%5\\<?=HJKGIB<4$SU-/Q)5]
M8>0BI*F(=XO:2%L>J&"F^MY#'83!BD&X)]W=_K1-]J=N/ *G!(?<^,B3:/PU
MA3E8#/-RX![]@;-=_C+^ :L*2']#D-TC;>I"9FE![LEJ>5Q<O#[U0/?L/9-A
MDRHZ5\ 5@%5AX;A$GQWI)%\.WW+X'OWA^[>X7LMQ6([#HSL.$] !U*(FS6$!
M8$I\L?9!:I8T<+-0W+,<F.7 //8#8QN60N0RR25[^3[E_8B\/"#QYX&N_:-G
M<R;#IJ?T'+_:\D"?1<>A\7J0EO6Z;U+%ZR!XSX#!6KX5%_$',&WV^3)MMDR;
M+=-F$X;I=\^6O2S:UVWRDH9]J5[\W'3@RJS33U%.#Q4,?+_@Z9]*D$E><'YB
MQK@*BEA/)8Z^:82-.$QU#!N3Q:%MW$U?8D_80>!8LC(-= PZ=IRMMX5CZ.=D
MU=19;@9'LKS>>XP2S&NN#LE^>V@+V&6<Z@#7H&"DZ6V-N&F$X;IU2/J]YO#Q
M$$&\^2(+8G,)E2HB.74'XW!OXE*"9'S.3%8\,>#W-MCG"/2#U5H<8//S^J/W
MUCA&X?[NFVL+(3UZBZUYC142)&P=(7WI*\49&0M,S=480O[;=R3]Q]_C[WEY
M.##3=O<\6 ?[!@O8N?4VJXI6"F$R;T>5+$(K$_[W&D'55=++0P ZTL2[G:(S
ME LXK]8$F3WRC(R[0,]&0 A'EBQU-3T=F8&6*S&30L?#;V@TRW/C*D?(B19U
M7F]!\&:]&V/[$0@<?&M3"/S;+]$,U_@='MWN")-X=)PRHAG#9AMN?4--F"55
MOULQP(7'+/#3I>]Y1.C<=.%+++S$PJ?&PAY)!5G&M7,MTF7^/!9M.(.L<DC_
M)(CG5/&Q'"DVP5@1NMR:QBS]?98,['*(/HA#A TS M[KT$?)UH>A,<L(?7^?
M*2\W>4*!V@/_,]L72^O:<B8^D#,ALETHWCN-XB!U.:$F!CS&8K="; GJ$Z,*
M]PU^D:"NP2I9[[W,!#/3#*^+2Z^0R/<X[(K/9J \E[.VG+5'?]:.Q\"<;R8L
MB8WX>:UUW#P_E[%1TOPIEHS1RME]PP.Y')CEP#SZ ^./2!3$"(Q\)4P2E'/!
M+(*[$]_LP.U51QTW0O.D.,<'04NHLYR<#^GDX & (*80LMM5D6$723 YPE=2
M>,PW)LJH[S)M4%[W!#[BS\RF;@347"P,)2&7\[.<GP_Q_$@O?-=H=SQ%0O#F
M"L:NJJM[ IC(N>/6+JE:M%VVV2P'9#D@C_^ ,(GPKFB)OY>K7HV[R8B+E6E/
MVP \IV;DP?+0<CB6P_'X#X=$*BW\;[L1.%DAGP@,UV]E4Z@2CFFYLC0N&'+\
M- 6#[?J2:4KG*H+S7]>(HE,H5#RZA'E-DRE(L .76H[=<NP>_;%3!G)*EODS
MXID7I_D*N,N,Z=DBP!V]@#:'VNPW=6&(,:L.0D<8IR7VV<''3'+GR/BEQ,@E
MA$"XXJ)J^X:2@U1]JI1 P_!37MA,>CIT,C6>6\[R<I8_B+-LVY6T.4DH6SRH
MCS8O$+?;9N,(S3RD#>-2;G2^ES+N<EP^F.-B\,XQM7>7-151$2#./]-C2O_D
M=]]<7_CXJ\Q6KE28 7N<EC.QG(E'?R8PRL%N9F&V9.ZWFLG6D!(:+,7+;W]Z
MM<CZ(NN/7M:)6U:[ "@$D50"YM0@5 A<K4*ZWC7%BJD3A6=^.0;+,7CTQX H
MBEN(J2D[C9%"MB*8HP%RTB:[K1LF=QQ\<PIR;)FH7X['!W$\ DN1YL+*0D-J
M!@F\9Y!^>ICVBJ\L@Z:/:'S\5X>)0!JS:EN<900Q#7F%4T8=!^D\&FO2D2T>
M9AS/366[&B&(W^7XFTYHWCD_PS<QML=<%[R<^[IOF2E\>F/PATHJ%_^,'W[E
M>,C0M"-NL\#\:N!+0E.62<DPGY['V"H/,:]-?IE<5^:!9(!-YDUYS)\9S:,!
MF=#HDNSK?5]:0@[<:GY0>6'"KU7E/ F8N[9H^)\\[D>!1 B;!<"+8+_::.*N
M9_*LR-%"H+&F6/MER2B"QNJ7R:_\1%G9UO@D<CO*7 E6H 50(J1=N!<(TCYC
MAKR(:=FBR^B>$9.A)3NW@$S(S1C\1$4@--%33&&F%R7FP<#^9F6O[[9U4W@$
M-LS$YTU&;7I%8U:U8?1!DBE\?;L]CA_%^P4RCKR=9D,%A"WSAX-VB"Z&<1V+
M"XZEHA +U]RQ=O/C4\MV3'EB#G)J7#BY8V0*=D90W /I=./VO;+'&P)J9G@T
M;V.=T4CS6Y-Z>T0+S^[] 2!8?+$@6"P(%@N"Q5%'\)T@/>#(MR@X9/1M.O0O
MM/,S8JR/W!X9U&EWB.C>L,6_PYJ-&J9W"9[PASW#7T^C1<:^"C:0!6X"^2RM
M<Z^#51AL"OWW]3=I\N(;4L/?_.UK4[Q%C=,(6$CN9$0?_2,P9XXZ<R4K0VK'
M#WL\__LKJ3V#)<XNDY_!?J!5WC'0AI_+#VY](%TB.F.%V,Z2VPRQ%LGO:\$,
MK9V=L4]:@FI WP4"@@X7!R;3NZ;P;*!;C8V1VT88XHR 6E,3,<H#7+P&%WK=
M10ZJF%GK*<G%VBTZ8\-=9=ID3.)&("*6GYO1':QK)Q+9U35+)3,D5BVX#HSI
MX#$2I,"81H (#F<'U.+'9<<Q:K+)JUG),(;<^**1)9ZG$O@5-P6VB'H30L=!
MVR-;"HHF>8 *;...!A&RH8&B,KJJA\#VW)8N=J/H;JVV*@U'U1F>HJQ;/2FM
M"RM,>>X0'4SU_9@A<U\>A-6"F5_0[AA_+_)S:Z7=C.@P#*K)OWI4</0,F7<(
M\8KP 8D*=XA0]-$4:V<!&E/Q#_$8-Q(/54?<Q<!+_)9^H'?_SDQ.'VGCTQ6P
M(* $'!;4;"G\K4%PE#L>,255TQ<E!6C9FH,SX1IH,@@4>A%2!G9NQ*\V;K<5
M92MU1T(%:>?1%]<:X" CR4=^S%#NCJD4B!DB8+H['[NU':ADOM4@GO.'J@1_
MUX.\TT.!&+!25]J%>Q[S_ME;PF,QZTG#*@:A#OQ)<&+@RG@G7#4\GZ?UQM(S
M,4>;NY^J0"@R-V$JFJ^Z;X^>5[5 <7#+>T3'0)HKI0(^#7 4HE4*Q54$\3'J
M4EZ\A?2"9>/;)XGAEX.K)DWCB&#<T[LE>%:/[ E34C4=0I)K0_1><,),R^CD
M<Z?)ZPKY>[#-Y?N?7@1,H2-[+WF=*,=B7X8*MO*($V4')Q*PE 0;258[:!E"
M5* @_;@JC7:=NW&&NM<F"N!XP%U!R53);[ [;2X9@&.,Y<&PH,J/]]5(YL:?
M72-[QX[!(*5QYPRI/"9:1"0\S[J9G7](\C5YHE/U:B_DFJG_ R7?.&<(&TU_
MW11H ^%2=56YDEZVV=K,;JYNX<0F']"4Y*W83;-%8&!T56^U6Z1?-YR,,9<;
M'&'AA/(D,YC0D;1-KUH:?T+G\JX@1:GK">_><3H,GR#JYCKVWA6M:UIVX(A3
M7FZ(I8P!CIIJ_OD$B&@!FRU6VJA:03I/[\LH4;=-XX.MXR+8(BS7&@,$=GL)
M)YW-Q.NB+-LH17B"5A45"8'=OWK'OHD!86>%"2("UIIH=(+P6@>9CD)>H"L$
MOL=!_:W&Z>55_'NV3"&'!W?;%JN"[)Z0)*0X8E6U&]?0BR,9DF?#O%N"N9V+
M?F_9,(.O1[>^<^&Q]+WJ-:/K\1L='&T.2U#N[%8B4MP-Q%\__1SP*EA*2!(U
MV6U_@N2U&VE,Q&W$:>1H!_7HM]$984]M[7+X3JMJ-[BJJ@S:#KZ9-7DKG<;H
MQ6*U8>3)XCXK>EN9'5I4(S48;%1;WIK06D6/<[YTM%I.IU?NAHY7[)..I?U(
M:W660*SJV,94CF0>UP"?K/H<HK;!N^!=IU_&BK.&*!"UQ6U=@NA-?LW;8]Y(
MOZ]M&W0 /Y,F\97_3EFZ5DV1$TFJ>F KU]UA),UGJ; .&0G@@;T=80X9)M_9
M.F:=QC##'?;9?A+<8)'Q>KG;P6NDF1 9I5+-'B!:HJ4P*=?4,X;G(T3-D%Z.
MEWOY?E'V?F>L\,Y0]A[1$W%ATH<]TV$SB-5K1UI!#@*Y9RR4<#R*ZC+YCH*>
M5@ BR4\SG[>^XY,(3\?U/#EL;=(Z&CH:NC(HV>0/4FF.$##%.[2!J/A^DVYS
M&OQ)<$,AE,WN3& 5_21-\J9'X[#BYQE<D')G^ 5]C.CCR^0Z,%".=V+"U:&P
M[*BS4[3BH2/Y<IZ"*F.^\ZP[[#EB$ENI.41*5=P4;<>%6\]\.5+-PY=(:*I-
M?<=%58XKWJ"O?T_,M.D;BFM$,;O\ S_9C[.>]>52SUKJ64L]ZP^KE0E@[!,M
MK&4NU8S-.*X74T413K$3NT !/R8;>5,XDHO"Y&#&)!46&4_R_+@$@?D76<G*
MP3.<F D$AY$@M^^PUE-2G4)3%!DW(%#L9-+58E:B1HM@[#4_[BBVPH@);GT8
M>.?4_&/J-A1?@.&G(&R0Q<![P#'82=X<;*^4TR+[.[T:C2<CAX#65U="7 VQ
M)F;<.#(#[^BF5K]=Z3ZHW ,:#P[C058J3QA-6;LHN3E,M^K2M!.&@@I?>)H*
M[(\GE#YL*_R(GHA./QT5/'4'UR7@C($%92*9V,M5UW!8FKHG@0[>9HDUPIMM
M7/XBEP#_NY:F)816YP0IQY9\!O4V9=97\"V)'4\#6T\G4R'FQKY]S]\\X7)*
M6Y_ +V;C2U8UX71JV[6DQ/I]7<7T3,E/X,*B6J45<[8(,:JQYMWT>YV_GF J
ML%7(Z.V@&%Y]_A7W#$KM3_\&=LHA4[V)15+)4DJV9WJ#FB83SNS?]?+'KX,R
M12)M4G'8N8PC(_[]@-?7^O,]*)J2R18PC59+0,^9&"SMASP2Y\%XQ52'7U.I
MYX0$*>V?%(^P.8 >D5L-3)X'K@@RT[8CO8DZT?\'?2O;*1?Q*A041B5.EA1,
MGW@1IP3G9,V9Y,GG<2DDOG-<UPT &&CPC'GR?7 ^X$JML-6A.ISW=*6B;7N,
M=Z6E,)1;?:I3=FN55:_Q,FL(6N5'[!=AKD;?\AK45;W#Q>L%C;V(#*8O]O"U
MTE";\DM((4J_P?^)KQ%:";'-@'X-ZL?G>,H#&^T\VR&6+RZ-.EJI+&K,X.\Z
M8;$ 8;J)Z>-1_XS3Y$4S3!R>D*RN30)QE;7%8D1G\T1_^FOD&I[V/J7:8SHG
MK/^J&B.J:#CJ5@\=SE(Q81:#]'[IE4N6Q6L4("T<%=4:3=M0'V*YG(> ;",0
M_Z1U(V5J%.;(/,264I/65C79%)#4K35A:S*T4]0[ Y>\HS0_)7H4D#$LYX)+
M]!,/NM*3:^_<R[3!O5M*&WB+?-F2B^O8^OM%;_I*:A1;>AQN7LODU8?RE2]B
MPF;5@CU)11-MIXA7';3\)1R%@K3CG:-ND/L73.IH,%' <0Z7=$36O%2012G8
MW3\B(>.ZAFGM\07X00&C&?L=>Q"A+=US$.NT SJJMZC#5K832?PV3-1&?4N#
M]J1!,5K.9E0#';A!P3D]S0W2HTUQ&$]3L ?H/P'3O:T;S&93)CDZ1_RE:2LR
M;.03XG7F>> TS/2\2KS&]]"7]^$9EG?=:?CSM RSLTP]F-3':B1?V**&34BI
M=J((DU=#W'S#Y#I^E>K.^\'!C@,O:6L"-1M <(,GKR;!TYG#66ANL,X\H6HU
M><1#0JT?C9*32)XSCMR8:2F[%"RKT/D:SNQ%#&32T!!TW*RZK?$=G^)-S%0.
M+*0>#^[Q,%XJ*&.PN*:G&3[[CDSB2T6 KG;1[U/_%_#=.?SC\YMB+4_TFL8!
M)3>?<=ORFET3L3M#PH[(?%#YG^-K"#I#&Y&?;;S'99+&AK@<[7!M9=%N*0DF
M(G_!.V2V;%KZ!\@R]A6S%$NG-8>6-;4+T2S@IAYV<T5.FN*\W=1U/N$7_;'G
M5QM]@E>+#N*@+\Z8X/K4CL/4-I 63"DXV6VL;C%W!9H^.X\UYV4QV&EK!+6Y
MF:X2OBQ-6.Q:<_QOVJ<9#KFDL%.]!1R)(!D8':4AK"M]ZYZ9N-#D?+R?>:+]
M^?$/MGWQ9"D$+H7 I1#X[YUI\6TT$I;:#JG2%W&&'5+2;=NZP46D?A='F5F#
M*;J^DZYDVQ&9]ZSOE2_W[2=32'-S=PG-DV5YB>IS.O__4!OJL7+5&=E6GUZ.
MJKHG3HV$OBE;W[4=VI3!\'WYE!#@ES\:GA^V8M[3AA^Z\-$;07B NN%O[?&M
M%VLN:G[_MQ?IZ&5^__S%H*5?JJ74=LFMG#3_1JF48QWS[%I$_?(VLS,0L^$]
MQ6#K3$H*H4I5P&WHWXU;UXSISDO R5!M2S3F>E0]Q56AK>$:"P%)^.98$+),
M+B=0V-@K[H<0J5ZP!D>_((0(+!RLX=5FG0MME4Q%PFDW<AKY(L8Y*6AZ :.%
MS< QXL@ 2S 4XV%R$9\(!W.&A][H#H7>P*ZZHNNEJF1(63$Q5MQD3&#L9P"\
M-$S@^:H2"4@&SU_^S+Z@RB4(S846";K)_@"\)KQ1\ZVA+-?5,>_5^W49<S%C
M? $/O2U*TU(02I7,]R=O'Q$<4$RUS][T3U3X_A!D#Y-+/(8F;R'Z$2<*[60%
MO+.R9Y1RZ<'@'_2<,\07FE$6\)?M4 ^39-]MZYU?">X^(Z&[=6\K'J?M*7WS
MWGW=8U]!7':"QW<3=D5F%,W5N0]BU8*XHH>/($TRID3R7F7E 2(__"T>%GK@
MD>E1^!)<J8-%U@?'5T_AF3$(H<>/6O 96F,TH^4''(E'.)+,X?"+T:1V- KB
MXYX+RJ%3)HREZ9'%9HS;FEM.1"2I8AB7S<U(S^B9S=$X_57>^QI3ON6.S62[
MQY!;1FA8<7FD%Y?9M.?TK88R0NVBM%[N%0=-!FHQ3'<AJ$E0'8+$4BKC65-W
M-8@&RT1P#LKLKK46@561"BUL'U<4!6 <=0H81->2L#12<>G]H&-DU>3YI43P
MGDMNO]L?F%EN]-_T3'_ZZT_#6OD#ZL_#"=$15JC[=EOLY1=#;"9LA] "@(<'
M8$W!N'ADW)ATG#/MAPBSR$RV3IR0=&R:-"U"#=RVF&7,A/ABW'F"$#]F/833
M)V&)GXB+M^:T:=NI(0[Q(HU3H3A,Q_QZNM*JE+/<IK9!X?[VA-;V)[2F00$_
MX'4<=?RQU%/0:)18S&"RZ2WW=#W-7E.5%73,FD@(&NG(\:4AFJ5&=VOM18W\
M-7K7$DY($WQ3[PJT)M)",9JZS_*M]&F(LB=MIADHT-WJ G/;@Z<&ED29'[BR
MY5C3KX,S-5'/C@Q&69!W(PAH1 O3G.(;.SB?R]DM,I!D ()"/;$KTZYRA?W_
M#"26:N'+O*=<^C<<_CN:4#@RJ7A/&&<+DIL,SG9=16 #N*O_^1]7GSWYB@UU
M,"-3O9=', <L9\V@'.B1!N[-]>JFXP%VN4Y#MYV^#RW!AEV_M\ZW'A05WW,)
M[]TH]4==K_N59H4'G0RJA'F8%Y[45;=%4U?:CH ,"SG7_6L<@M&6,0,XP^-\
MMGA#C8%\"@=L#\8(L=41E):I8[%R. ,MJD\+=EV@@%7\/T3A:U*NSF7Y+3I.
MN6]"'"(9]DU<?0OSD=/3P(-)>Y[WM?86JWRH\J:.#"L"7VN$_<$FM!T;(F\(
M)Q+C,RMD8ZQV$N:'M?Y4X@F[Y&=54>?;82_RL+>P/FGN$)_ =IQR9TD/W[?0
M2YO"H=HA"XPV')[^?SDP@G"IEG2':"6J/@59%[ '_2*$7MN,@K6*.GXIDNM9
M,X+Q1XQ.F?6D V0/S: ]_@%P#AU9)20J4X8>250\6$\]$;OL-YSW1K&!1?2=
MHH@RT5"JPWS(+G3T.X0O6-3^.!\,4]%=W93Y79'#SK_PB19[7LE#%*Q,.+C@
M4^W@],?)%,XOL # JUK[N[)'()R#'!D5MVP0!(.J;FY@(?]KT3TU3M3OI+QQ
MV$I&L2(^2'B=OLI)L3@G;5!.1DW!X7)&8-/AQ.*D '_@'8R/LP9WM=3@EAK<
M4H,[US#>+[YA)TNJ?K="G(@--YD,3=%]]L?[<Z$&M =OK==2Q:!/]@@^5S<D
M.*>?3H,T<A)$AA(DOR+&2-.:-HD2@T->@DCJTF5ILE+P3^EY^09M >\OBQ&M
MU8CR'AD33"E<XYY'X9NB/FJEX7JU^F<!?O<U DW\?^ 7K;,T^;JHP>ZFR7-7
MHJN4?)2U"JQ&KM'73=%V=9G\=, => 4?K%8?I\FW99'\K:")@^_+[$W]:@=+
M^9^2P$)_K+<5Q/')?V:[_5?Z7VGR=W#2(2J'!;W8@-2!F_:R7F_A^Z^RJMX4
MM$^_9*]=GD7-/5K*4@>*?!N?Q%)9($Q(W,^QVV<V,K6>]\C?]EFMD=-F[MD=
M]DY+&QQ8?. F_A$]4<B6#@#]]U/^:9I(7WE6RA2:5GV+)B$L%@?AJT=J2_G$
MQZ,N-Z@Y[.#. )B/<H$=0UO%Z*GW>9(V^R2CJ*G-:8[*&0&==&J&(#40K@&W
M-(!KMHE"^.8U1%$.F_V$JS@,/?O>B0<U-+S 'NM/?MR DES858BHL!1DATU:
M.8ZT*O3:&LJ3<=]EYO&%@XD8) 0NDU?R%:S;9$UYN"!\%*,7_)&V0+53^0QF
M5_4-P"6F(!JJ3MT3&Y"\L$Z.X@D"C),E:!UO%!CQ'YQ/UY* K)N^Z$+E7=]J
MP((S:11^J57&JS$#%M%:QO("SZ_TT@KWBY30GI%Z,PE$B=H2\:<8YHD,!',&
M:*+'"4H*K8;1Q5+.09O1AG10 _RYCTH1 85:Q[HI<XTMDI2A<5B2Y&QJ,1*'
M*&\21\=6T,<Y()_RD2.^<7<L4S1R3W X*#2Y?A.WHW&*T2(TVUVJ<';T*SSX
M5>O32)'9T:#>V)[+Y#N&<<&+IL:C&9]5D\QNUQ@]<_J9"_><Z?6O,7)LWA*2
M.IYJNJ$AJ*BI-"J"&[43X**E+DPY-@8NHAK_O2D/+Q/Q:3&\']]]<PW^QT]'
M&FQMJQ.K\D 82ZH'\Y-TO%GEF0L/VZ3"L)9\H6[V^"M=M'L#7EF+):M#F$+!
MSIT1(<EQ]![ON PARU1I#H5\T)HM"2D/"RX(%9(*E1&D>/"Y\ZCOP]G1J%_8
M'FR/+12Z".*T;(-UCV9Z>B$><'9P8NJ=(C#4J[;&X:P8CWLXX<# ;X'.[J3D
MZ0V"7D4*?G'4YO)$@VE2JE^CV)/CC7T(-YG.;$L>$&<+7$X$M\,,*O75K$$Z
M00/?H:>V+?9I N>XR&5TX"_4UT%@I /<5LX,#L:Y8_G6^6=_.+1:-2I-@"MR
M8X8.0KJZVJ"MA/7MBI:4S+[!^13_>(1]>EO49:CG'LDJ8V)]. KRT'K7,A4+
M$9K$Q3Q+JX4]0BL?J@I,D>.*M4![G_$:&USPS)Q+<"5/GWSUDGKO7HKE@6NC
M@O_!/M\+?3[ZQ=57])CF^$^6!8Z5'7&@@]L]46V@2Z==,52>)9%A51MRS^C'
MFO9*:E(C:B[,5O.@2$@6^]E)LKX9[E+CBMT*# 9[8C)I*4EKPGO8UT@YB-;M
MNU K]U8E@ 3K)04[06X47_YXS74PAFE?_&@8GPWT%EF7(LG.G0S&/E"0728H
MST38\OO.Q11SW7)*WN:48 GR[8[(>5L3?G=1-K(O88>Y-RC:^GC'P36,9,62
M&RI,C*8B?Z+.:L$+X/\H\M37^(9B-6BBEDD^I4S$$*YM=:J-"OG@^"G+H@3]
M:M@RY#Y&D7/MNBD8&H;[O-E7UQ6>(#LCS!QM3C#S@#IU?^_.;6KC+0RW,1H9
M?'B#XJIH0"/**HE>M3?\6,_"Q#SR0]LPIOOQ#WOR,5QA7_7H[:9FZ(#36W;?
MX"OTOXV'.M<>*M4)=4SCN*XOY#?BR'@A(7CYOO)O[D =!E3&%PH%BDATI.&>
MEREILG]4U#O]JN-GQ3]]VZ.? R\"/F/G%D3#W3$P@LZA>IK,DW<N]M"F'#3I
M7B#\"[M4^BK/#ZT1=S[<7(:*5-.-DB^VV^#R\1>$GRX%X:4@O!2$W[G+,3-W
M_-_R1.AHC7R4T%6&.=W&^29P;IM'NC )N7-2_*NB'M19HB"M1<*\M?.5G>HP
MY1BQY=OTK0[T$[790WZ(KX&(Q\NKH59.!'!PW/0)]O0V*_%'Y/46:_IVBE_5
M C81U(R2X5@T/5##IQJ;R^0'0DO1+FQ)TH^?B!Y(<5Z/)E5;1JK"%K-,APEI
M/*W>;'@VT3^T,?\>^K'U30"#I>^5B<YX.^VVOL,^4$[1$](+^<E-^*,O$*P=
M$S* $(9:BT>!G[+R&A;!SSQ$E=V4J'4 ]R;D>'@VJ[74)7%FY[Y18*E8&2F"
MPR#X@[?U:\&OBB0'PKZ.QXLR*A6$)'G=F*!0)'U#9:$[^BQ@;V&L90L=F8\1
M?=4&"1Y+V'+*9=,#\:@KG"WIJTUL?JUQX)]4ZO#RS)7Z:$<Y>#9#?XZ'J()O
MA&^WM?^-PH6+E7$Y7O0Q\JH_YFOK@3\V+9 E+0A6B[5DK(;8LO3QK3BI6686
M<V&+@3$-5,6 ?[Z2^=OND#0AV=HQ(YX@XMRC_+G3NCQ<C$J.U(XS&=,,30Z+
MY]$L0)E5IAT)KSB9!S#-5#QO6]&,3M/9<=O<\6B-=GL-TU;:-=YJAX):,%&'
M4CKEE/K]RQA;;Z(!RK"BF*-^F@KY2,FA>="07;,5/E*/MDD^-5,+-&QV]&UI
MJHQN,_&<E\DKC.B.>@4<#^\;=V&AS*.P731T ='OK12*'7D=B=S2S%9(O9$&
MQFB'@XV-TT#H@B#LTK8F9DP9/]9.*A-N[Q$,8(TD*_@0+8T[P<_X/X?/).G,
M-?HW4^6A!WR>LR"X+QKO+33>WVNDL*,Y3)+\@P!8G)92(R>CE<:B"?&9.K^"
MJ;;A?HP3;P3"0S.&B \8]8E1>P [L>B*XS\F6(K\;52YL9.HP&J%\J+Q\-\%
MNL+]3KN%9* QPB"4HVA1030,&#021>QBH&J]1XRG])[YE)I'Y/G16H>493BL
ME/(Q'*.QG9*Z]QXK(5#G 1)/!C;9US%IJ*)I.T]]-6BE:?K2C2;G\=\90YS$
MMQ8:P$W#( WX((4E940'BH!+T?\BE!?I6U!48W[(P%?'@ ;3BZ!F(0(K7E3-
M7)X($2P[ZO6:<'B$?5DP&RQ<76/Y72P%*GHE%#[&UIY*[@*F87T"J3B-0!XB
M"7-V2,V.HA&X*%X5CH<X]T579(RN",+("6ASNTG:7:T7Y'P0\7I%U0N",1GF
MEA+A4B_4*)6F%5L\VO>3[%*V8HWA:5-H9ESB0B32$<B=$ 6.:*$//F?BX4AV
M#H]<T>XH_N=J)KBS^J:D6M(>0(E0UZ%TC\L:L',#'#7338YTLV_$"4.<)Q.W
M#A?(=' "GR2*F!?%UR.-O"FZ"*C?;_Q $'R_B]$@NK]!)D*/&/,PVX!?L__C
M7HY[(_[KM4 ^B<9C.<0JV-'#,$X"W#,,+O4$;>5D<DM+4!K[SAKDKCAV\:B8
MMLAJR4LN+'N)5%\53H7V_M%JHT17_G]2%QL.&:/QL(([52BE?J:3G#OV/E9-
MG>4*E,#_@Z<EVW.JBX!93?3"V 64@\Q\[#(80JTE!X?5@]C7X8PB1'<,DS0\
M-Q1ZC[M]4\9VR@:>XL&G@.@>PNM,?IWWJ;0X>M^Q_S5P5D;$*KXA0W0][>(:
MN\O7(6W9&<SU(\<^H(1@*S+Q(MV!WR5MZ[Y]!+<W'1HV PRVT2]2!XBK&.HH
MVGEV)[U^+;&AG6LCJDN%(QG4.2W!FK'12X:G%7,^& J(V@:FT@N4G>^;&[41
MEIY8.ABT)YLF2EJMO=*#M6X0%429!ZQ()ZNL:8@B!U?+TQ,0IJQ-M@<'*0XZ
M.*^"- NTC/MUP <]<OQLJ3 O%>:EPOS> 6O"Y(QRL*&):B-K046>,2N<KU+Q
M+R+>'*F;8"Q >1$>#1OC)DY49B2DX[(M@@V?4N7Q(TF$:GK$@9F.WF!]WD?6
M^[R'AL0_S!3QAP!^,S,/@HFGJ7=LT&A_1YWM[7:=7S[L T2#19D+(9"L,.7U
M$=H;1&RKGJ<>V EB-D7O'50UZ$=/FA3+(%[R]=0(X@@OTV#6H:,:=0O<-V23
M,ZUJ32?D?F0:\#E<,0W$E%HN='NPLHD7)4_@'SE,S+(KM5?T8;MY\<:,7C"E
M)*=I@#S'D.080WT_$[*-Q*=5R3]6-<*<G<9'%@$9O&6=H0M+A2T\WLTQ9#")
M9NIH;D+HQ"C92;*EN182'QD"&^WJ$,O1-'LB35>J'%V">(29X%O<N3!HBO-K
M$%#T-/WI%8HE&*:;@B7+F3@WCCZZ1D97.]7 \0SR8%K5J#L^%MA'X+#\MM\*
M.C1L*OX(9V GKM>Y; >^<W7P8(2$ <:$Q5,5;BZ#4SZOU/-I9\SR>P1N2&PA
M2& Q2IYIR>=C&,JI@@VUWM9U*QQ .F/L)D\T)G5($/,"?7W9 1IH:D>CQ]&Z
M)>?E9]VQ2[F_X4T0@V8N-GYN^;W0AI6%ZW7S3OWI$6L[9,>U2FV"U<S"&[ZC
MQ@J[L!C/GZ/=<(6 (SHF8./F6\'=FK(JLO'3'L18EUM"W)/\"W\V)]9A4V%W
M2L@"Y[V/ZE-1X%RWK7L?T>(?\^Q&,V3?!]RPESXQ.N/)G7&+_+&AY6F"=#M/
M*%4]@J\VJ7%SP7;=P!FL#C,+]^&\G>+RW3,N'?RST&JPB@H$R@U_C+AA1#*5
M(EZ_*QEX ^)P,JK(SE7SU!*I>7!(!)FCWM5L8-L,T<4#7\+%:^?V%JF#^JBP
M(A/,BH4-AS7OBK85$X%X!$@*YGL(@TMHKB$,!R,33^G&C<LQ8\47[[BL:A[\
MJ$,;\U-L)#FO,PCDZT[34#S6K/H'F2F/6,W$/QP3.QL29R+,,]2[EBXDE"V5
MB.0TH8C/FI70&%8_<&%SJ2Q>KR>3X]0I?(F#&5CC]S^]L,51RI:B_T#&,0QF
M>RST::H[KRRDMDG]D;<%8DN3/\QL+)+0S] @"K9)$5#\<2F:=D;WG3H<.! I
M.+T+M\\=@^2:S'X$PZ-@'8,"W)VIT0YPWN_JYC4'FK8N2U$,AR]$Y>(.ZE9C
MJP(N :%;,)/,U0?_XL)3V9<U@B,B7:Q,%8.7MVB!N3P1Y53"Q-_@3$=JG@"7
MF-?%V#<MF;*)\[/_L5,)A^Z%?H4!M79]Y<<GA]UW#Q=,XOI^AA7^PC&R0>EN
MQ)[%A!6!W(04!Z5=G&D3"O4I8R\]?A4_AFC$-IQ,<@-\<,8]B/B<9D!^!.S2
M8'^4!09DQA.;J1+?CLM/6W <&<M*6]7QSA:VAYZ&?(-..S")'=EIE3-\5ZI*
M$^ URL2C;012&1J6%_W1]BY0,J+@E'XR;LWDN%>('[+VM5H.]G<&SLZ(7ZM.
M;O%P'*1RB Z/JBF9F]C$CFXHPTG\J;R;'KB*^'2HMZ*"X-)$<!..U\$P+/C#
MX3HIY&;RG2'^#JX5Q2EOLCMNDAT"J64?N@I\G!6W3Y:*VU)Q6RIN9_%#L'H0
MQ0<WQ&>MB'7(0@?^=MVWX)ST%7,I[B,>[2S8*)T7D7PKP4ARI-I72)),;'Z8
M%D:@/J&SD0;>]2&5WAAS:6H9YCCHD/#TO?$+B+?=,(_3!6#A1+!CKF R 5$I
M*EC2S>@AQCN"G@83M,5^#?569IV=HNNC>(J].?Q7;)SLDWA,.D5[XWSG[Z,A
M32??: #68@A_'P?"@T4,ZIC+K&[:_YJ_I3S1*')N6JT)J?X+2N/O6_=?^H^O
MWH$.5:MJ_H+J?/CH IB$J[HHLT/==_^U*=ZXR32ET2QJM'@?N@;^_UR?2K[V
M!7[V%_O!'WHJBC9 :<J::'GP0%^!_]PYTB2H_.^:;/^568!H3%GH?_['EY]]
M_B6\CRZWZXJ_-+8L[R 9?-PL'5&%1=M"C'Z7<;#%7X+#U"/I6DG3HO(7.$K?
M89KCDR^>M4'2\ '_@J_E+_1JW\6AB07GR3&@K>B$^ .P2/XB^:=*/MNU=7%;
M4/RV;@@_!FE=X?]B#G(1\T7,'[V8MWU+R5?!CT=7;*JVM\CZ(NL?C*Q;EH4X
MR[>(^2+FCU[, VB29,S19<D'-;LV3LVWYNMY_#W.YG>,GMXO1V0Y(H__B!Q)
M6E&+FY^+M@FK=5FWVD<W7: ?]RA\!4=L.2S+87GLAZ5UU(6*#<E4E@W=WS1H
MRO <F>G:Q([GR_<I^4<DYP'9/P^U]1\]I3.9=SFE;H+]ZX81EV':/!G&1B@F
M<N&*8*6+S(EWOFQMH5ZD*\AV^M*  S=4* ,7$Y/MX5I..6R)\$?;BI7Q6KAX
M"Z2AL'WV@TK"0_V76/&(L7&XATI[Z3,!J8Z'%H;TV?D(;)VK'9/M*C]$+4]M
M5FGS2!,P9K"_8#,5MV,]2./ZBH>4X:^]GWI6E =M/A/K1SN /02A[VSXC.^%
MPOY=]RW_=QB-]C/5<>^IY_NA6MXFNZVY37",6V'P+<S$-6$L[2Q42<IEL4I0
M]IF0$WM$^E(Z1@BF<T-%,0-^.&[,X$:;(1O84;BO,S)9/+T<4:G^<@06HSK<
MA]OBJHR&P;GLB4Y:'DW##[JIM$.(15+!],SKX2D.^\(+)7DCMVX(.>-!\SP6
M E[PIJGO4#ELC'J[V"/(WG#V/A*M"!TE'7F;,8S"J)>9V%05"U8TJ*+51BU=
MJP9^ZP:D !'Z(4Z[P2T.+L-2S7-0<@@?0//["DCK<L:,\&2)'E1PDO<BP@U3
M5%@GI*O[[:&%TY-5@EKPG+I=^$?^LDROZM$*7_DI/_C2\Y]>L:Z2.BTCJ/J[
MG :^2(U>^(BAK$MC!K=%.WRHQLLG?,,+2$# B-X<O1?$/ A;_!P/M-^^"+>(
MSF^ P_&7]'?!)C09IS$JBEVK 62.9^X >; #6M.P;E'?KIG>VA:ELV_7('KM
MT0X2("SL V$DKD#@$((F?G?\5WC#343KL,^(99=1WC8UP1+YW_@G%P0\:M84
MD \Z:9XL.&G!O9"S+ A&$Z\K0KAC<H"P_U-, 6K0R-+JM,'Q+8_)/S-/;!S=
MQM,Q,$)>M ^ST\CG\7_?J4%Y(8V3+QJD;/4]W=?$BD)V^SG*VC7VK.#)WSG2
MC"MNVF1O@+^"/_L6WB2_;+T >VPOD>4/HWCY<,WLF!@2^SE/O-[$;5EC9^I1
M\,EG^)P[$"AC+HI6\(UY?30#,P($4HE2IA1V<6,'E,<WVREV6^&R%>:UJ>46
M+4.WY-P+2YA"CN<76S*"EJJ%&^T%6H@VI&II4G9@)*W]E=1C"I9]2^,':-YX
MBD@H#LVW-TW6YX)NU)-#G^?41@QWJ5K$W$)K,+*2Y@K9@-4IXUEGI?1-M5V)
M+IJ]T:%XQR )$^3 "IC&X+%QRH??AES13"'* D31L8>(3;ZC?J+TJ!A!\,-&
M?3+'U+@52@4(J$AL3_R5P2J"(?P&U?=+_N(+-HHH9P:BB'JKP%;M^EWXF5R:
M_ H4274N?-!BO(\T+!.O]>R3)U^K_4W%**&QS66 >4-V44R6& /[>.PPT5&[
M_NE%S"@:N=.,%H>7&2R['<S,#(>$0#'3K&V 2(T, 'D,-#R$CS2\=FK;_A :
MBF'Y*Y2>"]BO"P$J"#\T9CHESX)<0WZ&@0GWOU%L*9+F 4B4DABC2T',W3GU
MX9<"ZTAP!OKV=F#'HF9ZE'CYNP^]]3,/8^]=.K*8 ^5PY!WHUO.6#$CYQ$JS
M<[]RH%IL/*_1MF*B(=Y(G6./O27L.79(+K'C"-:.DXP"P/5+]H;5M8\CJN0;
M<'Z)@OOITS1Y^N3J<U1A>SBB(ICM-F/OE[((8A0C_#$#)D#0S]J"Z!G=]!0%
M'B_O[?#);,58??KDR9-K;73\0>?W7TH.X'F=4V!^]>47GUG[E2:"9LM?:&0V
M1!>%,H,QX.4C;G?_=&EW7]K=EW;WQ>L?+I_!;B< $8U)\9DBSL76>^JG+QBU
M&\.Q5H%]CUH2= 6^[O,;UY&8XE3O-<_ @\6XFNH%3[T-WH%1I%%?R@QHK=UD
M4\#M\CD7-JSB"&0W-PCEW3G[;3 L/F@.='_U-!,!CA'L\5/8X/^'L#005+3H
MKV*N1UTH 5NXXZ0\3=-QP@'>^]6E8(=2A+!#_P[$!>PH!;&(65&XC=F+I]-[
MH="XDRNGT0;LL3GL&2;9K]^FR\!OV&/2EYQTQ@9:2^*(/!YTY0W^I'Z8*@J0
M4/V124<^GX[>N$TM(/A1G7ML>%.JH,20@)'"_[&+#WLM PF-<PRQ#.)'&36)
MKG3O7KIV#<;\19E58=^>7@5_IC5KQ"2F]_THXR(NW#K;IP8.KG7$)4&:BT8S
M\+MA"/0>;YJ$$B>SX994,Y'](EH,G)=$;LI]^)2F7%,X6/ &J.G[1[AH!LN\
M0N_IZ2?*KU1F=V-,^$'2)(1$1W*+ 2;"1H%]Y6&B L&X5%8,WK8 RDCZ7%->
MQS&_PIAK_,NILHF(B!_$T3%V_#7>91J>BWC . N[XB0V4JU<)G-3JH_<)OQ"
MSO-&HK:7/B$73MO31)+ZK4W(\ $+E1V*RZT*(OQ9Q:)2J*TL_(S*B757>&(+
MBJI1-!2>Y/+5)00<B'FD/Y>D$PKS?_>P13[3+6#G4>4S#E\#^'GF;^QR):8'
MCX>"#HA&Y+ K_[P-^UI7,KRNI\/;,R>1>[/&8]5!Q$0(SG5ET10F=T)4D^>M
MC9!7JL'B37C)MX:?,><9141>!;S(,/+[FC;H&T;_J[C0Q3NNFEWVJ^X[[*\@
M?&6)K$WE9)@ ,(PA-+W7RU+QIG W6MAE\LJ(B._N)S84FA-'  TA-HQV*4S3
M17)%-VQ5U74/RRK;CX<%&@6%H1'PY4BA><.J5:4WJ$9<ODK/J#YPYSP"X@!@
M>P@D2>!^JT.XBWQW U:5M88MNWMTRTZ0(77H,>)N#KQN.'M?\%O4]#SJ;T--
M@6DG3BS"30F70>QMV("'=D[NNNK!#*(+IGCF1Y*E=FY?V/,.8'UIS'/)Z;][
M33Z9O,<<X/-KAA@7Q 87P84I ZGSIPPDL#%L;SNNR:T99P$3B?H+_,&/?>7(
MG[EB7?>JWZ,F S\=+D*$-SGK&Q*4$A,]Q6;3@M>S1M@(5!>YX$.&ZQ)(?G8G
M['"(X9LS^:+TO3!J)(G:;ST(&G81.@7"HZ0:?Y%:$>!"B 0AZ!03=$OQDL$!
MH7OATI7;A/+S4CUFT!L-@9Y?)\%=PO)>4%J+B+_;Y0N=DP4S(:X9G[&?2O]+
MQ.8Y99&DI:"$K,Z;$Y<<M9YX=U3O(&\6)=%'QA3@@!QSX4:*X,?NSCY)E[V6
MEBKD 23?V=&3%,RZ;EJ=O&J-F=4M08,EEA)IGSSX#U?VHY(Z=G<0AQ@%9\>Z
M<S1"3Q."]N':G&#]()/6(+SFZE>J=HHGX^LX$<'U7Y.$;858YE1#.&A4\:6Z
MN<GO(S]^UYV/MH7!)/4OD9(V]*8BH@K,%]FV(RDRVXX-&_/F#DL:'DN(<D?3
M>,GJ(HZ;A,@MY]+V@-%-2ZP= W"S"SON)5)76^\D!=P899CZSO B94W<(>0(
MV<IJ."?$VQ)QQZ71@\+7X>!+(PMRFS+D5CB$AIX* ;/Z\G6R[YOUEC9Y=D*>
M/'(I'RA:DWB11I=43H"%@#^N)TW3)R=3([V>JN-@"[1C\FY:R1C5,V3=Y#88
MCPZJ^*&SK+)L\?9^(<NDQ-7WL%SR7SA#F;N=;,(@[$%,.1/XH!4-VSBB%)J=
M"/_?(:/Y;*D5+K7"I5;X?COG&6Q)";VSI-TA".NN+MVZ+R>@XB4[M^*DZR2M
MAE&GF$0#GZ1#ACO6YXRH'^">V#W7CB-TGK5IA6(=J5*P11BV:GJO.W<XWTT!
MOY!,;/ST0FA1.2^:TW#P!O;^'Q0;GC)Q0UV-6;?>7OR:O=EETJN8#?W/J"Z$
MN[4IB.LCN?[[-]=@8-WKT=C!<.L'H)_I4"!"04GV]3+YAP]QIY8X6A.E>00Z
M%+X&*TM'W3.??K3Z^*.G'VL>XSOQ+KZK:U@1=KQQP/J\;G<@7FN*9J7Y=\,H
MQUQ\^^Z;:U\\8VH4^_ 4,#SX>-=F/;B->B2$^9/!\)6%?B=]V&8W\2XUZ(F"
M,T*CZ_\RL7&\29+2;J-$/Q<WAPC)[@T$&BW$J)BGY=,"+@Q7GPD<6Q_[(X$H
M)7^_:-;]COFHX9#A]T!@M"3'6-,?BT"0!,%OH[V@))P>=PWW?2OY/2O,*K,3
M>&5!G,4]I4 -L?(( ;C,BITFO3-JRH5?WC386EH99%C3\<9YD= 2+]3@FK_W
MU#JDCE;87=EVEN/5(^RQ+_PS45\D7]?U:YK1"BPXND:YP/C[,5%":@Y;M)$R
MA:_]ZWA,6T/))6D[6M.*^N Q!B@:R]OBUT*XO-IVP"LJF@$:+U)U9,19D_SP
M3Y(KZM/C]+QF.77/06:*7. *!4-/FU'K#;=+ZRM"4JBBVB#<GY-2$N=Y9(-X
MC1(#XVJU)>'O1%*NCQ(MR,,FWQ1(32$BIE>Z@]TD634B1"'\)M5JW2>?)CGX
M>2R,6 GAE3(KNK+-#"\9"V7;RQ&4[]AG3$<*9?*@8$8/SME!RDO<RO'L"8*@
M=]N%H6 V3_2GO\84T^0<!0*DT]VD-%2? F!G,*ICOX@L-<H.B]J40X1A[."^
M4I"4*'HH=>W )CYXA?L5G(;2]ZYAK 53:17FA\-M&2S2:V+;PNU;IP;Z(..9
M8:1.B]6* IXCUJ@DL/UQ#!HVKSEQ3O^+=11N?![7=_BJC">>50RSCAGJCLT'
M5T^K0^HWJ>#JH[3R))@LV]1E41M]-^A'B9(M@>H-!+H0 @MZ1!IFG-A5S-9C
M@D9%)<B49_[*J16->UAX":G?'$^TU'(_=^AVT6]*;TS==T3]6V_"=]J^Z!:M
M-9<GHKS@4;9$\*H9(Y] \[F37?H7]LAA@#U?<H;V8=PJ'OS$$X+<AT2'P'T'
MJ@M)2M=,"FV(T"-B1K2J/+P.83M_.?>'@C.9C;O'CV+V!4N<IF>59JIPXHIQ
MC(\Z-LIEU%*?%TXB*F"!#* .HD4=1]GA7! LM$0D ="@P\/FBP;P(!QZWDF:
M]#7^1@-36%.1"XB 1JWEX<-ANYYG;N-G6[(<-)NHGJ8<,6M@SMO %[;%7B"T
M [1%C1VH<>IZXX@7BSI9B8VSQ.8B&O8JFOP"F\-HOH1^JF6?,1_\&IX#].LT
M]8]!O([2^#ZLPO;,.&,.P0&:V[[U35;"@C4G(<-7<XIBHY O,$&9G4$"EAH>
M<EQY&$P7RA;Y4AR'!F#53,\P*P&]U'75%1?_4ZQ?8XZ94 WZSL5?8;C8[^#=
MN^0Y!D"MY#NJ?+IC=L_AN_22V&YET2"-4PK9>+)2^Y)#I_5'?NX>]@.EM>)G
M_/C>EETN/L,>@Q_320^]!'2D1 ?[:0M)94U3DH%2S=0U_0C_SPA]X;A/B_JW
M0-U_+^U5VHG]-FV3Z;%?_(@"QDQ0OBA/7[ONX)Y(*E734EK;L'GD$D%HPG.:
MPE6TH>*1+MCPOQL7[+/PEP47[/'@@OES^(!^U+1CO07I(RJ&B0$2[HUK.9W4
ML3:A=@)L=^*^#**!!5/(KEY;$YP3*6XXV([)WD(NASN=.6F)Y8%=7XFA3X6'
MN#PD,MS)_Y72[(?\>2W_IBZ(==9NA</I=8&=$12(ZAA\X^ZPA\@DC2BR;A3
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MO\9A-EG$A<<G&G<AFP?"PMZ0B$=![7YTKQM8L KT\#WYN4%KN*O1UX9ENIC
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M8F:665@?,3)PO5.T0TH'#M\40:^00-X2;83-M8\RD)0.8H$BZ/R 5$K- 6R
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M:-^1J#>\C*XP)"JWQ-T8AS$*E<2:H$"HPE=3E9R^TF5)+A+V*OLG8L=3+I_
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ME;5J*!<9(H,1D['"7J&7::(L!7#47R:^%.8,*]:T*--Q1FBCB=J+LWE**JD
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M&:URCA.&RS1/A>PQ+8>;@ IA*R <L_Q=W#O)\$\$T\2U5@G:3$CQ"IQW$]O
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M&9U*LU)IM#(I":I%@Y9K:.O=LD"0T#TT7!?+.!AC>FJHN8^R?TN?DSKA^0%
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M'_NB+Q"Y48M6/Z(07AV<R[A06!3CN6.-?^*Z&KN,Z_8#H;'A0M#?)?ZY(#]
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M1@COLX^DD8\H05P-S */>N;2^9XS!5!Z9I,89?1-,593CBJE4C/!(U6CQE)
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M60F4TB=3-D<>N;"P, K)>MBE<6HO\0-2EGPZBB52@8=<V0J*>?%CZ((.A>G
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MMD_;&?!WUT3;SX.TJ\U"N;U&TLY>:.<7BN2LA;*?!UW7"K56Z<D%8F;,J^5
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M6X-WQIXA_)J^@,/%E:$5^P1%XXTIC2RB7(S^ IMWHP!$">H=QW0#6E)7.+:
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M0?Q$ZLS!7W !.+I_ HWN001Z%D,FI->OL3S'\^^^/'PC2"OX/XZ 4$>0#&^
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M-=VZ3MRJMT]3.=L$A$HPM,<)N(JTLZG#:^@Y%K:+J5X4>B3>!_R;^$-8G-S
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M?,9KYHLA,B2%@FTK,5]-(_1-"JBS]3KEC.-HY+G,/&3S8M"@D+9<K^.CH/<
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M,86W$G ];H0Y&YJ^D"YLW,WYQC-]ZJ#;CY$[B8X'+O=FG \%Z%41@?H-"G
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MV1V@1PZ#.UA_S=OA3#?-D;YH5*W03%$:KQC5218JDLF].S1YI/\G=H=B ,
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MC'P;&?G^SN*WZP+K<K*Y+*R+)8F8%E*V*W?4)7$N__&A)O!@%S27>8-8;VI
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M+G@Z+96'&7;K2VE'Y7>@@$(>[ V;Q*GE+S;X,AU($-MV5PGXUCP<VJ8.QXP
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M>B/+:9<L/M>N%4J-7&^:B40>*B[L#4<?JBZ7["B"CY1&(Z#O(CMK?:(Y8Y"
M! .)W>O(9Q3I.JB&9_0"Y8HLX;8Y)PSH8-,O?@XD7,H39XI<M_,#UZO\SGK"
M[N"31]+^V&O"4T]VD.J _I<>3KGF?3(#^H/H&$_?>#3RB$(14IRPJ;5'2XDG
MMERKN1BW-4)4Z:C&Y6O7S&+N!GG>Z!/Y1(Q]DS%4H>/\.L.UP2/VB7QC[^W9
M'2$?PK4ZW#'7..PEJ-LA(L1C!-VAZFN%] :#PL*<YK4T"1K=PM(:\=F&-E:9
M7=7,FQ3%X&P2[%6Y=*_*MPCYQ <T^E9Z.F(GTS:9IWDO1=AM$ H1:/!1@1^>
M_7Y=2']?@/.8?I7 53?QU9WO<'4GVH;7$?:K]P6[;O EGR^]Y/-Y,A)S=\1K
M)V*T).J?R&.[^P%_&P+X20>E:[BCQ#Q25;!G GLF+LLS<6:7K.BK\NBQ@5'(
MA'FE-P >2:?["Z[3+"[9TNJK#(PC9@)9IBKS5*T-I'*AL=V,K&XA/U^I3%0'
ME$[=I&A<N0+[%B[=M_"Y8D^K4*%)AJN0&RI@T*+J[;+0\)0XB7U^WFN0TV;?
M(N7)4&_F"PIO]B.Q1T$6ZH;C7Q/[BW0.O$_; 7#@Z?6<JU?YWY:UP4#H,-QP
M:(,OP<5_?6+&QN<O-38PR:JT)M,>4V-%Q32X)E&>T<M*-DXP2=*5?'O=+XE6
M7M;]@03Z]+#;4)FH[BG-W9#DX?4>["7YW 27[P 6;TQNN6*PN !3JEQ;\:,A
MVZ3)LCBK92R2Y7+3""SX-YA2\7<7O1I=:87SN1U5E=?LA&'ZNNWZH8>R84<)
MN& B4KK.W_/LV@#RO'5.SNXH^M)H\UE:EUT; YZW^,;9718Q9,#?'P0S2% ;
MQ,JXKGMW=UT1X)L.Q/ZH'TDP@7,:3^!/TS.(N>8%&UPN\UO$W#_9:OZV>NZG
MY36B\H _'^14'A7OI+2]$](VDM$Z$M'[FU]'M-SI4*ALI:E+D^&$Z%"+]J2W
M7D,MEXN2$9-GO-^)I3P&74'/:^Y>C92?+1'Q1%*>; MUMK=HC2TPE-)+G:LH
MH\(823FT99._O]/YGP"5RSJ_&+Y1\$Z>-J+#O07>[AW3@=\;_*3)6XI[ V:@
MUS]-:":;^C]'#.GV!$#K6'=G\(,;9"H[;H":MGGP;0=J5@$8>]#$1JH44K6"
M"? !8K4HU!95*-_K5W"0'\ WH@(DMZ??C8.Y/[OJ0M'WTG2X"_O/.8BA[;?"
MYPFI^"+-7IWZI\[SPTS_'\-<WOT+_[G[M&X#S4,8/=E_Q;UW$7W5'4*3_SY+
MNM5>;O9K0S>A[J]%[19*4<GGD_^?Q[-_.#0(W;5=[^>=(_31LB8[YJ*C4V0,
MB*$'-(O01O";?VKV2MOX=[93ZI:Y"UO_O/>E,A$+D+<,]^_$H]=H/PXV<Z:M
MB4=;MC^T"!N,@I_[C]V]%YTX]V^ZOHEP\V?45L!< O3T)\^-*!.X\Y\T-/ 0
M.\!?]PMCJ=LD=R9:/9,$YH$R_]42$P^=9?_;EC,O(]M>I(](.<0V="@@U,J@
MHS&ZVK9G5^TQR[[*K-'6$G ;'V:[W]J'-Y_2Y&"K=W^$1Y[^%QJ1^+\$'7WR
M[V=$>$;-!Z7DGI;HK1<>?T<6+3I257)$&09II%0CI0.59<F1.J1&@IIBAREZ
MR%.4P&D_=ANQ^T0-P7[@9AXA>^X.V%OWN+[_R)D0_47!/0*4&3E?*[:+<BW1
M+DA-L2XI[6*F=;/S;A1KF=O$?X?>?W[5Y+;4VKW9EA,9N=:2*\6LV):RB5RQ
M)M8R1;&2:+7A&U6IUFY%G_G+=. YYX8^5+K\&U1U <"O]2>[,]% 0?J[WV80
M&0)_=X]AIZ'4PAE<K'X2F^MI_" =^J8#?#\+?-TSHP9!HF.D-=_TY1%4P7SD
M#$?OMN'WINVH('JD7@U51>@.Y0';G2J$LLDZY=R 2(JKG<IH.B$PQ."5<2H:
M1OU(P._5YG!"@1>"DP' &Y241VPQ#?W '&W>>:A2MXE'FX8 X6XO(WK>\SG"
M"2.2KO-H<7\V^XP[=J))):"N!JT:$$+C!_)ET=%O$W^AYC#H,*;)?S([)2[Z
MC?KG[\1*\Z$"I[O>W/4B30W^KL&=L+458MZ[/T1;XB3$< RGEZ"I&PA/9/(6
M?5MB_\B$B3XY--TY9/L9-+#"R/Y*[-5&:#8L@>W.D?IHF#ZZ143,7 ,N-2H]
M'\W:A)L6P#6"((K'P&/RKL.- <;  5X$9G<?WQ$&_A*=E?Y>\TP@5$#:*!R^
MA/*9\#<^!*;$7W<;4&O=+QY]WD-?ICU9291UD_S'3\S-.8BZZ>AP9(1W?F(%
MO&@&N@LM3#@SQ"1C5$-N[ID 3GZ#ML!VQYM=7L\$S$P_@._.X4*0K>3#M: ;
M4KNV/2:B+]P#J%'#W4D87CC>[\#]ZE[>J8D6)"#X>XA'C8WO@7&XVZVY%DR0
M2I'PY] 2&R$RV' ^ON]"#D8#4-5_N$&AYQ[=V*=T12PR0MH-_*#K1'L,+<]%
MB+AC-H2;=R<PNX5'1 ?K.;*_H1F@18K1WB;8+^T&L=SN MF3G8,S1+..%@9F
MD(^0A"1&H1/9<_"Q<*ES>/@ ^(0(9!]]=@8,$QJ.B.'N]QQ9)M&TX4[#L4:H
M@]U&WR0F$#J(1:@AC37A0U7 AGML SV$RD!$A0>2W\9)T(M.HJ0Y(5HQ.A9N
M(G+<44I'U(-$FH/_S]Z;-B>N+.O"W^^O4/0^^]RUXAIO(>9>^^T(YGF>;'\A
MA%2 +"&!!@3\^K<F#8 \=-L8V>;$V:MM4TA5E4-E9F4^2406\I#)!*L&IC.X
M9QJ# MQ(QEYHB#\T&S&EX?;R.- ;7HN/ ^E!PJT Q%(2Y%@%<@7:,\H/Z.O]
MX,<UO)'.\VZALL)>IB[B,#WF4?05W]C#Y>I@"8DIDE;B@F M*?NWD8S@43I8
M -5 K T5H;8$S%_9=K[Z-S/E%?R.8Y' ^L/2=: *.P9J$=50R&IX$9&+X&\3
MK8'FB=0EHV@&P>1^=O$27IL[11% J91,:(!<D+<@.[55J.L%W(R%X6)(JW/<
MX2;/) 4OLP?F2*C(^EQC#RV\!+4:TX_$F+]*<"S3TFZ96"P6X9+I3(;[^Y"+
M%D"9>6>/L^5]*'<ZOGG'F^L4E:(Y0$DVT!L=]=TOYMWOPSTE!B[22J0%FNZ?
MY5&[M!NH \ ,Z+K3S^0&DF$*C3;W[3=0U^F0ZDA#(3EPK0%L6Q.E\Q]-)WU0
MT..QT/F4(&(\ /\._]]:H3G]S[DR4+@8R>I]6[_=Q=KB:GVUMY?K25%;U#.3
MAT0K^Z<AOB:_E9;6,CN?0S(@'!;ZL@ZT=<%Q0*\%=WHBU]4BITO%3G'7J*6U
M9C^[YPI=U'6'O8$.]$E$#XN1\WAR2F&6PF<4G)+"(^("7(B,I%[SM"5A[A@"
M><4L5\P?GG)PM1ICP/DKD"8 &@Y0(V+_ NDV%9*2QSWX((?"UQ/>Q_R;A^P"
M6:(DF?LY5*^*R/POOUS] Y][BYDY=\OTH%CL?$P>8);U\:.S<R?W%_,W :9%
MAR2D )ZU1G<4'J"TN1%^!VX.2!?FK.=L+.@Y*AX7$E?%^<W0S4D>.3U Q[>K
M+<@B'BN2#?/V"_HG>0TY*7B;O%V">T2Y]&T\WK":BSMES@V'G-+4NJ59-G57
M^N,P-N7Q$:]8S@P&6@Z@7E- '$)-JV<=_@CD^(2:CLW[\WQ^F#>GW$-%Z8'&
MW/[Q*_X$PZ.;:ZAK#MH^DF;-\"S 6@_]"\6",A)O1B 71)9X)R@GN6QC,,B*
M(ZQ$Y,;/@]E!TSN+(96IM<GL *\SQ(YRSXH8]@".[0\#>F*OO:7 SK$QB177
MZ^K$%F-RY+Z9;UJKZBS9MW_O.O)M_-$>&;%(-#4O%_NV6H_>5\O[_.: /ZJM
MTF\E\>'W$HX@VTA %'"?'@.>Y_@C+UN/];''8&-W][N-5I>Y6"*WO9MEX$YF
MH7>:09 J-]'T:6XO"3,8@9RRLG2D)DSG>(0DQKI$!2;2+J2_*#K'5O WR-A0
MJT*U=SZ-<1GZG;N''*;<IC!09M-U;S%,=IO12(U-;-31'/55NHDG3B'";IF.
M@E&VL$F"Z(.":TP:DV=FZ=B$%:%K(RF7=4". _V'\7GDF5S@JN0M"_!?\<[P
M_Q$[&#*7L&"B++$3#A7;D2$ Q0I:J,BY/;0%&BB2HJA,!_(I- Q6*%C%E.";
M;IA&(^_:L/YA[F&/Z XG&=C#]T!-=YR7NP>-I[6107/ZN8-P3SQK;-H^(K18
MJA3@TI8&]>9H:,N 1K&)ID0,=!U(1ZX7? &QMY%A?,-,+1/="1(;90J)XWAK
M&B-*.GK7P=8@=]R9)3%2'#YYD5!GTTVQ291U;\&]7YZW9>BJT*(HN1&U&\IO
M6BY/-\@<J1(KIO7:G$VNXUPQ\; <U[0_SK1YJ_'2Z:P3W?MQ^5X&@_O4E*W7
MN^DB--=CB4#CY=5$);%W> YY1]G!,2:I?N9SPW/0W""A.!3#0^R&0G(,[R0O
MDI>_(N+^N4CO(W8$NJX_14NW-5TT@'J8;T$%S*4H:O3AH^7#HC(;V):Q9->M
MVKT\V'0:$GS\*Z@52T8@:<R%J]L/MOC5Y"9EC)C0@&@Y[5@)'WIH3B0":C,4
MUS11;-?-\,?!5&C^_'&8 L=S'9,7,B'MM_X$1^(0Y9+?,5. 73$4"'9-ZU,-
M?,MD#7]Z1,"00_U*G_EJ"3JCT?VYI.,B5OOH3FRMX*M6\CKSD%DT(WOE,06=
M.FBNWZ03R3]7C,_9]KR!4VS@N4ZY'5D0QZ8%UI/H:Y+I2(E[\C[!VL_S\1_Y
MA:(D8O/  (J"8V9/295VL  L-7!,P-,O;R\\X<M<6"P:AJA':P/#8NMSM;6K
M--;:=/7'P8X>6/(2@M?Y8XM!J21U=FHD'XKM#@^2\3H[F)>1Q1"_266"\G)_
MRV) 43]^ UTDG,.!C$V=MT^<WB V_BWG*W0NS*M\L"?V+41NF>=TQ8.T!BK7
MPP?^3%,4S8Y X5U9T+D0W'@64@[G/?GBKHQ[O[Q22$MXUFVU@^=\'+2(EOE6
MFQ\LAM)VOTL5UJ-VV[(O='P9ZZ%5SHW6>]G:="/+H5FR^.W\QZ_D32(5O8D'
M-(;V*? @P_SPG#*QQWQ(N!6Z$D!??T$_%R3DN&+M3"G(UE)*83]EMW)RV[3$
MW$,+F+%YT"W)^U*LWYLD.\J&O2N"N&#HTTJZ6)3>%B;$"R(DPU<DD&+X;X%$
M2DUENV;;8%CDR]%EO=!OB5P+V1BW ?4-OO0C)^A ) UM!^.LS(L;'%FG 6-O
MZ+T_U/BV+IDHWP)L@2Y(!KF E71&6SDW<:Z)\=V%$Y^B0]^FM?$>#337.Q-)
MP(57"#<$DO[.:N=Y/CUJ%?/M>G]UW^<2:@Z2/I-.W*2BI['%WY%.U^?BTHX.
MO@KLNPCL.ODP+?.I6F:X*T(5N^X6F\M6]T6!)3XO/+@-PPO1DQN?8,DD&4GG
MC(M=3LY^K\#D-&Q?19DOO'+X]C+:VT!K%>S;R<QXWIS(RTR5>^P56W>[-")9
M[(;C HC&D\2FP^L43(X/NE#Y#,1Y[EHED#Z!I(ES.7/4C4ZY(;]H+^Y2YL9L
MS.88-3R=.?6PH19#J?5PMJ(EX&Q"]^BB"8@"SLIUDIAHF@GY7</VOZOZG!Q$
ME-.&<L_@4;G##L?AC?L7N:4YCN9]THJ-]+5BXUJQ\74J-J!0TCQ\$NM[-F>?
MYN*'1AF]JL:09'FBNT^D@LL:TKR0P +0528<X8K/?0U^G$@<E._N+^SQ53QX
MI3W,@M_ <P\ %>52KG"V'<J.9>:87@*EUQ35F]PP]D*"QBHV7)8H_1V0.V/*
MR(C4*%7235:^@2<M7-'>3=[D#</)@T??,^ 'QHQ:4/!C1>+Q=CMIHUZ8VW!N
M#*%.AJO049*FI1M8:4QI5<?AW=*"E$%8.#E41SEH^.A'N;WPZ? ; DJR0C4^
M^*+12U]'IA\=];)S%%X@!E_;79(IW2 V<G K%VR1C7="CY\8FZZ<[\;8A-0:
M\%T6>J6QV$TF=5J,[>8P/G=M@.EX[DW\B-[%K]W$5BY3 TFATV+YA^ZF:ZFS
M^9"W,8YC*AT0=WO%)L:>O#;!NWN:W++@Q:<;_9V#JS\&<Q/EE1[BXV7-/-SS
MG7.?$4@0?MVU5E-C7Y$C#R ]F]W5\D8B^R2PYED8]F-@!O]L?\0N/TG+@XPP
MM.Y:4[9IQ 5NU'T22_ &E^R0;&QE]XS.I3H4;:>*LKM1]C;!YX,N*@V ^.M:
MX#C$MWQ@6<7G9-H>NG!2@5CD=73G9OA*6@ID7<_KDC2G)N3J<I(<]KN;<J):
M:;>&*90[FDK<1),!N<5\L)HXI!+R>@6H!TS-K03%N1:(< [5'*T$_P4& -@^
MGUFFI8-0U4X1M>B$T/!B$T05(HL'7[([6?4NBL6+)M&A+IT"10(;IS@/W]D_
MJ5F?V'Z4VT]NRZT9HCJ]MI^A*CJ?!#A[3M-H'% S3:6' XE_^!=G+N"#9]!B
M0K65Q*:"GA@D&:YU@?* 0C$8R]6$5)<,-,6I9IF!061B>NT.V *7CAY8@I>.
MB0PT=$LA6' #$"T<VP\58ZI'E+,E!=6,T@HX9S?0KN-\!PWG&FDZ)2HU8=$5
MY*%2PI?/Y&US7;/-!8.SD< <*K\A_)("GP/9CV3O(QXYN/&$ZHR68P(LZKAV
M$])?ASR%=ABK05+):))R%,@M,P9^JA\EK'I22[)(R91\D_50\ #C)#L=)]T=
M70(83OW32H=,#*<(MU%PI "74KD9J_!5.HVC"30/UH FN  .:C\%35$@BSE3
MPCFT]$MX'<BR=Y]#]Q'.!Q?F$25&S7B2PDH+LKRT692@Q8MP<PP4A>5Q61!>
M\ +ZG,XLW336)R],\'Z@K\ 'W3+5@T%(6"W5R3_0IDB%.UQS=)VM68J(\L6@
MR FD)E6$SOX.'9&X,A4E $_A#B/WWC1<,M.Z:2>1=Z[S2Y]OA9Z)G3*>0<%F
M'3$M73*M@V+H\SSFI_ESQL6K#]\Q9.F/CIP?9J'OR28\I5$D&5VXPW,"JFOC
M%%HA(JPW8WM8XN1VM-A;<_4JIV?GI] *P>,^/;0"=\OTK>42^>%0PGQ[QWB;
MQSB[]S$P&000XXAV._+?4_K%Q;ML?5&MY>5UIMDOE=:3\O[.#A5%GMY]O%:T
M\7[XCS"992?H8B\BAP6%H5"W>DU%YC8R2_!1,KSMW]+S%.,?""A^@S**/*Z#
M)QE\^ H57SJ)$N5LMN/+C,!UYO#\ R0$1,U" H"&BD%6*T@BK/_GJ/P;CS*8
M): ):&Z&&3H*>,M<:+ID$O<&^2%P-MB4-%X_3P>-P8EQ^63(<6I0)$_$,F;Z
M:Z>S?:]V&MDJ@=\<KK"]Z'UGZ'Z''H^>%1SX@)P&_W&_7\KV<^YN!EXPG5O6
MAP9HSXJ0,='Y:+@RG4_&[M+;GE64Q[TBJ$E&Z4%4/XM,#TDLTUU5V,292*4;
MR V4X0"!#6;X ,F@K(\%/$ANH=A!1POEP, E\W.W0F#)R] L<G8-"P$/7;[E
MRK&)4>Z+9R;"54"+'TDBP7 Z"DH?!*#-(U_K%0"(;F0[Z#WH[^Z-LVCY2A/0
M6+Q%V/.#5IS_1'UZ<5 3*4#P=N\U$(W45@>XP MEDR&_5)&66'%1I0;=6<NE
M-#:5(U,,0X(0A$1OD=XX'J4=.&ZVZ$ RF/R6;BY! J&943<^$GK>)PH[& ZT
M]Y_[IW!]&TW9T(L)NG<^  ]"#[($N&J2<4HB&\2?EU02G\)I Y:)?[EE\AB^
M K.XCQXZ\&!#* -3YQW^1NQY^#<40\!0);*JV2H\@ 33(L@WEH(]3V3Q0^6.
MCA6:%J09/J:^C)(-#B@^94\)Y1([6Z=[3=F2]_W<* <*%3G '@X>%T)[^!E@
M+B?\@W_P[4V85/;3;>AQA8F!'$_(7;JD[ B4/JJ&-<S(%/!8+XD WU]C+;B!
M?T*P6YXZD50X)]/R8B1+385L3B *CN[AG(H6 RD)#-*D["BR#I)5X&#PD.,"
MRBGTW#'H$^1]A!NQ(Y*K T J!'"A&G;S%>3ZV@MD,M+<2ZS!IN!DT<$2]$7R
M8C+7O)AK7LR7SXMY/I#R&V$7[NEW/'LX72(HU0,"@#H,,L&3!V\FM6GQD52G
M(2_7/7XJWS=RB?$%G1Z'XOZ@W[/'*Z1Y&0%T,;[%?OQ)&E!:]?3A2N:K>_.E
M":4X7FR9Z*H!!\,=VU^T<(@8CI*64TLWL%1C3P :Q$[[,FQ;PQ-LCM'*G')A
MFI#:XBE<8I6>O%@K9.<828)Z2ZUJUHL%0'L2A5H]NS?X"17 *_#8]1Y1.0@G
M8+Q07M<E9/N;M"C$L4M%'.Q'%\%H.72MP3>-Z.3W;Q<]I;VO$_!' A4(UZ3L
M;LA=%@J\A.[6%]?HJ]8RJ$8_ZSA")4W/0Q](,E'&"&88PV/P/ 8D#*ZO9!-W
M@UIQHV@LV"?JZ[M^)-<%W1^_5"W@NM=UNQ![X7N^F:4X3K?A^,P.R*<!"'?Y
M:4%O##[*N\";A+>#Y-,\'Z5--H:5):B!PM"*V(\-;98 NV7VD_@)1$N098;)
M-? +J',U:5#&D BFIG.32'41=DKG"$U!Q0ZZEU'_%VJZZ'WR-S3+Y[Q*$_X@
M;Y7]3Y4,["W/X>?$7R;/H)_^14,C?S_C21]J4!3\QC?_&%;7=Z<&-VXC"=1!
M=_-1W- ,HB>N::.MQ/"\4)HB$!%B- U>'&R(#E8DU.YLE%L;0D3)T]3.SD+W
M2G.CQ.^\E%N$?/&ZS+O3W#"'Y$<K_,RICL=*)5"O"JS)6KNI&I7S[65^HW,Z
M9SW,,0Y;(OY!:6 ?VY_GI1U1M5CKH1R7E\5\2IG."PGI/K]"B7'QFS1[6AMU
MF/AUXPL@8/W@\#,-,[KU;= L(4A8<U)Y0QC]MUE8#)1+!!?P>=+",%4<!>.C
MSG/F0&I6R50:)K\9CI>+=G7RD,Y/DZA(^(9-GA9)?;+DQ3_9$.FQ7Q58(=]G
MUP]\:Z^,AT/S'E7TW:38TQSEHVS%L)W#](!U;'_/C< P=&+$6D'R4;PU'E\0
MTE\$#25S(;ER .'AHBR1IM<(BJ1BT'8398^XN24H><8)_\,CR=!4%2@.3!P*
M1I,XNH&2?\@+5KPD.@%WM*7>075PT'M0_+VV"W9[XPT^CA>BC"-\4Z&;DK4T
MG)B]&T2?4\1F'M5>(H 9N%1>\%<&\.(2+I' 0J&\4C1;['L8WJ;JY._,2L'!
MRRVZ$0$(OEY'L7SWRLH[DGT)0*XV$_$FHT@H@+3&KL[3],!H92@1[(:"X*&G
M+@E$FW/S  ]:P,,7NG0C"@VSP"W35I4=?1BYND*5I]C*1V_V@'Q\7X*T CI.
M4O*9:+1S@!N@)9JXXB5 ^1MIK[#Y[>#O"T!$ER%+A+*L.(A8@L+#98D';BP%
MN?*NO X. )YD(3JPA-"@-!$"(@^9]-2D1"E.<X09!HQ3+-Q;9KQ ^%[$@X&K
M<"@L:OCV"C$G6CZTYY ;3[ 1#5)_0M?MY9SYS=@Y!H5'*]3!1H*2'W3M! 4%
M:S+H91&I0&EKED#\=A<P7_( [GWY PIOXQH8EQ8W9*\=+C;<*W9G$P.1&YVK
M*^_![B;@Y#4*#NW>+SI1!40"DEA '&Y+]5@)G<CP%P%;@M(2]5T .KH,T%'Z
MX3$P)-X[&S5_V$@:2<QV$_1P]J,[H9O3:: -1G2: K]8437@?Q/E-==KQ<D6
MD*HX^PY%$:"9+B+L*8,\ PJ\AN]G3Y$LR?N ZJV?))CH2/: ?Z]IBJ%O1Y^$
MJ#I^"7[!4=P&LP#<3<SW]#Z7B#(\'(#JI?4VX;KHHU,' )YX'&+?R]S[.<=Q
M?H$Z>SP9=TQOZZQ@[84&:T5ZXK*;KJ:J^OR3N.:ND^<B+N21R@V;=> E$>-\
M6_APP]7U"ICS"C+"M1G A>[H-U^VA>>C'S3%!L!WL)"S*Z"/C*1&\$%@& YZ
MK2\-&./RT_US*^K)D65YZ=#^+^@D+P$E#)I(:K,XD=W]DU,;J)Z\[,;-:C#,
MT^MV?Q(O5=?.$W!>@$Z0 NC375@6;-1$4*X*36/V/&+Z-60*.0K56\<'1\I\
M( NH\<ZNHZ#45%5$%\XX-O"49#9!8CC1LNO,,)(KZ%E>2-;T1,!5?/"X3W45
M[^P-Z3'B;$R8Q/A@AL"9(3&.3,)SQ'B\P76GB%$/BI]6D.$ES$4H-.7]AFQ4
M9'A8IM?""5G#:",C&&IZ2I)$-]1@]*+VE@%0D%B19FY>$T[2.0K=NUDN&"7*
M]QUB2QQ<9Z*(>$3:1DA*]\\*_F?RJ.:-4H.K%H?@;M0=B'/-'.^Z@:7D[\!0
MS]VC)MQ[4_P/)L8S@GL2 7#05YZ4Q=QNL%L15$AG;,G256P P7$EZ ,C4X@"
ML51G [-F)Y4JNV0[_<AD-(D5-]G7X "_J!2&F% -2"<_VI1Q)[8JI4:S&!D:
MO;OH[JXQB-L_?B5)1@6*P!C'>@U;^CZ&A3LV<U9$?J-K"JH'Q&8RY"UDO4DZ
M31'A<>\N)YU6P.:%2 P>'/AE?,6#MYXTN]4N"NT01P*AR(G%IT"P#B#BY!V"
M_L0^*BX'J7).^RAC <"%>S@]9PD0/X4"M3M'(4K#(W>(JV!M@SW8)2(% ;9?
MP ,/Z054@F22@(&7WN86E0B2#C41<E$$_(F(DH]])4X"K2SU.;:H=A.I$O1(
M=)NZ\J57^KP R*'*#L\?S@)Y(YAK(%TQT)*J.2_32 M W]011H"&,@QPR)T^
M63P$L#6>C";"6>%JZB>S@0YO]S]G/A#'7O.!KOE WSD?B/NM?*#8T^]XUD*^
M3#X0":C"$[_@71(6R?E)_ '7#:@W1PLUN^1ZP_$DWVI,DNN*%O\LU1 ]_WVH
M;ZGA]M.EPTCVDY>ZR.J&*I4FON++,9QD"TBRJ]L,UX&IHX'DX#:X-S3J")\C
M6-BXR2I[J.@@#[HQ3/I$=(N&WBGQM+D-L'?,5!,EI_OJ'*!BU-4",B]O0EMB
ML6/^*F?_1OT4-12HW!%$[MU!(]\E+T!W1?<U]$7.2N^IQ7N^/+7[Q$/#[\DO
MNJ43O@QF5%""ZTB0\>/>:- K#*\JV8#6G8Y7Z:]F0/X3?")M;(->-X4+F$F4
M)@CA2-L!@*/(7@@%,C>V5G$HQ8<MZ-1A\_3]?NIIEOXT-Z";J@WM(NA-V0O.
MTIN/7>0$M1!;>5MX*GLO1?!+EHD2KAEHW(G0@KKQ3?+)FXM;IJ7!8P"@0.OS
M"0D>^=P@$)F&1TMBG)*YSC44_R3#D=&&@T;Z85H#C; CXN?=:RUW7<%;Y0:#
M:#8)H2BJ1%&A6>NO7\'Y%ZC(&MFT^"H+][=UJEN<6QB3-V3#/P$GT/8*NCTY
M&?QNWD0KH1SJ7"4X,T-DV$@BNFGQWTOY;^P.*T,.'@A=&@6'V!SQN7'3]HYK
M@UY3NV20*B_)QV)(-QDH)J%;^'[R!=F\3,BZ 4D+0 ,KS2=3R:2')IM):/IP
MI_3;>R$[*\V2G^4X)$L+T[&'$;"9;#_/I./<#4,FZ"]+17_W;H+]-R<B0!<O
MR,=$-TW(9?08GW2<)YT<*-J*B]%VZ[P%QY,5Z/Q!P24:!TA^'8QJNG0G;'!S
M*(W'MWN'NL*1>0%#>TL\N5VC\UG@Z#":._1M 4^P6%#!"L5G(:LD8T]2W=!'
M!S$&&FO&\3IM%K$,&H4C DP?XT0M=F@SR)]H<R7:].(@8D?E'8<"%YIN1O!<
MR==6."'"Z>,N2DY[(@(7@R%' M:)*VP"%GF(L**9WF)]>^" 5!Q&5@9.!M[A
MJGT)=D%D(CE[J &N0=(C5'(7KI  A$%[V[G7>HYZI9Q$+U>/-_6%EWIM[]Q"
M4[J9)'$0<:)DX&:^CF[&GX<JRZ0:7$Q)@VGT!IUV$T3;*J'+; 2XA1%KD)E(
MN5<A%J2?_!9Z!)51W4DFF&JZKMDXUPO?S+KB)ZDDOHGK1=T6+TXPR<?6!R6W
M9,<QL@I5&_1$QX0CL:_#L0YU0D6&MJN::)N:$Q&@QN31N(."9&Q%T5T0W:;U
M5,FX4<UG-_+0-#G>Q"/V=B\/3D2*I.\=31:'@CUCX$@)8E#19Z\H3MY"K)G
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M/UE6PXI^N=)T%!7T[Z,3V7,>/P7.39\3^C%-!<5Z'"Y &Q'(LS<'Q[?Z*H9
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M6I$'XW%<M-+F?;4O/YA* ;6I>[T+_!_<+RHTXGGM7@6^'* P$<=;-N%*99B
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M3OD!:]535NAMM*)2[,Z3Q?9LU&]GYK6N8IR+%:[P9.>%)V/C5ZR-P[KZ"Z$
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M;W9?YF -*!K4N.> NWJRD<^;Z9ZI=H8+4:DEY#8H :[:$.(CY2UT[R\TW1P
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M17CW9#]\"Z+0]X+"2\L;_"'D9+)))G ^Q7-%A.3A7-$?T1]NT-88EK X^(8
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MTLPLVJGH>8WL-2NPY@\/4TEO:!AH9)B]#N8KPMMY(.T!95X42C"%'5X3JM$
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M2(4PQB*_V3U4GLTD47;NL:!G*#D8 C*<LY-VB/PZY$!"9C/![JF 83S,BN(
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MA_?UUJB(U@VA6RC4:THJ.AB@8:(AI$<P6323U42?[28&5>\N2(RFL+,[CBK
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M74Q;8V5(-#(+I:MI,PLC)8Z"<(11H#IO:(#Z3(8#31:8EI_49+&RDMOT,NP
MRZ43.EM>D>:H P2)?(IZ6Q0%=N7U-=F@9:_ZC?ALB74K2J,V+0UR]33$PGI*
M7*B(_&8!T<RN)'$C2ZKXR'$"/^KI'Q\5>"@;:.>1[F0":@Z/RF@+W#PYT,18
M.3M06GEN+?=4P8QT5TZU!MA=;_E[$'\+)"TXHS\@::FN6LGTLW.:D5.C>(\T
M*OGBA':JG5Z3M,>+^>PO)R&@0>AOB(Q@_O,PGI,?M8(O5<!'"CM,P^*:4-(0
M3@G\S35I75"2:*DDR76!W;"$$M<(:YSMBK#W\Y& 1TQ)^"W:!F2KB\(]?%VX
MA^\1[C;@8ORX@8$EU0:"E8ZR,YP15+8XUW.)QJ\_\2>,.F^5%'(=G-!U]\SQ
MP]P]8P9,#9>,6)79K,O<G!B4*OS29WM&9SF=KJI\G2E5$M5-K5IM4/0*[AF!
M>=M+/8BF> R+PF>[\'8Y.+<$7I,#>9!*XXV-(&*U3$OJ%19RI9Q9^4L.\K/V
MN%M=%L;*ADZU%:+>2VT;-)0#W*,[7@J17&G_3G2OTDR*97O1:+"EI#ZO)H;Y
M12'5\-?^I8?3/&8URFVV-:AHS?:"X7MKI'O)Q/-Z!)E0_T'U;G\\H[ZDCN_4
ML+A>#9]?BFCEYRMHC^Q!2$VP_R><3>PX&]:P2B>6X[[ACP.3/0=SUT4'-\C!
M6CIOJ8C 90_/0!!(1] _"$7S&/53U,$V0;#^"0\QPNW12!9D"+8TD<'#'10@
M^#@#?"@X8+([E*Y=J>SIC'<H8T> XKNIN86XX;-O0 QP!&@+\5%LI[?WH1#7
ME&=S%Z1\)ED37?076NV+5$<WOS" &=I%,$--=//[ OV-R[?%$ O;H;-;N,P^
MM9Y"[1VD&0KYA03;6"(<+@> /.1RR6F-,R3A5C+TB* C://3!T&@,(CH'@+Z
MSD98[( Y4 ,B6.R,\-01X.4:E5&KFU,D1R\_NE"OIR1_(!+N!;=SE&7Z#/G8
M><C6P)A] UZ</.[ NQ,Y6(<^-^2ELW\32#@'/5\\""(?L@P>874Y<K@YQPY#
M@@R!R<*G,GA(AG7[\8(700Q/0Y\Y\/7 @.+'TK%X.Z*Z_Z)\@.L]AW W(>0<
M^,;<'JKHY(4+DEWN<.'?P+X#,AB;@Y+:M^(%K(4ZJKIJ"7W=0!78X .(B3>$
M8H\@\Y<20MAVU!W$65M"D,%]GYCG5<Y9?]GV\;Y#K-(=0@-\DK,Y%_<.[=>;
M]VJ_YKD$E^<PP?'2H8J#RY5ARY2+M$5X=BO-A18_TL/N'L U CEX(,G97T?T
MG>N(MYQYXLD5QCOP_[\PJDUXS4'-GL&J17!.WS_4AFS$; ,7J896ZRKI[M24
MJ$JL$^N/?_V!>M^+Z,J;'F:%BFC.RZYFVMD(L*V((,]1DSD>=0HZAL(TC\ N
M@<TB.>CSJ"_5%[+MI?@5^/^.FW_]H6%G#B3C$,#2Q0A!T-2FB^1Q1^R.8RXY
MQN[83?H9O([U>-@;$97*2.D*K-99XFRAV6I\'5['\W;]#P;B>+82,_Z4P']F
M[;3?BMB?DHF $'X@!/Y$1@-*^($2@4CX@Q _%_C$9X3 R:=X0 E?4"+037XA
M1" 1_B $]I3\H3!_?J-$H)M\0HA8X%U?E1+O3+Y[-;KQ=:O^,J"DUX3_]EDF
M5]V$/=A8\J-@8W'@S^.^QM!Y#33'C;LZH$)'+;D^!:03R,;#R\:-XEL_8Q>^
MA!5NK12)CRI%:)G<.1GQY1WQJ,& *[Z *XBG>, 5P;'Q(5_F[F92%_TFB1':
MR94)S*. SP/SR,^LX-^#,#"/ JZX@WGTV2.0'H\-:8S2NH>/0W"_ZT+?6SY-
M:<:C&HC Y D8W(\FSV<9O&H?6BKHHX=2;OX]S6YNX]S6H0OH_EVMF()F&;)F
MRD((51T\%-G]KNI];\NDP4>P&L3F54??E^51$,KQ';._@<RW;(OB6"R/?Z?[
M*+J-.F?P-Q'W:D;* Q.:64N&()M2J&[(PL.<97>CMV.</#"]_Y8U9V? /-V"
M<XBV]3ADOZ-6=XR31R9^P25^WP59^YC9\DJUWEU14,$S4[S*:X(4?J[7H=/D
MZTK<?N_%7MUFN2NB)*HK/:Y))I_BA\ID\,JW%KF;L$S8Y$AFL2AP*Y%4(OU*
MNF+/"Z-X:W5:YDZ;7&UTC'R43]LYMC>0#(Q(]1>Q3K.PC!97QW7MA6KV:U D
M73/L**G."37M2]FQ/6BDT-@0M=4\5L3L9JN8B)8Z XU<<7$(SQH-$S@9CF)>
MB/IO(P=?CY?F \AG\,S_N08%G;*MQQ9]!^F!8UN9G?!CQ82:V0ZQM1)?5VPQ
M-:A*%D2'_*3P$_<2_5V\T0TW[BQW9+A?4 B)Y%:/2!*99*1BE$S*F*#1"E0(
M,03R[NT7\FUTP?7.Q'O)Q?5%W*E^>FP1WY_N4,C[Q&JYFL>U%,-;!9+BJC$R
MQ]&?ENX(>2_QWH>5451Y+]#D7J#[&2W5U%1^PFZ*=)X:)T<C@88"3?WZ@X=C
M"6\'Q&\CT7= 0XW=RY=YC\!\ M_S.:3T6^-WOGJN[;,%CD+M$ KR@(].YVJK
M5GJ3D=FXKD6'_#@^'U%0$' ,Z)#X4^P5;,]K.+E?Q_Y[7*8X>KZ[?SN$R$<(
MV]S>:_633-[ 1?T\$MM7>ZPYR)UF0:LC2+Z<H9OF!1-U9.7[-M^/=['68!S3
MB4Q]DIFNN 3T68EH(AR[T.O@,1G^7N[IXQFJKT&(^$Z@/^9X7AM<\=,";;Y+
MHM_IB\[B]J(_C5L99C;,I@2I&)G0ZS$0=."+0FD,I/Q3'NIW7^1KT!TWUPEW
MHNU/8.";9_S<DK;?X\[L&0]#<I7Z]7R,>X<1OO=E&315_OX6S@=$\RV8IBV)
MX.5@"QV; YDGYC'4[\[L$"^8''6UANO#57_#\/1FDEA/^>+0:G 4]"V29)B,
M>5V+:W0=\P>C![=AP6W83W!*=@K@HW[)9IL2R+Z5Z[(S<;Y=S\7RMFV/@9*(
MP4Z+%!5$U*_MJOS =?OQZNV.#LT/Y  _WB7YPNVYNX\##JN1) ?W*/>_1_D^
MWLLGKTZR#DO:QL&JN111E?G$0.#+5292-G1V8LOSWFK%):%[@Q-A"O?F^EW/
MO?GF^CJX.@F\E&MZ*1<D^IU^2J\_W+9S6,EFTDQLW+5FK12N-X"T S\%<.L-
M,W^^N:@']R>^-S8#!@[N3Q[T_F0N&\'MR7MN3^Y86Q?X)V_T3QC(UN@[+_DG
M,C$JD<RL5U6(0G33++!%@HC1'(XA!R5,!-<O7W/]<F^)^L+KF7LO-7",WG]]
MXU$E[W2,%"-CIM18:<IVQW2V%L_6!O)V!=4,\HSB\> &YPMN<.XM>??>EV=O
M>.Z],?YTR7Z@Y#Q[ _1-.>0!;XC^?1-R1/0Q Q.WA;8B =N*N@W[DON ;^\
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M;V=);;U6^LQ"VTX'0SY3BZ;&_A?X9&D-&#]G=1@YL4J7*#.V9%. AM@3]8S
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M:(^0J_KFBI (U87/G]C%AX<R!L @@(UT7[.G:$0323-LYR^8CO3AU.LT0[8
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MJ[2Q\^EMV$:F.U@XY#+EU-W:9M!@V[DO_V6R5R07==M7/LM5H@M\9C)9&J*
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MQ7]PQD6'!8Q-UPE0C@T6$IJ-(;J#, D&T!!%&9(AHR2O9OAYB2"EMR\U((@
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MQSAV5?!%\C[>@QQPT1*X(TZ==J J+@19"Q/10]:$_A.UN?==*("RI[@ "O]
MOUZ=%A".'H-*)DKW&UC/':A4>"EPJ$.H]F+[(_'EY)NE<9(C1Z,(ES_[;<V!
MA/ )ZGAH]L&Z8 VI))K7]S6>1WJCXX62]A0$RX@=TT'NP%^TC WOS0&7/ 6*
MJX.F^AAZE?<2NMD$/T9!F'/;?4BK_2[9+TV];J?6U*2BZ[TE"/M;_X'W-$#[
MTJ&A(=E#SSF?2_X:=UQ]#(2()(PF7K0&#?MT^%H-^DH)_A;2A&LBB:^X=&FZ
M-E0^^YM_S*W_HC!'[&\'D4U=1W6''^$?AT-$*=4@G8KRA;*?D#Q*,L+ W3S.
M,.)OCK*"T:3@/HF>]1. CA7V*W@?Y2/!7^Z#<<S%KS?!_/;X@X/\Y<'[D$M4
MH11"5!E^3J&F?_@)<C2)_S8QO?M=&D/C<AWP$^6HWZIR\/C4J6N2W>>CHT$
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M>M5;7.;[RYOKZ/2!A_0'2C',X\[_S]%-Q#L0FI)-W;1^A$CS8%B! Z6QSYZ
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M:2DD(PM%U^A-D&8,PK;]-[O8Z:->^:^W_<<]0*@:FNLM%"7.-8> B V.[[%
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M.5Y)X/,#R6>@RDGN*TGB7@23$T5.DKA)$C=)XO*9<UWXFYR4\F%'J[-LELE
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M'Z$]RU\1!?%_!(V?_/9("(^DN3?OG2S15[]H/A2+%)YX>+?(.D7:&-Z1);?
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MBOH*_Q46#BX>'AX:)@$A/BXA-BX>[M].8$ O[\#!(\/#(^.BHZ+C_C^WY]\
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MP(BWL__ HT$(%,Y[L7:6GD^,D[Y8ZQEJW?S;!U8+W*DVK[>WEP*3PW!51[<
MN=^(@<B57Z^42:&''9]$SF(T)Z&% 0!S;?:(D[?="1VW^QR_WY"^',Y/;"2I
M!1UD?)J(X'JD@M)OT+-BSY 'AK/X$#<AW1[OIV@?R,Z9+T^Q4/*PZB%QL)PC
M.4.W7.(&ECF664?")VFJZBW KZC LTAI]O3TZ&@[>;?JO.7Q^EPZ;SA&-EW[
M*^.V+)T5KR I.:.:]]W<H/=<K*!$CLTGUI2#PYZJ/<Q*J#D)R 2N%,ZQ]8<B
M_\GY]\UZ"SWYB=B.=/N/533QX[4&$?[44(]2KM&:3:H2JQ64,QRI:R<W4.MC
M1<';/SS+2Q=>\H&PPZ8&K>WE@%^3%L95?(EGE\Q$[3*!=&NK%I>06:$"JG/9
M^QWZX41 ]/="8*;L=>5;:..&D!)+^(MSL;R9<4/']Y/X-+'6GC:0ADQ$=VL6
M&TB$HO CQK>%G'O+:^8'.?U4;27BD M/1.VR@/S<@_R"1@$MNHOW+$@Y?>#=
M:(/+#D<?CMQ3E:1OW=$7S#(/3!V>>!WH8F<;YUE*;>&!A/P9>3YI3_:G/Q(;
M(O5]Z"O&F0(_7S=KS60S3S!X88G39L.&RBVS1/E*;=K9=&2^/D/X(>BV?GBO
M#+>G4Y&5+\=Y(>?PDZEG/IG$V'C]#SX+F]=*@0(][4MT5NPBL_) LQ#4'"(0
M?G-&%_I@L(F.H]9RIGF-?#;26I'D>>PX\1J<QJG&F^@F_?6WO8Y*+L<3F-8G
M@9VA[=W9:91=@"&),HYRN?6"1W3N^#OB4[7S!=2]$PU+57,SLW[?4S@\OH'#
M3%'A8C1,>>OAN-&2M:^\AIC+O*.8:V(/-K\?D(1I+9]8S[;K O<WLI"> :M%
M[G2GC595RQ7*V4'[1&1)5<ZJ2+; 1?$J-T00:!AL$[V*""WM3>$A:..HSOH(
M37#!N$ZY.M;Y<[EA]V<5[1#+-H05;YG6,8^_9"-0>' %.-2+$2%H(7/:K%GK
MGCO&C'2\MT4VG,35/_G9;>>A?OL=-^7# &R;:OR&1ZPA5-_+Q:W$,Z>V5>(W
M.45+]7FY?4R?2MB&ZS391VGY@:>B$;4A6 PDODJG.5^I=0,B7Q7(29(3_&1E
M.%=X:VVD:_J7-]-I#";8"%BV6+E+[]^'_AI=]E?[@BGK$-%&K$"!O<)=:\G4
MPD/353IH$$VGE6*N+804)VGKS7I5=HKQ8 $QB$HSFQ(4LQ'H>N?8'T/,K9F@
M_^75&KFDO=C^>=IN&\Z\,D4W18R#FQ6GXY)GVHJN1T-H\FOUR2--;WQ"0S)"
M,V<85?ZHUC41S'ALYM(-,IT_+8\2VC[-6KL:&G$K>-SC:#RB_>5O^'$X2'U[
M X5(22<G,;Z"@0]2N/]'4E6=$$6.8E.0 M[0%^0&XN :IT0![U4G7JX9+/_]
M^D.4#CT,/<W+&13; OV0O>J9=JH7<$Q8X:#]Z7H!775'0*'NH^ST$&Q#[&C_
MA)+FC@K(GE33\.?/G(_P*JS )NX!/9 ;10_#IG<2OB;$T?7T=NY!S-I>!,S5
M&UKY/@E?FNU-_W7QNF.+TUR;HJNK"JQQS#_XVKDR *S2^F)=17"7TI-*]L:7
MQ,PUG*MRE7#E43!(W/OO+N?9XEPF)T21X G_P3WX@RBR-(-E-ES??S .Y/<P
MX0+?\G#!_^J7]!F(;L$I@DZX5OT4ZHSEOA827SVZ(#P3M*#O(W.46SL[U%TS
M_ ^],/Z !J^ATVTXA++X\E703NYKI@M"U[_G6J"L_UYJB?_^\6Q?_S4NT#\U
M)%H0;6CB0IJD],\!7\:YVG_AI2 W"J#_'RCLY("$4=N>^;4L921:H@(-_$<5
M=CFZ;-@VP[EV:X-7"Y;D7*'@>W2Z[C2"*+" @*>91@(SIYW\]0(OL^QK61?2
M&@8R?-F(CCX1I0-BOXI2$R<S'SN\[8QN.]S9BUYROE<Q>&9\<%@="%6U%.&9
M^#.[7I4M7/F?AL]>@I&3$6[, -$R<>+'1-Q T3VD35R8-9;[]Y[58^N:W4S&
M3"BKFF>((0\R/_<A,BA@IX,TOYB(&YS>1CK/D!9/(G+G0'9T!_VG"9[9=BSP
MM[1.A7C )MK!*1<:+UM_[ZM)=93F7O>=QN0=!^OMIEU,13;];5IKHR!'7L_6
MT619TL#G8Y-%VV!3IMB)2E*&WX-Q&/ R!5 1\0GTJBFPOG#7T41$]CU3OM.M
M+ )LQ3AW(#(A.1AFZQ,V=*C,5PZ:L;F,JMQ8#YE-73\48CO259_:UHWN;5+F
M*O+<9JN6A@53.65TS&?"SJ!6+H)D(@?%UC/,CS-,4[!0:,QP#U ^0UQ(^N]<
M(R*D%11>\=[6W8?>A(/3C\71I4\5:QK:ZO2K]!5A!:O0=E&V3-$"/85L!MKH
M/#77#;J96#1^G7$',5--56XT-GQVK<-T<:$1_-#$DGI_/CQ):0:W58<.6$)7
M-RK*<WR5H&PYNCI==B:;)$-[;DB5KQYS\:(5T_;Q9&T9D;$D'#W[R6M'][+
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MR3[<JE"ZSS)=JTW*-OC"F+<^\\>YS+KX'G%O!5YM (F74T++XMY$0=.:A8@
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M'[<;3E3_[1D 9\3?*P1?%52=&4;MOW.+=BE8Y4'2KD'K>PS?\P]'7 CDYV<
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M\7ES*&WO8^:U^!N/]QJB2$5E*X9HO6[3"MG=%C91U<3X=6+FSQ4-Q_.JGR/
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M31^!WHBE2TUBF117I4DTFU/\K4^-#E-Z0/<@JOOW2TTWX@XH?F >O+HS:Z]
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ME/8^GBVZE5/8H8TW@"_QV&-G"H7?/@,51-./YTBD;J%)<P.??1"W_-1HB9/
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M_*V+$_+8[[\,X$K\.4G67UVYY[\3W=I^_XW@/]#X_VS4=S/_!U!+ P04
M" #U.71:=!='D\)L  !E<@  &    &-G='@M,C R-#$R,S%X,3!K,# R+FIP
M9Z2[=51<3[<V>' ($ +!-3A!@[N%8.D (7AC">Z-N[MK@.#!'8)K(+@%M] 0
MH-'@W6@''7[O?>^=N=^:67/GF^JS^Y]SJLY^]JZ]Z]E5ZSS\>E@'GKU54%8
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M>DZ1CDIST;K:&=M/RYL^AAIDP$9$6*>&GZUEL>TS(P-#_;L:=*U/.WUW%TQ
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MY!-\SEXU!=' ._5H,!L*K[J1OE_-@I7$4,3/U[EF9I@&L69FA'F])06!H@\
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M"S#\[J3'NGZ?X6Y&&5^WP:7->H"_VB"=_@#X%K*1C _=2"'I[I];EU)J5CP
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M4\^<O^8B?"A!8&JG;] ],T(F:?_Z;5*"1]A4"E+'+TEVP/S"QA;6?F[OK_
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M"2.+YQQ?242.R3<^YM R6V/<Y=J[6Z;D %0.8;#MO2'H,<(?@*VX--JLU<:
M4\C]FW/<R<@NNI;81N_/.HK6[%PA;ZG02C0)#083-K"FFERJ]IVA5)*N6.KV
MWZ'X,4'9EHZ,Y<#'>3(XV<";648E*18]19^.W<F(3Z="-VP?EZXS81*2<+G^
MECS")ND6Y #$M</+5'@A?!Y&9G706O'WPXM8RY:?!(ZV+S<XC-@%C+ZOV'7M
MC,/""L=8V1'3KA\Z3G64_5F_V3P 9+=<Q0,4AO)N5%&J#(VS<Y/\>2J%QP_
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M@BXD)AY*]+I]^ONA$I1>'XO)S7$_VCWA7AO>=4HUL@@+NP"X<7!-4%[)MFS
MN _U!,>X'YT-D9$RK1/E[?#7$.S0C8=!SNG;F;ZV?;VXJD<^?&,*JZUR9.(9
M5%*^9Y#^%-@R+A..VOFN3*E#F-# /67DXX_JZC3A;SWR@P9$8T3-/+]S,7E=
M9PIXKS *^=BMFA+M+K%-')UY?_36RXY\%K_1FB#&&@4\U R.:5Z0I W6NJ+X
M/K<<)LWM:U5L"IVNZ3^B+6%9P.H"K"X#WJ:3<X^2Q'A-*Y9<E3T?.Z?QIBF+
M?;2U)LFF.-/S7B'97+X3\)H0 9'9M#^:X.,[FQT:91*LE7Z?(@$[1H%B21:B
M^V'IF.+I<3>FK&+Q1[T]E%ZO-YH6[9>6L[GXDG+(^I$) K8_;0?=<&*7+N')
M'6O,NO\V1/(9T3J5HU>L<Z/%LS(Z85D*QU7/ON@W3X1F548P1K_E<_D81>0;
MM'U*]J7DUB5,?=K>S)?XUP[Y\;,3TR8/8VIYM3+6^-+BE?,XA@OPI%-K[//+
M\^)-0T]Q9<;H0<)42K2LXB.]B6B]CB4U!,#M5_C34DWG @+>]A^C?^5[H^[A
MU)6Z4=\.?D/IZI%'R$)\(W\RS09RHD$GF+Q! +$7D)V&RRDWG9.GO+#$S25;
M;+SR0''AW-*F=X#3A^");U[>,P9B!U-C='W.[P1_G$MKSMDEAN"#D;0':FY"
M6/6BOD42QO?Y(G[4?Y6&>I+:OOBB/!]J&3R UQE5Q>$H(3DB>*2U<#^6AA$T
M4[^54698L?ZH1V=!O=6Q7XY)XA9BDM[@-A#X[&$IO\)70$[M*7Y^RBM:WB L
M#(5K3<RDV#G#[C('T<%9VP?C;#SCBD3QGQMPT%HEUP-\7W"_ ,6T2/%^Z'XQ
M:3)W,FD,W2-:HHC!>QL*8PD@<#8);Q#K_T*.E208G0-0%D^HU\:LPPSU=.P"
MI;LH\>M<J/I MN;26;IW.6L3AZPJ9^$'/QGUTWAMKVPN!8EG4%7H<-F/5G;U
M+M"VJE[ IQJ6&,>9OH$MK,>M!*G(-3K@;"OW9/:^?"-;2IYV9DDS9K70_*R>
M2$,:7%\QC* IK(I5HWA:-3(E+S@GU;N_U^\F("E1T,G TOWB2C,2L8S^A5A(
M :H[]U\8<_9?&.,JHHDI:;/.2>Q2]S,;*2*<0PP3I$N0(B+V+Q%1MJIA KWL
M\6..63K!WA#.PXB1[PFD#O(XB%-TD6I():@J,M(?B3Q^'D(I%!P5TW9)!O6P
M4&K[K-_8F*[?11Z$AW-1VE7$$Q 5)/LR2$AR*^#QJKH*E_5?U:?_FQHX]\C:
M-/TD5X=Y^YF!WG_&?/UWY+G3T9KZZ/42[;WTG9RV+Y+XH/]"NI0< P*8-F2X
M>V![PU@L U[W_P? W/P+7V9%AS_>2W=4AGU.]^_0_NVG(@_LZ%W>\X^+M.Y4
M\!WE-:11&JSV9)>6FY&_6U"2 !)AE!5I&VW*\ FUXQ>5TY<GQLU@G5IK8KOJ
ME.4(BD+'O9/X=!<)/#0"82C?XIZ."2,\)L^]:*11; L[T2E(8(!*7T4Z"(LQ
M6,?G#PNO_,/"-?^P\/*/L9@SUB9HDRYUQ,:=YFDV]#N7?VVQA_>Q-:^@'!C2
M_[=:-^7(=O9?2P3MAC)/9#2*K'OR]KV,AP?L?C!XB5ABQGS8^GHK<WS4G<FJ
M#JHUV(,,NLRSJ-:!XW(:B<15B+*IZ-S-W*N4$A2CJ1:#<J.2.0!"KZ"IZZF+
M&9"=M#OYMD0R!U[8='ROLX2.<TM:(]BO42I/"B>+.]CIR']\N61SB?8NA^><
MCGC@4F?TZ"RUBEEU-3S@*72%[,V6Y_L'JA@#'VB<6VT>Y%7?Y=<9#G*]NQ_J
M4"57?4GZ <NM]5'"_L"#E>9#2:@JU)=0XU@\[+RX4<^VQ?7,A]VNDB7.9Q$3
M_7P]YMS<^)7: SFA79A0;*)+Q&G4Q79F5H$+;=%#_^-<.A:=EM#=3HTW6"$^
M>US!0S4M#C/'#0MO/-GTSDTD)0+OY6S8#MHJA+7CU"(-^&M1&-\]<WV9/..G
MJ^5GOUXE<;35/GX 2Q6Y@!PYTV^[T&0HL#EY!V#WO7]5>4XG#E)W:VFI;S ,
MQ<;58,Z.KXZCD'F!(D$7@BI]S3]'(I_)_9G<X!.W XLB"PR'.:_$K/-V8X5,
M.C#V^<\[\76=I&+PU+7XC"CE42%(F)WLY/M&].QRNB7H_76@L5]BR8[4/O.Z
M1FOM)'/G&][R",8^"4FCF_MZ__WC!,+D-I?U C0)8_&U2:\O6*NC]9(%\[11
MH_E^6M!=*J-:J3C <O%D@]A#8MBB]W@)XX8V<6?L"S@J4;1@)FMSJ91*7E,M
M/9TDZH#5IXECXGW=O)W4@H(=ZE.LD8</,%D3KQ-5^9)LA'*_U3TO[II\3TND
M@'F*=I*-J^;$90/T\@K@_&&Q?[^>OTM."."T";YL[#A?0 !,!F1/GR,IG3?R
M@IV0^?U'9R[;:[ZL-5SRVLG]BG-<)<8Z"L$(HO@)QF/U_%\74F0)^CM3CGH&
M[&Y==I31%+(!$%W.; )GHROO;(^/NF':[=6GHE@6U@FK;!XS3+M%8$#A3++$
M)1;31I9FK+*<IP(T^X[GA/5$9#Z"[C(1"@ N@)FNY!H"H /+4A^[5N1+Z7>,
M%]2[\SHX< ^P,;BSX@<^=H7)/%H.N'U5[A'[_;*QI3+=O"5&]UDDC7LC'T"+
M\>D<D\7-$1(O3R.+HQC;+?8HDNRU"DX>@-\7.?K39:+4($5Q<3A31=:R_ O#
M3CHU#/Z* C[\D8Q3C5A[G65+&F)8A]+5!1]1J7_7?#_;HCC(($M2L_O\(N'%
M4Y3Y3;*,-=,@MWO&EN2SW4O58H>0E=9/GK$/H]723]"LY$*\[$A1UK/@.4@R
M>3^T)/B-OXE!YEE@/WI<V&73G' <@"FC2OMZD63EV]9'YVW^"#X^3456\]D/
M02S-D"@JFB!/>T(9L;,JG=P :=BS*QF^M-UQCT2MAT(HO)\(9&'<=H_F/P1&
MF'BA?N.<N"=6+[@*^G[-_9&*L2Y&PAS7VCQ-E&K!/>@I23H@W_D+/(%4N?_0
M-_]#&;.7KLSJ\F_"J]C[]E=([LGKPE'@O$2'%,4((!P![&W*G6F-8BK^L[0<
MC:; S_!^HIWBIX_H<4>O78F^*I@^SY?M/#]*5G_526# B^&)5'!7U63+AA^+
M#S<<UFLL-M?7,V?D%44^4=&C;QX31<@HL,%-0.F.238=6K7/X59G595LD8Q:
MFYXTH6,%8X"#8O%LTW1#VEZ6F^BK.A3NUAI^I-J@) GO"9Q5-L[^2O7K!62\
MO;Z89W_U:T/HTASEP<&J JUC3XZ6*!J*/"V "6B?1QMD3MG[CDB;,*V5#=3J
M-+U41(+*1S^&O;3E\,-S=08BFF=9:E_48QXH,5B>&@A-,.E00;ZFQT]R]E.-
M*#-->R1F$=J:GA]PW ?9RF'[]U?D(?$E7>Z:%XS;+8O1/":-<XV[S-O:.O3Z
M@&5 @:;Y#:GM[]^O7XQE]>N^+M)7+IPQ-'BFUXNN3DPNR<H)6"'UZ*)WU[55
M^$?1#:>Z4#D>H1=[@?>_'H-,5GZJ.Z#8C!F)#AU G#U@6R('W,K) ,H)^^3^
M8U]P(=+\R9<7=O#AI=3"&;:1/#L'2W1'$KSP*MG>N<J#QL>=O[2CS"PHR6B7
M:ZW""IH]YR[@*L>4J5K<KK&8?A#*6.LUI5]2J^WP8:^=_ 4,1NEQPD!JWLJX
M:R-WDA\6HEW):X]#E$\I@B@H<5X\V9P1%AAQ>J%4<\LZ9M80P^W)_\;C,+>-
MF"8TD9#>#4-WH;CM;A)'@FSND+1YFQ2E_PIW%0'<,O&Z'91JE Y":%^V71(I
MTL9H]KL+1FL+RKXYF&NYYBQ$NLR'%4W4,8TES@5A>8+<1)&ZO[%[]E5Y7-6I
MN'J,3BI)U "6QOK(:?]/K>[5;AOIB4N%^9C,R0'_/6$1!;X<CF7_(_*KY(ZS
MNJ,-38XS,EN+P-B6&P;?FF.>O8,>%C@Z$G:\C.R (X#.SYF$R-7[(I9# Q*!
M,0_;4:$( 2.T#7KK' VJ:P%BM]1R:^FU","UXXS%T%59>6)]_&S/6V_3)ID-
M>@G5VTZ ])FJM<KC_N7\XE[7HT8$;81>2!T.$W2WZU^,6I>>^/6/XS-Q<5)P
M&1OT2"_:4;3BPB.J/B_Q6 -DQ[_'6C=S*%3)5UB]S4)R?2J ]*R<GW#>2+EL
M;T+#'JXL.I#R<7U;,U(<CP2J[+4@Q,E(CB8CN?=$JC_G4^BK/\?8_OTT#@,#
M3A3.X;=@3=9:Q382Z /*F'MH6[#"U5C!PI6KJ[&#:L<8BQL^!8DJ;5Q<2HH@
M[LF#> O6XX[#0]I1S-9W4=,?#'P\X1FPN8V3JIS&AM2##4\L6$KU[W04)@PW
MY_3SSC[1<0_,M0>!Q^Q+U[Z4QBD5K'J+E:_7%S-F'HF31)41.'KL!&$#A[<6
M.>*1/ESEUCM.4R!_&]'BYM>L/<8XA\##"<G=1Y^[L[#E F\Y[/)5(73=RCSC
M"""OQSR4B;6",5*$]2 :S>YE)FJDU2SS_9[_<A\"H);]07%I>'\O=S6*^3)-
MV*CC_WA'LU.@UP-:"\?4:OUYSGT@#M6]UF].T UY*![^U#(/C>.*U5.%$DIK
MABILC #^_82G#JA?M1R'T[F2:B#3:*Z,T@/\ ;(\4IE?W)V/&31;R+7ZA!1%
M+ -Q25B45"PE'L]O8;I11FVCNR\17/E"5OVIKA+UQ7=XVRO7GMI_C9L/4W)C
M/7F@C0%84&V\GJ K/7>49$F=<9)D.7([VGFA[NU))$2WZR4TT,/0(PJX2N:)
M#MXE\!\VWMWZ'^?MQ_N[=ARM(X!H :FH*=-($<$U4T);ZC>I!]&3O,0CP5OA
M\=V$CIX,:H,WK*:+#C=(4;ZN_.^) *?6[8!')*P?# J72BH/LO2D9NU\$S3<
MQ9'(HK*T^G6V4[1JA3 X[2C$U9/?U9]R\2J"O?Y&Y.M"'M^:^-KS4-K;[4W&
MP,081V6+"VOQ@VTWX<;A]^O35(5U8OV.0Z0KZ50ICE((@ PPNP*OOLA9/:*;
M 6?-K]D)P52DM U4:N>*<5GL=9?[.(63.(HD]G8D*_4,OG<286/&/2M7N+/Q
M^[^QX?_7G6,$0.J#U7*,&5WI.M,FWQ"GSOS0EI>R)H>A0W--82B$B2E\X/=;
MPC9PT_^P/%SW*![M)[UF66LF!2Q89&@_B,QJ,!?;"(0384:Q1A!=:3OX@VVH
M0>]([G5207D%GB!3)':C:EW0=[=39^:$!Y@TOC_86Q% [?RA)6PHC]6S(D[F
MWM9^4%XR7IFF.?ULW^\2Y,6'J5B@WY!5:&#0%J0;2AJ=CULGB(,B<9#N4N8:
MG6?81]>=A$[W;3'V5+3V;_&OH]1AA3_WG4UK1OK-K'\\*4I%FK )9I[/ZPFV
M^BD'T0J"4Y7JZN8$RLIGG_$2<XFI+B440J"JZ%72Q!Y%P\=AW^.-YHMF^='Y
M^3^=_! 3VQ3G!M@D,9?MA9<"9+9%#5_5WH]-5%8\JU'8[AGSK(;_B%-2;AH!
M#[4QK740>BR!/TPPMG+C8 H]WR_MO#9_XB\@4VLL=R&3=7OB?W/'@;2X/"X<
MUO7*@^1)PO>U79H?)N\^#P6A$:\#>$%#ZK1OTT]45W2-TS;DJO<1P'8B EC>
MD;LJ_<\6L'>JL&,4]O>'*O_'&VC=/\JBJJXY4!F!X\%!4"HZM7G>S'7JI#LX
M89O3_L/&ATFS@5/-DW?ITH:L7&2P7CH#%R+*AC;#3^(IM$1"PA/-,&GJ<_;Q
M<LWBMX_T5M"D@SE&?1;&_=_I$7?B?;KI-)(;//_=E(T'(_01;!MK9S+R2/!]
M<T3LK1U2L4%,%U5*L3%(5 K)3.4H$?V56BG&^QB43D+.!JQ\:G;K.ELM00 S
M%_ZG/Q# T5G6[6O ]7>>:+^_Q2P"@"$'WS'N?ZS]GRV4R27#@LVZKVJMN4DX
M4O&3#X.XOU?)O:O0FU^@(:1=WIE.J.FW9U+",W4?_AE#FJT0.&$&1>GULOK[
MDFA(&4?6E&B5+W"*$Z/Z98F+H'1>@58X(EP(*0SW=!$ 43V=W9O4Y?W&>+H:
M%HM--CV+^$P)F";80?-*V%T\\O9QR<Q>]<X%M4Z.Z(U-F44SNY ];'@+OZ)_
M(W1G(NU73%81%V,2'HT]_N"V;)9W5;VD2!F5MA"7J\S4:O\==1Q=T-G_SR0[
M]TZ5P''W?4B4S 0A /]\!+!6_-^::%7#5)5/;^AA]YYR=_=(;XC,^WLC&P\4
MT8'%?GQ?9>=O5S&87R>0,@2!ZCW>WG0.(G 3B=@51\5BR22^O+ ]-AX$4?N\
MG-(:4(\P,J@Y5"!1_LJUG>XD@\71(;J[_'?SB.SH,'TG9>KO?P5A!ZVVQ-'Z
M%<$-#2;/HBG4FZ8/')AK0JT+VYOKXA:'AK!TB+'EY5%^?\*CGP%PCMH9/,S7
MN^[)Z\8/JS#.1D.'2D.4L%E1$E31"O42O--&Q*3,=@<D6;X4[2+S((-M<X&>
MOF\IE1D-W,,U8\'_U[-7:"6Y<7@X!O_\T!H7-?K Y.N\,9;6!NJ3JE?[,GM=
M%7XBIJ""870_JKKVQ@8]X0OK0_R6YIGN1TQF0BK:N$UA1NV]W;IU5X7ZV<D+
MO6*= [,T*(<R?O7AC9?A HV*GK!!ZAC_1]M)'@JS&9K=(_F>\>M^;%=9GD5L
M6\LA@KODI?8&AO[[=[-90Q\W/]4IN <F.^7\C$VJGP=;E(W?,^\F7[_K*%%<
M*:P_X7\34<Z[$F^?D2[BG3]/SFKVG6[H2Y*%W7S,>/TBOM(5D>(LNJ/ QUZF
MCF\2"$!-VN5N[OC5>9HO[G7!T^$VT^..'FJ*\*.S1;GOW2_#0-\,P1%YAJDH
MPXUI%%P/43)F7V(M=' [S#:#B^!A/<:O>EK.Q'0-\%K>OIA^M"9_LRI8*D"@
MKVT_2/98G!U2#V-N8>MH>W[0PIVE,NGK_9H.W%.6O3-A*Q4"#YK#0-D4"&4D
M!S@!8J<> %-+D4&_:%2V1'/W5Y5$XU5'MH:OLP5'!"]/586%$ CL18S-#+0?
M#%QM^C1RC )>1!H__%A_C:*^/59*I:379]O^8#&$ '0G$0"YDHS-G3GJ=?E-
M7FNE>(\)\%GO.//+&B5_=NC: &_X9[%,R!/T%,&OKIPT0]V!&5VDD,B@O36Q
M>/-I7,B:G1AY(TJA;AJ1!48#JN?ZUF._MM>N5R4Y5#Z%Q[)9>$M&6K]?M4':
M9UF$F+HM2E&7Y:VO>Z2[=VM/)/'%+ZPTY(SJ)AF,@@X8FX13V"<4B'TZ$WI^
M!.VCZ)K+FBFCD>W>$\![JX)]1-_D&?" \4N)GK_D43L<TI]AAK>FIJRX##M=
MFI*YX,K5_E[BGB YP"?NO9F).>6VBZ7<[POPTC+PT8=OWO+S5D75@<,3[;<C
M=Q_@-JTZ!R^<Y>T1G1*6POK/'G&'!J^));HB,YN5PIHZ]E'8ER\>&]$IGH;/
M4_LT<CZEGPV;+_FXPNM#ZMR)KTIA^R>_,XWZBW<XDK&=\EW1;#8@RE-,6PRO
MLUR\,LBZY'H.B)G70&0VD!IA[C(0UJ,!H<XHN+*_FKXLAS6$*OBJ5O4I=I0*
M]1J@V80A#*,)I#P?9M +2_'5\7O6\KD[U?Z>Q?"J!O?&@SV([,.SBR_Y9NBE
MVOVT##P1JK.Q;>'.4&XTPZN'#B6#V$$G YRY^D\*H.GL+#XUJE\9!/QVHE+B
MY3:ST>*-\3+E)IAK,P]!#W=V;-"7K9+=DADC."YQ7? /7C;VV#$^YKAEO;9Q
MS=HO0!]-8.]BEK8Z,J.7.E:>8NS>33R1 N'\,H5'77GUJ9^VC_+&%<*_4"3S
MAAAEE J'&*5SHM7;3F> CMV[+UK4=U]=%7['U8Y@=V91*B]=YTJ2WH@)IA+-
M$X\YNP';V',<8T2W"?1M#9Q*JS _YV([O72D$\[\$E;!H!> G+*RC:+G!@.Y
MCYPC7^15K3KN>VTUF(@:A=MB$4?QXTE4"=:UBET&(IZZWD;/^M>"(/Z$VJ=
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MN;@-!ZZ3GX[-LV;0X2IT=1H]K6ZY]CZF"LRJ0QU2/C7?EEI1E2:N,1!YQ8@
MB+-?[1L6@A>X!$&[>ZT44Y:S]$Q@.,F+"1>;N@JI*03PHCKMU^(/NOJ1J1_H
MI#J[94%*,MA;J9C[Y[D&9:Q2KF<O'VYZJGO,2T<EV!UGG;-6/Y8!&5P^,C#]
M,\L_8W-# +4ZP99DWPUF=I,++;%.GOH-7$&G4%IN![O. 9W":KC6LG;MS]P@
MW&$I7S5*QK2M)=,,'9[WG-C?&X!!5PFJ7]RSOWKES%J_7@]U)-'3$.[?%!A
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M;K43?QFYANX2W7OZUG[7[YL >+G$QM?8_<UYB9MR)%@.523#7X-<?,YN8S1
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M.??<V^\YI_OVO=UC?+]ZL6N,6K6J:LUGUERSGEE5P.9AZP#V6QEY&0#N&0#
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MP44L6V#C*FL>2T49;>U@KIVKIC[M%D$;1^= :G$<FC9GY!IVJO.S90&GYB(
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MSM-?WI^"N/.U3^TT-M;\RGI)U!C/$-XPV&.;DXO71=;\"W[O,5)$T05$</9
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M3I A9(NELS09A.3[PM3Y/0^IO%;U5P/]7,-W0_@!C)CX3<"&Q)B0GR)@QC'
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M&%.Y\D=L1+QG\WV/1S(EGB3B[U[,XJ*R"TFZVJQN32,2@@X<524#L)JW0?%
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M351APN:0H/.N&"(H Y%!IO@NF8>1W[V\+Q58MA=$#J%2F_AQ4D<AK"2_&>_
M$874OW/*1AMQJXT@+$O.702_^WB*C#Z_";+I^ 05 ^^<9,;" #2".GU%[XL[
M-GZI]LF3LK(3XOGEYN+&8-_-5_E<'_W]EN.81 D&\+_)MU#IYY5L!_QTWG=1
M&O4-O>?Q'P?AB^'/0S(O%FHY4"B4[-0)0TZN=YZ1I[AP!>!YFGV%JQ3[ !]Q
M9?BF+XO@"HE![WSFL:_6\E#>482-K>SPQ+0>0<Y"*BGU(UDV"0+GRZ;B69?
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ME9!ITP'FI) :TY(A$7>/2D,11*D<$O@/8\[IWNM0F=PC@=#KM=6^<?8]?1B
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M%4"? *8??B@/A4A=:8KO??:['LC^NW J"0@>!.&^8I)YT+PY^:F2E ^UKO5
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MP.29W2>1MV4?A0K]BW441 I?\,#W<)A62O?/#8&]_#V(AGYM&5B0+'UQ%>5
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M*CQS"9P '909TU60"%7!M?X1!7)55%?L]=VJ/O)CH !";XZCQSLB3>9M4L!
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M^UL+<2R<OJUNKVFJFOD5207?9M))TC'Y'HZ'6JB%[?R[&TL]//Z8(PQYX5N
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M@DRI&<&%/D>)L5^*\(%ZP]P0KQ!^CYSI@\D[LBTELBA>5/EMAEAJKQL+TH3
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M#KX$=LZ#%MTA][23U8TY['V!7#/'?!^5.1)UUWY$U;%PJ!42)2L3Q&O>%IM
M(E<SN[QOA,!\)Q.]>E^D$&]AW[_G5&=_]3*H]%H0_2. ;HWVZ2J]SC)U:.AT
ML&)*GOZIW7J=8L)G.$AYGK=I(;8GTSC/)?'Y[\6=3$0YLQI+7/_[%UHV]LC/
MD094)=:8[T*%0;08KZ>DL6M,P ZO;5H3=6Z>^6RWANYH.3>G69E,1WU9_6Y
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M/^#Y:J-L8"Y./S--:70H@T3-+-5@9[<L;-ZV(<<S,A^@995^ US_/<$@%2U
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ME6W0.X-.OWX%7H+)V*&[F9!AH4F$?N*7B8;&,?<S_84=*Z\Q7%J*WF_X64'
M%($5'!Y @DZ*<4J9SXS("EX>,(W0"Z:_?:CH*Z;,,_1RR?:1!Q,/ZP7EXPM_
M-9_V',< DXI#*71->?^C:NA@:0L.7F.EH0=:4'(12IWUDZ16Q+1^7GD73>^X
M#5%-]G@O&/90.WRS[6^PJF O]]1H'3G 7%"&VESF^OE?8NO=?Y1^<@9_& ED
M_)?>*>0=!& JH3YFP]CE7_'BGY%:=:3E#?CS]547;5$0C7AT(B(_J0JREK-E
M7.!N<0#)W<VVN SM%.GS/&($/A9^.T<,UDK!=IB55X%G?R[NR7<W33+1JCXT
M=ZI4RW_V@8:\9%J==EJU7F6F5Z^N;O@H%J#\"1N"4\#*+"/"A$_V7!;.<-H+
M$A1*);MQ/!CFM9B!.*(90[(<):*^U;@N&Z?,RLS/[T"ZFF.T.--?317IKGQ)
M?J%]+7:PC/O2W.SJ?YX9\BTV#GEX[NZ,) 4JVV#X.[C(86RGC5BK0ABBX_0:
MQHMZ2@807HZW-1IL78MUXL;V>2XA6S/HLK#K8^8=\M858&?1X@HP8E3F=0U@
M0J*J1TWS.D,RS_SS=W$ZSYY8%9TIMCS=4 3^3COM<N'\$H'ZI2]8\[&"Q^+
M+$R'I.8?/))YDD=(N7-'#"])5/>_JV=?6I.!JC^2&*453 V)$]M&X@R//SLD
ML'K[*,XN!:=BN)[_]9+$)A1LS63\."N=<,LKO:$RQ4Z$O?/=BZ_Y84(N SUJ
M=SG;;[9^-+Q3T<C9.-'0LD'-3/19[=U)&0QI6P8'9B/([5T,_72'WX_^K VM
MN1^!>??K;HA]E$B;J"TKGG%* GGYBGZYJ_ $D.2MQ/!D-6&*O*OV[SX>).G3
M,!@ 2GGLYR^P%*BAD8K[/2>J=J9$QLNS/+Y/S[[YVR0RS=)JU&+>^^AH\^T"
M*U8"I9!)HU+JE,'^Z4EM\.\WW"V?WOG(O!1H-2*LPE9\%E_/W6FIA]C?BFKR
M/L4(/U;/TI=D-N(,-&S5'PF2';7>KC!-LWICF5#$+P3U7ESN[!*A-\YC_O]3
M]6$P_OO72!G5G+5_63SAC0K% 2CO[8S\JF-X/<@S2)&N1^4)UVV\+-HM&"Z&
MXOI X$O0'$\ 88;#WCQZ=!=;XB5(W'--1%-_0=R=5(-W<URZ>5ZO]0T?W$@
M^]SO_[2WT**/=?L)?_27(&H&875L%:6'Z7;ZG#VJ<)E)^D8I/1'S2+4WU/6;
MS?S1C;_J9',:GF"3.Q\#Q9H<W7GS/I^$_<BXF##=X[7/?%[+)*,7F[<>_J"8
MH^=EHP4_,6DN7#^ A_#'&9(788CA.23-F#'Y]=<[V_G)POY8LC0JJO_<.\/R
M!?'C5\_Y?7LFD.Q>?NFD*,=0*0H%-YH%*Q4 K*2)]W:R_K>Z4MJ[>IC&+&A.
M81+W36*PL#.!%[O;/ND"0YJ8H',"WHUL'CKOT1B)2 V^'N)I%'Y.X8KA":'I
M)Y&Q(QXK>1,@ ,.A8CZF0#DG7R++)Y+U_9H=SJMQ87M[7F1458I/IRMX:OLH
M:I^^3L,7C;2$5SF;C] I0BC7Z)M<<.VU<D3E$I\6B96_'$U\68D)(S!@#9:*
M&@?\Y+Q$3,R@DGEAQD[71+9\/M*V1G/\!9I"]Z"<JO'>TGI+4)5$JB;5<)*K
MM.BW-4>'7<\ZQ16Y;J<;+IC,R(O%R..R._@GJ:B]JFU.L;K*<JCR6,_-K&^Y
ML=)W"S-_L>/W-;@$+#D6?EN>?AU:$)MD^)8BY@:I>3Y:^0FWBV*!Y^[UT^JR
M503UNVQE:WL:;K!4IZ?OG@8\QY9N@V?YNV9D@MQ*](YUNN+?C4.?E-?TAQEV
M>ROO%S1^46IV.0W!W<;&M"G?QV8NJS?^57Q#X"UO^;CXM"%J[^]:!LI>E:?D
M%_SKD/L8I4W+>BM'OI)0S':LZR'THFKS"C!!J2;[Z_56>XK?8?>D27/JXHND
M*DWL4?LBT?4U\6L#WSR^E&FW9AK95V3+;R;DT4QPJ UF6#RUOW7_E;E:W*K-
M^\?$L1[REQI+;IU^GIC*Y4D]='?.@N+GW-SL'D_(J3=-Q#MQG6\D-Q7"B.Y8
M4KZ&E7V7 M-M7M"CVPI<:J7I= F%"D6)83FKU(EB+*O1&34%QODJSHCM"7RT
MUOI4V$!Z%V0-V3P\<05P.O\A&K3(D%6'Y?P$0F?+?'PL1;D]23S8U3A#+73)
MM7XY<)ZVLL'V'CYNL[+DV/E-.$"L75$%Y>C&4?$X(6\NOX:$IU8!^=Z'JRK/
M[=QY>/X<LKFR$"17>$I#:!:VO<P#_P#[G-5? 8"'RN]T/R!H'3"B[2!C,"/L
M_;0B$_04DFKA_\B8226Q0U#=6;RQI#U_Z.VYZU?B"&P4C@^NCCGH. B]N#4<
M!I>17!"8+#F9]0X?\?/Z,#J@86PS'&L3K A0/EU)8\61Q"=TM&OEG9^;CB2Y
MAV?+C@4E1)7LE\:O[\UA;=4O0YNLLO%:6*D2G<MD7[>E2^69R9?U$8:PB#Z.
MSLHB#9K ?8IUX@&J\YZ^R)0 ULL4I%/9)P0UW+*%!0.7+PN7@C[M*N'D4!T\
MA*X<X9= ,WLL1P\VQ;TSM7'#]#7)8ULE1I-XJ>C)3M.^+3UU'1"[:WK.FEMS
MX^S/D%YSGQ"$\R\"'Y9\^\@@KDF(Y(M3 _[!_F#8HTZWC?3OKF]JA^O;]JQU
M?= 4IU&7.2T4VQELV!A/AM(J2*D9V%2YZ76T!'G;VX1;TKUS^S ">A=R_/*X
M5&+YK/,95A=]!3#$J&[M%?#&?$DU3'P&AA=P+=Q;83L:K:'K4!].>3%S(D2=
M;F(0Z:3W,P]V6,-A *J9+-G%%\-G4>= )W (DD918BF5BE.A+&1&(P2ZF_GR
MXQ!_5*G-:*B"G<,=E5]&Q \5[MSR%(,_O2SM:>=K0E!I$L0(LYJ?J7)G-G:!
M#AZ_JY473[+4/3/<P5X :MG<&:5;X')_OB'[5/6M 2I0L^B[DYH#__>+X&?P
M (+LY4^-+HLB-?36%>"SIA.?4RFP:N\<21BX0^?S+1.+[U]AWAM-.3Z8END$
M,C9I+)48(R(NS$9..I'3$)::<*H_OBZ>H5.?CEQ7)^NAG!\# 9MB)JPOQ-?7
MWZR5Q02Y6/>]_/S./.<@S^K,7^U'N-#WPZ?A_[V94MED5##P ^MF@ P4 D&A
M/+WL]EI&/(ZSX7U8VY59W3!EBM&:V:?T0X&Z=Q6[!(C?<V5M[:J4& DVN!9:
M;WLC4^4R^!(AQ0H!.%#NO C7NM<[/36[=U_^#]FA+X?&N:7;THB:"^=3@G)-
M5;@%5G'@YAB_)KR*5%K?7 09>T;K?_+E)^TM;N) ZHF\7+AM 5P"$Q"',]@Z
M,\Y@FG#%\WHMTR.3+J"VUROWM^F?U)#0?I&5E\R%-TIB^#F\_Y!.#XPDI>0
M!'W( 6CD?^69,G+LM8;FUT*#"<TGR$M>\S/S:[@K;WJ$4;R83$2+,0UR]3;X
MAD+#.DAP4:.KUH"V;9!KQI>$[TTQCPK6I09N-;Y".B7Q ]Y8TSG.6S?)7"/0
M@T"IS7^K,XA->WEC0KE^F;G:G5V0;7Z;;M5BNB/JD',C(URA8LG(RK:3SK^B
MNN2!5,/X8YDJQ[X:TFQ-C<WLA%VY4J$E9'LF'5QYO,D(L>S&#(QP&"_]7+O'
MPT95;0N\UR?+'I,(SW8K*+:7\Q3HLK[TXPP25A*UE1__>;W'.=R$6I*,M=R*
M3#:]&W1#UB#CXU(^%B6ZS%$FEZ!\8 >STJ7EH7\(PY\2WX/NQ9NPHIX%*L(@
M.B8\LUT^;X8[<>%'O!D]OB^N=SC_N$?5JB4&XFZ;:S8[/\\VFY^EN59O3V[_
M]KM$K+S=ZLI"FH6^>VUZ7]'M_DB(W[/56<M:GW#CJID)GY&A"X7DZVD80_UG
M,X.U67#L&FG^+UH6 G+<&CQ'Z:NCSD" @/>P3RI8%P1D0$1':_R$2J=39(5.
MN:S TNGC6O4*^VF<&NV\XL!:MVL.[D%E#Q^CLXD33?&G8T'9ET)+_JH=UMR9
MI\BJ2>AP<%Z,!49?BRHZRC'G]VFJ'T>^J^LC#L)8)8^^I5W^N4-@3Z2\+ Y%
M0D_M EAM$8'U$;C@"I.*JAS=7QPF[OHBG2?V6=DT@Y<H>GN+.P%:Y-F>L?2O
MRKDWK("GO1B#B/&Q)B;;G/D9YS\]TIE>/@_F>/&U$>_BY?<4H$_E0_@WGFK*
MW0N_T%AVS4-!V5HO2LZBN*N3.Z0Q8:*T%[-[8@R4TNM*);_V9S]\&A*S5G/$
M9"\5-$<O#&M4VA!H/QF(N/U0]]XR(88;KST].#_[>(]<Y9'L@ ?1(#9D)7%!
M^6\ X\P"UM$DG'#6-8'1+3 U;6IXKC^]76G>"VH#WHO[+LI:WF?R_!"RG8B+
M."Z[@<D,QXLL V_ 99([2&8F06Z,SF\MIG@>C"\]7O35[UJ]2\Z\&OW,ON<6
MVTAS[7 GJ_W\T91*_@S(_ZZR?;5GMO;7G2^DW.Q>]*62J5,CI3XZ00G=*:O!
M?$9^?D]XI$L_5&R\Y7UDA,GX8%CJ*_(+NNEIV1U;0<V)#1HC$C*?)KG_O8]X
MN(<<O@@^24-X8K="MP6I^% '>KECXHWJ\=D-)T:O-/$"Q*'8#WGFUE@D:L?2
MO.UMAW$FE;#V*N*[%2<9NP<17JALPLOIG0C?D5X])73OON_JX:1(C6%%Z_Y;
M*O@E3F=[D;%861#/'X,B)/S<9M79UF>K%S53YSE,$Z\09C'874=5?D_+/PBT
MP>9B4G7091]:Y,"S5E> =I#GCR^UK%;I2_$Z7DDSS$-K-\]=>)TIV-\:]>B%
M;W@96I;E(OLWRMAO:5=D]X[5)_5M-^];^5DU/_)GR%O4*)BRF.]D5E.$/'1E
M5C"](8%E7<?3>?K[%&,+7$_8(GJ+3R0@;O01S*8KA_<2N!Y^?&'GJJ5H4U_V
M <$DB0SEN@WG*NW/G!+?EM;D+A^S?Y:8J&SVD(PM\4M_.?M'689K<7HC0!2+
MPMMBHL$<6"F\$BJ=6]_O:PVS3=RW\.ZP.D>^)Z^C!7T$5GQ^=9S&G<&O +V_
M7Q7FFDDF!&_5(,)G?,ZY0",.15.+/0@(^V9\=R5E4(IXM'*A+\.W%1']@V?H
M>4*6_2K+GHT$T=OBWJ>'*FTW_2&0$\4UQD7!.D.I$@0(O?>]85R* B0]5JXK
M?^@5),/YR?.NN+]@N4L$Q-TY;V&8SL7@V>$'6GH3PX?,@5K=,F4WS\IDL"6X
M)W!YM$_'GJ[U6)-:GHN\5W%%ZU:>9G*E[]"+SMN?\3T06UE<WI^Q?FW!VM_Y
M?]-=XO)NURZZYN5/;3/.I.?(&"??G;=XGK620D:<7;!I]*&-<[D)<=K!?)D!
MU[L"N"Y>&#&\V>(40+M%*)JATC5T,) JEQ2G,<D]>0XKE,Y7=?)?U7/BCRWD
MK'N /M' TS&,=T1NP+#Y4N/87I:,IX5%6_+\NM8&3ZJZQ-#4W"7]A)%=NJ#"
ML:,W>>1*5#:;PI&&CF\&H1E(IR);^%ZZPKYLB]$\(]V38RUH5]#=S9VF7X<M
MJK_UXJY*T>?P3<6?*=Z.TN603]VOHRO(_J9PWQLEM,I$ I [=5< V,8^SD0'
M#%3%Z>C([+T-H$6TWX?':;P:0;A^TTU"O..;KW)0;)%VG3_#=OD3I0S111[T
MGSI:\U.;4/?M&=7_R*D=5\K(+/WQ5XTAJ_N_+_IE5E:P(E!.3$[TNUT")KO!
M54Q=,5B3!6&0.,&J@:]07Y#"XW[R#V#YAO.IW![8&=OF@S4QX:R-C\&_G5R7
M9297*CJ.9FPWZ$&)F;HTZB2O-6?VXG5C/,FGC6T_=/\)./9M<=G>68\96^H<
MF0PC# (9@2A%=,PI"#][4B)H+",<X)RU&>^7T8,^*7M3=CT)+J^*AJF-($R7
MP&\7$Q8QV2FO!5<$@-XNA/3)PO<,/?\&#O;_XK^L*-W[!ZR4Q<(]<=H[!+++
M?%[T?M[*,*FS-46P$ZV?Q4"BUMZ?'PI"!9&]]J^1I&^?Y%([E)6!X$8K(N0#
M/< :DBK4SA;_R'%$!#;[5SG.NO+6;HE+T6D^_E=+?S3]9Y8$P$]31WJB3007
MX1$LM0-)<\Q!W3J3=B9?M37JXF,.KWCZQGQ<[S2P2Z;/73B545)]24B,>0@&
MOHEWPJ;F8Y/;DZI<ZNHNH%V[[A;#?)FL5P!(MJY+'5%OZ*NG\99W#1POFM)G
M[P1T5(SN'>/8(*8/3)=JHVS#Y'>-  ")S5MF70 X:D4$;#@&A(A^_K/HI+]E
MC%8K*682MU(3J.=RU(O-U[*6.Z\ :YK\-X4O@/M;IAFL,78SW=R'9V"QX2E0
M[4&<W#"^YGKVTB\05-",+Y]09J_C_3W['],V?!(ZI].Z3U6A3, <UNE^";"T
MK9<D0O[3G^%S44C-?[,4[[MJ^CI*1S'Z;2&I/HCHU^$42;U?B<U!YR2MF5-\
M*-36)ED^'Q"D-'(7YG#B&K$/R^^9P;_U#"M65/;=UO?[BQ^1N +XRY3OC%E8
MJ#G>4+WI3"GP3_>#^#MQC497;0_H"\=)\E(S'-]"Z++BTJC^LSLQ,Z(4%C\X
MZ#$BMCW8DV0[E]*<DI</8635JF.JJSUU6%:A?.!K#!0;5K.,B_<GE>J"VV%G
M45> #Q>\T07+-YOC%P[WH-R,+WVCFALSGA #<!<.B7GD[AX)E6HO.VS$:K*U
M(RWSE.+G,X+" 5T:D+?)WG]U.>'U+^577RU%1BL8UF3UCZ=_O<;3V_^Y9/3_
M/C^3G4X9JQFX5!E+C=(W9!JY79SG<7#7=.H@RD<<,T;)GOF&%8!57=K855T9
MO@';:;^(SD8=A$@GR=NED"7AM#,\82$OS":TLJE<LP=_T<5(""LO];DNOK\W
M$ZYT"\Z[) *QNOP)]T+ILO&>A4KY$[>G_#"-:.91<?;\52GS3:EA3E+[SA(O
MS"KSE9T?K'=E?VU3@!C8*:^&#)74N13?2Q<I$UFM^Y(-+:89*[AW*LN?@B$#
MVH-#/,RWC/4AK-DS6^9*U8QOI;,Y[YF*J!6;%!TZ#M(\C-P8X"$1C$LYB0DC
M4,8L<W4LTL!<C4Q ^MT0JTIM3);P9P$'U497]S0O%N9[RRUF(T!;(/-6K=ZL
M5@'V_3(8JUZ-8ZR/RSVZU57[C2K5] I0)%<1M^QLBO:8.CSZ#7@/C%9FPEJT
M$ABP[IQQ$*K=VH5'HVL1Q@VFZPUQI5+$BH>^;1Z*?;QQO<]%!Y\ W"W/VOW
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MO*L!P^!4DWC=Y<P0!*D4D,E4Q[;D=\%<=;M%7;VOR2Z3'Z_-;A=%*=MK1<=
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M"K"Z%4!Q!9ALN1:F.476.T]N0[@Z*ON$&\KC?KY*CBQ:G]-X1-*)>NK?1AB
MS^L^%7HU(1-R7PQ43$<3X[\C#?I:-W_(+T=ZEGEPMC43*%U Y9[)0!#!>BX-
M!]]!+D/"2G8I^UQ;GJEK.-JV @+XT244,6RFM<EY<UNX&A8O9F,_(=@O7[W
M^]$!VX$JPN_]8<67.;YI;H7R+06A[[(MX@ZUJM.KH>;;!!.37><=UOF?04ZN
MCU:GOI$7$CEX*S$8>@SZ$9E.S$A-ACE&XRQB^FO5J:&Y=%^>RBO.?\/M;;9L
MI'1B0CJ@NMT9=.-+"58).ABJO:HV:(&Y8'<&6[7JO:,_=93^O^@/J+&0SBO
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M0J+4F1:"P&,QL-SDWOD=LP]E27\+C"/M^=)GM7%5YV[A1W.C%.DV G\ZA\1
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M D_ZL(O+NO\62%2]S)5*_M%$/TA4Z"9U_QG& ?XW$S7&_@0/>O9VBNQ(#UH
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M0P$7-NOW;U0)%-]*J PN8FMR8J;<IOIH18O1=?5KB$$7^UX@@YYDA%%F?D%
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M@-\:;2<E1,@32"$LXN1BA"LK<W/C&E?47/DL1<]&X8\#K&1>Y]+:7D@;\OK
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M>7CMC",>Z6B_L<]0R:)UU"6-HPT>U*F@B>#$C+T#1.\A>>1VG-KO #TX97>
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MY&!#O_LW1*AU[T<54F$K?9M1J]PB78D<^4]NZA6+]C6K_[!NX'0X#X5*P>\
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M(DB!(_UY%S-R0@]^,N!&A;).Z<LG:$7FLC>=Q =+2;=0G90H,(SY:BY-,XD
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MS-B\5>^#?,MHG'A)3C (T4C6NP/XQ+PL@[=#,Q/@,3T7ZW0_L7OWFH^/(W9
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MK--_,>4;?$ T;59CI$(O2^2C(,N;%\VIY7*JKNX;[/2T8]%I_L]3Y,<!]<T
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MEZ:'$W%!PL&V/^F,A='M:4.>)6:F7'(V";!*UF6W?.>$XE1PB((=F^#D'])
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M->:L]$NQ8@U7Z?V2><1TXP^;9]NFSY%VH'6N76[?W0'UJ8(0QNC:,D,< Q(
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M#.\1%,'E<6&XYD9$*N.MU^G!ZW ',)<^I19LY6)B76) 4, "AQGLKWS[__*
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M!J#I;@H^A0:H4/:T;O,[2(3%C?UI!0ZO2ZCXPNB0;66TX+&X_MG^TQ >#^?
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M8AJOI_CMN_Q0?)1?.IIO-0(^;%!-Q]:3Y+&K&^!)YD[%!*SX7%LGEY)9KI=
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M(U@#<\A!O<#WN:BD;(05<PA_W?=I-WI;M8^U+1$:[=E[]*GYO".<[DWN%C@
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MB%FGP1_4W:0D/IZRWKXUU^G-B^GMHIC7C[<7+VR8:=E=7$8Q>MU\Q7P+U1Q
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M?M&5P5+RBV=J28LR+=?&UZ?B5^M2(/$YYX%!]IM)K<^F:@]TYL-]0 S/='*
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MWJG<W'T@4O?%#><AM'2(M:;O6B];+!JV]Z/\.,2,#[G=!?S7YVLT;NBX/2/
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M9CQM="S'D^=R74=(;?:""33$N@OO $*,\./D0]; O6GUC1<2-*7V^$M:D:#
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MGS&[_;J,5P6Q2FY]0\#S1O(_N^U>D[#46-GW[CC>5DVC#VJ2&!=XO7Z?2^Q
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MK5*!';#CUXK;2II*8X S<W,+YS0H?B IS*I$<\K7I<+#I'6L\M_:9)LVI!7
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M;^CO=V%<2O461V2;+T9/BFQD-D3C]4DV3!5KB]\5T=*?;LQGVWT9UO%MT6/
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M.W-5V^3KS]PC"A1F]%RMA76VP>BBO4]'*SY]KVM,6U!CJ3#;]C%G<R5+NEH
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M+VE2I/H:WHB0*E",(,]Z_5E/"E(+YNP$^GTD4UU!#@]9.,WO]&-8F%Z9#,P
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M,NR8K%;.5)^7+ELAWSOUH$:,J;JNT\(>*VD[C?+6&6+G7VPU2=75!H58[V
M(X.G%*5'L8W E5H\.%8^QP\+#KW[KRXN*]4"_.E$L= M/O.1!.'=DW\?)_[5
MQS6A.]+#_FVNDO+E8&T*JXOS/6P_+T4D,Q/N"2"MC]I8;E!9:=MKRR\NP^U=
M*Y]K!74+GG[_NZB^, L>PHW1^/D-_,UBK>&$G"VT1%Q()-(&%9W+;9%VRX4!
MX!EB (EV)QYWT1,8P"Y#OO\7O>TKU&-G\TO[__%GP+@1 V3V\0BZ& -8! ZT
MI7"4<UOBWQY.[-G=9&?\]ZG"[OI3/3LWZUR81(SKL)@4>X*3K/# 6 7)M--4
MF?R29;\CC;JBUK&J[ (%W9<)46:8]XX@"<X%S?RC?J%F:^*XE5JOB_UVH;T/
MSLGLNIHJ<O"^[1)-P?6AEWJ1(#:5]!L%"\N[\2(:-N;-]@-IW8O=(PY&@]^)
M3HX@ +&SE/A%>9#F:6[BK2A3U:/"X3C'>9:@N #7TZ  ,M<1BA&*J*$OS^>\
ML[YM3]"4LAUK0\ D-XE*BV+ 78:AD.JI)<"D0NHV$?RE%X,1ZV/]J).)%%.R
M&LAI6'40X;9;20H @9_O84A9^QP1DU/ U7J1@$M?F0DM><*9ABNV>!JE1_&Y
M8,&$-_YQ<\W*>A;,\*;Y2/1A3^PDJWL.H^6<[E7;TR"BUZZ3.H)7;7)F7Z7M
M>2:8LUM\_(6L04$#*?Q_B@PJTD@7O"^.95V[++8_],\']7AX!^U(P[)TT^6]
MNNIPQ6AVP116R\VQ6FMJ7-%<FN.*W /2A[&_5=NC CV?P9SV#:[RNMCBE"MB
MGW\5ZS_6.Z0IC%'@HLUOK-IZU\$6 +C)EDZFS"I\5Z3T/&5]($)T=N-;<6>
MZ(J+DB@ TD\?P:#G S87;=4Y=A/V?1BH]G8E1-K.L%IXTY-#@"DNBM19!ACR
M<=\Y4DIS]3WJZ\'3[#?X-*+'/79YB)YBO,;,Q[]W"V8,NYF?N1ALQ^6\RX0^
MM2Y\\P"_A>FQRL/4X1#FTZH0XWO4-^OC+?6K.7H\R1X<HDVL?Q<VHS8JN(0:
M^7(_6E/S?^'\G2GWC%6/N?A*K' G&/;(IH$EMKH[>BFCV[K_N3O+!9M0_FK/
M<MENT9N.QDC\T6-#A#ACA.[D'2$V/B83,0"BD79F='[O_WK1/GR?Q#GZ16H4
M;Y_INF3$W2-LFW&9;90+XA%N_.HT\%J(U=_K-Q$WSN.8C:FGWC.=N7^S&Q :
M]D)DT;34OVI]7LF-6@;7GI)CY6NT!W:1O(HHJ#]9;(W[HJJ;,O#./&NH'ZVS
MB0'@2'YT6@6%>^M,CG*>*#T+2)Q\VK-J^N76V%/S2OEDSBZZ5D5*_MG[F"*]
M(F"6KYHAQ.""5<]1/M>_?'OSVT\-8XVPRWF?E[D>S7#XT+\/86B"RX=W,=*4
MV_!+<VLT!C (?J<W D2 ^HG;*GH[IZ74ORW?2!O>T+:>V/O7D(48O_H181E"
MKO'F_O^X&)_>NH(91"Z5D;G.S*'OTSD;8CRO<N\-/&0>#81F^>-Z-DY)B1BP
M@6Q2E1KZ:^*.XBW4%KBW.D29\45[Q/6."P_7G;B6#T).U*EUL@T$#1X_QN'\
MW?@!()XX<0+O: 'JAG74#MJ?&.V[5 D8Z]NR6U;5V"=;:O?]:2:N[UD*8HOG
M<YHSI*W-ADWUPL*O+ H9+.<;!C_5JORT0^CW<W317Q'01U;_ F12[D_> ZUX
ME4><:8ZZ*<B.GROQ.![FOU2)5MY1?CD'>LE*2/YTA--%5&RK6LC/]%@K]%AC
MU*'Z\&7GJ8%YVK/J&#'[^"2>E-,0&CW-]L?1[2*X+RM*JTW>=9]^$]R7R#BO
MB]8]70<>?M0_9L=I;]?TT6/)'Q%A3S?*O[G.'+8MR]>8Y4Z=O3[<,;=-SQ]N
M*E6#^ ZR'O[)F%NYT/0F%9T?Q8D! " Z$PJMC>DL$4SB!L[WGN-GGN^CO:<N
MI@,^#Q)0JZS>3H5[,(D,6(4G@SAI7,@FF7IJ43PK*BF45^E329=SJHG7O+*S
M==E;\LR/<T4E](Z?()_==T22;YJ2YWK6%%X4%(S_'L\G_:1DX.U/F^(+S!W,
MFYFW%4^43;>*)UR4<6+VK4NMW!Z(.NL1/C8?Y;2 -&5%AG/[RJV>2 YP\]3
MB-,V,FNWTE54.@WR6$Z5Y?K/<>&&'<@V'R?7-9MJ!RG*WG>C&RD#4UR_XVO0
M'ISR!O/EZDIS^&\X?E:>D-3&GA2")HXX90WM26_\8?R/?L^KX<=3#8[%UST8
M 6?%FG+\24P,+'&PWW1B+6MU',KF4M!TFWJQ=)&9<&J8OS>O=C<WR_CN0=S9
M0FFKP>F&E44=R6U_J_U].4"VZS1#[+J=04W*3)>= ,\<UV1)P  %O\=]TVT:
ML1$7F[G6T#G2W,_FC"7W3.68YX;CF^KO\Y+2:&\\>=@G)2]=93HC'5V0X7PI
M\EB:E>H=H[DY3KS7B-:"-2!^<GKR(Q^D4$@KY\BUV*7ZV"]@)V&GPF@(@J>E
M])G&(KR?E0J76/T-_L2HUHMP^SFJF$5AAY<&EEVAZS\"R0KQL_V3BTN0CD(!
MB45S\[^;*,HL^+WVWIC\_JA<>W!$;<87D\5.C6*<,S8[V'/GCUK]8&-@7(R7
M&/I>](B /EL K!(&5V\V2VW,KMN_\Z8?J*9MSH?G\O&P"NNV&ON8JF$ @BW7
MN)MB*^NPJ53EK'(&YD_-4]SU +?MRIB6_?<V5\*VS'\=A>?ZIZA3_UAVK#OR
MMGUE<9>R]1,9L+YEA-T3ZC$W.:N]XC2BCB+&F9Z82-\/4=)-*AR>I +MIHN'
MR_>#_T"_HK0@-D7+[^P<8QT3Q0F4(6=\S//X17 S++GY@HU-T'-M1-D^6:<,
MRDZ+Y;PX-3 I4=RY9MCO1J[D">.%06>P6U0QVS>#P*/.K!8$OLR^:<6_LL:)
M"=!=K32-49IY@O[%:YQ/_1] LR]9+-;Q&,4_EW->TD0#+8G-JCDSG]CDM>AI
M&8N\B*B</(2NE!)@ #3A9?0K),SJV^A9VNL''&G/O^32%W?Q,IPLM79AQU36
M7H6>\3XRHG-S$(UUW:1%GBXQK'.6!3Q<T>LW^;QCHU&P.**(=/UAB"P$M?A(
MR-/6PC" I_CNSO%TGNV<)0NMD"B]6O2T/\5DLQ'PR\4MD8[B<:GR']%K>L"*
M@,=*G, N6-03K)_:Y4'9_L;1_&Q<Z7"0X@F/&XL+#L4%/'PXM0P]-#R5WE23
MY-&I)E6@%E58TG%$GB"BUV^E7L[$)-]LFCEE"%;")D'R_AHP]5I<H4YS\U*O
M3-WH72'K*\%TDW+_9 R@0VK5#HI5]&ZJO/T%]4!PM0I85F^D[1?-R $4T4L?
M>S"% 8R=3H_J7/0>""ZN9!RX *F@&\F>O>CVZ?_.-"B=6 T\5DIC,:<T,0'3
M5^%$-Q.;9[?^O7N-,L4 $K36>6YQ3:$[8? M:]56N[=\+?(RUP1,QC?C@2W@
MI@NQG]T#H-3!"Z'>,/@!FT&P%7^P>)U)H5A_KZK_YXR?UWJ-2>.Y #B'L#;]
M(Y#CA?^9CMTQ]]*;BBX:4>F&/5 Y9.FG[:"#[:V#HR2RC\9\&IL%N;20+;K*
M+U2<31WW=2;"^+<7RJ1*JN#)]26D M/[R$DENKQO1/6?KYMT(HW@W(M_%:U8
M7/3B]X.N=3+<8A0MK(#BL&N;3*9\K_/U(0WE!T?J(O6#GN_"S>4\/-HU<Q.D
M@(SLS</&[ 'O"ETGTZ=KZTVXM\3*-OZ$/- 8-8^_N!C2: C4_98:'94@?=@B
MXK%[/3TER4E)2&'^<FN^L3;<QMI_BR]K<T//D^:'E?-[H..WCQ,((5,["]E8
MNJC,8X:67W;%4RM5)L*+#C-']D^\+^](7'_,O60Y@@2U,Y>Y;C78=:G)/]%T
MB7!<7&KSTK;S43RSU]*_3$SB6'Z9.D0HJAJK:2L?(>M.Z$*J)UW=[Q A3+"A
M-\1)X?7R6KVDL'[C(P<%-7$7  -0!E75B3XD>Y="D_>(_]ZLE 1I]0\=)?S!
M9DB<S[BGC1:T>52*<&/SERO,]AP#F/52O,M'/ZERQ0 HW!.CH-,;.MLNHFE1
M02FWO\F4S\&S7\71$T "CWMM)WHV^-F%=_SL_1PB+A,-5PHHRC\80+?K_RE+
MDJ9%S4T<S0UOB5$A]>GU=GE0E!.Q]"CN_W&V0MQJJ+<>RQ5?45)Y6M6:IJ-C
MRC&]\O<$*3MZWR[XB]JQ]"OY9/^K!!<^_0^TYY"JS]=\I%<)4W=3L<?+6RZC
MXY)9U4 KX$ID,&P6WCV+ >340N^8J^&CM*A_&W,"N:/;JJPC%>[4JOZW[->C
M=Y>B/@A5^T_W"Z%^+>!N#[C&IK5E0;7^G]/B8EPCP_U$A 4N?L[D,)L-5@N3
MTR?N&MV0K!D8F/99^YW*C_WXD;E-PX6$(&&VV[\>G07MB>LT5Z>\.P;D?=2V
ML%Z>:'%2+EWEZ#Z^IM8)S/0R;3]MKE=7G(]1>K9> $QA=WA[(U:0 /GT2^DY
M?IC5'.3,;\T[VPO%(>(.),QBY9=]89Y,8TE]#%IT:1PMI&C(+[0UU7[Z=H0E
M6I1=G_Z^L2O,\/LI/(G\B$EXA>[7.6I'$Q#,.92L%=*[R%94E'>]T?NVV<6/
M@[I[65XY4*U2?Z"6>1B56;PSF0#-?V[FO'Y4+N%-*/?RY4=FWF'_8^/+O @9
M^I-?[>PR_33;P.V(N9)TX\H=G<8?^C/4DC72^G%1M=X!4GS[J)^+DTJ%AIPX
M]"!A5BO)UQIQY-[;B;"N&CD_&J_<3Z/VU,.3[;J2R<PSV_L1%6ML6N[,7RD\
M<Q0W<09]VTE^0ZNR/2_*/0<DHXUT+7WZ7[1FX$7]:4^BYV7M)'THI72#UB'-
M@Y/FBC<W#9^%XS^+0LA+:!E_W5!,))67MMP#0:Y/U*VB=44W>-I7B!GR,(#L
MK"*M!-W6T!3?A6Z1J  ZO* EN*<K!]SF-SUOP]?8VP,=W72Y876^GK%>D&W#
MZAK8=&(F$P/(ETN +I-'@\:<D%P$NLC9%<'%FM@P&.S6.Z%-@M@?_%YQ%_R#
M"6'X H9H:B9H.B8C%<-%+^7!1X0;K7%;1;=^>8N81WALN8O#0[XN(S)VB'^E
MO5WZ[;X.'QION;V</JF46@I?K3>G^_'.53#/A6!5V\=<:!C=GTU(NQQM_K=\
ME<FZ6G/,/,<?EF_C/\GOZ?.;Z0GMV+&J=TBS#5U@@_%V"+Z4W8K=VNOID8^,
M1K>BM8=C;:= MIZU(K/Z\F!Z^I9@EGG#V1;X[C6L#(8 O86N1K52_%/8&,#.
MO^^HB+89'_5$I;ND5KK9P8 3FSQZZ+3!PSN.18YS=A>MP(19V*_Q]&)U@9BA
ME^0:<I]L_S_G5/,<+D)8"P_"3G0_6? II[.4EI?*:#4XRS"0^.,8=EFOW38\
M<;G42UO<>O?D@"^V>23P^X=[KE$P%U?P!%NXI$B^9YML\UC-$/^$_K@3,Y_Q
MS/+;JG?\T,]C7XA%=^2\)H&581V>DB,\JR*!/\ZHS ]&'4(WST75%6K>12].
M177FBW"9'=S"1HX2*:[""KPD@26=C:H924O',Q.0Z"@R?W4<W!31K?P3U<:6
M<S*GTKW+VM,J OPY A*.5^QYP9K&(73O6D5%Z5W!HQ2%!Q4(QP&+E/E5O2"N
MC3<4IE*$LXJ #=*G%5LYP$JG#GFNIE6V0",/XQW*0B!R4PUHHW;4X@!?OO.-
MX2D>G'.MA2_-P8;W6?]&5X^-E#_\&/6*LI]9+)'AWD]4\#V?;('Q1O #VUV?
M-1]5):F>5(MENP2#(\)%KT^0TZQY'03R/:G4M=C=-080^@[)$ 7MA"&$I8"K
MC#48P!K[)Z E,(@R#H0')$!1$ L<GIG'RM2^OU77<R88)F->^I$/M*',G^Z;
M*Z#0#HKT0<5N.W632,/7ADR51)OL&NK$L_K441\R5TBIMS& :2/OX[3<W25"
M^029$OT.R9^/W04AX7.*>=>AWM=A\5=O,XG/[G#A!UD( ]5@7U;$>WX+,=K[
M=4.)B;#$],3W=\FM)'M77! _1$E':AT>>UJY((<-?0" QBP8 <"=T;PT['8#
M;W[P=%^@4L0 DEL/#5!HSY RE,GWKC42PO9=\?2E:ZHYO\RA%Q))-I2>9V>O
M5CONQ]#A?2[7[>D1^YY^<_I15!?_8'Y^."O&DR0H0#SS+"9HXH8S[%(;*>!D
M![&CZH3>[W5P)E<CW!'N8)US:0K]0\\H;RMXEX FZ*P'!?L_E,E<]07:BF$
MK1P_HXO92%,G6EK>9A%H109Z@]4O#Z'[[ZYO,K03AL=9:B,&EK1HFX"I#65?
M3 JO@B'M]%'K;-DVELU5C:-O$K8,G/Z4-AWJA+MQU"?\)C[E=6[=R)P^)\4
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M$Q BWM(:YLXA_F6<J9DSP;^?Z&V$9WHVK$$TV(I\9[W4/G<0QE9[2W%Q+;2
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M8R$*\;HNGIG*FWYGUA3?'*=JLHA"XL-Q>'@SY4;\>=<=3+\4YUP^Z'N!KQ)
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M"<E"0?,*BQXWSZ&Z=8P>Z5=,;OFWG!8)**W,18_)[=35?IW-K[L0^"/,,4\
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MW1U7:F)R](W)K*I(GH 4+V8B'8PK?:=)TGP>91*1*J"R6P'V9@P1GZ:?1SV
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M%+2U)U=J;DF]MPN3(,S9%+'YZV?>DGT5<:,1J?Q [ZGI=\+)=%Y@]I+&WT4
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MTQS@-O3>$$N5\[P>IV^R%:R_]SK%2EBI1[>$U'DJ4&'@"=!N)#JUQMTTT+I
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MTQ93?@#3**1&M3;(2;WL<Q&=O;;6(G@U>YL-EXCB)ICLT.I2->YCAU\ G9X
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MM4Z">X>C6;&OV =I5"6<(,@^16)?]EOJBSQZQ#T5L8ZGI;[$.-5C/M"2[EG
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M+\1L/.P[]>M[1V0F5^D9N^SRT 6'7G^ZT >JH-_DSP"GIVHQZIG4H,PSV[(
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MU=% >=VU_)93[,F)"O$]=NM_XI6O'R:31.A,JFN[TE[+J5771)F0J'A0K3&
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M#@@C6!/H?2^73S+_%J!V4RU35H3+$"^9"$2%1W-K [2Q"[AB+#2LD44O\*@
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MC-(6]W*T^Y=TN_,BOCVK:[\&L8CSR!L[I._*.A1M*N2,SKJ,EFK4QC\TO.,
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MS\TM?EY$<@^XV1\-,(<AC?*(/A(KFM$\1\758?B/&$9L5/&^R%+-M"ZCBV1
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M'>ZA$NG?1C=/4'1OELN) +-T#CT%^:!B;^)1EU$GLUQ(0XG )48)^:_OJ,%
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M:=>^DBE*+;VJV.H5CQRMOTGT _?QB^95._P%"/E\UW!>P9R$>7TL]GS4"P
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MZV5DID'?S=IV)\Y&)& (\)4"MO,IW[X=_4D?88KS(GM ;WA@$G!^1W;!D77
MO9[%5LLT/6O@Q!4HKWE,5"C(7'/#RG%K<LXXQB>.90.ZKRA@LV>6,["V1??8
M\0L<),//Q&3,]RF> YI2K*==3%WIO2Z11:DHJ2]G_ZQ9'2J9'7#;-N$S I_(
M,7P(MI1%\[<>EI5U6&B)>:K3SA0%CX!OT4'E T3!SR<L+7!_/&>8LI4JNB@"
MSQN,?[IT$5G^5.A4+[AVX^F1\0BX(\IDQ7X$0.&4,@6H^EH?X.<NY LSVT6S
M:&HFL0,ARIOID2PT,0/J'RW,,RAC$/!"('^E^V)AMM8C%DA*X]).&W;9>L62
M[(6'/.T\Z6'QY\]/W2=+-MU'1. E!?:<P^/C=1#_$%1XVO_*;#],LM?,*5NB
M?I:12,MVS-L3G<[%JHTP;;]K=&U _3L]3K:(_*,?@=!0E@#EM28V^XAD^.V_
M/-K "Z'&/Q?_\'=L94'(@;<XH[^8<3#YX \8'2/3:<@']:1G/Z9L'*MTQ1WH
MWD<KK67=@,6]QV\E;2Y,J"7(W?U6WB7J0LJ+P3<U&62R;SZ\7@_=C5@K\_)A
MW5Z\^B#6QU!_K$1NY;%2/3YI]G=/]ZYO!%-X&%3R9XA%M6BZZQ)69<)@?[3!
M4</(":-4OS\3[X,U_'+V8VSPTLLJ_IL8XYQ7)%%P#7S 2?D?4> WLN,C_\MN
MS.4RF?%:(:/A(@"WLE*B/P((*6Q9CU@D7S[C'J_20/M+R&>[[!!,1@MX-9&X
MVJ_M-&/J PXS["1T1Z7O+W;[.&C,RWX-8^K['-MX&#A]##?!)E;F*7OH'Y^&
M7=]%Y!YFJZ4Y=('X_@SHQKP.CV^UG/JV"A?SCV(.IJ3YJGDP#'"(/<^_-C].
MH#YZ;VR8EE@R]C?GF<I0H'ZJ1')J1)K^ <57K+[T<M(#1[3M>YN$%%V+A17F
M9X$GC?:.W#.3O3^K$2"WKM,:@5#9 [R*E6;O%JZ(YCR=G(GNTGWKV!TWZ9WU
MIA9::A:'*,QG1;0_8ECO>O$&T?;/8?-S(!=6$.VAV7PR8=0D(?%7^V?1EU6&
M,Q&&Q9I.=NI_WNGF&E>C'', :B\%I+Q?>:ZWXDW<3.A JG $OHLRW=OTA+@,
M1./:3%U.P<F5WBTWQYJW63#-O<-[95.S44\*?O-&: !/.2O/>;14.4]8XY?6
M#7 P'*32&T<E*__-MK0S&90@I?HVG3K?D_!?='>AO1RC-> T*C^=.(5,\;O(
MJIN&$G?DZJ:ZT##62E.H%&S')LX ]^=W2F%DW>;ZL \FPL?O:5^5F@-KH@.E
MA8!;GED47'(WE!DJGE<W4L/HSS#KX&5^2[_:./>+E^X2^JHFRGF F\/Z]+"&
M$-L<OW;U%3T@-(N2Q#Z,9OQT[A'0DVN$Z7E=#B%)C)^9FYWM(:M"\W74RS=U
MJKOH0?A(/0*>?RSW:/WV"* 4:3NQ#51!]N.15D>U?/;AV767@?)DR9 ] G N
M"Y:,6&R:/S6,;SA.1-@TRF\_,+B/BJFL3+96!W?/?M5D%4C#_MX(Q:@RCZ\C
M7[4]H&]Z J!<<)[K@"AEXF4QWI^%7&EM1#+#2@J3[]$.RXJU.GL&8M#7K-\P
M] L7U\GQI;)#8*8?RVK'D@2YIM9^#F^V0B)).KC=.B'V=O;I=4RHMU8P=KR1
MPMR;EL-\:/UO;O<_$0C#R[? BMH.#XY0WC1(1F?9XK57,JY$,CR7=:@06R,]
MFWV\8IX$J13I5[>H\.#:"FU6UWT$0#@C'+)//B+/!SG733'5&.P78[;G=,X4
M_M?TK2U?E,"8X<,T]5LD/0'6W2?WD0 )56HR_G#0 8$:9$%, 9\S@4O2M9SB
M)QGI[CU0(<C<_%LABSPM[;\C&^N$5QK,29:2-"1+L3./  4S%@O7N!>C=57H
M(YZF^L$7)\NTE=+36+[R2]U+/$Y!U"8;$/.N9R^==:%[Y]C$N7%^HJRDPA1D
MI%_D<;PV-ZA8RI(@4'">H4W<"$4OI=0KJ6G/>C+.6GLA].QN7KT&ES\[@J&V
M5E'4_-_!%F8(.==OYDN.2O2B"[>T*7FLB!R3Z<&QNI\&2,D81:A35I;O!AL:
MY3,1#I&;J(>$UF+P9=:LIS-^8DN=EQ/O)TM9]HDXA]X'SI0H/ W#-$7TMF.Q
MH(^0FO<X$:*VM\..HH3#XIA$,YD0BI\6P:O6\\GSYJKV>)ADJS!/Y)GQ<=7M
M]-->&QS6S&/ENSBH%3$H95@Y&*8BH1(Q@,H*$-"]VK/,F"LX21!8:U&6/!LR
M[V_("^BQ*]RNZK,5B*4:M/W!!/QKSYUN]J%9??<B[5B\!4YW:;^=^J-2G_W/
MYW\L<VT G+%//.DET9&H8'OY+GN1D5"33IWX1?&I0@^J$IF^MVX!<OXR$>_I
M3KYSDZ''.?GK%H4Y.:8;9>4\ L3Q1+'%S,;Q09_L7%AW'D#9%U]?:KAXP<0<
M]!OZ*#VA8V^3$U5S-VVQT$)QE=&,)86*]"UK"]V-#Q1%W=SW&=@II\ID0C1.
M*LLQ,00PU\19>%>*YUFN%,%\UE($7>1U"5"4,"E[C,'TCJRHMN'2SB'_V _%
M]!3ZC\@B1P\63)7?94WBI/5%OTR:2O8NQZN>@%8BQ#%W?E*SY!%0ZC>X)V:Q
M?.N'O4L^@:^[V 5ULB)J<)Q_WA=9DVB)M)>\;J.MPYA^GS^W$*PH;S&3Q%-,
M[()A2P8X$1^Y?M9,T=["EZ9ZE#>54"B06$ID=^&CO9P SU&M.WG+QDUQV*,,
M$X]TN+%,XJ\-_U/K0<LC1_-!AD:,:5AJY#?\3X>%ZB!$U3GI8)T>LQ39V-+<
M@&HN<UC>F?AAI=QPF5.[<&'P",A*]I9LJ#+RW%09.RCC."N6F\6H*I!YWS:W
MCODR/E.<6_<-R(6J&D[V!=W_969/1KO?\=P#T;YD8CWX&>F/XOCZT]:)>VQB
M$VMD( V!AV@P]X.3\3NST$1>8O62&CL5NFK%M6IQ&[X)YFZ*AQ:KK>C]PZ=6
M1GO+X#=#3GU/$] JNJJ5ZG*::RXK5D\&-/&\)[QORO;*FC&X4 BFYU% \KU7
M\V!_\,>46FB5@/)!YK_^/^V]950<0;<N/#@$=X<$)UB"$P8)! O!W0+!81A<
MAN#N;@&">[ 07()K@. 0!IW!96"&!)@$R>5]WW/N/?><L[YUUUWWY_?C6;VZ
M:E?7KJK=6[JZ>T.OS@32.?/8U7.IQ EQZ.@G=I.S#F1'OV3:H*1#!GZ<!I.I
M;,/@G6-QB,L@Y765!#KOCB%@AD/29+A'8J$,G\-56'/*C9]6=ZQ%?69;MU7R
MD<=3C&M%AS7J";0"/ 3_6"-PY3ETG<,!T$$D$W9<_VN__J17I 7%'0]NN#3>
MA$]:CPB7WVX381+\ MZLE!CA\+=E'AMTUQAP3H9$/U^^.MQ%7+,^!\JHY-:9
M,V;JFVZ>[+:H]=YIK5JB.8QN<^__M]=9@0_VV]"D(N>TPK[IM7U[$$@[G9YD
M_0NM;GD4!VE%4,Q;;]ORS+1?R/2/^CG:I?%/_TM27;+0]_/^H$.YISY4@(V$
MAR.P]?[PMF91&\M7J/BVFJ?J\S]/@*V_6+,P.5D'Y9X&_1LAD?/[ZG_5E<]L
ML&;Q)*F\^ZU776S(V!2$MZ>2W?=0]B(>5\+Z#^FWI(C91SY4&-.@(F(@.QRT
MTK-T*U3FG.,*<#KW/K1/^_Q,>*K\(PD?,) "_1YC+*Q';,82G;$6@NI".!8;
M2IEI1;TE7$#LAZ\,FE*W4(;4Q3,+8QO]!4"P!VZ=SV. !+ ^O)[S$D>&M_$+
MH9S@%]_XO![3]X/C11(+>UN[E3!UXL$5':'6V?$\/"7UCJ9^<:*KWG>F@RMZ
MG_-9[.IW^42UPO&_/7N\'>K/+-]@<T\5,S3SAQPH\C"S(+=["8M6*HP1H0&Y
MF$_]C6$]HOB[Y&4/G%%)# C%U*G)XB#G.'8SRM:\_@*2C4!*TE]#X2$PM4 9
MUI]L:-"#25K>NE5B198'LX3,QL&*;BG-_C&HZG(\R@=[J0([O\/O9?@+&!!K
M_PM@K)##OF<E*T8S#KT2DO<.<)5#?4,X5OG^DU01=G"'7TC_[Z1E_PV3H?"U
M[:JA?0.][1#B+,LNDA1PV*_?O&7;*4/](;M*R)5[@OH^](;OHLYG)J-;7KF8
MK5_L$!#K%5[;O_( J]X^B%()[9 <FNNA9,=G34?SE(3[/_=C]$LKZIX$^;V,
M^3X-9D&IWIM(EB-NZD+VK3B1C%Z;/"W5OZ$P7E["^N!!='[\2P( ;MF]$1=E
MDWH_@O6/>3  6,4C E3:&.:%)<B< 8;6RQ'$=<0OPLG)&&$-#X^* 8[TY\<F
M\11JEV++.O),6K>\K#%%O_[G7+JFH'7E2.4.7R%G_GT\VGA4#^Z)+*OJWEK_
M)J.]C/'AU?!?P"%5TRTU.H025PL+#:;SLV#YP7J'V?V:ASJ9X_9!R,:X^WL9
MN!</_W')C'\,\GL(/!(Y(W>)^Z_!S\E__R>=IE98H%C1#=8_E@UO@#6F[-[6
MDCAD.^_!J4]: 2L!/.20Y;(/:YL :_S7VKJC!9"W:OND6&@76:_N&Y8UN<)O
M")XR*\DRI#KLA*D($^WX\8!;Y9^]/ UD1C)Y\==L]Y'4U5Y;>.>[J\R>-@S&
M5_ *?,C3\HIW"P\AS6?L(895]O=_3P$OW*/+_P*BV)$_[R.UB/[QO]!_XT)U
M2KH/"^)[/Z/9TCGK/9E@(8GS)=R,)U<@6APNQA>YC7&Q$S\9L7T0BFC__980
M>6J&ZK;/<!6)2/O(Z4NET]R1I^7MD7Y+A\0^,]7"AG@JRZ@[T?QS"N<>>#[\
M#B2&E13VH;C_R3-T3J-=P-B$75H!N9\%"\!IFONUIO%TPKBCK:E=U8;H?4$U
M8**>@:?\66D\#^#_&*D?=6<QE!ZDXE^8W_:1_#.+]7";B+8 =)2H_A=4Z5@R
M_T.1JB8O5K@[J2C@F*><&TL4T**+2?K:%,#S<$&B/( I;T7HN68Q9CPO%J;[
MBUG,N7\UX2$B&'7$</QO'H_]W^+"#=HWPC 6]A?@P!I;R(Z\KQ!/:W!B$!BY
MRSI]E#@WR7!NF;64%3:*_WB7<G8[L8\Y>'[Y+X#TO,>RJC$"J-$H%^G=+>.@
MU]ED%L)C/,7I4,"@EMF7_?G-:YL JB?Z*7G=K,E%1 ?H"63^\#U!A*$&&6A9
MV.EB2Z8*^L9#5;Q3?[-(_ 6%NPRQ9S WFJ >4NH6FR*7P ]G>8ZLZ(OFU)]+
M%G@#<J]_$5)NUQ[4H/?YUV#@&)X[KF'9S=M#J$9[HD,GLC$6T]$4F^5IB_'R
MQIK^O!U_K0\9Q6VHL*Q-CLL'P*G4B!)\"PH7PE."H_R1U\/[YT/O7=X^Z6RE
M,,$-HNZ97H'UW!7SAGOL9NRG1Q!$PY,[;SB.W[>8YBGM. KT;B"OMOJ)QI0V
M=25S?VR0_@J58'U^K]C_VU]2:@'5=SI2C89?CXFLH[N@I.C7@82TX1SDAP?7
MY#4?6_O_ E1_?\BO^?P1(.[I6]#/+!0;XCA-./1>(J55ND!"'V2)ZV0(74*I
M[DQ=92AQ?)H-_PL0P8D;,%P;WY&:]KKGN:MKV2(YZ>5H2AG89%\4 (K4.G79
MM];(9Y_@Y&V6:Q#M>)>4RPL^X:\FY+$VYF$:V!%:C=!'^:;MR(BBY_D8M6@A
MFFM#IGDC9=&RML_7E=N?T^3O8IM[T6_<U[T;X%BX5;L1/LY;EZ-BCQBEN8H8
M;7]A\2UG[G;(VF4G'!C2R&+EX4HJ[6Y\N:V-.Q,?XI1$.(BH/=8UWK" *+Y<
M4DYH@,3C*I(4>+YQ'BGC#AAA?)W $4\RJ/GRT5Z@S<Y6 M "SM@'-634HCIY
M2RM'<LL+JCWT.C2*7J^;=O#S$/K84U<RQ=/W[!O&!;5-UU<Y_;OLZ JGG0(
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MB3T;/7FCS!U[CX>^VNE/.QXR_()\5?BD\%C<C*^>13I!/4Z PS8U^J<7EOC
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MCJTU]$Q2715ZB_ 1=+R70%['NDXWY#0<Y26-Z]YK5.SJ]LXM(@RYF9*#CH2
M'C"$W+#X'^+OG55K)T:$O0*RZIDFZ^\CO_L?L'3(9F7!W**7[ZD7IT]-,U<T
M]EJ"S;/%GR5[?#\$[[AN2-@LLO"- ?VWY6BAM^\CAN_)YGU$F+_75"C5F1PK
M+Q\H+PJ0NU_7?(UL:S<\-,=]<_Y\5#QU.%Z&?4N@QZ9X\VCVF.;/<I%,Y/SO
MYQ9*WDE4*3/?&D@(MI&D-D?ZHB%Q]Z0HFIXNKAQX :WNLND:HDRK99$MV\NM
MHRJ/W5"@V9VOFVZ\D1KMCX1>#Q4Q]H#*G@[X;S-SH=&U;SY'9$??WW-3FE%)
M:I.GPWTLS?: 8-,+RZ@0K!X3F!O6+4U3/BR@H;[,D85M00QRE@?E,015+[[*
MF&"J2/2D'O!>ES_ #)7M:T&W;N>?,.M>;(UT<;3EF<6>5UDH"&37><JGM;_S
MBDB\'!CU,.[EORN1946K#P3SH5[U\BR($4L,43 &:3NUZZQ/N'FDUKI^2_3]
M-F6@T"8%W$F7Y40/(0]&W_L-:+&<%#Y&9EW%57$/TGG7E':E+PXX!+GY&IN^
M)!(6'X<KOV/TR@3D"!H7J:(/D(0CK.1LZ-IZB.* 4/% +81=<U9 U 2GM7X$
ML6XT[3E%(T44H,MM/"1-]/FIK$XZQJ5%55)9-ZJAHHJKJEBM8O6HR>+%2/59
M7[S"><\DR48-R0Q_;?8$YP  H%D5W6-3 OD&-4LB-&Y:?AQWV\DR"N/$W]H
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M5TNN;6+:HBL>/?.8\S>M>%F2M"6C$5-V$2: & \!]_U-@\-V2LQ(=%;CL<.
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M.RIA%JL4*YRF<?R1FV/E*OU:=5OS=/#9F4A@(,GSAD'FMM\[R5Y4JB[?US3
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MQQ-#69JP!GO(!^?G>VZRGBH:#Y/C%Z6FVI9UT92GKA-KE$S5SC^HXZ.I8]J
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M76)<'>6S:$"[V$HHF,_L2.P,K]+BH><4#0_7P8 -X]VC%\'.SWU^K315G+]
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MAO=G1R!FI_ M?89]_(S55]JZH3W% :;8>N!("34V:2>DYAJH_36PI[_5'C4
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M99'MF:7&*KU;Z/>>-0ZHG\:IH/JKQ P'("(U@NI\I&.\^<UY9!4CW1]_24S
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M%)OIZ0[M*%DM7!DYA'/\>>S_T)XNZWKR%+FDMUD7%S+?H9)79!BV7NH=100
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MR/=7PQA$4;058),,RB*6[3Z+[UFKVEBE6))M0O3FD!'?URH#ZM/ST+/N^T2
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M!M(&=SC:+.V]ZXV_+Q21_%?PYX@]D(4A.ZD*M,ZDW1%Y/4Y'ABZKJ82/.+-
MH0GT47/N#OY@!S]8X;!K.:3*M@=ZS/I4%?C/XSHG@A\V>3:PAU)I0&5J&Z0_
M+Q]S9.Y>-]3HOZ#Z@+XO=9H(B+717;O^*7YLZ^,32AW1QV'J(R7%3B>G[)AB
MS54-L^IW[U+X$P/Z(0H>(;_L>>_E?D^*SG@C]>SI/5Y:/W2%"48WZ9O.-^_
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M2XED8\R.&,]O92$9'$ZX"#3))'EML>!RMO<-1E+7>]Y?_]X6Z!$&MB$E21+
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M9IBN(6FO8?(+*Q^98T:1VQT\LD]17MMG+%?6D%RJ$+*BR*'7# $9&1V/-6,
M4M !1110 4444 %%%% '_]E02P,$%     @ ]3ET6@#=7LM1B   L(D  !@
M  !C9W1X+3(P,C0Q,C,Q>#$P:S P.2YJ<&><NG547$$3+SA8<'=/ @1W=TGP
MX#*X! @.P9U!@CL$"!X\Z(0PN 5W=W>W&72"/O)]^W;/V?/>.?NV[NU_;K7\
M?EW5U=7W]//"\P8 3TE.40Z @ @ (+P\@.=EP'L $B+BO_=%D%]>%#04%&1D
M% Q4U%=H6!A86)@8F)C8. 1XV#CX.)B8>"1X^(1$Q,3$6+BD9"1$9 1$Q$3_
M.D% >FF#C(*.@H).A(V)3?1_+,]_ /AH"$@(<4@(;P&(^ A(^ C//0#:%YPH
M"/\1P/\E"(@O&%^AHJ%C8+Y4J,,#("(@(2$B(_U#_:(->-$#D/%1"-YP2[\B
MU#!'?>M"Q!.<E(]&)U/32:PY":7G_>0:@HY!0DI&3L'PCI&)F86/7T!02%CD
M_0=9.7D%124M;1U=H)Z^@86EU6=K&UL[-W</3R]O']_0KV'A$9%1T<DIWU+3
MTK]G9!84%A67E/XL*_]="ZFK;VAL:N[J[NGMZQ\8')J:GIF=FU]87-K<VM[9
MW=L_.#R"75Q>7=_<PO_>_>.% $!"^)_RO^2%_\(+$1D9"1GU'R\$1*]_%?"1
M4=YPOR*0UD U=R%\RQ.,1B23E%_3B4['JPDE_N0ZB4%"S[?) /M'[3_,_K\1
M"_G_Q>S_)O;_\%H"8"$AO!@/"1\@"7C4*HAF OQO2W):$ 93P?]Y8>:5LT&P
M*8@&,/V_"NM7^#+,31%.#IW7AY74$??VIF7_E!BW:TJVI9X3FO"DS)FQA/*F
M_*D^:\J+? ;@^$O"+#J;T\-:-4I+2@N.T CL/3^5AI#KZ[E65B*]H@I!^(&C
MO*G6KPR*)H2OH5T9MDF8HJ\_ SZOODJR(E1]2R"4 +#$"AM$>M>Z+??8<*7B
M]6=),M:Q5=3K&8#VN-:!$QK ESY!WRR6S*4RGU2#C:Z/TZ<U_CHV-.FX S<0
MTQNTF5-2ZUPX7/9MCG*T7=#W:VV&M6C#^"5M&G#UDF?[#=X7(H0_QY*_GS)(
M4KPV3^G4IL#NM/C-\ELQ<1XE:4]':(6LJ.EL5EXB5&[O%%&BZ*\!/?"L>^NE
M!\Z9<W8/VE=V7IC6!<\ 9Q5ZP2_5[.US['!@)_LEW392>+^ZW5S^O=4AA75L
MP805=*ZP7@W/=@F_[?[#6S[21/+"[-A]&\R0-M< UBIXU#V;-^Y68(4'J,I@
M'9T#4C3)$#YUO1%5.2>;] FME6FMW)4K4)TWGJ4^_Y[N06RFU=!^2['*@ZY\
MV6C1I.^X;.3MO4KYMW +$D_2)<]D^;=!8L#MAE/G+173#:>*K?6(.9&&" C\
M;)/".1HT6=K0HA%8/R5GX>%8'+YG% _,#NWU-&%_K"*X[UX3J)FX6G5=NY4+
MN5DY]JR/>?O>Q1FCI>:2<,CH[(U7/5FLF270V.V>TE^H:4+L?;X/Q8PO3H,_
M/_G5M[GJP$&B+FEFKAZC2L,BA/@)<1$7 \VG81K4Y/.>6J:Y-Q$]7!#?L&\&
MD&.["Q[D9(\@P;1:D2#RKIT)5(22IX4:O6,#ZXA]Z%EQ&<3SCJEESK(IY.UY
M(+$%B-GO3-B,"]5I=N7!_K'X*B'4Y/4TA)FO8M09V#)=?6WA;$OO\M>S?KA9
MGFT'T1?0]BC+^,!C'=0!&87':)%^T.. _52,U<=S#!?Q+\(%^\_+PY0W!+]*
M< Y;2T:R[=NWZ!77*U<HAX=H(1<2=.G[%L:C'1_( OSS*IYFUEAHN&%M/29,
MLZ<///RXN/6IQ'4Y*:/.Q&=3DWG<J$-_@A09TK,IKE+N ^%.E%4FR@E8=O7-
M)FF91>F"FFKHJ22#7=Q<(7K.GP1VKG:V6JJT;H3@+N7KID;BN?F(:RK6?/50
M.P)ZPRKN&S/27Q^Q$#K/,[<?R._?V==+O)T#;;Z%Q=W4;;;9&8)/'6E.-QM#
M[LB5B6-%I3@(K8=O2\TDOR($2Y'(G]85#Q89J=%^]5#DIW344IM^]XN4ZQ6V
M#YDWM5%BD=EF!+)%VV>XW\T3M+V8AUJMZVXNSM+!0[2T.5GALXX]Z;*8N48,
M5;:C@]E^-C!?/W"0%M?!'5PC;QNH=R1PE[7*?YFQD[DJT]G44FD'P(SUW;G4
MX>M8Z-\,3PW 'K)-KZU4#,!K:&I/5E R$3A.9?)^,RY16$.$T#]^[[KXLI /
M2$E,<1]D01PM9?TEAY,5LHC&?(E_?TX.<LN:)Z3^^E+:5+V^^0PX922-#61;
M>W%N,7Z/S3S\A27VV=F20C^$1%:FUSU$23S[N^SDK_''J69N0+_30QSYUC'T
M6N\>3R1(VY\FIC*? 0:-37X^@*4?Y&0/T1U,JD&>U77M.' G4&2B]]S1FN&J
MTRPU.\V1*3>[X.,E'AUK"S5O@A034D-Q$1(1!* A2P30,@Z)30EBGOF**/P#
M%PEN>Z^O]Z , T>(2=IN&FM.\A]C5FE.72A^<C?4L[H('2!*#LL2,G&)KV.,
M!MG9.V)N,<;ZDUIO5K1IF4#/,I=*%\)6U-5 @"CZ=8=XU$P):RU(,CF7_$A=
MQR;G(NA/+CK,L2'RJD(9SD\I90%!U?S>ZXC.YO]59>&B0;2^.RDEMYM"@A^N
MRNDO*QC'Q^TL&<_.]KE^2K6)[;>>(21+,"3R/8IC3"(.JCJ/JI38Q3/@IONW
M&@K<NI?".<R9WYBUQS<MI^APG/@*PV3K[%T*#BX3'6O=Y9A;F- ^U=-J)LM!
M)O%#+N',9)T*K=YL:QZDZZ-RZ?FE>N[7^FY(O#!Y]:W\8[H8 VDW&!UN\#31
M^RJT_%T;@:V;>"MH"2'C80U'8>7\(I?+A[H\O/B>U)]OEL^8]F/FN+9R  ?K
MO3<%MJY-D8TS[TUDSDS(0&]4Y^'55M ;:,.IHB.,8E_M-_0\C']5MK1AVG)F
MY[>-_RJ#\P^>7CI6_#8-)1*K <IF@2G6T7;<IR5-QM!V:INU-S5S8N;;*H;R
MH=HSC--51+_?LV_4ZPO(?:>WR@G"0)3K%_XC,;YYONC\9XT )I$./D@Z:E8M
MM"AY7\RK?Y0B3[V#Q[$,@OQPK(5(/51N;*\C5MB ?IL&M?*6><NK3P$-ICG]
M>9WF=-T6[07QQ.I+WC,N[C-UCT4*KQ#_%G<5^H'+ -T_36&,X*N2,5S&]NHC
M-(*G]U#XT[CI&U)JF&,:D:6;J4]&;G^I=NV)]XV^7@7>?)^ G"^>R\-_99H4
MNI38W=SP+-I&_N0H2CY3V ZG&_OCI<"C^*=SKTS^GMI?))XXYN2N\'7'##]=
MCI*J$V>^C5/V,Z ]?IN:U(7N57/I8]X#I61GBUHXX8**RZ:HJ$V5HWG:[L@$
MVT<*$D5I+!J><IW:1&V/'[@H\R"[BF< L;\:U+@TPMGYRMXP -AK0@-[%Z^+
MSNM5JD^N7A0;T22OBXQ(]HI:5GG3=%E7G':S-+2H>=H#1&)/VBP0Y<6PNVVH
MK^+#4>QZ SV-YGJ?.-FBN,N,QMTIW%_)>9*_058ZY510WQ'^#%!KF?% \",^
MKJQ=77^C/+A+%^%#E.@J$"\0')P@,O<,L#BU?C]WY2-!!9_7A%K51Q7(%ME,
MO0J_TD=;LZ9Q\.(:LM3:.WV<[NJ5F_N,\ 6AY!G00!LVWYN>R31Q+2,QO86)
MB5DU>=+6,GDZY=?X9TQ#J?:KY\;W+*&A_>^09T!(F*VU4HQ6&U2UV/:S>Q6M
MB9<AW(K9_*<Q>Z5:D'"2I<<J[:WBF\;.:YL.RX0(C>/,DFJ^IN1+=8I0?.)A
M>MUIT[ZD]5%$][A]O107\CZ<B98L(;? ;DG,:K[2:<NZV;@46T\1YDB[Y%C]
MQ9':Y0]H.\BI.K4Y/?&*5.HHCLHW8Y,.9P\.:6O$\^>GK5S-0Z->V+5D!L8"
M_#X:.\N[O7N!5W)C< L:G*DA'(_UTP;'(ILGK)DZ,.+1&DT]S/]S (FQZLVB
M18L:"SJ=]%M>%A7.[$VZQ'P)+<MJJ>J[[1M]*-^M"4\B!Q@;'*/I4FX[:3==
ME3(L]EDT:FK=*YUJ*I]EBB7$U9= Q7!>\O/Z*WA"9S-IF ?:-64<ID)#R)"H
M0$>*PQRT6<Q%^1%:1>3M1.7XQPS3$G&\+R\ZY4%PZNH6,LVOO)R5(S.&>.-K
MU. 2N=,<+4STC0Q'9]F&D7Z;O!IXDP%__.E/_YCE+PW#E)[:-59:'PJ96S:H
M3U[IIZ\M>K,F@/"K^-91:#6(AS?S)D=>OF;NM1YGU9O6,"O%-.$)D0AYG+C0
M5?WW2 M!=@DQK90%WK?=P"=:&$Z&<X7-/(S,R>$,Z*I06G-UC>R*AFPV@8I;
M\B ,BQ41Z6?L9?^\M[<U;C4[<^>1>YU]*N& 8(&)1\NUT"4=(CPP>"&Y&-J3
M*P*;JX&]/3> /57]7(8;]@+O^-M21^ORH^TMO_J8W\C$M1F'.HV+?I%#!_M"
MK;O:1#LUWA.W%U8<X2_UF?TV5GT\"QS$!_C8&"8# *\"1H/C5K+WX:@;UA'M
M%+);EA-[,S\DWC8G/ST6M_"0-B4"+CGDAWH0IN-%U%$'/9\!$+5>^_7%E.XU
MYE"]=.#\.UCQ7!:() <%8I"Z&NNJT*[S[6,8A121 )?J;*#??*&_)'QWZQS/
M6_G&=R:KER0S'Z9;*I%765>5R9E+P+RCOJAND>1?! 3@9GER<9OD%#\-F;R:
M]&>U^J'/4>9L7WKD7*GWL3DTHXIC12A98>49X*VP4?'*]#N458YVL:'3D\0$
MY_>TX[E[!2?Z*O]-NK.5]T'-BL#IA:36&W/ZH#-ZZO[X[X#=RA)XNOF]^GLK
MQZU^&&W0_G1ITRQD.$<$K7"*]K4A&^_;"&M7VC>+C;IB+@E^U*R#?*:+H$X1
MQMZR)WK&F]GQZ,^I>[9.=5D9[-T\#EN(3WI=4 D3UKE^(@!$0Q9 I&&"?N_F
MKP>C[:1=3.EMYX86']DNG>7>?%K;4K9LQ-PSEJ7TC\?(KD@:_[B7,H'K5]"!
MH?9 S'H3"Z"%?X1LGSZ&VCX#>H#EWN-/&(RPFD!T;\[>)=*8RL*.-+\X4?VX
M*T-K&M_-[43$#B9+H?[RS.VJF%(9]VV^QUNK15%!\*JSAD"R8^T-1O3#.V<X
MB^DI%7<"V>%?R6N$EUBQQ?3?3X5/\M2BSP!D@;P'68_+-\:T+7S S3<OL:3D
M:7*UU:+4^NG//Y4P:*.L V*[_42(+7K\7UP:(Q'N@2>3IE\+GS"R[N7WG^2Q
M10\?P_ZIU"7_U?;\XF_^/]N32KL'GFJ81CU1OW2=&3BAJ>+A5^&=UL4N,K>2
M'FM3/S#^CNL'08YB9Z_K]A-&^KU<^G:?B.?Z/6 )!"/^QBKGZF*,O:_2^6[M
M%-SXN%#0@;[\A)%Z+\\T_O#.P/;.YM\0^,^ 3LT.FWT'4)=%J<5_A[4=BS6)
M..LEAMN6@CK5G@$V@V=3PJV&GX]4!7I_+#E)?BP6U7L!]"-PLCY=0@HF&U>9
M%/>;]2 M5O'Z/CN 1;S2I\DWQU0WK^;FD=.I ]I_ID(,?^D&5^&Q2-#BB9!:
M5/+F/Y/)^ID3SAQQ2DC<JCF^'<<=FI!!*%VW%C%-R92J]]X-37ITD;;A"KBI
ML_Y _)( *&=\H.&I\9;N(N?#E.KQBTL%O& H#9Q<> 8D]:O>@<S^D2Y(MML9
M=&T@G7A<>?$+]HZ-GWF0XN5O$;UI/(TH]27!-JJH6K<LG'!?KU/:Z1<H0K3W
M" 8@&)$;>W!)<HH!;<LWX.;K_]JQ![9-+4I[@_@?I(?/ #@CZ+0%%KI]>_IJ
MC036$>G(+XYG*T@J0^;>R+X\(A.LNJ,.BH3)3B1,#S&S;H'@S/NGO##4&WMH
M7K!S*T*%=+&177H#URK?C8;1N?8'%D BE6M_L3JMPZ1IZ#, >DV[)/D402WY
MXE2Z+R;0KWD!4?8T*6&/WFI8JD"N!'Y0.'U%6;/)8OB[B7V1MOEE7GC_F4[2
MECB@M/?.6R)"^A]0%N67*7U)@5G]3VK@S7\V7$&_'+DDJ;]E;Z4N<XP\SA9T
M8._\\Z6G2=A;9UA? GF?7@[!Q':>9;GU/]=X'Z4$ZG(I-0,1P -G7F#%:[/4
MI/7YP]H25I58H6>X_TBAL#F,;F>A0876-Y=-O]\%+$'RH%KC"1=A\;ADMEX\
M'4@4#+]_2<K4X>*C3#[V0:/3EQJJG@$#C\T%'?A6+V,G!D[C:!3 5!*^!<(H
M4,KZGX2UO%^\U_I>RMO+T(_5F>SP-\J'\0=%=E6RGXQP<15[X6;76&N2IM2Y
MG([-$2OZ<C^^\_9E6^=+24<F<%?]2X_%3Y/Y@IPQ;.*7^086SP"IB@E0I\HS
MP);R./$US"KHZ_:^XZMY:F%:U^+96)U%#I?HO;2(,WYB>#KI U'%370SQEO8
MY^SRI'1;TP]UE%"?/XL:G ]$Z3?)R1/CJ#&0XV(IK!!V@G'6\9(U>]JJJ:.!
M.!O%1=Z;O>B'C[]?1D]YFN2Q;2!8]>Y6K4]C5.LH6"Q;<ELHG8J2W"A9I[F"
M$YAOBXMJH 2Q\"EKZXC/Y.0-I<\=K@V=$%LQ#B,O+ZL=]9_F$,.!D@_$I#>)
MJZ+@F*N>#TZA[R%"R+"$E$QE7#B+VBFY^(R+8*S[=FMPTH]_;CX]EMDL4HPN
MK\]*VPP!;J']@Q$XI2$SK;(M+JYMC?X8;-N8<+]76_AOB3Q-_(9TP'066,JA
MDK].T<<?80:SL0?+2[(5*8HL8Y/69P'$\.X-9S@S:O^JO,),';5R;SVO+,V"
MF>PD.Y"'<$S!I*M##60)CO0][U4+HB&&248Y;;7-@0M3JQG#B:/T*BL+,0J1
M@D2 #&P?6,;4XV'B&-\IOOV:[!7(MER:/"YU6[ IB#X2VP!_>P9L_)2\L'R2
M> 949WH]I7>:Z@*'0%!MVK\\(%K0O,I+2%7>*.H9[R)9P#AE4Y5PN-MOV#0I
M@X9 X3&J\P^XHNAO9AU'YO([PH]>&XBWGPX]\>]6+\<,!C4)=\4B7%5Q8A^3
M!A+/7ZWJ4D^..[(8R?E:8^=*LES OAG[\D3#&TPJ=.#99$<$8!F78IA[H+WU
M[;?/JV1<S;^;A5<J_1Y%W7_^X4ENM:9V,QG?5HNX\^J9;X')!YWI;BF'[J_;
M$'(9MO@HK-)]*#SOS=Z(EW<Q$12/G=OXFR0FJU?H3-9Y=3>SR>T.XYY69)]>
ME3P^QY)X)Q0V]"14[#$+,AYD<_C1Q+ZWRE ]\_G=QYP>=P#.7MJ<7XRAK7\'
MYW"C%F4(<20Y;>3=C&LG:3JZXK#2QIEF*Z>8F^[;">==!X;LGE/V6UPZ\H&;
M7H\&6LC5I;CW:">'PF)U67M'>*^08^OB)ZFC=@N+E*[+]:G2&;:IJ=/ML(>#
M0L=<5ZI"P9JKJU);*S;PZ]R]A17#",I"^I\@ATF^'T=L[2;#;@*;B(00K"O:
ML'?K EEZBM+OC1DN.\#V@8SOMXQEK9JG'$HX;8ET)V-"\H0]A44'Q%71'BJ^
M):5RT%_$\)DE5LJA4\>+ E5@!)3:,+YQ:ZJYF\JDI[,-/ O'4-8SR;Z* Q&4
M[)L$4+FQ>''0.WZ;/S[DL$3$'2J_FVH#WC 1[KS O'DM+Z6B_1/C;/!+0E3!
MZK,\TQW-S,%;$ZA#SOBCS-%A+\F*N\M2FS+GF[7-=56*BX4'T:VZCZZ+H2/>
MX<6K;P/](;V-Y^/\)I2>3;J-J2N&L1G8OS=^2K0%C5<Y'(DZ6MAYOUMR33WW
M,UCV<BXMKF==/'8[O$GGZDH*_H(("7,]0C7S^_SCMUQ'JODKIL6HQQ,P!"%^
M+\?:H:I,GD#,N2D(EZLK0-5NQ\#2U1[W\UBQ3CWY&S/I?DU<7\JOSHZWA*FF
M5N1S7E]-V9N]0- M@^7'^.D1&P/]/:&OVV']6CIG3CE+\I8(M2D)L"IJW2=1
MOV7SDF&>3BQSKUP<-<W .J6+68V<3]EJ^$]<Q6Y_9Z17+Q6=S"-*=I5TZ%I
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M27Y:I\D@:G:>OD UA3^%M)?^]VH%Z,*R7?(9 %)[!DS!F?D]S,43>CNP'A1
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M/_.OHOE7T]E8.NPB[/DP;17Y4]_ Q 6-=]FI"E^_VAI[/#S>XRG20;D'V<*
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MD!4(G!'?X3&VC8+<E._R_!G@B*=#05)RY)NZ+V0O%FOD\^F_.K2FN*^0U&?
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MR/;27^B+J0SAFH$[GN>01T3U,V#+YV'\\SE?SB;3KB]FO.#WC'6[$HW&MV2
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M<+8GG/H7#CY#DZZ%+RF:.KJ2.XS_V23-AD(M..%=>7_B[0!Q!^_@OM!<KU'
MB@-X=_I#I&E5%-Z]>;ZT5](@3JZ3IQB\Z!=)MXR. SX+&4T.X5R?LJJ"/=?J
MJ>PT+&KFO;H!&;.V9FH^OIR\?YO?AT(!=%J3G\=W00"*\?BG]]!8A-;&L>&H
MK:E8K$LZT6)8DUSZ!*!C\%VB(6J4UBM*OM=RNRC!\8)4@#I[Q5[^)O^9WBXK
MZ^)HS1EZLTNZC +W3+D)<\9;H-]2ZC33.N2#LMAQ&Z?R)E$(/D2Y:/$;2;YW
M_M1W?GERG="AQ&3J?M:BD@&M[SNAJ7<A>RH!K'!'">#0ZJIM#S2ITZ2Q$EJM
MIXT61]> \6HQ(RS)$I"8RRNQ_*X,(*S[^'ORI%\#.H60X(']99]VX;^Q$< =
M9:NN7O\XABDE*/JAH^^FXF!W8_NH9C'_L-IP?UB@,7-8'<K/=/2&$-VSHL<(
MA'D)D&,4Z-ST"UP7-58_IPJ^QE;M'H9EM(@7?U-FO^_';A[V&29W+OTR7D<2
M_6E76&,8EE,7"K(V)G'S946W5U/W-;4F7(XXNAQTQNM.TP2J9DK+&Y9<\M4P
M_8@!G0+\R5&9;7=YS]_W.;OG$5\=?]/@!H]NN5K/XG93;GTXGH^,-J?P9,4R
M-T12P2 E97\&] G7 RED6,%"3Y,#A6:?S45CKXZ,1,9Y/0:)->JZ[OP8/K76
M!.'XY5>V$)8<D((BC@MGW Y;.=6^:#:$GQ=X<-NI]_!X:1LF\;\V7$?D0ZW^
M=VU]>3R1[<TJP5D?!/Q-*>VFR;\0ZC+,1*^&BXGG/ 8@A&BY4_#-Z50#A^X7
MR8:%?W(I.SH3)PF^BR$TIPY!/[)"[JCE7%34,A):4YKFP>=KI0#7JJ_)LSEU
MLB_1QV>*A%DD\<JV2W<>?*WP1CFQ%:]UT9U?7%V$:Q\\J#17-4QO-@F%E<O?
MZ**=&H6*2:J;OI8;,Z.,C?\:VDE)59<\$B$U19.<F\,&TQBFI92ZM8*):VK,
M?Q??0#T[F466G#S;-/]^P]2(_]$Z^,Y'$ "]_86R$R32I;IHJE17G6CY[P1<
MQ[0%7#E:W$2[,(^D&&JFI6AGL_,)Q'1?=/[6?Y-4!VUJK&J;.N'@C?:UVLD<
MFK),KY6U,4MB9&3#_":#1)6UY6AWGXD0/QLRC$X].TF"OLKIR>]CW\CUN,QI
M'/:.3U[SM2PI,3F3C3AVR&^,^#Q%TQ"Y^B5-6&!F(D>J&>D]=75I">U? .5K
M@+<?5=W;*'8&WU:6D]D-??8$< ]>NOQ;/ FMIPT86M[;"/&/Q;94Q.[L_!N\
M]96WL\Z'^N&@_Z_W,GU+ D' .)ZHJ:22%WB$F&:B:(J6"EIYX(DU8X9'XU*)
M0XAY7VTR>1M>M53>>:2,HJ+@;1YXD9%)Y7A?F.F.NN*:ND4U/;O_PWYXG]^7
M]]/OP_L\KR$SR^/*Z2)0&QL+ZX<@,IN'/DHQ1MWWI[_IQ@<;.I9!!<=/^N':
M5!1/X'YW'9]QE'H#,!&C(0(F_UF.5^N#F?0 ,GW#/G]&44WJPVOO.P]^N"GM
M^Q6CK(/9GIP.XA,/SC"<C OU6P+8/K V#T6;E]FX/45&P<2)]:^UY(9/QH2.
MW84A/&%L[#/U';EM4&:2,_]GM[Z6Q&B=],%P8H[887>('H''9$0_YOSF5V:L
M/0@K&%M*>!^[;,'C08NN'MU;>8H04GL<JMD6R_!;([#Z=%,D:CEYJ)QQ*L76
M1TD<BK84(4KP=SM9;Y]QNCM[LT4G:F+2_@8<-QF*V*.6.2E$1#A95QTM+B*G
MHA= CFW%WAV]\9#M0]_J.@.ZUBD9L,VK 9PL$!*7R]GL"DUE!ZF'F)57AQU8
M-@0[)I'\A3"T\JLZ/3-'8:UD#D6>2(\:L-)&ETNW[>QQX;&L>I<=Y%:ULCQ4
M]?QA!4A)M#3:FS1PJ'OVK<980+>=;;6 8KZ%MPWBFD9UDV,7;;"ZDVD\0R<F
M1>7;&Z6;SZ=K4A$'?=:>CS6./^<)L6+&;Q7W"K*NZJM& !,_,9(A%1-DPYXB
MLU*XZKF"59+;RU9U17]:AU$$$%VAG73DXQRW..M\'U,4;DDF3#QQ.;;_95KH
M0)3B-Z'MYK"A4>M'P7NK\!:O2\\Z.3?I[P]6G<=77AR>>4?HO>'SY<(TGN2W
M=_$V/?'RP!F^A(I68XFTPLF3_;:(">G26LG>,'O0RH8XI4N97BD7/*MO6JD;
MZ#7NTF>ND%2W?%@WROWQQE)_^@Y(C<-._W[<?!K6CXL$+FS( <$2W(#D6UTB
M\]0>I_J-64^_.]<J<E]_O/(B#=;18?S P);R\%]4NK[:-I\0;R?<MYDUJSWH
MX\R3Z HW^@0[(6TM'6^;Y4SZ7_H%JN2/^1]W44I<"P9/DO>[:2@$;- !O48O
MFD005-Q]+H_)0FQUG/TH@/@P 9@""C/-[Y]BG6;ER*N<LV@:'WS(\QT&))3^
ML0U1RJ7)S)^7.6"H86;XDQT<JOUR]XRFEB6RYZ.T'OX-ZVN%%9_@+=C98I/J
MF]KG(;:/)ZB*<4YQFM>C:,S<#,US?P;-[ +3/?.,Q 9=WH?W+.:V+&X6AR\,
M;:]M"]$ET8R\^U;JN?ZOLVK!]$M%SJ@[*PNR*IESO$!%W2H.(.3(:#6HG68=
MY.KU;?R%@-(@>;=RR=?959%K&ZBJ<T=,="_'+R=?%^D-+ZJ)9.8EOP-^;&#]
M8PJ,N.4^3ODP,@$S_K?;(^$O6@.F/K>O-OO'7W<3E'#H_R#<&G[:[G0[,W(I
M?A=HU,>\W'R4M'(7 ?? *(>I9\$'/TP=D\NWJJK.4+#DML94@) <T>&#1C8Y
M].?"?PH,[[M]P;)R>3:S@=OSK(8\)#9 +P&+.YL2-1Q3!A7%UC:)40]]W^G^
M@>U$98Y\CK\_XJ%O.C*/^J!?B%+CC>)(R<E6N_F%*Z-I^[A#-<30*ZN-*'AV
M9..2N:G\F%'!%4Q*CQTB[>NC640:OU2\OKZSN+I@F)N Y<7Y25M,, 'QC2Q1
MU=#?)=F["TS^B_((>'9"HST3[;_>X<0*<5NYX&>#, U(7X>6$+0:1X>^G189
MI:_W35V_G,;>MG.S:<<'A'%AY*I?SV0L7LO$F-F^W".]*1Y,/!N6O\GU9'MH
MPI!<"M0D2Q6:7 =6JJ(."BOV*[\#!C^'UP(?.C1;:!&>OM>L?<*C%1\4]"@J
M0PRHFXZZ'JN@686/[J+8K.<ZJJ0D6:)W34P7RD*>?E$7W/P?1UJ1RUK%*%")
MVA,CO#"U38X)96Q&D2I!G)D!C=FJ5G+Q,<<;(\?4QV\@@YCM\.Q/I":9#8W^
M')J:5XEFD:IA*ZT5 FV)[(LNC#ROG>>VJY=AC['NF0VFUFRVS(U,7CB@^UZ:
M-$"M_VQ2!2AS@ZKQ ;>2'43.2]G>G=;<.4ZU=@V_M)R.ZLS5V)N+X/$6F1//
MSU\-H6Y>Z[J7'DTS\:]N%6PQX9EN*LMMETQTVM%RT/!P'\;:5"G@E(RK=8.-
MC/UTH1>M-Z[.+N!=HEXB/1O@"7)'Y;GCC250V?\CTL0NQS]\E5B;=8K&>E1P
M42K75;:F,D6-6$6<^&\OSQVIA  #GH#)0,X/%KO6:(+9.$F # *,DW#^_P3X
M?>8O4$L#!!0    ( /4Y=%K@:FPOH6L  (9V   8    8V=T>"TR,#(T,3(S
M,7@Q,&LP,3 N:G!G[+M50%S-LC^Z<(>@P2%!@P9W3; 0@@5W]Q!\< L0/$"
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MZ^,W7_3.='5U[34^FM+5Y+2TP/BV5IM[,YPK?%8#<X=L=J7^78_H=FAHIA=
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M8_+#AUZR%>GY@'DJ]?L;A4G?T02L7Z.Y-FM]D9%7 )PUC:]_!V@C #EN!@0
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M6?IR!5_P/><$9?#4F[DNB$X)4FQC9#9,07WP&.]*!!!6*8, XC2P\J=,O1
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MT-,0,<XNB@#SL$ =)LCQV*S[C;MASI-'%$_X<Z//'VDGR_&\T4<5WKY-[T4
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MB'B[OMMQVMUUQFH?V#69A]3X3@8(@.)^!E(W )>+4WM(]/WQ$^?U#5'<UM=
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MK -YM2/Y!'R9#D]5,/ER8&PW<'I#D@/OJNBZ^,[Q9^B?6!-9G]\C4=M37>0
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MSWZC)+ZG)'SU;8%[KB8S;X,AQ$\F$EV/_Y40MRE>&:_+)<X&[OQ9;2JFD#&
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M<)[J<U]1Z#*R';=5W79"W[5E<+L7)5A-JB^44%V\Z)CF,M+4'F&#9!D4<X6
M.RAOK]]UGRL##!W$V>]CI9!YII#3ZY,Y^O35]ZQ>69-F@OI2/18T,LUZ/O+X
M'07ARS9X5W7W)1,U5=S6&][?S0.5+G8_LU98RA>/_89OM07UXN]Q8#.5]P90
MMOACUWL9GOB2?;UR.[QEV<F?QF%CM"%M 8?">P"A'/I>HC4=IZ$7DZ[DU,)Y
M#>A5,_5XA)<#<_;!28J1+Y]]?LSL%NYZIT#P<$T1 ECP5T$ TS#.CBJ\+9'[
M6&JSAZCZG ?>L!")C*]#I/QYWL"G@K*K:I$V6$[5]X,C!(!-7^9&MZ%_@JVW
MY/#5E02-WLA>2N,Y\R.<(],4/IOXF*HKM"=*P8XW\PA@4V^@J :\'2Z;N?;8
M^K?@(OZY\M-?'%,5]O>?65]T1)-8UUKHH:,UML&B-XD(3.-Y7\&L2D?R%Q6_
MIQB,T-I_#WJKOX'&C$JXSM?P_KU':.76!#TLJ_>VH9U:*6P/2I<4&W#]:+E5
MG,\\3_/E:YHRJS1CE-7F\F#: !57C)N:?;"FT]0H]:*1J4.MZM7'$);M9AOV
MW-KL1\X<H^'?NM\N3@PPT.L?!%',/H%XW4^O+HWQ%#B1?YBX<EU%H627=EF0
M$CAT"^U&L=B:B&[L?)9XI]17[9,_*B%/L3J5_WQG[ZV/NQ$[NAL?(ZKD>)2D
M:<J --M<O?V:-H3_$"P\N3+!7;2-21DW]1I=GG]X.TT>]ZM'&.C M++(>#2P
MV-!X>4DHM;^&.=FH920Z)NQM]C:)TH9N8S42GIEU=_*E#XQXGRT:_<9^Y1PC
MT26N04G/K!;[(PR[FXM0_*JJA.QC3#ANGE(N98D&YN,$F>VWLUU'.9?DS>*X
M?="A^YC,] </>'X3EIPLK4]\U[8]Q.<A: 0!Y(]YLQ7]^__*.6VR#((&L#0$
MH/%043QU?%G^6W!_BV<2 3BN?-#5&56Z<D=_Z;E? @X"56O".B!;^M!-!Q+[
MUE^9:F-QM1*6N_I;28;\S39O*+?CWAW,>IB*%3II''8U>LU]7QURY\YW@10F
M*Y8Q)@)_',:O<-^_*E[UL\N\+6D  KH*[A]!3\,$OVE=:T-MVG_$"_SDI*U;
M<=G[$J;:\,J',,@Y^ZN>?C8.K,,7ZJ,^7X\ : ZNS/#'/R?1H7=3;QO[ROIF
MQ2DQ^8BNP?1*[I5)&-".Y"D44OZ,A3]-8_C$=#/?&8X &%6);J\3$8 <^91B
M?:F8:.%)YAQ;E].?^VM2/;%*)EEH'$%98\&FJG_^<199Y)B5<N0ORS<XP5G9
MV+<Q>W_N6: <!([P0S-RHQ$[H:J%8\QE9A@:R.K=JX02-*;LMY?5;_.3*^8N
M#&\8:[;A3!#P0.R*O%A],/E!IDOM>D/]IXK<^R\<*N%B*^-_XJ!G<1[E1%%P
M1M8(+_1.EKHLK>?]C*U&GK+,V.@1Z:-,^+^9T!((L6G4\Z;4P"[L9Y62Z;L4
MDEG&D/0!/ 3PV,A$'_1]26URLRE2I.EC6:9NGV]1[!*_=3*V.99<]TEF5T0G
MI[I[SN]5CIKZ)EV701T5:H6E,_/ K!V)'T9I$Z)+TQV.,=45J@H_Z\_D+*NR
MR'_I4ASX<JAYUY2FO:34=7:7O9W[SEZE^=5NT PP#-""F6RZXIH.N$DUEEM?
MG=)5C.+'9\OJF<M_#1TAWS/#D$0JC;K$OL2H8*+Z,5PK.\X15TXSQVCFQO$7
MKX:>T3-C?;6B*_]].>;7U]?([5.ZPE(!1&"T\ SE?T\P2+0!4LRX@Y \1@;G
M&(#J;0A_V^"-NE;;.%9]BWJDG^ICO#C87= XKB6I^&LK:.OLK* ("'38Y5GG
M1Y%".7U3Y2,'$4[-,\F:C3%:4?M<[BAR5G^-3I\K$3@ULV-,B$6KIR"+O2)#
M;&S6,W'#MNAS-XW4(O-54ZU!3YN[PG/.U.M/KY$7WU2E+,6]MM-F6[S\[+[>
M8F##)^-?31POV_I0 0E]<IOEDA"])Z'.+I)( !4%YQAR[[* FF8]5=T]B=EG
MM$=99K+F=#F/N.&O>.QMM&L<YQ*@ ?,HAUVZ*'[;C/9$<W[Y@ZR>U->CC,6&
MRB(999"&::G2O>Z>.[S7E+UA_ETGXXCE&;EJ^JP)R>X5>=@\2;SPCD13-V5M
MZ*_FH=<ACH=!%+"L0*=\59?-<E6:YMR,Z@T)F^B]YZD?"K ??2:A^T6)OZ$H
MNEO<L)$3F][:6>=5 JI6JFD0/B+,H%&T)FXTY^8J^-DGX)R3X'T3@NKO_!LD
MOZ<*32L"23H).)S=6%R4%=G:QW9_4O3)X,?CIT!/S,A*\.6:D28]]#;%3I=/
M'\S\=5VW.N#&4URG0AO&G&0T_!'K8?JS290%G<J@2BX>Z;ZTA'^EV@Z4KO"3
MBAO*#V5N'8QZR[<.(I%4'C_$][P)_QS3HNAXKD6/;F+OP6>GEE35Y#=6?Q>)
M94[61Z)OKO$U8PJY9G1N/$EP,[CJPI8T%QQ37+S>S&[R$IS7,EI2I<7!;LH8
M3<O".Z\C&*UW19%?Q[=R*+BGZX#L=GD%K4K,,6?"+^DE'(K?US$K=[Y6OQN;
M%A^BH)9]H9Q[NA(:0A",<[!&PE55OW\O]WW_-C57>?'$2=XBPQIWJ;<Z66>R
M<1+K9(E*HI7;CWV?\]>[3G)8FO_8FQ.&CWX#]>"FD?=6T7(Q$EZ)KK^G:'_$
M4=R,YNJ*#KJ9?A4E0QD,,$5>G\\0P-'M*!*-Y%?]\JP2V+R^C_Y7)QC 3:;Y
M?YQ\0>+(WIS((=54". "S2@U:JOZAJ3A]!::@P!DA5IDZ97NWAC9@\T(K4R"
MCG3JI@?SG&VR7L\DY#[>VQH/P5RC<&O;$5V_JN9Z*'YWZ>2*%2 Q(\G'>BJJ
M0"MMI.+B(2EC9XYD[B,\01MMPL)UIBT.Y9Z+T\6<;NKJ_JX(#WL_Z;3;RN6F
M]V()5$G,\>1GXV$J3(J,P7C/:?=*R;?6ZA^'O)-4@$QLO-:#T[9,"MTYC3H]
M.W81'&[(*BV(E[;62A80])7MVV,*,:97  (M2HV,3?9]'AD9JSIX,6,P-2<Z
M@!:JT BZX\(GF.CGSE*O^V028[A?^XU7>F/&.KAZYT ^<1'.%&:D_+1QZ;0B
M-%74[$919]8#ZQ[5DFFI](8F/_?S]RP3%439$E=(C''N%(3I!*B5.[1^S8$D
MFGQ_B!Q8M_DD].-36X:^M!&SR\NA(G\IW_DFI$4.[D4 5QBS,A<V'7[X*4.D
M^6W?Z[ZR,Z,.3?I-HG^.*F+=&!+\L*,&@)HB3[81P >]3:&BU+%6QSHGD7(G
M@OZ/(EVI%)C@]?-#/N.@U,V=J2 <)VE**'V1G>NF;\5N,AZV/"?E3X@;)=["
MY6Z]I 1$7146NVGB8=P^RUMQXKE&;/QQ'FR.M?-A.TU+[E9W;8 H#$X_(\E9
M#8H5 1LV5'U[JB T,&*>^VS+'J OJ0Q8,=0_V-(!*;#0":4E\(RUL4!YHJ:G
M*T-*0D&^(TV\_LJ'A57);<%X*Y=2>MWW,!%Y),-@RUP8SJ?E?3<X$(8''L]2
MO#_!V356KJG:?(^)%,'-N@!"OO45(G@[-Y*Q#,$Q</ J ST/Y%MQ5@7(57.N
M78S\N*,G2Q4,?O-Y&0<KC9*,N=29ON$B:HQ!/CR3Z%4_Q+GU:S9# W5GMN?2
M GC4WA!BPH<+X%OCYJ;,0HT\4?;\!C]>FY'6=P1*.D@5ISB@#7CD54+T;=-A
ME%5N0VZK'<3*-NBT8>(QYRMF/8OX7<2"M;>LF;M&OM]&#?I5A968C[?OP+GY
M7/;DLCJ:(4 W:HADZ[_"^!E>G<5I"Y*33P48)DON;D.BHK?@C'_'\VT!C<O>
M580J?]C1>NY)(2*&D\=J".!CNPJZB'8O8_+(RUJCWM=%64[MRW6H7<_QAM>M
M8J:A2KWAQ?9^'V0@J3V%BX?RG!1I_@9K/V-];DL;E]FUAF MDIF55A &^98I
M+_8\Z&J-AUW9<FQZQCN7!:93KORG&A_0T $I*<?1>Z*I2[REN_@7 X]]O%T]
M"'Y9KZ*./M>@"5*1IP&. 7\-S-2)GD!YN'X  B#!7D]4C^P;;6C,%$85L5VM
M>(>CI6*F?1:73,CY<2;8[EAK<,^D-FM@2ZEE'C_I]W?!F9_#%14SI0(\8"::
MS];XE\<FA$V0%%W71_L$A:"R;?B82D9NEQF7H&OWTG8^?K6HV/ 6XUQ;-?Z^
M>$=$A5]Z3,3IPLE>;7T,"\6"ST) %+N(,+[5+B4SZ=?=$#Y7!&"GHOY[NQ,:
M%_1:C]CD5SI%+=FG_I]W/\#HJ&W*VO=/LIXT,[UX#<%,VO ?L],TH]BO*;HJ
M$!HQ8'I&(GCZRR4VM#DI=3ON$S8:.GU!'P3FKS-5'TLSYDUGZ,^60O4UU]>*
MR:U'XJ.\$M70Z[V8R=CN;/KD,]78<)< ZY"(\S01+^/D7\PRTF*7O5<#@)>?
MYQ68PDVH<$H=H-'9,!\=HGVD9E!%HP:-BFRGL5TTF8C./JY\A=7<^7E8[Y=,
MFS8CS1MWU+CMN1FH:A\>K;O*]PJ<)[U4><E2R[E;[G%QP^$RQ[C T=]#9L"F
M%51RM.%C[H_^%E@#'"V=9.ZU4XUE_T?4S-SD/QQ_O/_B^,LE(H&Y;#CEH ?X
MP%((PUWS1RP$&9QC1H\_%9TN?N'$2'HI_S(Z49%E*.B-D_^5]KQ+@PR.4S1]
M^G<'O?>'M;&E7FJ!0NXV3U3X1FC(] >]O^=JGNU1,6>)L\5YEG8^!\%[!QD$
M-&:.TW9W-X0DRO+BVPN?4,\FE]Y;?TE/:BIC;8#C'#91+U,/YCTD%>TOFN;Q
MFR[TE!PD&RE/M>*WGVT/"<:]_5J*3I 7Z<M(BQ4=[.0:E2TT*6FR,4JSU-R
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M'0&()X2P8JWA;3:S&O5MX.,[*2TUM:K[CQ:?GRWF"R_/[$UY<UPR9EZ9D2(
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MQ5(T%60*?W)-)C.DQI*^OOB,66V3M?N'&6Z=EV*[;Z!JQ3?CYU$R((E8#U5
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MN_O@KTHZV%66LR78W?ZJ$<+T_%F8A68X'Q\IV1@ 6+;8%6*P-(7OKZ_]&7=
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MLF$B-)JJIDOI=%%MX WK'7AU>M/EQH=4[@@7&+K.SOO^WO J?Y4DCD+311/
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M-[2.7\\&>)7];]N[>DI1 L>I^/"*?V5'86@K=JO'D3]E20(:"7P!$M@<@.8
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M==&\NZX==&']:,='*'AX*I9XE"8ZI!6U63F8:!R%;)K2ZL5P0/#@C,(I1FM
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M,O?[+/+317;907MSQ_="HH4<W\>L0<0F4%WT,)S-P$R1Q[N+.W7O3E18Z;P
MS3Z-BI G1OHK7&@=Z.QC)FXV42""B4$..ILNVB5\(]ZN-6#PH*()95J(F.[6
M_I9;O0\&$[86XJ%_PKS*YS#[ IX1?AO^\O<PGBM*I;D9+TFK;9O'&W/%)@V&
M[H4GOUOO+>//F2](MKPX3&N/%/N)E20/6GT%.DJZ+7W^JI_KKNGF3+2#3YAD
MUXW+]9[H$Z2_O&QQ]?-X)%,5LKU [R6%DF#ZB+Z6\=<RM!YPY=$P#C.RLP>2
MWJ-Q>X OE23Y(KX.DRBDS*7CLR]S'*^B:\H4(D,2B Z^SD^SRGFQKKNXU6S
MATDREQ,LH\VI#<QZ0RV&TRF'(Y[A8-/BP.Y_L9A14$#EPS#F60UC]$ER3+&*
MS+9@78M:P4T-HSRH$TS,8EX2$XC<_Z+ _A=\X@Y/^]OT7G@Q"_4 /D%2X<2M
MP(B+,<<&#QQC:]5,/+*?89N3E/\YFF<Z3,+:!W</'WV]'<0JN<)L\-C_$_P%
M+WS./DO*$C\TLXX8/I)2U:,#EI!K&"C;_^#CP"S1!4,-%PW9HUNF%5&@AFRN
MYK!2<9@QXH2]3NL5T#DW1^]VQ0/'<I[C"$N1EJLT)9\1IOSG?'0UU?ZK?T.4
M;@48)&=II^D\L9&J292A6[+G!ZL<'8&7>T+U?DJN:3T746OFKM3YTM(%QBM0
MX]G4!,G(VP&#-IH59L!V_&SOIJAI1LM736;&26B*_I![0<_**-_?9R7#%HT,
MC'VUTL=7OJR%>U1::'%KV0^W=[0;L'-F;EP_4GG.6^$5E9@>*6HU<C9[P$?(
M7GG.674DQNY)DX.[5PYNKZ$ ;U)=&Y?JLK 0-MMMB!YS 92/0"66WUF+%3H@
M[H501*&MU_]QE2;K. S:P"JX,4FZE13:#!*$=0)CM]U(JZ;RT J>/9"KZE2T
M W=#/O$L->K?Q'A:M3>FU>W)'.UST/;7:33B2"+>\-K:UHE L(.I7,^Y7<%L
M&L^S4@R[-@S&]W-E#!&9K3DW7S6@/7PCYKX&=I41^P%'SH8#X.:%VR<J.#**
MXZ)-28HH<WTE>1*& /VG993FRQ&<A:#@ZS0&@R7,(H:/18GS"[I_V;FU@5L>
M]LJ]?JC!W6F_MGO=:>^\H[W&6#C,L%B8[&O9L!#1]$(+56??2.*20X'\_YB9
M&Y)E2MY\.:T&6Q^GR16L1#6"?.O;5R[9XX;;^?1&F(L<^L<>Y-8YOW#LAP0&
M5(3$VV@$WNMV<'AR?'YQ=GEXT3\Y#DX^^>#AVYZQWF3')D#^J$[KK5L4(*GG
M7*(YG6W4(ZCLHX24EO@@GA9ALYBU3!Y.E0Y>&)BG#F"<!_WS2@!#(B.[V^QI
M(KH6-'::?6GA2HO/3^D'>&>*QCUF@$IYJJB2?1MA9-)-O,$<0OM6/Y*VT4=Z
MOQW\UCWO!6>;@1-]W7[S_607G@4F:IQ%R8J7(1FN!68^V\(_D5N)B:C1M<E"
M86QHI*:AQ8"" .<%^;8880K!XH'+2B6C4'HA:U@Y?E-#@ Z<*B 2_?6&RRIK
M4(TA\ZS&:)"5IH.?X&B#_99UW2F C%HJL4E?LM<09H3?WV8XB@Q!L$L"XN=0
M0O[TJN('A6D_"SZE:_,<5@K_ 6< JTP,0$/'&OV42TCI=8)QP^%1BS7+2?6>
MHW(B:_N[NB.RA1HZ9FX%A!,JNN)FQ+=P3K5)=GDD5IFG[LLB<DQ!-JAZ0Y";
M<L674DARV>O@&CU='LF6,JXX_ W1H2U=!2*YR73LY 1L#.[6%TE@.*9@-G54
M8!><(^DPZ@G!2'CJF-L**?U0CO,1: ;,'<:L,9"BG"N3<R!C)@B@L7\&</)0
M7E#W$+1.-+>3FD54!0;T/;P+O'OASKL='*?)+0FZ@5JDXH'Z:44G""DQ! GF
M#Q'&R!'/=8-/=:E# HJN8'2HSF27,5'ZM-)B,B"JY<1<R<^+E1\,=[]"*QE1
M"@3/JKN$1@!(XC/RTVGS>#?&5+#*GXX$@W:#[AHE5D8:3L,1D6@HPS69%"]3
MP=Y]2XX*W$Y.',"[GMPC(F'JL5M)2_%YF^WR0D1.L#XT@7 :[)2O0?X.2;ID
MWO"8P\&/:2:#,(]R<\>*< [C$)8$CI\3UDY&U?PP+%\.![V@R\'-T&9JK#+1
M458YG%E!;6[1)\7(K.,6/64QP=+F^:\$7!#!R0V>R@(V4?.3E36:6ZL5!0,,
MSOF0W4#"BE'Q7PO1T:_2\9@@PW@D549G,M@2K$'HR:8+I;9:9%LKYUD6)<-H
M%L::;%<#+TPB+<./LHQR!(OJ.LMX<P2ZB:87I3&"BWA8H)J66\)U.&$P;%-3
M-ML12I2VDI$J^247V^.-+K@)":KI7 Y: >C(DM@%[B7EXVD=)*T&6IYQ8E?=
M;O0\L; NDTT)3&QLR[+OOOWNZZ;^K4D*-DG!.T;U.NV]^\7UWK0II!?TS@^[
M1UV,5F] =&_W^[&*GB6V=X8PK![#L"["KTCVAH:WRE?'^LA;*=G8+?\.KVF&
MI8T9,=T1#D.AL-) "%(H"&'7N!","AH#J](?CYMF-C$\! B7RO#([?@G_SZK
MF8FN,APJ24?<;[)DZ)EW/+LK8B3.N$FER?@832],80";X=55IJZH)(\/ AX+
M6@GRW*C 1W.+7$<4[Z'?<;XWFC) @7+D928.B^7R$C]P] C3AWYB+01UV;XQ
MOE&U:I&--3#&7-V02YD0;TI8V'^XT]HBGQQM_,RZ!DA,DX4)W H6$[G 'RF;
M^94Q"HE@12G'9,,Q^*DMH9[!8-<PBP8(.DZY#D366,-,T0V_5@P1F OAS@J!
MVGO]J )EF5HP%A#'>C88ZR[GRP@20;-D0 0?%-A1?1 &'/"Z3"*,>IP7A**%
MAW2G<.Z'8<L4%:7)#>P88S]]L"^CL&&9%DM.4+0R K6W_Z@K),=5+PS^,PZN
ML)@LF?(V3N=)1)XB&"4M3/5/4NJ[A=^X4K"V+?^,S$#K$Q0 BZC 1(ET$1U]
M9"PP91#,%/1.>ZE$P-E+M5C0UCFQFF&:"SN40'U]A'"=#,6@".)@K)0&RLZS
M@I^S;?4B!T 3R?P[Y4QI@874J<:"BGM>FE2(LZ)XKE4RN#)6(%N@3!@6HC62
M!_:_ZX-MK1EYWQI/A6,DH$=8W.GNVGM<B!3Y_A;=24![K?;">OU2U2Z&V,IJ
MEQ8*!2MHNYPLCOA5/*M3.:K.X?04$B\NOL]$F_5F$MT3;>[8BRZ4(@I(E34&
M,0BSB)BXRO6J%BCK&"LX9W,_R5&F0U8Y\W!;,*[$*F/W*I+9.S,VTFFGC!18
MD9I71.QV"7-&QE<6'7B^MKBPBI%A]0_2,9,KT/-)X)DO+=<"<S(E!$;'A5IO
MT9IO6IE= 8.XA#]+?8%U)B$+*R1H<L/:+"J?H^U*]-HUL/Q1$,9C4#, PS;@
MKOAZQ?F"30-G^G>>%R>6"'_GUV\CYA,<A@5.,!WJ8O3J S!V6."B8,6Y,.0M
M.$WE!3/UX[D,/(.+Z&[6(F;J],W"U3$+&, L0GG*"UB:5I H^D@Z!=F&88_9
M6$("A^&0R\+%BAJCS([AIR$,2V&ASA@<%#'6"!D(^Q@QX04]@<I=2,CEZUHU
M8JB7J$.$6[.LYD/[#3F)KD$JDFLX!44PC7J+JC9LS5>X)H8L)'"QXH+R159%
M@N\!QV>I(T$;XJ:60'/A,CC15[K -L>[>/'^_+-@!4Y,I=4A&%#/Y\[[XUCM
MS-_=O2X_N>)<W^?5F^5:>UPNHB]+LUGE6W/.NF*"B]'Z)6*[%_8/$^OKO;9J
M]T%80/SMAU^:BL$6.2U#_@D-Z2'_-L8WT4\3)1_$:@4#F*3?@#U ^ZQI4#6C
MJZ;Y-"=,]&Q+[G;-<2J>@L>BHC'TL13U,3Q E'0^GY&$R',=E=X*.)90(658
ML0FO'UKEZ\'.=]IO=QE#K4O"),D8\^'(,?^ =*S@-NK[0)<ELFG ]XT%-9A+
M6CRZ)F_UX+S5?E,SUJ2'-JYFS+N,;+AF^Y8K1I0VQT4)D\":S_F'5;]4  U6
M^2K]][B^IB68&##W% P[BN-Y/A8T&HX/G1 [XP^VKDE4X<(-54M,H 1>)/>"
MG?["1%ITV""\"M%3]8(:[(8+%M"_) \"N%]B:K!V0#=,3#]IEFSXL4A3_ ]=
M=W2SE(ORS8S(5&@QW41&\6<I6[<42O#7,)_#>F.U%-:3(Q4F.1K9?*9W%W:2
M6);L*W$QQC%6FM.Q"+-B\J]Y^$79CVP?:%[V?.6V/S:3)+7DUO3CY,WC1F',
M\8 .,UUX*KN.AGR4T4Q#0*7B&A--9>8LK#T,SK6)#]P^T(?"C?BWY#49?J;>
M)ET2XG3]0O8VX>D)SA9T[ 07W+%/D'.QR*(AO<FYP:^R<,J'$A'EI$S,O)$8
M W:%S[\S0>9JHZ?:\SY&(TI)T TCM!*]9QG)P?Q/#35CIJ[F<:C)YW'&^-C1
MG&H/9:J*2]T1- B:^Q55 5@UXF@*36&/5M[="%(>^0QYQAS5"_UK'LV,4A,6
M%R3IHB24<.RSCI1_N*T&X$"H"(N#X">4FXRR1?$7S""!;9KI_]ZH.(:?5:RN
M0V;3BU-FVQ_!D'.*=>039C?!,XJ+IAL+H(V:#\.96IG<V7E<6Y^;*=BC]&>8
M8',5T#>MX"H$RX#M\QP/!:D<Z;KB484D<!\IC.',\!2P!Q#/IP/ZB8IY,;<3
MH[[*X  7&&4RS@!R-42Q'*.J9\"M#V#!\PF/1#/[K\Z#/7+TD]H;%!'R=ASH
M])Q<J@RE<Y(K&)R[(6$8$] ;R=PB2U-2N:;F^>J=?^2DE>:L\.YX(]$U0NR(
M%5QD$XQM7X=P4DPRJ65M#*IQB9"L)Q=OC*,-3D..*EV/@XJ\2>?QB*M<C0:>
MA)4.'Z#=5!*@#:9+DD>4N $UQ]CAI?%51O2'4_0!_VTVYI1N'U1UAQ+*[.&,
MX#B2B[F,+VK-.$;/X/O&*.^M40LWQNL1(WT0NY)L(;I?6AQ]C?E9A$ZW8/9"
MZ$8YMY-+'M&2,]/WE&.BPFV<HKSH.P=?GJBKM- RA#795#VL?6"B^A&_UPN]
M6GK)W,GTQ>%-COU2#K2!7/-"V-M0B(D)>&[_B1F= 5_<H/.=LE$;GJB)$WNA
MY,(2D?.:S-*(<B6#+/VB,HGCF51K")Y@EJB%\_L#J2C#_B5Y&'-2C4,=CI6
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M1^?PF=43PZM5>2.=/*NAY&:K>1CLCC\9"G$'NJ'&JM<+H_P-DY[*>6AI"T"
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MM,/+-SC,748IDQZOL"0N/7U^#:$MPW#3XCB.VWM.6YX!(8_2 _&A#V2ZN>=
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MLY1P9$RYQII"T:K@(D2X8B?F$<28ZKW>?(_>ORTTZ-ZZ\/V;F[QT\!L.S%S
M)<BR,UGT#MQ^Y&)\51:=C2.[P;82,TE-,).:'E>YD0@Z3A%->B!A?QF5Q]_3
M[[_V)N60HDE#9"]V+=!$W*R8X&44!' "UG)8#S!%-E!ZF:A-I&'*L6'=,I>)
M!A--1&AH-/;LVB,JH0?06I&V8S"J0^V,-%<%^(E@_.1<1.#_J1)[MR7V&*V2
MV/3MGQH(^C)O:8RWE"QP7J'L7&QV5/5U._C8^]2]/+K8%*BO22PQ8#[CQD:2
MQS#M>#0:E.SSW-K7%O6NI<2>G;*@K)&S^'MWSBOM:=:*M?EDJ[D=5"+V'5L.
M@5WJ;?I(XPK#UL$:#PV8IJL:Q#TBV>+KYR);+$<9NTNZGX0<OI=HLKY'[-5K
MO5P->43M$&R]K2(>Y]J#Q@M"O\UYAW,;YO.I=NW+5/Z"6S U;K>%+\IL9)PS
M:4[3D\<)NX1.3$9I4LNU8/:OV8HG9W;"K<B10=/NA&>TS@>QV.@54&H27$=I
M7 ,T.+C]JNGLO 2PT(]\2-2=M7^+4T*CN90+ERZ"TAV GO5-2ARQE&G,R)X,
M&28DNMK)Z>"ANE$Q^ A;G=UM,B71/V:G(2DF>:,?'GWKQZ6MOR"H9,WF._1J
MNJPW]+M<%!,IMC'D#*;,]6W0W+5/M(%7=Y/==("X5LEQN*V5=+B!LE=V_Q@Y
M<BTT4]XUP9:7/' D[=RJG>MNN$(!K3@](IU\R:4ZX!Y66BG59%)0!_#^YE ]
M]J&:U&F%*-8LKK#A!0- F&Q,PQ-U5I#XP/^<CW00DG@1P #\DLUG!;<%R]/X
M6B-J"'>:9E=A$OW;1"UU_0C"!$#ST WCH@\H#)82(9A <> [:D1TC/I5PX7[
M,OA7'-[P! 1UPQP7&>RT<EQ7S2PG/' '4E#CV$V#19.=NU]V[GU36](DP3:X
MML117:AU!BI1XXANOF&&M-1IEA]H@ ,G_&L"6Y8YTD3!!.^X3%-Y'$KI> PW
M'H?,KTA?T24\SV :K 7QNAV/B7I6CW15F.]QX3+P#5"F<ZVDXPC,OY%Q"2TK
MI1Z=H<XR(!>-.EV(X: 1J:VE/>%;#I[#P"HI31&-;:0H% Q%SOR\"?(%E>ZE
M.RS78Z.++$E0A1)&!\<CLVY$)9%;W@CA9HIR)#Q3=57$JQSOA\YFO_VV;O/]
M")XU"'"TFYUCV6\'IV<G?^^?]T^.SX.SWE'WHO<QN#@ITP$CJ]?'_KK3VC\F
MM'U-[3J9_HJIQ2\UZ*J:UF*4&?Q#RV6N"LE3,X^$K8=V.TQ0L9_ME2U."W[V
M*@N'NJZZPCWAP_MR08(+4Y>P5Y"@V5'X3:QGAG5J0&:MWQ>;U0;H761SR]4L
MS'0%S' ^G?-%JP%PHPIWF'$+!:4O)&(+@S;GZ X9TUZ/$NL\CI\GQ_>]]R7M
M+&M0C3GY>E1HN8FLJ;RPY@O639":E6,H?ZD$Z4>*B#0SZC:-/=JFU"2E5.'!
M9P$.!U&#JS 1#A7=.H(<>1[2!],$>IY0)H?A&P;(JF>$1PIS10>V0;-4LF*_
M#SSW*QFM.P]EM*Z_V#6CM3MN%L";=$ZMP5%C#(?9',T0<V66)^2V-QB$<9A8
M/A'J#ZQY58@#B;"BICUXQC:CZ:CG;18+:,BE,:7BM14V0V?GP:WQ7.9ODD0P
M@+B9 "LOAX.)+6BP:%-<)=I*V%&T)MA(G-!ITFCBJ*C)'J\B3^UT'DH<M]>V
M.VYZ_$V1$;9P>XSK"\&)7A.RK,Q+Z"%T,(P*FS8DWX!*F>S5@+0?4E::J5>\
M=ZXQ&)+@5;HO%A)PP_$<IM)(\4SI/,Y6B$W3QL2 "^\^A;O@"A<CV+K:IKJH
MFVVVICUE E?'/&.F]A$CVEA#D*WMOCWF'64LE=,/2?>1-)6S"&'7%5W.I'7_
M'6EEC]KD*Q'IQ M-XVB"BJ+"W&2QA#*I?]^MS>JPK G$26K&*+?PK[DBH4 0
MT2A"]EN#VPK-@-K!)UOY1DN+LY@;C)$MJ<]T\H,RT+"@]U(%+7^.[F1PB<X4
M#*G'_N-%^%6JO$X,,S%OO-L3ZD_AC_'1YJ%N:R;@=<W>:>K/(B+'7R]+HB%I
MJ$ ] MW'H%9[;G'-!G?Y8BFL81F#1RA%;1-SX;_C-:FK*C;J5=,Y86>U"[/-
MN6R^<(L.L9VJ;?;BD6NAUAW&[-'Q;3$B-2X#!"D1*XVT7_T#5^W"FT?=!7B[
MFN%(;.>N&?;H((-6VD+)J1FGH!RV7O]EVY3[4+/Q))E/M9U*"ZWK)NF66LEG
M]<A$GXW5^4A6Y^[=K,[G-S,U MHH"M+1?L/2!YBAI&N<:!^6?IFRH]5FR$/1
M#[Y!I0W/R!]J9BW/PE)L\'7C=<\B>])V%KAM2K[2%4K /^>C*PTB-S5O"_]V
M,X_77R+'6N@TS0/2@>UCHX_2=HL5MK#PY]%(.ESK3(T\O&KW$$9Z/,_H.(Q4
M/LRB@4:>HU^.=>].VJC&_''!X'?M]]/I/%3W[K=W7M?HWDTSEYS&"/"VJEE9
M-JA6+=?C&@SW,=_\/J,NN% O>HGMW)C<?*PIQF',-OI#S:%W:DK8V!J!J9^,
MN)N=E*"LJY^7WZ7PP5F<QTXFT;#>?=.07D"F<W>GJ4-L4K!-"K;#6^BL^$Z[
ML[_:F'XE'[LM&2+JV+'R:FQ/O.ZL@1/FMD\R^^BMX [14^=;X)^Q/Q=L=;8E
M)S!85&KB6UZ30GHTV1_*!;2;4+_#Y'(-U[0._YBOUQ66.>D&,'\;>HLG*X)8
M4X)*+"K.4/7+B.R5)]LWW<TW-.+>]Z_\0\^.C_7)$&Z;J=(7N",\_1(WD4KN
M"/0;#+"MRS <*>(#G'*2;.%QE;<L*Y'QV6I0$H46R?5&\5T@I-X@-&UQ,EC+
MRS^#GT5=1>-"?!)< H^/W;9_EZ@PUCVMLHC?/W JK]MOK%]HPM..<F$DA%\[
MJKD,^:10M*\4^X+SR.&H3.E$X"SCI*A0JJ[8FW>/B_(GHD5$I6HJ=8DKN:TA
M9K@YF1,D9RBA<5%,RV;Z'3=%$A8AG^3%/'1+)TN9(BWD_K*,&8R1S ,=#'!
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M-1)2$RB0\FUY&B*-*2["S>E!%5@3H_)\>G5DMV+I*=9VX_(SS(=OO21!!,!
MY4HKT+*KSPN,V0(A7:!YTZ+-$Z;8E)6HM#1%2ZU M#8K5C30N:Q,P71Y!VL
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M<8+6,V6<J\1"[34T.H6PL]7R>E^[W>#L>.5EU2M,56LN!IVMGBE]KJ I+(Q
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MO[6_:ZG86<V)F7>.,-K#T.#T:E#\? O$EUR':U.54D=H(XH!D;/PV0#C=#+
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M^31==?7ANEO]<O7<I;0':/0]8Y=(9(Z.@E[O?!V7^%NJ'T92]_!C!;+J$V0
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MO+R/\:NF^QRBI;'L-\+X]4JXB.;>]GX;3-K^#E\VM3',1P*[:F)QR=U3'@)
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M#B$3F4EV. 31  &\@FM*7M3@^C3"8D(BK[NXK*(9''DLIH3=& N8O,5>OTS
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M$WC%HEFIN.PBNZO1F,>BP#IAOHHZ>[,:;5Y<Z=^D&<XHAW+!.>3!J094DHH
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MCYC:&W5$O@_T' $6\HM1*N.W^#C<>ITG3+$*DY/+ ?$ND Q'M5S92)-H,*J
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M#591K)L9T') RRVA9955%I4+@*LATXH=..Z 7=O"KB:]JJ#8SX[#;:P,8=R
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M]97WO7S*5E?K5N_!LY#(#4+$($3<-A(>VS=SM/$X["7D_+[<%0Z;VR>#X6-
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M[:'9LPI%GHA(.DNF320(<]_U>3<CKIE;4^E:7@79'>"EX/H!0L(-02:"]_<
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MR5_UH8M=YJGJ<*A;GBW] U!+ P04    " #U.71:2W'UT#,)   =0P  &
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MP:(*4N\.[3UWX?S*-L><6I7WKRUS??LO4$L#!!0    ( /4Y=%JOF RA\04
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MYTG"(JIZH3K:^J@8-F;8>J??[NIO^F_MV7_IR/1C,<-DFZ<-&'>6^M< X2^
MN7X4R4)H<T9<P6E[@\]<[Y;BY49D,Z5]C.6"ZB1=8NF-@9"7!Q<LAYEB&HMU
MG))H>Q)9GTK&$,Y73R3-]4U*<@@ICL^4O&(QCM+RV]<0)LK.S!5T: X\JQ,:
M9'TO45(HP?*TG.*A]PP*F,Z-,DD"188M1AN::_?.)C1=G"R$)/H\4>C.L3GE
MD"JH0]O27?%J1[6[-XO/41^G>JZ#X<HM==6T<DE]^P(\(Q/JE)4 2315 ;F2
M+*[@_>; W6TM@G#9YMGCR/)BO6GOY?\#4$L#!!0    ( /4Y=%K3-L7U-0<
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M,2YX<V102P$"% ,4    " #U.71:'(:R]9 /  "MX   %0
M@ $T$0  8V=T>"TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ ]3ET6D2X
M&^]%*P  YK0" !4              ( !]R   &-G='@M,C R-#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( /4Y=%KEP^PPJ&@  %$#!P 5              "
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M,2YJ<&=02P$"% ,4    " #U.71:=!='D\)L  !E<@  &
M@ '">P4 8V=T>"TR,#(T,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ ]3ET
M6H>LON(T<P  +X4  !@              ( !NN@% &-G='@M,C R-#$R,S%X
M,3!K,# S+FIP9U!+ 0(4 Q0    ( /4Y=%I_*Q%7)^T  %T  0 8
M      "  21<!@!C9W1X+3(P,C0Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4
M" #U.71:>#R#2)%3  !T5@  &               @ &!20< 8V=T>"TR,#(T
M,3(S,7@Q,&LP,#4N:G!G4$L! A0#%     @ ]3ET6K X>]Y[A $ >XP! !@
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M,"YJ<&=02P$"% ,4    " #U.71:1I#JP[^_  "#<08 &
M@ %5J@H 8V=T>"TR,#(T,3(S,7AE>#$P9#,N:'1M4$L! A0#%     @ ]3ET
M6I]IQ^]/(0  @?\  !@              ( !2FH+ &-G='@M,C R-#$R,S%X
M97@Q.60Q+FAT;5!+ 0(4 Q0    ( /4Y=%J$)[%+T (  -4+   8
M      "  <^+"P!C9W1X+3(P,C0Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4
M" #U.71:0"=Q2U<$  #<&@  &               @ '5C@L 8V=T>"TR,#(T
M,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ ]3ET6DMQ]= S"0  '4,  !@
M             ( !8I,+ &-G='@M,C R-#$R,S%X97@S,60Q+FAT;5!+ 0(4
M Q0    ( /4Y=%IZN<7&Y@@  .=!   8              "  <N<"P!C9W1X
M+3(P,C0Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " #U.71:C8O! ND%   _
M'@  &               @ 'GI0L 8V=T>"TR,#(T,3(S,7AE>#,R9#$N:'1M
M4$L! A0#%     @ ]3ET6J^8#*'Q!0  &"   !@              ( !!JP+
M &-G='@M,C R-#$R,S%X97@S,F0R+FAT;5!+ 0(4 Q0    ( /4Y=%K3-L7U
M-0<  '0C   7              "  2VR"P!C9W1X+3(P,C0Q,C,Q>&5X,V0S
:+FAT;5!+!08     &0 9 +\&  "7N0L    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>cgtx-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgtx="http://www.cogrx.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgtx-20241231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_r3tUz6_Kt02MxBdQeEQGEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_afVnL3lb_EefS-cEGQ-jZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ZUcWSgSFkE2BmPuI7ICu_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_2iDgdVMqskqqMckLxknrRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_JcEslU1uvkSAJq_z28KWWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_xK7RvHxIJE-jH9loOV_v-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_-GLOfDTDzEKj9t_Ctbu54Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7tSX_qWQF0CIUXnoJZQz_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_alChYiDeMkO9Ns2J7rmKPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_kEmqrIBPs0isxn2okOqBaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AJXFpogTYkiyXpWcopwd_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vT5FlUfgiEqOtSWVevEpAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yK322Z1bEU6-t8t4b8J1mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jrmNuQdewkuQ3tIVwaV50A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rv7evwVvGkaNCERTqKzo4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3GnPNkowakSAyYLtWMwr0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nl1R_JUOlEOS0QXSjoW9fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3B_2Jrx_WkO-PPVkUC_P7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_JlfyE0xns0CU4LcciEPTeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_9IPUhdlJ5kOeFe2ILc4Vlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_wRqYBX88ck2Z32XFXD3SKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_QnBbkut1Gkme18p813MRFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0Ur3_enFS0W4_rr4CTlI6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Hkyrmv-pfEyH9afz2yTZxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_FGsA0l5PX0ikfIe99ENvTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:AmendedAndRestatedEquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_EZEO1er5NEyxL_p2ZKMavg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_4KKeiPcUyU2k6n2tgFWd3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_iZBC1Qycd0ODSeXIqiMLDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_kR9dLuqQQUK9opN7bHqIBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_v1k3Dg8VREagvH4eZzhc2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mjymGu0RfUeiL7Co7NPZdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_o-vcv2H3AUS1ElrISMMh5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsTimeBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cgtx:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_8KtOhdlvBUG2HVj7Nj0Rvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_1YSK4YZY_EWesDCIHCGuNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wq0C1MAIcUClHQZnNmyrcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_OmwuH19ITkWRHopUzOVYJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3QteG7Thn0O_-zTGlyV6yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_R4fyJmu5eUuklOk2TqC2fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5QUb6H7RJEmzgSXAtn5DaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kPOqaHj9s0i-PXHu6jVcxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_-QVbP29W8UCUFnMbcV9xXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_GafOTV2hp0qNoyDaJ5nlAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_HTF3nxxkYEqnzjZbaDO4Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_6WFEkFQXEUSicyyzDQI4qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_3ws-31ywLkGQlI_tbXjBpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cgtx:InsurancePremiumFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TMZ1hC5jjUm23pil46C8GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jrR6f4WA_E-O8mTJmjvxRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_XKQMBwzNm0isw3SpIMHyCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_WWHICw6P30W1vl__ISJXDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_k0qbPwttZEipB5XrOo8yFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l87oZJuNJEGMXeOLZRLP6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_6nqsHazxDUGfwWNKMnAR-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_SVdrYoXmtkuaCv6uYbJIpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_gX0jdGPEx0-lwTPLQjPt9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_P2TM13gBZU6xZncj0GmnAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_N80InueOO0ax6JSU1_GDkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratoryAndOfficeSpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_O4eMoPkn-UiB3yEL9wwhEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:OfficeSpaceLocatedInPittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_SefUZ0-stEK6Wo6PqsHRnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JSDRzJzk2kCr9Ut2IvY5WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_YMzsuYYScUGAVgdtaKBakQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BZ1BPutL2kCFpmBC9iHmpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cz7E_hdUVUWwa9Vuq9Mihg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2Q9ZkTw_DUCugaCKI_H91Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6w45MJ0QnUikkNsbjaNclg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynoIxvwk10KeE1sFcDzURw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DNorcmrr9ECUu3JPRu-YqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_77w6B15sK0-_YLNNtOcqPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2025_6c0TrOxXNESMzxicg2S8JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="Duration_3_28_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_qj_sVYxNbUS8cYEAWDZ8pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_wg_K7cTOH0eZ6E1DJZAUYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_r74j6G3Wr0ynHLld-HIi-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_jRWdRQ2nq0mpessnxLTvMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_EKWIjPiMsU2M7X5y-zyRPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgtx:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_JXRbb9ivf0eQ2WygjyfFaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgtx:RestrictedStockUnitsPerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgtx:LifeScienceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cgtx:LifeScienceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IEL8SilDn0ONwVf8eHAjSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:LincolnParkCapitalFundLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:EquityLineFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_LuMhXlg2UU2lMoQFfA7XFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2022_To_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_Q6DBrXT7LEaflz65yXd2EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgtx:LaboratorySpacePittsburghPaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_lease_9ytlK5UIFkOJ1P2Vw2TIqQ">
        <measure>cgtx:lease</measure>
    </unit>
    <unit id="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_item_2EZlvjH0wki-oLaHkndxvg">
        <measure>cgtx:item</measure>
    </unit>
    <unit id="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw">
        <measure>cgtx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      id="Hidden_yB3S44WBzkSCxQ_MyylJDw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      id="Hidden_lJMDeb9ukUanvgtD5SPkYA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_3SBPfqdtO0K558WUPv34rg_2_1">0001455365</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_LT4igiY0fEGzBeH5uDSYYg_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_m-BwCBI14EWUvACw2rExkg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc__SSz0MQCa0Kts8n_7VNtmQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Hidden_GL-2adXFeUizAwQ5N41cTQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Hidden_Urf2s1Q96USpg0nHJ-TRoA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Hidden_uMeajRfbFUGIUvxcTr5haQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Hidden_VySIEQuZ8k-gIQvt_w4Aag"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_SVdrYoXmtkuaCv6uYbJIpg"
      decimals="-3"
      id="Hidden_gQWcEjdNw0GcGiE_v49Xrg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l87oZJuNJEGMXeOLZRLP6g"
      decimals="-3"
      id="Hidden_azpgbY7v70GTdLavwIY4qw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Hidden_W3VI9jjkKkCKLtXgnWQvTg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Hidden_yK0ETgeUAkG1nAZvss5hbg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      id="Hidden_ubdKuvpJkkaqTeUDY-0ehg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      id="Hidden_eE1i52D_kU6U1m60PuvXSw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Hidden_zXsuiyXa10mQAw1pz6nYnw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">59854877</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Hidden_HBFneHzl_k27D95-1wTmDQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">32165478</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw"
      id="Hidden_jnCsFL2IEUeXVQTdgotWyQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_1YSK4YZY_EWesDCIHCGuNw"
      decimals="-3"
      id="Hidden_Z7RNwB4W3kOANqH6RLEDhQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">544000</us-gaap:RepaymentsOfDebtMaturingInMoreThanThreeMonths>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Hidden_1URyjcdy8kqivgwhPCDv3A"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">32165478</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Hidden_S56iJzBGFkm4V3mtGIvG2w"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">59854877</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_v1k3Dg8VREagvH4eZzhc2g"
      id="Hidden_z0Vdnv6oQU-dhLEWmZmyvg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg"
      id="Hidden_aC02QIKoOUyPVq4UeX7GUA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg"
      id="Hidden_Nt8kwa65QE2wzlLEyRX9NA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg"
      id="Hidden_u4Jf8gqGbEGJb2oeDKiKTw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_363P_m6awkS44u_8RiHCBg"
      id="Hidden_wu-IG5I7IEGcFveZXiNmug">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_rH9CF9xq6UCGRc7sUIRyeg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_W7JoiO9k906_TxXN3aL_jw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_dgTlXsIo1UWh_89mLTQVZw">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_umWSqSjG70am2c10XYXY3Q">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_6NMIXRN9jk23cVagUiHezw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_7vZZyBkcG06CQkSV2KJUCQ">001-40886</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_6guUTVRaYU6q_ByhuKrP3g">COGNITION THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_cUFHBjVeike6nip9kmufAQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_8WEjFKGokEO3dDRiXW1cbQ_1_1">13-4365359</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_XHUTOz27n06KSwn-PwKQtA_4_0">2500 Westchester Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_t4_lZZeD2UijamiYiJFyDA">Purchase</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_wDgVh0OO5k6VCBssPmylZQ">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_H1LZfNfHaESkFQ59jCsL1Q_5_1">10577</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_cWICjoDkHkyzONDByPtUtQ">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_Pc70zPQ9WkOy_RwOwluzPA">481-2210</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_RFx2fZi19k6LrIT0T4cEqA_3_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_BakisGNLvk6xRBewoQFjAA_3_2">CGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_OnXrX6HbRESn87EkDxAMcQ_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_ir01iOrvDEKTKmJwxdbFhw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_zsleFX3YW0ut7ac9fr-eUw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_yTJcsw-y7kGA9e3RKEyNVA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_ZRyxiKVdYESmnOkW-69f-Q">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_DER5W-6HT06xBYISc2eupw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_MWFb1ljlj0mK25cUObvWyw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_clcvGsnKGku5HmSR1KEFuA">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_E9g2xWpRPUmvX1ilKM8LDg">false</dei:EntityExTransitionPeriod>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_co17D4skd0yTD3h6Z32vwQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_UYv7kEfxZEulpO6mko3mxg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2024_77w6B15sK0-_YLNNtOcqPg"
      decimals="0"
      id="Narr_NUf_G-6HekSDPB13XoJdew"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">56312451</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_17_2025_6c0TrOxXNESMzxicg2S8JA"
      decimals="INF"
      id="Narr_-KUYTp1_zkSGqQqfeGdNPg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">61972946</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_Azrh82Xfxk-PNp270GJhug">&lt;span style="font-size:8pt;"&gt;Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2024.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_TF7ONv0Bo0K95mM_TJLvPw_1_1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_LgGnw0RVYkODCQ2DVnIjBw_1_3">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_yNKcrE21GU6lQXkDs9fyaQ_1_5">Philadelphia, PA</dei:AuditorLocation>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_MweEvaBAm0uxPBwZ09dBew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cyber Risk Management and Strategy&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cognition Therapeutics, Inc. has implemented and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises. We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate. Employees are required to complete an annual cybersecurity awareness training program designed to raise awareness of cybersecurity threats across functions, as well as to encourage consideration of cybersecurity risks across our Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of our cybersecurity risk management, we have adopted an incident response plan that has been designed to identify and manage significant events that may impact our information technology infrastructure, including those arising from or related to cybersecurity threats. We recently tested our incident response plan using a tabletop exercise with the goal of improving our processes and preparedness.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not materially affected, and we do not believe they are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats related to our data and systems, including phishing attacks. For more information about risks from cybersecurity threats, see the risk factor entitled &#x201c;Significant disruptions of information technology systems and infrastructure, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition&#x201d; included in Item 1A &#x201c;Risk Factors.&#x201d; &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_7bPEZznDXE2NgkaY97kYuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cognition Therapeutics, Inc. has implemented and maintains an enterprise risk management program that includes processes designed to identify, assess, and mitigate cybersecurity risks. These processes include the deployment of third-party security solutions and tools designed to monitor, identify, and address cybersecurity risks. We engage a third-party information technology advisor to support our cyber risk management efforts and, periodically, we engage additional third-party consultants for penetration testing and threat simulation exercises. We also maintain processes to assess and review the cybersecurity practices of third-party vendors and service providers prior to onboarding, including through review of System and Organization Controls (SOC) reports provided by potential vendors and inclusion of security requirements in contracts, as appropriate. Employees are required to complete an annual cybersecurity awareness training program designed to raise awareness of cybersecurity threats across functions, as well as to encourage consideration of cybersecurity risks across our Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of our cybersecurity risk management, we have adopted an incident response plan that has been designed to identify and manage significant events that may impact our information technology infrastructure, including those arising from or related to cybersecurity threats. We recently tested our incident response plan using a tabletop exercise with the goal of improving our processes and preparedness.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_43POmQF7XUq9E4pxSogMsw">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_o8R502OJi0O7WG7kD-sbfg">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_P0OofV7gokStjsH0upEpbw">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_z7XRxDJNEUyAJEhosdgigA">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_-ZMEZMqEg0KERnzwJFmWZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Governance Related to Cybersecurity Risks&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Corporate Controller reports to and meets with the Chief Financial Officer periodically to discuss and review risk management processes related to cybersecurity and potential cybersecurity risks, with input from the Company&#x2019;s third-party information technology advisor as appropriate. The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter. The audit committee is responsible for discussing cybersecurity-related risks with management, including the steps management has taken to monitor and control such risks, including our risk assessment and risk management policies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors. The board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_x0hCs0nBxUiZVygH0qoUbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_lCzb_cEJgkab_rtUwBA-Zg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cyber risk management program and related operations and processes are managed by the Chief Financial Officer in consultation with other members of the finance team of the company, who collectively have expertise and experience in accounting, financial reporting and auditing, and law and compliance, including as it relates to the assessment of the adequacy of cybersecurity processes.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_sxLtDH0WI0G9ZHg_0BsKiw">Chief Financial Officer</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_JzT7dOZfj0SX5lPdKkHnIg">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Group_9TPNBNlffUqD_HcO6hPUqQ">The Chief Financial Officer reports on a quarterly basis to the audit committee, which oversees cybersecurity risks pursuant to the audit committee charter.The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_ARNaWKM7ekGnEMWi2ZoGgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Chief Financial Officer and the audit committee periodically report on cybersecurity risk management to the board of directors. The board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the board of directors has the responsibility to confirm that the risk management processes designed and implemented by management are appropriate and functioning as designed.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_eGhg_RnnrEiV-r1lXHMXLw">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_mQSl3ecybUWdCkFyLU-wFA">The board of directors</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_KYBX0BN9W02B5fmQ6z8aJw_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">25009000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Ow1ftq1pMkaYtV8_G1GU7Q_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_xRzvqcjphUCjVPji1c39Rg_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2686000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_S82APCHRwUajyuhGFbmdyA_7_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1281000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_TWPHX26qgE2CYinoFIUhjw_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1860000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_aHigSl2r7kGneR1JcXhGfA_8_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3019000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_Nyf2KQO-PU-PZpOffkHO5w_9_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29555000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_7MS7BpPtkk6ngIgMxzYfCw_9_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">34222000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_WMcx1LBViUiFw4O5rNGxIA_10_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">181000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_ljLVruDTe0WT7WEV9Hq9TQ_10_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">284000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_OhG5uS93DkO9iB4eJ4n3XQ_11_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">498000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_3gkJ6OrsdkmtNB3PUSJpCw_11_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">657000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_C3gbwFQIB02OZQkp6FNxxQ_12_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">30234000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_p5TWqtwm7kiLSgpAgEQy6A_12_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">35163000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_VFC3gAYXuEug1p7IuVDeyA_15_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1984000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_OKEX7W_CRUyuWe_mYMsUyA_15_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3695000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_ojDft0olqUa4ueU_ukQHRg_16_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">7620000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_M2PqWPkoSEWxeZ6L6HEeyg_16_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4055000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_S0-mE5n3JkeCqHsDd6t7Iw_17_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1066000</cgtx:DeferredGrantIncomeCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_kWRiFtJAwUu9MdyfDFt46g_17_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1701000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_aevqQlGbHEyHRtphhOD3Sw_18_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">193000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_2uJ7jQwGr0aQNXN_55Sgyw_18_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">174000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_7f2kO6LHLU6yCJvO3oj9OA_19_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">279000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_BzQBLlOJREiR1TMM4g-tXg_19_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">544000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_piIoLKs540CmwIoRAB1axw_20_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11142000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_HoCOmrLT6EO5LZwu3qW4Ug_20_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">10169000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_zqM97PvO-0mjx7-OJlFAmg_21_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">342000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_S-FtkagpFkeeFhvMeCqOWQ_21_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">520000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_2PCXJL1_cUG4pN4o_NDfKA_22_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11484000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_zJL0nr7jd0SqOstCSvJp8A_22_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">10689000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_iBlDNZYbvkm10m2u0bmuQw"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr__NXL8OqvpUumnpwQKMVQxA"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_jHmfYhBlUUWuCMW0a11DvQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_0jWFiaIFRk-eOv1gHhtRcw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_OaIyhNKdokaW1jDAik5RaA"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_W9m4RdndxkGcMZMRVa21fw"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_NWjklu6yQ0qOxwZ2OXZDiQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_puGP3Bl-2kGhVjebQptCRw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_rVhitrU-s0uEFPTo_tF8YA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">59854877</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_qLmiIJMY9kyU5ENdFiQmHQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">32165478</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_E2G2OjzO1UuhgyGpFtLnQQ_26_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">60000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_emMnTLds8EaZt1ElDsI8FQ_26_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">32000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_m8xkWY_3ikqiY6XmlO2drg_27_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">193850000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Q6_q4NGPZkS7jr0Mzn1Z6A_27_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">165826000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_GnBqF7LDDE6uO37z3jxz7Q_28_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-175160000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_iruigIXhj0KK8W-wYYqFig_28_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-141189000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_OJC2g6YuTUGyx5RR4qFMQQ_29_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-195000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_B53PKZjyH0-xkAMuXZlyJQ_30_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">18750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_qh3Ev9-3gk6yXQ4b4PMXaA_30_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24474000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_Vty5N8Rxgk68XmGodiWOQg_31_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">30234000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_XbPwPacjdUKowpKizU4NOw_31_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">35163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_vFSUskrTxU-3zlA7gB_16Q_5_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">41676000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_0HHyikgs20y6pa8t1nnIxQ_5_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">37196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_KTtgisTyVkWdQhGins6qFA_6_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12290000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_uoLrgXnoqkSwrfpP2j1zBQ_6_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">13528000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_V6NhkpmS_0u_-sbho1wmTA_7_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">53966000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_U1CRA2wRYUCEWRVFWz1InQ_7_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">50724000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_r-CXQkeHfUG0LPKNBQu8GA_8_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-53966000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_bbRWp7frIUONc0RrAl8-Yw_8_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-50724000</us-gaap:OperatingIncomeLoss>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_mwchgxzsCE-OTu804b9WAg_10_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">19549000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_1NbbwFzoRkiy8LYyRn4xcQ_10_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24805000</cgtx:GrantIncome>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_6YcHT9W1oUWnm4yfqJbEvg_11_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">666000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_uSzfohJRaECfgrZkJFEmkA_11_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">158000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_efbWzqCkZ0mauk7gypyRLg_12_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_4pB7OOminUGW97CDfA_kfA_12_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-27000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_biTluad0K0ycQvLxzqny4w_13_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">195000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_XTJK3oTdK0Wf1rSY-VT09w_14_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">19995000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_rmK-Nlhmt0yFyyiecCOEZg_14_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24936000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_CzOQYH9ALkekLW1tQVPfJA_15_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_vfH4zbAQX0GBMvpfpTRIiA_15_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc__FKBKQiwOEO8iYby3HRJsg_16_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">195000</cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications>
    <cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_FFxZ3Qytbkqd9NiRY4axJQ_16_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</cgtx:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxTotalIncludingReclassications>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_njyRfcqQMkui91a6UdMhDg_17_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33776000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_FFPfHe6QrECt3LpB3IWQ4Q_17_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_SPcidUsVw0ednS7US4ZsAQ_19_4"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="2"
      id="Tc_M6isVoZqvkKTptRfRJZTbA_19_7"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_Fq6iDrSQy0eG7Eesm64vfA_20_4"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="2"
      id="Tc_UOP9NApCxUW1ic8s99ZPGQ_20_7"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="0"
      id="Tc_7NnNomaHVkyaU9D9efmwNw_22_4"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">39730148</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="0"
      id="Tc_2Z2oAbNbwUqRHJrlrrvOlA_22_7"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">30029087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="0"
      id="Tc_DGKYr5P9mEOPgXg88OM5jw_23_4"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">39730148</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="0"
      id="Tc_drgYhUbpYEKFh4ydAzVGAQ_23_7"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">30029087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg"
      decimals="INF"
      id="Tc__zcPJziEiUK1kDuDCRM8tw_5_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">28991548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Br6XMlFKGkWaMgD1EiyUDg"
      decimals="-3"
      id="Tc_1fOibsT4wEevrVfYXe6GIw_5_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nl1R_JUOlEOS0QXSjoW9fQ"
      decimals="-3"
      id="Tc_hIkYKCgvLE29UW4iO5cgBA_5_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">155820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3GnPNkowakSAyYLtWMwr0A"
      decimals="-3"
      id="Tc_Czyp7xUGLUq2uuO8dJ9RnQ_5_10"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-115401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3B_2Jrx_WkO-PPVkUC_P7w"
      decimals="-3"
      id="Tc_VOtdr8bNxE22AV_0IYdUWQ_5_13"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw"
      decimals="-3"
      id="Tc_O6cH3K8Aakq6vqmd7e_bVA_5_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">40249000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g"
      decimals="INF"
      id="Tc_t8Zf-cOc0UGKTTyAsZYwhA_6_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">2859074</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_uD_QF0snKEqaP7-6Zoh86g"
      decimals="-3"
      id="Tc_WzzkpVELUUyVSv_U5L-pFw_6_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_afVnL3lb_EefS-cEGQ-jZA"
      decimals="-3"
      id="Tc_Jpc3R2aeNUeiLIW74I55lQ_6_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">5124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg"
      decimals="-3"
      id="Tc_jc5HZhHN2ECw-bztr90cgw_6_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">5127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_kEmqrIBPs0isxn2okOqBaw"
      decimals="INF"
      id="Tc_e4I1zFIrskiZvKyKhShR5w_7_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_xK7RvHxIJE-jH9loOV_v-A"
      decimals="-3"
      id="Tc_RvGd-xyNeEWA18b2tH6WYw_7_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingCommitmentSharesMember_-GLOfDTDzEKj9t_Ctbu54Q"
      decimals="-3"
      id="Tc_8zbIWy9j-EOzur3uQFt3Iw_7_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_alChYiDeMkO9Ns2J7rmKPA"
      decimals="INF"
      id="Tc_ODlnGFZD8UCClcfFpisD2g_8_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_JcEslU1uvkSAJq_z28KWWg"
      decimals="-3"
      id="Tc_qsiEPubfWkyHQSX4CyW73A_8_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg"
      decimals="-3"
      id="Tc_Vze4JiUZ4UmUJitt4WZ6Aw_8_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DNorcmrr9ECUu3JPRu-YqA"
      decimals="-3"
      id="Tc_KMmRysrjRkKnsbvTfKDCmw_9_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_zcs6Mr-yHUakDhDuVhNcoA_9_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3QteG7Thn0O_-zTGlyV6yQ"
      decimals="-3"
      id="Tc_ZEBU2ND0QkeLhwplXck5Tg_10_13"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_9w6S222wDECHw9KScPIblA_10_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kPOqaHj9s0i-PXHu6jVcxg"
      decimals="-3"
      id="Tc_PQ0I8Rp-MU60Z3ZYcSRIkQ_11_10"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_SNUcA8nP9UKt-SJnV4uVSA_11_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg"
      decimals="INF"
      id="Tc_wF82MNzH8kGdoR2xK6Bl4g_12_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">32165478</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vozPckEzZ0udOX56suWVqg"
      decimals="-3"
      id="Tc_M96xKsssaUeSNN8MdO9oJw_12_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jrmNuQdewkuQ3tIVwaV50A"
      decimals="-3"
      id="Tc__RFV1x3JKkKiMIP57AwRvQ_12_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">165826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yK322Z1bEU6-t8t4b8J1mg"
      decimals="-3"
      id="Tc_1Y-D9Q_au0GFzyQyLrBAwg_12_10"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-141189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rv7evwVvGkaNCERTqKzo4Q"
      decimals="-3"
      id="Tc_FiPJcjcteEGIlW7HG--2aA_12_13"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_uTQP7q62BEKbC4zsEBn_6A_12_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24474000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ"
      decimals="-3"
      id="Narr_DdYdpDCBWUitS-wn2cJKQQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1329000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg"
      decimals="INF"
      id="Tc_SK6sUdJCEU26eN6m5fLGRA_13_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">7557142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_d71yCilChUuEvbTqDmwneg"
      decimals="-3"
      id="Tc_X32cKDNA_Uq1lc0X3emK-w_13_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_ZUcWSgSFkE2BmPuI7ICu_w"
      decimals="-3"
      id="Tc_TC5Sm4tHSkiR_Q5STXJ-Pw_13_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11888000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ"
      decimals="-3"
      id="Tc_kvxd1a54fk-uv44yHz27nQ_13_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11896000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA"
      decimals="INF"
      id="Tc__lPoLpYzaE25XNW6eTM-Aw_14_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">19913189</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_XHq_q9-uzUO1ETlLHhwetA"
      decimals="-3"
      id="Tc_m-B2Nbq3j0aOY4hhlu2DUA_14_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_2iDgdVMqskqqMckLxknrRA"
      decimals="-3"
      id="Tc_jKLwZVt_5ky_38a9YeKogw_14_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12434000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="-3"
      id="Tc_Q18M_iEPs0GerGyj6W-Ing_14_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12454000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgtx:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_jRWdRQ2nq0mpessnxLTvMw"
      decimals="INF"
      id="Tc_L2qPTAUii0ua5St0UMVdNw_15_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">125718</cgtx:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_wg_K7cTOH0eZ6E1DJZAUYA"
      decimals="-3"
      id="Tc_lBXbsXaCWkmNipRBA6MzAQ_15_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-128000</cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_r74j6G3Wr0ynHLld-HIi-A"
      decimals="-3"
      id="Tc_fmRPYJeaRE-byMrQ18VtLg_15_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-128000</cgtx:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7tSX_qWQF0CIUXnoJZQz_A"
      decimals="INF"
      id="Tc_eRkDR21W60eqpo-2Pi4y5g_16_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">93350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA"
      decimals="-3"
      id="Tc_bzq6nP-hSUGhkmo5AI3CKw_16_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_niFwyRZ440WnnMWg7MIclg_16_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekIb_Bw5pEizX75BCbciMA"
      decimals="-3"
      id="Tc_bcB4rVZ4v0KleE2rVZjbZQ_17_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3748000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_7IZvn4Q8dEqH0aRH2YvViA_17_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3748000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IEL8SilDn0ONwVf8eHAjSA"
      decimals="-3"
      id="Tc_jPMmxBSPu0mg3kpODelg-w_18_13"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">195000</cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary>
    <cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_iEmSbenlN0CBwXV9AatuXg_18_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">195000</cgtx:ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5QUb6H7RJEmzgSXAtn5DaA"
      decimals="-3"
      id="Tc_xUG4ewqqcUmVjYP061lo_Q_19_10"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_jEmsOJeSbEaaoWUs0DFmCA_19_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg"
      decimals="INF"
      id="Tc_qYiGMJtl40mT4WyBE2zobw_20_1"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">59854877</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v2FJx-gy9Em1HEGz8fNpIg"
      decimals="-3"
      id="Tc_jTtspkdpCEyNK8Ky_NpQag_20_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vT5FlUfgiEqOtSWVevEpAA"
      decimals="-3"
      id="Tc_YUxUe7YNhEew62G_CYd7lA_20_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">193850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AJXFpogTYkiyXpWcopwd_A"
      decimals="-3"
      id="Tc_L9YfWQlTQkeKqbqKSDlOEA_20_10"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-175160000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_bAQcfFAlhUmMbxJg36ZNqQ_20_16"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">18750000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_4Ynr5J_210e1GqwJ8H3UCA_4_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_V5oXfGynokGWm2K53saErw_4_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_a8JLGSM4DketerdqJMCKTA_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">107000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_71G84C-ybkSkXZfIwK2Q-w_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc__8Zi5O9ah0OmGBZSmBCeQQ_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3748000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_x_nlpUgukkmUb5aTh8Qrcg_7_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4354000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_D8HBOSnXYECmsVmOx8Ighg_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">159000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_oK73YIu2ZkGxQNzgkZNjRw_8_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">156000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_sKGIxy4qMUaIvIKPQ5HEIg_9_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">195000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_4wsoGYMRZkquhBbaEPAJ1Q_10_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">318000</cgtx:IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_e6QdQBjZ70e54pxg-wDMig_12_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1405000</cgtx:IncreaseDecreaseInGrantReceivables>
    <cgtx:IncreaseDecreaseInGrantReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_VNXI5Da2ik-E3IoFbm3sXg_12_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-2391000</cgtx:IncreaseDecreaseInGrantReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_VYPzt6IpFUWLHwo8j066Tw_13_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-1633000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_HlG4xjIDqUqwWEJIfcTedA_13_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-1852000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_6BCsZPykgEOvSELgPNFTTg_14_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1854000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_D9QxZPLTrkSdLxDQifVE5Q_14_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2440000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc__2uvzYNgwUC9LXrhmRMATw_15_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-635000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_nWoMbJnve02gjHsuJfaZJw_15_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-1687000</cgtx:IncreaseDecreaseInDeferredGrantIncomeCurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_mQ-vYEaHy0Ol1QGxWOLgLg_16_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-159000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_R1NOYNJBD0ihGPGRinQyIw_16_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-150000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_VWx0j381bk2x377q1durKw_17_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-28474000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_LH91wlDKBEOl3SSfpbizHg_17_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-16018000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_cg4CFks3XEKkHyMq78sA0A_19_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_ge7z0KLHlECH0_GRvR9sjQ_19_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">147000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_NHoCHwOLck6CvHFhIJO5CA_20_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_KbXYur--MUaR_SMNL9e7tA_20_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-147000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_iN4UKPUS9kSEqsmqZ8JtpQ"
      decimals="-3"
      id="Tc_FJgSUJ58zkCix8Et5IYDuw_22_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11896000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="-3"
      id="Tc_Ckqv-8_V60SSS3Mr2zUJ-g_23_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12454000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_DFzGKkCByUmtheIu3yYjwg"
      decimals="-3"
      id="Tc_xRJVE9no_0qMZCqSd10m9Q_23_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">5127000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_mRjgVQlPk0KD-cM8x5OHzg_24_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">82000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_oxKJNVXP7kaf5_8PszFwIg"
      decimals="-3"
      id="Tc_O-NMNtixsU-2BokgEbSRAA_25_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_6vvgRCn5lk-MwN41nhCHvg_26_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">128000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_kF18paSWEUeCRnSAnYzrtg_27_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">739000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_Jet9hb2CY0qP45hocSnHiQ_27_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">811000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_xh2JZf9RCEaNnFJ4vozFBw_28_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">23565000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_aBIrfknTJk6FTNHJQFXjCw_28_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4521000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_u158yNTfvE6-z5SRqgTa-A_29_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_ZZHqijGaB0eQWHvkf6DQag_30_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-4913000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_YkBjf4hjT0G26r9-lTeu8g_30_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-11640000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_0K1Lp9NTeEKHQzyfkWHGpw_32_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_kgr7uwu5bUeZS1PTK8QrUw"
      decimals="-3"
      id="Tc_GpXQ0jRYk0OhbcRGHU6iYw_32_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">41562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_02LGTxYJAkGOcsZEeY2bWQ_33_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">25009000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_KNw6fb4R20KAmNCk045FjQ_33_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_jb8LzEjo20uh-V1qThXxxQ_35_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">475000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_7T8P4XqSgkebEBvc5LUfHg_35_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">721000</cgtx:PrepaymentOfInsuranceThroughThirdPartyFinancing>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_U8WbOZ4WjU-UyDnKFZ-7Aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Description of Business and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cognition Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease-modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (&#x201c;CNS&#x201d;) and retina. The Company&#x2019;s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, the Company ceased operations at Cognition Therapeutics PTY LTD, a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) and completed its liquidation of the Subsidiary (the &#x201c;Liquidation&#x201d;). In accordance with the Liquidation, the Company removed the Accumulated Other Comprehensive Income (AOCI) balance associated with the currency translation adjustments and recorded a loss on liquidation of the Subsidiary in accumulated deficit. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc. (the &#x201c;Sales Agents&#x201d;) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf (the &#x201c;ATM&#x201d;). During the year ended December 31, 2024, the Company sold 19,913,189 shares of its common stock pursuant to the ATM for net proceeds of approximately $12,454. Please refer to Note 8 for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) for an equity line financing (the &#x201c;Purchase Agreement&#x201d;). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$35,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;of shares of common stock in the Company&#x2019;s sole discretion, over a&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;36-month&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;189,856&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of its common stock as consideration for Lincoln Park&#x2019;s commitment to purchase shares of common stock under the Purchase Agreement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$34,795&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;was available to draw pursuant to the Purchase Agreement. Please refer to Note 8 for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;On March 14, 2024, the Company closed a follow-on public offering of 6,571,428 shares of the Company&#x2019;s common stock at a public offering price of $1.75 per share (&#x201c;March 2024 Offering&#x201d;). As part of the March 2024 Offering, the underwriters exercised their option to purchase 985,714 shares of the Company&#x2019;s common stock on March 28, 2024, at a public offering price of $1.75 per share. The gross proceeds from the March 2024 Offering were $13,225 and the net proceeds were approximately $11,896, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $33,971 for the year ended December 31, 2024 and $25,788 for the year ended December 31, 2023. As of December 31, 2024 and 2023, the Company had cash and cash equivalents of $25,009 and $29,922, respectively. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $175,160 as of December 31, 2024. The Company expects to continue to incur losses for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 20, 2025, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of December 31, 2024, is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA"
      decimals="-3"
      id="Narr_kKnE2riEPEyLJ8oMSAz2DQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_srt_CounterpartyNameAxis_cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_LuMhXlg2UU2lMoQFfA7XFg"
      decimals="-3"
      id="Narr_5n83gSgCCUCtb2ZHlReLgw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="INF"
      id="Narr_TvwQzyvoKk235BxXf9onFA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">19913189</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="-3"
      id="Narr_vDTlfbqRhU6QM1-J05vnVg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12454000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      decimals="-3"
      id="Narr_PPq5QYWGYkeTY7b0KKQ8EQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">35000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <cgtx:PurchaseAgreementTerm
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      id="Narr_ZhHfTwusm0qNJYkTvPLioQ">P36M</cgtx:PurchaseAgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      decimals="INF"
      id="Narr_VXdNpforpkq9Z9hM-zlj7w"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgtx:RemainingValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg"
      decimals="-3"
      id="Narr_lH6r0bs6ZEOPae64K0TgGQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">34795000</cgtx:RemainingValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw"
      decimals="INF"
      id="Narr_sqUuGBVqzkuvQ-mUtFuaxg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">6571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig"
      decimals="INF"
      id="Narr_7bkwJwweUEaG1mKDSNd2Nw"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.75</us-gaap:SharesIssuedPricePerShare>
    <cgtx:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw"
      decimals="INF"
      id="Narr_XuOCaa8VNECOKSpYS25nBw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">985714</cgtx:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_SR_6Plv0XEe4csrbH8EEig"
      decimals="INF"
      id="Narr_q6ZbGa7J9UyE_sqqQEMmNQ"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.75</us-gaap:SharesIssuedPricePerShare>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw"
      decimals="-3"
      id="Narr_ezO69WgM_km9I2jRENXy8Q"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">13225000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_O1GaNOaThUixzy7DqVOOuw"
      decimals="-3"
      id="Narr_42BtVQ1b2UahOhX7tvtLfg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11896000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_WycRa_svQkCQ305iNTaQ0w"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_NB9Je6cPN0aZQvQunfgUaw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr_aqQupbszHk-Ze8ffXJCs5A"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">25009000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Narr_dQa_8kT9cUuXNb0Ms4c2VQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr_82n5kIm_6USQvG5IHONU7A"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-175160000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_-cqvWwUF2kO1ERq2KI2rAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management&#x2019;s assessment of the Company&#x2019;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (&#x201c;NIA&#x201d;) a division of the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2024 and 2023, the Company generated grant income of $19,549 and $24,805, respectively, primarily from reimbursements from the NIA for aging research. For the year ended December 31, 2024 and 2023, deferred grant income was $1,066 and $1,701, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the financings. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be &lt;span style="-sec-ix-hidden:Hidden_jnCsFL2IEUeXVQTdgotWyQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt; and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2024 or 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#x2019;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC 842, Leases (&#x201c;ASC 842&#x201d;), the Company determines if an arrangement is a lease at its inception. Leases are classified as either operating or finance, based on the Company&#x2019;s evaluation of certain criteria. If a lease has a term greater than one year, the lease is recognized in the balance sheet as a right-of-use asset and a lease liability at lease commencement. The Company elected the short-term lease practical expedient, therefore, if a lease has a term less than one year, the Company will not recognize the lease on its balance sheet. The right-of-use asset represents the Company&#x2019;s right of use to an underlying asset for the term of the lease and the lease liability represents the Company&#x2019;s obligation to make lease payments arising from the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Company&#x2019;s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease right-of-use assets and operating lease liabilities are determined and recognized on the commencement date of the lease based on the present value of lease payments over the term of the lease. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease, and right-of-use assets are subsequently re-measured to reflect the effect of uneven lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;For finance leases, right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset. Expenses for finance leases include the amortization of right-of-use assets, which is recorded as depreciation and amortization expense, and interest expense, which reflects interest accrued on the lease liability. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2024 and 2023 that met the recognition threshold.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to note 9 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other Comprehensive Gain&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $0 and $4 in other comprehensive gain related to foreign currency translation for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 13 &#x2013; Segment Reporting for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 13 - Segment Reporting for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements&lt;/i&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_4dXAKhIJCkq9MSFFq_GzXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_C63X8xRuEkWREeJisFZdnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the valuation of stock-based awards and the valuation allowance of deferred tax assets. In addition, management&#x2019;s assessment of the Company&#x2019;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_cGF0fq8RMkukzSBVBeDHkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three&#160;months or less when purchased to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_97vNa-7PLkmqRabkYLB5Ww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;Grant Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (&#x201c;NIA&#x201d;) a division of the National Institute of Health (&#x201c;NIH&#x201d;) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. &lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <cgtx:AllowanceForCreditLossGrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr_05XTJEvlo0ez5KqXS-BQeQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</cgtx:AllowanceForCreditLossGrantsReceivableCurrent>
    <cgtx:GrantIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_6LUHmeJeDUu-wjLof5eymA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the year ended December 31, 2024 and 2023, the Company generated grant income of $19,549 and $24,805, respectively, primarily from reimbursements from the NIA for aging research. For the year ended December 31, 2024 and 2023, deferred grant income was $1,066 and $1,701, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (&#x201c;CROs&#x201d;), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company&#x2019;s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of December 31, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.&lt;/p&gt;</cgtx:GrantIncomePolicyPolicyTextBlock>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_c0t0uybn1kCOmCvr2r2uZg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">19549000</cgtx:GrantIncome>
    <cgtx:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_no3NZG4kmEC7lbgD5iYCpA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24805000</cgtx:GrantIncome>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr_7fH9HLtavUWmhOI_Z8Cb6w"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1066000</cgtx:DeferredGrantIncomeCurrent>
    <cgtx:DeferredGrantIncomeCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Narr_ijSIc0cCS0qZaNzlWUUtYQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1701000</cgtx:DeferredGrantIncomeCurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_8xK0cuzcL0u-RdmQ8I7Irg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the financings. &lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_Me5U_oAq9U-BDrAac6Jr5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the asset. The Company estimates the useful life to be &lt;span style="-sec-ix-hidden:Hidden_jnCsFL2IEUeXVQTdgotWyQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt; and 6&#160;years for equipment and furniture and fixtures, respectively. The cost of repairs and maintenance is charged to expense as incurred. Equipment finance leases are included in Property and Equipment, net and other liabilities on the consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recorded values of property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. There were no indicators of impairment of long-lived assets during the years ended December 31, 2024 or 2023.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA"
      id="Narr_XsXdNHFLME-UsRX1yXLT4w">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_KMVhnAm2RUW_CNL_6qHo4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer&#x2019;s disease, dementia with Lewy bodies, and geographic atrophy (GA) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_6iZM095orUylSOzcAfFf6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC 842, Leases (&#x201c;ASC 842&#x201d;), the Company determines if an arrangement is a lease at its inception. Leases are classified as either operating or finance, based on the Company&#x2019;s evaluation of certain criteria. If a lease has a term greater than one year, the lease is recognized in the balance sheet as a right-of-use asset and a lease liability at lease commencement. The Company elected the short-term lease practical expedient, therefore, if a lease has a term less than one year, the Company will not recognize the lease on its balance sheet. The right-of-use asset represents the Company&#x2019;s right of use to an underlying asset for the term of the lease and the lease liability represents the Company&#x2019;s obligation to make lease payments arising from the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Company&#x2019;s leases do not provide an implicit rate within the lease, the Company uses its incremental borrowing rate, based on information available at the commencement date of the lease to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease right-of-use assets and operating lease liabilities are determined and recognized on the commencement date of the lease based on the present value of lease payments over the term of the lease. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease, and right-of-use assets are subsequently re-measured to reflect the effect of uneven lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;For finance leases, right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset. Expenses for finance leases include the amortization of right-of-use assets, which is recorded as depreciation and amortization expense, and interest expense, which reflects interest accrued on the lease liability. &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_2kR4QummV06hc6irpqNWqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to authoritative guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Under this authoritative guidance, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If it is more likely than not that some portion or all of a deferred tax asset will not be recognized, a valuation allowance is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the uncertainty occurs if the recognition threshold is met. The Company has determined that there were no uncertainties as of December&#160;31, 2024 and 2023 that met the recognition threshold.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Narr_RUqcEa9IPUudA8THKtxMSw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr__iycQKia9UamFzaprYlgBQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_FJwfKL5mV0S0sxlYqcm03g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the provisions of ASC 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company would recognize compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. Grant date fair value is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to a lack of sufficient public market data for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to note 9 for additional information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Narr_itfOAqqNYk26c_zBICJx9A"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_9DO4kNA4zkST7VFSjhXslA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_oS0tuzuv1EKiZQlJA9TtCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the Company&#x2019;s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:20.15pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_kbkbH7qWbEiDSB2oW1QQVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other Comprehensive Gain&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $0 and $4 in other comprehensive gain related to foreign currency translation for the&#160;years ended December&#160;31, 2024 and 2023, respectively. The Company presents comprehensive gain and loss in a single statement within its consolidated financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_goArU09pDke5EJigFIm6Zw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_riIwN4SKJEWrsBz-xsiNBw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_87Q9bj1HrkSVQcjq4FhQ_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or vesting of securities, such stock options and restricted stock units, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_QRiuhOlEHEyXaeeOcBvF3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 13 &#x2013; Segment Reporting for more information.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Narr_1dfo9wqowE2cB4YwSy8kmQ"
      unitRef="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw">1</us-gaap:NumberOfOperatingSegments>
    <cgtx:EmergingGrowthCompanyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_xNnDxhasM0OivEpv7ESvgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</cgtx:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_6qepeRTeP0C8gDpRVoZriw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 13 - Segment Reporting for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements&lt;/i&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The amendments apply to all reporting entities within the scope of the affected topics unless otherwise indicated. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_EQwUC08ZJ0u3c_6HqkjmTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Financial Instruments and Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Financial assets and liabilities measured at fair value are summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;There were no Level 3 financial instruments during the year ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_HrOvCM1Tl0yE2ynE5JON8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Priced&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_jrR6f4WA_E-O8mTJmjvxRA"
      decimals="-3"
      id="Tc_vuyOqrgqVEmnLzb8HXhcZA_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">23999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_XKQMBwzNm0isw3SpIMHyCg"
      decimals="-3"
      id="Tc_S5_lkPOTQkKJGx7Tarc1nQ_7_12"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">23999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_6nqsHazxDUGfwWNKMnAR-Q"
      decimals="-3"
      id="Tc_7xjmSN5ZC0KXHS3WBFvwkg_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">23999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_f95N-ZsjWEu8tYISkZtlDQ_8_12"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">23999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_WWHICw6P30W1vl__ISJXDQ"
      decimals="-3"
      id="Tc_U_vDdgHOuEKPGIw12ZDW7A_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29391000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_k0qbPwttZEipB5XrOo8yFw"
      decimals="-3"
      id="Tc_kMvSv2fqh0qkoIrml2j0kA_7_12"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29391000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_gX0jdGPEx0-lwTPLQjPt9A"
      decimals="-3"
      id="Tc_8gfYbTOfqkaMxdZ-_X_Hkg_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29391000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Dl1UHDQcGUm12jOf6hxrhg_8_12"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29391000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_NQSoBwRANkGOb_4p4VlAxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Property and equipment, net, consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Depreciation expense for the&#160;years ended December&#160;31, 2024 and 2023 was $107 and $96, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_sDDJ6a-rmkOIRCtDknhgkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_b4fLw2y3l0KxeSRZkBesPw"
      decimals="-3"
      id="Tc_4V2lLZkI50e3bUlSERsjLQ_3_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_OmwuH19ITkWRHopUzOVYJQ"
      decimals="-3"
      id="Tc_HGs6dcTvfUSH8zy2AWUlWg_3_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1193000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IfTtJw6lI0m0PS-_V_3EvA"
      decimals="-3"
      id="Tc_sz3eBn3Rh0On5LYqPU1ezw_4_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wq0C1MAIcUClHQZnNmyrcA"
      decimals="-3"
      id="Tc_WFnI15rlb0-GLt8kTdlkFQ_4_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_f_NQ-Tz7u0CANlDeJf7MeA_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1337000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_53No9keJX0WWtIML1V7chg_5_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_HjaEjpid8USWfhu7fQxDzw_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1156000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_wDijjjXM_kaB11U775elog_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1049000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_6yGw_N5tUEy8jJunu3Ii4Q_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">181000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_GP9h1ADzj02BtoHXN-wNqw_7_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">284000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_f6pcA9aqfkq0TB96-MKw4Q"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">107000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_Radge8zKV06g4ivGg47qZg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">96000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_Cow9T_VNN0SVJ0Acg5lquA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Accrued expense consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Professional fees and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_RvoElEQg6EOfVSO9gJQlsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee compensation, benefits, and related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Professional fees and other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_aRH5IHCeAkGx6y36bRbhJw_3_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1526000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_iFOwC-mOLEmJPVh7RP6l2w_3_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1165000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_cnAVL8q3RUq83GJVOB2Cuw_4_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">5654000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <cgtx:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_kMrsSvL4YkeqY-YmK2trLg_4_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2520000</cgtx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_vEekVP1hbkmnY-ajRmw3DQ_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">440000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_f18o1NaAGk6kO7HY9czNMw_5_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">370000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_ycExTxqLmk-Aq-9PyVKhXw_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">7620000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Bwlm0d-wzESKSFyTkAruZQ_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4055000</us-gaap:AccruedLiabilitiesCurrent>
    <cgtx:OtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_XM828ogD3k6snLqdOLuvJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through October 2024. As of December 31, 2023, the outstanding principal of the loan was $544 and the amount was paid off in &lt;span style="-sec-ix-hidden:Hidden_Z7RNwB4W3kOANqH6RLEDhQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2024&lt;/span&gt;&lt;/span&gt;. In October 2024, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $356 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $41, including interest and principal, are due monthly from November 2024 through July 2025. As of December 31, 2024, the outstanding principal of the loan was $279.&lt;/p&gt;</cgtx:OtherCurrentLiabilitiesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ"
      decimals="-3"
      id="Narr_bLp8qxcDbE6lPG67I0B-Bg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">721000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_Iz0Vxd9kv02XjgJNMjNImQ"
      decimals="INF"
      id="Narr_C9V0e_i9FUWbafaiTYtKsw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0865</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_3ws-31ywLkGQlI_tbXjBpg"
      decimals="-3"
      id="Narr_jJ-4qwEX90mS3_jE-Lm77A"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">62000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_9IPUhdlJ5kOeFe2ILc4Vlg"
      decimals="-3"
      id="Narr_5WYpckqpeUytCDHmlqhePg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">544000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw"
      decimals="-3"
      id="Narr_vn6A4M638UWPNSay_J_DXA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">356000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_3K5Y5ru-1UWgy78IlMO4jw"
      decimals="INF"
      id="Narr_1dDq6NOGUkOBZ1xJwrH6vw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0865</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_6WFEkFQXEUSicyyzDQI4qw"
      decimals="-3"
      id="Narr_a57mhVbqYkqPknTp2y9-7Q"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">41000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreement2Member_JlfyE0xns0CU4LcciEPTeg"
      decimals="-3"
      id="Narr_DDtuG6FVCEGPjMSx8wy8Vw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">279000</us-gaap:ShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_o_r1qLoyekCrRnvGUehe_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s principal executive offices are located in Purchase, New York where we currently occupy 2,864 square feet of office space under a lease that expires in May of 2029. The Company also leases approximately 6,068 square feet of laboratory and office space located in Pittsburgh, Pennsylvania under leases that expire in June of 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 31, 2022, the Company entered into a lease agreement for approximately 2,980 square feet of office space located in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. Additionally, on August 31, 2022, the Company and Landlord modified one of its existing lease agreements for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of December 31, 2024 and 2023 were as follows, in thousands:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease costs for the year ended December 31, 2024 and 2023 was $218 and $215, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2024 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating cash flows used for operating leases for the year ended December 31, 2024 and 2023 was $224 and $209, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Litigation and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;As of December&#160;31, 2024 and 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceNewYorkMember_P2TM13gBZU6xZncj0GmnAg"
      decimals="INF"
      id="Narr_8N4DQ9hxF06Bw2h0WLesfw"
      unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w">2864</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratoryAndOfficeSpacePittsburghPaMember_N80InueOO0ax6JSU1_GDkg"
      decimals="INF"
      id="Narr_wXqVbT2rPkCs6XQQVMz7kg"
      unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w">6068</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_O4eMoPkn-UiB3yEL9wwhEA"
      decimals="INF"
      id="Narr_tqLenB_kL06An8YfF1GPKQ"
      unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w">2980</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_1_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_OfficeSpaceLocatedInPittsburghPaMember_-QVbP29W8UCUFnMbcV9xXA"
      id="Narr_gISGfd3-g0afzlWpcj6wtQ">P45M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw"
      decimals="INF"
      id="Narr_FO5VzQH2G0yZ-iXmFvM4eA"
      unitRef="Unit_Standard_lease_9ytlK5UIFkOJ1P2Vw2TIqQ">1</cgtx:LesseeOperatingLeaseNumberOfBuyoutOptionsInDollars>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_8_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cgtx_LaboratorySpacePittsburghPaMember_io1gq7wB-EimGVinztLdXw"
      decimals="INF"
      id="Narr_oOwTKNosH0m0Npilt_mVYw"
      unitRef="Unit_Standard_sqft_Q_ry29lMr0SukrNtuSce8w">3706</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Group_x7cRPiKUGkigcDc-NhZUYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.19%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities, net of current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the lease term and discount rate as of December 31, 2024 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <cgtx:OperatingLeaseAssets
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_8Zj8I6rcrESHWQ1Q157zQQ_4_2"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">498000</cgtx:OperatingLeaseAssets>
    <cgtx:OperatingLeaseAssets
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_H8lyrDkk_E2eCJo7GrPGmQ_4_5"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">657000</cgtx:OperatingLeaseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc__mqHjQ--z0SYpoee9eHViQ_5_2"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">498000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_LNP8cbGKnUKcD_wOSDPj7g_5_5"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">657000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_gR-wrtw9aEKwpzTAKDO7HA_8_2"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">193000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_y-6Bo7GUiUOjR4mQwtc0_w_8_5"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">174000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_4zH8DhnQhU22DYe1Xs47Fg_10_2"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">342000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_t1JsaLZJDUGXMWmZJyYphQ_10_5"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">520000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_Mj2hRSG6X0CrGmPRLEqdug_11_2"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">535000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Nl7l8JDz00OvRgqLOwPMqw_11_5"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_F9WGg6fHp0GILoYx-pjZBA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">218000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_2wr3LC8uWkSeV1EgIB_3uA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">215000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_eauDUlYYaUSsVDhV97yeqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The maturities of the operating lease liabilities and minimum lease payments as of December 31, 2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_pE5obtDbiEq5hHldSrfKJw_2_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_3OGEexEmQE2aODCyoSIVhQ_3_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">158000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_CiVg5Ea56Um5nVFxnKekPg_4_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_b521lRMMCkaOuCqhLoCgKQ_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">92000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_uVqUr-mBCkeu1YVUgAgtBQ_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">39000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_Ce9C_7X_YEaQ5WLnExjpkQ_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">605000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_iirlxRK1QkOwLU9GMq-2Pw_9_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">70000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_6mRd_MdNwkyz0aI29ng0Ug_10_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">535000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      id="Tc_6QhQ1wm8nEuUrH9BCHhxjw_4_1">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      id="Tc_DHAEGcZ3zkuLbp1kKAfNvg_4_3">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="3"
      id="Tc_SiJwpTEVrE2wLAT9pVoEwA_6_1"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="3"
      id="Tc_u7M7QESOiEmsl9h3ZYGVfQ_6_3"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_9bsTzbPD6k6JfK9POIdPYA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">224000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_CSil1_dMbkasZ3fnrFvpig"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">209000</us-gaap:OperatingLeasePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_Rsw8SPKW9Emq0TEevEgKtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2024 and 2023, there were 59,854,877 and 32,165,478 shares of common stock &lt;span style="-sec-ix-hidden:Hidden_1URyjcdy8kqivgwhPCDv3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_S56iJzBGFkm4V3mtGIvG2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Common stockholders are entitled to dividends if and when declared by the Company&#x2019;s board of directors subject to the rights of the preferred stockholders. As of December&#160;31, 2024, no dividends on common stock had been declared by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;ATM&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000&#160;in aggregate (the &#x201c;Shelf&#x201d;). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000&#160;of its common stock from time to time in ATM offerings under the Shelf. &#160;The Company sold&#160;19,913,189&#160;shares of common stock pursuant to the ATM during the year ended December 31, 2024 for gross proceeds of approximately $12,840. As of December 31, 2024, there was $21,874&#160;remaining of common stock available for sale under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lincoln Park Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000&#160;of shares of common stock in the Company&#x2019;s sole discretion, over a&#160;36-month&#160;period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued&#160;189,856&#160;shares of its common stock as consideration for Lincoln Park&#x2019;s commitment to purchase shares of common stock under the Purchase Agreement (the &#x201c;Commitment Shares&#x201d;). The Company recorded $318&#160;to other expense, net during the year ended December 31, 2023 in connection with the issuance of the Commitment Shares. During the year ended December 31, 2023, the Company sold&#160;125,000&#160;shares of common stock to Lincoln Park for proceeds of $205, as part of the equity line financing arrangement. During the year ended December 31, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of December 31, 2024, $34,795&#160;was available to draw pursuant to the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;March 2024 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwriters&#x2019; option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwriters&#x2019; option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_DE--e9CilkKZKhu-FPjgWA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_yUEvrM_7bEqibpYVKIggkQ"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_uh91Fqs5DECqTlL7wzea9Q"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_rjn4C7oPG06EbvJL0FEuXA"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Narr_9K8AU7d9N06BKPISHINnpg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">59854877</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Narr_hGg8jdc_lU222rd6JQiI_g"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">32165478</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_UEmnHCzNx0eOPhEMZEfntA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:DividendsCommonStock>
    <cgtx:MaximumAggregateOfferingPrice
      contextRef="As_Of_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_hqu2JSnRzkK6dohK9_Z5NA"
      decimals="-3"
      id="Narr_d9lF9ppN-kCNVOWFSA_YcA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">200000000</cgtx:MaximumAggregateOfferingPrice>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_12_23_2022_To_12_23_2022_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_Q6DBrXT7LEaflz65yXd2EA"
      decimals="-3"
      id="Narr_vKmXMJVkcUWzJKekF9r0IQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">40000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="INF"
      id="Narr_UD5vrIPd_0i3MSNlVttang"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">19913189</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_OVs3-17gGESwnK1YIGzCvg"
      decimals="-3"
      id="Narr_Tvljg-sJ7UqSQGkMgNnTEw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12840000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_EKWIjPiMsU2M7X5y-zyRPg"
      decimals="-3"
      id="Narr_NxHpafApvUubdxapLc-mUw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">21874000</cgtx:SharesOfferingAgreementRemainingValueOfStockToBeIssued>
    <cgtx:MaximumValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      decimals="-3"
      id="Narr_FqlgUW00CkOoTdcd83v4Wg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">35000000</cgtx:MaximumValueOfStockToBeIssuedUnderAgreement>
    <cgtx:PurchaseAgreementTerm
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      id="Narr_7vbkdd7TDEyaq86fQUFj9Q">P36M</cgtx:PurchaseAgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Vni0d8rJg06q42E5ZmWJoQ"
      decimals="INF"
      id="Narr_K0__uDJXiE2AHb2njPuJtw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">189856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g"
      decimals="-3"
      id="Narr_3-zBgVAql0SvJDsVCh8NLw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">318000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g"
      decimals="INF"
      id="Narr_A2d2e-0x9UudhRWUl0CT0A"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_U0xKk5jVC06LosZjGOuh9g"
      decimals="-3"
      id="Narr_DFqodTPiu0G7O8BP9Nj6gQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">205000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cgtx:RemainingValueOfStockToBeIssuedUnderAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_cgtx_LincolnParkCapitalFundLlcMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_EquityLineFinancingMember_Lsdr1JTsu0KgnNyHLqobpg"
      decimals="-3"
      id="Narr_rZ4H-eaZnku_LSj1Eplq7Q"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">34795000</cgtx:RemainingValueOfStockToBeIssuedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA"
      decimals="INF"
      id="Narr_VLoEsFsbhkqrCJC0oUeSqg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">7557142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgtx:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_3_14_2024_To_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_mQwGI33v1kuKLTqpH3--aA"
      decimals="INF"
      id="Narr_i8N77viL9kO_cyMjzYthcg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">985714</cgtx:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_3_14_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_8KtOhdlvBUG2HVj7Nj0Rvg"
      decimals="INF"
      id="Narr_7tcZTSkBoEOWSi-bNHaHWA"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.75</us-gaap:SaleOfStockPricePerShare>
    <cgtx:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="Duration_3_28_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_qj_sVYxNbUS8cYEAWDZ8pw"
      decimals="INF"
      id="Narr_djuEHSd5IECmAJUwoZmjrA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">985714</cgtx:UnderwritersOptionToPurchaseAdditionalShares>
    <cgtx:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA"
      decimals="-3"
      id="Narr_8RjS99hvAEm4VMoHn3XRMQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11896000</cgtx:ProceedsFromIssuanceInitialPublicOfferingGross>
    <cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses
      contextRef="Duration_3_14_2024_To_3_28_2024_us-gaap_TypeOfArrangementAxis_cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember_86lP9TezvUy71Aq20UuCyA"
      decimals="-3"
      id="Narr_5xl_Lpc1oUuh_B2sIoSsAA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1329000</cgtx:UnderwritingDiscountsCommissionsAndOfferingExpenses>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_sLrdLyTbQkWSGwu0xL0yPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Equity-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 7, 2021, the date upon which the Company&#x2019;s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units, or RSUs, and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the aggregate number of shares of common stock of the Company that may be issued under the Plan is 2,587,917. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by 643,309 shares, representing 2% of total common shares outstanding at December 31, 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company&#x2019;s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company&#x2019;s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the &#x201c;2007 Plan&#x201d; and collectively with the 2017 Plan, the &#x201c;Prior Plans&#x201d;) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 15, 2017, the Company&#x2019;s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The Board, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company&#x2019;s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan allows for a provision for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised to subsequently be available for reissuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s board of directors approved the Employee Stock Purchase Plan, or ESPP, prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company&#x2019;s common stock at a discounted purchase price. As of December 31, 2024, a total of 209,532 shares of common stock was authorized and reserved for issuance under the ESPP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of our common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.78%&#x2009;&#x2013;&#x2009;92.29%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.47%&#x2009;&#x2013;&#x2009;92.68%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.23%&#x2009;&#x2013;&#x2009;4.45%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46%&#x2009;&#x2013;&#x2009;4.71%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.08 &#x2013; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.18&#x2009;&#x2013;&#x2009;6.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2009;&#x2014;&#x2009;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#x2019; expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#x2009;&#x2014;&#x2009;Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividend Yield&lt;/i&gt;&#x2009;&#x2014;&#x2009;The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;Activity for options was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:61.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 247,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (93,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,815)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,353,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,688,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The weighted-average grant date fair value of stock options granted was $1.56 and $1.56 during the years ended December 31, 2024 and 2023, respectively. There were 247,500 stock options granted at an aggregate fair value of $385 for the year ended December 31, 2024 and 628,769 stock options granted at an aggregate fair value of $983 for the year ended December 31, 2023. During the year ended December 31, 2024 and 2023, there were 93,350 and 0 stock options &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;exercised, respectively, with an aggregate grant date fair value of $58 and $0, respectively. The intrinsic value of stock options exercised during the year ended December 31, 2024 and 2023 was $121 and $0, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair values of RSUs are based on the fair market value of the Company&#x2019;s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon vesting. RSUs with time base vesting conditions for employees vest annually over &lt;span style="-sec-ix-hidden:Hidden_z0Vdnv6oQU-dhLEWmZmyvg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or four years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. RSUs with performance conditions for employee&#x2019;s vest on the one-year anniversary of the performance achievement date, assuming continued service from the employee during that period of time. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2024 and 2023, the Company granted 358,200 and 542,419 RSUs awards, respectively, containing time based vesting conditions to employees and non-employee directors. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2024 and 2023, the Company granted 515,600 and 0 RSUs awards, respectively, containing performance based vesting conditions to employees. During the year ended December 31, 2024, the performance conditions were achieved and RSUs will vest on the one-year anniversary of the achievement of the performance condition. As of December 31, 2024, the Company had no outstanding performance condition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s RSU activity for the year ended December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 873,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183,482)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,172,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 670&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2024, total future compensation expense related to unvested time-based awards yet to be recognized by the Company was $2,055, which is expected to be recognized over a weighted-average remaining vesting period of approximately 1.9 years. As of December 31, 2024, total future compensation expense related to unvested performance-based awards yet to be recognized by the Company was $462, which is expected to be recognized over a weighted-average remaining vesting period of approximately 0.8 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ"
      decimals="INF"
      id="Narr_oGMCdwzfIEam4flhzJxGxA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">2587917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TMZ1hC5jjUm23pil46C8GQ"
      decimals="INF"
      id="Narr_uvhCJ7LKzk6Ii5lqaCU_Tg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">643309</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_QnBbkut1Gkme18p813MRFg"
      decimals="2"
      id="Narr_OQTrT-JqrECM0wZDfo31iw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_wRqYBX88ck2Z32XFXD3SKQ"
      decimals="2"
      id="Narr_LqPPj9k0qEWL9oCkVIcsfA"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ"
      decimals="INF"
      id="Narr_B5mjxP_v_UCcg2VfDgRccw"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">7543185</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EquityIncentivePlan2021Member_TXPBWEsKy0q6fxVvfHArkQ"
      decimals="INF"
      id="Narr_-dw2mJ14xk-Ra572lQV-oA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4334131</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_qSIVc-no90OmF0KHnGel5A"
      decimals="INF"
      id="Narr_q6unYfC8qkuDXCuMsqUs1g"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4334131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_FGsA0l5PX0ikfIe99ENvTQ"
      decimals="INF"
      id="Narr_7bZ75CLe-UKw6TpeCXJXSA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">209532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g"
      decimals="INF"
      id="Narr_o-jKPUlZBUioRmU5d46iGQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_cgtx_EmployeeStockPurchasePlanMember_8DGYjHFvBEOGqiOVE26q1g"
      decimals="2"
      id="Narr_P0aQTSJEQ0az_sFPFCVNLw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_f6L5hLlV4UK0Z0BbyECLsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.78%&#x2009;&#x2013;&#x2009;92.29%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;91.47%&#x2009;&#x2013;&#x2009;92.68%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.23%&#x2009;&#x2013;&#x2009;4.45%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.46%&#x2009;&#x2013;&#x2009;4.71%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.08 &#x2013; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.18&#x2009;&#x2013;&#x2009;6.37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="4"
      id="Narr_eW72qFbwZU-OgFNkeiMnLA"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.9178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="4"
      id="Narr_0UiSUFGZAUWFDypQLHDQ1w"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.9229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="4"
      id="Narr_QQ5wHE-cQUC-0Ume8DO_pA"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.9147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="4"
      id="Narr_9v-Z97BlmkWY6q9NoYGDRw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.9268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="4"
      id="Narr_WrXaWSuAnkuoNdQ66KIuIQ"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="4"
      id="Narr_Atgkb2QDqkWnnmt03e_8Tg"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="4"
      id="Narr_5LkGyXDUZ0GC7oULw3sfVg"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="4"
      id="Narr_ZSuwYQ6mv0WMkQOjKZGPCA"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.0471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="4"
      id="Tc_p9Znd5LFZkSH_xiXlcs-Ww_5_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="4"
      id="Tc_BWlMDYFpAEiBf6X3rMHJhA_5_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_4KKeiPcUyU2k6n2tgFWd3g"
      id="Narr_uteOZctC4Um1EclUJpoG7Q">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_EZEO1er5NEyxL_p2ZKMavg"
      id="Narr_AF_oANlaPEKM7NyONNQ8Aw">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_iZBC1Qycd0ODSeXIqiMLDw"
      id="Narr_HmTgWNvIgkyABTk2PXBzQA">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_kR9dLuqQQUK9opN7bHqIBQ"
      id="Narr_CbjH0tQLTUSZMnRTqEaXxQ">P6Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Narr_FQ1d8QnOWkCWjse8M5V5Yg"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_xgbXf2MMfkWcUnVv1UIRSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:61.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;000&#x2019;s)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In&#160;Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 247,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (93,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,815)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,353,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,688,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="INF"
      id="Tc_cQy2Owp5J0uRSJ74KVZn3w_6_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4213405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="2"
      id="Tc_79zo-ee39EeJ439i0cnAkw_6_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_YDnBRnlahUyJAH8g9ffcAw_6_8"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      id="Tc_AGOwSCyDiU6on4bag6pf8w_6_10">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Tc_ftHYuaY6W0SZg5o2DPhDjw_7_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">247500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_m6uqYj6tDEmbFBceJ-hAxg_7_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Tc_PlO1obwYyEaAyh7xjaJbtQ_8_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">93350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_yzBc3YtGWUmdpzxpdLzTug_8_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">0.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Tc_mia7ZcaLNE-LroUhuipXww_9_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">12815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_XYbzTG0KuECE5gWtmSB1oQ_9_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">2.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Tc_i2fK3EmXNk2I4yRIUJ225A_10_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Tc_krDsBl5KjUWgAFO6FOZizw_10_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">2.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Tc_F7bt3glgk0CBTsFYuD4-mg_11_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4353490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="2"
      id="Tc__nVZrRCo8UWRJ72jANv1lA_11_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_rv4nATE_Y0u7HUCeYlvvJg_11_10">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="INF"
      id="Tc_4xlLMpMig06p1EXXVAcPjQ_12_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">3688126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="2"
      id="Tc_JAPzVUrFl0yQgW3ohD9EgA_12_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_rdctpMYs00ynLDm_dq7qHA_12_10">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Narr_3FCsVfeEpkucfbgHMiliuQ"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="2"
      id="Narr_EavnrQGuyUq5s9rUlc4JRA"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Narr_cX8nR_PK1EyyCBNysJAixA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">247500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_a0yy9ZJKhk2_gaeNhN6TaA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">385000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="INF"
      id="Narr_0IVz5PCI106ewKroggeT5Q"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">628769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_Ri_KjwIGEkWigwxT66Bclw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">983000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Narr_6H7v3kB36kW6oNBlejeqNQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">93350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="INF"
      id="Narr_tnXEjC64-0aWCGfMA61NsQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_cOV9QkON7kKxZBqdob-Qqg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">58000</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_YdIlcxE9qEmFro0GfJ2UUQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_HmgvmMqiPkKYpGW2BXrQcQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_X78mf6Fag0GKNPRdstdB8Q"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="INF"
      id="Narr_ANu-2HaS6EOXfU5O9lbDYg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">1</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mjymGu0RfUeiL7Co7NPZdA"
      id="Narr_XLeJj_TXSUKdp25EiS6l6w">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsTimeBasedVestingMember_us-gaap_GranteeStatusAxis_cgtx_NonEmployeeDirectorMember_o-vcv2H3AUS1ElrISMMh5A"
      id="Narr_O2j0kaOiGkyo8deoqFOMnw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA"
      id="Narr_M3K_G0bufEehYVEvbvLxhg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="INF"
      id="Narr_Gs623ATbik2Oe4zo2D13OA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">358200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Hkyrmv-pfEyH9afz2yTZxQ"
      decimals="INF"
      id="Narr_3UEbsfixV0elENK10LLNxA"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">542419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA"
      decimals="INF"
      id="Narr_jlzi-Gd0bEqT83ac3hyXlg"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">515600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0Ur3_enFS0W4_rr4CTlI6A"
      decimals="INF"
      id="Narr_yqKXqKfKQ0GmmqlYLTbdPQ"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aR14Zci-TUu77iK0qsGJdA"
      id="Narr_5Mbz5yMawEygnFWLL7hjDA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_RestrictedStockUnitsPerformanceBasedVestingMember_JXRbb9ivf0eQ2WygjyfFaA"
      decimals="INF"
      id="Narr_Yf3JYl_tK02WnCYmdDPbEg"
      unitRef="Unit_Standard_item_2EZlvjH0wki-oLaHkndxvg">0</cgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetsOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_l6xBcSdBe0mb-xodUU8-tw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 873,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183,482)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,172,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ"
      decimals="INF"
      id="Tc_I9ygSIfkgUCv0l44Z5TfbQ_3_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">522155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_T-GO284nzEat7ePhSOdmKQ"
      decimals="2"
      id="Tc_1TM6VunOuUmtujN0VuJszg_3_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="INF"
      id="Tc_uXFTi5EC7UeG7-F-7bbj8w_4_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">873800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="2"
      id="Tc_0MGeyndVUUK70TI7nL9Y4Q_4_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="INF"
      id="Tc_crOog6cDckaKxnTTJ7RGDw_5_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">183482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="2"
      id="Tc_y6RkuNFPnk6qmUR91ZBHig_5_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="INF"
      id="Tc_WcDJXBfoN0ysW3UQUOVYZA_6_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">39509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_BIMd1CSaE0OhMCCg5YIZIQ"
      decimals="2"
      id="Tc_Vbmo5p_QnEmnH1xBZoc5jw_6_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ"
      decimals="INF"
      id="Tc_8XoN7_JJ9kKXO8IZ65q-6Q_7_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">1172964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_R8Bett3Y-EyhVvCNiy_zEQ"
      decimals="2"
      id="Tc_rNk4AczNRUK22RMZWtF0yQ_7_5"
      unitRef="Unit_Divide_USD_shares_0J7lDzb0xk6xMudBZNet3g">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_TyKT3nY1ekKivxZNi5d_rA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 670&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cz7E_hdUVUWwa9Vuq9Mihg"
      decimals="-3"
      id="Tc_JthONBD3Fka3uwTZmEfc6w_3_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">1080000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6w45MJ0QnUikkNsbjaNclg"
      decimals="-3"
      id="Tc_CxG-kTNsjUmqtqvqFr-gIg_3_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2Q9ZkTw_DUCugaCKI_H91Q"
      decimals="-3"
      id="Tc_dMyZVynBVUaLV-1aaJaYmA_4_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynoIxvwk10KeE1sFcDzURw"
      decimals="-3"
      id="Tc_hBbtzbbuUkmSnRae4XcOfA_4_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3684000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_GJXnFrVnQUiRqQK6pQ-cXg_5_4"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_aVB5lGgxtUixkrfU2HwLAQ_5_7"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Narr_dz8CP6PLZkqLWBdEigMlig"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2055000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Narr_W0HsNXJ1bEiB_0on8HSfUA">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_GafOTV2hp0qNoyDaJ5nlAA"
      decimals="-3"
      id="Narr_OH55Gsd7TEmepJ17nA2yuw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">462000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_cgtx_PerformanceBasedStockOptionsMember_HTF3nxxkYEqnzjZbaDO4Bg"
      id="Narr_9KxI38GtVEi7wCK8s5vUBw">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_xaYaAfCNFEqsIJR89xKpSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,353,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Restricted stock units issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,172,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,526,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,735,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_gX-BseuqUUOCI5i13Hf0bA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,353,490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,213,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Restricted stock units issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,172,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 522,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,526,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,735,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_SefUZ0-stEK6Wo6PqsHRnA"
      decimals="INF"
      id="Tc_4-ZlksmwLUyneAqpu4KqvA_3_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4353490</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_YMzsuYYScUGAVgdtaKBakQ"
      decimals="INF"
      id="Tc_Df2ZHHCv80WK8dFSLAjSww_3_4"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4213405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JSDRzJzk2kCr9Ut2IvY5WQ"
      decimals="INF"
      id="Tc_-EMeXP2xdEWSY1RnRtQUPw_4_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">1172964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BZ1BPutL2kCFpmBC9iHmpg"
      decimals="INF"
      id="Tc_yu4n_7aynUSlx0YbckHgYg_4_4"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">522155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Tc_NX0eQeVqtUGu_Mlscjajyw_5_2"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">5526454</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="INF"
      id="Tc_q2s2fOK0BkWKf9Np_yJ0Fg_5_4"
      unitRef="Unit_Standard_shares_3EqqI_wd3k-YMCMupIf6Sw">4735560</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_bVRtltxHXkaxa8T91yaVgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Retirement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The Company maintains a 401(k)&#160;retirement plan to provide retirement and incidental benefits for its employees. Employees may contribute a&#160;percentage of their annual compensation to the 401(k)&#160;retirement plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company matches employee contributions dollar for dollar up to a maximum of 6% of the employees&#x2019; compensation per person per&#160;year. All matching contributions vest immediately. Company matching contributions to the 401(k)&#160;retirement plan totaled $265 and $199 for the&#160;year ended December&#160;31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="2"
      id="Narr_fOFMLM-CuEqgxsZ9Fokmtw"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_IWmT25LCaUKONjfvVDIMbw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">265000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_xG-AdUGXIUepPGcC2vqgiQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">199000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_BUbmIO2kt0q2ylJRFXWWuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The net loss consists of the following components:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,767)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2024 and 2023, the Company recorded no current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 requires the Company to capitalize, and subsequently amortize R&amp;amp;D expense over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside of the United States. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,089&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,207)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets as of December 31, 2024 and 2023. Management has considered the Company&#x2019;s history of cumulative net losses and has concluded as of December 31, 2024 and 2023, that it was more likely than not that the Company will not realize all of the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. The valuation allowance increased by $7,193 and $5,772 for the years ended December 31, 2024 and 2023, respectively. The increase in valuation allowance in 2024 was primarily a result of operating losses and tax credits generated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred net operating losses (&#x201c;NOL&#x201d;) since inception through December 31, 2021 and year ended December 31, 2024. Due to tax law changes, effective January 1, 2022, requiring the Company to capitalize and amortize R&amp;amp;D expenses, the Company was in a taxable position as of December 31, 2023 and 2022, and has utilized NOL generated in prior years to fully offset their income tax expense. As of December 31, 2024, the Company had federal net operating loss carryforwards of $38,063, net of Section 382 limited amounts. Included in federal net operating loss carryforwards of $38,063 is $11,503 that begin to expire in 2035 and $26,560 that can be carried forward indefinitely. As of December 31, 2024, the Company had state net operating loss carryforwards of $12,613, available to reduce future state taxable income, which will begin to expire in 2028. During the year ended December 31, 2024, the Company ceased operations of its wholly owned foreign subsidiary. As a result, all foreign net operating loss and research tax credit carryforwards were written off with an offsetting decrease to the valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;Utilization of the Company&#x2019;s net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The amount of the limitation is determined based on the value of the Company immediately prior to the ownership change and could be subject to additional adjustments as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. In 2023 the Company completed an analysis covering the periods from inception through December 31, 2022 to determine whether there may have been a Section 382 ownership change. This analysis showed an ownership change occurred in January 2009 and the Section 382 limitation would result in $589 of federal net operating loss carryforwards expiring unutilized. &#160;The Company updated the analysis through December 31, 2024 and determined that it is more-likely-than-not that the Company&#x2019;s existing net operating loss and research and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;development tax credit carryforwards could be utilized to offset current and future taxable income or tax, respectively, due to the conclusion that an ownership change did not occur in 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to further tax examination under statue for tax years beginning on or after January 1, 2021; however, carryforward attributes that were generated prior to January 1, 2021 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_OrM5AzJddEW1O8CHUR9QfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 20.15pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:60%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,767)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_nmSx3eMirkOFVE37EywSYQ_3_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_wmulIUc5eEiROvqS77hRMw_3_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_Qj9VxoqQ6EO1KQ20mua-ww_4_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-21000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_lUM1rRnnCEKMsDpWbTvQ_A_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_aiQ-3zYC-0WW8T19mHb4qA_5_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_lIzPUnRHZEGBRCcNLv-PlA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_Zwi6dgP5IE-Ot1f_Ko0hLQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_GFNzS38JXEqNIBDpQd_yig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D Credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_PDVTuC9eP0Wxgc3fJflXmw_3_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_4-4RjaV_TUy3EgjLjJlPuA_3_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_gjd689tlskapRTLDv2q10w_4_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_iDuhBy94LEG0-6NglX9nyw_4_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_zlDWqelg-Eu6zMMcpqqHKw_5_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_GT2M47WApkyyiMisx0rx1g_5_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.224</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_bCDDIw8TO0qrQadReDEnPA_6_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_93Citm8Tc0qNjW-JzpNENg_6_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_adU3I8wWck6TkL4XzGGScw_7_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_aI4eKXXx4U2NKkgNcTdG3Q_7_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="3"
      id="Tc_uE_J7rUhyEuAyCdiOLtsiA_8_2"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="3"
      id="Tc_r-q0enk4okGS2RQie7DJsQ_8_4"
      unitRef="Unit_Standard_pure_5Mx0s9EekkKdnm9rwnAg3Q">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_071RJqjYLUCydZTLamzQ4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,089&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,207)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (139)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (147)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_toxutnBT2UmHCMsJ-9Whzg_4_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">8491000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_uIIX5KG5W0GOpKnfyZKwiw_4_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">6847000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_u7ISu3DLs0K-fLZo9SbQLQ_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3791000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_EIOFV82WnkOXu9A0QJQahA_5_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3112000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_2uSKhpRU-USBl-BqrHyRSQ_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">477000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_zBo8JaDvtUyVSOfLK6KF-g_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">407000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cgtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_cT6zAmE7gU-E-LoBss9LhQ_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">114000</cgtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <cgtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Pdqv_VuJjUuiYN-MyLZ67w_7_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">148000</cgtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_mxZniesUek2nqHrk5-41BQ_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">16089000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Cdl7g7JxREyKJz6_i-vdIA_8_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11371000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_n3FEkgCsmkumzYCiSLx8ew_9_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">224000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_a3k3Qifnf0COeVC29ZJZrQ_9_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">223000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_ndw8eMM_4E2mh0mnWKegYg_10_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">324000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_yJkBtyUsBk2OZvnFYdp6uA_10_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">246000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_-rMZ8uTicUapLXpHcwusMQ_11_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29510000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_IzqbLhlSQku_MuPW_S0UbA_11_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">22354000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_8tPQTh-6D02DprS7R3nslg_12_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">29400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_Wkxu4qnbjkW3MRP5_KmqUQ_12_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">22207000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_w-L0HEwAIU6PskWJ_E3fpA_13_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">110000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_LHmTrkvISkmM8sWerXS6xA_13_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">147000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_6udT3rFM9Uaur-9Vdf6O5w_16_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_-kJufBliiUyISqyJGrTc7A_16_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">8000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_iHz56uBj1EyqBQrnf6j5AA_17_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">106000</cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_NFsR6ILQJ0-Eerb2F5HveQ_17_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">139000</cgtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2024_2aO2r3N4AUid5R-Km2vLDw"
      decimals="-3"
      id="Tc_EgCySVP5FUyPuLrpVgZDtg_18_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">110000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2023_HCuGUXZer02BYq5VRIv4Jw"
      decimals="-3"
      id="Tc_9QMyvWTdi0WfmZ8UL17r1A_18_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">147000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Narr_3a1HunjfMkirhf18HP93Cw"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">7193000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Narr_6W6heKWxwUCjaLSCHI6Bng"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">5772000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw"
      decimals="-3"
      id="Narr_Ty5N7SVpt0q-tMuLyVN5QA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">38063000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw"
      decimals="-3"
      id="Narr_eVZJB182o0egvEoPsomYNg"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">38063000</us-gaap:OperatingLossCarryforwards>
    <cgtx:OperatingLossCarryForwardsSubjectToExpiration
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw"
      decimals="-3"
      id="Narr_JKLtf1qMs0KPwEKD3ElJzQ"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">11503000</cgtx:OperatingLossCarryForwardsSubjectToExpiration>
    <cgtx:OperatingLossCarryForwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FAxGvuNi-0C-84WIcXLpQw"
      decimals="-3"
      id="Narr_PpVfxBeAuEiIHwdtkaNn-w"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">26560000</cgtx:OperatingLossCarryForwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_R4fyJmu5eUuklOk2TqC2fg"
      decimals="-3"
      id="Narr_iXigpGvdwE6iXKIbyRtU0w"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">12613000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_r3tUz6_Kt02MxBdQeEQGEQ"
      decimals="-3"
      id="Narr_ugjf17RWikSVd8qsz0zKqA"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">589000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_5YDV4qDqB0GVp9hAj4TXag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company&#x2019;s Chief Executive Officer (CEO) serves as the CODM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#x2019;s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company&#x2019;s consolidated net loss. The measure of segment assets is reported on the consolidated balance sheets as total assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;R&amp;amp;D Personnel costs&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,523&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Preclinical programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;General and administrative expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (131)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; R&amp;amp;D Personnel costs exclude equity-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt; General and administrative expenses exclude equity-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt 0pt 0pt 56.15pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt; Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="INF"
      id="Narr_7gmChiSwG0mV5IoODBsb4g"
      unitRef="Unit_Standard_segment_dOrQRoATRk-eKNjIZSYXJw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tb_tHSj4fUS0UGhwSRLOiaFuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;R&amp;amp;D Personnel costs&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,523&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Preclinical programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;General and administrative expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Equity-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:57.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (131)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; R&amp;amp;D Personnel costs exclude equity-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt; General and administrative expenses exclude equity-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt 0pt 0pt 56.15pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt; Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <cgtx:SegmentGrantIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_0rZt3CywmkiRJOEySlOnPA_3_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">19549000</cgtx:SegmentGrantIncome>
    <cgtx:SegmentGrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_m14G457Wb0mWpp9msxT-RA_3_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">24805000</cgtx:SegmentGrantIncome>
    <cgtx:ResearchAndDevelopmentClinicalPrograms
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_HbIl6SGWEkmj2SX2R47qZg_5_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">27675000</cgtx:ResearchAndDevelopmentClinicalPrograms>
    <cgtx:ResearchAndDevelopmentClinicalPrograms
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_0LH9_qQo4kCZ9VICebnNnw_5_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">21180000</cgtx:ResearchAndDevelopmentClinicalPrograms>
    <cgtx:ResearchAndDevelopmentPersonnel
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_dULuOXE6akO0UGyU0fchdQ_6_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">9672000</cgtx:ResearchAndDevelopmentPersonnel>
    <cgtx:ResearchAndDevelopmentPersonnel
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_xcuz2ARI30mPpqUCAx5MAQ_6_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">8523000</cgtx:ResearchAndDevelopmentPersonnel>
    <cgtx:ResearchAndDevelopmentPreclinicalPrograms
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_9Htpa336yEyysxXbhpTyGQ_7_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">810000</cgtx:ResearchAndDevelopmentPreclinicalPrograms>
    <cgtx:ResearchAndDevelopmentPreclinicalPrograms
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_YZP47GMu20aawFxBX3Wbhw_7_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3503000</cgtx:ResearchAndDevelopmentPreclinicalPrograms>
    <cgtx:ResearchAndDevelopmentManufacturing
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_evBR-1Rvpkuy7OTEOAb5qQ_8_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2241000</cgtx:ResearchAndDevelopmentManufacturing>
    <cgtx:ResearchAndDevelopmentManufacturing
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_jzTY1tTtTUeglIuOwdC01g_8_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">2890000</cgtx:ResearchAndDevelopmentManufacturing>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_PhNHz9VgK0aUc5l3ShR-Og_9_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">198000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_56h36bGDLUOVrAapwiMqdA_9_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">430000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_HwEPTHFshECsAnPpq5woow_10_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">9622000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_lSJ88HqHgEW3b-JGW_hh5Q_10_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">9844000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_9GmZ8uAKeUibQVYlZ-jnCw_11_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">3748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_uKWwt8vKc0ezj7shEFqTXQ_11_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">4354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_895Ij_qF70-zhW7X-I3uEg"
      decimals="-3"
      id="Tc_uqW-ORNPikGhfCCu-YSiQQ_12_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-446000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_cgtx_LifeScienceSegmentMember_LSxPd6br5UOdN-vbYkslFw"
      decimals="-3"
      id="Tc_cGSmp1wSVkaAKfgWOxYrlw_12_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-131000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      decimals="-3"
      id="Tc_eeaFBgY_AUaijH22NRc-Rg_13_3"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-33971000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_lrFihZsn40qg9YhCrJJ3Wg"
      decimals="-3"
      id="Tc_LR_w5N7VLUeDMxsMQrXnfg_13_6"
      unitRef="Unit_Standard_USD_Y2wvwp6nBEatI38_N53G_A">-25788000</us-gaap:NetIncomeLoss>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_7Jq21hYfLkCiQ_bzv9TFhQ"
      id="Tc_abw6P4GxnkqyNTDsyoaKZw_36_0">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
